PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FINKELSTEIN, AV; REVA, BA				FINKELSTEIN, AV; REVA, BA			A SEARCH FOR THE MOST STABLE FOLDS OF PROTEIN CHAINS	NATURE			English	Article							SECONDARY STRUCTURE; GLOBULAR-PROTEINS; SPIN-GLASSES; PATTERNS	IT is generally believed that it is not sensible to search for a thermodynamically stable structure of a protein 1,2 because neither a molecule nor a computer can look through all the 3 100 possible (for 100 residues) chain conformations. Here we show that the use of a molecular field theory for the long-range interactions, the use of one-dimensional statistical mechanics for the short-range ones and the discovery that there are 3,4 and there must be 5,6 only a small discrete set of folding patterns, make it possible to examine all the variety of 'potentially stable' structures. The general approach and its application is demonstrated here by calculation of stable folds for some beta-domains. The most stable of these folds correspond to the observed structures.	ACAD SCI USSR,RES COMP CTR,PUSHCHINO 142292,USSR	Russian Academy of Sciences	FINKELSTEIN, AV (corresponding author), ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR.		Reva, Boris/AAB-8932-2022; Reva, Boris A./B-6436-2014; Finkelstein, Alexey V/M-1440-2015	Reva, Boris A./0000-0002-8805-389X; Finkelstein, Alexey V/0000-0002-2138-4803				BINDER K, 1986, REV MOD PHYS, V58, P801, DOI 10.1103/RevModPhys.58.801; BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; Creighton T. E., 1984, PROTEINS; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FINKELSTEIN AV, 1990, BIOFIZIKA+, V35, P402; FINKELSTEIN AV, 1977, BIOPOLYMERS, V16, P525, DOI 10.1002/bip.1977.360160304; FINKELSTEIN AV, 1978, BIOORG KHIM+, V4, P340; FINKELSTEIN AV, 1987, PROG BIOPHYS MOL BIO, V50, P171, DOI 10.1016/0079-6107(87)90013-7; FINKELSTEIN AV, 1983, PROGRAM ALB; FRIEDRICHS MS, 1989, SCIENCE, V246, P371, DOI 10.1126/science.246.4928.371; KUBO R, 1965, STATISTICAL MECHANIC; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIFSHITZ IM, 1978, REV MOD PHYS, V50, P683, DOI 10.1103/RevModPhys.50.683; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; MURZIN AG, 1988, J MOL BIOL, V204, P749, DOI 10.1016/0022-2836(88)90366-X; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1983, BIOPOLYMERS, V22, P15, DOI 10.1002/bip.360220105; REVA BA, 1987, 2ND P INT M MOL BAS; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSSMANN MG, 1983, J MOL BIOL, V165, P711, DOI 10.1016/S0022-2836(83)80276-9; SASAI M, 1990, PHYS REV LETT, V65, P2740, DOI 10.1103/PhysRevLett.65.2740; SHAKHNOVICH EI, 1989, J PHYS A-MATH GEN, V22, P1647, DOI 10.1088/0305-4470/22/10/019; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; SHAKHNOVICH EI, 1989, STUD BIOPHYS, V132, P47; VEDENOV A. A., 1967, MOL BIOL, V1, P313; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	29	125	131	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					497	499		10.1038/351497a0	http://dx.doi.org/10.1038/351497a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	2046752				2022-12-01	WOS:A1991FP75800061
J	MOLNAR, Z; BLAKEMORE, C				MOLNAR, Z; BLAKEMORE, C			LACK OF REGIONAL SPECIFICITY FOR CONNECTIONS FORMED BETWEEN THALAMUS AND CORTEX IN COCULTURE	NATURE			English	Article							CEREBRAL-CORTEX; CORTICAL AREAS; VISUAL-CORTEX; RAT; CULTURES; PROJECTIONS; PATHWAY; NEURONS	THE mammalian cerebral cortex consists of many structurally 1 and functionally 2 specialized areas, with characteristic input from particular nuclei of the thalamus. Some localized external influence, such as the arrival of fibres from the appropriate thalamic nucleus before or around the time of birth 3-6, could trigger the emergence of committed cortical fields from an undifferentiated 'protocortex' 7,8. The guidance of axons from each thalamic nucleus to its appropriate target area in the cortex could, then, be crucial in the regulation of cortical differentiation. Recently, Yamamoto et al. 9 and Bolz et al. 10 have demonstrated that cocultured explants of rat lateral geniculate nucleus and visual cortex can form layer-specific interconnections. We have now tested the possibility that each cortical area exerts a selective trophic influence on axons from its appropriate thalamic nucleus, and vice versa, by coculturing explants of different regions of the thalamus and cortex taken at various stages of development.			MOLNAR, Z (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Molnar, Zoltan/J-7281-2012	Molnar, Zoltan/0000-0002-6852-6004; Blakemore, Colin/0000-0003-2659-7899	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAKEMORE C, 1990, COLD SPRING HARB SYM, V55, P491; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; Brodmann K., 1909, VERGLEICHENDE LOKALI; GAHWILER BH, 1988, TRENDS NEUROSCI, V11, P484, DOI 10.1016/0166-2236(88)90007-0; HENDERSON Z, 1986, Neuroscience Research, V3, P628, DOI 10.1016/0168-0102(86)90059-3; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; JONES EG, 1986, CEREBRAL CORTEX, V5; LUND RD, 1977, J COMP NEUROL, V173, P289, DOI 10.1002/cne.901730206; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; MCCONNELL SK, 1989, TRENDS NEUROSCI, V12, P342, DOI 10.1016/0166-2236(89)90041-6; MILLER MW, 1988, CEREB CORTEX, V7, P133; MOLNAR Z, 1990, J PHYSIOL-LONDON, V430, pP104; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PETERS A, 1985, CEREBRAL CORTEX, V3; PETERS A, 1985, CEREBRAL CORTEX, V4; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; ROMIJN HJ, 1988, J NEUROSCI METH, V23, P75, DOI 10.1016/0165-0270(88)90025-8; SHATZ CJ, 1988, CEREB CORTEX, V7, P35; VALVERDE F, 1989, J COMP NEUROL, V290, P118, DOI 10.1002/cne.902900108; YAMAMOTO N, 1989, SCIENCE, V245, P192, DOI 10.1126/science.2749258	20	193	195	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					475	477		10.1038/351475a0	http://dx.doi.org/10.1038/351475a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	2046749				2022-12-01	WOS:A1991FP75800053
J	PARDES, H; WEST, A; PINCUS, HA				PARDES, H; WEST, A; PINCUS, HA			PHYSICIANS AND THE ANIMAL-RIGHTS MOVEMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; AMER PSYCHIAT ASSOC, RES OFF, WASHINGTON, DC 20009 USA	New York State Psychiatry Institute	PARDES, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, 630 W 168TH ST, NEW YORK, NY 10032 USA.							BEHAR R, 1989, FORBES MAGAZINE 0320, P43; COHEN C, 1986, NEW ENGL J MED, V315, P865, DOI 10.1056/NEJM198610023151405; COHEN C, 1987, NEW ENGL J MED, V316, P553; COWLEY G, 1988, NEWSWEEK        1226, P50; DeBakey M E, 1988, J Invest Surg, V1, P81, DOI 10.3109/08941938809141078; DEBAKEY ME, 1989, PHYSICIANS MANAGE, V29, P17; FEENEY DM, 1987, AM PSYCHOL, V42, P593, DOI 10.1037/0003-066X.42.6.593; HORTON L, 1989, J NATL CANCER I, V81, P736, DOI 10.1093/jnci/81.10.736; HORTON L, 1988, SRA-J SOC RES ADMIN, V19, P5; KOOP CE, 1990, COMMUNICATION; NASSAR R, 1988, AM HUMANE ASS ANIMAL; Regan T., 2004, CASE ANIMAL RIGHTS; SHARPE R, CRUEL DECEPTION USE; Singer Peter, 1977, ANIMAL LIBERATION; SMITH SJ, 1988, JAMA-J AM MED ASSOC, V259, P2007, DOI 10.1001/jama.259.13.2007; THOMAS JA, 1988, NEW ENGL J MED, V318, P1630, DOI 10.1056/NEJM198806163182429; WOOLSEY TA, 1988, CIRCULATION, V77, P1197, DOI 10.1161/01.CIR.77.6.1197; 1990, 1990 P HOUS DEL RES, P392; 1986, OTABA273 PUBL; 1990, PAMPHLET AM ASS ACCR	20	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1640	1643		10.1056/NEJM199106063242306	http://dx.doi.org/10.1056/NEJM199106063242306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030720				2022-12-01	WOS:A1991FP30700006
J	PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H				PIRCHER, H; ROHRER, UH; MOSKOPHIDIS, D; ZINKERNAGEL, RM; HENGARTNER, H			LOWER RECEPTOR AVIDITY REQUIRED FOR THYMIC CLONAL DELETION THAN FOR EFFECTOR T-CELL FUNCTION	NATURE			English	Article							BONE-MARROW CHIMERAS; TRANSGENIC MICE; ANTIGEN RECEPTOR; TOLERANCE; SELECTION; ANTIBODY; COMPLEX; ANERGY; GENES	CLONAL deletion in the thymus plays a major part in T-cell tolerance to self antigens 1-3. But the mechanism of negative selection, its fine specificity and the threshold of affinity and avidity remains unknown. We have now examined these aspects of negative selection with mice expressing a transgenic T-cell receptor with specificity for lymphocytic choriomeningitis virus (LCMV) glycoprotein in association with the class I H-2D(b) molecule. These mice were rendered tolerant to LCMV by neonatal infection with mutant LCMVs bearing point mutations in the T-cell epitope recognized by the transgenic T-cell receptor (ref. 4). Variant LCMVs were also tested for their ability to elicit antiviral responses in transgenic mice in vivo and in vitro. Comparison in vivo revealed that a low-avidity receptor interaction, which was unable to induce effector T cells in the periphery, was still sufficient for clonal deletion in the thymus.			PIRCHER, H (corresponding author), UNIV HOSP ZURICH,INST PATHOL,CH-8091 ZURICH,SWITZERLAND.							AEBISCHER T, 1990, EUR J IMMUNOL, V20, P523, DOI 10.1002/eji.1830200310; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PULLEN AM, 1989, J IMMUNOL, V142, P3033; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	18	264	269	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1991	351	6326					482	485		10.1038/351482a0	http://dx.doi.org/10.1038/351482a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1710780				2022-12-01	WOS:A1991FP75800056
J	STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR				STOVER, CK; DELACRUZ, VF; FUERST, TR; BURLEIN, JE; BENSON, LA; BENNETT, LT; BANSAL, GP; YOUNG, JF; LEE, MH; HATFULL, GF; SNAPPER, SB; BARLETTA, RG; JACOBS, WR; BLOOM, BR			NEW USE OF BCG FOR RECOMBINANT VACCINES	NATURE			English	Article							ESCHERICHIA-COLI; STRESS PROTEINS; LYMPHOCYTES-T; INVIVO; MYCOBACTERIA; EXPRESSION; SEQUENCE; TUBERCULOSIS; CLONING; OPERON	BCG, a live attenuated tubercle bacillus, is the most widely used vaccine in the world and is also a useful vaccine vehicle for delivering protective antigens of multiple pathogens. Extrachromosomal and integrative expression vectors carrying the regulatory sequences for major BCG heat-shock proteins have been developed to allow expression of foreign antigens in BCG. These recombinant BCG strains can elicit long-lasting humoral and cellular immune responses to foreign antigens in mice.	UNIV PITTSBURGH, DIV BIOL SCI, PITTSBURGH, PA 15260 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	STOVER, CK (corresponding author), MEDIMMUNE INC, GAITHERSBURG, MD 20878 USA.		Barletta, Raul G./V-9053-2019	Stover, Charles/0000-0002-7406-1696; Lee, Mong-Hong/0000-0001-8675-8215; Jacobs, William/0000-0003-3321-3080				ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; AUSUBEL FM, 1987, CURR PROTOCOLS MOL B; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; Calmette A, 1927, VACCINATION PREVENTI; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CERRONE MC, 1991, INFECT IMMUN, V59, P79, DOI 10.1128/IAI.59.1.79-90.1991; CONVIT, 1982, INT J LEPROSY, V50, P514; CONVIT J, 1987, LANCET, V1, P401; CURRY RC, 1987, J IMMUNOL METHODS, V104, P137, DOI 10.1016/0022-1759(87)90497-2; CURTISS R, 1989, IMMUNOL INVEST, V18, P583, DOI 10.3109/08820138909112265; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; HALPERN JL, 1990, INFECT IMMUN, V58, P1004, DOI 10.1128/IAI.58.4.1004-1009.1990; HART P D, 1974, Infection and Immunity, V10, P742; HENDERSON RH, 1989, ANN NY ACAD SCI, V569, P45; JACOBS WR, 1987, NATURE, V327, P532, DOI 10.1038/327532a0; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; LAMB JR, 1982, J IMMUNOL, V129, P1465; LATHIGRA R, IN PRESS MOL MICROBI; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; LOTTE, 1988, B INT UNION TB LUNG, V63, P47; MILSTIEN JB, 1989, WHOEPIGEN893 DOC; MULLER I, 1987, INFECT IMMUN, V55, P2037; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; RAUZIER J, 1988, GENE, V71, P315, DOI 10.1016/0378-1119(88)90048-0; RUSSELL SM, 1979, NATURE, V280, P147, DOI 10.1038/280147a0; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHERLE PA, 1986, J EXP MED, V164, P1114, DOI 10.1084/jem.164.4.1114; SNAPPER SB, 1988, P NATL ACAD SCI USA, V85, P6987, DOI 10.1073/pnas.85.18.6987; STOVER CK, 1990, INFECT IMMUN, V58, P1360, DOI 10.1128/IAI.58.5.1360-1368.1990; TAKAHASHI H, 1990, J EXP MED, V171, P571, DOI 10.1084/jem.171.2.571; THOLE JER, 1987, INFECT IMMUN, V55, P1466, DOI 10.1128/IAI.55.6.1466-1475.1987; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988; WALSH JA, 1986, STRATEGIES PRIMARY H, P1; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P4267, DOI 10.1073/pnas.85.12.4267; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401; 1990, STATE WORLDS CHILDRE	37	1235	1452	4	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 6	1991	351	6326					456	460		10.1038/351456a0	http://dx.doi.org/10.1038/351456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP758	1904554	Bronze			2022-12-01	WOS:A1991FP75800046
J	TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA				TUTTLE, KR; BRUTON, JL; PERUSEK, MC; LANCASTER, JL; KOPP, DT; DEFRONZO, RA			EFFECT OF STRICT GLYCEMIC CONTROL ON RENAL HEMODYNAMIC-RESPONSE TO AMINO-ACIDS AND RENAL ENLARGEMENT IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; DIETARY-PROTEIN RESTRICTION; INCREASED KIDNEY SIZE; NEPHROPATHY; TRANSPLANTATION; INFUSION; DISEASE; SURFACE; PATHOGENESIS; AMELIORATION	Background. Many patients with insulin-dependent diabetes mellitushave an increase in the glomerular filtration rate and renal enlargement early in the course of their disease. Both these changes may be risk factors for the later development of diabetic nephropathy. Their cause is not known, but they could be due to augmented renal responses to the increase in plasma amino acid concentrations that occurs when dietary protein intake is high, a factor known to increase glomerular filtration and renal blood flow in normal subjects. Methods. We measured the glomerular filtration rate and renal plasma flow after an overnight fast and during an infusion of amino acids in 12 patients with insulin-dependent diabetes mellitus and 9 normal subjects. The diabetic patients were studied when they were hyperglycemic, when they were euglycemic after an insulin infusion for 36 hours, and after intensive insulin therapy for 3 weeks. Kidney volume was measured by ultrasonography before and after the period of intensive insulin therapy. Results. The glomerular filtration rate and renal plasma flow were normal after fasting when the patients were hyperglycemic (mean [+/- SE] fasting plasma glucose level, 11.5 +/- 0.7 mmol per liter). After the amino acid infusion, these values increased more in the patients (glomerular filtration rate, 2.65 +/- 0.07 ml per second per 1.73 m2 of body-surface area; renal plasma flow, 13.30 +/- 0.68 ml per second per 1.73 m2; P < 0.05 for both) than in the normal subjects (2.25 +/- 0.08 and 11.20 +/- 0.65 ml per second per 1.73 m2, respectively). The 36-hour infusion of insulin in the diabetic patients did not alter the glomerular filtration rate or renal plasma flow either before or during the amino acid infusion. After three weeks of intensive insulin therapy (fasting plasma glucose level, 5.3 +/- 0.2 mmol per liter), the glomerular filtration rate and renal plasma flow after the amino acid infusion (2.33 +/- 0.03 and 11.30 +/- 0.43 ml per second per 1.73 m2, respectively) were similar to those in the normal subjects. The kidney volumes in the normal subjects and the patients with diabetes were 219 +/- 14 and 312 +/- 14 ml per 1.73 m2, respectively (P < 0.01); the volume decreased to 267 +/- 22 ml per 1.73 m2 (P < 0.001) in the diabetic patients after three weeks of intensive insulin therapy, which was not significantly different from the volume in the normal subjects (P = 0.1). Conclusions. Conventionally treated diabetic patients who have normal renal function while fasting have augmented renal hemodynamic responses to increased plasma amino acid concentrations. The concomitant decrease in these hemodynamic responses and in kidney size with strict glycemic control suggests that these phenomena are related and influenced by the metabolic state.	UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV DIABET,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	TUTTLE, KR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV NEPHROL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		Lancaster, Jack L/F-2994-2010	Tuttle, Katherine/0000-0002-2235-0103	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001346] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR01346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOUNA GM, 1983, LANCET, V2, P1274; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BOSCH JP, 1986, AM J MED, V81, P809, DOI 10.1016/0002-9343(86)90350-5; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BROUHARD BH, 1986, AM J DIS CHILD, V140, P473, DOI 10.1001/archpedi.1986.02140190083032; CASTELLINO P, 1986, AM J PHYSIOL, V251, pF132, DOI 10.1152/ajprenal.1986.251.1.F132; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; CIAVARELLA A, 1987, DIABETES CARE, V10, P407, DOI 10.2337/diacare.10.4.407; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; EVANOFF G, 1989, ARCH INTERN MED, V149, P1129, DOI 10.1001/archinte.149.5.1129; FELDTRASMUSSEN B, 1986, NEW ENGL J MED, V314, P665, DOI 10.1056/NEJM198603133141101; HIROSE K, 1980, LAB INVEST, V43, P434; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; JONES TB, 1983, J ULTRAS MED, V2, P151; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUPIN WL, 1987, DIABETES, V36, P73, DOI 10.2337/diabetes.36.1.73; LEE CS, 1974, J EXP MED, V139, P793, DOI 10.1084/jem.139.4.793; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MOGENSEN CE, 1976, DIABETES, V25, P872; MOGENSEN CE, 1973, DIABETES, V22, P706, DOI 10.2337/diab.22.9.706; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; NOSADINI R, 1989, DIABETES, V38, P75, DOI 10.2337/diabetes.38.1.75; PARVING HH, 1980, DIABETOLOGIA, V19, P350, DOI 10.1007/BF00280519; PETERSEN J, 1988, DIABETES, V37, P1346, DOI 10.2337/diabetes.37.10.1346; Pitts RF, 1944, AM J PHYSIOL, V142, P0355, DOI 10.1152/ajplegacy.1944.142.3.355; PULLMAN TN, 1954, J LAB CLIN MED, V44, P320; SCHWIEGER J, 1990, SEMIN NEPHROL, V10, P242; SLOMOWITZ LA, 1988, AM J PHYSIOL, V255, pF755, DOI 10.1152/ajprenal.1988.255.4.F755; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; STACKHOUSE S, 1990, DIABETES, V39, P989, DOI 10.2337/diabetes.39.8.989; STALDER G, 1959, ANN PAEDIATR-BASEL, V193, P129; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; TANK GW, 1954, AM J PHYSIOL, V178, P165, DOI 10.1152/ajplegacy.1954.178.1.165; VIBERTI GC, 1988, DIABETES METAB REV, V4, P147, DOI 10.1002/dmr.5610040205; WALKER JD, 1989, LANCET, V2, P1411; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WISEMAN M, 1983, DIABETOLOGIA, V25, P530; WISEMAN MJ, 1985, NEW ENGL J MED, V312, P617, DOI 10.1056/NEJM198503073121004; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	43	154	156	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1991	324	23					1626	1632		10.1056/NEJM199106063242304	http://dx.doi.org/10.1056/NEJM199106063242304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP307	2030719				2022-12-01	WOS:A1991FP30700004
J	ATTIE, M				ATTIE, M			HYPOCALCEMIC SYMPTOMS FOLLOWING PARATHYROIDECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ATTIE, M (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.							Parfitt A. M., 1989, ENDOCRINOLOGY, P1049; PORTER RH, 1978, NEW ENGL J MED, V298, P577, DOI 10.1056/NEJM197803162981101	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033749				2022-12-01	WOS:A1991FN85500043
J	BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL				BEDELL, SE; DEITZ, DC; LEEMAN, D; DELBANCO, TL			INCIDENCE AND CHARACTERISTICS OF PREVENTABLE LATROGENIC CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED VENTRICULAR FLUTTER; DIGITALIS THERAPY; MEDICAL INPATIENTS; INTENSIVE-CARE; DRUG REACTIONS; FIBRILLATION; POINTES; DEATHS; TOXICITY; ILLNESS	We studied the contribution of iatrogenic illness to cardiac arrest among patients hospitalized in 1981 in a university teaching hospital. During this 1-year period, 28 (14%) of 203 arrests in which resuscitation was attempted followed an iatrogenic complication. Seventeen (61%) of the 28 patients died. The demographic characteristics of patients with iatrogenic arrest did not differ strikingly from those of other patients who arrested. However, patients with iatrogenic arrest were less likely to be in cardiogenic shock or to have suffered an acute myocardial infarction prior to arrest. They were more likely to survive to discharge from the hospital and tobe taking digoxin or antiarrhythmic medication prior to arrest. Among the 28 cases of iatrogenic cardiac arrest, 18 (9% of all arrests) might have been prevented by stricter attention to the patient's history, findings on physical examination, and laboratory data. The most common causes of potentially preventable arrest were medication errors and toxic effects (44%) as well as suboptimal response by physicians to clinical signs and symptoms (28%), most frequently dyspnea and tachypnea. Rapid, appropriate response to abnormal drug levels, to electrocardiographic signs of adverse drug effects, and to signs and symptoms of congestive heart failure or toxic effects from digoxin might decrease the incidence of cardiac arrest among hospitalized patients.	HARVARD UNIV, SCH MED, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; CHARLES A DANA RES INST, BOSTON, MA USA; HARVARD THORNDIKE LAB, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard University; Beth Israel Deaconess Medical Center								ARMITAGE P, 1971, STATISTICAL METHODS; BAZATT HC, 1920, HEART, V7, P353; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN DS, 1978, GERIATRICS, V33, P47; BUCHANAN DS, 1978, GERIATRICS, V33, P59; BURCHELL HB, 1983, J AM COLL CARDIOL, V1, P506, DOI 10.1016/S0735-1097(83)80080-1; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; COUCH NP, 1981, NEW ENGL J MED, V304, P634, DOI 10.1056/NEJM198103123041103; De Mey C, 1979, Acta Tuberc Pneumol Belg, V70, P183; DENES P, 1981, AM J CARDIOL, V48, P9, DOI 10.1016/0002-9149(81)90566-X; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FRIEDMAN GD, 1971, J AMER MED ASSOC, V217, P567, DOI 10.1001/jama.217.5.567; FRIEDMAN M, 1982, POSTGRAD MED, V71, P123, DOI 10.1080/00325481.1982.11716096; INGELFINGER JA, 1976, NEW ENGL J MED, V294, P867, DOI 10.1056/NEJM197604152941603; KEREN A, 1981, CIRCULATION, V64, P1167, DOI 10.1161/01.CIR.64.6.1167; KOSSMANN CE, 1978, AM J CARDIOL, V42, P1054, DOI 10.1016/0002-9149(78)90695-1; KOSTER RW, 1976, AM J CARDIOL, V38, P519, DOI 10.1016/0002-9149(76)90471-9; LASAGNA L, 1976, NEW ENGL J MED, V294, P898, DOI 10.1056/NEJM197604152941609; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCLAMB JT, 1967, SOUTHERN MED J, V60, P469, DOI 10.1097/00007611-196705000-00006; MOORMAN JR, 1985, SOUTHERN MED J, V78, P561, DOI 10.1097/00007611-198505000-00016; MYERS JD, 1981, NEW ENGL J MED, V304, P664, DOI 10.1056/NEJM198103123041109; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; RAVIN CE, 1976, AM J ROENTGENOL, V126, P423, DOI 10.2214/ajr.126.2.423; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; SHAPIRO W, 1978, AM J CARDIOL, V41, P852, DOI 10.1016/0002-9149(78)90724-5; SMITH WM, 1980, ANN INTERN MED, V93, P578, DOI 10.7326/0003-4819-93-4-578; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TRUNET P, 1980, JAMA-J AM MED ASSOC, V244, P2617, DOI 10.1001/jama.244.23.2617; VENULET J, 1975, INT J CLIN PHARM BI, V12, P387; WILLIAMSON JW, 1967, J AMER MED ASSOC, V201, P938, DOI 10.1001/jama.201.12.938	37	115	115	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2815	2820		10.1001/jama.265.21.2815	http://dx.doi.org/10.1001/jama.265.21.2815			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033737				2022-12-01	WOS:A1991FN85500029
J	COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS				COWAN, DN; BRUNDAGE, JF; POMERANTZ, RS; MILLER, RN; BURKE, DS			HIV-INFECTION AMONG MEMBERS OF THE UNITED-STATES-ARMY RESERVE COMPONENTS WITH MEDICAL AND HEALTH OCCUPATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARITAL-STATUS; CANCER; RISK; MEN; AIDS; PREVALENCE	Over 58 000 members of the US Army Reserve Components tested for human immunodeficiency virus (HIV) antibody had military or civilian medical occupations. The availability of HIV status and occupational information permits the assessment of prevalence and incidence of infection in this population. Levels of infection were not higher among women or among currently married men with medical occupations compared with those with nonmedical occupations. Prevalence and incidence were elevated among never-married men with either military or civilian medical occupations compared with never-married men with nonmedical occupations. Based on reported civilian occupation, male registered nurses and men with other medical occupations, excluding physicians and dentists, had a significantly higher prevalence of infection than men with nonmedical occupations. The patterns of infection suggest that the higher levels of infection found among never-married men with medical occupations may not be entirely due to occupational exposure. These findings may have applications in the design and interpretation of results of health care worker HIV surveillance programs.	WALTER REED ARMY MED CTR,DIV RETROVIROL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,DIV PREVENT MED,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	COWAN, DN (corresponding author), SRA TECHNOL INC,4700 KING ST,SUITE 300,ALEXANDRIA,VA 22302, USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BEEKMANN SE, 1990, INFECT CONT HOSP EP, V11, P371; BERNSTEIN L, 1989, CANCER RES, V49, P466; BIGGAR RJ, 1989, INT J CANCER, V43, P979, DOI 10.1002/ijc.2910430605; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P24, DOI 10.1111/j.1600-0447.1988.tb08544.x; BURKE DS, 1987, NEW ENGL J MED, V317, P132; CHAMBERLAND M, 1990, 6TYH INT C AIDS SAN; COWAN DN, 1990, J INFECT DIS, V162, P827, DOI 10.1093/infdis/162.4.827; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; GAGNON JH, 1989, AIDS SEXUAL DEHAVIOR, P102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GUENEL P, 1990, BRIT J IND MED, V47, P473; HARRY J, 1990, J HOMOSEXUAL, V19, P89, DOI 10.1300/J082v19n01_05; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KATO I, 1989, JPN J CANCER RES, V80, P306, DOI 10.1111/j.1349-7006.1989.tb02311.x; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; LEMESHOW S, 1984, AM J EPIDEMIOL, V119, P147, DOI 10.1093/oxfordjournals.aje.a113732; MCKUSICK L, 1985, PUBLIC HEALTH REP, V100, P622; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NUTTER RD, 1990, SOC SCI MED, V30, P83, DOI 10.1016/0277-9536(90)90331-L; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; WELLS JA, 1990, 6TH INT C AIDS SAN F; 1988, JAMA-J AM MED ASSOC, V259, P2817; 1990, RCS DDRAM11471148 PU; 1977, DICT OCCUPATIONAL TI	25	19	20	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2826	2830		10.1001/jama.265.21.2826	http://dx.doi.org/10.1001/jama.265.21.2826			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN855	2033739				2022-12-01	WOS:A1991FN85500031
J	HAUKEBO, N				HAUKEBO, N			MEDICINE MAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2788	2788						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033731				2022-12-01	WOS:A1991FN85500007
J	KLEBANOFF, MA; SHIONO, PH; RHOADS, GG				KLEBANOFF, MA; SHIONO, PH; RHOADS, GG			SPONTANEOUS AND INDUCED-ABORTION AMONG RESIDENT PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANESTHETIC-GASES; PREGNANCY; COMPLICATIONS; EXPOSURE; OUTCOMES	Female resident physicians are believed to be at an increased risk for a variety of third-trimester pregnancy complications. However, early pregnancy complications have been less well studied. This report compares spontaneous and induced abortions in a nationally representative sample of 5096 female medical school graduates (who experienced 1284 pregnancies) and of the sexual partners of 5000 of their male classmates (who experienced 1481 pregnancies). The response to the survey was 86.1%. The life-table probability of spontaneous abortion was 14.8% for female residents compared with 12.6% for the sexual partners of male residents. However, female residents were more likely than the male residents' sexual partners to terminate a pregnancy voluntarily (8.2% vs 2.7%). The increased risk of voluntary termination persisted when only married women were studied (3.6% vs 1.4%). However, female residents' pregnancies were at approximately half the risk of voluntary termination compared with pregnancies among the general US population of women aged 25 to 34 years. These results provide reassurance to those residents who would like to become pregnant but are concerned about the possible effect of their occupation on the course of the pregnancy.	DAVID & LUCILE PACKARD FDN,CTR FUTURE CHILDREN,LOS ALTOS,CA; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	KLEBANOFF, MA (corresponding author), NICHHD,DIV PREVENT RES,BLDG EPN,ROOM 640,BETHESDA,MD 20892, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092923] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-9-2923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AXELSSON G, 1982, INT J EPIDEMIOL, V11, P250, DOI 10.1093/ije/11.3.250; CUNNINGHAM FG, 1989, WILLIAMS OBSTETRICS, P489; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; GRUNEBAUM A, 1987, AM J OBSTET GYNECOL, V157, P79, DOI 10.1016/S0002-9378(87)80350-2; HARLAP S, 1980, LANCET, V2, P173, DOI 10.1016/S0140-6736(80)90061-6; KATZ VL, 1988, WESTERN J MED, V149, P704; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KNILLJONES RP, 1975, LANCET, V2, P807; LEE ET, 1980, STATISTICAL METHODS; MILLER NH, 1989, J REPROD MED, V34, P790; OSBORN LM, 1990, J FAM PRACTICE, V31, P618; PHELAN ST, 1988, OBSTET GYNECOL, V72, P431; SCHENKER MB, 1990, AM J EPIDEMIOL, V132, P96, DOI 10.1093/oxfordjournals.aje.a115648; SCHWARTZ RW, 1985, OBSTET GYNECOL, V66, P672; SELEVAN SG, 1985, NEW ENGL J MED, V313, P1173, DOI 10.1056/NEJM198511073131901; TANNENBAUM TN, 1985, J OCCUP ENVIRON MED, V27, P659; VENTURA S J, 1988, American Journal of Public Health, V78, P506, DOI 10.2105/AJPH.78.5.506; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; 1985, SAS USERS GUIDE STAT, P529	19	34	34	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2821	2825		10.1001/jama.265.21.2821	http://dx.doi.org/10.1001/jama.265.21.2821			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033738				2022-12-01	WOS:A1991FN85500030
J	ZWERDLING, RG; BROWN, J				ZWERDLING, RG; BROWN, J			PULMONARY-EMBOLISM IN CHILDREN - RISKS AND PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ZWERDLING, RG (corresponding author), UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01605, USA.							BERNSTEIN D, 1986, AM J DIS CHILD, V140, P667, DOI 10.1001/archpedi.1986.02140210065028; BUCK JR, 1981, J PEDIATR SURG, V16, P385, DOI 10.1016/S0022-3468(81)80700-2; BYARD RW, 1990, ARCH PATHOL LAB MED, V114, P142; GRACEY DR, 1982, MAYO CLIN PROC, V57, P742; RAMAN K, 1971, CHEST, V60, P555; 1986, JAMA-J AM MED ASSOC, V256, P744	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1991	265	21					2888	2888						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN855	2033750				2022-12-01	WOS:A1991FN85500042
J	ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM				ABRAMSON, SB; DOBRO, J; EBERLE, MA; BENTON, M; REIBMAN, J; EPSTEIN, H; RAPOPORT, DM; BELMONT, HM; GOLDRING, RM			ACUTE REVERSIBLE HYPOXEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLEMENT ACTIVATION; NEUTROPHIL AGGREGATION; INCREASED EXPRESSION; C5A ANAPHYLATOXINS; RECEPTOR CR3; DISEASE; C3A; HEMODIALYSIS; GLYCOPROTEIN; LEUKOSTASIS	Objective: To determine the frequency of unexplained reversible hypoxemia in patients with systemic lupus erythematosus and to assess the relation between hypoxemia and elevated plasma levels of complement split products. Design: Cohort study. Setting: Inpatient and outpatient facilities of the New York University Medical Center/Bellevue Hospital and the Hospital for Joint Diseases. Patients: Case patients were 22 patients hospitalized with disease exacerbation and no evidence of parenchymal lung disease on chest roentgenogram. Four patients with stable disease were followed in the outpatient clinic, and five healthy normal volunteers served as controls. Measurements: Plasma levels of complement split products (C3a, factor Bb fragment), alveolar-arterial (A-a) Po2 gradients, and pulmonary function were measured. Main Results: Nine episodes of hypoxemia or hypocapnia (mean A-a gradient, 30.4 +/- 4.8 mm Hg) or both (despite normal chest roentgenogram results) were noted in six hospitalized patients (group 1). Gas exchange improved within 72 hours of steroid therapy (mean A-a gradient, 11.6 +/- 4.3 mm Hg; P < 0.01). These patients had an elevated initial mean C3a level (938.4 +/- 246.8 ng/mL) that decreased within 72 hours (407.8 +/- 80.9 ng/mL; P < 0.01), concomitant with improved oxygenation. Ventilation-perfusion scans, obtained for four of six group 1 patients, excluded pulmonary emboli. Four hospitalized patients (group 2) had a normal A-a gradient (mean, 7.5 +/- 2.7 mm Hg). The mean C3a level of this group (358.3 +/- 39.2 ng/mL) was lower than that of group 1 (P < 0.05). Four patients with stable disease (group 3) had a mean A-a gradient and a mean C3a level of 3.3 +/- 2.7 mm Hg and 237.8 +/- 105.7 ng/mL, respectively, similar to values found in five normal volunteers, in whom the mean A-a gradient was 3.7 +/- 1.7 mm Hg and the mean C3a level was 124.8 +/- 9.2 ng/mL. Conclusion: A syndrome of reversible hypoxemia, unassociated with parenchymal lung disease, is unexpectedly common in acutely ill, hospitalized patients with systemic lupus erythematosus. The pathogenesis of this syndrome is unclear, although the data are compatible with the hypothesis that hypoxemia may be related to pulmonary leukoaggregation.	NYU MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT MED, DIV PULM CRIT CARE, NEW YORK, NY 10016 USA	New York University; New York University	ABRAMSON, SB (corresponding author), HOSP JOINT DIS & MED CTR, INST ORTHOPAED, DEPT RHEUMAT DIS, 301 E 17TH ST, NEW YORK, NY 10003 USA.		Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824; Abramson, Steven/0000-0002-0668-6344; Rapoport, David/0000-0002-4855-2600; Reibman, Joan/0000-0001-7878-1511; Belmont, Howard/0000-0003-3389-2976; goldring, roberta/0000-0003-3319-4932				ABRAMSON SB, 1983, ARTHRITIS RHEUM-US, V26, P630, DOI 10.1002/art.1780260509; ALARCONSEGOVIA D, 1961, DIS CHEST, V39, P7; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; BELMONT HM, 1986, ARTHRITIS RHEUM, V29, P1085, DOI 10.1002/art.1780290905; BURGESS JH, 1974, CIRCULATION, V49, P541, DOI 10.1161/01.CIR.49.3.541; BUYON J, 1988, CLIN RES, V36, pA531; BUYON JP, 1988, CLIN IMMUNOL IMMUNOP, V46, P141, DOI 10.1016/0090-1229(88)90014-1; BUYON JP, 1987, LEUKOCYTE TYPING, V3, P844; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; CRADDOCK PR, 1977, NEW ENGL J MED, V296, P769, DOI 10.1056/NEJM197704072961401; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; GIVEN WP, 1984, ARTHRITIS RHEUM, V27, P631, DOI 10.1002/art.1780270605; GOLDSTEIN I, 1973, P NATL ACAD SCI USA, V70, P2916, DOI 10.1073/pnas.70.10.2916; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HAMMERSCHMIDT DE, 1978, BLOOD, V51, P721; HARVEY AM, 1954, MEDICINE, V33, P291, DOI 10.1097/00005792-195412000-00001; HOFFBRAND BI, 1965, BMJ-BRIT MED J, V1, P1273, DOI 10.1136/bmj.1.5445.1273; HOPKINS P, 1988, ARTHRITIS RHEUM, V31, P632, DOI 10.1002/art.1780310508; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JACOB HS, 1980, NEW ENGL J MED, V302, P789; JESSAR RA, 1953, ANN INTERN MED, V38, P717, DOI 10.7326/0003-4819-38-4-717; MOORE FD, 1986, NEW ENGL J MED, V314, P948, DOI 10.1056/NEJM198604103141503; MYERS JL, 1986, AM J CLIN PATHOL, V85, P552, DOI 10.1093/ajcp/85.5.552; MYHRE JR, 1959, ACTA MED SCAND, V165, P55; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; POLLEY MJ, 1983, J EXP MED, V158, P603, DOI 10.1084/jem.158.2.603; RATNOFF WD, 1985, COMPLEMENT, P215; SEGAL AM, 1985, SEMIN ARTHRITIS RHEU, V14, P202, DOI 10.1016/0049-0172(85)90040-X; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8	32	57	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					941	947		10.7326/0003-4819-114-11-941	http://dx.doi.org/10.7326/0003-4819-114-11-941			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024861				2022-12-01	WOS:A1991FM97900005
J	ASHBY, M; STOFFELL, B				ASHBY, M; STOFFELL, B			THERAPEUTIC RATIO AND DEFINED PHASES - PROPOSAL OF ETHICAL FRAMEWORK FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS		ROYAL ADELAIDE HOSP,PALLIAT MED,ADELAIDE,SA 5006,AUSTRALIA; FLINDERS UNIV,MED CTR,MED ETH UNIT,BEDFORD PK,SA 5042,AUSTRALIA	Royal Adelaide Hospital; Flinders University South Australia								AHRONHEIM JC, 1990, LANCET, P278; BLACK D, 1990, BRIT MED J, V300, P1321, DOI 10.1136/bmj.300.6735.1321; CASSIDY S, 1986, J ROY SOC MED, V79, P717; GILHOOLY MLM, 1988, PALLIATIVE MED, V2, P64; Glover J., 1977, CAUSING DEATH SAVING; HIGGINSON I, 1989, PALLIATIVE MED, V3, P267; HIRSCHFIELD MJ, 1989, PALLIATIVE MED, V4, P25; JONES A, 1980, CLIN RADIOL, V31, P121, DOI 10.1016/S0009-9260(80)80135-8; KEARSLEY JH, 1986, BMJ-BRIT MED J, V293, P871, DOI 10.1136/bmj.293.6551.871; LUNT B, 1987, PALLIATIVE MED, V1, P136; MITCHELL JRA, 1979, BRIT MED J, V1, P1523, DOI 10.1136/bmj.1.6177.1523; Rachels J, 1986, END LIFE; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SMITH T, 1988, BRIT MED J, V297, P438, DOI 10.1136/bmj.297.6646.438; STOLL BA, 1990, J MED ETHICS, V16, P71, DOI 10.1136/jme.16.2.71; SUTHERLAND HJ, 1989, J ROY SOC MED, V82, P260, DOI 10.1177/014107688908200506; TIMOTHY AR, 1988, BRIT MED J, V297, P471, DOI 10.1136/bmj.297.6646.471; 1989, LANCET, V1, P476	18	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1322	1324		10.1136/bmj.302.6788.1322	http://dx.doi.org/10.1136/bmj.302.6788.1322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1711907	Green Published, Bronze			2022-12-01	WOS:A1991FQ44400024
J	BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA				BLANC, P; WONG, H; BERNSTEIN, MS; BOUSHEY, HA			AN EXPERIMENTAL HUMAN-MODEL OF METAL FUME FEVER	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; BRONCHOALVEOLAR WASHINGS; FACTOR-ALPHA; ZINC; INTERLEUKIN-1; INFLAMMATION; MEDIATOR; CYTOKINE; LAVAGE; CELLS	Objective: To examine the pathogenesis of metal fume fever in humans by studying functional, cellular, and biochemical responses after exposure to zinc welding fume. Design: Clinical experimental study. Participants: We studied 14 welders recruited through public advertisements. Interventions: Participants welded galvanized steel. Measurements: We measured lung volumes, airflow, diffusing capacity for carbon monoxide, and airway reactivity at baseline as well as either 6 or 20 hours after welding. We carried out bronchoalveolar lavage either 8 hours (early follow-up, 5 participants) or 22 hours (late follow-up, 9 participants) after welding, assaying the fluid for total and differential cell counts and bronchoalveolar lavage supernatant concentrations of interleukin-1 and tumor necrosis factor (TNF). Main Results: Changes in pulmonary function and airway reactivity were minimal. Cumulative zinc exposure and polymorphonuclear leukocyte count in bronchoalveolar lavage fluid at late (r = 0.87; P < 0.01) and early (r = 0.93; P < 0.05)follow-up were positively correlated. Among the late follow-up group, the mean proportion of polymorphonuclear leukocytes was 37% (range, 19% to 63%), a statistically greater proportion than the 9% (range, 2% to 21%) seen among the early follow-up group (P < 0.05). We did not detect TNF or more than a trace amount of interleukin-1 in the bronchoalveolar lavage supernatant. Conclusions: Zinc oxide welding fume was associated with a marked dose-dependent increase in the number of polymorphonuclear leukocytes recovered in bronchoalveolar lavage fluid 22 hours after exposure but was not associated with a clinically significant change in pulmonary function or airway reactivity. Although we did not identify increases in either interleukin-1 or TNF levels in bronchoalveolar lavage fluid, cytokines or a cytokine-like mechanism may mediate the syndrome of metal fume fever.	UNIV CALIF SAN FRANCISCO, DIV OCCUPAT & ENVIRONM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV PULM MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline; PHS HHS [K010H00079] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEECKMANS JM, 1963, ARCH ENVIRON HEALTH, V7, P346, DOI 10.1080/00039896.1963.10663544; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIBBY DC, 1989, J PHYSIOL-LONDON, V410, P367, DOI 10.1113/jphysiol.1989.sp017538; BROCKS A, 1977, BRIT MED J, V1, P1390, DOI 10.1136/bmj.1.6073.1390; CALLENDER G. R., 1937, Military Surgeon, V80, P67; CONNER MW, 1988, J TOXICOL ENV HEALTH, V25, P57, DOI 10.1080/15287398809531188; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; DRINKER PHILIP, 1927, JOUR INDUST HYG, V9, P98; GELB AF, 1973, AM REV RESPIR DIS, V107, P50; KUNKEL SL, 1990, PROG CLIN BIOL RES, V349, P433; LAM HF, 1985, TOXICOL APPL PHARM, V78, P29, DOI 10.1016/0041-008X(85)90301-1; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LECOURS R, 1986, THORAX, V41, P924, DOI 10.1136/thx.41.12.924; LEHMANN KB, 1910, ARCH HYG, V72, P358; LITOVITZ TL, 1989, AM J EMERG MED, V7, P495, DOI 10.1016/0735-6757(89)90252-0; MALO JL, 1990, EUR RESPIR J, V3, P111; MALO JL, 1987, CHEST, V92, P375, DOI 10.1378/chest.92.2.375; MARCHAT-AMORUSO B, 1990, American Review of Respiratory Disease, V141, pA423; MITCHELL MM, 1968, AM REV RESPIR DIS, V97, P571; MORI T, 1975, INT ARCH OCC ENV HEA, V36, P29, DOI 10.1007/BF01267849; MORIMOTO A, 1988, AM J PHYSIOL, V254, pR633, DOI 10.1152/ajpregu.1988.254.4.R633; MORIMOTO A, 1989, AM J PHYSIOL, V256, pR35, DOI 10.1152/ajpregu.1989.256.1.R35; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MUELLER E J, 1985, Journal of Emergency Medicine, V2, P271, DOI 10.1016/0736-4679(85)90106-4; MURPHY JV, 1970, J AMER MED ASSOC, V212, P2119, DOI 10.1001/jama.212.12.2119; NELSON S, 1989, J INFECT DIS, V159, P189, DOI 10.1093/infdis/159.2.189; NETA R, 1988, ANN INTERN MED, V109, P1, DOI 10.7326/0003-4819-109-1-1; OLGILVIE CM, 1957, J CLIN INVEST, V36, P1; PERNIS B, 1960, CLIN LAVORO, V51, P579; RYAN L K, 1990, American Review of Respiratory Disease, V141, pA678; SCHMIDTKEHL L, 1928, ZENTRALBLATT GEWERBE, V5, P272; SCUDERI P, 1990, CELL IMMUNOL, V126, P391, DOI 10.1016/0008-8749(90)90330-T; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633; STURGIS CYRUS C., 1927, JOUR INDUST HYG, V9, P88; TANAKA Y, 1990, SCAND J IMMUNOL, V31, P547, DOI 10.1111/j.1365-3083.1990.tb02805.x; TAYLOR G, 1986, OCCUPATIONAL RESPIRA, P607; VACHERON F, 1990, J GEN VIROL, V71, P477, DOI 10.1099/0022-1317-71-2-477; VOLGELMEIER C, 1987, CHEST, V92, P946; WANKOWICZ Z, 1988, J LEUKOCYTE BIOL, V43, P349, DOI 10.1002/jlb.43.4.349; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; WINCHURCH RA, 1987, EUR J IMMUNOL, V17, P127, DOI 10.1002/eji.1830170121; 1990, AM REV RESPIR DIS, V141, pS165; 1975, OCCUPATIONAL EXPOSUR; 1988, CRITERIA RECOMMENDED; 1989, OSHA3112 US DEP LAB	48	69	72	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					930	936		10.7326/0003-4819-114-11-930	http://dx.doi.org/10.7326/0003-4819-114-11-930			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024859				2022-12-01	WOS:A1991FM97900003
J	BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M				BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M			LIVER-CELL DYSPLASIA AND RISK OF HEPATOCELLULAR-CARCINOMA IN CIRRHOSIS - A PRELIMINARY-REPORT	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; ALCOHOL		FATEBENEFRATELLI HOSP,DEPT PATHOL,I-20129 MILAN,ITALY; PREDABISSI HOSP,DEPT MED 1,MELEGNANO,ITALY; CASTELLANA GROTTE HOSP,DEPT MED,BARI,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT MED 1,I-20122 MILAN,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT PATHOL 2,I-20122 MILAN,ITALY; BOLOGNINI HOSP,DEPT MED,SERIATE,ITALY	University of Milan; University of Milan	BORZIO, M (corresponding author), FATEBENEFRATELLI HOSP,DEPT MED 1,I-20129 MILAN,ITALY.			Roncalli, Massimo/0000-0002-7901-8910; Leandro, Gioacchino/0000-0001-6624-4532; Bruno, Savino/0000-0002-3887-864X				ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217; FARBER E, 1976, CANCER RES, V36, P2532; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RONCALLI M, 1986, CANCER, V57, P1515, DOI 10.1002/1097-0142(19860415)57:8<1515::AID-CNCR2820570813>3.0.CO;2-J; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0	5	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1312	1312		10.1136/bmj.302.6788.1312	http://dx.doi.org/10.1136/bmj.302.6788.1312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1647827	Green Published, Bronze			2022-12-01	WOS:A1991FQ44400020
J	FORMAN, D; NEWELL, DG; FULLERTON, F; YARNELL, JWG; STACEY, AR; WALD, N; SITAS, F				FORMAN, D; NEWELL, DG; FULLERTON, F; YARNELL, JWG; STACEY, AR; WALD, N; SITAS, F			ASSOCIATION BETWEEN INFECTION WITH HELICOBACTER-PYLORI AND RISK OF GASTRIC-CANCER - EVIDENCE FROM A PROSPECTIVE INVESTIGATION	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; POPULATION; STOMACH; PREVALENCE; CARCINOMA; CHINA	Objective-To investigate the association between gastric cancer and prior infection with Helicobacter pylori. Design-Case-control comparison of prevalence of IgG antibodies to H pylori in blood samples collected prospectively, before diagnosis of gastric cancer in the cases. Presence of H pylori antibody (> 10-mu-gIgG/ml) determined by enzyme linked immunosorbent assay (ELISA). Subjects-29 men with a subsequent diagnosis of gastric cancer and 116 aged matched controls selected from over 22 000 middle aged men participating in two ongoing cohort studies (the British United Provident Association study and the Caerphilly collaborative heart disease study), who had provided blood samples during 1975-1982. Results-20 of the 29 cases (69%) and 54 of the 116 controls (47%) were positive for H pylori specific antibody. The median specific IgG concentration was significantly higher in the cases than controls (90-mu-g/ml v 3.6-mu-g/ml, p < 0.01). The estimated odds ratio for the risk of gastric cancer in those with a history of infection with H pylori was 2.77 (95% confidence interval 1.04 to 7.97, 2p = 0.039). Conclusions-H pylori infection may be an important cause of gastric cancer; between 35% and 55% of all cases may be associated with such an infection.	LLANDOUGH HOSP,MRC,EPIDEMIOL UNIT,PENARTH CF6 1XX,S GLAM,WALES; PUBL HLTH LAB SERV,CTR APPL MICROBIOL RES,DEPT PATHOL,SALISBURY SP4 0JG,WILTS,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,DEPT ENVIRONM & PREVENT MED,BUPA EPIDEMIOL RES GRP,LONDON EC1 6BQ,ENGLAND	University of London; Queen Mary University London	FORMAN, D (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021	Sitas, Freddy/0000-0001-9679-1481				BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BRESLOW N. E., 1980, STATISTICAL METHODS; CORREA P, 1989, CAMPYLOBACTER PYLORI, P139; DIXON MF, 1989, CAMPYLOBACTER PYLORI, P106; FENG YY, 1988, LANCET, V1, P1055; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JASKIEWICZ K, 1989, S AFR MED J, V75, P417; KWA G, 1981, BRIT J CANCER, V28, P673; Logan WPD, 1982, STUDIES MED POPULATI; MARSHALL BJ, 1990, REV INFECT DIS, V12, pS87; PAULL G, 1989, CAMPYLOBACTER PYLORI, P73; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; ROBEYCAFFERTY SS, 1989, MODERN PATHOL, V2, P473; SIPPONEN P, 1986, GASTRIC CARCINOMA, P152; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1988, GUT, V29, P909, DOI 10.1136/gut.29.7.909; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; TALLEY NJ, 1990, REV ESPANIOLA ENF S1, V78, P7; TALLEY NJ, IN PRESS J CLIN MICR; WALD N, 1980, LANCET, V2, P813; YANG PC, 1988, INT J EPIDEMIOL, V17, P293, DOI 10.1093/ije/17.2.293; 1990, AM J GASTROENTEROL, V85, P819; 1984, J EPIDEMIOL COMMUNIT, V38, P259	25	1185	1229	2	36	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1302	1305		10.1136/bmj.302.6788.1302	http://dx.doi.org/10.1136/bmj.302.6788.1302			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	2059685	Bronze, Green Published			2022-12-01	WOS:A1991FQ44400017
J	HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE				HAMMANS, SR; SWEENEY, MG; BROCKINGTON, M; MORGANHUGHES, JA; HARDING, AE			MITOCHONDRIAL ENCEPHALOPATHIES - MOLECULAR GENETIC DIAGNOSIS FROM BLOOD-SAMPLES	LANCET			English	Article							DNA; MUTATION; DELETIONS; EPILEPSY; MERRF	Point mutations of mitochondrial DNA have been described in the muscle of patients with syndromes of myoclonic epilepsy and ragged red fibres (MERRF) and of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS). We have found the MERRF mutation in members of 6 British kindreds; 2 of these had unusual phenotypes but all index patients had myoclonus. The MELAS mutation was detected in 17 patients from 16 families, who had a wide range of clinical features that particularly affected the central nervous system; stroke-like episodes were observed in 10.3 patients with mitochondrial DNA mutations did not have ragged red fibres on muscle biopsy, generally considered to be the morphological hallmark of mitochondrial diseases. In all 6 patients with the MERRF mutation, and 10 of 11 with the MELAS mutation, the genetic defect was easily detected in blood cells as well as muscle (blood samples were not available in 6 patients with MELAS mutations in muscle). Molecular genetic analysis of blood samples represents an inexpensive and reliable screening test for mitochondrial encephalopathies, and use of such techniques could influence diagnosis and genetic counselling in patients with seizure disorders and young-onset stroke.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND	University of London; University College London								AICARDI J, 1990, ANN NEUROL, V28, P113; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; POULTON J, 1989, LANCET, V1, P236; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; ZEVIANI M, 1991, AM J HUM GENET, V48, P203	11	173	175	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1991	337	8753					1311	1313		10.1016/0140-6736(91)92981-7	http://dx.doi.org/10.1016/0140-6736(91)92981-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674297				2022-12-01	WOS:A1991FP08400004
J	KINGDOM, JCP; KELLY, T; MACLEAN, AB; MCALLISTER, EJ				KINGDOM, JCP; KELLY, T; MACLEAN, AB; MCALLISTER, EJ			RAPID ONE-STEP URINE TEST FOR HUMAN CHORIONIC-GONADOTROPIN IN EVALUATING SUSPECTED COMPLICATIONS OF EARLY-PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							ECTOPIC PREGNANCY	Objective - To determine the ability of a sensitive one step urine test to detect human chorionic gonadotrophin in women with suspected complications of early pregnancy. Design - Test on women presenting to accident and emergency department with gynaecological problems over six months. Results were validated using a quantitative assay for human chorionic gonadotrophin in serum and urine. Setting - Accident and emergency department and gynaecology wards of a university teaching hospital. Subjects - 130 unselected women. Main outcome measures-Detection of human chorionic gonadotrophin by one step test, presence of ectopic pregnancy, and results of quantitative analysis of chorionic gonadotrophin in serum and urine. Results - 79 women had a positive urine test-result and 51 a negative result. All 12 women with ectopic pregnancy had a positive test result, although urinary concentration varied from 191 IU/1 to 47 800 IU/1. Only one woman, who had a faintly positive result, was found not to be pregnant on subsequent examination. The sensitivity and negative predictive values of the urine test were 100% respectively. 33 women were sent home from the accident and emergency department with normal clinical findings after a negative urine test result. All these women had undetectable concentrations of chorionic gonadotrophin in matched samples of urine and serum. Conclusions - A simple, rapid one step test for chorionic gonadotrophin should be available for the initial evaluation of emergency gynaecological problems. The additional cost of the test is offset by not admitting those patients whose clinical findings are normal and who have a negative urine test result and by reducing the number of women requiring quantitative assays of chorionic gonadotrophin.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT GYNAECOL,GLASGOW G11 6NT,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,DEPT BIOCHEM,GLASGOW G11 6NT,SCOTLAND				Kingdom, John/AAF-2145-2020; Kingdom, John/A-3247-2013					BATEMAN BG, 1990, OBSTET GYNECOL, V75, P421; DIMARCHI JM, 1989, OBSTET GYNECOL, V74, P851; NORMAN RJ, 1988, OBSTET GYNECOL, V71, P315; SHEPHERD RW, 1990, OBSTET GYNECOL, V75, P417; TINDALL VR, 1987, JEFFEOATES PRINCIPLE, P212; TURNER MJ, 1991, BRIT J OBSTET GYNAEC, V98, P306, DOI 10.1111/j.1471-0528.1991.tb13398.x; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	7	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1308	1311		10.1136/bmj.302.6788.1308	http://dx.doi.org/10.1136/bmj.302.6788.1308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	2059687	Bronze, Green Published			2022-12-01	WOS:A1991FQ44400019
J	ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD				ROSS, PD; DAVIS, JW; EPSTEIN, RS; WASNICH, RD			PREEXISTING FRACTURES AND BONE MASS PREDICT VERTEBRAL FRACTURE INCIDENCE IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL MEASUREMENTS; OSTEOPOROSIS; ABSORPTIOMETRY; RISK	Objective: To determine the independent contributions of bone mass and existing fractures as predictors of the risk for new vertebral fractures. Subjects: Postmenopausal Japanese-American women. Measurements: Baseline measurements of the distal radius, the proximal radius, and the calcaneus were obtained in 1981 using single-photon absorptiometry. Measurements of the lumbar spine were obtained in 1984 using dual-photon absorptiometry. Prevalent vertebral fractures were identified using dimensions measured on lateral radiographs; vertebral height values more than 3 SD below vertebra-specific means were considered to indicate fracture. Statistical models were used to evaluate the utility of bone mass and existing (prevalent) fractures to predict the risk for new fractures during an average follow-up of 4.7 years. Main Results: Differences of 2 SD in bone mass were associated with fourfold to sixfold increases in the risk for new vertebral fractures. A single fracture at the baseline examination increased the risk for new vertebral fractures fivefold. Presence of two or more fractures at baseline increased the risk 12-fold. A combination of low bone mass (below the 33d percentile) and the presence of two or more prevalent fractures increased the risk 75-fold, relative to women with the highest bone mass (above the 67th percentile) and no prevalent fractures. Stature, body mass index, arm span, and spinal conditions such as scoliosis, osteoarthritis, and sacroiliitis did not predict fracture incidence (P > 0.05). Weight was marginally predictive (P = 0.04) of fracture incidence but became nonpredictive after adjusting for bone mass (P greater-than-or-equal-to 0.05). Conclusions: Both bone mass and prevalent vertebral fractures are powerful predictors of the risk for new vertebral fractures. Combining information about bone mass and prevalent fracture appears to be better for predicting new fractures than either variable alone. Physicians can use these risk factors to identify patients at greatest risk for new fractures.	MERCK SHARP & DOHME LTD, W POINT, PA 19486 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA	Merck & Company; University System of Maryland; University of Maryland Baltimore	ROSS, PD (corresponding author), HAWAII OSTEOPOROSIS CTR, 932 WARD AVE, SUITE 400, HONOLULU, HI 96814 USA.							BENGNER U, 1988, CALCIFIED TISSUE INT, V42, P293, DOI 10.1007/BF02556362; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; Heilbrun L K, 1985, Hawaii Med J, V44, P294; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; ROSS PD, 1988, J BONE MINER RES, V3, P1; ROSS PD, 1991, BONE, V12, P107, DOI 10.1016/8756-3282(91)90008-7; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; WASNICH RD, 1989, J NUCL MED, V30, P1166; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS 1987, P394; WASNICH RD, 1989, OSTEOPOROSIS CRITIQU; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; YANO K, 1984, AM J EPIDEMIOL, V119, P751, DOI 10.1093/oxfordjournals.aje.a113796	16	881	915	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					919	923		10.7326/0003-4819-114-11-919	http://dx.doi.org/10.7326/0003-4819-114-11-919			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024857				2022-12-01	WOS:A1991FM97900001
J	SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R				SATTLER, FR; KO, R; ANTONISKIS, D; SHIELDS, M; COHEN, J; NICOLOFF, J; LEEDOM, J; KODA, R			ACETAMINOPHEN DOES NOT IMPAIR CLEARANCE OF ZIDOVUDINE	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; DOUBLE-BLIND; PHARMACOKINETICS	Objective: To determine whether concurrent treatment with acetaminophen and zidovudine impairs clearance of zidovudine, thereby increasing the risk for zidovudine-induced hematologic toxicity. Design: Dose escalation, drug interaction study. Setting: University clinical research center. Patients: Patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Interventions: Acetaminophen and 200 mg of zidovudine simultaneously every 4 hours. For 13 patients, the unit dosage of acetaminophen was 325 mg for 3 days; for 8 patients, the dosage was 650 mg for 3 days; and, for 6 patients, the dosage was 650 mg for 7 days. Measurements: Zidovudine clearance and production of the glucuronide conjugate of zidovudine were assessed after acetaminophen treatment. Main Results: Neither zidovudine clearance nor production of the glucuronide conjugate of zidovudine was impaired after treatment with acetaminophen. Clearance of zidovudine was actually accelerated by 5%, 11%, and 33% with the three acetaminophen regimens,respectively (P = 0.002 by analysis of variance; P = 0.04 for linear trend when changes in the area-under-the-curve for zidovudine were compared). Conclusion: Because serum concentrations of zidovudine decrease after the coadministration of acetaminophen, a pharmacokinetic interaction between zidovudine and acetaminophen is unlikely to increase the risk for hematologic toxicity associated with zidovudine.			SATTLER, FR (corresponding author), UNIV SO CALIF, LOS ANGELES CTY MED CTR, 1175 N CUMMINGS ST, LOS ANGELES, CA 90033 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI062540] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR-43] Funding Source: Medline; NIAID NIH HHS [N0I-AI-62540] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUM MR, 1988, AM J MED, V85, P189; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GOOD SS, 1988, J CHROMATOGR-BIOMED, V431, P123, DOI 10.1016/S0378-4347(00)83075-3; JENNRICH R, 1988, BMDP STATISTICAL SOF, V1, P483; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; LEVY G, 1971, J PHARM SCI, V60, P215, DOI 10.1002/jps.2600600212; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; SINGLAS E, 1989, EUR J CLIN PHARMACOL, V36, P639, DOI 10.1007/BF00637752; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; Winer BJ., 1971, STAT PRINCIPLES EXPT	12	22	22	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1991	114	11					937	940		10.7326/0003-4819-114-11-937	http://dx.doi.org/10.7326/0003-4819-114-11-937			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM979	2024860				2022-12-01	WOS:A1991FM97900004
J	SEDGWICK, DM; AKOH, JA; MACINTYRE, IMC				SEDGWICK, DM; AKOH, JA; MACINTYRE, IMC			GASTRIC-CANCER IN SCOTLAND - CHANGING EPIDEMIOLOGY, UNCHANGING WORKLOAD	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the changes in incidence of and mortality from gastric cancer in Scotland between 1978 and 1987 and in the operative workload in Lothian between 1979 and 1988. Design-Analysis of national incidence statistics for gastric cancer derived from the Scottish national cancer registry, deaths from gastric cancer recorded by the registrar general for Scotland, and Lothian surgical audit data. Setting-Scotland and Lothian Health Board area. Patients-Patients in Scotland with gastric cancer during 1978 to 1987 inclusive; patients in Scotland with gastric cancer recorded on their death certificate as cause of death during 1978 to 1987; patients who had an operation in Lothian for gastric cancer during 1979 to 1988. Main outcome measures-Changes in incidence of and mortality from gastric cancer in Scotland from 1978 to 1987 and in the number of operations performed for gastric cancer in Lothian from 1979 to 1988. Results-Mortality from gastric cancer in Scotland fell by about 25% over the 10 years. The incidence and standardised incidence of gastric cancer showed a marginal decline of about 9%. The differences in trends between incidence and mortality were significant (p < 0.05). Conclusions-This study shows that the surgical workload associated with gastric cancer is not declining. This is because the incidence has remained almost static, which may be due to the relative increase in the numbers of older people in the population, who are at greater risk of developing gastric cancer. Gastric cancer should not be regarded as a disease in decline. Incidence and workload should determine resources allocated to this disease rather than mortality statistics.	WESTERN GEN HOSP,GASTROINTESTINAL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,SURG REVIEW OFF,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh				Macintyre, Iain/0000-0003-2716-8500				AKOH JA, 1991, BRIT J SURG, V78, P349, DOI 10.1002/bjs.1800780325; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; ARMITAGE P, 1987, STATISTICAL METHODS; BOYLE P, 1989, RECENT RESULTS CANC, P41; COGGON D, 1984, BRIT MED BULL, V40, P335, DOI 10.1093/oxfordjournals.bmb.a072000; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; GRUER R, 1986, LANCET, V1, P23; HISAMICHI S, 1989, WORLD J SURG, V13, P31, DOI 10.1007/BF01671151; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; MACINTYRE IMC, 1970, IN PRESS BR J SURG; WATERHOUSE J, 1982, CANCER INCIDENCE 5 C, V4; WATERHOUSE JAH, 1986, CANCER STOMACH, P1; 1990, 1989 ANN REP 1	13	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1305	1307		10.1136/bmj.302.6788.1305	http://dx.doi.org/10.1136/bmj.302.6788.1305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	2059686	Green Published, Bronze			2022-12-01	WOS:A1991FQ44400018
J	STRINGER, MD; CAPPS, SNJ				STRINGER, MD; CAPPS, SNJ			RATIONALIZING THE MANAGEMENT OF SWALLOWED COINS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							FOREIGN-BODIES	Objective - To assess the management of swallowed coins in children and identify aspects that could be improved. Design - Study of records of three hospital departments for 1986-90. Setting - Accident and emergency, radiology, and operating theatre departments in a children's hospital. Subjects - 50 children reported to have ingested coins. Main outcome measures - Radiological investigations performed, position of coin, symptoms of child, and surgical intervention. Results - 50 children were recorded to have swallowed coins during 1986-90. Five children had only chest radiography, five only abdominal radiography, and 40 had both. A coin was detected in the oesophagus in 15 children, six of whom had symptoms, and below the cardia in 26, none of whom had symptoms; no coin was seen in nine children. Eleven children had further abdominal radiographs despite the absence of gastrointestinal symptoms; one child had a coin removed from the stomach. Conclusions - Children are being unnecessarily exposed to radiation and surgical intervention, and a consensus on management of swallowed coins is needed. Most children require only a single chest and neck radiograph.			STRINGER, MD (corresponding author), QUEEN MARYS HOSP CHILDREN,DEPT PAEDIAT SURG,CARSHALTON SM5 4NR,SURREY,ENGLAND.							BROWN WM, 1971, BMJ-BRIT MED J, V4, P620, DOI 10.1136/bmj.4.5787.620-a; Groff D. B., 1986, PEDIATR SURG, P907; JONES PG, 1963, MED J AUSTRALIA, V50, P236; MANDELL GA, 1977, PEDIATRICS, V60, P460; SPITZ L, 1971, BMJ-BRIT MED J, V4, P469, DOI 10.1136/bmj.4.5785.469; 1989, LANCET, V2, P659	6	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1321	1322		10.1136/bmj.302.6788.1321	http://dx.doi.org/10.1136/bmj.302.6788.1321			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1953854	Green Published, Bronze			2022-12-01	WOS:A1991FQ44400023
J	TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD				TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD			HEPATITIS-C VIRUS - EVIDENCE FOR SEXUAL TRANSMISSION	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; NON-A; ANTIBODIES	Objective-To determine the prevalence of hepatitis C virus infection and associated risk factors in patients attending a genitourinary medicine clinic, as evidence for sexual transmission. Design-Seroprevalence estimated by reactivity in an enzyme immunoassay for antibodies to C100 protein with supplementary testing with a recombinant immunoblot assay and an assay for hepatitis C virus RNA. Setting-Outpatient genitourinary medicine clinic in central London. Patients-The panel of 1046 serum samples was from 1074 consecutive patients attending the clinic during November and December 1987 and having blood taken for routine testing for syphilis. Before samples were anonymised demographic and risk factor information was extracted from the clinic notes. Samples had already been tested for antibody to HIV-1 and antibody to hepatitis B core antigen. Main results-Significantly more homosexual subjects than heterosexual subjects were positive for hepatitis C antibody determined by enzyme immunoassay alone (19/275 (6.9%) v 8/771 (1.0%), odds ratio 7.14, p < 0.0001) and also when reactive serum samples were also tested by recombinant immunoblot assay (6/270) (2.2%) v 3/770 (0.4%), odds ratio 5.88, p < 0.02). There were also significant associations in patients positive for hepatitis C antibody with positivity for antibodies to HIV and to hepatitis B core antigen, lifetime number of sexually transmitted diseases (homosexual men only), and age (all groups combined). Most patients whose serum samples contained specific antibodies to hepatitis C virus were viraemic. Conclusions-The study provides strong evidence for the sexual transmission of hepatitis C virus. Assays derived from other gene products are desirable to investigate the specificity and sensitivity of the enzyme immunoassay for C100 antibody as a marker of hepatitis C virus infection.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	TEDDER, RS (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT UROL,LONDON WC1E 6JJ,ENGLAND.		Garson, Jeremy A/C-5357-2008; RIESTRA, SABINO/N-2897-2019; Kelly, Gabrielle E./A-4147-2015	Kelly, Gabrielle E./0000-0003-2769-9555; Garson, Jeremy/0000-0003-0553-0126; Tedder, Richard/0000-0002-9672-5721				ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORTIMER PP, 1989, LANCET, V2, P798	10	132	134	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1299	1302		10.1136/bmj.302.6788.1299	http://dx.doi.org/10.1136/bmj.302.6788.1299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ444	1647826	Bronze, Green Published			2022-12-01	WOS:A1991FQ44400016
J	[Anonymous]				[Anonymous]			HOW CUBA CONTROLS HIV-INFECTION	LANCET			English	Editorial Material																		PEREZSTABLE EJ, 1991, AM J PUBLIC HEALTH, V81, P563, DOI 10.2105/AJPH.81.5.563	1	0	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 1	1991	337	8753					1340	1341						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP084	1674309				2022-12-01	WOS:A1991FP08400024
J	BAINTON, R; GAMAS, P; CRAIG, NL				BAINTON, R; GAMAS, P; CRAIG, NL			TN7 TRANSPOSITION INVITRO PROCEEDS THROUGH AN EXCISED TRANSPOSON INTERMEDIATE GENERATED BY STAGGERED BREAKS IN DNA	CELL			English	Article							ESCHERICHIA-COLI CHROMOSOME; BACTERIOPHAGE-MU; RETROVIRAL DNA; TN10 TRANSPOSITION; TY1 TRANSPOSITION; INTEGRATION; SEQUENCE; IDENTIFICATION; REPLICATION; MECHANISM	We have developed a cell-free system in which the bacterial transposon Tn7 inserts at high frequency into its preferred target site in the Escherichia coli chromosome, attTn7; Tn7 transposition in vitro requires ATP and Tn7-encoded proteins. Tn7 transposes via a cut and paste mechanism in which the element is excised from the donor DNA by staggered double-strand breaks and then inserted into attTn7 by the joining of 3' transposon ends to 5' target ends. Neither recombination intermediates nor products are observed in the absence of any protein component or DNA substrate. Thus, we suggest that Tn7 transposition occurs in a nucleoprotein complex containing several proteins and the substrate DNAs and that recognition of attTn7 within this complex provokes strand cleavages at the Tn7 ends.	UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAINTON, R (corresponding author), UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Gamas, Pascal/0000-0002-6253-4249	NIGMS NIH HHS [GMO 7618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BARTH PT, 1976, J BACTERIOL, V125, P800, DOI 10.1128/JB.125.3.800-810.1976; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHOLS H, 1990, J BIOL CHEM, V265, P14697; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GRINDLEY NDF, 1978, COLD SPRING HARB SYM, V43, P1257; GRINGAUZ E, 1988, J BACTERIOL, V170, P2832, DOI 10.1128/jb.170.6.2832-2840.1988; HANIFORD DB, 1991, CELL, V64, P171; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; KLECKNER N, 1990, ANNU REV CELL BIOL, V6, P297, DOI 10.1146/annurev.cb.06.110190.001501; KUBO K, 1990, J BACTERIOL, V182, P2774; LEE CH, 1983, P NATL ACAD SCI-BIOL, V80, P6765, DOI 10.1073/pnas.80.22.6765; LICHTENSTEIN C, 1982, NATURE, V297, P601, DOI 10.1038/297601a0; MCKOWN RL, 1988, J BACTERIOL, V170, P352, DOI 10.1128/jb.170.1.352-358.1988; MCKOWN RL, 1987, P NATL ACAD SCI USA, V84, P7807, DOI 10.1073/pnas.84.22.7807; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NKLECKNER N, 1989, MOBILE DNA, P227; ORLE KA, 1990, GENE, V96, P1, DOI 10.1016/0378-1119(90)90333-M; Pato ML, 1989, MOBILE DNA, P23; QADRI MI, 1989, J MOL BIOL, V207, P85, DOI 10.1016/0022-2836(89)90442-7; ROBERTS D, 1988, P NATL ACAD SCI USA, V85, P6037, DOI 10.1073/pnas.85.16.6037; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; THOMPSON JF, 1989, MOBILE DNA, P1; VARMUS H, 1989, MOBILE DNA, P53; WADDELL CS, 1989, P NATL ACAD SCI USA, V86, P3958, DOI 10.1073/pnas.86.11.3958; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137	49	127	132	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					805	816		10.1016/0092-8674(91)90388-F	http://dx.doi.org/10.1016/0092-8674(91)90388-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645619				2022-12-01	WOS:A1991FP51600011
J	BERATAN, DN; BETTS, JN; ONUCHIC, JN				BERATAN, DN; BETTS, JN; ONUCHIC, JN			PROTEIN ELECTRON-TRANSFER RATES SET BY THE BRIDGING SECONDARY AND TERTIARY STRUCTURE	SCIENCE			English	Article							TUNNELING PATHWAYS; CYTOCHROME-C; MOLECULES	The rate of long-distance electron transfer in proteins rapidly decreases with distance, which is indicative of an electron tunneling process. Calculations predict that the distance dependence of electron transfer in native proteins is controlled by the protein's structural motif. The helix and sheet content of a protein and the tertiary arrangement of these secondary structural units define the distance dependence of electronic coupling in that protein. The calculations use a tunneling pathway model applied previously with success to ruthenated proteins. The analysis ranks the average distance decay constant for electronic coupling in electron transfer proteins and identifies the amino acids that are coupled to the charge localization site more strongly or weakly than average for their distance.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA	California Institute of Technology; University of California System; University of California San Diego	BERATAN, DN (corresponding author), CALTECH, JET PROP LAB, PASADENA, CA 91109 USA.		Beratan, David N/C-5098-2011	Beratan, David N/0000-0003-4758-8676				BALAJI V, 1987, J AM CHEM SOC, V109, P6957, DOI 10.1021/ja00257a010; BERATAN DN, 1984, J AM CHEM SOC, V106, P1584, DOI 10.1021/ja00318a008; BERATAN DN, 1987, J CHEM PHYS, V86, P4488, DOI 10.1063/1.452723; BERATAN DN, 1990, J AM CHEM SOC, V112, P7915, DOI 10.1021/ja00178a011; BERATAN DN, 1985, J CHEM PHYS, V83, P5325, DOI 10.1063/1.449694; BERATAN DN, 1989, PHOTOSYNTH RES, V22, P173, DOI 10.1007/BF00048296; BERATAN DN, 1991, MET IONS BIOL SYST, V27, P97; BOWLER BE, 1989, J AM CHEM SOC, V111, P8757, DOI 10.1021/ja00205a049; Broo A., 1989, INT J QUANTUM CHEM, V16, P185; CONRAD DW, 1989, J AM CHEM SOC, V111, P3461, DOI 10.1021/ja00191a070; COWAN JA, 1988, ANN NY ACAD SCI, V550, P68, DOI 10.1111/j.1749-6632.1988.tb35324.x; DEVAULT D, 1984, QUANTUM MECHANICAL T; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; FARVER O, 1989, FEBS LETT, V244, P379, DOI 10.1016/0014-5793(89)80567-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; JACKMAN MP, 1988, J AM CHEM SOC, V110, P5880, DOI 10.1021/ja00225a046; JACOBS BA, IN PRESS J AM CHEM S; JORTNER J, 1980, BIOCHIM BIOPHYS ACTA, V594, P193, DOI 10.1016/0304-4173(80)90001-4; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; ONUCHIC JN, 1990, J CHEM PHYS, V92, P722, DOI 10.1063/1.458426; ONUCHIC JN, 1991, PHYS REV A, V43, P4500; PETERSONKENNEDY SE, 1986, J AM CHEM SOC, V108, P1739, DOI 10.1021/ja00268a004; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054	24	684	690	0	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1285	1288		10.1126/science.1656523	http://dx.doi.org/10.1126/science.1656523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1656523				2022-12-01	WOS:A1991FN85700032
J	CROSS, FR; TINKELENBERG, AH				CROSS, FR; TINKELENBERG, AH			A POTENTIAL POSITIVE FEEDBACK LOOP CONTROLLING CLN1 AND CLN2 GENE-EXPRESSION AT THE START OF THE YEAST-CELL CYCLE	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MATING-PHEROMONE; FISSION YEAST; DIVISION; CONJUGATION; MITOSIS; ARREST	The CLN1, CLN2, and CLN3 genes of S. cerevisiae form a redundant family essential for the G1-to-S phase transition. CLN1 and CLN2 mRNAs were previously shown to be negatively regulated by mating pheromone and by cell cycle progression out of G1, whereas CLN3 mRNA is not. The CLN3-2 (DAF1-1) allele prevents both cell cycle arrest and the turnoff of CLN1 and CLN2 mRNAs in response to mating pheromone, but only in the presence of an active CDC28 gene. An internally deleted nonfunctional cln2 gene was used as a reporter gene to demonstrate that in the absence of mating pheromone, efficient expression of cln2 mRNA requires both an active CDC28 gene and at least one functional CLN gene. mRNA from a nonfunctional cln1 gene was regulated similarly. Thus, CLN function and CDC28 activity jointly stimulate CLN1 and CLN2 mRNA levels, potentially forming a positive feedback loop for CLN1 and CLN2 expression.			CROSS, FR (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.							Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; CARTER BLA, 1980, GENETICS, V96, P561; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, 1989, J CELL SCI S12, V94, P117; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SHERMAN F, 1989, METHODS YEAST GENETI; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	37	297	299	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					875	883		10.1016/0092-8674(91)90394-E	http://dx.doi.org/10.1016/0092-8674(91)90394-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040016				2022-12-01	WOS:A1991FP51600017
J	ENG, FJ; WARNER, JR				ENG, FJ; WARNER, JR			STRUCTURAL BASIS FOR THE REGULATION OF SPLICING OF A YEAST MESSENGER-RNA	CELL			English	Article							RIBOSOMAL-PROTEIN GENE; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; BINDING PROTEINS; EXON SEQUENCES; DNA FRAGMENTS; SEX-LETHAL; EXPRESSION; LEVEL; ELEMENTS	In S. cerevisiae, ribosomal protein L32 regulates the splicing of the transcript of its own gene, RPL32. We have identified an RNA structure within the transcript that is responsible for this regulation. Initial deletions limited essential sequences to the 5' exon and the first few nucleotides of the intron. To take advantage of phylogenetic comparison of RNA structures, RPL32 was cloned from the closely related species, Kluyveromyces lactis. The splicing of its transcript is similarly regulated. Sequences conserved between the S. cerevisiae and K. lactis transcripts suggested a structure involving base pairing of a region encompassing the 5' splice site with another near the 5' end of the transcript. Analysis of numerous site-directed mutations supports this structure. We infer that stabilization of this structure by L32 inhibits splicing by precluding the interaction of U1 RNA with the 5' splice site.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	ENG, FJ (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.				NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM25532, 5T32GM07128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532, T32GM007128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOZZONI I, 1984, J MOL BIOL, V180, P987, DOI 10.1016/0022-2836(84)90267-5; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DRAPER DE, 1989, TRENDS BIOCHEM SCI, V14, P335, DOI 10.1016/0968-0004(89)90167-9; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUTELL RR, 1986, EMBO J, V5, P1111, DOI 10.1002/j.1460-2075.1986.tb04330.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; KIM CH, 1983, J MOL BIOL, V165, P79, DOI 10.1016/S0022-2836(83)80243-5; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; KRUSE C, 1985, P NATL ACAD SCI USA, V82, P7515, DOI 10.1073/pnas.82.22.7515; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P5027, DOI 10.1093/nar/13.14.5027; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; McKeown M, 1990, Genet Eng (N Y), V12, P139; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NEWMAN A, 1987, EMBO J, V6, P3833, DOI 10.1002/j.1460-2075.1987.tb02720.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PEARSON NJ, 1982, CELL, V29, P347, DOI 10.1016/0092-8674(82)90151-9; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; POTASHKIN JA, 1990, MOL CELL BIOL, V10, P3524, DOI 10.1128/MCB.10.7.3524; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWIDA U, 1988, YEAST, V4, P209, DOI 10.1002/yea.320040306; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WITTEKIND M, 1990, MOL CELL BIOL, V10, P2049, DOI 10.1128/MCB.10.5.2049; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WRAY LV, 1987, MOL CELL BIOL, V7, P1111, DOI 10.1128/MCB.7.3.1111; WRNER JR, 1977, J CELL BIOL, V80, P767	54	145	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					797	804		10.1016/0092-8674(91)90387-E	http://dx.doi.org/10.1016/0092-8674(91)90387-E			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040015				2022-12-01	WOS:A1991FP51600010
J	EVAVOLD, BD; ALLEN, PM				EVAVOLD, BD; ALLEN, PM			SEPARATION OF IL-4 PRODUCTION FROM TH-CELL PROLIFERATION BY AN ALTERED T-CELL RECEPTOR LIGAND	SCIENCE			English	Article							ANTIGEN-PRESENTATION; B-CELLS; ACTIVATION; EXPRESSION; INVIVO; IDENTIFICATION; HYDROLYSIS; MOLECULES; RESPONSES; PATHWAYS	In the presence of antigen presenting cells, a murine T helper (Th) cell specific for murine hemoglobin (Hb) responded to its immunogenic peptide by both cytokine (interleukin-4) secretion and proliferation. An altered Hb peptide with a single amino acid substitution induced only cytokine secretion and did not induce proliferation. Interleukin-1 costimulated and restored the Th proliferative response to normal levels. The altered peptide also supported cognate T cell-B cell interactions indicative of T cell helper function. Thus, this result suggests that the T cell receptor has the capacity of differential signaling.	WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Evavold, Brian/0000-0002-3561-3494	NIAID NIH HHS [AI24157] Funding Source: Medline; NIEHS NIH HHS [ESO7066] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024157, R37AI024157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007066] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EVAVOLD BD, UNPUB; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KRZYCH U, 1982, J IMMUNOL, V128, P1529; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; OROURKE AM, 1990, SCIENCE, V249, P171, DOI 10.1126/science.2164711; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIGETA M, 1986, J IMMUNOL, V136, P34; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TITE JP, 1987, J IMMUNOL, V139, P2892; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181	22	539	566	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1308	1310		10.1126/science.1833816	http://dx.doi.org/10.1126/science.1833816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1833816				2022-12-01	WOS:A1991FN85700040
J	FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J				FROMHERZ, P; OFFENHAUSSER, A; VETTER, T; WEIS, J			A NEURON-SILICON JUNCTION - A RETZIUS CELL OF THE LEECH ON AN INSULATED-GATE FIELD-EFFECT TRANSISTOR	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MICROELECTRODE ARRAY; PLANAR; POTENTIALS; CULTURE; INVITRO	An identified neuron of the leech, a Retzius cell, has been attached to the open gate of a p-channel field-effect transistor. Action potentials, spontaneous or stimulated, modulate directly the source-drain current in silicon. The electronic signals match the shape of the action potential. The average voltage on the gate was up to 25 percent of the intracellular voltage change. Occasionally weak signals that resemble the first derivative of the action potential were observed. The junctions can be described by a model that includes capacitive coupling of the plasma membrane and the gate oxide and that accounts for variable resistance of the seal.			FROMHERZ, P (corresponding author), UNIV ULM,BIOPHYS ABT,W-7900 ULM,GERMANY.		Offenhäusser, Andreas/E-7990-2012	Offenhäusser, Andreas/0000-0001-6143-2702				BERGVELD P, 1976, IEEE T BIO-MED ENG, V23, P136, DOI 10.1109/TBME.1976.324574; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAKE KL, 1988, IEEE T BIO-MED ENG, V35, P719, DOI 10.1109/10.7273; GROSS GW, 1977, NEUROSCI LETT, V6, P101, DOI 10.1016/0304-3940(77)90003-9; JOBLING DT, 1981, MED BIOL ENG COMPUT, V19, P553, DOI 10.1007/BF02442768; KUPERSTEIN M, 1985, NEUROSCIENCE, V15, P703, DOI 10.1016/0306-4522(85)90072-7; NOVAK JL, 1986, IEEE T BIO-MED ENG, V33, P196, DOI 10.1109/TBME.1986.325891; PARSONS TD, 1989, BIOPHYS J, V56, P213, DOI 10.1016/S0006-3495(89)82666-9; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; REGEHR WG, 1988, IEEE T BIO-MED ENG, V35, P1023, DOI 10.1109/10.8687; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; TAKAHASHI K, 1984, SENSOR ACTUATOR, V5, P89, DOI 10.1016/0250-6874(84)87009-2; Wolf S., 1986, PROCESS TECHNOL INT, V1, P199	13	450	468	0	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1290	1293		10.1126/science.1925540	http://dx.doi.org/10.1126/science.1925540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925540				2022-12-01	WOS:A1991FN85700034
J	HALL, DH; HEDGECOCK, EM				HALL, DH; HEDGECOCK, EM			KINESIN-RELATED GENE UNC-104 IS REQUIRED FOR AXONAL-TRANSPORT OF SYNAPTIC VESICLES IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTION; CELL; MIGRATIONS; EXPRESSION; SYNAPSIN; NEURONS; MUTANTS; GROWTH	unc-104 encodes a novel kinesin paralog that may act as a microtubule-based motor in the nervous system. Neuronal cell lineages and axonogenesis are normal in unc-104 null mutants, but axons have few synaptic vesicles and make only a few small synapses. By contrast, neuron cell bodies have surfeits of similar vesicles tethered together within the cytoplasm. Based on behavioral and cellular phenotypes, we suggest that UNC-104 is a neuron-specific motor used for anterograde translocation of synaptic vesicles along axonal microtubules. Other membrane-bounded organelles are transported normally.	ROCHE INST MOLEC BIOL,DEPT CELL & DEV BIOL,NUTLEY,NJ 07110; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	HALL, DH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS07512, NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BLACK MM, 1989, TRENDS NEUROSCI, V12, P211, DOI 10.1016/0166-2236(89)90124-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHENG TPO, 1988, J NEUROSCI, V8, P3190; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; HALL DH, 1991, J NEUROSCI, V11, P1; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MORI I, 1988, GENETICS, V120, P397; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROGALSKI TM, 1988, GENETICS, V118, P61; ROSE M, 1991, GUIDE CYTOSKELETAL S; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHUBERT D, 1991, TRENDS NEUROSCI, V14, P127, DOI 10.1016/0166-2236(91)90078-9; SIGURDSON DC, 1984, GENETICS, V108, P331; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS JH, 1990, GENETICS, V124, P855; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VENOLIA L, 1990, GENETICS, V126, P345; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; [No title captured]	43	439	447	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					837	847		10.1016/0092-8674(91)90391-B	http://dx.doi.org/10.1016/0092-8674(91)90391-B			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710172				2022-12-01	WOS:A1991FP51600014
J	KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB				KASLOW, DC; ISAACS, SN; QUAKYI, IA; GWADZ, RW; MOSS, B; KEISTER, DB			INDUCTION OF PLASMODIUM-FALCIPARUM TRANSMISSION-BLOCKING ANTIBODIES BY RECOMBINANT VACCINIA VIRUS	SCIENCE			English	Article							SEXUAL STAGES; EXPRESSION; ANTIGENS; SURFACE	Many candidate antigens of malaria vaccines have limited immunological recognition. One exception is Pfs25, a cysteine-rich, 25-kilodalton sexual stage surface protein of Plasmodium falciparum. Pfs25 is a target of monoclonal antibodies that block transmission of malaria from vertebrate host to mosquito vector. The surface of mammalian cells infected with a recombinant vaccinia virus that expressed Pfs25 specifically bound transmission-blocking monoclonal antibodies. Furthermore, major histocompatibility complex-disparate congenic mouse strains immunized with recombinant Pfs25 elicited transmission-blocking antibodies, demonstrating that the capacity to develop transmission-blocking antibodies is not genetically restricted in mice. Live recombinant viruses may provide an inexpensive, easily administered alternative to subunit vaccines prepared from purified recombinant proteins to block transmission of malaria in developing countries.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KASLOW, DC (corresponding author), NIAID,PARASIT DIS LAB,BETHESDA,MD 20892, USA.		Isaacs, Stuart/HGA-3405-2022	Moss, Bernard/0000-0002-2154-8564				ANDREW ME, 1989, IMMUNOL CELL BIOL, V67, P331, DOI 10.1038/icb.1989.48; CARTER R, 1988, PROG ALLERGY, V41, P193; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; GOOD MF, 1988, SCIENCE, V242, P574, DOI 10.1126/science.2902690; ISAACS S, UNPUB; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KASLOW DC, UNPUB; LANGFORD CJ, 1986, MOL CELL BIOL, V6, P3191, DOI 10.1128/MCB.6.9.3191; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; PONNUDURAI T, 1987, T ROY SOC TROP MED H, V81, P491, DOI 10.1016/0035-9203(87)90172-6; QUAKYI I, UNPUB; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; QUAKYI IA, 1980, TROP MED PARASITOL, V42, P325; SADOFF J, COMMUNICATION; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460	16	70	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1310	1313		10.1126/science.1925544	http://dx.doi.org/10.1126/science.1925544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925544				2022-12-01	WOS:A1991FN85700041
J	LAWRENCE, MB; SPRINGER, TA				LAWRENCE, MB; SPRINGER, TA			LEUKOCYTES ROLL ON A SELECTIN AT PHYSIOLOGICAL FLOW-RATES - DISTINCTION FROM AND PREREQUISITE FOR ADHESION THROUGH INTEGRINS	CELL			English	Article							INCREASED SURFACE EXPRESSION; GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; NEUTROPHIL ADHERENCE; INTERCELLULAR-ADHESION; ENDOTHELIAL-CELLS; BLOOD-FLOW; TRANSENDOTHELIAL MIGRATION; VASCULAR ENDOTHELIUM; CULTURED ENDOTHELIUM	Rolling of leukocytes on vascular endothelial cells, an early event in inflammation, can be reproduced in vitro on artificial lipid bilayers containing purified CD62, a selectin also named PADGEM and GMP-140 that is inducible on endothelial cells. Neutrophils roll onthis selectin under flow conditions similar to those found in postcapillary venules. Adhesion of resting or activated neutrophils through the integrins LFA-1 and Mac-1 to ICAM-1 in a lipid bilayer does not occur at physiologic shear stresses; however, static incubation of activated neutrophils allows development of adhesion that is greater than 100-fold more shear resistant than found on CD62. Addition of a chemoattractant to activate LFA-1 and Mac-1 results in the arrest of neutrophils rolling on bilayers containing both CD62 and ICAM-1. Thus, at physiologic shear stress, rolling on a selectin is a prerequisite for activation-induced adhesion strengthening through integrins.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LAWRENCE, MB (corresponding author), HARVARD UNIV,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [CA 31799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031799, R37CA031799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; ARFORS KE, 1987, BLOOD, V69, P338; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; BUCHANAN MR, 1982, BLOOD, V60, P160; BUYON JP, 1988, J IMMUNOL, V140, P3156; Chien S, 1982, Adv Shock Res, V8, P71; COHNHEIM J, 1989, LECTURES GENERAL PAT; DEFOUGEROLLES AR, 1991, IN PRESS J EXP MED; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FIEBIG E, 1991, INT J MICROCIRC, V10, P127; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GOLDSMITH HL, 1984, MICROVASC RES, V27, P204, DOI 10.1016/0026-2862(84)90054-2; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HARLAN JM, 1985, BLOOD, V66, P167; HATTORI R, 1989, J BIOL CHEM, V264, P7768; Heisig N., 1968, ADV MICROCIRCULAT, V1, P89; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JUTILA MA, 1989, J IMMUNOL, V143, P3318; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAWRENCE MB, 1990, BLOOD, V75, P227; LAWRENCE MB, 1987, BLOOD, V70, P1284; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MARCHESI VT, 1961, Q J EXP PHYSIOL CMS, V46, P115, DOI 10.1113/expphysiol.1961.sp001522; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NOBIS U, 1985, MICROVASC RES, V29, P295, DOI 10.1016/0026-2862(85)90020-2; PHILIPS MR, 1988, J CLIN INVEST, V82, P495, DOI 10.1172/JCI113623; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; PRICE TH, 1987, J IMMUNOL, V139, P4174; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; Tanford C., 1961, PHYS CHEM MACROMOLEC; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WATTS TH, 1986, NATURE, V320, P179, DOI 10.1038/320179a0; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351	68	1983	2045	2	78	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					859	873		10.1016/0092-8674(91)90393-D	http://dx.doi.org/10.1016/0092-8674(91)90393-D			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710173				2022-12-01	WOS:A1991FP51600016
J	MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ				MAHADEVAN, LC; WILLIS, AC; BARRATT, MJ			RAPID HISTONE H3 PHOSPHORYLATION IN RESPONSE TO GROWTH-FACTORS, PHORBOL ESTERS, OKADAIC ACID, AND PROTEIN-SYNTHESIS INHIBITORS	CELL			English	Article							SWISS 3T3 CELLS; C-FOS; KINASE-C; CHROMATIN STRUCTURE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CELLULAR-REGULATION; REVERSIBLE CHANGES	When quiescent cells are stimulated with growth factors, phorbol esters, okadaic acid, or protein synthesis inhibitors, the early-response genes, which include c-fos and c-jun, are rapidly induced. The earliest growth factor- and phorbol ester-stimulated nuclear signaling events concomitant with proto-oncogene induction are the rapid phosphorylation of two chromatin-associated proteins, pp33 and pp15. We show here that the tumor promoter okadaic acid, which inhibits protein phosphatases 1 and 2A, and the protein synthesis inhibitors anisomycin and cycloheximide also stimulate pp33 and pp15 phosphorylation. Using transcriptional inhibitors, we show that this response is not a consequence of early gene induction. By peptide mapping and microsequencing, chromatin-associated pp15 is identified as histone H3. Upon stimulation, histone H3 is rapidly phosphorylated on serine residues within its highly charged, basic N-terminal domain. Thus, these diverse agents elicit a common early nuclear signal modulating nucleosomal structure or function, potentially contributing to conformational regulation of proto-oncogene induction.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford								ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL HA, 1990, IN PRESS CELLULAR RE; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dixon G. H., 1975, CIBA F S, V28, P229; FALK MM, 1990, J VIROL, V64, P748, DOI 10.1128/JVI.64.2.748-756.1990; FENG JL, 1990, MOL CELL BIOL, V10, P1126, DOI 10.1128/MCB.10.3.1126; GLOTOV BO, 1978, FEBS LETT, V91, P149, DOI 10.1016/0014-5793(78)80037-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HARDISON RC, 1977, CELL, V12, P417, DOI 10.1016/0092-8674(77)90118-0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JONES SD, 1988, COLD SPRING HARB SYM, V53, P531, DOI 10.1101/SQB.1988.053.01.061; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIM RW, 1987, ONCOGENE, V1, P263; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MAHADEVAN LC, 1989, ONCOGENE, V4, P699; MAHADEVAN LC, 1988, ONCOGENE, V2, P249; MAHADEVAN LC, 1990, ONCOGENE, V5, P327; MAHADEVAN LC, 1990, RECEPTOR EFFECTOR CO, P181; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAPINSKI BR, 1986, NATURE, V321, P81; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PYRWES R, 1988, P NATL ACAD SCI USA, V85, P7206; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, COLD SPRING HARB SYM, V53, P935; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; TAYLOR SS, 1982, J BIOL CHEM, V257, P6056; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VACQUIER VD, 1989, DEV BIOL, V133, P111, DOI 10.1016/0012-1606(89)90302-3; VAZQUEZ D, 1979, MOL BIOL BIOCH BIOPH, V130, P513; WELLS D, 1989, NUCLEIC ACIDS RES, V17, pR311, DOI 10.1093/nar/17.suppl.r311; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	60	388	402	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					775	783		10.1016/0092-8674(91)90385-C	http://dx.doi.org/10.1016/0092-8674(91)90385-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040014				2022-12-01	WOS:A1991FP51600008
J	MILNER, J; MEDCALF, EA				MILNER, J; MEDCALF, EA			COTRANSLATION OF ACTIVATED MUTANT P53 WITH WILD-TYPE DRIVES THE WILD-TYPE P53 PROTEIN INTO THE MUTANT CONFORMATION	CELL			English	Article							TUMOR SUPPRESSOR PROTEIN; HEAT-SHOCK PROTEINS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; LUNG-CANCER; IMMUNOLOGICAL VARIANTS; TRANSFORMED-CELLS; ONCOGENE; GENE; MUTATIONS	Activating mutations of p53 promote tumor progression. The mutant protein adopts a characteristic conformation, which lacks the growth suppressor function of wild-type p53. We show that mutant p53 can drive cotranslated wild-type p53 into the mutant conformation: a similar effect in vivo would block wild-type suppressor function with dominant negative effect. The cotranslational effect of mutant p53 on wild-type conformation depends upon interaction between nascent polypeptides and oligomerization of the full-length proteins. We also show that oligomers of p53 proteins can be induced to change conformation in a cooperative manner. Cell growth stimulation induces a similar conformational change in p53, and our present results indicate that this may involve allosteric regulation.			MILNER, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1222; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	38	619	637	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					765	774		10.1016/0092-8674(91)90384-B	http://dx.doi.org/10.1016/0092-8674(91)90384-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	2040013				2022-12-01	WOS:A1991FP51600007
J	SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ				SHON, KJ; KIM, YG; COLNAGO, LA; OPELLA, SJ			NMR-STUDIES OF THE STRUCTURE AND DYNAMICS OF MEMBRANE-BOUND BACTERIOPHAGE-PFL COAT PROTEIN	SCIENCE			English	Article							N-15 CHEMICAL-SHIFT; PHOTOSYNTHETIC REACTION CENTER; SOLID-STATE; SPECTROSCOPY; BACTERIORHODOPSIN; RESOLUTION; MICELLES; TENSORS; MODEL	Filamentous bacteriophage coat protein undergoes a remarkable structural transition during the viral assembly process as it is transferred from the membrane environment of the cell, where it spans the phospholipid bilayer, to the newly extruded virus particles. Nuclear magnetic resonance (NMR) studies show the membrane-bound form of the 46-residue Pfl coat protein to be surprisingly complex with five distinct regions. The secondary structure consists of a long hydrophobic helix (residues 19 to 42) that spans the bilayer and a short amphipathic helix (residues 6 to 13) parallel to the plane of the bilayer. The NH2-terminus (residues 1 to 5), the COOH-terminus (residues 43 to 46), and residues 14 to 18 connecting the two helices are mobile. By comparing the structure and dynamics of the membrane-bound coat protein with that of the viral form as determined by NMR and neutron diffraction, essential features of assembly process can be identified.	UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Colnago, Luiz Alberto/E-9693-2012	Colnago, Luiz Alberto/0000-0002-9516-9022	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020770] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02301] Funding Source: Medline; NIAID NIH HHS [AI20770-06] Funding Source: Medline; NIGMS NIH HHS [GM34343-06] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKY MJ, 1985, BIOCHEM BIOPH RES CO, V127, P540, DOI 10.1016/S0006-291X(85)80193-5; BOGUSKY MJ, 1987, J MAGN RESON, V72, P186, DOI 10.1016/0022-2364(87)90187-9; BOWERS JL, 1988, BIOCHEMISTRY-US, V27, P5156, DOI 10.1021/bi00414a031; CHIRLIAN LE, 1990, ADV MAGN RESON, V14, P183; COLNAGO LA, 1986, BIOMOLECULAR STEREOD, V3, P147; CROSS TA, 1980, BIOCHEM BIOPH RES CO, V92, P478, DOI 10.1016/0006-291X(80)90358-7; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; HARBISON GS, 1984, J MAGN RESON, V60, P79, DOI 10.1016/0022-2364(84)90027-1; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5967; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENRY GD, 1990, BIOCHEMISTRY-US, V29, P6303, DOI 10.1021/bi00478a027; KENIRY MA, 1984, NATURE, V307, P383, DOI 10.1038/307383a0; LEO GC, 1987, BIOCHEMISTRY-US, V26, P854, DOI 10.1021/bi00377a029; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; OAS TG, 1987, J AM CHEM SOC, V109, P5962, DOI 10.1021/ja00254a011; Opella S J, 1986, Methods Enzymol, V131, P327; OPELLA SJ, 1987, Q REV BIOPHYS, V19, P7, DOI 10.1017/S0033583500004017; OPELLA SJ, 1989, METHOD ENZYMOL, V176, P242; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; ROWITCH DH, 1987, J MOL BIOL, V195, P873, DOI 10.1016/0022-2836(87)90491-8; SCHIKSNIS RA, 1987, BIOCHEMISTRY-US, V26, P1373, DOI 10.1021/bi00379a025; SHON K, 1989, J MAGN RESON, V82, P193, DOI 10.1016/0022-2364(89)90182-0; SHON K, UNPUB; TENG Q, 1989, J MAGN RESON, V85, P439, DOI 10.1016/0022-2364(89)90235-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	25	152	152	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1303	1304		10.1126/science.1925542	http://dx.doi.org/10.1126/science.1925542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925542				2022-12-01	WOS:A1991FN85700038
J	SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C				SIEGEL, JM; NIENHUIS, R; FAHRINGER, HM; PAUL, R; SHIROMANI, P; DEMENT, WC; MIGNOT, E; CHIU, C			NEURONAL-ACTIVITY IN NARCOLEPSY - IDENTIFICATION OF CATAPLEXY-RELATED CELLS IN THE MEDIAL MEDULLA	SCIENCE			English	Article							RETICULAR-FORMATION NEURONS; LOWER BRAIN-STEM; UNRESTRAINED CAT; REM-SLEEP; CHOLINE-ACETYLTRANSFERASE; BEHAVIORAL ORGANIZATION; PONTINE TEGMENTUM; MOVEMENTS; ATONIA; PROJECTIONS	Narcolepsy is a neurological disorder characterized by sleepiness and episodes of cataplexy. Cataplexy is an abrupt loss of muscle tone, most often triggered by sudden, strong emotions. A subset of cells in the medial medulla of the narcoleptic dog discharged at high rates only in cataplexy and rapid eye movement (REM) sleep. These cells were noncholinergic and were localized to ventromedial and caudal portions of the nucleus magnocellularis. The localization and discharge pattern of these cells indicate that cataplexy results from a triggering in waking of the neurons responsible for the suppression of muscle tone in REM sleep. However, most medullary cells were inactive during cataplexy but were active during REM sleep. These data demonstrate that cataplexy is a distinct behavioral state, differing from other sleep and waking states in its pattern of brainstem neuronal activity.	VET AFFAIRS MED CTR,DEPT PSYCHIAT,SAN DIEGO,CA; STANFORD UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,STANFORD,CA 94305; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SIEGEL, JM (corresponding author), VET AFFAIRS MED CTR,SEPULVEDA,CA 91343, USA.			Chiu, Charles/0000-0003-2915-2094	NHLBI NIH HHS [R01 HL041370, R37 HL041370, HL41370] Funding Source: Medline; NIMH NIH HHS [R01 MH064109] Funding Source: Medline; NINDS NIH HHS [P50 NS023724, R01 NS014610, NS23724, NS14610, R37 NS014610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL041370, R01HL041370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023724, R01NS014610, R37NS014610, P50NS023724] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH MS, 1989, SLEEP, V12, P254, DOI 10.1093/sleep/12.3.254; Baker TL, 1985, BRAIN MECH SLEEP, P199; BILLIARD M, 1985, ANN CLIN RES, V17, P220; CHASE MH, 1989, J NEUROSCI, V9, P743; CHASE MH, 1983, INT REV NEUROBIOL, V24, P213, DOI 10.1016/S0074-7742(08)60223-8; FORT P, 1990, CR ACAD SCI III-VIE, V311, P205; GUILLEMINAULT C, 1988, LANCET, V2, P511; GUILLEMINAULT C, 1976, NARCOLEPSY, P125; HENLEY K, 1974, ACTA NEUROBIOL EXP, V34, P215; Honda Y, 1984, FOLIA PSYCHIATR NEUR, V38, P360; JANKOWSKA E, 1968, ARCH ITAL BIOL, V106, P124; JOUVET M, 1965, CR SOC BIOL, V159, P895; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; LAI YY, 1988, J NEUROSCI, V8, P4790; LAI YY, 1989, SOC NEUR ABSTR, V17, P391; Lim R. K. S., 1960, STEREOTAXIC ATLAS DO; MCGINTY DJ, 1976, SCIENCE, V193, P240; MIGNOT E, 1989, BRAIN RES, V500, P1; MITLER MM, 1987, PSYCHIAT CLIN N AM, V10, P593; MITLER MM, 1974, EXP NEUROL, V45, P332, DOI 10.1016/0014-4886(74)90122-8; MORALES FR, 1982, SLEEP RES, V11, P26; MORI S, 1987, PROG NEUROBIOL, V28, P161, DOI 10.1016/0301-0082(87)90010-4; NETICK A, 1977, BRAIN RES, V120, P197, DOI 10.1016/0006-8993(77)90900-3; RECHTSCHAFFEN A, 1963, ELECTROEN CLIN NEURO, V15, P599, DOI 10.1016/0013-4694(63)90032-4; SAKAI K, 1990, BRAIN RES BULL, V24, P437, DOI 10.1016/0361-9230(90)90098-K; Sakai K., 1980, RETICULAR FORMATION, P427; SCHENKEL E, 1989, NEUROSCI LETT, V98, P159, DOI 10.1016/0304-3940(89)90503-X; SHIROMANI PJ, 1990, BRAIN RES, V517, P224, DOI 10.1016/0006-8993(90)91030-K; SHIROMANI PJ, 1988, SLEEP, V11, P1; Siegel J., UNPUB; SIEGEL JM, 1979, EXP NEUROL, V65, P691, DOI 10.1016/0014-4886(79)90055-4; SIEGEL JM, 1978, SCIENCE, V199, P207; SIEGEL JM, 1979, BRAIN RES REV, V1, P69, DOI 10.1016/0165-0173(79)90017-1; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P696, DOI 10.1152/jn.1983.50.3.696; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P717, DOI 10.1152/jn.1983.50.3.717; SIEGEL JM, 1979, BRAIN RES, V179, P49, DOI 10.1016/0006-8993(79)90488-8; SUZUKI SS, 1989, BRAIN RES, V484, P78, DOI 10.1016/0006-8993(89)90350-8; TOHYAMA M, 1979, BRAIN RES, V173, P383, DOI 10.1016/0006-8993(79)90237-3; VINCENT SR, 1987, BRAIN RES BULL, V18, P371, DOI 10.1016/0361-9230(87)90015-3	39	109	110	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1315	1318		10.1126/science.1925546	http://dx.doi.org/10.1126/science.1925546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925546	Green Accepted			2022-12-01	WOS:A1991FN85700043
J	SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF				SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF			THE NEUROTROPHIC FACTORS BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 ARE LIGANDS FOR THE TRKB TYROSINE KINASE RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; PDGF BETA-RECEPTOR; MOLECULAR-CLONING; FACTOR FAMILY; SIGNALING COMPLEX; MESSENGER-RNA; GENE-TRANSFER; EXPRESSION; ONCOGENE; CELLS	Neurotrophic factors are essential for neuronal survival and function. Recent data have demonstrated that the product of the tyrosine kinase trk protooncogene binds NGF and is a component of the high affinity NGF receptor. Analysis of the trkB gene product, gp145trkB, in NIH 3T3 cells indicates that this tyrosine kinase receptor is rapidly phosphorylated on tyrosine residues upon exposure to the NGF-related neurotrophic factors BDNF and NT-3. Furthermore, gp145trkB specifically binds BDNF and NT-3 in NIH 3T3 cells and in hippocampal cells,but does not bind NGF. Thus, the trk family of receptors are likely to be important signal transducers of NGF-related trophic signals in the formation and maintenance of neuronal circuits.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA 94080; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Roche Holding; Genentech; Salk Institute	SOPPET, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC EMBRYOL SECT,FREDERICK,MD 21702, USA.		Parada, luis F/B-9400-2014		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Black I.B., 1990, Current Topics in Developmental Biology, V24, P161; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Cajal SR, 1909, HISTOLOGIE SYSTEME N; CHAO MV, 1990, HDB EXPT PHARM, P135; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HIGASHIYAMA S, 1991, SCIENCE, V251, P72; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MARTINZANCA D, 1990, AVIAN MODEL IN DEVELOPMENT BIOLOGY : FROM ORGANISM TO GENES, P291; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSENTHAL A, 1991, IN PRESS ENDOCRINOLO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SUTTER A, 1979, J BIOL CHEM, V254, P5972; VETTER ML, 1991, IN PRESS P NATL ACAD	56	715	743	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					895	903		10.1016/0092-8674(91)90396-G	http://dx.doi.org/10.1016/0092-8674(91)90396-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645620				2022-12-01	WOS:A1991FP51600019
J	SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD				SQUINTO, SP; STITT, TN; ALDRICH, TH; DAVIS, S; BIANCO, SM; RADZIEJEWSKI, C; GLASS, DJ; MASIAKOWSKI, P; FURTH, ME; VALENZUELA, DM; DISTEFANO, PS; YANCOPOULOS, GD			TRKB ENCODES A FUNCTIONAL RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 BUT NOT NERVE GROWTH-FACTOR	CELL			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NGF RECEPTOR; MOLECULAR-CLONING; GENE-TRANSFER; PROTO-ONCOGENE; FACTOR FAMILY; EXPRESSION; IDENTIFICATION; GANGLIA; DIFFERENTIATION	A variety of findings seem to functionally link brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), while distinguishing both of these factors from the third member of the neurotrophin family, nerve growth factor (NGF). Here we demonstrate that all three of these neuronal survival molecules bind similarly to the low affinity NGF receptor, but that BDNF and NT-3, unlike NGF, do not act via the high affinity NGF receptor. However, both BDNF and NT-3, but not NGF, bind to full-length and truncated forms of a receptor-like tyrosine kinase, trkB, for which no ligand had previously been identified. In addition to binding BDNF and NT-3, trkB can mediate functional responses to both of these neurotrophins when it is expressed in PC12 cells, although BDNF appears to be the more effective ligand. Thus trkB encodes an essential component of a functional receptor for BDNF and NT-3, but not for NGF. Further evidence predicts the existence of additional functional receptors for the neurotrophins.			SQUINTO, SP (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Glass, David/AAI-3910-2021					BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAISONPIERRE PC, 1991, IN PRESS GENOMICS; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, 1991, IN PRESS P NATL ACAD; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMANN A, 1978, J SUPRAMOL STR CELL, V9, P351, DOI 10.1002/jss.400090306	48	771	800	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					885	893		10.1016/0092-8674(91)90395-F	http://dx.doi.org/10.1016/0092-8674(91)90395-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710174				2022-12-01	WOS:A1991FP51600018
J	STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C				STEIN, D; ROTH, S; VOGELSANG, E; NUSSLEINVOLHARD, C			THE POLARITY OF THE DORSOVENTRAL AXIS IN THE DROSOPHILA EMBRYO IS DEFINED BY AN EXTRACELLULAR SIGNAL	CELL			English	Article							MATERNAL-EFFECT MUTATIONS; FEMALE-STERILE MUTATIONS; RECEPTOR TYROSINE KINASE; DORSAL-VENTRAL POLARITY; DNA-BINDING SUBUNIT; WILD-TYPE CYTOPLASM; TOLL GENE-PRODUCT; FAINT-LITTLE-BALL; NF-KAPPA-B; REL ONCOGENE	Twelve maternal effect loci are required for the production of Drosophila embryos with a correct dorsoventral axis. Analysis of mosaic females indicates that the expression of the genes nudel, pipe, and windbeutel is required in the somatic tissue, presumably in the follicle cells that surround the oocyte. Thus, information coming from outside the egg cell influences dorsoventral pattern formation during embryogenesis. In transplantation experiments, the perivitelline fluid from the compartment surrounding the embryo can restore dorsoventral pattern to embryos from females mutant for nudel, pipe, or windbeutel. The positioning of the transplanted pervitelline fluid also determines the polarity of the restored dorsoventral axis. We propose that the polarizing activity, normally present at the ventral side of the egg, is a ligand for the Toll receptor. Presumably, local activation of the Toll protein by the ligand initiates the formation of the nuclear concentration gradient of the dorsal protein, thereby determining dorsoventral pattern.			STEIN, D (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL, SPEMANNSTR 35, W-7400 TUBINGEN, GERMANY.		Roth, Siegfried/E-8241-2010	Roth, Siegfried/0000-0001-5772-3558; Vogelsang, Lisa/0000-0002-6817-5953				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSSON D, 1983, GENETICS, V105, P309; CamposOrtega J. A., 1985, EMBRYONIC DEV DROSOP, P9, DOI DOI 10.1007/978-3-662-22489-2_2; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FASANO L, 1988, DEVELOPMENT, V104, P245; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; IP YT, 1991, CELL, V64, P439; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; King RC., 1970, OVARIAN DEV DROSOPHI; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KONRAD KD, 1988, DEV BIOL, V127, P133, DOI 10.1016/0012-1606(88)90195-9; KONRAD KD, 1988, ROUX ARCH DEV BIOL, V197, P75, DOI 10.1007/BF00375930; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LIND JH, 1990, SLAVON E EUR REV, V68, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LINDSLEY DL, 1987, DROS INF SERV, V65, P40; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RICE TB, 1973, THESIS YALE U NEW HA; Roberts D.B., 1986, P1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL CELL ITNERACTIO; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; Wieschaus E., 1986, P199	58	220	226	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 31	1991	65	5					725	735		10.1016/0092-8674(91)90381-8	http://dx.doi.org/10.1016/0092-8674(91)90381-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1904007				2022-12-01	WOS:A1991FP51600004
J	VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V				VANOPSTAL, AJ; HEPP, K; HESS, BJM; STRAUMANN, D; HENN, V			2-DIMENSIONAL RATHER THAN 3-DIMENSIONAL REPRESENTATION OF SACCADES IN MONKEY SUPERIOR COLLICULUS	SCIENCE			English	Article							ALERT RHESUS-MONKEY; EYE-MOVEMENTS; OCULOMOTOR SYSTEM; LISTINGS LAW; STIMULATION; DEFICITS; NEURONS; COIL	Saccades are controlled by neurons in the brainstem reticular formation that receive input from the superior colliculus and cortex. Recently two quantitative models have been proposed for the role of the colliculus in the generation of three-dimensional eye movements. In order to test these models, three-dimensional eye movements were measured in the alert monkey to investigate whether the saccadic motor map of the superior colliculus is two-dimensional, representing retinal target vectors, or three-dimensional, representing three-dimensional motor error for the rotation of the eye. Electrical stimulation of the superior colliculus produced two-dimensional, not three-dimensional, eye movements. It is therefore concluded that the collicular motor map is two-dimensional.	UNIV HOSP ZURICH, DEPT NEUROL, CH-8091 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, DEPT PHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich			van Opstal, John/D-1907-2010	van Opstal, John/0000-0001-5957-5712				ALBANO JE, 1982, J NEUROPHYSIOL, V48, P338, DOI 10.1152/jn.1982.48.2.338; FERMAN L, 1987, VISION RES, V27, P811, DOI 10.1016/0042-6989(87)90078-2; HAUSTEIN W, 1989, BIOL CYBERN, V60, P411, DOI 10.1007/BF00204696; HENN V, 1991, VESTIBULAR BRAIN STE; HEPP K, 1990, COMMUN MATH PHYS, V132, P285, DOI 10.1007/BF02278012; HEPP K, 1990, Society for Neuroscience Abstracts, V16, P1084; HEPP K, 1989, NEUROBIOLOGY SACCADI, P105; HESS BJM, 1990, VISION RES, V30, P597, DOI 10.1016/0042-6989(90)90070-2; HIKOSAKA O, 1986, EXP BRAIN RES, V61, P531; HIKOSAKA O, 1985, J NEUROPHYSIOL, V53, P266, DOI 10.1152/jn.1985.53.1.266; JAY MF, 1987, J NEUROPHYSIOL, V57, P35, DOI 10.1152/jn.1987.57.1.35; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; RAYBOURN MS, 1977, J NEUROPHYSIOL, V40, P861, DOI 10.1152/jn.1977.40.4.861; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHILLER PH, 1980, J NEUROPHYSIOL, V44, P1175, DOI 10.1152/jn.1980.44.6.1175; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; SCHILLER PH, 1972, J NEUROPHYSIOL, V35, P915, DOI 10.1152/jn.1972.35.6.915; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; SPARKS DL, 1980, BRAIN RES, V190, P39, DOI 10.1016/0006-8993(80)91158-0; STRAUMANN D, 1990, EUR J NEUROSCI, V3, P163; STRAUMANN D, IN PRESS EXP BRAIN R; TWEED D, 1988, Society for Neuroscience Abstracts, V14, P958; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1988, ANN NY ACAD SCI, V545, P128; TWEED DB, 1990, NEURAL NETWORKS, V3, P75, DOI 10.1016/0893-6080(90)90046-N; VANOPSTAL AJ, 1990, EXP BRAIN RES, V79, P299, DOI 10.1007/BF00608239; VANOPSTAL AJ, 1990, SOC NEUR ABSTR, V16, P1084; von Helmholtz H, 1896, HDB PHYSL OPTIK; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	30	91	92	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	1991	252	5010					1313	1315		10.1126/science.1925545	http://dx.doi.org/10.1126/science.1925545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925545				2022-12-01	WOS:A1991FN85700042
J	VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST				VERKERK, AJMH; PIERETTI, M; SUTCLIFFE, JS; FU, YH; KUHL, DPA; PIZZUTI, A; REINER, O; RICHARDS, S; VICTORIA, MF; ZHANG, FP; EUSSEN, BE; VANOMMEN, GJB; BLONDEN, LAJ; RIGGINS, GJ; CHASTAIN, JL; KUNST, CB; GALJAARD, H; CASKEY, CT; NELSON, DL; OOSTRA, BA; WARREN, ST			IDENTIFICATION OF A GENE (FMR-1) CONTAINING A CGG REPEAT COINCIDENT WITH A BREAKPOINT CLUSTER REGION EXHIBITING LENGTH VARIATION IN FRAGILE-X SYNDROME	CELL			English	Article							SOMATIC-CELL HYBRIDS; GEL-ELECTROPHORESIS; MOLECULAR-CLONING; SITE; DNA; CHROMOSOME; SEQUENCES; FRAGMENTS; CONSTRUCTION; METHYLATION	Fragile X syndrome is the most frequent form of inherited mental retardation and is associated with a fragile site at Xq27.3. We identified human YAC clones that span fragile X site-induced translocation breakpoints coincident with the fragile X site. A gene (FMR-1) was identified within a four cosmid contig of YAC DNA that expresses a 4.8 kb message in human brain. Within a 7.4 kb EcoRl genomic fragment, containing FMR-1 exonic sequences distal to a CpG island previously shown to be hypermethylated in fragile X patients, is a fragile X site-induced breakpoint cluster region that exhibits length variation in fragile X chromosomes. This fragment contains a lengthy CGG repeat that is 250 bp distal of the CpG island and maps within a FMR-1 exon. Localization of the brain-expressed FMR-1 gene to this EcoRl fragment suggests the involvement of this gene in the phenotypic expression of the fragile X syndrome.	BAYLOR UNIV,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322; SYLVIUS LAB,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Emory University; Emory University; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	VERKERK, AJMH (corresponding author), ERASMUS UNIV,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS.		Sutcliffe, James S/C-1348-2012; Warren, Stephen T/A-2498-2012; Reiner, Orly/E-9455-2010	Sutcliffe, James S/0000-0001-5200-6007; Reiner, Orly/0000-0001-7560-9599; PIZZUTI, Antonio/0000-0003-3245-1925; Verkerk, Annemieke JMH/0000-0002-7523-3656	NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1989, NUCLEIC ACIDS RES, V17, P3425, DOI 10.1093/nar/17.9.3425; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KRAWCZUN MS, 1985, HUM GENET, V69, P209, DOI 10.1007/BF00293026; LEDBETTER DH, 1986, NATURE, V324, P161, DOI 10.1038/324161a0; LEE CH, 1987, NUCLEIC ACIDS RES, V15, P7639, DOI 10.1093/nar/15.18.7639; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINPONTHIEU A, 1991, EUR J BIOCHEM, V195, P611, DOI 10.1111/j.1432-1033.1991.tb15744.x; NELSON DL, 1991, IN PRESS P NATL ACAD; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, AM J MED GENET, V23, P715, DOI 10.1002/ajmg.1320230162; NUSSBAUM RL, 1990, METABOLIC BASIS INHE, P327; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; Sambrook J., 1989, MOL CLONING LAB MANU; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; Smith C.L., 1988, P41; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTHERLAND GR, 1985, FRAGILE SITES HUMAN, P53; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VANOMMEN GJB, 1986, HUMAN GENETIC DISEAS, P113; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1988, AM J MED GENET, V30, P613, DOI 10.1002/ajmg.1320300162; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WARREN ST, 1987, SCIENCE, V237, P420, DOI 10.1126/science.3603029; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759; YU S, 1991, IN PRESS FRAGILE X G	40	2804	2887	3	151	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					905	914		10.1016/0092-8674(91)90397-H	http://dx.doi.org/10.1016/0092-8674(91)90397-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1710175				2022-12-01	WOS:A1991FP51600020
J	WILSON, DK; RUDOLPH, FB; QUIOCHO, FA				WILSON, DK; RUDOLPH, FB; QUIOCHO, FA			ATOMIC-STRUCTURE OF ADENOSINE-DEAMINASE COMPLEXED WITH A TRANSITION-STATE ANALOG - UNDERSTANDING CATALYSIS AND IMMUNODEFICIENCY MUTATIONS	SCIENCE			English	Article							POINT MUTATION; XANTHINE-OXIDASE; ESCHERICHIA-COLI; INHIBITORS; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; TRANSPORT; CRYSTALLOGRAPHY	The crystal structure of a murine adenosine deaminase complexed with 6-hydroxyl-1,6-dihydropurine ribonucleoside, a nearly ideal transition-state analog, has been determined and refined at 2.4 angstrom resolution. The structure is folded as an eight-stranded parallel alpha/beta-barrel with a deep pocket at the beta-barrel COOH-terminal end wherein the inhibitor and a zinc are bound and completely sequestered. The presence of the zinc cofactor and the precise structure of the bound analog were not previously known. The 6R isomer of the analog is very tightly held in place by the coordination of the 6-hydroxyl to the zinc and the formation of nine hydrogen bonds. On the basis of the structure of the complex a stereoselective addition-elimination or S(N)2 mechanism of the enzyme is proposed with the zinc atom and the Glu and Asp residues playing key roles. A molecular explanation of a hereditary disease caused by several point mutations of an enzyme is also presented.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005	Baylor University; Howard Hughes Medical Institute; Rice University					NATIONAL CANCER INSTITUTE [R01CA014030] Funding Source: NIH RePORTER; NCI NIH HHS [CA14030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; AKESON AL, 1987, P NATL ACAD SCI USA, V84, P5947, DOI 10.1073/pnas.84.16.5947; AKESON AL, 1989, J CELL BIOCHEM, V39, P217, DOI 10.1002/jcb.240390302; AKESON AL, 1988, J BIOL CHEM, V263, P16291; ASHTON D, 1987, EUR J PHARMACOL, V142, P403, DOI 10.1016/0014-2999(87)90079-3; BONTHRON DT, 1985, J CLIN INVEST, V76, P894, DOI 10.1172/JCI112050; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; COOPER BT, UNPUB; COWAN MJ, 1983, P NATL ACAD SCI USA, V83, P1089; DAWICKI DD, 1988, BIOCHEM PHARMACOL, V37, P621, DOI 10.1016/0006-2952(88)90134-7; EVANS BE, 1973, BIOCHEMISTRY-US, V12, P392, DOI 10.1021/bi00727a005; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GAN TE, 1987, BLOOD, V69, P1376; GLAZER RI, 1980, CANCER CHEMOTH PHARM, V4, P227; GROSS RL, 1980, PHYSIOL REV, V60, P188, DOI 10.1152/physrev.1980.60.1.188; HAMPTON A, 1972, BIOCHEMISTRY-US, V11, P4736, DOI 10.1021/bi00775a016; Harrison MP., UNPUB; HIRSCHHORN R, 1989, J CLIN INVEST, V83, P497, DOI 10.1172/JCI113909; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; IKEHARA M, 1974, BIOCHIM BIOPHYS ACTA, V338, P512, DOI 10.1016/0304-4165(74)90313-4; IKEHARA M, 1972, BIOCHIM BIOPHYS ACTA, V11, P4736; JONES W, 1989, BIOCHEMISTRY-US, V28, P12242; KANNO H, 1988, JPN J EXP MED, V58, P1; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P8450, DOI 10.1021/bi00399a063; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; KURZ LC, 1980, BIOCHEMISTRY-US, V19, P1616; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LOLIS E, 1990, ANNU REV BIOCHEM, V59, P597, DOI 10.1146/annurev.bi.59.070190.003121; MAQUIRE MH, 1971, EUR J BIOCHEM, V23, P22; MARTIN DW, 1981, ANNU REV BIOCHEM, V50, P845, DOI 10.1146/annurev.bi.50.070181.004213; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mcilwain H., 1983, CENTRAL NERVOUS SYST, P3; MILLER DM, 1983, J BIOL CHEM, V258, P3665; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P3386, DOI 10.1021/bi00768a011; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; RENOUF JA, 1989, CLIN CHEM, V35, P1478; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAWA T, 1967, J ANTIBIOT, V20, P317; SCHRAMM VL, 1985, BIOCHEMISTRY-US, V24, P641, DOI 10.1021/bi00324a016; VALERIO D, 1986, EMBO J, V5, P113, DOI 10.1002/j.1460-2075.1986.tb04184.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISS PM, 1987, BIOCHEMISTRY-US, V26, P7378, DOI 10.1021/bi00397a027; WILSON DJ, UNPUB; WILSON DK, 1988, J MOL BIOL, V200, P613, DOI 10.1016/0022-2836(88)90549-9; WOLFENDEN R, 1967, J BIOL CHEM, V242, P977; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V8, P2412, DOI 10.1021/bi00834a024; WOLFENDEN R, 1969, BIOCHEMISTRY-US, V16, P5071; WOO PWK, 1974, J HETEROCYCLIC CHEM, V11, P641, DOI 10.1002/jhet.5570110438; YEUNG CY, 1985, J BIOL CHEM, V260, P299; ZIELKE CL, 1971, ENZYMES, V4, P47	60	454	464	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1278	1284		10.1126/science.1925539	http://dx.doi.org/10.1126/science.1925539			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925539				2022-12-01	WOS:A1991FN85700031
J	WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J				WILSON, TE; FAHRNER, TJ; JOHNSTON, M; MILBRANDT, J			IDENTIFICATION OF THE DNA-BINDING SITE FOR NGFI-B BY GENETIC SELECTION IN YEAST	SCIENCE			English	Article							HORMONE RECEPTOR SUPERFAMILY; COUP TRANSCRIPTION FACTOR; SEQUENCE-ANALYSIS; ACTIVATOR PROTEIN; MAMMALIAN-CELLS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; INDUCIBLE MEMBER; GAMMA-SUBUNIT; II GENE	An in vivo selection system for isolating targets of DNA binding proteins in yeast was developed and used to identify the DNA binding site for the NGFI-B protein, a member of the steroid-thyroid hormone receptor superfamily. The feasibility of the technique was verified by selecting DNA fragments that contained binding sites for GCN4, a well-characterized yeast transcriptional activator. The DNA binding domain of NGFI-B, expressed as part of a LexA-NGFI-B-GAL4 chimeric activator, was then used to isolate a rat genomic DNA fragment that contained an NGFI-B binding site. The NGFI-B response element (NBRE) is similar to but functionally distinct from elements recognized by the estrogen and thyroid hormone receptors and the hormone receptor-like proteins COUP-TF, CF1, and H-2RIIBP. Cotransfection experiments in mammalian cells demonstrated that NGFI-B can activate transcription from the NBRE with or without its putative ligand binding domain.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MILBRANDT, J (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110, USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [P01 CA49712] Funding Source: Medline; NINDS NIH HHS [NS01018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BALCKHART BD, 1986, J BIOL CHEM, V261, P15364; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHAPLIN DD, 1986, P NATL ACAD SCI USA, V83, P9601, DOI 10.1073/pnas.83.24.9601; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; CROWDER CM, 1988, MOL CELL BIOL, V8, P5257, DOI 10.1128/MCB.8.12.5257; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; GLASS CK, 1988, CELL, V54, P321; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LORCH Y, 1985, J MOL BIOL, V186, P821, DOI 10.1016/0022-2836(85)90400-0; MILLBRANDT J, 1988, NEURON, V1, P183; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; SASAKI H, 1985, GENE, V37, P191; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SHERMAN F, 1986, LABORATORY COURSE MA; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON T, UNPUB; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; [No title captured]	54	503	520	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1296	1300		10.1126/science.1925541	http://dx.doi.org/10.1126/science.1925541			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1925541				2022-12-01	WOS:A1991FN85700036
J	COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD				COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD			MEMBRANE-PROTEIN ASSOCIATION BY POTENTIAL INTRAMEMBRANE CHARGE PAIRS	NATURE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL RECEPTOR; MOLECULAR-COMPONENTS; ANTIBODY; DEGRADATION; IGM	THE transmembrane domain of the alpha-chain of the T-cell receptor is responsible both for its assembly with the CD3 delta-chain 1 and for rapid degradation of the unassembled chain within the endoplasmic reticulum 2, 3. The determinant for both assembly and degradation is located in a segment of eight residues containing two basic amino acids (Fig. 1). We show here that placement of a single basic residue in the transmembrane domain of the Tac antigen can induce interaction with the CD3 chain, through its transmembrane acidic residue. This interaction is most favoured when the interacting residues are located at the same level in the membrane. The ability to induce protein-protein interaction by placing charge pairs within transmembrane domains suggests an approach to producing artificial dimers.			COSSON, P (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Bonifacino, Juan S./0000-0002-5673-6370				BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	16	233	234	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					414	416		10.1038/351414a0	http://dx.doi.org/10.1038/351414a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827877				2022-12-01	WOS:A1991FN85600061
J	DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A				DIEKMANN, D; BRILL, S; GARRETT, MD; TOTTY, N; HSUAN, J; MONFRIES, C; HALL, C; LIM, L; HALL, A			BCR ENCODES A GTPASE-ACTIVATING PROTEIN FOR P21RAC	NATURE			English	Article							RAS P21; GENE-PRODUCT; ESCHERICHIA-COLI; GAP; LEUKEMIA; DOMAIN; CELLS; CDNA; IDENTIFICATION; INTERACTS	MORE than thirty small guanine nucleotide-binding proteins related to the ras-encoded oncoprotein, termed Ras or p21ras, are known 1. They regulate many fundamental processes in all eukaryotic cells, such as growth, vesicle traffic and cytoskeletal organization. GTPase-activating proteins (GAPs) accelerate the intrinsic rate of GTP hydrolysis of Ras-related proteins, leading to down-regulation of the active GTP-bound form 2. For p21ras, two GAP proteins are known, rasGAP and the neurofibromatosis (NF1) gene product 2-5. There is evidence that rasGAP may also be a target protein for regulation by Ras and be involved in downstream signalling 6-8. We have purified a GAP protein for p21rho, which is involved in the regulation of the actin cytoskeleton 9. Partial sequencing of rhoGAP reveals significant homology with the product of the bcr (breakpoint cluster region) gene, the translocation breakpoint in Philadelphia chromosome-positive chronic myeloid leukaemias. We show here that the carboxy-terminal domains of the bcr-encoded protein (Bcr) and of a Bcr-related protein, n-chimaerin, are both GAP proteins for the Ras-related GTP-binding protein, p21rac. This result suggests that Bcr could be a target for regulation by Rac and has important new implications for the role of bcr translocations in leukaemia.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; INST NEUROL,LONDON WC1 1PJ,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London			Hall, Christine/C-8390-2009; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Tapon, Dagmar/0000-0003-3837-4764				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMSON RB, 1989, ONCOGENE, V4, P243; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GARRETT MD, IN PRESS BIOCH J; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P636; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LI WJ, 1989, ONCOGENE, V4, P127; LIFSHITZ B, 1988, ONCOGENE, V2, P113; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OTSU M, 1991, CELL, V65, P1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	29	413	424	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					400	402		10.1038/351400a0	http://dx.doi.org/10.1038/351400a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1903516				2022-12-01	WOS:A1991FN85600056
J	DILEO, AJ; ALLEGREZZA, AE				DILEO, AJ; ALLEGREZZA, AE			VALIDATABLE VIRUS REMOVAL FROM PROTEIN SOLUTIONS	NATURE			English	Article											DILEO, AJ (corresponding author), MILLIPORE CORP,80 ASHBY RD,BEDFORD,MA, USA.							BECHTEL MK, 1988, BIOMATER ARTIF CELL, V16, P123, DOI 10.3109/10731198809132562; DILEO AJ, MEMBRANE PROCESS SYS; DILEO AJ, UNPUB BIOTECHNOLOGY	3	7	8	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					420	421		10.1038/351420a0	http://dx.doi.org/10.1038/351420a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034293				2022-12-01	WOS:A1991FN85600065
J	DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J				DINHXUAN, AT; HIGENBOTTAM, TW; CLELLAND, CA; PEPKEZABA, J; CREMONA, G; BUTT, AY; LARGE, SR; WELLS, FC; WALLWORK, J			IMPAIRMENT OF ENDOTHELIUM-DEPENDENT PULMONARY-ARTERY RELAXATION IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NITRIC-OXIDE; RELAXING FACTOR; SMOOTH-MUSCLE; GUANOSINE-MONOPHOSPHATE; RAT; VASOCONSTRICTION; CIRCULATION; CELLS; TRANSPLANTATION; INHIBITION	Background. Endothelial cells release endothelium-derived relaxing factor (EDRF) in a variety of vascular beds, including the pulmonary circulation. However, the role of EDRF-mediated pulmonary-artery relaxation in chronic hypoxic lung disease is unknown. Methods. We studied endothelium-dependent relaxation mediated by EDRF in vitro in pulmonary arteries that had been obtained from 22 patients undergoing heart-lung transplantation for end-stage chronic obstructive lung disease. Control pulmonary arteries were obtained from 15 patients undergoing lobectomy for lung carcinoma who did not have evidence of other chronic lung disease. The responses of all vascular rings (external diameter, 1.2 to 3.4 mm) to the endothelium-dependent vasodilators acetylcholine and adenosine diphosphate were studied immediately after lung excision. Results. Pulmonary arterial rings from the patients with chronic lung disease developed a greater tension (2.19 +/- 0.16 g) in response to phenylephrine (10(-6) M) than the rings from control patients (1.28 +/- 0.18 g, P < 0.05). Inhibition of EDRF synthesis by treatment with N(G)-monomethyl-L-arginine (10(-4) M) eliminated this difference, increasing the tension in the rings from the controls (P < 0.01) but not in those from the patients with chronic lung disease. Rings from control patients relaxed in response to cumulative doses (10(-10) to 10(-5) M) of acetylcholine (maximal relaxation, 81.3 +/- 3.9 percent) and adenosine diphosphate (maximal relaxation, 85.3 +/- 2.6 percent). By contrast, rings from patients with chronic obstructive lung disease achieved only 41.3 +/- 4.8 percent of maximal relaxation in response to acetylcholine (n = 32) and 49.4 +/- 5.5 percent in response to adenosine diphosphate (n = 24) (P < 0.001, as compared with control rings). Rings from both the controls and the patients with chronic lung disease relaxed similarly in response to the endothelium-independent vasodilator sodium nitroprusside (10(-4) M). There was an inverse correlation between the degree of intimal thickening and the level of maximal relaxation of the rings from the patients with chronic lung disease (r = -0.60, P < 0.001). Maximal relaxation was also related directly to the partial pressure of arterial oxygen before transplantation (r = 0.68, P < 0.01) and inversely to the partial pressure of arterial carbon dioxide before transplantation (r = -0.55, P < 0.01), but not to the forced expiratory volume in one second (r = 0.19, P not significant). Conclusions. Endothelium-dependent pulmonary-artery relaxation in vitro is impaired in arteries from patients with end-stage chronic obstructive lung disease. Such impairment may contribute to the development of pulmonary hypertension in chronic hypoxic lung disease.	PAPWORTH HOSP, DEPT RESP PHYSIOL, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT CARDIOTHORAC SURG, CAMBRIDGE CB3 8RE, ENGLAND; PAPWORTH HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB3 8RE, ENGLAND	Papworth Hospital; Papworth Hospital; Papworth Hospital			Pepke-Zaba, Joanna/AGW-3073-2022; DINH-XUAN, Anh Tuan/A-9691-2008	DINH-XUAN, Anh Tuan/0000-0001-8651-5176				ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; [Anonymous], 1963, CIRCULATION, V27, P594, DOI DOI 10.1161/01.CIR.27.4.594; ARCHER SL, 1989, BIOCHEM BIOPH RES CO, V164, P1198, DOI 10.1016/0006-291X(89)91796-8; ARMITAGE P, 1987, STAT METHODS; BORLAND CDR, 1989, EUR RESPIR J, V2, P56; BRASHERS VL, 1988, J CLIN INVEST, V82, P1495, DOI 10.1172/JCI113757; BURROWS B, 1972, NEW ENGL J MED, V286, P912, DOI 10.1056/NEJM197204272861703; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; CRAWLEY DE, 1990, BRIT J PHARMACOL, V101, P166; Dinh Xuan AT, 1989, EUR J PHARMACOL, V163, P401, DOI 10.1016/0014-2999(89)90217-3; Dinh Xuan AT, 1990, BRIT J PHARMACOL, V99, P9, DOI 10.1111/j.1476-5381.1990.tb14643.x; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KON V, 1990, J CLIN INVEST, V85, P1728, DOI 10.1172/JCI114628; LIU SF, 1991, AM REV RESPIR DIS, V143, P32, DOI 10.1164/ajrccm/143.1.32; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MAGEE F, 1988, THORAX, V43, P183, DOI 10.1136/thx.43.3.183; MAZMANIAN GM, 1989, J APPL PHYSIOL, V66, P1040, DOI 10.1152/jappl.1989.66.3.1040; MEYRICK B, 1978, LAB INVEST, V38, P188; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; MONCADA S, 1987, THROMB DIATH HAEMO, P597; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OGAWA S, 1990, BRIT J HAEMATOL, V75, P517, DOI 10.1111/j.1365-2141.1990.tb07792.x; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANG JA, 1982, AM REV RESPIR DIS, V125, P194; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PENKETH A, 1987, BRIT MED J, V295, P311, DOI 10.1136/bmj.295.6593.311; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; REEVES JT, 1989, PULMONARY CIRCULATIO, P27; ROBERTSON BE, 1990, EXP PHYSIOL, V75, P255, DOI 10.1113/expphysiol.1990.sp003399; SCOTT J, 1988, LANCET, V2, P192; VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P512, DOI 10.1056/NEJM198808253190809; WARREN JB, 1989, CLIN SCI, V77, P671, DOI 10.1042/cs0770671; WILKINSON M, 1988, Q J MED, V66, P65; XUAN ATD, 1989, J INT MED RES, V17, P305, DOI 10.1177/030006058901700401; YAMAGUCHI T, 1989, EUR J PHARMACOL, V161, P259, DOI 10.1016/0014-2999(89)90856-X	40	454	470	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1991	324	22					1539	1547		10.1056/NEJM199105303242203	http://dx.doi.org/10.1056/NEJM199105303242203			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN051	2027358				2022-12-01	WOS:A1991FN05100003
J	ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A				ELLIOTT, T; CERUNDOLO, V; ELVIN, J; TOWNSEND, A			PEPTIDE-INDUCED CONFORMATIONAL CHANGE OF THE CLASS-I HEAVY-CHAIN	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-A VIRUS; HLA-B ANTIGENS; SURFACE EXPRESSION; SYNTHETIC PEPTIDES; VIRAL PEPTIDES; NUCLEOPROTEIN; MOLECULES; BETA-2-MICROGLOBULIN; INVITRO	THERE is evidence that peptide ligands take part in the assembly of class I molecules 1-8. In particular, addition of peptides to extracts of the mutant cells RMA-S and .174/T2, in which stable assembly of class I does not occur 9-11, results in a conformational change in the class I heavy chain and stable association of the heavy chain with beta-2-microglobulin (beta-2m) (refs 1-3). Thus specific peptides may stabilize or induce a conformational change in the class I heavy chain that results in a rise in the binding affinity of the heavy chain for beta-2m (Fig. 1a). Here we show that peptides have two cooperative roles in class I assembly. Specific short peptides (9-10 amino acids) can induce folding of the heavy chain in the absence of beta-2m. Both short (nine amino acids) and longer sequences (15 amino acids) can stabilize performed low-affinity complexes of heavy chain and beta-2m. To alter the conformation of free heavy chains, the peptides must be exactly the correct size, and they are found to correspond to the sequences isolated from infected cells 12. This property may therefore be the basis for selection of epitopes presented in vivo.			ELLIOTT, T (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.			Cerundolo, Vincenzo/0000-0003-0040-3793; Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, IN PRESS EUR J IMMUN; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; HUDDLESTON JA, 1982, NUCLEIC ACIDS RES, V10, P1029, DOI 10.1093/nar/10.3.1029; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; OZATO K, 1981, J IMMUNOL, V126, P317; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	19	246	252	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					402	406		10.1038/351402a0	http://dx.doi.org/10.1038/351402a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034289				2022-12-01	WOS:A1991FN85600057
J	MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA				MOZZARELLI, A; RIVETTI, C; ROSSI, GL; HENRY, ER; EATON, WA			CRYSTALS OF HEMOGLOBIN WITH THE T-QUARTERNARY STRUCTURE BIND OXYGEN NONCOOPERATIVELY WITH NO BOHR EFFECT	NATURE			English	Article							HUMAN-HEMOGLOBIN; SINGLE-CRYSTALS; STEREOCHEMISTRY; MECHANISMS; CONSTANTS; AFFINITY; ENZYME; STATE	THE relationship between the structure and function of haemoglobin has mainly been studied by comparing its X-ray crystal structures with its function in solutions 1-11. To make a direct comparison we have studied the functional properties of haemoglobin in single crystals, an approach that has been an important part of the investigation of several enzyme mechanisms 12, 13. Here we report on the oxygen binding by single crystals of human haemoglobin grown in solutions of polyethylene glycol. Unlike haemoglobin crystals formed in concentrated salt solution, which crack and become disordered on oxygenation 14-16, crystals grown in polyethylene glycol remain intact. X-ray studies have shown that the T (deoxy) quaternary structure of haemoglobin in this crystal at pH 7.0 is maintained at atmospheric oxygen pressure, and that the salt-bridges are not broken 17-19. We find striking differences between oxygen binding by haemoglobin in this crystal and by haemoglobin in solution. Not only is oxygenation of the crystal noncooperative, but the oxygen affinity is independent of pH in the range 6.0-8.5, and is much lower than that of the T state in solution. The lack of cooperativity without a change in quaternary structure is predicted by the two-state allosteric model of Monod, Wyman and Changeux 1, 5. The absence of a Bohr effect without breakage of salt-bridges is predicted by Perutz's stereochemical mechanism 2, 4, 9-11. In contrast to the X-ray result that oxygen binds only to the alpha-haems, our measurements show that the alpha-haems have only a slightly higher affinity than the beta-haems.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MOZZARELLI, A (corresponding author), UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY.		Mozzarelli, Andrea/C-3615-2014; Henry, Eric R/J-3414-2013	Mozzarelli, Andrea/0000-0003-3762-0062; Henry, Eric R/0000-0002-5648-8696; Rivetti, Claudio/0000-0003-3775-6779				ACKERS GK, 1987, ANNU REV BIOPHYS BIO, V16, P583; Antonini E., 1971, FRONT BIOL, DOI DOI 10.1126/SCIENCE.178.4058.296; BALDWIN JM, 1975, PROG BIOPHYS MOL BIO, V29, P227; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; BRZOZOWSKI A, 1984, HEMOGLOBIN, P37; CHU AH, 1984, BIOCHEMISTRY-US, V23, P604, DOI 10.1021/bi00299a004; Eaton W A, 1981, Methods Enzymol, V76, P175; EDELSTEIN SJ, 1975, REV BIOCH, V44, P209; Gill S J, 1981, Methods Enzymol, V76, P427; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; Haurowitz F., 1938, Z PHYSIOL CHEMIE, V254, P266; IMAI K, 1975, J BIOL CHEM, V250, P2227; Imai K., 1982, ALLOSTERIC EFFECTS H; KILMARTIN JV, 1978, J MOL BIOL, V123, P71, DOI 10.1016/0022-2836(78)90377-7; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIDDINGTON RC, 1986, THESIS U YORK; LUISI B, 1990, J MOL BIOL, V214, P7, DOI 10.1016/0022-2836(90)90139-D; MAKINEN MW, 1974, NATURE, V247, P62, DOI 10.1038/247062a0; MARDEN MC, 1990, BIOPHYS J, V57, P397, DOI 10.1016/S0006-3495(90)82556-X; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5351; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1953, ACTA CRYSTALLOGR, V6, P859, DOI 10.1107/S0365110X53002507; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1964, NATURE, V203, P687, DOI 10.1038/203687a0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; ROSSI GL, 1970, J MOL BIOL, V49, P85, DOI 10.1016/0022-2836(70)90377-3; SAWICKI CA, 1977, J BIOL CHEM, V252, P7138; SHIBAYAMA N, 1986, J MOL BIOL, V192, P323, DOI 10.1016/0022-2836(86)90367-0; SHULMAN RG, 1975, Q REV BIOPHYS, V8, P325, DOI 10.1017/S0033583500001840; SZABO A, 1972, J MOL BIOL, V72, P163, DOI 10.1016/0022-2836(72)90077-0	35	116	116	3	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					416	419		10.1038/351416a0	http://dx.doi.org/10.1038/351416a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034292				2022-12-01	WOS:A1991FN85600062
J	SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ				SIXMA, TK; PRONK, SE; KALK, KH; WARTNA, ES; VANZANTEN, BAM; WITHOLT, B; HOL, WGJ			CRYSTAL-STRUCTURE OF A CHOLERA TOXIN-RELATED HEAT-LABILE ENTEROTOXIN FROM ESCHERICHIA-COLI	NATURE			English	Article							AERUGINOSA EXOTOXIN-A; ADP-RIBOSYLTRANSFERASE ACTIVITY; AMINO-ACID-SEQUENCE; X-RAY-DIFFRACTION; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; NUCLEOTIDE-SEQUENCE; B-SUBUNIT; DIPHTHERIA-TOXIN; 3-DIMENSIONAL STRUCTURE	Examination of the structure of Escherichia coli heat-labile enterotoxin in the AB5 complex at a resolution of 2.3 angstrom reveals that the doughnut-shaped B pentamer binds the enzymatic A subunit using a hairpin of the A2 fragment, through a highly charged central pore. Putative ganglioside G(M1-) binding sites on the B subunits are more than 20 angstrom removed from the membrane-crossing A1 subunit. This ADP-ribosylating (A1) fragment of the toxin has structural homology with the catalytic region of exotoxin A and hence also to diphtheria toxin.	STATE UNIV GRONINGEN, DEPT CHEM, BIOCHEM LAB, 9747 AG GRONINGEN, NETHERLANDS	University of Groningen	SIXMA, TK (corresponding author), STATE UNIV GRONINGEN, BIOSON RES INST, NIJENBORGH 16, 9747 AG GRONINGEN, NETHERLANDS.		Witholt, Bernard/A-7340-2012	Sixma, Titia K/0000-0001-6180-0632				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLEMENS JD, 1986, LANCET, V2, P124; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DERTZBAUGH MT, 1990, INFECT IMMUN, V58, P70, DOI 10.1128/IAI.58.1.70-79.1990; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5489; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; FINKELSTEIN RA, 1988, IMMUNOCHEMICAL MOL G, P85; FOSTER JW, 1985, CRC CR REV MICROBIOL, V11, P273; FUJINAGA M, 1989, J APPL CRYSTALLOGR, V22, P1, DOI 10.1107/S0021889888009550; GALLOWAY TS, 1987, BIOCHEM J, V244, P225, DOI 10.1042/bj2440225; GEARY SJ, 1982, INFECT IMMUN, V36, P215, DOI 10.1128/IAI.36.1.215-220.1982; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GOINS B, 1988, BIOCHEMISTRY-US, V27, P2046, DOI 10.1021/bi00406a035; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HARFORD S, 1989, EUR J BIOCHEM, V183, P311, DOI 10.1111/j.1432-1033.1989.tb14930.x; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HOFSTRA H, 1984, J BIOL CHEM, V259, P5182; IIDA T, 1989, J BIOL CHEM, V264, P14065; JACOB CO, 1985, EMBO J, V4, P3339, DOI 10.1002/j.1460-2075.1985.tb04086.x; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LAI CY, 1983, BIOCHEM BIOPH RES CO, V116, P341, DOI 10.1016/0006-291X(83)90420-5; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LUDWIG DS, 1985, J BIOL CHEM, V260, P2528; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MCDANIEL RV, 1986, BIOPHYS J, V49, P94, DOI 10.1016/S0006-3495(86)83606-2; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1981, J BIOL CHEM, V256, P2861; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; OKAMOTO K, 1988, J BACTERIOL, V170, P2208, DOI 10.1128/jb.170.5.2208-2211.1988; PETERSON JW, 1989, SCIENCE, V245, P857, DOI 10.1126/science.2549637; PICKETT CL, 1989, J BACTERIOL, V171, P4945, DOI 10.1128/jb.171.9.4945-4952.1989; PRONK SE, 1985, J BIOL CHEM, V260, P3580; RATTI G, 1983, NUCLEIC ACIDS RES, V11, P6589, DOI 10.1093/nar/11.19.6589; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; SANCHEZ J, 1988, FEBS LETT, V241, P110, DOI 10.1016/0014-5793(88)81041-X; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SCHODEL F, 1989, INFECT IMMUN, V57, P1347; SPICER EK, 1982, J BIOL CHEM, V257, P5716; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUJI T, 1985, J BIOL CHEM, V260, P8552; TSUJI T, 1990, J BIOL CHEM, V265, P22520; VANHEYNINGEN S, 1983, CURR TOP MEMBR TRANS, V18, P445; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987	65	487	508	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1991	351	6325					371	377		10.1038/351371a0	http://dx.doi.org/10.1038/351371a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034287				2022-12-01	WOS:A1991FN85600047
J	SOKOL, S; MELTON, DA				SOKOL, S; MELTON, DA			PREEXISTENT PATTERN IN XENOPUS ANIMAL POLE CELLS REVEALED BY INDUCTION WITH ACTIVIN	NATURE			English	Article							NEURAL INDUCTION; LAEVIS; MESODERM; EMBRYOS; AXIS; DIFFERENTIATION; GASTRULATION; HOMOLOG; SIGNALS; MARKER	ACTIVIN, a peptide growth factor related to tumour growth factor-beta, has been implicated in early inductive interactions in vertebrates 1-4 and can induce Xenopus blastula ectodermal explants to develop a rudimentary axial pattern with anteroposterior and dorsoventral polarity 4, 5. Here we demonstrate that prospective dorsal and ventral regions of the ectoderm respond differently to the same concentration of activin. Thus, activin does not seem to endow ectodermal cells with polarity but rather reveals a pre-existent pattern. Our results suggest that patterning of mesoderm is determined not only by a localized inducer, but also by the differential competence of cells in the responding tissue.			SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Sokol, Sergei/0000-0002-3963-9202				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; DALE L, 1987, DEVELOPMENT, V100, P279; DIXON JE, 1989, DEVELOPMENT, V106, P749; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0	20	189	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					409	411		10.1038/351409a0	http://dx.doi.org/10.1038/351409a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	2034291				2022-12-01	WOS:A1991FN85600059
J	WIKLER, KC; RAKIC, P				WIKLER, KC; RAKIC, P			RELATION OF AN ARRAY OF EARLY-DIFFERENTIATING CONES TO THE PHOTORECEPTOR MOSAIC IN THE PRIMATE RETINA	NATURE			English	Article							RHESUS-MONKEY RETINA; LINEAGE; GREEN; BLUE	THE retina of diurnal primates, including humans, contains a reiterative mosaic of red-, green- and blue-sensitive cones whose visual pigments are maximally sensitive to long, middle or short wavelengths, respectively 1. Although the distribution of the cone subtypes in the adult rhesus monkey has been quantified using opsin-specific antisera 2, the mechanism for the phenotypic specification of the cone subtypes and the establishment of their ratios in the retinal mosaic remain unknown. Here we present immunocytochemical evidence that a subset of cones (about 10%) express their cell-specific opsin two to three weeks before the surrounding cones. Remarkably, these precocious cones are evenly stationed throughout undifferentiated regions of the retinal surface from several weeks after their last mitotic division 3, and at least one month before the formation of their synapses with bipolar and horizontal cells 4. Use of confocal laser microscopy reveals that the inner segments of immunolabelled and surrounding unlabelled cones are transiently in apposition with one another, enabling surface mediated interactions to occur during this period. We suggest that the early maturing cones induce neighbouring undifferentiated cones to express an appropriate opsin phenotype, and therefore constitute a 'protomap' for the emergence of the species-specific retinal mosaic.			WIKLER, KC (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,POB 3333,NEW HAVEN,CT 06510, USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; CURCIO C A, 1989, Society for Neuroscience Abstracts, V15, P1206; FINLAY BL, 1989, DEV VERTEBRATE RETIN; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobs GH, 1981, COMP COLOR VISION; JOHNSON LV, 1988, INVEST OPHTH VIS SCI, V29, P550; LAVAIL M, 1983, INVEST OPHTHALMOL, V24, P7; LAVAIL MM, IN PRESS J COMP NEUR; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NISHIMURA Y, 1985, J COMP NEUROL, V241, P420, DOI 10.1002/cne.902410403; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAPAPORT DH, 1982, DEV BRAIN RES, V5, P273, DOI 10.1016/0165-3806(82)90126-2; REH TA, 1989, J NEUROSCI, V9, P417; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WATANABE T, 1990, NEURON, V2, P461; WETTS R, 1989, DEV BIOL, V136, P254, DOI 10.1016/0012-1606(89)90146-2; WIKLER KC, 1990, J COMP NEUROL, V297, P499, DOI 10.1002/cne.902970404; WIKLER KC, 1990, J NEUROSCI, V10, P3390	20	77	77	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					397	400		10.1038/351397a0	http://dx.doi.org/10.1038/351397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827876				2022-12-01	WOS:A1991FN85600055
J	BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS				BADWE, RA; GREGORY, WM; CHAUDARY, MA; RICHARDS, MA; BENTLEY, AE; RUBENS, RD; FENTIMAN, IS			TIMING OF SURGERY DURING MENSTRUAL-CYCLE AND SURVIVAL OF PREMENOPAUSAL WOMEN WITH OPERABLE BREAST-CANCER	LANCET			English	Article							CLINICAL-TRIALS; SURGICAL CURE; GROWTH; REGRESSION; AUTOCRINE	Timing of operation in relation to menstrual phase might affect outlook in premenopausal women with operable breast cancer. We examined the records of 249 such women treated between 1975 and 1985, and compared overall and recurrence-free survival in those whose operation was 3-12 days after their last menstrual period (LMP) (group 1, n = 75) with those in whom it was 0-2 or 13-32 days after LMP (group 2, n = 174). Overall and recurrence-free survival were greatly reduced in group 1 women (p < 0.001 for both). Actuarial survival at 10 years was 54% in group 1 versus 84% in group 2. This effect was independent of other factors, was of much the same importance as nodal status in multivariate analysis, was largely confined to histologically node-positive cases, seemed to be greater in women with small tumours (less-than-or-equal-to 2 cm), and was seen in patients with oestrogen-receptor positive and negative tumours. Thus phase of menstrual cycle at operation is of great importance for long-term outlook in premenopausal women with breast cancer.	GUYS HOSP,IMPERIAL CANC RES FUND,CLIN ONCOL UNIT,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust			Fentiman, Ian/AAB-9886-2020; Fentiman, Ian S/I-7644-2019					ANDERSEN PK, 1982, BIOMETRICS, V38, P67, DOI 10.2307/2530289; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1989, CANCER RES, V49, P1996; GELBER RD, 1989, LANCET, V2, P1344; HANNA N, 1982, J IMMUNOL, V130, P974; HISSOM JR, 1987, BIOCHEM BIOPH RES CO, V145, P706, DOI 10.1016/0006-291X(87)91022-9; HOEWITZ KB, 1985, CANCER RES, V45, P167; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIPPMAN ME, 1986, BREAST CANCER RES TR, V7, P59, DOI 10.1007/BF01806790; MANNI A, 1990, BREAST CANCER RES TR, V15, P73, DOI 10.1007/BF01810779; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P88; RICHARDS MA, 1990, J CLIN ONCOL, V8, P2032, DOI 10.1200/JCO.1990.8.12.2032; ROCHEFORT H, 1988, BIOCHIMIE, V70, P943, DOI 10.1016/0300-9084(88)90236-2; RUBENS RD, 1983, LANCET, V1, P839, DOI 10.1016/S0140-6736(83)91385-5; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; YEN S, 1986, REPROD ENDOCRINOLOGY, P126	22	166	166	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1261	1264		10.1016/0140-6736(91)92927-T	http://dx.doi.org/10.1016/0140-6736(91)92927-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674070				2022-12-01	WOS:A1991FN04700011
J	DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE				DWYER, T; PONSONBY, ALB; NEWMAN, NM; GIBBONS, LE			PROSPECTIVE COHORT STUDY OF PRONE SLEEPING POSITION AND SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							COT DEATH	Studies of the link between prone sleeping position and sudden infant death syndrome have been criticised on grounds of recall bias and for not taking into account possible confounding effects. To avoid recall bias and to allow measurement of important biological factors a prospective cohort study of the cause of sudden infant death syndrome (SIDS) is being conducted. The infants included are those at high risk of the syndrome as assessed by a perinatal score. Of the 3110 members of the cohort born between January, 1988, and end of March, 1990, 23 infants later died of SIDS. Sleep position information was available for 15 of these. Matched analysis to control for the confounding effects of infant birthweight and maternal age indicated that prone sleeping position was associated with an increased risk of SIDS (OR 4.47 95% Cl [1.30-15.43]). The findings are strengthened by the results of a concurrent retrospective case-control study of 42 SIDS cases in which the prone position was also associated with an increased risk of SIDS (unadjusted OR 3.45 [1.59-7.49]).			DWYER, T (corresponding author), UNIV TASMANIA,MENZIES CTR POPULAT HLTH RES,43 COLLINS ST,HOBART,TAS 7000,AUSTRALIA.		Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657				BEAL S, 1988, MED J AUSTRALIA, V149, P562, DOI 10.5694/j.1326-5377.1988.tb120774.x; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; Breslow N. E., 1987, STATISTICAL METHODS, VII; BRESLOW N. E., 1980, STATISTICAL METHODS; CAMERON MH, 1986, AUST PAEDIATR J, V22, P37; DAVIES DP, 1985, LANCET, V2, P1346; DEJONGE GA, 1989, BRIT MED J, V298, P722, DOI 10.1136/bmj.298.6675.722; DEJONGE GA, 1989, LANCET, V2, P1149; DESPAIGNET ET, 1990, TASMANIA PAED PERIN, V4, P422; EMERY JL, 1988, LANCET, V2, P738; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; ENGELBERTS AC, 1990, BRIT MED J, V301, P493; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FROGGATT P, 1970, SUDDEN INFANT DEATH, P40; GILLES FH, 1979, AM J DIS CHILD, V133, P30, DOI 10.1001/archpedi.1979.02130010036005; GUNTHEROTH WG, 1990, BRIT MED J, V301, P492; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; LEE M, 1988, LANCET, V1, P1332; MANTEL N, 1959, NAT CANCER I, V22, P819; MCGLASHAN ND, 1986, LANCET, V1, P106; MORRIS JA, 1989, BRIT MED J, V298, P958; NELSON EAS, 1989, LANCET, V1, P199; NEWMAN NM, 1986, AUST PAEDIATR J, V22, P111; NICHOLL JP, 1988, LANCET, V2, P106; SATERNUS KS, 1985, FESTSCHRIFT LEITHOFF, P67; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; SENECAL J, 1987, ARCH FR PEDIATR, V44, P131; SOUTHALL D, 1990, BRIT MED J, V301, P492; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1986, NEW ZEAL MED J, V99, P324; TONKIN SL, 1979, PEDIATRICS, V63, P261; WAILOO MP, 1990, BRIT MED J, V301, P492, DOI 10.1136/bmj.301.6750.492-b; 1990, SUDDEN INFANT DEATH	33	279	283	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1244	1247		10.1016/0140-6736(91)92917-Q	http://dx.doi.org/10.1016/0140-6736(91)92917-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674061				2022-12-01	WOS:A1991FN04700002
J	FOSTER, A				FOSTER, A			WHO WILL OPERATE ON AFRICA 3-MILLION CURABLY BLIND PEOPLE	LANCET			English	Article								About half the 6 million blind people in sub-Saharan Africa have surgically curable cataract. The available manpower and resources can only provide services for less than 10% of the new blind cataract patients each year, and little is being done for the estimated 3 million "cataract backlog". A serious limiting factor to the development of prevention of blindness programmes is lack of trained manpower. Despite an increase in the number of ophthalmologists trained in cataract surgery (which varies greatly from country to country), this number is not keeping pace with increased demand for eye-care services, especially in large rural populations. Initiatives that will help to overcome this dilemma are specific post-graduate courses in community ophthalmology in Africa, plans to develop a one-year diploma in ophthalmology course for English-speaking West African countries, and a proposal to upgrade a similar course in Zimbabwe. Additionally there is a need for the training of more ophthalmic assistants, cataract surgeons, and nurses in the diagnosis and management of common ophthalmic disorders. Experienced expatriate ophthalmologists also have an important role in the teaching of doctors and ophthalmic assistants how to select patients and carry out successful inexpensive cataract surgery with appropriate technology and limited facilities.			FOSTER, A (corresponding author), INT CTR EYE HLTH,27-29 CAYTON ST,LONDON EC1V 9EJ,ENGLAND.			Foster, Allen/0000-0003-2368-4436				FOSTER A, 1991, CLIN OPHTHALMOLOGY, V5; 1990, OPHTHALMIC MANPOWER; 1988, OPHTHALMIC MANPOWER	3	52	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1267	1269		10.1016/0140-6736(91)92929-V	http://dx.doi.org/10.1016/0140-6736(91)92929-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674072				2022-12-01	WOS:A1991FN04700013
J	GARDOSI, JO; SCHRAM, CM; SYMONDS, EM				GARDOSI, JO; SCHRAM, CM; SYMONDS, EM			ADAPTATION OF PULSE OXIMETRY FOR FETAL MONITORING DURING LABOR	LANCET			English	Article							OXYGEN	Application of pulse oximetry to intrapartum monitoring was investigated in 105 women. No adequate reading could be obtained in 44 cases. Two major sources of artifact, related to probe apposition and signal processing, were identified and excluded. The average arterial oxygen saturation from the fetal scalp was 82% (SD 6%), which is higher than has been inferred from pO2 levels. Readings below 60% or the development of an unstable baseline suggest the presence of substantial hypoxia and acidosis.			GARDOSI, JO (corresponding author), QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND.		Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ANDREWS BF, 1965, AM J OBSTET GYNECOL, V91, P85, DOI 10.1016/0002-9378(65)90590-9; DAMIANOU D, 1991, IEE ABSTR, V89, P3; GARDOSI J, 1989, LANCET, V2, P692; HARRIS AP, 1988, J CLIN MONITOR, V4, P175, DOI 10.1007/BF01621812; JOHNSON N, 1991, BRIT J OBSTET GYNAEC, V98, P36, DOI 10.1111/j.1471-0528.1991.tb10308.x; JOHNSON SB, 1990, HEALTH PSYCHOL, V9, P493, DOI 10.1037/0278-6133.9.4.493; PEAT S, 1988, LANCET, V2, P213; ROSEN M, 1990, 1ST INT S INTR SURV; SCHRAM CMH, 1991, BRIT J OBSTET GYNAEC, V98, P113, DOI 10.1111/j.1471-0528.1991.tb10327.x; SOUTHALL DP, 1987, ARCH DIS CHILD, V62, P882, DOI 10.1136/adc.62.9.882; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; 1990, LANCET, V335, P1130	12	68	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1265	1267		10.1016/0140-6736(91)92928-U	http://dx.doi.org/10.1016/0140-6736(91)92928-U			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674071				2022-12-01	WOS:A1991FN04700012
J	JENNETT, B; DYER, C				JENNETT, B; DYER, C			PERSISTENT VEGETATIVE STATE AND THE RIGHT-TO-DIE - THE UNITED-STATES AND BRITAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FATE WORSE; DEATH				JENNETT, B (corresponding author), INST NEUROL SCI, NEUROSURG, GLASGOW G51 4TF, SCOTLAND.							ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1990, NEW ENGL J MED, V323, P686, DOI 10.1056/NEJM199009063231020; BOYD K, 1991, LANCET, V337, P96; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRAHAMS D, 1988, LANCET, V1, P779; FEINBERG WM, 1984, AM J DIS CHILD, V138, P128, DOI 10.1001/archpedi.1984.02140400014003; GILLON R, 1988, J MED ETHICS, V14, P59, DOI 10.1136/jme.14.2.59; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, ARCH NEUROL-CHICAGO, V33, P595, DOI 10.1001/archneur.1976.00500090001001; JENNETT B, 1988, ANAESTHESIA, V43, P921, DOI 10.1111/j.1365-2044.1988.tb05650.x; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; LO B, 1990, NEW ENGL J MED, V322, P1228, DOI 10.1056/NEJM199004263221711; Minderhoud J M, 1985, Ned Tijdschr Geneeskd, V129, P2385; 1991, PROPOSALS ESTABLISHM; 1991, MENTALLY INCAPACITAT; 1986, JAMA-J AM MED ASSOC, V236, P471; 1990, JAMA-J AM MED ASSOC, V263, P426	18	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1256	1258		10.1136/bmj.302.6787.1256	http://dx.doi.org/10.1136/bmj.302.6787.1256			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043853	Bronze, Green Published			2022-12-01	WOS:A1991FP27200029
J	LOCK, M				LOCK, M			CONTESTED MEANINGS OF THE MENOPAUSE	LANCET			English	Editorial Material							REPLACEMENT THERAPY; WOMEN				LOCK, M (corresponding author), MCGILL UNIV,DEPT HUMANITIES & SOCIAL STUDIES MED,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; Fedor-Freybergh P, 1977, Acta Obstet Gynecol Scand Suppl, V64, P1; GOSDEN RG, 1985, BIOL MENOPAUSE, P1; GREENBLATT RB, 1980, MENOPAUSE COMPREHENS, P151; KASE N, 1974, JAMA-J AM MED ASSOC, V227, P318, DOI 10.1001/jama.227.3.318; KAUFERT PA, 1984, SOC SCI MED, V18, P279, DOI 10.1016/0277-9536(84)90091-1; KAUFERT PA, 1986, CULT MED PSYCHIAT, V10, P7, DOI 10.1007/BF00053260; LOCK M, 1988, MATURITAS, V10, P317, DOI 10.1016/0378-5122(88)90067-9; LOCK M, 1988, BIOMEDICAL KNOWLEDGE; MCKINLAY SM, 1986, CLIMACTERIC PERSPECT, P59; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P8; THORNEYCROFT IH, 1989, AM J OBSTET GYNECOL, V160, P1306, DOI 10.1016/S0002-9378(89)80018-3; WEISS KM, 1981, OTHER WAYS GROWING O, P25; WRIGHT Peter, 1982, PROBLEM MED KNOWLEDG	14	100	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1270	1272		10.1016/0140-6736(91)92931-Q	http://dx.doi.org/10.1016/0140-6736(91)92931-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN047	1674073				2022-12-01	WOS:A1991FN04700014
J	OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM				OCALLAGHAN, E; SHAM, P; TAKEI, N; GLOVER, G; MURRAY, RM			SCHIZOPHRENIA AFTER PRENATAL EXPOSURE TO 1957 A2-INFLUENZA EPIDEMIC	LANCET			English	Article							INFLUENZA; BIRTH	The birth dates of schizophrenic inpatients in eight health regions in England and Wales were reviewed for any effect of the 1957 A2 influenza epidemic. 5 months after the peak infection prevalence, the number of births of individuals who later developed schizophrenia was 88% higher than the average number of such births in the corresponding periods of the 2 previous and the next 2 years. This finding is in accordance with a study from Helsinki and with clinical and neuropathological evidence of aberrant fetal brain development in the pathogenesis of schizophrenia.	INST PSYCHIAT,DEPT PSYCHOL MED,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT COMMUNITY MED,LONDON SW1P 2AP,ENGLAND; UNIV LONDON KINGS COLL HOSP,LONDON SE5 8RX,ENGLAND	University of London; King's College London; Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Takei, Nori/GWZ-7464-2022; Takei, Nori/AAC-8578-2019; Murray, Robin M/F-8658-2012	Murray, Robin M/0000-0003-0829-0519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOWLER AE, 1990, ARCH GEN PSYCHIAT, V47, P877; COFFEY VP, 1959, LANCET, V2, P935; DEGREEF G, 1988, BIOL PSYCHIAT, V24, P461, DOI 10.1016/0006-3223(88)90186-2; GUY JD, 1983, SCHIZOPHRENIA BULL, V9, P571, DOI 10.1093/schbul/9.4.571; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JOHNSTONE EC, 1976, LANCET, V2, P924; KENDELL RE, 1989, ARCH GEN PSYCHIAT, V46, P878; LECK I, 1963, BRIT J PREV SOC MED, V17, P70; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCDONALD JC, 1958, P ROY SOC MED, V51, P1016; MEDNICK SA, 1990, ARCH GEN PSYCHIAT, V47, P875; MEDNICK SA, 1988, ARCH GEN PSYCHIAT, V45, P189, DOI 10.1001/archpsyc.1988.01800260109013; MENINGER KA, 1926, AM J PSYCHIAT, V82, P469; MURRAY RM, 1988, SCHIZOPHRENIA MAJOR, P90; MURRAY RM, 1985, GENETICS ASPECTS HUM, P63; OCALLAGHAN E, IN PRESS BR J PSYCHI; WEINBERGER DR, 1980, AM J PSYCHIAT, V137, P1410; ZIPURSKY RB, 1987, BIOL PSYCHIAT, V22, P1288, DOI 10.1016/0006-3223(87)90040-0; [No title captured]; 1958, REPORT REGISTRAR GEN	22	329	332	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1248	1250		10.1016/0140-6736(91)92919-S	http://dx.doi.org/10.1016/0140-6736(91)92919-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674062				2022-12-01	WOS:A1991FN04700003
J	OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM				OCARROLL, RE; HAYES, PC; EBMEIER, KP; DOUGALL, N; MURRAY, C; BEST, JJK; BOUCHIER, IAD; GOODWIN, GM			REGIONAL CEREBRAL BLOOD-FLOW AND COGNITIVE FUNCTION IN PATIENTS WITH CHRONIC LIVER-DISEASE	LANCET			English	Article							HEPATOCELLULAR DISEASE; SCAN ABNORMALITIES; ENCEPHALOPATHY; SYSTEM; BRAIN	Subtle impairments of cognitive function may be an important cause of occupational and psychosocial morbidity in patients with chronic liver disease. Correlation of structural brain abnormalities with cognitive deficits has yielded inconsistent results. 10 patients with cirrhotic liver disease were compared with 10 age, education, and intelligence matched control subjects. Neuropsychological assessment revealed significant overall cognitive impairments in cirrhotic patients compared with controls (p = 0.02). Regional cerebral blood flow was measured by single photon emission computed tomography (SPET or SPECT) and showed increased uptake of radiotracer in the right and left posterior parts of the basal ganglia and right occipital lobe, together with reduced uptake in the right anterior cingulate region. The degree of cognitive impairment was directly correlated with functional abnormalities in the basal ganglia and limbic cortex (p < 0.05). Our results suggest that impaired cognitive status may be associated with abnormalities of regional brain function in patients with chronic liver disease. Since these deficits are clinically inapparent, our findings have important implications for identification and management of patients with chronic liver disease.	ROYAL INFIRM,DEPT MED,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT MED RADIOL,EDINBURGH EH3 9HB,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh	OCARROLL, RE (corresponding author), ROYAL EDINBURGH & ASSOC HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,SCOTLAND.		O'Carroll, Ronan E/A-5040-2009; Dougall, Nadine J/O-8145-2015; Ebmeier, Klaus Peter/B-4789-2008	O'Carroll, Ronan E/0000-0002-5130-291X; Dougall, Nadine J/0000-0003-3462-6960; Ebmeier, Klaus Peter/0000-0002-5190-7038	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERNTHAL P, 1987, HEPATOLOGY, V7, P107, DOI 10.1002/hep.1840070122; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DELONG MR, 1990, FUNCTION DYSFUNCTION; DUNK AA, 1989, DEV CLIN EXPT NEUROP, P39; GAMMAL SH, 1989, MED CLIN N AM, V73, P793, DOI 10.1016/S0025-7125(16)30639-3; HUNTER R, 1989, PSYCHOL MED, V19, P847, DOI 10.1017/S0033291700005560; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P331, DOI 10.1038/jcbfm.1991.66; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MOORE JW, 1989, J HEPATOL, V9, P319, DOI 10.1016/0168-8278(89)90140-2; NEIRINCKX RD, 1988, J CEREBR BLOOD F MET, V8, pS4, DOI 10.1038/jcbfm.1988.27; Nelson H.E., 1982, WIND UK NFER NELSON; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; SCHOMERUS H, 1981, DIGEST DIS SCI, V26, P622, DOI 10.1007/BF01367675; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; TARTER RE, 1987, INT J NEUROSCI, V32, P901, DOI 10.3109/00207458709043346; TARTER RE, 1988, MED NEUROPSYCHOLOGY, P75	18	128	129	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 25	1991	337	8752					1250	1253		10.1016/0140-6736(91)92920-W	http://dx.doi.org/10.1016/0140-6736(91)92920-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN047	1674063				2022-12-01	WOS:A1991FN04700004
J	PRETTYMAN, RJ; FRIEDMAN, T				PRETTYMAN, RJ; FRIEDMAN, T			CARE OF WOMEN WITH PUERPERAL PSYCHIATRIC-DISORDERS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER GEN HOSP,LEICESTER LE5 4PW,ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital								KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; Marce LV, 1858, TRAITE FOLIE FEMMES; OATES M, 1988, MOTHERHOOD MENTAL IL, V2, P138	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1245	1246		10.1136/bmj.302.6787.1245	http://dx.doi.org/10.1136/bmj.302.6787.1245			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043849	Green Published, Bronze			2022-12-01	WOS:A1991FP27200025
J	RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF				RANIERI, E; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; POLLARD, AC; ROBERTSON, EF			NEONATAL SCREENING STRATEGY FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							ASSAY; POPULATION; MUTATIONS	Objective - To assess the effectiveness of a two tier neonatal screening strategy for cystic fibrosis, which combines estimation of immunoreactive trypsinogen followed by direct gene analysis in dried blood spot samples collected at age 5 days. Design - Prospective study of two tier screening strategy. The first tier of testing immunoreactive trypsinogen concentration was measured in dried blood spot samples from neonates aged 4-5 days. In the second tier direct gene analysis to detect cystic fibrosis mutations DELTA-F508 and DELTA-I506 was performed in those blood spot ssmples which produced the highest 1% of immunoreactive trypsinogen values. Direct gene analysis was also performed on blood spot samples from infants with suspected or confirmed meconium ileus, regardless of the immunoreactive trypsinogen value. Setting - The South Australian Neonatal Screening Programme, operating from the department of chemical pathology at Adelaide Children's Hospital. Subjects - All 12 056 neonates born in South Australia between December 1989 and June 1990. No selection criteria were applied. Interventions - All infants found to have two recognised cystic fibrosis mutations on direct gene analysis were referred directly for clinical management, and those with one recognised cystic fibrosis mutation were recalled for a sweat test; their families were given genetic counselling. Main outcome measures - Diagnosis or exclusion of cystic fibrosis by sweat testing of neonates identified as being at high risk of cystic fibrosis on screening and of those at minimum risk but whose subsequent clinical history raised suspicion about the disease. Results - Of the 12 056 infants screened, 11 907 (98.8%) were reported as "cystic fibrosis not indicated" on the basis of low immunoreactive trypsinogen values. Of the 148 (1.23%) infants with raised immunoreactive trypsinogen values and one (0.008%) with meconium ileus, 132 (1.09%) were reported as cystic fibrosis not indicated, four (0.033%) were identified as having cystic fibrosis, and 13 (0.108%) were recalled for sweat testing after direct gene analysis for the presence of the DELTA-F508 and DELTA-I506 cystic fibrosis mutations. No cases of affected infants are known to have been missed to date. Conclusion - The strategy of measurement of immunoreactive trypsinogen followed by direct gene analysis is a highly specific neonatal screen for cystic fibrosis, requiring only 2.8 families to be contacted for every case of cystic fibrosis diagnosed.	ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA					Morris, Phillip/0000-0001-8976-619X				ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOWLING FG, 1987, ADV NEONATAL SCREENI, P391; CASSIO A, 1984, ACTA PAEDIATR SCAND, V73, P554, DOI 10.1111/j.1651-2227.1984.tb09970.x; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CORSSLEY JP, 1979, LANCET, V2, P472; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; GIBSON LE, 1959, PEDIATRICS, V23, P545; HAMMOND K, 1987, ADV NEONATAL SCREENI, P377; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KING DN, 1979, LANCET, V2, P1217; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; PEDERZINI F, 1984, LANCET, V1, P959; ROCK MJ, 1990, PEDIATRICS, V85, P1001; RYLEY HC, 1988, J CLIN PATHOL, V41, P726, DOI 10.1136/jcp.41.7.726; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILKEN B, 1985, LANCET, V2, P1319; WILKEN B, 1987, ADV NEONATAL SCREENI, P385; WILKEN B, 1983, J PEDIATR, V102, P383	23	54	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1237	1240		10.1136/bmj.302.6787.1237	http://dx.doi.org/10.1136/bmj.302.6787.1237			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043846	Green Published, Bronze			2022-12-01	WOS:A1991FP27200021
J	SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL				SEIDMAN, DS; LAOR, A; GALE, R; STEVENSON, DK; MASHIACH, S; DANON, YL			BIRTH-WEIGHT, CURRENT BODY-WEIGHT, AND BLOOD-PRESSURE IN LATE ADOLESCENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; ADULT LIFE; PREGNANCY; CHILDHOOD; CHILDREN; SIZE	Objective - To study the effect of birth weight and body weight on blood pressure in late adolescence. Design - Analysis of data on weight, height, and blood pressure at age 17 of subjects from the Jerusalem perinatal study, according to their birth weight. Data for men and women were analysed separately. Setting - Jerusalem, Israel. Subjects - 32 580 subjects (19 734 men and 12 846 women) born in the three major hospitals in Jerusalem during 1964-71 and subsequently drafted in to the army. Main outcome measures - Correlations between birth weight and blood pressure at age 17 and weight and height at age 17 and blood pressure. Results - Diastolic and systolic blood pressures were associated with birth weight in both young men and young women, but the correlation coefficients were low. A high body weight at age 17 (> 66 kg for women, > 75 kg for men) rather than a low birth weight (< 2500 g) was linked with higher systolic and diastolic blood pressures in both men and women (p < 0.01). Conclusions - Intrauterine environment, as reflected by birth weight, has little effect on blood pressure in young men and women. Modification of factors which lead to excess weight during adolescence may have a major role in preventing hypertension in adults.	ISRAELI DEF FORCES, MED CORPS, MED STAT BRANCH, JERUSALEM, ISRAEL; BIKUR CHOLIM HOSP, DEPT NEONATOL, JERUSALEM, ISRAEL; STANFORD UNIV, MED CTR, SCH MED, DEPT PAEDIAT, STANFORD, CA 94305 USA; TEL AVIV UNIV, SACKLER SCH MED, BEILINSON MED CTR, DIV PAEDIAT IMMUNOL, TEL AVIV, ISRAEL	Stanford University; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	SEIDMAN, DS (corresponding author), CHAIM SHEBA MED CTR, DEPT OBSTET & GYNAECOL, IL-52621 TEL HASHOMER, ISRAEL.							BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Cater J, 1984, LOW BIRTH WEIGHT MED, P191; DAVIES AM, 1969, ISRAEL J MED SCI, V5, P1095; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HACK M, 1990, PEDIATR RES, V27, pA93; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; LAUER RM, 1989, PEDIATRICS, V84, P633; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; SIMPSON A, 1981, HYPERTENSION YOUNG O, P154; WILSON SL, 1985, HYPERTENSION, V7, P417, DOI 10.1161/01.HYP.7.3_Pt_1.417; 1985, SAS USERS GUIDE	17	128	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 25	1991	302	6787					1235	1237		10.1136/bmj.302.6787.1235	http://dx.doi.org/10.1136/bmj.302.6787.1235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	2043845	Bronze, Green Published			2022-12-01	WOS:A1991FP27200020
J	TAITZ, LS				TAITZ, LS			CHILD-ABUSE AND METABOLIC BONE-DISEASE - ARE THEY OFTEN CONFUSED	BRITISH MEDICAL JOURNAL			English	Article							OSTEOGENESIS IMPERFECTA				TAITZ, LS (corresponding author), CHILDRENS HOSP,PAEDIAT,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND.							PATERSON CR, 1989, BMJ-BRIT MED J, V299, P1451, DOI 10.1136/bmj.299.6713.1451; PATTERSON CR, 1989, BMJ, V295, P213; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; TAITZ LS, 1988, BRIT MED J, V296, P292, DOI 10.1136/bmj.296.6617.292-a; TAITZ LS, 1987, CHILD ABUSE REV, V1, P6	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1244	1244		10.1136/bmj.302.6787.1244	http://dx.doi.org/10.1136/bmj.302.6787.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP272	2043847	Green Published			2022-12-01	WOS:A1991FP27200023
J	TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S				TATTERSALL, R; GREGORY, R; SELBY, C; KERR, D; HELLER, S			COURSE OF BRITTLE DIABETES - 12-YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							HYPOGLYCEMIA; IDDM	Objective - To determine the course of brittle diabetes. Design - 12 year follow up of patients identified in 1977-9 as having brittle diabetes; retrospective review of the case notes. Setting - Nottingham health district. Subjects - 25 brittle diabetic patients were identified in 1979-9; 11 (five men) had three or more admissions with ketoacidosis between June 1977 and 1979 and 14 (eight men) had three or more attendances at the accident and emergency department with hypoglycaemia in 1978. Two controls from our diabetic register were matched to each patient for age, sex, and duration of diabetes. Main outcome measures - Frequency of ketoacidosis and severe hypoglycaemia in the 12 years after ascertainment; diabetic control and complications in 1988-90; retrospective attribution of the cause of brittleness. Results - Patients with recurrent ketoacidosis had had a median (range) of 28 (8-67) episodes. One man died of a cerebral tumour but five of the surviving nine patients had not been admitted in the past two years, although diabetic control remained poor (median haemoglobin A1 concentration 14%). Seven patients had pure hypoglycaemic brittleness, and five had also had eight or more admissions with ketoacidosis (mixed brittleness). Two died of uraemia within a year after ascertainment and two others in hypoglycaemic coma seven and 12 years later. Brittle diabetes was in most cases related to a specific situation, usually unhappiness at home or school. Conclusions - Brittle diabetes is often episodic and almost always related to stressful life circumstances. Once the underlying cause is removed it tends to improve. Recurrent hypoglycaemic brittleness of psychological origin has a poor prognosis.			TATTERSALL, R (corresponding author), UNIV NOTTINGHAM HOSP,DEPT DIABET,NOTTINGHAM NG7 2UH,ENGLAND.			Heller, Simon/0000-0002-2425-9565				AMBLER J, 1983, CLIN CHEM, V29, P340; [Anonymous], 1968, CLIN DIABETES MELLIT, V15, P307; BRINK SJ, 1986, JAMA-J AM MED ASSOC, V255, P617; CHAPMAN J, 1988, DIABETIC MED, V5, P659, DOI 10.1111/j.1464-5491.1988.tb01075.x; CLAUSENSJOBOM N, 1989, DIABETOLOGIA, V32, P818; CRYER PE, 1989, DIABETES, V38, P1193, DOI 10.2337/diabetes.38.9.1193; FARBEROW NL, 1970, PSYCHOL REP, V27, P935, DOI 10.2466/pr0.1970.27.3.935; FLEXNER CW, 1984, AM J MED, V76, P691, DOI 10.1016/0002-9343(84)90297-3; GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; GRIFFITH DNW, 1989, DIABETIC MED, V6, P440, DOI 10.1111/j.1464-5491.1989.tb01201.x; HARDY KJ, 1991, DIABETIC MED, V8, P69, DOI 10.1111/j.1464-5491.1991.tb01518.x; HEDLEY AJ, 1982, BRIT MED J, V285, P509, DOI 10.1136/bmj.285.6340.509-a; JONES RB, 1983, METHOD INFORM MED, V22, P4; O'Brien I A, 1985, Diabet Med, V2, P392; POTTER J, 1982, BRIT MED J, V285, P1180, DOI 10.1136/bmj.285.6349.1180; SCHADE DS, 1985, DIABETES CARE, V8, P12, DOI 10.2337/diacare.8.1.12; SCHULER G, 1989, DIABETES RES CLIN PR, V6, P145, DOI 10.1016/0168-8227(89)90119-8; TATTERSALL R, 1977, CLIN ENDOCRINOL META, V6, P403, DOI 10.1016/S0300-595X(77)80045-5; TATTERSALL RB, 1985, BMJ, V291, P55; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13; Woodyatt RT., 1934, TXB MED AM AUTHORS, V3rd ed, P628; 1988, DIABETES CARE, V11, P669	23	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1240	1243		10.1136/bmj.302.6787.1240	http://dx.doi.org/10.1136/bmj.302.6787.1240			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1904287	Green Published, Bronze			2022-12-01	WOS:A1991FP27200022
J	CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD				CALNAN, BJ; TIDOR, B; BIANCALANA, S; HUDSON, D; FRANKEL, AD			ARGININE-MEDIATED RNA RECOGNITION - THE ARGININE FORK	SCIENCE			English	Article								Short peptides that contain the basic region of the HIV-1 Tat protein bind specifically to a bulged region in TAR RNA. A peptide that contained nine arginines (R9) also bound specifically to TAR, and a mutant Tat protein that contained R9 was fully active for transactivation. In contrast, a peptide that contained nine lysines (K9) bound TAR poorly and the corresponding protein gave only marginal activity. By starting with the K9 mutant and replacing lysine residues with arginines, a single arginine was identified that is required for specific binding and transactivation. Ethylation interference experiments suggest that this arginine contacts two adjacent phosphates at the RNA bulge. Model building suggests that the arginine eta-nitrogens and the epsilon-nitrogen can form specific networks of hydrogen bonds with adjacent pairs of phosphates and that these arrangements are likely to occur near RNA loops and bulges and not within double-stranded A-form RNA. Thus, arginine side chains may be commonly used to recognize specific RNA structures.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; MILLIGEN BIOSEARCH, NOVATO, CA 94949 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute				/0000-0002-3320-3969	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CALNAN BJ, UNPUB; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P17; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VLASSOV VV, 1981, EUR J BIOCHEM, V119, P51, DOI 10.1111/j.1432-1033.1981.tb05575.x; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	32	588	594	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1167	1171		10.1126/science.252.5009.1167	http://dx.doi.org/10.1126/science.252.5009.1167			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1709522				2022-12-01	WOS:A1991FN05600049
J	CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R				CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R			REQUIREMENT OF GTP HYDROLYSIS FOR DISSOCIATION OF THE SIGNAL RECOGNITION PARTICLE FROM ITS RECEPTOR	SCIENCE			English	Article								The signal recognition particle (SRP) directs signal sequence specific targeting of ribosomes to the rough endoplasmic reticulum. Displacement of the SRP from the signal sequence of a nascent polypeptide is a guanosine triphosphate (GTP)-dependent reaction mediated by the membrane-bound SRP receptor. A nonhydrolyzable GTP analog can replace GTP in the signal sequence displacement reaction, but the SRP then fails to dissociate from the membrane. Complexes of the SRP with its receptor containing the nonhydrolyzable analog are incompetent for subsequent rounds of protein translocation. Thus, vectorial targeting of ribosomes to the endoplasmic reticulum is controlled by a GTP hydrolysis cycle that regulates the affinity between the SRP, signal sequences, and the SRP receptor.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CONNOLLY T, UNPUB; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69	27	172	174	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1171	1173		10.1126/science.252.5009.1171	http://dx.doi.org/10.1126/science.252.5009.1171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1851576				2022-12-01	WOS:A1991FN05600050
J	ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W				ENGEL, AK; KONIG, P; KREITER, AK; SINGER, W			INTERHEMISPHERIC SYNCHRONIZATION OF OSCILLATORY NEURONAL RESPONSES IN CAT VISUAL-CORTEX	SCIENCE			English	Article								Neurons in area 17 of cat visual cortex display oscillatory responses that can synchronize across spatially separate columns in a stimulus-specific way. Response synchronization has now been shown to occur also between neurons in area 17 of the right and left cerebral hemispheres. This synchronization was abolished by section of the corpus callosum. Thus, the response synchronization is mediated by corticocortical connections. These data are compatible with the hypothesis that temporal synchrony of neuronal discharges serves to bind features within and between the visual hemifields.			ENGEL, AK (corresponding author), MAX PLANCK INST HIRNFORSCH, DEUTSCHORDENSTR 46, W-6000 FRANKFURT 71, GERMANY.		Engel, Andreas K./AAH-6384-2019; Singer, Wolf/D-6874-2012; Engel, Andreas K/C-7781-2012; König, Peter/ABB-2380-2020	Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466; König, Peter/0000-0003-3654-5267				ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1990, PARALLEL PROCESSING IN NEURAL SYSTEMS AND COMPUTERS, P105; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; ENGEL AK, 1990, SOC NEUR ABSTR, V16, P5231; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1967, J NEUROPHYSIOL, V30, P1561, DOI 10.1152/jn.1967.30.6.1561; INNOCENTI GM, 1980, ARCH ITAL BIOL, V118, P124; Innocenti GM., 1986, GEN ORG CALLOSAL CON, P291, DOI [10.1007/978-1-4613-2149-1_9, DOI 10.1007/978-1-4613-2149-1_9]; Konig P, 1991, NEURAL COMPUT, V3, P155, DOI 10.1162/neco.1991.3.2.155; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; TOYAMA K, 1988, NEUROBIOLOGY NEOCORT, P203; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; Woelcke M, 1942, J PSYCHOL NEUROL, V51, P199	17	680	685	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1177	1179		10.1126/science.252.5009.1177	http://dx.doi.org/10.1126/science.252.5009.1177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031188				2022-12-01	WOS:A1991FN05600052
J	LUPAS, A; VANDYKE, M; STOCK, J				LUPAS, A; VANDYKE, M; STOCK, J			PREDICTING COILED COILS FROM PROTEIN SEQUENCES	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; TRANSFER-RNA-SYNTHETASE; LEUCINE ZIPPER MOTIF; DNA-BINDING PROTEIN; ESCHERICHIA-COLI; INTERMEDIATE FILAMENTS; MYOSIN ROD; EXPRESSION; SUBUNIT; GENE	The probability that a residue in a protein is part of a coiled-coil structure was assessed by comparison of its flanking sequences with sequences of known coiled-coil proteins. This method was used to delineate coiled-coil domains in otherwise globular proteins, such as the leucine zipper domains in transcriptional regulators, and to predict regions of discontinuity within coiled-coil structures, such as the hinge region in myosin. More than 200 proteins that probably have coiled-coil domains were identified in GenBank, including alpha- and beta-tubulins, flagellins, G protein beta-subunits, some bacterial transfer RNA synthetases, and members of the heat shock protein (Hsp70) family.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NIAID NIH HHS [AI20980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYER PD, 1987, NUCLEIC ACIDS RES, V15, P2309, DOI 10.1093/nar/15.5.2309; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; FEDOROV OV, 1988, FEBS LETT, V241, P145, DOI 10.1016/0014-5793(88)81048-2; FREYMANN D, 1990, FASEB J, V4, pA2166; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; FU JH, 1989, MOL CELL BIOL, V9, P1120; HARRINGTON WF, 1984, ANNU REV BIOCHEM, V53, P35, DOI 10.1146/annurev.bi.53.070184.000343; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JASIN M, 1984, CELL, V36, P1089, DOI 10.1016/0092-8674(84)90059-X; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; KUWAJIMA G, 1988, J BACTERIOL, V170, P3305, DOI 10.1128/jb.170.7.3305-3309.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; YANEVA M, 1989, J BIOL CHEM, V264, P13407	31	3495	3593	8	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1162	1164		10.1126/science.252.5009.1162	http://dx.doi.org/10.1126/science.252.5009.1162			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031185				2022-12-01	WOS:A1991FN05600047
J	OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL				OBERLE, I; ROUSSEAU, F; HEITZ, D; KRETZ, C; DEVYS, D; HANAUER, A; BOUE, J; BERTHEAS, MF; MANDEL, JL			INSTABILITY OF A 550 BASE PAIR DNA SEGMENT AND ABNORMAL METHYLATION IN FRAGILE X-SYNDROME	SCIENCE			English	Article								The fragile X syndrome, a common cause of inherited mental retardation, is characterized by an unusual mode of inheritance. Phenotypic expression has been linked to abnormal cytosine methylation of a single CpG island, at or very near the fragile site. Probes adjacent to this island detected very localized DNA rearrangements that constituted the fragile X mutations, and whose target was a 550-base pair GC-rich fragment. Normal transmitting males had a 150- to 400-base pair insertion that was inherited by their daughters either unchanged, or with small differences in size. Fragile X-positive individuals in the next generation had much larger fragments that differed among siblings and showed a generally heterogeneous pattern indicating somatic mutation. The mutated allele appeared unmethylated in normal transmitting males, methylated only on the inactive X chromosome in their daughters, and totally methylated in most fragile X males. However, some males had a mosaic pattern. Expression of the fragile X syndrome thus appears to result from a two-step mutation as well as a highly localized methylation. Carriers of the fragile X mutation can easily be detected regardless of sex or phenotypic expression, and rare apparent false negatives may result from genetic heterogeneity or misdiagnosis.	FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, F-67085 STRASBOURG, FRANCE; INSERM, U73, F-75016 PARIS, FRANCE; HOP NORD ST PRIEST JAREZ, F-42277 St Priest En Jarez, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)				Devys, Didier/0000-0001-9655-3512				BAKER E, 1985, AM J MED GENET, V22, P433; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CAMERINO G, 1983, NATURE, V306, P701, DOI 10.1038/306701a0; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JACKY PB, 1991, AM J MED GENET, V38, P400, DOI 10.1002/ajmg.1320380249; JENKINS EC, 1991, AM J MED GENET, V38, P447, DOI 10.1002/ajmg.1320380262; KENNERKNECHT I, 1991, AM J MED GENET, V38, P467, DOI 10.1002/ajmg.1320380266; LAIRD CD, 1990, AM J HUM GENET, V46, P696; LAIRD CD, 1991, AM J MED GENET, V38, P391, DOI 10.1002/ajmg.1320380247; LAIRD CD, 1987, GENETICS, V117, P587; MIGEON BR, 1986, P NATL ACAD SCI USA, V83, P2182, DOI 10.1073/pnas.83.7.2182; NUSSBAUM RL, 1986, AM J MED GENET, V23, P457, DOI 10.1002/ajmg.1320230137; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1986, HUM GENET, V72, P43, DOI 10.1007/BF00278816; PEMBREY ME, 1985, AM J MED GENET, V21, P709, DOI 10.1002/ajmg.1320210413; RHOADS FA, 1982, AM J MED GENET, V12, P205, DOI 10.1002/ajmg.1320120211; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; ROUSSEAU F, UNPUB; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; SUTHERS GK, 1991, AM J HUM GENET, V48, P460; SVED JA, 1990, AM J HUM GENET, V46, P443; TOMMERUP N, 1989, HUM GENET, V81, P377, DOI 10.1007/BF00283696; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; VOELCKEL MA, 1989, HUM GENET, V81, P353, DOI 10.1007/BF00283690; VOGEL F, 1990, HUM GENET, V86, P25; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; WEBB T, 1989, FRAGILE X SYNDROME, P40; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]	37	1315	1343	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1097	1102		10.1126/science.252.5009.1097	http://dx.doi.org/10.1126/science.252.5009.1097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031184				2022-12-01	WOS:A1991FN05600035
J	OLSON, DJ; CHRISTIAN, JL; MOON, RT				OLSON, DJ; CHRISTIAN, JL; MOON, RT			EFFECT OF WNT-1 AND RELATED PROTEINS ON GAP JUNCTIONAL COMMUNICATION IN XENOPUS EMBRYOS	SCIENCE			English	Article							EARLY AMPHIBIAN EMBRYO; PROTO-ONCOGENE INT-1; MURINE INT-1; DROSOPHILA HOMOLOG; CELL COMMUNICATION; GENE; PROTOONCOGENE; EXPRESSION; WINGLESS; PATTERNS	The proto-oncogene wnt-1 (previously referred to as int-1) is thought to be important in embryonic pattern formation although its mechanisms of action are unknown. Premature and increased expression of the Wnt-1 protein, achieved by injection of synthetic wnt-1 RNA into fertilized Xenopus eggs, enhanced gap junctional communication between ventral cells of the developing embryo. This result is consistent with the hypothesis that Wnt proteins activate a receptor-mediated signal transduction pathway and that gap junctional communication can be a target of this pathway. The effects of two Wnt-1-related proteins on gap junctional communication were also investigated: overexpression of Xwnt-8 increased gap junctional coupling in a manner similar to Wnt-1, whereas Xwnt-5A did not. These findings are consistent with the existence of multiple receptors for Wnt proteins.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837, R01AR040089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007023] Funding Source: NIH RePORTER; NIAMS NIH HHS [KO4-AR01837, R01-AR40089] Funding Source: Medline; NIDCR NIH HHS [DE-07023] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BERRIDGE MJ, 1982, BIOCHEM J, V206, P507; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, IN PRESS DEVELOPMENT; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FAWCETT DW, 1981, CELL, P124; FRASER SE, 1987, SCIENCE, V237, P49, DOI 10.1126/science.3037697; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GUTHRIE S, 1988, DEVELOPMENT, V103, P769; GUTHRIE SC, 1984, NATURE, V311, P149, DOI 10.1038/311149a0; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1989, TECHNIQUE, V1, P76; MOON RT, UNPUB; NAGAJSKI DJ, 1989, DEVELOPMENT, V105, P747; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; OLSON DA, UNPUB; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, IN PRESS GENES DEV; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WARNER AE, 1986, SOMITES DEV EMBRYOS, P91; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	42	128	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1173	1176		10.1126/science.252.5009.1173	http://dx.doi.org/10.1126/science.252.5009.1173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031187				2022-12-01	WOS:A1991FN05600051
J	PIATIGORSKY, J; WISTOW, G				PIATIGORSKY, J; WISTOW, G			THE RECRUITMENT OF CRYSTALLINS - NEW FUNCTIONS PRECEDE GENE DUPLICATION	SCIENCE			English	Editorial Material							ALPHA-B-CRYSTALLIN; LENS CRYSTALLINS; TRANSGENIC MICE; ALDEHYDE DEHYDROGENASE; ENZYME-CRYSTALLINS; STRUCTURAL PROTEIN; DELTA-CRYSTALLIN; DUCK LENS; EYE LENS; EXPRESSION				PIATIGORSKY, J (corresponding author), NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892, USA.							ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KIMURA M, 1974, P NATL ACAD SCI USA, V71, P2848, DOI 10.1073/pnas.71.7.2848; KLEMENT JF, 1989, J BIOL CHEM, V264, P19837; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KONDOH H, 1987, DEV BIOL, V120, P177, DOI 10.1016/0012-1606(87)90116-3; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; PIATIGORSKY J, ADV DEV BIOCH, V1; RAO PSS, COMMUNICATION; THOMAS G, 1990, New Biologist, V2, P903; WAWROUSEK EF, 1990, DEV BIOL, V137, P68, DOI 10.1016/0012-1606(90)90008-7; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	39	274	275	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1078	1079		10.1126/science.252.5009.1078	http://dx.doi.org/10.1126/science.252.5009.1078			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031181				2022-12-01	WOS:A1991FN05600031
J	PRIME, KL; WHITESIDES, GM				PRIME, KL; WHITESIDES, GM			SELF-ASSEMBLED ORGANIC MONOLAYERS - MODEL SYSTEMS FOR STUDYING ADSORPTION OF PROTEINS AT SURFACES	SCIENCE			English	Article							HYDROPHOBIC CHROMATOGRAPHY; GOLD; THIOLS; CHAIN; FILMS; COADSORPTION; ELLIPSOMETRY; INTERFACES; POLYMERS; SERIES	Self-assembled monolayers (SAMs) of omega-functionalized long-chain alkanethiolates on gold films are excellent model systems with which to study the interactions of proteins with organic surfaces. Monolayers containing mixtures of hydrophobic (methyl-terminated) and hydrophilic [hydroxyl-, maltose-, and hexa(ethylene glycol)-terminated] alkanethiols can be tailored to select specific degrees of adsorption: the amount of protein adsorbed varies monotonically with the composition of the monolayer. The hexa(ethylene glycol)-terminated SAMs are the most effective in resisting protein adsorption. The ability to create interfaces with similar structures and well-defined compositions should make it possible to test hypotheses concerning protein adsorption.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ALLMER K, 1990, J POLYM SCI POL CHEM, V28, P173, DOI 10.1002/pola.1990.080280112; ANDRADE JD, 1986, ADV POLYM SCI, V79, P1; [Anonymous], [No title captured]; ARNEBRANT T, 1985, PROG COLL POL SCI S, V70, P62; BAIN CD, 1989, J AM CHEM SOC, V111, P7155, DOI 10.1021/ja00200a039; BAIN CD, 1989, J PHYS CHEM-US, V93, P1670, DOI 10.1021/j100341a095; BAIN CD, 1989, J AM CHEM SOC, V111, P7164, DOI 10.1021/ja00200a040; BAIN CD, 1988, SCIENCE, V240, P62, DOI 10.1126/science.240.4848.62; BJORLING M, 1990, J PHYS CHEM-US, V94, P471, DOI 10.1021/j100364a082; BOHNERT JL, 1988, INVEST OPHTHALMOL VI, V29, P363; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; CHIDSEY CED, 1989, J CHEM PHYS, V91, P4421, DOI 10.1063/1.456776; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DETTRE RH, 1965, J PHYS CHEM-US, V69, P1507, DOI 10.1021/j100889a012; EVERETT DH, 1988, BASIC PRINCIPLES COL, P45; FLEMINGER G, 1990, J CHROMATOGR, V510, P271, DOI 10.1016/S0021-9673(01)93761-6; GRAINGER DW, 1989, J COLLOID INTERF SCI, V132, P161, DOI 10.1016/0021-9797(89)90226-9; HALPERIN G, 1984, J CHROMATOGR, V317, P103, DOI 10.1016/S0021-9673(01)91651-6; Horbett T. A., 1986, HYDROGELS MED PHARM, V1, P127; IVERSSON B, 1986, CRIT REV BIOCOMPUT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; Jeon I, 1991, J COLLOID INTERF SCI, V142, P149; JEON SI, 1991, J COLLOID INTERF SCI, V142, P159, DOI 10.1016/0021-9797(91)90044-9; KARLSTROM G, 1985, J PHYS CHEM-US, V89, P4962, DOI 10.1021/j100269a015; Macritchie F, 1978, Adv Protein Chem, V32, P283, DOI 10.1016/S0065-3233(08)60577-X; MATSUURA H, 1985, J MOL STRUCT, V126, P251, DOI 10.1016/0022-2860(85)80118-6; MATSUURA H, 1991, J AM CHEM SOC, V113, P1193, DOI 10.1021/ja00004a020; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; MUIRHEAD H, 1987, BIOL MACROMOL, V3, P143; NUZZO RG, 1990, J AM CHEM SOC, V112, P558, DOI 10.1021/ja00158a012; NUZZO RG, 1990, J CHEM PHYS, V93, P767, DOI 10.1063/1.459528; PALEGROSDEMANGE C, 1991, J AM CHEM SOC, V113, P12, DOI 10.1021/ja00001a002; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; SADA E, 1985, BIOTECHNOL BIOENG, V27, P514, DOI 10.1002/bit.260270418; SCHAKENRAAD JM, 1989, COLLOID SURFACE, V42, P331; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; WEST TP, 1985, BIOCHIM BIOPHYS ACTA, V839, P32, DOI 10.1016/0304-4165(85)90178-3; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010	43	2056	2141	14	555	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1164	1167		10.1126/science.252.5009.1164	http://dx.doi.org/10.1126/science.252.5009.1164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	2031186				2022-12-01	WOS:A1991FN05600048
J	VAGELOS, PR				VAGELOS, PR			ARE PRESCRIPTION DRUG PRICES HIGH	SCIENCE			English	Article							COENZYME-A REDUCTASE; FAMILIAL HYPERCHOLESTEROLEMIA; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; HYDROXYMETHYLGLUTARYL-COENZYME; CHOLESTEROL; MEVINOLIN; INHIBITOR; FIBROBLASTS; ML-236A; COSTS	The U.S. pharmaceutical industry has been criticized because its products are perceived to be too expensive, yet prescription medicines remain the least expensive form of therapy. At this time, we are experiencing a dramatic increase in the risks and costs of pharmaceutical research and development (R&D). An example may be seen in the R&D history of lovastatin. The U.S. pharmaceutical industry continues to lead the world in the discovery and development of important new medicines because it assumes greater financial risk and invests more of its sales dollar in R&D than virtually any other industry. Where such a risk is posed, there must continue to be the potential for profits. Pharmaceutical companies must set responsible prices, must keep price increases down, and must help improve access to important medicines.			VAGELOS, PR (corresponding author), MERCK & CO INC,RAHWAY,NJ 07065, USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ALBERTSSCHONBERG G, 1980, Patent No. 4231938; Anitschkow N, 1913, BEITR PATHOL ANAT AL, V56, P379; BILHEIMER DW, 1983, T ASSOC AM PHYSICIAN, V96, P1; Bloch K, 1942, J BIOL CHEM, V145, P625; BROUN M, 1990, J NATL CANCER I, V82, P1811; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BROWN MS, 1975, J BIOL CHEM, V250, P4025; BUCHER NLR, 1960, BIOCHIM BIOPHYS ACTA, V40, P491, DOI 10.1016/0006-3002(60)91390-1; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHANG TY, 1977, P NATL ACAD SCI USA, V74, P832, DOI 10.1073/pnas.74.3.832; CLAYTON RB, 1956, J BIOL CHEM, V218, P319; DIMASI JA, IN PRESS J HLTH; ECKHOLM E, 1989, NY TIMES MAGAZI 0108, P20; EISENBERG JM, 1984, REV INFECT DIS S4, V6, P909; ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9; ENDO A, 1979, J ANTIBIOT, V32, P852, DOI 10.7164/antibiotics.32.852; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804; GOULD RG, 1950, FED PROC, V9, P179; GRABOWSKI H, 1990, MANAGE SCI, V36, P804, DOI 10.1287/mnsc.36.7.804; HANSEN R, 1976, THESIS U ROCHESTER; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HUANG LF, 1988, PUBLIC HEALTH REP, V103, P3; ILLINGWORTH DR, 1984, J CLIN INVEST, V74, P1972, DOI 10.1172/JCI111618; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; Lubitz J, 1985, Health Care Financ Rev, V6, P103; LYNEN F, 1959, ANGEW CHEM INT EDIT, V71, P657, DOI 10.1002/ange.19590712102; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MANDELLBROWN M, 1984, OTOLARYNG HEAD NECK, V92, P520, DOI 10.1177/019459988409200504; MOSSINGHOFF G, 1989, COMMUNICATION   0718; NARIN F, 1989, SCIENCE, V245, P600, DOI 10.1126/science.245.4918.600; OTTKE RC, 1951, J BIOL CHEM, V189, P429; RISTOW W, 1990, NOV IMS INT PLYM M; SILVERBERG SH, 1990, COMMUNICATION    NOV; SLOAN FA, 1989, UNPUB DRUG FORMULARI; TAVORMINA PA, 1956, J AM CHEM SOC, V78, P4498, DOI 10.1021/ja01598a089; TOBERT JA, 1982, ATHEROSCLEROSIS, V41, P61, DOI 10.1016/0021-9150(82)90070-3; TOBERT JA, 1982, J CLIN INVEST, V69, P913, DOI 10.1172/JCI110530; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; WRIGHT LD, 1956, J AM CHEM SOC, V78, P5273, DOI 10.1021/ja01601a033; 1985, MODERN MED SAVINGS L; 1986, JAMA-J AM MED ASSOC, V256, P2829; 1988, JAMA-J AM MED ASSOC, V260, P359; 1988, PUBLIC HLTH REP, V103, P206; 1989, HLTH US 1989, P228; 1983, VITAL HLTH STATISTIC, V10; 1987, METROPOLITAN LIF JUL, P15; 1989, STATISTICAL ABSTRACT	50	95	98	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 24	1991	252	5009					1080	1084		10.1126/science.252.5009.1080	http://dx.doi.org/10.1126/science.252.5009.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN056	2031182				2022-12-01	WOS:A1991FN05600032
J	BAYER, R				BAYER, R			PUBLIC-HEALTH POLICY AND THE AIDS EPIDEMIC - AN END TO HIV EXCEPTIONALISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BAYER, R (corresponding author), COLUMBIA UNIV,NEW YORK,NY 10027, USA.							ABRAHAM L, 1988, AM MED NEWS     0708, P4; ALBAEK E, IN PRESS PASSIONS PO; [Anonymous], 1988, REPORT PRESIDENTIAL, P130; Bayer R., 1991, PRIVATE ACTS SOCIAL; FRANKENBERG G, IN PRESS PASSIONS PO; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; HENRIKSSON B, IN PRESS PASSION POL; JONES L, 1990, HIV INFECTION LABELE, P3; KRAUTHAMMER C, 1990, TIME            0625, P80; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1989, 43RD AMA P HOUS DEL, P76; 1989, REPORT HOUSE DELEGAT, P23; 1990, MMWR, V39, P861; 1988, FED REGISTER, V53, P3554; 1990, MMWR, V39, P110; 1988, C LOCAL HLTH OFFICES; 1990, HAS FEDERAL RES AIDS; 1988, CONFRONTING AIDS UPD, P82; 1990, 1989 INT AIDS REP, P3	19	174	175	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1500	1504		10.1056/NEJM199105233242111	http://dx.doi.org/10.1056/NEJM199105233242111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023610				2022-12-01	WOS:A1991FM46000011
J	BRENNAN, TA				BRENNAN, TA			TRANSMISSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS IN THE HEALTH-CARE SETTING - TIME FOR ACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RIGHTS COMMISSION DECISIONS; AIDS LITIGATION PROJECT; UNITED-STATES; HOUSEHOLD CONTACTS; NATIONAL SURVEY; HIV INFECTION; RISK; PHYSICIANS; WORKERS; EMERGENCY				BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABRAHAM K, 1986, DISTRIBUTING RISK, P227; ALTMAN LK, 1991, NY TIMES        0207, P4; ALTMAN LK, 1991, NY TIMES        0223, P9; ALTMAN LK, 1991, NY TIMES        0118, pA3; ANNAS GJ, 1988, HASTINGS CTR REPORT, V18, P26; ARRAS JD, 1988, HASTINGS CENT REP S, V18, P10; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BRENNAN TA, 1987, ANN INTERN MED, V107, P581, DOI 10.7326/0003-4819-107-4-581; BRENNAN TA, IN PRESS JUST DOCTOR; BRENNAN TA, 1988, DUKE LAW J, P243; Calabresi Guido, 1970, COSTS ACCIDENTS; CHELIUS JR, 1977, WORKPLACE SAFETY HLT; COOKE M, 1989, NEW ENGL J MED, V321, P1334, DOI 10.1056/NEJM198911093211911; CRISP R, 1990, AIDS MORAL ISSUE, P62; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; EDGAR H, 1990, AM J LAW MED, V16, P155; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FIELD MA, 1990, AM J LAW MED, V16, P33; FOY C, 1990, BRIT MED J, V300, P1048, DOI 10.1136/bmj.300.6731.1048; FRIEDLAND G, 1988, JAMA-J AM MED ASSOC, V259, P2898; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V263, P2413, DOI 10.1001/jama.263.18.2413; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; HENDERSON DK, 1986, ANN INTERN MED, V104, P644, DOI 10.7326/0003-4819-104-5-644; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JASON JM, 1986, JAMA-J AM MED ASSOC, V255, P212, DOI 10.1001/jama.255.2.212; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1990, J ACQ IMMUN DEF SYND, V3, P987; LEWIS CE, 1990, JAMA-J AM MED ASSOC, V264, P2764, DOI 10.1001/jama.264.21.2764; LIFSON AR, 1986, JAMA-J AM MED ASSOC, V256, P3231, DOI 10.1001/jama.256.23.3231; LO B, 1989, ANN INTERN MED, V110, P727; MANGIONE CM, 1991, AM J MED, V90, P85, DOI 10.1016/0002-9343(91)90510-5; MARSHALL PA, 1990, ARCH INTERN MED, V150, P1501, DOI 10.1001/archinte.150.7.1501; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; Peterson L M, 1989, Law Med Health Care, V17, P139; REED RR, 1987, JAMA-J AM MED ASSOC, V258, P3279, DOI 10.1001/jama.258.22.3279; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RIZZO JA, 1990, MED CARE, V28, P251, DOI 10.1097/00005650-199003000-00005; ROGERS DE, 1988, JAMA-J AM MED ASSOC, V259, P1368, DOI 10.1001/jama.259.9.1368; SADE RM, 1971, NEW ENGL J MED, V285, P1288, DOI 10.1056/NEJM197112022852304; SMITH TJ, 1990, TENN LAW REV, V57, P539; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SWARTZ MS, 1988, J HEALTH POLIT POLIC, V13, P607, DOI 10.1215/03616878-13-4-607; Turkington Richard C, 1989, Villanova Law Rev, V34, P871; VOLBERDING P, 1989, JAMA-J AM MED ASSOC, V261, P747, DOI 10.1001/jama.261.5.747; WATERS RC, 1990, FLA STATE U LAW REV, V17, P441; WEIL PA, 1990, MED CARE, V28, P468, DOI 10.1097/00005650-199005000-00006; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1990, NEW ENGL J MED, V322, P1392; 1987, JAMA-J AM MED ASSOC, V258, P2097; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2, V36, pS1; 1991, NATIONS HLTH     JAN, pA1; 1990, AAMC WEEKLY REPORT; 1989, PROTECTION DISCRIMIN; 1991, MMWR, V40, P21	65	35	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1504	1509		10.1056/NEJM199105233242112	http://dx.doi.org/10.1056/NEJM199105233242112			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM460	2023611				2022-12-01	WOS:A1991FM46000012
J	KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G				KIM, CM; KOIKE, K; SAITO, I; MIYAMURA, T; JAY, G			HBX GENE OF HEPATITIS-B VIRUS INDUCES LIVER-CANCER IN TRANSGENIC MICE	NATURE			English	Article							HEPATOCELLULAR-CARCINOMA; X-PROTEIN; MOUSE MODEL; TAT GENE; EXPRESSION; ANTIGEN; TUMORS; ACTIVATION; INTEGRATION; SECRETION	THE exact role of hepatitis B virus in the development of liver cancer is not known. The recent identification of a viral regulatory gene HBx suggests a possible direct involvement of the virus whereby the HBx protein, acting as a transcriptional transactivator of viral genes, may alter host gene expression and lead to the development of hepatocellular carcinoma. We have tested this possibility by placing the entire HBx gene under its own regulatory elements directly into the germline of mice. Transgenic animals harbouring this viral gene succumbed to progressive histopathological changes specifically in the liver, beginning with multifocal areas of altered hepatocytes, followed by the appearance of benign adenomas, and proceeding to the development of malignant carcinomas. Male mice developed disease and died much earlier than females. This transgenic animal model appears ideal for defining the molecular events that follow the expression of the viral HBx gene and are responsible for the development of liver cancer.	AMER RED CROSS,JEROME H HOLLAND LAB,VIROL LAB,ROCKVILLE,MD 20855; NATL INST HLTH,DEPT ENTEROVIRUSES,HEPATITIS VIRUSES LAB,TOKYO 141,JAPAN	American Red Cross; National Institute of Health Sciences - Japan			Jay, Gregory/C-6346-2013; Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BABINET C, 1985, SCIENCE, V230, P1160, DOI 10.1126/science.3865370; BANNASCH P, 1985, DIGESTIVE SYSTEM, P10; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEASLEY RP, 1981, LANCET, V2, P1129; BECKER FF, 1982, CANCER RES, V42, P3918; BROOKS PN, 1985, DIGESTIVE SYSTEM, P47; BURK RD, 1988, J VIROL, V62, P649, DOI 10.1128/JVI.62.2.649-654.1988; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; COSMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P4947, DOI 10.1073/pnas.79.16.4947; DEJEAN A, 1984, J GEN VIROL, V65, P651, DOI 10.1099/0022-1317-65-3-651; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FARZA H, 1988, J VIROL, V62, P4149; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KLIMEK F, 1984, CARCINOGENESIS, V5, P265, DOI 10.1093/carcin/5.2.265; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; KOIKE K, 1988, VIROLOGY, V163, P233, DOI 10.1016/0042-6822(88)90256-5; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POPP JA, 1985, DIGESTIVE SYSTEM, P39; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TREININ M, 1987, MOL CELL BIOL, V7, P545, DOI 10.1128/MCB.7.1.545; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545	39	1011	1052	7	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					317	320		10.1038/351317a0	http://dx.doi.org/10.1038/351317a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034275				2022-12-01	WOS:A1991FM97600061
J	KIM, J; CHEONG, C; MOORE, PB				KIM, J; CHEONG, C; MOORE, PB			TETRAMERIZATION OF AN RNA OLIGONUCLEOTIDE CONTAINING A GGGG SEQUENCE	NATURE			English	Article							5'-GUANOSINE MONOPHOSPHATE; FIBER DIFFRACTION; TELOMERIC DNA; X-RAY; MODEL; ACID	POLY rG can form four-stranded helices 1. The Hoogsteen-paired quartets of G residues on which such structures depend are so stable that they will form in 5'-GMP solutions, provided that Na+ or K+ are present (see for example, refs 2-4). Telomeric DNA sequences, which are G-rich, adopt four-stranded antiparallel G-quartet conformations in vitro 5,6, and parallel tetramerization of G-rich sequences may be involved in meiosis 7,8. Here we show that RNAs containing short runs of Gs can also tetramerize. A 19-base oligonucleotide derived from the 5S RNA of Escherichia coli (strand III), 5'GCCGAUGGUAGUGUGGGGU3', forms a K+-stabilized tetrameric aggregate that depends on the G residues at its 3' end. This complex is so stable that it would be surprising if similar structures do not occur in nature.			KIM, J (corresponding author), YALE UNIV, DEPT CHEM, 225 PROSPECT ST, NEW HAVEN, CT 06511 USA.		Cheong, Chaejoon/GWC-3135-2022					BORZO M, 1980, J AM CHEM SOC, V102, P1124, DOI 10.1021/ja00523a032; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; MOORE PB, 1988, METHOD ENZYMOL, V164, P158; PINNAVAIA TJ, 1978, J AM CHEM SOC, V100, P3625, DOI 10.1021/ja00479a070; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; STUDENCKI AB, 1981, THESIS U ILLINOIS; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZIMMERMAN SB, 1976, J MOL BIOL, V106, P663, DOI 10.1016/0022-2836(76)90257-6; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	12	137	144	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					331	332		10.1038/351331a0	http://dx.doi.org/10.1038/351331a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	1709723				2022-12-01	WOS:A1991FM97600066
J	KONDRASHOV, AS; CROW, JF				KONDRASHOV, AS; CROW, JF			HAPLOIDY OR DIPLOIDY - WHICH IS BETTER	NATURE			English	Article							SELECTION	ALTHOUGH the evolutionary advantages of sexual reproduction have been extensively discussed 1-3, much less attention has been paid to haploid and diploid phases of the sexual life cycle. The relative lengths of these phases differ greatly in various taxa, including as extremes those with one or the other phase reduced to a single cell. Here we consider the efficiency of elimination of deleterious mutations as an evolutionary force and compare the mutation loads under haploid and diploid selection, L(n) and L2n. With truncation-like selection, partial dominance, and heterozygous effect of a mutation less than about 1/4 its hemizygous effect, L2n < L(n); otherwise L2n > L(n). The difference becomes important when the genomic deleterious mutation rate exceeds about 1 per genome. This suggests that the mutation rate, degree of dominance and mode of selection can be important in life-cycle evolution.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; ACAD SCI USSR,CTR RES COMP,PUSHCHINO 142292,USSR	University of Wisconsin System; University of Wisconsin Madison; Russian Academy of Sciences								CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; CROW JF, 1979, P NATL ACAD SCI USA, V76, P396, DOI 10.1073/pnas.76.1.396; EFROIMSON V, 1932, J BIOL, V1, P87; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KARLIN S, 1974, THEOR POPUL BIOL, V5, P59, DOI 10.1016/0040-5809(74)90052-5; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Michod R. E., 1988, THE EVOLUTION OF SEX; MILKMAN R, 1978, GENETICS, V88, P391	13	148	151	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					314	315		10.1038/351314a0	http://dx.doi.org/10.1038/351314a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034273				2022-12-01	WOS:A1991FM97600059
J	LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM				LAI, KN; LI, PKT; LUI, SF; AU, TC; TAM, JSL; TONG, KL; LAI, FM			MEMBRANOUS NEPHROPATHY RELATED TO HEPATITIS-B VIRUS IN ADULTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; SURFACE ANTIGENEMIA; NEPHROTIC SYNDROME; VIRAL-HEPATITIS; GLOMERULONEPHRITIS; INFECTION; ANTIBODY; CHILDREN; ASSOCIATION; INTERFERON	Background. The natural course of adult hepatitis B virus (HBV)-related membranous nephropathy in areas where HBV infection is endemic (characterized by vertical and horizontal transmission of HBV in early childhood) has not been fully defined. Methods. We evaluated the clinical features, pathological findings, serologic profiles, therapeutic responses, and prognoses of 21 patients with adult-onset HBV-related membranous nephropathy. The patients were followed for a mean of 60 months (range, 12 to 108). Only patients with evidence of glomerular capillary deposition of hepatis B e antigen (HBeAg) in a renal-biopsy specimen were included. Results. The clinical features and serologic studies suggested that the patients had acquired chronic HBV infection in early childhood; moreover, other causes of membranous nephropathy had been excluded. All were seropositive for hepatitis B surface antigen and had high titers of antibody to hepatitis B core antigen at first clinical presentation. HBeAg was detected in the serum of 17 patients (81 percent), yet only 3 had even slightly increased plasma alanine aminotransferase levels. The clinical response to therapy with interferon alfa was disappointing; only one of the five patients treated had a complete remission with seroconversion to antibody to HBeAg. Contrary to reports of studies in children, spontaneous remission of the nephrotic syndrome or proteinuria was uncommon in the adults with HBV-related membranous nephropathy whom we studied. Proteinuria and HBV antigenemia persisted in untreated patients. During the follow-up period, 29 percent of the patients had progressive renal failure and 10 percent required maintenance dialysis therapy. Conclusions. The course of HBV-related membranous nephropathy in adults in areas where HBV is endemic is not benign. Regardless of treatment, the disease has a slowly but relentlessly progressive clinical course in approximately one third of patients.	CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MED,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PATHOL,SHA TIN,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Li, Philip K. T./D-4051-2017					BRZOKO W, 1974, LANCET, V2, P476; COGAN MG, 1977, AM J GASTROENTEROL, V68, P386; COMBES B, 1971, LANCET, V2, P234; FURUSE A, 1982, NEPHRON, V31, P212, DOI 10.1159/000182649; GARCIA G, 1985, HEPATOLOGY, V5, P317, DOI 10.1002/hep.1840050228; GUERRA IL, 1987, AM J KIDNEY DIS, V10, P385, DOI 10.1016/S0272-6386(87)80107-5; HIROSE H, 1984, KIDNEY INT, V26, P338, DOI 10.1038/ki.1984.178; HSU HC, 1983, CLIN NEPHROL, V20, P121; ITO H, 1981, LAB INVEST, V44, P214; KLEINKNECHT C, 1979, J PEDIATR-US, V95, P946, DOI 10.1016/S0022-3476(79)80281-4; KNECHT GL, 1978, GASTROENTEROLOGY, V75, P1152; KNIESER MR, 1974, ARCH PATHOL, V97, P193; KOHLER PF, 1974, ANN INTERN MED, V81, P448, DOI 10.7326/0003-4819-81-4-448; LAI KN, 1989, AM J CLIN PATHOL, V92, P159, DOI 10.1093/ajcp/92.2.159; LAI KN, 1989, ANN TROP PAEDIATR, V9, P45, DOI 10.1080/02724936.1989.11748595; LAI KN, 1990, NEPHRON, V54, P12; LAI KN, 1987, Q J MED, V63, P323; LEVY M, 1982, ADV NEPHROL, V11, P341; LIN CY, 1990, NEPHRON, V55, P37, DOI 10.1159/000185916; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1988, LANCET, V2, P298; MCCOLLUM RW, 1981, J MED VIROL, V8, P1, DOI 10.1002/jmv.1890080102; MIZUSHIMA N, 1987, GASTROENTEROLOGY, V92, P524, DOI 10.1016/0016-5085(87)90152-1; NAGY J, 1979, CLIN NEPHROL, V12, P109; PIGNATELLI M, 1987, J HEPATOL, V4, P15, DOI 10.1016/S0168-8278(87)80004-1; SEGGIE J, 1984, NEPHRON, V38, P115, DOI 10.1159/000183291; Szmuness W, 1978, VIRAL HEPATITIS, P297; TAKEKOSHI Y, 1978, LANCET, V2, P1065; THOMAS HC, 1985, BRIT MED BULL, V41, P374, DOI 10.1093/oxfordjournals.bmb.a072079; WONG VCW, 1984, LANCET, V1, P921	30	193	206	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1991	324	21					1457	1463		10.1056/NEJM199105233242103	http://dx.doi.org/10.1056/NEJM199105233242103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM460	2023605				2022-12-01	WOS:A1991FM46000003
J	PERROT, V; RICHERD, S; VALERO, M				PERROT, V; RICHERD, S; VALERO, M			TRANSITION FROM HAPLOIDY TO DIPLOIDY	NATURE			English	Article							DOMINANCE	AS a direct consequence of sex, organisms undergo a haploid and a diploid stage during their life cycle. Although the relative duration of haploid and diploid phases varies greatly among taxa, the diploid phase is more conspicuous in all higher organisms. Therefore it is widely believed that diploidy offers more evolutionary possibilities 1-3 and is thus nearly always selected for. We have now performed computer simulations to investigate one possible advantage of diploidy, that is, protection against the expression of deleterious mutations. Instead of comparing isolated haploid and diploid populations, we considered interbreeding haploids and diploids. Diploids invaded the population only when the dominance degree of a single deleterious mutation was smaller than about 1/2, and the condition allowing diploidy to invade depended on how harmful the mutation was.	UNIV SCI & TECHNOL LILLE FLANDRES ARTOIS, GENET & EVOLUT POPULAT VEGETALES LAB, CNRS, URA 1185, F-59655 VILLENEUVE DASCQ, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	PERROT, V (corresponding author), UNIV BASEL, INST ZOOL, RHEINSPRUNG 9, CH-4051 BASEL, SWITZERLAND.		Valero, Myriam/C-7550-2011; Valero, Myriam/M-6052-2019	Valero, Myriam/0000-0002-9000-1423; Valero, Myriam/0000-0002-9000-1423				BERNSTEIN H, 1981, AM NAT, V117, P537, DOI 10.1086/283734; CHARLESWORTH B, 1979, NATURE, V278, P848, DOI 10.1038/278848a0; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; Fisher RA, 1928, AM NAT, V62, P115, DOI 10.1086/280193; Haldane JBS, 1937, AM NAT, V71, P337, DOI 10.1086/280722; KACSER H, 1981, GENETICS, V97, P639; KIMURA M, 1961, JAPAN J GENET      S, V36, P179; KONDRASHOV AS, 1991, NATURE, V351, P314, DOI 10.1038/351314a0; LEWIS J, 1979, J THEOR BIOL, V78, P425, DOI 10.1016/0022-5193(79)90341-2; Maynard-Smith J., 1978, MODELS ECOLOGY; PAQUIN C, 1983, NATURE, V302, P495, DOI 10.1038/302495a0; Stebbins G.L., 1950, VARIATION EVOLUTION; Wright S, 1934, AM NAT, V68, P24, DOI 10.1086/280521	14	109	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1991	351	6324					315	317		10.1038/351315a0	http://dx.doi.org/10.1038/351315a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034274				2022-12-01	WOS:A1991FM97600060
J	SPIES, T; DEMARS, R				SPIES, T; DEMARS, R			RESTORED EXPRESSION OF MAJOR HISTOCOMPATIBILITY CLASS-I MOLECULES BY GENE-TRANSFER OF A PUTATIVE PEPTIDE TRANSPORTER	NATURE			English	Article							HLA-B ANTIGENS; LYMPHOBLASTOID CELLS; T-CELLS; MHC; COMPLEX; REGION; DETERMINANT; BINDING; PROTEIN; PATHWAY	CYTOTOXIC T lymphocytes recognize antigen-derived peptides bound to major histocompatibility complex (MHC) class I molecules with which they assemble in the endoplasmic reticulum or in an undefined subcompartment 1-10. There is genetic evidence that the peptides that are products of cytosolic protein degradation are transported into this compartment by a peptide supply factor (PSF), encoded in the MHC class II region 11. Like the corresponding genes RING4, HAM1 and mtp1 (refs 12-14), PSF is related to the multidrug-resistance family of transporters 11 and may be a peptide pump, as translocation of peptides across membranes must occur independently of the secretory pathway 15. There is, however, no functional evidence for this role so far. Here we report gene transfer experiment showing that expression of PSF complementary DNA in the human lymphoblastoid cell line mutant 721.134 (refs 11, 16, 17) restores normal levels of surface HLA-A2 and -B5. No similar effect was observed in 721.174 mutant cells, in which a homozygous deletion includes PSF among several other closely linked genes 11. At least one of these genes may therefore also be required for PSF function.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	SPIES, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA.							BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; LONG EO, IN PRESS HUM IMMUN; MANN DL, 1983, NATURE, V305, P58, DOI 10.1038/305058a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHIMIZU Y, 1986, MOL CELL BIOL, V6, P1074, DOI 10.1128/MCB.6.4.1074; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBLEEK GM, 1990, NATURE, V348, P213; WAYS JP, 1986, J IMMUNOL, V137, P217	25	417	432	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					323	324		10.1038/351323a0	http://dx.doi.org/10.1038/351323a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034277				2022-12-01	WOS:A1991FM97600063
J	THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A				THELEN, M; ROSEN, A; NAIRN, AC; ADEREM, A			REGULATION BY PHOSPHORYLATION OF REVERSIBLE ASSOCIATION OF A MYRISTOYLATED PROTEIN-KINASE-C SUBSTRATE WITH THE PLASMA-MEMBRANE	NATURE			English	Article							PHORBOL ESTERS; GROWTH-FACTORS; OKADAIC ACID; ACTIVATION; RECEPTOR; BINDING; BRAIN	PROTEIN kinase C (PKC) transduces receptor-mediated signals by phosphorylating membrane-bound substrates which then act as effectors of specific cellular responses 1. The myristoylated alanine-rich C kinase substrate (MARCKS) is a specific PKC substrate which has been implicated in macrophage activation, neurosecretion and growth factor-dependent mitogenesis 2-5. Myristoylation of MARCKS is required for effective binding to the plasma membrane 6 where it colocalizes with PKC 7. Here we report that PKC-dependent phosphorylation displaces MARCKS from the membrane and that its subsequent dephosphorylation is accompanied by its reassociation with the membrane. This cycle of phosphorylation-dependent membrane attachment and detachment of a myristoylated protein represents a novel mechanism of reversible membrane targeting. As MARCKS is a calmodulin- and actin-binding protein (ref. 8, and J. Hartwig et al., manuscript submitted), the cycle of membrane attachment/detachment represents a mechanism through which PKC might reversibly regulate actin-membrane interaction.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University				Nairn, Angus/0000-0002-7075-0195				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; DEWALD B, 1988, J BIOL CHEM, V263, P16179; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	17	355	365	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1991	351	6324					320	322		10.1038/351320a0	http://dx.doi.org/10.1038/351320a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM976	2034276				2022-12-01	WOS:A1991FM97600062
J	DAVANZO, J; PARNELL, AM; FOEGE, WH				DAVANZO, J; PARNELL, AM; FOEGE, WH			HEALTH CONSEQUENCES OF CONTRACEPTIVE USE AND REPRODUCTIVE PATTERNS - SUMMARY OF A REPORT FROM THE UNITED-STATES NATIONAL-RESEARCH-COUNCIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		RAND CORP,SANTA MONICA,CA 90406; DUKE UNIV,DEPT SOCIOL,DURHAM,NC 27706; EMORY UNIV,CARTER CTR,ATLANTA,GA 30322; NATL RES COUNCIL,COMM POPULAT,WASHINGTON,DC 20418	RAND Corporation; Duke University; Emory University; National Academies of Sciences, Engineering & Medicine								HAAGA J, 1989, CONTRACEPTION REPROD, V2; HOBCRAFT J, 1987, OCT INT C BETT HLTH; KRAMER MS, 1987, PEDIATRICS, V80, P502; KWAST BE, 1986, STUD FAMILY PLANN, V17, P288, DOI 10.2307/1966906; SCRIMSHAW SCM, 1978, POPUL DEV REV, V4, P383, DOI 10.2307/1972856; 1989, CONTRACEPTION REPROD	6	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2692	2696						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	2023350				2022-12-01	WOS:A1991FL98900034
J	GOODWIN, FK				GOODWIN, FK			CLOZAPINE RESPONSE THRESHOLD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		PERRY PJ, 1991, AM J PSYCHIATRY  FEB	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	1850809				2022-12-01	WOS:A1991FL98900008
J	GOODWIN, FK				GOODWIN, FK			ARE NEUROSTEROIDS BRAINS VALIUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-01	WOS:A1991FL98900007
J	GOODWIN, FK				GOODWIN, FK			CONTINGENT INEFFICACY AND TOLERANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		WEISS SRB, 1991, EPILEPSIA, V322, P140	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-01	WOS:A1991FL98900006
J	KUNG, AWC; PUN, KK				KUNG, AWC; PUN, KK			BONE-MINERAL DENSITY IN PREMENOPAUSAL WOMEN RECEIVING LONG-TERM PHYSIOLOGICAL DOSES OF LEVOTHYROXINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE; OSTEOPOROSIS; HYPERTHYROIDISM; THYROTOXICOSIS; CALCITONIN; HYPOTHYROIDISM; REPLACEMENT; DEFICIENCY; THERAPY	Total body and regional bone mineral density (BMD) levels were determined in 26 premenopausal women with Hashimoto's thyroiditis receiving long-term physiological doses of levothyroxine sodium replacement therapy. The BMD levels of each patient were compared with the mean of the BMD levels of age-matched normal controls. The mean levothyroxine sodium dose was 111 +/- 6-mu-g/d, and the mean duration of treatment was 7.5 +/- 5.3 years (range, 1 to 24 years). Dietary calcium intake was similar in both groups, as were serum thyroxine, triiodothyronine, free thyroxine index, and thyrotropin levels. Women receiving the levothyroxine treatment had normal total body BMD levels but had significantly lower BMD levels at the femoral neck (-5.7%), femoral trochanter (-7.0%), Ward's triangle (-10.6%), both arms (right,-7.8%; left, -8.9%), and pelvis (-4.9%). In contrast, lumbar spine BMD levels were similar in the two groups. There was no correlation between the total body or different regional BMD levels and the duration or dosage of levothyroxine treatment or thyroid function test results. However, the z score of the femoral neck of these patients showed a significant negative correlation with their serum free thyroxine index levels. We conclude that patients receiving physiological doses of levothyroxine may have decreased bone density. Thyroid functions in patients receiving long-term levothyroxine treatment should be closely monitored and bone densitometry should be performed in patients at risk for osteoporosis.			KUNG, AWC (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG.							CALDWELL G, 1985, LANCET, V1, P1117; COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48; DANIELL HW, 1974, NEW ENGL J MED, V291, P102; ERIKSEN EF, 1986, BONE, V7, P101, DOI 10.1016/8756-3282(86)90681-2; ETTINGER B, 1982, WESTERN J MED, V136, P473; FALLON MD, 1983, ARCH INTERN MED, V143, P442, DOI 10.1001/archinte.143.3.442; FLEISH H, 1987, OSTEOPOROSIS, P1159; FRAME B, 1983, ANN INTERN MED, V99, P725, DOI 10.7326/0003-4819-99-5-725; FRASER SA, 1971, LANCET, V1, P981; GARREL DR, 1986, J CLIN ENDOCR METAB, V62, P1052, DOI 10.1210/jcem-62-5-1052; GONZALEZ D, 1986, CALCIFIED TISSUE INT, V38, P71, DOI 10.1007/BF02556832; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; MCDERMOTT MT, 1983, J CLIN ENDOCR METAB, V56, P936, DOI 10.1210/jcem-56-5-936; MEEMA HE, 1970, RADIOLOGY, V97, P9, DOI 10.1148/97.1.9; MELSEN F, 1977, ACTA PATH MICRO IM A, V85, P141; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; MULLEN BJ, 1984, AM J CLIN NUTR, V39, P136, DOI 10.1093/ajcn/39.1.136; NIELSEN HE, 1979, ACTA RADIOL ONCOL, V18, P122, DOI 10.3109/02841867909128198; NORD RH, 1989, 21 EUR S CALC TISS J; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PERRY HM, 1986, ARCH INTERN MED, V146, P41, DOI 10.1001/archinte.146.1.41; PUN KK, IN PRESS OSTEOPOROSI; PUN KK, IN PRESS J APPL NUTR; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; TIEGS RD, 1985, NEW ENGL J MED, V312, P1097, DOI 10.1056/NEJM198504253121705; TIEGS RD, 1983, CALCIFIED TISSUE INT, V369, P479	30	74	75	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2688	2691		10.1001/jama.265.20.2688	http://dx.doi.org/10.1001/jama.265.20.2688			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023349				2022-12-01	WOS:A1991FL98900033
J	NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y				NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y			REVERSAL OF NONRESPONDERS AND POSTEXPOSURE PROPHYLAXIS BY INTRADERMAL HEPATITIS-B VACCINATION IN JAPANESE MEDICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DTH SKIN REACTION; IMMUNE GLOBULIN; FINAL REPORT; VIRUS-INFECTION; SURFACE-ANTIGEN; HEPTAVAX-B; IMMUNOGENICITY; EFFICACY; HBSAG; IMMUNOPROPHYLAXIS	Thirty-one Japanese nonresponders to subcutaneous hepatitis B vaccination and 15 medical personnel who were accidentally exposed to specimens positive for hepatitis B e antigen and were given hepatitis B immunoglobulin were intradermally immunized with 5-mu-g of plasma-derived hepatitis B vaccine every 2 weeks until delayed type hypeersensitivity skin reaction to hepatitis B surface antigen became positive. Thirty (97%) of the 31 nonresponders developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen after 2.3 +/- 1.2 (mean +/- SD) revaccinations. Twenty-nine (94%) of the 31 nonresponders had anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. The immunoglobulin subclass of the antibody to hepatitis B surface antigen was mainly IgG1. After 1 year, 23 (74%) of the 31 nonresponders continued to have anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. Persons accidentally exposed to specimens positive for hepatitis B e antigen developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen following 3.1 +/- 1.1 revaccinations. None developed clinical hepatitis. There was no production of anti-hepatitis B core antigen antibody 1 year after exposure, indicating that protection was 100%. Intradermal hepatitis B vaccination is useful in reversing nonresponsiveness to hepatitis B surface antigen and for prophylaxis after exposure.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT PEDIAT,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT GEN MED,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University	NAGAFUCHI, S (corresponding author), KYUSHU UNIV,FAC MED,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN.							ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; CASALI P, 1986, SCIENCE, V234, P476, DOI 10.1126/science.3020687; CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q; CLARKE JA, 1989, JAMA-J AM MED ASSOC, V262, P2567, DOI 10.1001/jama.262.18.2567; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; DIENSTAG JL, 1989, HEPATOLOGY, V10, P385, DOI 10.1002/hep.1840100323; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HAYASHI J, 1989, J INFECTION, V19, P119, DOI 10.1016/S0163-4453(89)91839-2; HEIJTINK RA, 1989, J MED VIROL, V27, P151, DOI 10.1002/jmv.1890270216; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; IRVING WL, 1987, LANCET, V2, P561; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KARASAWA T, 1983, J INFECT DIS, V147, P327, DOI 10.1093/infdis/147.2.327; KASHIWAGI S, 1984, MICROBIOL IMMUNOL, V28, P1355, DOI 10.1111/j.1348-0421.1984.tb00793.x; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; MATHIESEN T, 1989, J NEUROL, V236, P238, DOI 10.1007/BF00314506; MILLER KD, 1983, LANCET, V2, P1454, DOI 10.1016/S0140-6736(83)90800-0; MITSUI T, 1989, HEPATOLOGY, V10, P324, DOI 10.1002/hep.1840100312; NAGAFUCHI S, 1987, LANCET, V2, P1522; NAGAFUCHI S, 1984, MICROBIOL IMMUNOL, V28, P257, DOI 10.1111/j.1348-0421.1984.tb00678.x; NAGAFUCHI S, 1989, MICROBIOL IMMUNOL, V33, P539, DOI 10.1111/j.1348-0421.1989.tb02004.x; NAGAFUCHI S, 1985, CLIN EXP IMMUNOL, V61, P569; NAKAMURA M, 1988, J IMMUNOL, V141, P4165; Paul W.E., 1989, FUNDAMENTAL IMMUNOLO, P95; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; VANDVIK B, 1977, SCAND J IMMUNOL, V6, P651, DOI 10.1111/j.1365-3083.1977.tb02145.x; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WATANABE H, 1988, HUM IMMUNOL, V22, P9, DOI 10.1016/0198-8859(88)90047-X; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZOULEK G, 1984, J MED VIROL, V14, P27, DOI 10.1002/jmv.1890140105; ZUCKERMAN AJ, 1988, CURR OPIN INFECT DIS, V1, P829, DOI 10.1097/00001432-198811000-00002; 1985, MMWR, V34, P313	37	39	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2679	2683		10.1001/jama.265.20.2679	http://dx.doi.org/10.1001/jama.265.20.2679			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1827167				2022-12-01	WOS:A1991FL98900031
J	SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D				SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D			MAHARISHI AYUR-VEDA - MODERN INSIGHTS INTO ANCIENT-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSCENDENTAL MEDITATION; ANTINEOPLASTIC PROPERTIES; CARE		ALL INDIA AYUR VEDA CONGRESS,NEW DELHI,INDIA; AMER ASSOC AYURVED MED,LANCASTER,MA		SHARMA, HM (corresponding author), OHIO STATE UNIV,COLL MED,DEPT PATHOL,ROOM M3685L,320 W 10TH AVE,COLUMBUS,OH 43210, USA.							ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; CHOPRA D, 1990, PERFECT HLTH; Chopra Deepak, 1989, QUANTUM HEALING EXPL; Chopra R., 1982, INDIGENOUS DRUGS IND; DILEEPAN KN, 1990, BIOCHEM ARCH, V6, P267; GHISAGRANTNE KL, 1963, SUSHRUTA SAMHITA; Janssen G., 1989, NED TIJDSCHR GENEES, V5, P586; NIWA Y, 1991, INDIAN J CLIN PRACT, V1, P23; ORMEJOHNSON D, 1987, PSYCHOSOM MED, V49, P493, DOI 10.1097/00006842-198709000-00006; ORMEJOHNSON DW, 1988, J CONFLICT RESOLUT, V32, P776, DOI 10.1177/0022002788032004009; PATEL V, 1990, FASEB Journal, V4, pA637; PRASAD KN, 1990, 8TH BIENN M INT SOC; SCHNEIDER RH, 1990, J SOC BEHAV PERS, V5, P1; SHARMA HM, 1990, EUR J PHARMACOL, V183, P193, DOI 10.1016/0014-2999(90)93027-N; SHARMA HM, 1990, PHARMACOL BIOCHEM BE, V35, P767, DOI 10.1016/0091-3057(90)90356-M; SHARMA HM, 1989, CLIN TER CARDIOVAS, V8, P227; SHARMA RK, 1977, CHARAKA SAMHITA; THYAGARAJAN SP, 1988, LANCET, V2, P764; VASISHTA SD, 1983, ESSENCE PULSE DIAGNO; WALLACE RK, 1970, SCIENCE, V167, P1751, DOI 10.1126/science.167.3926.1751; Zaman H, 1974, TRADITIONAL MED, P231	21	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2633	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1817464				2022-12-01	WOS:A1991FL98900001
J	SULLIVAN, LW				SULLIVAN, LW			CHILD SURVIVAL AND AIDS IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		1991, PUBLIC HLTH REP, V106, P105	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2652	2652						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	2023337				2022-12-01	WOS:A1991FL98900005
J	ALCOLADO, JC; ALCOLADO, R				ALCOLADO, JC; ALCOLADO, R			IMPORTANCE OF MATERNAL HISTORY OF NON-INSULIN-DEPENDENT DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To assess the family history of diabetes in non-insulin dependent diabetes mellitus with particular emphasis on parental phenotype. Design - Family histories were obtained from an existing computerised database and supplemented by postal questionnaires. Setting - Diabetic service of a provincial teaching hospital. Subjects - A total of 1326 patients with non-insulin dependent diabetes who had been referred to diabetic clinics over the past 10 years and from whom data had been collected for inclusion in the database, of whom 347 had affected first degree relatives. Nineteen non-white patients were excluded because of the differential hereditability of the disease, and 230 (70%) patients with an affected first degree relative responded to the postal questionnaire. Results - Mothers were implicated in significantly more cases than fathers in patients with a single affected parent: 125 mothers and 48 fathers from database; 82 mothers and 34 fathers from postal questionnaire; p < 0.001 in both cases. Conclusions - Maternal influences seem to have an important role in the inheritance of non-insulin dependent diabetes.	SOUTHAMPTON GEN HOSP,MED PROFESSORIAL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton	ALCOLADO, JC (corresponding author), ST BARTHOLOMEWS HOSP,MED PROFESSORIAL UNIT,LONDON EC1A 7BE,ENGLAND.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				Bell G I, 1987, Ciba Found Symp, V130, P167; HARDING AE, 1988, J MED GENET, V25, P528, DOI 10.1136/jmg.25.8.528; KAHN LB, 1990, DIABETES CARE, V7, P796; Mohan V., 1986, PRACT DIAB, V3, P254; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; PETTITT DJ, 1986, DIABETES, V37, P622; 1983, CENSUS 1981 NATIONAL	7	175	177	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1178	1180		10.1136/bmj.302.6786.1178	http://dx.doi.org/10.1136/bmj.302.6786.1178			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043812	Green Published, Bronze			2022-12-01	WOS:A1991FN04500019
J	AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K				AYA, T; KINOSHITA, T; IMAI, S; KOIZUMI, S; MIZUNO, F; OSATO, T; SATOH, C; OIKAWA, T; KUZUMAKI, N; OHIGASHI, H; KOSHIMIZU, K			CHROMOSOME-TRANSLOCATION AND C-MYC ACTIVATION BY EPSTEIN-BARR-VIRUS AND EUPHORBIA-TIRUCALLI IN LYMPHOCYTES-B	LANCET			English	Note								Dual exposure to Epstein-Barr virus and purified 4-deoxyphorbol ester derived from the plant Euphorbia tirucalli induced a high frequency of chromosomal rearrangements in human B lymphocytes in vitro. Rearrangements most commonly affected chromosome 8, the chromosome most often showing structural changes in Burkitt's lymphoma (BL) cells. E tirucalli is indigenous in parts of Africa where BL is endemic and may be an important risk factor for the disease.	HOKKAIDO UNIV, SCH MED, INST CANC, DEPT VIROL, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO UNIV, FAC AGR, DEPT FOOD SCI & TECHNOL, KYOTO 606, JAPAN; HOKKAIDO UNIV, SCH MED, INST CANC, MOLEC GENET LAB, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Kyoto University; Hokkaido University								EPSTEIN MA, 1979, EPSTEINBARR VIRUS, P1; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; OSATO T, 1987, LANCET, V1, P1257	3	30	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1991	337	8751					1190	1190		10.1016/0140-6736(91)92861-U	http://dx.doi.org/10.1016/0140-6736(91)92861-U			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673740				2022-12-01	WOS:A1991FM26100005
J	BENDEFY, IM				BENDEFY, IM			HOME NEBULIZERS IN CHILDHOOD ASTHMA - SURVEY OF HOSPITAL SUPERVISED USE	BRITISH MEDICAL JOURNAL			English	Article							NEBULIZERS	Objective - To review the management of and outcome in asthmatic children using home nebulisers under hospital supervision. Design - Postal questionnaires sent to parents. Setting - Paediatric departments of a children's hospital and a district general hospital. Subjects - Parents of 93 asthmatic children who had been loaned home nebulisers for administration of bronchodilators with verbal instructions on their use. Main outcome measures - Drugs administered with nebuliser, side effects, frequency of hospital admission, and theoretical management of a severe attack. Results - 84 children took salbutamol and 37 received more than 10 mg a day during attacks; side effects were reported in 54 children. Parents of 16 children said that they would give another dose of bronchodilator rather than seek medical help if their child failed to respond to the first dose. Since being loaned nebulisers 65 children were admitted to hospital less frequently and 16 were not readmitted; over two thirds of parents thought that there had been a marked improvement in their child's asthma. Conclusions - Home nebulisers are valuable in childhood asthma. Excessive doses of bronchodilators may be given, however, and a weight related dose may be more appropriate. Parents should be given written as well as verbal instructions, especially regarding the management of severe attacks.	DEPT COMMUNITY CHILD HLTH,COMMUNITY HOUSE,MORDEN,SURREY,ENGLAND									FORFAR JO, 1984, TXB PAEDIATRICS, P554; LAROCHE CM, 1985, BRIT MED J, V290, P1611, DOI 10.1136/bmj.290.6482.1611; LENNEY W, 1978, LANCET, V1, P440; MILNER AD, 1981, ARCH DIS CHILD, V56, P84, DOI 10.1136/adc.56.2.84; MILNER AD, 1987, UPDATE          0215, P398; REISER J, 1986, ARCH DIS CHILD, V61, P88, DOI 10.1136/adc.61.1.88; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; 1982, BMJ, V285, P1251	9	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1180	1181		10.1136/bmj.302.6786.1180	http://dx.doi.org/10.1136/bmj.302.6786.1180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043813	Bronze, Green Published			2022-12-01	WOS:A1991FN04500020
J	BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD				BRIDGES, BA; COLE, J; ARLETT, CF; GREEN, MHL; WAUGH, APW; BEARE, D; HENSHAW, DL; LAST, RD			POSSIBLE ASSOCIATION BETWEEN MUTANT FREQUENCY IN PERIPHERAL LYMPHOCYTES AND DOMESTIC RADON CONCENTRATIONS	LANCET			English	Article							LEUKEMIA; CELLS; LUNG	To investigate whether previously found geographical correlations between leukaemia incidence and exposure to radon are reflected in a detectable mutagenic effect on individuals, the frequency of mutations in the hypoxanthine guanine phosphoribosyl transferase gene (hprt) in peripheral blood T lymphocytes was measured in subjects with known domestic radon concentrations. These concentrations were measured in December, 1989, in house in Street, Somerset, UK, by passive alpha-track radon detectors. 20 non-smoking subjects aged 36-55 years were selected from the patient list at the local health centre on the basis of the radon concentrations in their homes - the range selected varied by a factor of ten. Blood samples for preparation of T lymphocytes were taken in July, 1990. There was a significant association between the log mutant frequency and radon concentration (t = 3.47, p < 0.01). A second analysis of a further set of radon measurements (October, 1990, to January, 1991), in both living rooms and bedrooms, and repeated mutant frequency determinations also showed a significant relation, which remained significant even after exclusion of the highest frequency and adjustment for subject's age and cloning efficiency. These data must be regarded as preliminary and further more extensive studies should be done to determine whether the observed association is causal.	UNIV BRISTOL, HH WILLS PHYS LAB, BRISTOL BS8 1TL, AVON, ENGLAND; HLTH CTR, SOMERSET, ENGLAND	University of Bristol	BRIDGES, BA (corresponding author), UNIV SUSSEX, MRC, CELL MUTAT UNIT, BRIGHTON BN1 9RR, ENGLAND.							ALEXANDER FE, 1990, LANCET, V335, P1336; BAVERSTOCK KF, 1990, LANCET, V335, P1337; BRIDGES BA, 1989, LEUKEMIA, V3, P846; CLARKE RH, 1989, NATURE, V338, P197, DOI 10.1038/338197a0; COLE J, 1990, PROG CLIN BIOL RES, V340, P25; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLT PG, 1988, IMMUNOLOGY, V64, P649; HOLT PG, 1986, CLIN EXP IMMUNOL, V66, P188; LUCIE NP, 1989, LANCET, V2, P99; Pabst R, 1988, Adv Exp Med Biol, V237, P553; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; Pohl-Ruling J., 1988, BERZELIUS S, P103; RICHARDSON RB, IN PRESS BR J RADIOL; SANKARANARAYANAN K, 1988, AM J HUM GENET, V42, P651; THACKER J, IN PRESS ADV RAD BIO; WRIXON AD, 1988, R190 NAT RAD PROT BO; 1988, BIER4 REP	18	69	71	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1187	1189		10.1016/0140-6736(91)92859-Z	http://dx.doi.org/10.1016/0140-6736(91)92859-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673739				2022-12-01	WOS:A1991FM26100004
J	COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I				COURSAGET, P; YVONNET, B; GILKS, WR; WANG, CC; DAY, NE; CHIRON, JP; DIOPMAR, I			SCHEDULING OF REVACCINATION AGAINST HEPATITIS-B VIRUS	LANCET			English	Article							ENDEMIC AREA; ANTI-HBS; VACCINE; DIALYSIS; EFFICACY; INFANTS	Studies have shown that to maintain protection against infection after a primary course of hepatitis B immunisation, revaccination can be scheduled on the basis of an anti-hepatitis B virus surface antigen (anti-HBs) titre obtained 1 month after the booster dose. However, schemes which require post-booster testing may present practical difficulties. We applied a random-effects regression model to data from 118 Senegalese infants given three injections of hepatitis B vaccine about 6 weeks apart and a booster injection at 13 months, and show that revaccination can be scheduled on the basis of an anti-HBs titre recorded at the time of the booster dose. We also show that titre-at-booster is no less accurate in predicting future titre than 1-month post-booster titre. In several other studies the post-booster decline in anti-HBs conforms to the same mathematical description, indicating the generality of our findings.	FAC PHARM TOURS, INST VIROL TOURS, TOURS, FRANCE; FAC MED & PHARM DAKAR, DAKAR, SENEGAMBIA; ACAD SINICA, INST STAT, TAIPEI 115, TAIWAN; FAC PHARM TOURS, MICROBIOL LAB, TOURS, FRANCE	Academia Sinica - Taiwan								BENHAMOU E, 1986, NEW ENGL J MED, V314, P1710; COUROUCE AM, 1984, NEW ENGL J MED, V311, P1515; COURSAGET P, 1986, LANCET, V2, P1143; CROSNIER J, 1981, LANCET, V1, P455; DENTICO P, 1990, COLLOQ INSE, V194, P325; GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; GESEMANN M, 1989, LANCET, V2, P1274; GILKS WR, 1990, COLLOQ INSE, V194, P409; GILKS WR, 1989, LANCET, V2, P1273; GOUDEAU A, 1990, COLLOQ INSE, V194, P123; GROB PJ, 1990, COLLOQ INSE, V194, P437; GROB PJ, 1985, SCHWEIZ MED WSCHR, V115, P394; JILG W, 1990, LANCET, V335, P173, DOI 10.1016/0140-6736(90)90050-F; LAPLANCHE A, 1987, LANCET, V1, P1206; NOMMENSEN FE, 1990, LANCET, V335, P479, DOI 10.1016/0140-6736(90)90716-I; NOMMENSEN FE, 1989, LANCET, V2, P847; OON CJ, 1990, COLLOQ INSE, V194, P475; RAWAL BK, 1989, LANCET, V2, P1274; SIEGEL S, 1956, NONPARAMETRIC STAT, P47; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; YVONNET B, 1987, J MED VIROL, V22, P315, DOI 10.1002/jmv.1890220404; ZACHOVAL R, 1984, J INFECT DIS, V150, P112, DOI 10.1093/infdis/150.1.112; ZANETTI AR, 1990, COLLOQ INSE, V194, P79; 1988, LANCET, V1, P875	25	64	64	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1180	1183		10.1016/0140-6736(91)92857-X	http://dx.doi.org/10.1016/0140-6736(91)92857-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673737				2022-12-01	WOS:A1991FM26100002
J	GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P				GOLDING, J; ROWLAND, A; GREENWOOD, R; LUNT, P			ALUMINUM SULFATE IN WATER IN NORTH CORNWALL AND OUTCOME OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether the excess aluminium sulphate accidentally added to the local water supply in north Cornwall in July 1988 had an adverse effect on the outcome of pregnancies. Design - Outcomes of all singleton pregnancies in the affected area at the time of the incident (n = 92) were compared with those in two control groups: pregnancies in this area completed before the incident (n = 68) and pregnancies in a neighbouring area (n = 193). Subjects - Mothers in the three groups, among whom there were 13 miscarriages, five terminations of pregnancy, and 336 live births. Main outcome measures - Fetal and perinatal loss, birth weight, gestation, obstetric complications, neonatal condition, and congenital defects. Results - Among 88 pregnancies in women exposed to excess aluminium sulphate there was no excess of perinatal deaths (n = 0), low birthweight (n = 3), preterm delivery (n = 4), or severe congenital malformations (n = 0). There was, however, an increased rate of talipes in exposed fetuses (four cases, one control; p = 0.01). Conclusions - Because of small numbers it is not possible to say that high doses of aluminium sulphate are safe in pregnancy, but there is no evidence from this study of major problems apparent at birth.	CORNWALL & ISLES SCILLY HLTH AUTHOR,TRURO TR1 1NR,ENGLAND		GOLDING, J (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND.		Lunt, Peter/AAF-8265-2020	Golding, Jean/0000-0003-2826-3307				Akar N, 1989, Paediatr Perinat Epidemiol, V3, P102; BERNUZZI V, 1989, TERATOLOGY, V40, P21, DOI 10.1002/tera.1420400104; GOLDING J, 1984, CHILD HLTH, V3, P31; LAPPE M, 1988, TRACE ELEMENTS HLTH; MARLOWE M, 1985, ARCH ENVIRON HEALTH, V40, P221, DOI 10.1080/00039896.1985.10545922; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; MORTON MS, 1976, BRIT J PREV SOC MED, V30, P36; OLIVER JMT, 1983, LANCET, V1, P181	8	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1991	302	6786					1175	1177		10.1136/bmj.302.6786.1175	http://dx.doi.org/10.1136/bmj.302.6786.1175			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN045	2043811	Bronze, Green Published			2022-12-01	WOS:A1991FN04500018
J	LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ				LAWSON, HW; BRAUN, MM; GLASS, RIM; STINE, SE; MONROE, SS; ATRASH, HK; LEE, LE; ENGLENDER, SJ			WATERBORNE OUTBREAK OF NORWALK VIRUS GASTROENTERITIS AT A SOUTHWEST UNITED-STATES RESORT - ROLE OF GEOLOGICAL FORMATIONS IN CONTAMINATION OF WELL WATER	LANCET			English	Article							NONBACTERIAL GASTROENTERITIS	From April 17 to May 1, 1989, gastroenteritis developed in about 900 people during a visit to a new resort in Arizona, USA. Of 240 guests surveyed, 110 had a gastrointestinal illness that was significantly associated with the drinking of tap water from the resort's well (relative risk = 16.1, 95% confidence interval 14.5 to 17.8) and this risk increased significantly with the number of glasses of water consumed (p < 0.005). Three of seven paired sera tested for antibodies to the Norwalk agent had a four-fold or greater rise in titre. Water contaminated with faecal coliforms was traced back to the deep water well, which remained contaminated even after prolonged pumping. Effluent from the resort's sewage treatment facility seeped through fractures in the subsurface rock (with little filtration) directly into the resort's deep well. Although the latest technology was used to design the resort's water and sewage treatment plants, the region's unique geological conditions posed unexpected problems that may trouble developers faced with similar subsurface geological formations and arid climatic conditions in many parts of the world. In these areas, novel solutions are needed to provide adequate facilities for the treatment of sewage and supply of pure drinking water.	CTR DIS CONTROL,CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA 30333; ARIZONA DEPT HLTH SERV,PHOENIX,AZ 85007; CTR DIS CONTROL,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Arizona Department of Health Services; Centers for Disease Control & Prevention - USA				Monroe, Stephan/0000-0002-5424-716X				CRAUN GF, 1988, J AM WATER WORKS ASS, V80, P40; GARY GW, 1985, J CLIN MICROBIOL, V22, P274, DOI 10.1128/JCM.22.2.274-278.1985; Gerba C., 1984, GROUNDWATER POLLUTIO, P65; GERBA CP, 1979, AM J PUBLIC HEALTH, V69, P1116, DOI 10.2105/AJPH.69.11.1116; GLASS RI, 1988, VIRUSES GUT, P87; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1990, MMWR, V39, P1	13	79	81	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1200	1204						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673747				2022-12-01	WOS:A1991FM26100012
J	LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE				LEE, HP; GOURLEY, L; DUFFY, SW; ESTEVE, J; LEE, J; DAY, NE			DIETARY-EFFECTS ON BREAST-CANCER RISK IN SINGAPORE	LANCET			English	Article							CHINESE; POPULATION; FAT	It is suspected that diet influences the risk of getting breast cancer. A study of diet and breast cancer was done among 200 Singapore Chinese women with histologically confirmed disease and 420 matched controls. A quantitative food-frequency questionnaire was used to assess intakes of selected nutrients and foods 1 year before interview. Daily intakes were computed and risk analysed after adjustment for concomitant risk factors. In premenopausal women, high intakes of animal proteins and red meat were associated with increased risk. Decreased risk was associated with high intakes of polyunsaturated fatty acids (PUFA), beta-carotene, soya proteins, total soya products, a high PUFA to saturated fatty acid ratio, and a high proportion of soya to total protein. In multiple analysis, the variables which were significant after adjustment for each other were red meat (p < 0.001) as a predisposing factor, and PUFA (p = 0.02), beta-carotene (p = 0.003), and soya protein (p = 0.02) as protective factors. The analysis of dietary variables in postmenopausal women gave uniformly non-significant results. Our finding that soya products may protect against breast cancer in younger women is of interest since these foods are rich in phyto-oestrogens.	GLENEAGLES HOSP, SINGAPORE, SINGAPORE; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND; INT AGCY RES CANC, F-69372 LYONS, FRANCE	MRC Biostatistics Unit; World Health Organization; International Agency for Research on Cancer (IARC)	LEE, HP (corresponding author), NATL UNIV SINGAPORE, DEPT COMMUNITY OCCUPAT & FAMILY MED, LOWER KENT RIDGE RD, SINGAPORE 0511, SINGAPORE.							ARMSTRONG BK, 1985, CANCER RISKS PREVENT, P68; BARNES S, 1990, PROG CLIN BIOL RES, V347, P239; BRESLOW N. E., 1980, STATISTICAL METHODS; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; GOURLEY L, 1988, EUR J CLIN NUTR, V42, P333; HIROHATA T, 1987, JNCI-J NATL CANCER I, V78, P595; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; ISCOVICH JM, 1989, INT J CANCER, V44, P770, DOI 10.1002/ijc.2910440504; La Vecchia C, 1987, Nutr Cancer, V10, P205; LEE HP, 1989, INT J CANCER, V43, P1007, DOI 10.1002/ijc.2910430609; LEE HP, 1988, INT J CANCER, V42, P159, DOI 10.1002/ijc.2910420204; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; ROHAN TE, 1988, INT J CANCER, V41, P390, DOI 10.1002/ijc.2910410312; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROHAN TE, 1988, INT J CANCER, V41, P695, DOI 10.1002/ijc.2910410510; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; ZARIDZE DG, 1990, INT J CANCER, V45, P807, DOI 10.1002/ijc.2910450502; ZARIDZE DG, 1991, IN PRESS INT J CANCE	20	647	662	1	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1197	1200		10.1016/0140-6736(91)92867-2	http://dx.doi.org/10.1016/0140-6736(91)92867-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673746				2022-12-01	WOS:A1991FM26100011
J	VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D				VENTO, S; GAROFANO, T; DIPERRI, G; DOLCI, L; CONCIA, E; BASSETTI, D			IDENTIFICATION OF HEPATITIS-A VIRUS AS A TRIGGER FOR AUTOIMMUNE CHRONIC HEPATITIS TYPE-1 IN SUSCEPTIBLE INDIVIDUALS	LANCET			English	Article							CHRONIC ACTIVE HEPATITIS; ASIALOGLYCOPROTEIN RECEPTOR PROTEIN; AUTOANTIBODIES; LYMPHOCYTES; AUTOREACTIVITY; ANTIBODIES; ANTIGENS; MEASLES; LECTIN	To identify factors contributing to the pathogenesis of autoimmune chronic active hepatitis (CAH) healthy relatives of 13 patients with the disorder were followed prospectively for 4 years. 58 relatives were monitored for various serological markers and for T-lymphocyte migration inhibitory activity every 2 months. 3 cases of subclinical acute hepatitis A occurred during the study. In 2 of the 3 subjects, before hepatitis A virus (HAV) infection, there was a defect in suppressor-inducer T lymphocytes specifically controlling immune responses to the asialoglycoprotein receptor, an antigen expressed on the hepatocyte surface. In these 2 subjects, specific helper T cells and antibodies to the asialoglycoprotein receptor persisted and increased after acute hepatitis A, and autoimmune CAH type 1 developed within 5 months. Thus, in susceptible individuals HAV is a trigger for autoimmune CAH.	BORGO TRENTO CITY HOSP,DEPT MICROBIOL,VERONA,ITALY; UNIV VERONA,BORGO TRENTO HOSP,DEPT INFECT DIS,I-37100 VERONA,ITALY	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	VENTO, S (corresponding author), A PUGLIESE HOSP,INFECT DIS UNIT,I-88100 CATANZARO,ITALY.		Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062				ALLISON AC, 1971, LANCET, V2, P135; ESTEBAN JI, 1989, LANCET, V2, P294; FENZI G, 1978, J ENDOCRINOL INVEST, V1, P17, DOI 10.1007/BF03346766; HARFORD J, 1981, P NATL ACAD SCI-BIOL, V78, P1557, DOI 10.1073/pnas.78.3.1557; HARFORD J, 1984, GLYCOCONJUGATES, V4, P27; JOHNSON AH, 1980, 8TH INT HIST TEST WO, P285; LONGO A, 1980, 8TH INT HIST TEST WO, P283; MACKAY IR, 1962, Q J MED, V31, P485; MCFARLANE BM, 1985, J IMMUNOL METHODS, V77, P219, DOI 10.1016/0022-1759(85)90034-1; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1984, CLIN EXP IMMUNOL, V55, P347; MIELI VERGANI G., 1979, Clinical and Experimental Immunology, V38, P16; MIELIVERGANI G, 1989, LANCET, V2, P688; OBRIEN CJ, 1986, LANCET, V1, P350; ROBERTSON DAF, 1987, LANCET, V2, P9; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TERASAKI PI, 1974, DHEW NIH75545 PUBL, P67; TREICHEL U, 1990, HEPATOLOGY, V11, P606, DOI 10.1002/hep.1840110413; TREICHEL U, 1989, HEPATOLOGY, V10, P637; VALLBRACHT A, 1986, HEPATOLOGY, V6, P1308, DOI 10.1002/hep.1840060614; VENTO S, 1986, GASTROENTEROLOGY, V91, P810, DOI 10.1016/0016-5085(86)90680-3; VENTO S, 1987, LANCET, V1, P886; Vento S, 1990, Prog Liver Dis, V9, P335; VENTO S, 1988, J CLIN LAB IMMUNOL, V25, P1; VENTO S, 1984, LANCET, V1, P1200; VENTO S, 1988, J AUTOIMMUN, V1, P299, DOI 10.1016/0896-8411(88)90034-0	26	199	204	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1991	337	8751					1183	1187		10.1016/0140-6736(91)92858-Y	http://dx.doi.org/10.1016/0140-6736(91)92858-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM261	1673738				2022-12-01	WOS:A1991FM26100003
J	BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L				BLUM, B; STURM, NR; SIMPSON, AM; SIMPSON, L			CHIMERIC GRNA MESSENGER-RNA MOLECULES WITH OLIGO(U) TAILS COVALENTLY LINKED AT SITES OF RNA EDITING SUGGEST THAT U-ADDITION OCCURS BY TRANSESTERIFICATION	CELL			English	Article							LEISHMANIA-TARENTOLAE; CYTOCHROME-OXIDASE; KINETOPLASTID MITOCHONDRIA; TRYPANOSOME MITOCHONDRIA; SUBUNIT-III; GUIDE RNAS; MODEL; SEQUENCES; ENZYME; INTRON	Chimeric RNA molecules were detected by polymerase chain reaction amplification of kinetoplast RNA using a 3' primer specific to mRNA and a 5' primer specific to guide RNA (gRNA), and directly by Northern analysis. Covalent linkage of the 3' oligo(U) tail of the gRNA to the mRNA occurs at editing sites. Chimeric molecules were isolated for NADH dehydrogenase subunit 7 and cytochrome oxidase subunits II and III. We propose that these molecules are intermediates in the editing process and that successive transesterifications result in the transfer of uridine residues from the gRNA 3' oligo(U) tail to an editing site, with the number of uridine residues determined by base pairing with adenine and guanine "guide" nucleotides in the gRNA.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	BLUM, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 09102] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MOUNT SM, 1983, CELL, V33, P209; SHAW JM, 1989, P NATL ACAD SCI USA, V86, P6220, DOI 10.1073/pnas.86.16.6220; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON AM, 1985, NUCLEIC ACIDS RES, V13, P5977, DOI 10.1093/nar/13.16.5977; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; WARING RB, 1984, GENE, V28, P277, DOI 10.1016/0378-1119(84)90145-8	29	132	132	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					543	550		10.1016/0092-8674(91)90087-F	http://dx.doi.org/10.1016/0092-8674(91)90087-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709591				2022-12-01	WOS:A1991FM03700005
J	CARTER, WG; RYAN, MC; GAHR, PJ				CARTER, WG; RYAN, MC; GAHR, PJ			EPILIGRIN, A NEW CELL-ADHESION LIGAND FOR INTEGRIN ALPHA-3-BETA-1 IN EPITHELIAL BASEMENT-MEMBRANES	CELL			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTOR; KERATINOCYTE ADHESION; FIBRONECTIN RECEPTOR; SURFACE RECEPTORS; ANCHORING FIBRILS; VII COLLAGEN; MULTIPLE; BINDING; ALPHA-2-BETA-1	Epiligrin is a new glycoprotein in most epithelial basement membranes (BMs) and is a ligand for cell adhesion via integrin alpha-3-beta-1. In the extracellular matrix of human foreskin keratinocytes (HFKs), epiligrin contains three disulfide-bonded, glycoprotein subunits, E170, E145, and E135, based on molecular size in kilo-daltons. Epiligrin, immunopurified with MAb P1E1, induced cell adhesion and localization of integrin alpha-3-beta-1 in focal adhesions (FAs). Cell adhesion to epiligrin was inhibited with an anti-alpha-3-beta-1 MAb. Epiligrin also colocalized with integrin alpha-6-beta-4 in hemidesmosome-like stable anchoring contacts (SACs). Alpha-3-beta-1-FAs encircled alpha-6-beta-4-SACs in a complex adhesion structure. Alpha-3-beta-1 and epiligrin localized in BM junctions of epithelial cells primarily in organs of endodermal/ectodermal origin. In epidermis, epiligrin was detected in the lamina lucida of BMs. Alpha-3-beta-1 localized in plasma membranes of basal cells in contact with epiligrin and also in lateral/apical membranes. Epiligrin is the ligand of an adhesion super complex composed of alpha-3-beta-1-FAs and alpha-6-beta-4-SACs (hemidesmosomes).	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	CARTER, WG (corresponding author), UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R01CA049259] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA49259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CARTER WG, 1990, J CELL BIOL, V111; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GRIEPP EB, 1988, EPITHELIUM CELL TISS; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HEMLER ME, 1989, J BIOL CHEM, V26, P1; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IZZARD CS, 1976, J CELL SCI, V21, P129; JONES JCR, 1986, CELL MOTIL CYTOSKEL, V6, P560, DOI 10.1002/cm.970060604; KATZ SI, 1984, J AM ACAD DERMATOL, V11, P1025, DOI 10.1016/S0190-9622(84)80189-9; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; Lever WF, 1990, HISTOPATHOLOGY SKIN; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; MAR H, 1989, COLLOIDAL GOLD PRINC; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cb.03.110187.000421; NEYFAKH AA, 1983, EXP CELL RES, V149, P387, DOI 10.1016/0014-4827(83)90351-8; Oi V.T., 1980, SELECTED METHODS CEL, P351; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; POTTEN CS, 1988, J CELL SCI S, V10, P45; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SHIENVOLD FL, 1976, CELL TISSUE RES, V172, P289, DOI 10.1007/BF00399513; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WOLPERT L, 1988, J CELL SCI S, V10, P1; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	60	583	599	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					599	610		10.1016/0092-8674(91)90092-D	http://dx.doi.org/10.1016/0092-8674(91)90092-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032285				2022-12-01	WOS:A1991FM03700010
J	GOLIC, KG				GOLIC, KG			SITE-SPECIFIC RECOMBINATION BETWEEN HOMOLOGOUS CHROMOSOMES IN DROSOPHILA	SCIENCE			English	Article							GENETIC MOSAICS; CELL LINEAGE; MELANOGASTER; PARAMETERS	The ability to mark a cell and its descendants genetically so that the resulting cell clone can be distinguished from neighboring cells facilitates studies in animal biology and development. A method of generating clones by inducing homologous mitotic recombination in Drosophila with a site-specific yeast recombinase is described. This method allows for frequent mosaicism after mitotic exchange is induced at predefined sites in the genome.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25874-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER HJ, 1976, GENETICS BIOL DROS C, V1, pCH25; FRIESEN H., 1936, ZEITSCHR INDUKT ABSTAMM U VERER BUNGSL, V71, P501, DOI 10.1007/BF01848879; GARCIABE.A, 1972, MOL GEN GENET, V115, P54, DOI 10.1007/BF00272218; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GOLIC K, UNPUB; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HALL JC, 1976, GENETICS BIOL DROS A, V1, pCH6; HERMAN RK, 1984, GENETICS, V108, P165; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; Le Douarin N., 1984, CHIMERAS DEV BIOL; LINDSLEY DL, 1968, PUBLICATION CARNEGIE, V627; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, pCH24; RUSSELL LB, 1978, GENETIC MOSAICS CHIM; Stern C, 1936, GENETICS, V21, P625; SZABAD J, 1983, MUTAT RES, V113, P117, DOI 10.1016/0165-1161(83)90224-8; WOODRUFF RC, 1977, HEREDITY, V38, P291, DOI 10.1038/hdy.1977.92	17	351	360	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					958	961		10.1126/science.2035025	http://dx.doi.org/10.1126/science.2035025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035025				2022-12-01	WOS:A1991FM04000034
J	GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG				GRIEM, P; WALLNY, HJ; FALK, K; ROTZSCHKE, O; ARNOLD, B; SCHONRICH, G; HAMMERLING, G; RAMMENSEE, HG			UNEVEN TISSUE DISTRIBUTION OF MINOR HISTOCOMPATIBILITY PROTEINS VERSUS PEPTIDES IS CAUSED BY MHC EXPRESSION	CELL			English	Article							CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; CYTOTOXIC RESPONSE; VIRAL PEPTIDES; Y-ANTIGEN; H-Y; CELLS; COMPLEX; GRAFT	Naturally processed minor histocompatibility (H) peptides corresponding to H-4b, H-Y, and an unmapped BALB.B minor H gene were quantified in a relative way in 15 different tissues of male BALB.B mice. For one of these minor H antigens, we could also determine the relative content of the respective protein. For each minor H peptide, an individual tissue distribution was found. Tissues expressing little or no MHC (major histocompatibility complex), like brain, contained only small amounts of minor H peptides or none at all, although the same tissues contained minor H protein in substantial quantities. By contrast, K(b)-expressing brains from mice transgenic for K(b) under control of the glial acidic protein promoter contained both minor H peptide and protein in high amounts. Thus, the expression of minor H peptides in a given tissue is dependent on coexpression of the restricting MHC class I molecules.	DEUTSCH KLIN DIAGNOST,INST GENET,W-6200 WIESBADEN,GERMANY		GRIEM, P (corresponding author), MAX PLANCK INST BIOL,IMMUNGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY.		Roetzschke, Olaf/GXH-0012-2022	Schonrich, Gunther/0000-0002-5346-5704				BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BEVAN MJ, 1975, NATURE, V256, P419, DOI 10.1038/256419a0; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; COUNCE S, 1956, ANN SURG, V144, P198, DOI 10.1097/00000658-195608000-00009; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLAJNIK MF, 1985, EUR J IMMUNOL, V15, P540, DOI 10.1002/eji.1830150603; FORMAN J, 1984, J EXP MED, V159, P1724, DOI 10.1084/jem.159.6.1724; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GRAFF RJ, 1979, BIOL HDB, V3, P118; Klein J., 1986, NATURAL HIST MAJOR H; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOVELAND B, 1986, IMMUNOL TODAY, V7, P223, DOI 10.1016/0167-5699(86)90109-X; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; OHLEN C, 1990, J IMMUNOL, V145, P52; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STEINMULLER D, 1981, J IMMUNOL, V126, P1754; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANBLEEK GM, 1990, NATURE, V348, P213; VONBOEHMER H, 1979, J EXP MED, V150, P1134, DOI 10.1084/jem.150.5.1134; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WETTSTEIN PJ, 1989, HUMAN IMMUNOGENETICS, P339; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	32	73	75	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					633	640		10.1016/0092-8674(91)90095-G	http://dx.doi.org/10.1016/0092-8674(91)90095-G			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032287				2022-12-01	WOS:A1991FM03700013
J	HEDLEY, ML; MANIATIS, T				HEDLEY, ML; MANIATIS, T			SEX-SPECIFIC SPLICING AND POLYADENYLATION OF DSX PRE-MESSENGER-RNA REQUIRES A SEQUENCE THAT BINDS SPECIFICALLY TO TRA-2 PROTEIN INVITRO	CELL			English	Article							DROSOPHILA DOUBLESEX GENE; MELANOGASTER; SITE; DIFFERENTIATION; IDENTIFICATION; TRANSFORMER; EXPRESSION; INTRON; RECOGNITION; EFFICIENCY	Somatic sex determination in Drosophila involves a hierarchy of regulated alternative pre-mRNA processing. Female-specific splicing and/or polyadenylation of doublesex (dsx) pre-mRNA, the final gene in this pathway, requires transformer (tra) and transformer-2 (tra-2) proteins. The mechanism by which these proteins regulate RNA processing has not been characterized. In this paper we show that tra-2 produced in Escherichia coli binds specifically to a site within the female-specific exon of dsx pre-mRNA. This site, which contains six copies of a 13 nucleotide repeat, is required not only for female-specific splicing, but also for female-specific polyadenylation. These observations suggest that tra-2 is a positive regulator of dsx pre-mRNA processing.			HEDLEY, ML (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42231, GM 13344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; McKeown M, 1990, Genet Eng (N Y), V12, P139; MCLAUCHLAN J, 1989, CELL, V59, P1093, DOI 10.1016/0092-8674(89)90765-4; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SLEE R, 1990, Q REV BIOL, V65, P175, DOI 10.1086/416718; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	41	213	217	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					579	586		10.1016/0092-8674(91)90090-L	http://dx.doi.org/10.1016/0092-8674(91)90090-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1674449				2022-12-01	WOS:A1991FM03700008
J	INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M				INOUYE, S; SUNSHINE, MG; SIX, EW; INOUYE, M			RETRONPHAGE-PHI-R73 - AN ESCHERICHIA-COLI PHAGE THAT CONTAINS A RETROELEMENT AND INTEGRATES INTO A TRANSFER-RNA GENE	SCIENCE			English	Article							SATELLITE BACTERIOPHAGE-P4; MUTANTS; DNA	Some strains of Escherichia coli contain retroelements (retrons) that encode genes for reverse transcriptase and branched, multicopy, single-stranded DNA (msDNA) linked to RNA. However, the origin of retrons is unknown. A P4-like cryptic prophage was found that contains a retroelement (retron Ec73) for msDNA-Ec73 in an E. coli clinical strain. The entire genome of this prophage, named phi-R73, is 12.7 kilobase pairs and is flanked by 29-base pair direct repeats derived from the 3' end of the selenocystyl transfer RNA gene (selC). P2 bacteriophage caused excision of the phi-R73 prophage and acted as a helper to package phi-R73 DNA into an infectious virion. The newly formed phi-R73 closely resembled P4 as a virion and in its lytic growth. Retronphage phi-R73 lysogenized a new host strain, reintegrating its genome into the selC gene of the host chromosome and enabling the newly formed lysogens to produce msDNA-Ec73. Hence, retron Ec73 can be transferred intercellularly as part of the genome of a helper-dependent retronphage.	RUTGERS STATE UNIV,UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa			Inouye, Sharon/R-7216-2019		NIAID NIH HHS [AI04043] Funding Source: Medline; NIGMS NIH HHS [GM44012] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertani LE, 1988, BACTERIOPHAGES, V2, P73; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; GIBBS W, 1973, VIROLOGY, V53, P24, DOI 10.1016/0042-6822(73)90462-5; INOUYE M, 1991, TRENDS BIOCHEM SCI, V16, P18, DOI 10.1016/0968-0004(91)90010-S; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; SIX EW, 1975, VIROLOGY, V67, P249, DOI 10.1016/0042-6822(75)90422-5; SUN J, IN PRESS J BACTERIOL; WALKER JT, 1983, J VIROL, V45, P1118, DOI 10.1128/JVI.45.3.1118-1139.1983	8	77	79	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					969	971		10.1126/science.1709758	http://dx.doi.org/10.1126/science.1709758			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1709758				2022-12-01	WOS:A1991FM04000037
J	JOHNSON, EF				JOHNSON, EF			A PARTNERSHIP BETWEEN THE DIOXIN RECEPTOR AND A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Editorial Material							HEAT-SHOCK PROTEIN; XENOBIOTIC RESPONSIVE ELEMENTS; DNA-BINDING ACTIVITY; AH RECEPTOR; PEROXISOME PROLIFERATORS; AROMATIC-HYDROCARBONS; P-450C GENE; SUPERFAMILY; ENHANCER; CYTOCHROME-P-450				JOHNSON, EF (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.							BARINAGA M, 1991, SCIENCE, V251, P1176, DOI 10.1126/science.1848724; CONNEY AH, 1982, CANCER RES, V42, P4875; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILLETTE JR, 1979, DRUG METAB REV, V10, P59, DOI 10.3109/03602537908993901; GREENLEE WF, 1990, PROG CLIN BIOL RES, V331, P177; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHNSON EF, 1980, CANCER RES, V40, P4456; JONES PBC, 1986, J BIOL CHEM, V261, P6647; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REDDY JK, 1989, MUTAT RES, V214, P63, DOI 10.1016/0027-5107(89)90198-X; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	28	16	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					924	925		10.1126/science.1852074	http://dx.doi.org/10.1126/science.1852074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1852074				2022-12-01	WOS:A1991FM04000025
J	KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC				KESTLER, HW; RINGLER, DJ; MORI, K; PANICALI, DL; SEHGAL, PK; DANIEL, MD; DESROSIERS, RC			IMPORTANCE OF THE NEF GENE FOR MAINTENANCE OF HIGH VIRUS LOADS AND FOR DEVELOPMENT OF AIDS	CELL			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; OPEN READING FRAME; RHESUS-MONKEYS; PERSISTENT INFECTION; MUTATIONAL ANALYSIS; MACAQUE MONKEYS; HTLV-III; SOR GENE; TYPE-1; PROTEIN	When rhesus monkeys were infected with a form of cloned SIVmac239 having a premature stop signal at the 93rd codon of nef, revertants with a coding codon at this position quickly and universally came to predominate in the infected animals. This suggests that there are strong selective forces for open functional forms of nef in vivo. Although deletion of nef sequences had no detectable effect on virus replication in cultured cells, deletion of nef sequences dramatically altered the properties of virus in infected rhesus monkeys. Our results indicate that nef is required for maintaining high virus loads during the course of persistent infection in vivo and for full pathologic potential. Thus, nef should become a target for antiviral drug development. Furthermore, the properties of virus with a deletion in nef suggest a means for making live-attenuated strains of virus for experimental vaccine testing.	APPLIED BIOTECHNOL,CAMBRIDGE,MA 02142		KESTLER, HW (corresponding author), HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772, USA.			Mori, Kazuyasu/0000-0002-1841-6376	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025328, R37AI025328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168] Funding Source: Medline; NIAID NIH HHS [AI25328] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ARMSTRONG JA, 1984, LANCET, V2, P370; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; COHEN EA, 1988, NATURE, V334, P532, DOI 10.1038/334532a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; CULLEN BR, 1990, VIROLOGY, V178, P1, DOI 10.1016/0042-6822(90)90373-Y; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1988, J VIROL, V62, P4123, DOI 10.1128/JVI.62.11.4123-4128.1988; DESROSIERS RC, 1981, J GEN VIROL, V56, P119, DOI 10.1099/0022-1317-56-1-119; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAMINCHIK J, 1990, J VIROL, V64, P3447, DOI 10.1128/JVI.64.7.3447-3454.1990; KAMINCHIK J, 1991, J VIROL, V65, P583, DOI 10.1128/JVI.65.2.583-588.1991; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1988, NATURE, V331, P619, DOI 10.1038/331619a0; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; MALIM MH, 1989, P NATL ACAD SCI USA, V86, P8222, DOI 10.1073/pnas.86.21.8222; MILMAN G, 1981, SOMAT CELL GENET, V7, P161; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P8219, DOI 10.1093/nar/13.22.8219; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RINGLER DJ, 1989, AM J PATHOL, V134, P373; SAKAI H, 1990, J VIROL, V64, P2202, DOI 10.1128/JVI.64.5.2202-2207.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VIGLIANTI GA, 1990, J VIROL, V64, P4207, DOI 10.1128/JVI.64.9.4207-4216.1990; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329; ZWEIG M, 1990, VIROLOGY, V179, P504, DOI 10.1016/0042-6822(90)90325-L	49	1495	1523	1	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					651	662		10.1016/0092-8674(91)90097-I	http://dx.doi.org/10.1016/0092-8674(91)90097-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032289				2022-12-01	WOS:A1991FM03700015
J	MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ				MEISTER, M; WONG, ROL; BAYLOR, DA; SHATZ, CJ			SYNCHRONOUS BURSTS OF ACTION-POTENTIALS IN GANGLION-CELLS OF THE DEVELOPING MAMMALIAN RETINA	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; OCULAR DOMINANCE COLUMNS; CATS RETINOGENICULATE PATHWAY; RECEPTIVE-FIELD CHARACTERISTICS; PRENATAL DEVELOPMENT; FUNCTIONAL CONNECTIONS; VISUAL-CORTEX; RABBIT; TETRODOTOXIN; SEGREGATION	The development of orderly connections in the mammalian visual system depends on action potentials in the optic nerve fibers, even before the retina receives visual input. In particular, it has been suggested that correlated firing of retinal ganglion cells in the same eye directs the segregation of their synaptic terminals into eye-specific layers within the lateral geniculate nucleus. Such correlations in electrical activity were found by simultaneous recording of the extracellular action potentials of up to 100 ganglion cells in the isolated retina of the newborn ferret and the fetal cat. These neurons fired spikes in nearly synchronous bursts lasting a few seconds and separated by 1 to 2 minutes of silence. Individual bursts consisted of a wave of excitation, several hundred micrometers wide, sweeping across the retina at about 100 micrometers per second. These concerted firing patterns have the appropriate spatial and temporal properties to guide the refinement of connections between the retina and the lateral geniculate nucleus.			MEISTER, M (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA.			Meister, Markus/0000-0003-2136-6506	NEI NIH HHS [EY 05750] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005750] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], [No title captured]; CUCCHIARO J, 1984, PROC R SOC SER B-BIO, V223, P141, DOI 10.1098/rspb.1984.0087; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; GUILLERY RW, 1972, J COMP NEUROL, V144, P117, DOI 10.1002/cne.901440106; HARRIS WA, 1981, ANNU REV PHYSIOL, V43, P689, DOI 10.1146/annurev.ph.43.030181.003353; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JEFFERY G, 1989, DEV BRAIN RES, V46, P187, DOI 10.1016/0165-3806(89)90282-4; KALIL RE, 1986, NATURE, V323, P156, DOI 10.1038/323156a0; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVICK WR, 1973, HDB SENSORY PHYSL, V7, P575; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MASLAND RH, 1977, J COMP NEUROL, V175, P275, DOI 10.1002/cne.901750303; MASLIM J, 1986, BRAIN RES, V373, P35, DOI 10.1016/0006-8993(86)90313-6; Miller K.D., 1990, CONNECTIONIST MODELI, P255; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; PAYNE B, 1988, CEREB CORTEX, V7, P309; Pine J., 1982, SOC NEUR ABST, V8, P670; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RAPISARDI SC, 1975, EXP BRAIN RES, V22, P295; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; SCHWARTZ EA, 1982, J PHYSIOL-LONDON, V323, P211, DOI 10.1113/jphysiol.1982.sp014069; SCHWARTZ EA, 1986, J PHYSIOL-LONDON, V376, P411, DOI 10.1113/jphysiol.1986.sp016160; SHATZ CJ, 1984, J NEUROSCI, V4, P1378; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1990, J NEUROBIOL, V21, P197, DOI 10.1002/neu.480210113; SPEAR PD, 1972, BRAIN RES, V45, P67, DOI 10.1016/0006-8993(72)90216-8; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; STRYKER MP, 1986, BIOL CHANGE OTOLARYN, P211; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190	38	840	853	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	1991	252	5008					939	943		10.1126/science.2035024	http://dx.doi.org/10.1126/science.2035024			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	2035024				2022-12-01	WOS:A1991FM04000028
J	MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR				MILLER, K; SHIPMAN, M; TROWBRIDGE, IS; HOPKINS, CR			TRANSFERRIN RECEPTORS PROMOTE THE FORMATION OF CLATHRIN LATTICES	CELL			English	Article							COATED PIT FORMATION; MEDIATED ENDOCYTOSIS; CARCINOMA A431-CELLS; VESICLES; CELLS; INTERNALIZATION; FIBROBLASTS; MICROSCOPY; FLOW	Gold conjugates have been used to quantitate human transferrin receptors (hTfnRs) on transfected chick embryo fibroblasts. No relationship could be found between the number of hTfnRs and the number of clathrin-coated pits. However, hTfnRs are also associated with flat clathrin lattices that lie outside invaginated pits. With increasing levels of receptor expression, the density of hTfnRs within flat lattices increases, and at the highest levels of expression the total area of flat lattice increases up to 3-fold. These results show that increased receptor numbers can promote clathrin lattice growth and suggest that the recruitment of receptors like hTfnRs is an essential step in lattice construction. We conclude that the process of invagination, which gives rise to coated pits, is regulated separately.	SALK INST BIOL STUDIES,DEPT CANC BIOL,SAN DIEGO,CA 92138	Salk Institute	MILLER, K (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND.							BEAUMELLE BD, 1990, J CELL BIOL, V7111, P1811; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRETSCHER MS, 1983, COLD SPRING HARB SYM, V46, P707; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HOPKINS C, 1985, MOL MECHANISMS TRANS, P337; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1985, J CELL SCI S, V3, P173; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAUPIN P, 1983, J CELL BIOL, V96, P51, DOI 10.1083/jcb.96.1.51; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; NICOL A, 1987, EUR J CELL BIOL, V43, P348; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; RINNERTHALER G, 1988, J CELL BIOL, V106, P747, DOI 10.1083/jcb.106.3.747; RUTTER G, 1985, European Journal of Cell Biology, V39, P443; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	30	109	109	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					621	632		10.1016/0092-8674(91)90094-F	http://dx.doi.org/10.1016/0092-8674(91)90094-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1903330				2022-12-01	WOS:A1991FM03700012
J	MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS				MUCENSKI, ML; MCLAIN, K; KIER, AB; SWERDLOW, SH; SCHREINER, CM; MILLER, TA; PIETRYGA, DW; SCOTT, WJ; POTTER, SS			A FUNCTIONAL C-MYB GENE IS REQUIRED FOR NORMAL MURINE FETAL HEPATIC HEMATOPOIESIS	CELL			English	Article							EMBRYONIC STEM-CELLS; DNA-BINDING DOMAIN; MOUSE ERYTHROLEUKEMIA-CELLS; AVIAN-MYELOBLASTOSIS VIRUS; HOMOLOGOUS RECOMBINATION; PROTO-ONCOGENE; LEUKEMIA-VIRUS; V-MYB; NUCLEOTIDE-SEQUENCE; INSERTIONAL MUTAGENESIS	The c-myb proto-oncogene encodes a sequence-specific DNA-binding protein. To better understand its normal biological function, we have altered the c-myb gene by homologous recombination in mouse embryonic stem cells. Resulting homozygous c-myb mutant mice displayed an interesting phenotype. At day 13 of gestation these mice appeared normal, suggesting that c-myb is not essential for early development. By day 15, however, the mutant mice were severely anemic. Analysis indicated that embryonic erythropoiesis, which occurs in the yolk sac, was not impaired by the c-myb alteration. Adult-type erythropoiesis, which first takes place in the fetal liver, was greatly diminished in c-myb mutants, however. Additional hematopoietic lineages were similarly affected. These results are compatible with a role for c-myb in maintaining the proliferative state of hematopoietic progenitor cells.	UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT HEMATOL ONCOL,CINCINNATI,OH 45229	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	MUCENSKI, ML (corresponding author), UNIV CINCINNATI,CHILDRENS HOSP,COLL MED,RES FDN,CINCINNATI,OH 45229, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496, HL15996] Funding Source: Medline; NICHD NIH HHS [HD24517] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE RJ, 1966, J EMBRYOL EXP MORPH, V15, P245; COLLINS MD, 1989, AM J PHYSIOL, V257, P542; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; CRAIG RW, 1984, CANCER RES, V44, P442; CUDENNEC LA, 1981, P NATL ACAD SCI USA, V78, P2412; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DYSON PJ, 1989, DIFFERENTIATION, V42, P24, DOI 10.1111/j.1432-0436.1989.tb00603.x; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FANTONI A, 1967, SCIENCE, V157, P1327, DOI 10.1126/science.157.3794.1327; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; HENRY JB, 1979, TS DAVIDSOHN CLIN DI; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUANG E, 1990, CELL, V63, P255; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; KRAKOWSKY JM, 1989, DNA-J MOLEC CELL BIO, V8, P715, DOI 10.1089/dna.1989.8.715; KUCZUK MH, 1984, TERATOLOGY, V29, P427, DOI 10.1002/tera.1420290314; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P115; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SHEHEE WR, 1989, J MOL BIOL, V205, P41, DOI 10.1016/0022-2836(89)90363-X; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SIRACUSA LD, 1987, GENETICS, V117, P85; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; Tavassoli M, 1983, BONE MARROW STRUCTUR; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WAHLS WP, 1990, MOL CELL BIOL, V10, P794, DOI 10.1128/MCB.10.2.794; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wilson J.G., 1965, TERATOLOGY PRINCIPLE, P251; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	100	923	950	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					677	689		10.1016/0092-8674(91)90099-K	http://dx.doi.org/10.1016/0092-8674(91)90099-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1709592				2022-12-01	WOS:A1991FM03700017
J	NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G				NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G			BIOCHEMICAL FRACTIONATION AND ASSEMBLY OF THE MEMBRANE-COMPONENTS THAT MEDIATE NASCENT CHAIN TARGETING AND TRANSLOCATION	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; SECRETORY PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; RIBOSOME BINDING; ROUGH MICROSOMES; BOUND RIBOSOMES; RECEPTOR; COMPLEX; SEQUENCE	Fractionation of a microsomal detergent extract with ammonium sulfate allows separation of the signal recognition particle receptor (SR-alpha), which is required for targeting of the nascent chain, from other microsomal proteins, such as signal peptidase, whose activity is displayed during subsequent translocation. The reconstituted SR-alpha-enriched fraction is functional in assays of precursor targeting and elongation arrest release but lacks translocation activity. This defect can be complemented by addition, prior to reconstitution, of a separate protein subfraction. In addition, protein components necessary for translocation can be reversibly depleted from the complementary fraction, under conditions where precursor targeting is retained, by sulfhydryl-directed chromatography. Thus, precursor binding and translocation can be biochemically uncoupled, indicating that they are sequential reactions mediated by distinct components.			NICCHITTA, CV (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIBICH G, 1983, METHOD ENZYMOL, V96, P520; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	41	43	44	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					587	598		10.1016/0092-8674(91)90091-C	http://dx.doi.org/10.1016/0092-8674(91)90091-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851670				2022-12-01	WOS:A1991FM03700009
J	PHILPOTT, A; LENO, GH; LASKEY, RA				PHILPOTT, A; LENO, GH; LASKEY, RA			SPERM DECONDENSATION IN XENOPUS EGG CYTOPLASM IS MEDIATED BY NUCLEOPLASMIN	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HEN ERYTHROCYTE NUCLEI; CELL-FREE PREPARATIONS; PRONUCLEAR FORMATION; RABBIT SPERMATOZOA; HISTONE COMPLEXES; DNA-REPLICATION; LAEVIS OOCYTES; ACIDIC PROTEIN; SOMATIC CELLS	At fertilization, sperm chromatin decondenses in two stages, which can be mimicked in extracts of Xenopus eggs. Rapid, limited decondensation is followed by slower, membrane-dependent decondensation and swelling. Nucleoplasmin, an acidic nuclear protein, occurs at high concentration in Xenopus eggs and has a histone-binding role in nucleosome assembly. Immunodepleting nucleoplasmin from egg extracts inhibits the initial rapid stage of sperm decondensation, and also the decondensation of myeloma nuclei, relative to controls of mock depletion and TFIIIA depletion. Readdition of purified nucleoplasmin recues depleted extracts. A physiological concentration of purified nucleoplasmin alone decondenses both sperm and myeloma nuclei. We conclude that nucleoplasmin is both necessary and sufficient for the first stage of sperm decondensation in Xenopus eggs.	UNIV CAMBRIDGE, DEPT ZOOL, CANC RES CAMPAIGN, MOLEC EMBRYOL GRP, CAMBRIDGE CB2 3EJ, ENGLAND	CRUK Cambridge Institute; University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY JM, 1972, EXP CELL RES, V71, P90, DOI 10.1016/0014-4827(72)90267-4; BEDFORD JM, 1974, J EXP ZOOL, V188, P137, DOI 10.1002/jez.1401880203; BERRIOS M, 1990, EXP CELL RES, V191, P64, DOI 10.1016/0014-4827(90)90036-A; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Calvin H. I, 1971, Journal Reprod Fertil, VNo. 13, P65; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GLEDHILL BL, 1972, EXP CELL RES, V73, P33, DOI 10.1016/0014-4827(72)90098-5; GRAHAM CF, 1966, DEV BIOL, V14, P349, DOI 10.1016/0012-1606(66)90020-0; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1968, J EMBRYOL EXP MORPH, V20, P401; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNTER RHF, 1967, J EXP ZOOL, V165, P451, DOI 10.1002/jez.1401650313; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; JOHNSON RT, 1970, J CELL PHYSIOL, V76, P151, DOI 10.1002/jcp.1040760204; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAMBERT SF, 1986, EUR J BIOCHEM, V160, P191, DOI 10.1111/j.1432-1033.1986.tb09957.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1983, PHILOS T ROY SOC B, V302, P143, DOI 10.1098/rstb.1983.0047; LEAKE RE, 1972, EXP CELL RES, V71, P17, DOI 10.1016/0014-4827(72)90257-1; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; SAWICKI W, 1971, EXP CELL RES, V66, P145, DOI 10.1016/S0014-4827(71)80022-8; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; THANDANI VM, 1979, J EXP ZOOL, V210, P161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULITZUR N, 1989, FEBS LETT, V259, P113, DOI 10.1016/0014-5793(89)81507-8; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; ZELENIN AV, 1974, CELL DIFFER DEV, V3, P95, DOI 10.1016/0045-6039(74)90031-1	43	248	256	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					569	578		10.1016/0092-8674(91)90089-H	http://dx.doi.org/10.1016/0092-8674(91)90089-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032284				2022-12-01	WOS:A1991FM03700007
J	ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B				ROCK, KL; GAMBLE, S; ROTHSTEIN, L; GRAMM, C; BENACERRAF, B			DISSOCIATION OF BETA-2-MICROGLOBULIN LEADS TO THE ACCUMULATION OF A SUBSTANTIAL POOL OF INACTIVE CLASS-I MHC HEAVY-CHAINS ON THE CELL-SURFACE	CELL			English	Article							RESTRICTED T-CELLS; HISTOCOMPATIBILITY MOLECULES; ANTIGEN PRESENTATION; DENOVO SYNTHESIS; LYMPHOMA-CELLS; MOUSE LYMPHOMA; LYMPHOCYTES-T; RECOGNITION; PEPTIDES; BINDING	A large pool of free class I heavy chains is detected in situ on the plasma membrane of living cells. These chains are present on cells of different MHC genotypes and appear to exist under physiological conditions in vivo. These molecules arise from the dissociation of previously assembled class I heterodimers at the cell surface. The ratio of intact to dissociated heterodimers is strongly affected by the occupancy of the peptide-binding site of the class I molecule. Upon dissociation of the heterodimer, the class I molecule is functionally inactive. These finding may help to explain why class I molecules on the cell surface are unreceptive to binding peptides yet readily associated with peptides in the presence of exogenous beta-2-microglobulin. These results have implications for understanding the distinct functions of class I versus class II molecules and how the immunological identify of cells is preserved.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROCK, KL (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.				PHS HHS [A120248] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CORNETTE JL, 1989, METHOD ENZYMOL, V178, P611; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; FALO LD, 1985, P NATL ACAD SCI USA, V82, P6647, DOI 10.1073/pnas.82.19.6647; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HAUSTEIN D, 1975, BIOCHEMISTRY-US, V14, P1826, DOI 10.1021/bi00680a004; HICKLING JK, 1990, INT IMMUNOL, V2, P435, DOI 10.1093/intimm/2.5.435; HYAFIL F, 1979, P NATL ACAD SCI USA, V76, P5834, DOI 10.1073/pnas.76.11.5834; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KVIST S, 1979, EUR J IMMUNOL, V9, P991, DOI 10.1002/eji.1830091214; KVIST S, 1978, BIOCHEMISTRY-US, V17, P4794, DOI 10.1021/bi00615a029; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MYERS NB, 1989, J IMMUNOL, V142, P2751; NATORI T, 1976, J IMMUNOGENET, V3, P123; OZATO K, 1981, J IMMUNOL, V126, P317; PARHAM P, 1983, HUM IMMUNOL, V8, P207, DOI 10.1016/0198-8859(83)90038-1; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PERKINS DL, 1989, J EXP MED, V170, P279, DOI 10.1084/jem.170.1.279; REISER H, 1986, CELL, V47, P365, DOI 10.1016/0092-8674(86)90593-3; ROBINSON PJ, 1983, TRANSPLANT P, V15, P2051; ROCK KL, 1983, J EXP MED, V157, P1618, DOI 10.1084/jem.157.5.1618; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; STALLCUP KC, 1981, J IMMUNOL, V127, P923; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TADA N, 1980, IMMUNOGENETICS, V11, P441, DOI 10.1007/BF01567813; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796	49	161	163	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					611	620		10.1016/0092-8674(91)90093-E	http://dx.doi.org/10.1016/0092-8674(91)90093-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032286				2022-12-01	WOS:A1991FM03700011
J	WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R				WILLEY, J; SANTAMARIA, R; GUIJARRO, J; GEISTLICH, M; LOSICK, R			EXTRACELLULAR COMPLEMENTATION OF A DEVELOPMENTAL MUTATION IMPLICATES A SMALL SPORULATION PROTEIN IN AERIAL MYCELIUM FORMATION BY S-COELICOLOR	CELL			English	Article							STREPTOMYCES-COELICOLOR; COLONY MUTANTS; A-FACTOR; GRISEUS; DIFFERENTIATION; QUANTITIES; SEQUENCE; CLONING; A3(2)	The filamentous bacterium S. coelicolor differentiates by forming aerial hyphae, which protrude into the air and metamorphose into chains of spores. Aerial hyphae formation is associated with the production of a small, abundant protein, SapB, which is present in a zone around colonies of differentiating bacteria. Production of SapB is impaired in bld mutants, which are blocked in aerial hyphae formation, but not in whi mutants in which spore formation is prevented. We report that aerial hyphae formation by a newly identified bld mutant is restored by juxtaposition of the mutant near colonies of SapB-producing bacteria or by the application of the purified protein near mutant colonies. These observations implicate SapB in aerial mycelium formation and suggest that SapB is a morphogenetic protein that enables hyphae on the surface of colonies to grow into the air.			WILLEY, J (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138, USA.		Moya GUIJARRO, Arsenio Jesús/GXH-0909-2022; Santamaria, Ramon I/M-9069-2019; Santamaria, Ramon I/K-2870-2014	Santamaria, Ramon I/0000-0002-2181-6776; Santamaria, Ramon I/0000-0002-2181-6776; Willey, Joanne/0000-0003-4544-4417				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; BIRO S, 1980, EUR J BIOCHEM, V103, P359, DOI 10.1111/j.1432-1033.1980.tb04322.x; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; Chater K. F., 1982, CURR TOP MICROBIOL I, V96, P69; Chater K. F., 1984, MICROBIAL DEV, P89; CHATER KF, 1972, J GEN MICROBIOL, V72, P9, DOI 10.1099/00221287-72-1-9; CHATER KF, 1989, REGULATION PROCARYOT, V1, P277; GUIJARRO J, 1988, J BACTERIOL, V170, P1895, DOI 10.1128/jb.170.4.1895-1901.1988; HARA O, 1982, J ANTIBIOT, V35, P349, DOI 10.7164/antibiotics.35.349; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KHOKHLOV AS, 1973, Z ALLG MIKROBIOL, V13, P647, DOI 10.1002/jobm.3630130803; KHOKHLOV AS, 1985, 6TH P INT S ACT BIOL, P791; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCANN PA, 1979, J ANTIBIOT, V32, P673, DOI 10.7164/antibiotics.32.673; MENDEZ C, 1987, J BACTERIOL, V169, P5715, DOI 10.1128/jb.169.12.5715-5720.1987; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; PIRET JM, 1985, J BACTERIOL, V163, P965, DOI 10.1128/JB.163.3.965-972.1985; Segrest JP, 1972, METHOD ENZYMOL, V28, P54, DOI DOI 10.1016/0076-6879(72)28007-7; Thomas J O, 1978, Methods Cell Biol, V18, P429	23	152	155	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					641	650		10.1016/0092-8674(91)90096-H	http://dx.doi.org/10.1016/0092-8674(91)90096-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	2032288				2022-12-01	WOS:A1991FM03700014
J	XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P				XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P			CLONING, EXPRESSION, AND TRANSCRIPTIONAL PROPERTIES OF THE HUMAN ENHANCER FACTOR TEF-1	CELL			English	Article							UBIQUITOUS NUCLEAR PROTEINS; SIMIAN VIRUS-40 ENHANCER; FIBROBLAST GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; CELL TYPE-SPECIFICITY; DNA-BINDING DOMAIN; NON-AUG CODONS; SV40 ENHANCER; MESSENGER-RNA; MAMMALIAN-CELLS	We describe the cDNA encoding the SV40 transcriptional enhancer factor 1 (TEF-1) and show that its translation initiates exclusively at an AUU codon in vivo. Cloned TEF-1, which is unrelated to other known transcription factors, specifically binds the SV40 GT-IIC and Sph enhansons. Cloned TEF-1 does not activate these enhansons in lymphoid MPC11 cells where they are known to be inactive, but represses the endogenous HeLa TEF-1 activity in vivo and in vitro. Repression is also observed with chimeras where the DNA-binding domain of the GAL4 activator replaces that of TEF-1, showing that repression results from interference/squelching. Such chimeras stimulate transcription in HeLa, but not in MPC11, cells in vivo and in HeLa cell extracts in vitro. However, high concentrations result in self-interference/squelching. These results strongly suggest that the trans-activation function of TEF-1 is mediated by a highly limiting, possible cell-specific, titratable transcriptional intermediary factor(s).	FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Davidson, Irwin/0000-0001-5533-1171				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAMBON P, 1984, RECENT PROG HORM RES, V40, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; COSMAN D, 1987, IMMUNOL TODAY, V8, P16, DOI 10.1016/0167-5699(87)90826-7; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA KC, 1988, J BIOL CHEM, V263, P8553; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATZOPOULOS AK, 1988, TRANSCRIPTION SPLICI, P43; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1979, J BIOL CHEM, V254, P4731; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; LAMAIRE P, 1990, MOL CELL BIOL, V10, P3456; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PAYRE V, 1988, FEBS LETT, V234, P245; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUSZTAI R, 1989, J VIROL, V63, P3516, DOI 10.1128/JVI.63.8.3516-3518.1989; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TOOZE J, 1982, MOL BIOL TUMOR VIR 2, P799; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	120	359	366	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					551	568		10.1016/0092-8674(91)90088-G	http://dx.doi.org/10.1016/0092-8674(91)90088-G			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851669				2022-12-01	WOS:A1991FM03700006
J	FORSBURG, SL; NURSE, P				FORSBURG, SL; NURSE, P			IDENTIFICATION OF A G1-TYPE CYCLIN PUC1+ IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MATING-PHEROMONE; DNA-REPLICATION; MESSENGER-RNA; CONTROL GENE; M-PHASE; MITOSIS; PROTEIN; DIVISION	IN rapidly growing cells of the budding yeast Saccharomyces cerevisiae, the cell cycle is regulated chiefly at Start, just before the G1-S boundary 1, whereas in the fission yeast Schizosaccharomyces pombe, the cycle is predominantly regulated at G2-M (ref. 2). Both control points are present in both yeasts, and both require the p34cdc2 protein kinase 3-5. At G2-M, p34cdc2 kinase activity in S. pombe requires a B-type cyclin in a complex with p34cdc2 (refs 6-14); this complex is the same as MPF (maturation promoting factor 15,16). The p34cdc2 activity at the G1-S transition in S. cerevisiae may be regulated by a similar cyclin complex, using one of the product of a new class of cyclin genes (CLN1, CLN2 and WHI1 (DAF1/CLN3)) (refs 17-22). At least one is required for progression through the G1-S phase, and deletion of all three leads to G1 arrest 19. WHI1 was isolated as a dominant allele causing budding yeast cells to divide at a reduced size 21 and was later independently identified as DAF1, a dominant allele of which rendered the cells refractory to the G1-arrest induced by the mating pheromone alpha-factor 22. The dominant alleles are truncations thought to yield proteins of increased stability, and the cells are accelerated through G1 (refs 20, 22). Without WHI1 function, the cells are hypersensitive to alpha-factor 22, enlarged and delayed in G1 (refs 20, 22). Heretofore, this G1-class of cyclins has not been identified in other organisms. We have isolated a G1-type cyclin gene called puc1+ from S. pombe, using a functional assay in S. cerevisiae. Expression of puc1+ in S. pombe indicates that it has a cyclin-like role in the fission yeast distinct from the role of the B-type mitotic cyclin.			FORSBURG, SL (corresponding author), UNIV OXFORD, DEPT BIOCHEM,MICROBIOL UNIT,IMPERIAL CANC RES FUND, CELL CYCLE GRP, S PARKS RD, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598				BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOEBL M, 1988, CELL, V54, P739; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SAZER S, 1990, J CELL SCI, V97, P509; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	32	87	88	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					245	248		10.1038/351245a0	http://dx.doi.org/10.1038/351245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828291				2022-12-01	WOS:A1991FL99000061
J	FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H				FRANK, D; KESHET, I; SHANI, M; LEVINE, A; RAZIN, A; CEDAR, H			DEMETHYLATION OF CPG ISLANDS IN EMBRYONIC-CELLS	NATURE			English	Article							X-CHROMOSOME INACTIVATION; DENOVO METHYLATION; DNA METHYLATION; CHROMATIN STRUCTURE; TRANSGENIC MICE; 2 GENES; MOUSE; EXPRESSION; EMBRYOGENESIS; LINES	DNA in differentiated somatic cells has a fixed pattern of methylation, which is faithfully copied after replication. By contrast, the methylation patterns of many tissue-specific and some housekeeping genes are altered during normal development 1. This modification of DNA methylation in the embryo has also been observed in transgenic mice and in transfection experiments 2. Here we report the fate in mice of an in vitro-methylated adenine phosphoribosyltransferase transgene. The entire 5' CpG island region became demethylated, whereas the 3' end of the gene remained modified and was even methylated de novo at additional sites. Transfection experiments in vitro show that the demethylation is rapid, is specific for embryonic cell-types and affects a variety of different CpG island sequences. This suggests that gene sequences can be recognized in the early embryo and imprinted with the correct methylation pattern through a combination of demethylation and de novo methylation.	AGR RES ORG, VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	FRANK, D (corresponding author), HEBREW UNIV JERUSALEM, SCH MED, DEPT CELLULAR BIOCHEM, POB 1172, JERUSALEM, ISRAEL.		Levine, Alex/A-6867-2008					ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DRISCOLL DJ, 1990, SOMAT CELL MOLEC GEN, V16, P267, DOI 10.1007/BF01233363; EINAT P, 1987, GENE DEV, V1, P1075, DOI 10.1101/gad.1.10.1075; GARTLER SM, 1975, EXP CELL RES, V91, P454, DOI 10.1016/0014-4827(75)90127-5; GAUTSCH JW, 1983, NATURE, V301, P32, DOI 10.1038/301032a0; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KEITH DH, 1986, MOL CELL BIOL, V6, P4122, DOI 10.1128/MCB.6.11.4122; KOLSTO AB, 1986, NUCLEIC ACIDS RES, V14, P9667; KRATZER PG, 1981, P NATL ACAD SCI-BIOL, V78, P3093, DOI 10.1073/pnas.78.5.3093; KRATZER PG, 1983, CELL, V33, P37, DOI 10.1016/0092-8674(83)90332-X; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOWRY I, 1980, CELL, V22, P817; MONK M, 1987, DEVELOPMENT, V99, P371; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PONZETTOZIMMERMAN C, 1984, NUCLEIC ACIDS RES, V12, P2807, DOI 10.1093/nar/12.6.2807; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SHEMER R, 1990, J BIOL CHEM, V265, P1010; SHIMADA T, 1987, MOL CELL BIOL, V7, P2830, DOI 10.1128/MCB.7.8.2830; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; STEIN R, 1983, P NATL ACAD SCI-BIOL, V80, P2422, DOI 10.1073/pnas.80.9.2422	27	133	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					239	241		10.1038/351239a0	http://dx.doi.org/10.1038/351239a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041571				2022-12-01	WOS:A1991FL99000059
J	HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA				HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA			IMPAIRMENT OF MITOCHONDRIAL TRANSCRIPTION TERMINATION BY A POINT MUTATION ASSOCIATED WITH THE MELAS SUBGROUP OF MITOCHONDRIAL ENCEPHALOMYOPATHIES	NATURE			English	Article							TRANSFER RNALYS; DNA-SEQUENCE; BINDING; INVITRO; PURIFICATION; SELECTION; EPILEPSY; GENOME	DEFECTS in mitochondrial DNA (mtDNA) are associated with several different human diseases, including the mitochondrial encephalomyopathies. The mutations include deletions but also duplications and point mutations 1. Individuals with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) carry a common A-to-G substitution in a highly conserved portion of the gene for transfer RNA(Leu(UUR)) (refs 2, 3). Although the MELAS mutation may be comparable to the defect in the tRNA(Lys) gene associated with MERRF (refs 4, 5) (myoclonus epilepsy associated with ragged-red fibres), it is also embedded in the middle of a tridecamer sequence necessary for the formation of the 3' ends of 16S ribosomal RNA in vitro 6. We found that the MELAS mutation results in severe impairment of 16S rRNA transcription termination, which correlates with a reduced affinity of the partially purified termination protein for the MELAS template. This suggests that the molecular defect in MELAS is the inability to produce the correct type and quantity of rRNA relative to other mitochondrial gene products.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMYN A, 1987, CURR TOP BIOENERG, V15, P295; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P78; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDER ES, 1990, CELL, V61, P925, DOI 10.1016/0092-8674(90)90055-J; Maxam A M, 1980, Methods Enzymol, V65, P499; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; YONEDA M, 1990, BIOCHEM INT, V21, P789	19	217	220	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					236	239		10.1038/351236a0	http://dx.doi.org/10.1038/351236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1755869				2022-12-01	WOS:A1991FL99000058
J	HYMAN, AA; MITCHISON, TJ				HYMAN, AA; MITCHISON, TJ			2 DIFFERENT MICROTUBULE-BASED MOTOR ACTIVITIES WITH OPPOSITE POLARITIES IN KINETOCHORES	NATURE			English	Article							CYTOPLASMIC DYNEIN; PROTEIN; SPINDLE; KINESIN; DROSOPHILA; POLEWARD; MITOSIS; FORCE; DEPHOSPHORYLATION; MICROMANIPULATION	The movement of microtubules on the kinetochores of isolated chromosomes has been examined by video microscopy. Two different microtubule-based motors on the kinetochore were identified, which have opposite directions of movement. The activities of these two motors can be regulated by factors that can influence phosphorylation.			HYMAN, AA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; 				BAJER AS, 1972, INT REV CYTOL      S, V3, P1; BEGG DA, 1979, J CELL BIOL, V82, P528, DOI 10.1083/jcb.82.2.528; CHLEBOWSKI JF, 1972, J BIOL CHEM, V247, P6007; COHN SA, 1989, J BIOL CHEM, V264, P4290; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; Dustin P., 1984, MICROTUBULES; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; EUTENEUER U, 1982, J CELL BIOL, V94, P644, DOI 10.1083/jcb.94.3.644; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HAYMAN AA, IN PRESS J CELL SCI; HAYS TS, 1990, J CELL BIOL, V110, P391, DOI 10.1083/jcb.110.2.391; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; INOUE S, 1975, BIOPHYS J, V15, P725, DOI 10.1016/S0006-3495(75)85850-4; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KOSHLAND D, 1988, NATURE, V311, P499; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1989, CELL MOVEMENT, V2, P421; MITCHISON TJ, 1985, J CELL BIOL, V101, P767; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; RIEDER CL, 1981, CHROMOSOMA, V84, P145, DOI 10.1007/BF00293368; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; Salmon E. D., 1989, CELL MOVEMENT, P431; SAXTON WM, IN PRESS CELL; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WORDEMAN L, 1987, CELL, V50; WORDEMAN L, IN PRESS J CELL BIOL; WRIGHT BD, IN PRESS J CELL BIOL; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1846	43	179	180	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					206	211		10.1038/351206a0	http://dx.doi.org/10.1038/351206a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041567				2022-12-01	WOS:A1991FL99000047
J	KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN				KRAPF, R; BEELER, I; HERTNER, D; HULTER, HN			CHRONIC RESPIRATORY ALKALOSIS - THE EFFECT OF SUSTAINED HYPERVENTILATION ON RENAL REGULATION OF ACID-BASE-EQUILIBRIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HYPOCAPNIA; RADIOIMMUNOASSAY; PLASMA; SERUM; H+	Background. In normal subjects, chronic hyperventilation lowers plasma bicarbonate concentration, primarily by inhibiting the urinary excretion of net acid. The quantitative relation between reduced arterial carbon dioxide tension (PaCO2) and the plasma bicarbonate concentration in the chronic steady state has not been studied in humans, however, and the laboratory criteria for the diagnosis of chronic respiratory alkalosis therefore remain undefined. We wished to provide such reference data for clinical use. Moreover, because chronic hyperventilation paradoxically lowers blood pH still further in dogs with metabolic acidosis, we desired to study the effect of chronic hypocapnia on the plasma bicarbonate concentration (and blood pH) in normal human subjects in whom acidosis had been induced with ammonium chloride. Methods. Under metabolic-balance conditions, we used altitude-induced hypobaric hypoxia to produce chronic hypocapnia in nine normal young men, five of whom received ammonium chloride daily to cause metabolic acidosis (the mean [+/- SE] steady-state plasma bicarbonate level in these five was 12.0 +/- 0.5 mmol per liter). Results. For each decrease of 1 mm Hg (0.13 kPa) in the PaCO2, the plasma bicarbonate concentration decreased by 0.41 mmol per liter in the subjects who started with a normal plasma bicarbonate concentration and by 0.42 mmol per liter in the subjects with acidosis. In contrast to the findings in previous studies of dogs, hypocapnia increased blood pH similarly in both groups; the blood hydrogen ion concentration decreased by about 0.4 nmol per liter for every decrease of 1 mm Hg (0.13 kPa) in PaCO2. Conclusions. These results provide reference data for the diagnosis of chronic respiratory alkalosis in humans. Although chronic hypocapnia decreased plasma bicarbonate levels similarly in normal subjects with acidosis and without acidosis, the percent reduction in PaCO2 was always greater than the corresponding percent reduction in the plasma bicarbonate concentration. Therefore, as was not true of the response in dogs, the subjects' blood pH always increased with hyperventilation, regardless of the initial plasma bicarbonate concentration.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,DIV NEPHROL,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	KRAPF, R (corresponding author), INSELSPITAL BERN,DEPT MED,CH-3010 BERN,SWITZERLAND.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; ALTMAN PL, 1971, RESP CIRC, P12; ARBUS GS, 1969, NEW ENGL J MED, V280, P117, DOI 10.1056/NEJM196901162800301; BARKER ES, 1957, J CLIN INVEST, V36, P515, DOI 10.1172/JCI103449; BRACKETT NC, 1965, NEW ENGL J MED, V272, P6, DOI 10.1056/NEJM196501072720102; BRACKETT NC, 1969, NEW ENGL J MED, V280, P124, DOI 10.1056/NEJM196901162800302; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BURNELL JM, 1956, J CLIN INVEST, V35, P935, DOI 10.1172/JCI103352; COHEN JJ, 1976, J CLIN INVEST, V57, P1483, DOI 10.1172/JCI108418; COTLOVE E, 1961, CLIN CHEM, V7, P285; DEMPSEY JA, 1972, RESP PHYSIOL, V16, P213, DOI 10.1016/0034-5687(72)90052-7; DEMPSEY JA, 1974, J CLIN INVEST, V53, P1001; DICKINSON JG, 1987, BRIT MED J, V295, P1161, DOI 10.1136/bmj.295.6607.1161; DOUGLAS C. G., 1933, JOUR PHYSIOL, V78, P404, DOI 10.1113/jphysiol.1933.sp003012; DUGGAN J, 1982, CLIN CHEM, V28, P1407; FISHMAN AP, 1988, PULMONARY DISEASES D, V3; FORSTER HV, 1975, J APPL PHYSIOL, V38, P1067, DOI 10.1152/jappl.1975.38.6.1067; FORSTER HV, 1972, J APPL PHYSIOL, V32, P134, DOI 10.1152/jappl.1972.32.1.134; FORWAND SA, 1968, NEW ENGL J MED, V279, P839, DOI 10.1056/NEJM196810172791601; FOSTER LB, 1974, CLIN CHEM, V20, P365; GENNARI FJ, 1972, J CLIN INVEST, V51, P1722, DOI 10.1172/JCI106973; GIEBISCH G, 1955, J CLIN INVEST, V34, P231, DOI 10.1172/JCI103076; GLEDHILL N, 1975, KIDNEY INT, V8, P376, DOI 10.1038/ki.1975.130; GRIMBERT F, 1977, B EUR PHYSIOPATH RES, V13, P659; HELGER R, 1974, Z KLIN CHEM KLIN BIO, V12, P344; LOGSDON EE, 1960, ANN NY ACAD SCI, V87, P801, DOI 10.1111/j.1749-6632.1960.tb23237.x; MADIAS NE, 1977, J CLIN INVEST, V60, P1393, DOI 10.1172/JCI108900; MOSTELLAR ME, 1964, J CLIN INVEST, V43, P138, DOI 10.1172/JCI104888; OGIHARA T, 1977, J CLIN ENDOCR METAB, V45, P726, DOI 10.1210/jcem-45-4-726; RELMAN AS, 1953, J CLIN INVEST, V32, P972, DOI 10.1172/JCI102823; ROSENTHAL TB, 1948, J BIOL CHEM, V173, P25; SCHAMBELAN M, 1987, AM J PHYSIOL, V252, pE454, DOI 10.1152/ajpendo.1987.252.4.E454; SENDROY J, 1932, J BIOL CHEM, V106, P463; SEVERINGHAUS JW, 1956, J APPL PHYSIOL, V9, P197, DOI 10.1152/jappl.1956.9.2.197; SEVERINGHAUS JW, 1963, J APPL PHYSIOL, V18, P1155, DOI 10.1152/jappl.1963.18.6.1155; YOUNG DB, 1988, AM J PHYSIOL, V255, pF811, DOI 10.1152/ajprenal.1988.255.5.F811	36	92	93	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1394	1401		10.1056/NEJM199105163242003	http://dx.doi.org/10.1056/NEJM199105163242003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1902283				2022-12-01	WOS:A1991FL12500003
J	LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR				LOGAN, GM; WEIMER, MK; ELLEFSON, M; PIERACH, CA; BLOOMER, JR			BILE PORPHYRIN ANALYSIS IN THE EVALUATION OF VARIEGATE PORPHYRIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTOPORPHYRINOGEN OXIDASE; ENZYMATIC DEFECT; HEMOGLOBIN; FECES; HEME	Background. Variegate porphyria is a genetic disorder of porphyrin metabolism in which patients may have both neurologic dysfunction and photocutaneous lesions. Biochemical confirmation of the diagnosis can be difficult, particularly in patients without neurologic dysfunction at the time of testing. The demonstration of increased fecal excretion of porphyrin is frequently used for this purpose, but levels may be normal. Since elevated fecal porphyrin levels in variegate porphyria are presumably a consequence of increased biliary excretion, we evaluated whether analysis of porphyrins in bile distinguishes better between patients with variegate porphyria and controls. Methods. Bile samples were collected by duodenal aspiration from 10 patients with proved variegate porphyria who had no neurologic symptoms when they were studied and 17 control subjects. Bile and fecal porphyrin levels were measured fluorometrically. Results. The mean total porphyrin concentration in bile in the patients with variegate porphyria was significantly higher than that in the controls (67.8 vs. 0.71-mu-mol per liter; P < 0.00002). There was more than a ninefold difference between the highest level in any control subject and the lowest level in any patient with variegate porphyria. The mean fecal porphyrin level in the patients with variegate porphyria also differed significantly from that in the controls (0.79 vs. 0.14-mu-mol per gram of dry weight; P < 0.007), but four patients had levels within the control range. Conclusions. The concentration of porphyrin in bile is higher in patients with variegate porphyria than in controls, and the difference is greater than that for fecal porphyrin. Bile porphyrin measurements may be helpful in the evaluation of asymptomatic patients suspected of having variegate porphyria.	UNIV MINNESOTA,DEPT MED,DIV GASTROENTEROL HEPATOL & NUTR,BOX 36 UMHC,HARVARD ST & RIVER RD,MINNEAPOLIS,MN 55455; MINNEAPOLIS MED RES FDN INC,DEPT MED,MINNEAPOLIS,MN; ABBOTT NW HOSP,DEPT MED,MINNEAPOLIS,MN; ST PAUL RAMSEY MED CTR,GASTROENTEROL SECT,ST PAUL,MN 55101	University of Minnesota System; University of Minnesota Twin Cities; Minneapolis Medical Research Foundation; Saint Paul Ramsey Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034931, R01DK026466, R37DK026466] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34931, DK 26466] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZIZ MA, 1969, CLIN CHIM ACTA, V26, P525, DOI 10.1016/0009-8981(69)90083-7; BELCHER RV, 1969, CLIN CHIM ACTA, V25, P45, DOI 10.1016/0009-8981(69)90225-3; BEUKEVELD GJJ, 1987, CLIN CHEM, V33, P2164; BRENNER DA, 1980, NEW ENGL J MED, V302, P765, DOI 10.1056/NEJM198004033021401; COREY TJ, 1980, J AM ACAD DERMATOL, V2, P36, DOI 10.1016/S0190-9622(80)80290-8; DEYBACH JC, 1981, HUM GENET, V58, P425, DOI 10.1007/BF00282829; DUANE WC, 1976, J LIPID RES, V17, P211; Eales L, 1966, S Afr Med J, V40, P380; EALES L, 1990, INT J BIOCHEM, V12, P837; ELDER GH, 1975, J CLIN PATHOL, V28, P601, DOI 10.1136/jcp.28.8.601; FORD RE, 1981, CLIN CHEM, V27, P397; FROMKE VL, 1978, AM J MED, V65, P80, DOI 10.1016/0002-9343(78)90696-4; GROSSER Y, 1973, S AFR MED J, V47, P2162; JENDRASSIK A, 1938, BIOCHEM Z, V296, P71; MORTON KO, 1988, GASTROENTEROLOGY, V94, P1488, DOI 10.1016/0016-5085(88)90690-7; MUSTAJOKI P, 1978, ANN INTERN MED, V89, P238, DOI 10.7326/0003-4819-89-2-238; MUSTAJOKI P, 1976, ACTA MED SCAND, V200, P171; POHFITZPATRICK MB, 1980, ARCH DERMATOL, V116, P543, DOI 10.1001/archderm.116.5.543; RIMINGTON C, 1968, CLIN SCI, V35, P211; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SCHWARTZ S, 1985, GASTROENTEROLOGY, V89, P19, DOI 10.1016/0016-5085(85)90740-1; SIEPKER L, 1986, S AFR MED J, V70, P819; VILJOEN DJ, 1983, EUR J CLIN INVEST, V13, P283, DOI 10.1111/j.1365-2362.1983.tb00102.x; WATSON CJ, 1960, NEW ENGL J MED, V263, P1205, DOI 10.1056/NEJM196012152632401; 1989, SAS STAT GUIDE PERSO, P261	25	34	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1408	1411		10.1056/NEJM199105163242005	http://dx.doi.org/10.1056/NEJM199105163242005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020296				2022-12-01	WOS:A1991FL12500005
J	MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA				MOORE, JM; PEATTIE, DA; FITZGIBBON, MJ; THOMSON, JA			SOLUTION STRUCTURE OF THE MAJOR BINDING-PROTEIN FOR THE IMMUNOSUPPRESSANT FK506	NATURE			English	Article							CIS-TRANS ISOMERASE; PEPTIDYL-PROLYL ISOMERASE; FK506-BINDING PROTEIN; H-1-NMR SPECTRA; CYCLOSPORIN-A; CYCLOPHILIN; DISTINCT; PATHWAYS; CELL	THE major FK506 binding protein (FKBP, relative molecular mass approximately 11,800; M(r) 11.8K) and cyclophilin (M(r) approximately 17K) belong to a class of proteins termed immunophilins 1. Although unrelated at the amino-acid sequence level, they both possess peptidyl-prolyl cis-trans isomerase activities which are inhibited by immunosuppressants that block signal transduction pathways leading to T-lymphocyte activation. FK506 and rapamycin strongly inhibit the peptidyl-prolyl cis-trans isomerase activity of FKBP, whereas cyclosporin A inhibits that of cyclophilin 2-12. The significance of this enzyme activity and the role of the immunophilins in immunoregulation is unknown 1,13. To understand better the function of the immunophilins and their interaction with inhibitors, we are investigating the solution structures of FKBP and FKBP-inhibitor complexes by multidimensional NMR methods. Here we report the solution conformation of FKBP, as generated by NMR, distance geometry and molecular dynamics methods. The regular secondary structure of FKBP is composed mainly of beta-sheet (approximately 35%) with little helical structure (< 10%). The hydrophobic core of the molecule, containing the buried side chains of six of the protein's nine aromatic amino acids, is enclosed by a five-stranded antiparallel beta-sheet on one side, a loop and a short helix at residues 51-56 and 57-65, and an aperiodic loop at residues 81-95. Examination of the structure suggests a possible site of interaction with FK506.			MOORE, JM (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.			Moore, Jonathan/0000-0001-8633-3313				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ECCLES C, 1989, 10TH M INT SOC MAGN; ENGLANDER SW, 1987, BIOCHEMISTRY-US, V26, P5953, DOI 10.1021/bi00393a001; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GUENTERT P, IN PRESS J MOL BIOL; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; Wuthrich K., 1986, NMR PROTEINS NUCL AC	27	150	154	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					248	250		10.1038/351248a0	http://dx.doi.org/10.1038/351248a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041572				2022-12-01	WOS:A1991FL99000062
J	MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE				MOORE, RD; HIDALGO, J; SUGLAND, BW; CHAISSON, RE			ZIDOVUDINE AND THE NATURAL-HISTORY OF THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; SAN-FRANCISCO; DOUBLE-BLIND; AIDS; SURVIVAL; EXPERIENCE; EFFICACY; AZT	Background and Methods. We sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records. Results. The median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs. 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P < 0.03), among persons less than 45 years old than among older persons (P < 0.001), among non-Hispanic whites than among minorities (P < 0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P < 0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P < 0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival. Conclusions. For Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival.	AIDS ADM,DEPT HLTH & MENTAL HYG,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; UNIV MARYLAND,SCH PHARM,CTR DRUG POLICY,BALTIMORE,MD 21201	Maryland Department of Health & Mental Hygiene; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027668] Funding Source: NIH RePORTER; NIAID NIH HHS [5U01AI27668] Funding Source: Medline; PHS HHS [223-89-3603] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; Hidalgo J, 1990, QRB Qual Rev Bull, V16, P355; HIDALGO J, 1990, EVAL PROGRAM PLANN, V13, P39, DOI 10.1016/0149-7189(90)90007-J; HIDALGO J, 1990, 118TH ANN M AM PUBL; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MOORE RD, IN PRESS ARCH INTERN; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; TSAI WY, 1987, BIOMETRIKA, V74, P883	15	299	300	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1412	1416		10.1056/NEJM199105163242006	http://dx.doi.org/10.1056/NEJM199105163242006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020297				2022-12-01	WOS:A1991FL12500006
J	MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE				MURPHY, TJ; ALEXANDER, RW; GRIENDLING, KK; RUNGE, MS; BERNSTEIN, KE			ISOLATION OF A CDNA-ENCODING THE VASCULAR TYPE-1 ANGIOTENSIN-II RECEPTOR	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CONVERTING ENZYME; MOLECULAR-CLONING; SYSTEM; EXPRESSION; CAPTOPRIL; PROTEINS; SUBTYPES; CALCIUM; FAMILY	ANGIOTENSIN II is an important effector molecule controlling blood pressure and volume in the cardiovascular system 1. Its importance is manifested by the efficacy of angiotensin-converting enzyme inhibitors in the treatment of hypertension and congestive heart failure 2,3. Angiotensin II interacts with two pharmacologically distinct subtypes of cell-surface receptors, AT1 and AT2 (ref. 4). AT1 receptors seem to mediate the major cardiovascular effects of angiotensin II 5,6. Here we report the isolation by expression cloning of a complementary DNA encoding a unique protein with the pharmacological specificity of a vascular AT1 receptor. Hydropathic modelling of the deduced protein suggests that it shares the seven-transmembrane-region motif with the G protein-coupled receptor superfamily 7. Knowledge of the AT1 receptor primary sequence should now permit structural analysis, definition of the angiotensin II receptor gene family and delineation of the contribution of AT receptors to the genetic component of hypertension.	EMORY UNIV,SCH MED,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	MURPHY, TJ (corresponding author), EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322, USA.			Griendling, Kathy/0000-0002-9456-8582; Bernstein, Kenneth/0000-0001-8097-3272				ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BAUER JH, 1984, AM J MED, V77, P43, DOI 10.1016/S0002-9343(84)80057-1; BOUSCAREL B, 1988, J BIOL CHEM, V263, P14913; BUMPUS FM, IN PRESS HYPERTENSIO; CAPPONI AM, 1981, BIOCH REGULATION BLO, P205; CHANG RSL, 1990, MOL PHARMACOL, V29, P347; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIU AT, 1989, J PHARMACOL EXP THER, V250, P867; CHIU AT, 1989, EUR J PHARMACOL, V170, P117, DOI 10.1016/0014-2999(89)90145-3; DAVIS R, 1979, NEW ENGL J MED, V301, P117, DOI 10.1056/NEJM197907193010301; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOUGLAS JG, 1987, AM J PHYSIOL, V253, pF1, DOI 10.1152/ajprenal.1987.253.1.F1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ESCHER E, 1988, PHARMACOL THERAPEUT, V37, P37, DOI 10.1016/0163-7258(88)90018-6; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MILLAN MA, 1989, SCIENCE, V244, P1340, DOI 10.1126/science.2734613; MURPHY TJ, 1988, J PHARMACOL EXP THER, V244, P571; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; Sakarai T., 1990, NATURE, V348, P732; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	31	1235	1261	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					233	236		10.1038/351233a0	http://dx.doi.org/10.1038/351233a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041570				2022-12-01	WOS:A1991FL99000057
J	SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T				SASAKI, K; YAMANO, Y; BARDHAN, S; IWAI, N; MURRAY, JJ; HASEGAWA, M; MATSUDA, Y; INAGAMI, T			CLONING AND EXPRESSION OF A COMPLEMENTARY-DNA ENCODING A BOVINE ADRENAL ANGIOTENSIN-II TYPE-1 RECEPTOR	NATURE			English	Article							BINDING-SITES; SOLUBILIZATION; MEMBRANES; SEQUENCE; SUBTYPES; CORTEX	ANGIOTENSIN II elicits different responses which affect cardiovascular, neuronal and electrolyte transport regulation 1. To understand the mechanisms responsible for its various actions, the receptor for angiotensin II has long been sought, but numerous attempts to purify the receptor have been unsuccessful owing to its instability and low concentration 2-6. We report here the expression cloning of a complementary DNA encoding a bovine angiotensin II receptor to overcome these difficulties. The receptor cDNA encodes a protein of 359 amino-acid residues with a transmembrane topology similar to that of other G protein-coupled receptors. COS-7 cells transfected with cDNA expressed specific and high-affinity binding sites for angiotensin II, angiotensin II antagonist and a non-peptide specific antagonist for type-1 receptor. Dithiothreitol inhibited ligand binding. The concentration of intracellular Ca2+ and of inositol-1,4,5-trisphospate increased in the transfected COS-7 cells in response to angiotensin II or angiotensin III, indicating that this receptor is the type-1 receptor for angiotensin II. Northern blot analysis revealed that the messenger RNA for this receptor is expressed in bovine adrenal medulla, cortex and kidney.	VANDERBILT UNIV, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, TOKYO 194, JAPAN	Vanderbilt University; Vanderbilt University; Kyowa Kirin Ltd								AKIYAMA F, 1984, BIOMED RES-TOKYO, V5, P9, DOI 10.2220/biomedres.5.9; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CAPPONI AM, 1980, J BIOL CHEM, V255, P2081; CARSON MC, 1987, MOL ENDOCRINOL, V1, P147, DOI 10.1210/mend-1-2-147; CHANG RSL, 1982, BIOCHEM PHARMACOL, V31, P1903, DOI 10.1016/0006-2952(82)90495-6; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; GLOSSMANN H, 1974, J BIOL CHEM, V249, P825; GUILLEMETTE G, 1983, BIOCHEMISTRY-US, V22, P5591, DOI 10.1021/bi00293a021; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAGLIN S, 1982, P NATL ACAD SCI-BIOL, V79, P3739, DOI 10.1073/pnas.79.12.3739; PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; ROGERS TB, 1984, J BIOL CHEM, V259, P8106; RONDEAU JJ, 1990, BIOCHEM J, V268, P443, DOI 10.1042/bj2680443; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKORECKI KL, 1983, FED PROC, V42, P3064; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	26	807	825	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					230	233		10.1038/351230a0	http://dx.doi.org/10.1038/351230a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	2041569				2022-12-01	WOS:A1991FL99000056
J	SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD				SIDDIQUE, T; FIGLEWICZ, DA; PERICAKVANCE, MA; HAINES, JL; ROULEAU, G; JEFFERS, AJ; SAPP, P; HUNG, WY; BEBOUT, J; MCKENNAYASEK, D; DENG, G; HORVITZ, HR; GUSELLA, JF; BROWN, RH; ROSES, AD			LINKAGE OF A GENE CAUSING FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS TO CHROMOSOME-21 AND EVIDENCE OF GENETIC-LOCUS HETEROGENEITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR NEURON DISEASE; COMMITTEE; MAPS	Background. Amyotrophic lateral sclerosis is a progressive neurologic disorder that commonly results in paralysis and death. Despite more than a century of research, no cause of, cure for, or means of preventing this disorder has been found. In a minority of cases, it is familial and inherited as an autosomal dominant trait with age-dependent penetrance. In contrast to the sporadic form of amyotrophic lateral sclerosis, the familial form provides the opportunity to use molecular genetic techniques to localize an inherited defect. Furthermore, such studies have the potential to discover the basic molecular defect causing motor-neuron degeneration. Methods and Results. We evaluated 23 families with familial amyotrophic lateral sclerosis for linkage of the gene causing this disease to four DNA markers on the long arm of chromosome 21. Multipoint linkage analyses demonstrated linkage between the gene and these markers. The maximum lod score - 5.03 - was obtained 10 centimorgans distal (telomeric) to the DNA marker D21S58. There was a significant probability (P < 0.0001) of genetic-locus heterogeneity in the families. Conclusions. The localization of a gene causing familial amyotrophic lateral sclerosis provides a means of isolating this gene and studying its function. Insight gained from understanding the function of this gene may be applicable to the design of rational therapy for both the familial and sporadic forms of the disease.	MCGILL UNIV, CTR RES NEUROSCI, MONTREAL H3A 2T5, QUEBEC, CANADA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; MIT, CAMBRIDGE, MA 02139 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	McGill University; Duke University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	SIDDIQUE, T (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT NEUROL, SEARLE 11-543, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Haines, Jonathan/C-3374-2012; halperin, john/X-6433-2019; Siddique, Teepu/AAT-8166-2021	Haines, Jonathan/0000-0002-4351-4728; halperin, john/0000-0003-1170-1710; Siddique, Teepu/0000-0001-7293-9146; mathews, katherine/0000-0003-4160-0435	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS021442, P01NS021442, R01NS020012, P01NS026630] Funding Source: NIH RePORTER; NINDS NIH HHS [P0-NS-21442, P0-NS-26630, NS-20012] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Emery A E, 1982, Adv Neurol, V36, P139; ENGEL WK, 1959, BRAIN, V82, P203, DOI 10.1093/brain/82.2.203; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HORTON WA, 1976, NEUROLOGY, V26, P460, DOI 10.1212/WNL.26.5.460; Hughes J T, 1982, Adv Neurol, V36, P61; KEATS B, 1989, CYTOGENET CELL GENET, V51, P459, DOI 10.1159/000132805; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KURLAND LT, 1955, NEUROLOGY, V5, P182, DOI 10.1212/WNL.5.3.182; KURLAND LT, 1955, NEUROLOGY, V5, P249, DOI 10.1212/WNL.5.4.249; Kurtzke J, 1989, CLIN NEUROLOGY, P1; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Mulder D W, 1982, Adv Neurol, V36, P15; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MYRIANTHOPOULOS NC, 1954, AM J HUM GENET, V6, P387; OSLER W, 1880, ARCH MED, V4, P316; OTT J, 1985, ANAL HUMAN GENETIC L, P111; SIDDIQUE T, 1990, ANN NEUROL, V28, P269; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; SIDDIQUE T, 1990, Neurology, V40, P315; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; WILLIAMS DB, 1988, J NEUROL SCI, V86, P215, DOI 10.1016/0022-510X(88)90100-1	22	378	382	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1381	1384		10.1056/NEJM199105163242001	http://dx.doi.org/10.1056/NEJM199105163242001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020294				2022-12-01	WOS:A1991FL12500001
J	STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S				STEENLAND, K; STAYNER, L; GREIFE, A; HALPERIN, W; HAYES, R; HORNUNG, R; NOWLIN, S			MORTALITY AMONG WORKERS EXPOSED TO ETHYLENE-OXIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SISTER-CHROMATID EXCHANGES; COHORT; CANCER	Background. Ethylene oxide is a sterilant gas that causes leukemia and other cancers in animals. Studies in Sweden have shown an excess of leukemia and stomach cancer in humans exposed to ethylene oxide, but other studies have generally failed to confirm these findings. Methods. We conducted a study of mortality in 18,254 U.S. workers exposed to ethylene oxide at 14 plants producing sterilized medical supplies and spices. The subjects averaged 4.9 years of exposure to the gas and 16 years of follow-up. The exposure levels in recent years averaged 4.3 ppm (eight-hour time-weighted adjusted exposure) for sterilizer operators and 2.0 ppm for other workers. The levels in earlier years are likely to have been several times higher. Mortality in this cohort was compared with that in the general U.S. population. Results. Overall there was no significant increase in mortality from any cause in the study cohort. The standardized mortality ratios (SMRs) were 0.97 for leukemia (95 percent confidence interval, 0.52 to 1.67; 13 deaths observed), 1.06 for all hematopoietic cancers (95 percent confidence interval, 0.75 to 1.47; 36 deaths), and 0.94 for stomach cancer (95 percent confidence interval, 0.45 to 1.70; 11 deaths). Analyses according to job category and according to the duration of exposure showed no excess in cancers, as compared with the rate in the general population, but there was a significant trend toward increased mortality with increasing lengths of time since the first exposure for all hematopoietic cancers. The rate of death from hematopoietic cancer (especially non-Hodgkin's lymphoma) was significantly increased among men (SMR, 1.55; 27 deaths). Mortality from leukemia in recent years (1985 through 1987) was significantly increased among men (SMR, 3.45; 5 deaths). Conclusions. For the entire cohort, there was no increase in mortality from hematopoietic cancer. There was a slight but significant increase among men, however. Among men and women combined, there was a trend toward an increased risk of death from hematopoietic cancer with increasing lengths of time since the first exposure to ethylene oxide.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	STEENLAND, K (corresponding author), NIOSH,R-13,4676 COLUMBIA PKWY,CINCINNATI,OH 45226, USA.							AXELSON O, 1988, AM J IND MED, V13, P105, DOI 10.1002/ajim.4700130107; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; CHECKOWAY H, 1990, ARCH ENVIRON HEALTH, V45, P95, DOI 10.1080/00039896.1990.9935932; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; GALLOWAY SM, 1986, MUTAT RES, V170, P55, DOI 10.1016/0165-1218(86)90082-0; GARDNER MJ, 1989, BRIT J IND MED, V46, P860; GARRY VF, 1979, ENVIRON MUTAGEN, V1, P375, DOI 10.1002/em.2860010410; GREENBERG HL, 1990, BRIT J IND MED, V47, P221; HOGSTEDT C, 1986, JAMA-J AM MED ASSOC, V255, P1575, DOI 10.1001/jama.255.12.1575; HOGSTEDT C, 1979, JAMA-J AM MED ASSOC, V241, P1132, DOI 10.1001/jama.241.11.1132; HOGSTEDT C, 1979, BRIT J IND MED, V36, P276; HOGSTEDT C, 1988, INT AGENCY RES CANCE, V89, P265; KIESSELBACH N, 1990, BRIT J IND MED, V47, P182; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAURENT C, 1984, INT ARCH OCC ENV HEA, V54, P33, DOI 10.1007/BF00378726; LYNCH DW, 1984, TOXICOL APPL PHARM, V76, P69, DOI 10.1016/0041-008X(84)90030-9; MORGAN RW, 1981, J OCCUP ENVIRON MED, V23, P767, DOI 10.1097/00043764-198111000-00011; PATTERSON BH, 1986, J NATL CANCER I, V77, P877; RICHMOND GW, 1985, ARCH ENVIRON HEALTH, V40, P20, DOI 10.1080/00039896.1985.10545884; ROTHMAN KJ, 1979, NIH791649 PUBL; SARTO F, 1984, MUTAT RES, V138, P185, DOI 10.1016/0165-1218(84)90043-0; SNELLINGS WM, 1984, TOXICOL APPL PHARM, V75, P105, DOI 10.1016/0041-008X(84)90081-4; STEENLAND K, 1990, J OCCUP ENVIRON MED, V32, P1091, DOI 10.1097/00043764-199011000-00008; STEENLAND K, 1987, AM J IND MED, V12, P419, DOI 10.1002/ajim.4700120407; STOLLEY PD, 1984, MUTAT RES, V129, P89, DOI 10.1016/0027-5107(84)90127-1; THIESS A, 1982, OCCUPATIONAL SAFETY, V46, P249; YAGER JW, 1983, SCIENCE, V219, P1221, DOI 10.1126/science.6828851; 1985, NIH TECHNICAL REPORT, V275; 1987, NIH882582 NAT TOX PR; 1985, IARC MONOGRAPHS S7, V1; 1988, ETHYLENE OXIDE; 1990, DHHS NIOSH89102 NAT	32	93	94	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1402	1407		10.1056/NEJM199105163242004	http://dx.doi.org/10.1056/NEJM199105163242004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	2020295				2022-12-01	WOS:A1991FL12500004
J	STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M				STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M			DEPHOSPHORYLATION AND ACTIVATION OF A P34CDC2 CYCLIN-B COMPLEX INVITRO BY HUMAN CDC25 PROTEIN	NATURE			English	Article							M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; PERIODIC ACTIVATION; POSSIBLE MECHANISM; MITOTIC INDUCER; KINASE; PURIFICATION; STARFISH; MITOSIS	OOCYTES arrested in the G2 phase of the cell cycle contain a p34cdc2/cyclin B complex which is kept in an inactive form by phosphorylation of its p34cdc2 subunit on tyrosine, threonine and perhaps serine residues (see refs 1 and 2 for review). The phosphatase(s) involved in p34cdc2 dephosphorylation is unknown, but the product of the fission yeast cdc25+ gene 3,4, and its homologues in budding yeast 5 and Drosophila 6 are probably positive regulators of the transition from G2 to M phase. We have purified the inactive p34cdc2/cyclin B complex from G2-arrested starfish oocytes. Addition of the purified bacterially expressed product of the human homologue of the fission yeast cdc25+ gene 7 (p54CDC25H) triggers p34cdc2 dephosphorylation and activates H1 histone kinase activity in this preparation. We propose that the cdc25+ gene product directly activates the p34cdc2-cyclin B complex.	LAB ARAGO, F-66650 BANYULS SUR MER, FRANCE; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; INSERM, F-34033 MONTPELLIER, FRANCE	Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	STRAUSFELD, U (corresponding author), CNRS, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, Didier/A-1490-2009; labbe, jean-claude/B-2277-2009; Fesquet, didier/M-9750-2019	Fesquet, didier/0000-0001-5657-9689				Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GOULD K, 1991, NATURE, V250, P1573; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LABBE JC, IN PRESS METH ENZYM; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TONKS NK, 1988, J BIOL CHEM, V263, P6722	21	532	550	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					242	245		10.1038/351242a0	http://dx.doi.org/10.1038/351242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828290				2022-12-01	WOS:A1991FL99000060
J	WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E				WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E			DIFFERENTIATION THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA WITH TRETINOIN (ALL-TRANS-RETINOIC ACID)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ACUTE MYELOID-LEUKEMIA; RECEPTOR-ALPHA GENE; T(15-17) TRANSLOCATION; CELL-DIFFERENTIATION; CYTOGENETIC ANALYSIS; 15-17 TRANSLOCATION; REMISSION INDUCTION; INVITRO; PATIENT	Background and Methods. Patients with acute promyelocytic leukemia have a characteristic (15;17) translocation, with a breakpoint on chromosome 17 in the region of the retinoic acid receptor-alpha (RAR-alpha). Since this receptor has been shown to be involved with growth and differentiation of myeloid cells in vitro, and since recent clinical studies have reported that tretinoin (all-trans-retinoic acid) induces complete remission in patients with acute promyelocytic leukemia, we studied the effects of tretinoin on cellular maturation and molecular abnormalities in patients undergoing the induction of remission with this agent. Results. Eleven patients with acute promyelocytic leukemia were treated with tretinoin administered orally at a dose of 45 mg per square meter of body-surface area per day. Nine of the 11 patients entered complete remission. In two patients, complete remission was preceded by striking leukocytosis that then resolved despite continued drug treatment. Serial studies of cellular morphologic features, cell-surface immunophenotypic analysis, and fluorescence in situ hybridization with a chromosome 17 probe revealed that clinical response was associated with maturation of the leukemic clone. All patients who responded to treatment who were tested by Northern blot analysis had expression of aberrant RAR-alpha. As patients entered complete remission,the expression of the abnormal RAR-alpha message decreased markedly; however, it was still detectable in several patients after complete morphologic and cytogenetic remission had been achieved. Conclusions. Tretinoin is a safe and highly effective agent for inducing complete remission in patients with acute promyelocytic leukemia. Clinical response to this agent is associated with leukemic-cell differentiation and is linked to the expression of an aberrant RAR-alpha nuclear receptor. Molecular detection of the aberrant receptor may serve as a useful marker for residual leukemia in patients with this disease.	MEM SLOAN KETTERING CANC CTR, HEMATOPOIET CANC IMMUNOCHEM LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, LEUKOCYTE BIOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, MOLEC MED LAB, NEW YORK, NY 10021 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MED ONCOL, HOUSTON, TX 77030 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	WARRELL, RP (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA & DEV CHEMOTHERAPY SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263	NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ANDREEFF M, 1980, BLOOD, V55, P282; ANDREEFF M, 1985, TUMOR ANEUPLOIDY, P81; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V2, P746, DOI 10.1016/S0140-6736(89)90812-X; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAENEN S, 1986, BLOOD, V67, P559; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; GROOPMAN J, 1979, AM J HEMATOL, V7, P395, DOI 10.1002/ajh.2830070412; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HITTELMAN WN, 1988, BLOOD, V72, P1950; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P793, DOI 10.1200/JCO.1985.3.6.793; KESSLER JF, 1983, LANCET, V1, P1345; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LICHTMAN MA, 1982, BLOOD, V60, P279; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLER WH, IN PRESS CLIN RES; MOHAMED AN, 1986, CANCER GENET CYTOGEN, V20, P209, DOI 10.1016/0165-4608(86)90076-2; MUINDI J, IN PRESS P AM SOC CL; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRATT, 1990, MOL CELLULAR BIOL, V0010; SCHEINBERG DA, 1989, LEUKEMIA, V3, P440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE RM, 1988, BLOOD, V71, P690; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOBLER A, 1986, J CLIN INVEST, V78, P303, DOI 10.1172/JCI112565; WALLACE PJ, 1989, AM J HEMATOL, V31, P266, DOI 10.1002/ajh.2830310410; WIJERMANS PW, 1989, BLOOD, V73, P800	48	1228	1270	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1385	1393		10.1056/NEJM199105163242002	http://dx.doi.org/10.1056/NEJM199105163242002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1850498				2022-12-01	WOS:A1991FL12500002
J	DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ				DELORON, P; LEPERS, JP; RAHARIMALALA, L; DUBOIS, B; COULANGES, P; POCIDALO, JJ			PEFLOXACIN FOR FALCIPARUM-MALARIA - ONLY MODEST SUCCESS	ANNALS OF INTERNAL MEDICINE			English	Note							NORFLOXACIN; INVITRO; MICE; DRUG	To assess the efficacy of pefloxacin in treating Plasmodium falciparum malaria in Madagascar, an area of chloroquine resistance, we conducted a case series intervention study in a rural population. Twenty-two adults with pure P. falciparum parasitemia, and no glucose-6-phosphate dehydrogenase deficiency, pregnancy, or other illness, were given an oral dose of 400 mg of pefloxacin every 12 hours for 3 days. Pefloxacin and chloroquine susceptibilities of 10 isolates were measured by an in-vitro microtest. The overall success rate of treatment was 9 of 22 (41%; 95% CI, 20% to 61%). Sixteen patients cleared parasitemia, but late recrudescence occurred in 7. Early therapeutic failure occurred in the 6 other patients. Efficacy of pefloxacin treatment was not related to the in-vitro activity of chloroquine or pefloxacin against the corresponding strain. These data contrast with those from a preliminary report from India of successful malaria therapy with a similar regimen of norfloxacin, the main metabolite of pefloxacin in humans.	INST PASTEUR MADAGASCAR, ANTANANARIVO, MADAGASCAR	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar	DELORON, P (corresponding author), HOP CLAUDE BERNARD, INSERM, UB, 10 AVE PORT DAUBERVILLIERS, F-75019 PARIS, FRANCE.		Deloron, Philippe/G-6305-2010	Deloron, Philippe/0000-0003-4705-2484				ASTAGNEAU P, 1991, AM J EPIDEMIOL, V133, P177, DOI 10.1093/oxfordjournals.aje.a115856; Bruce-Chwatt L.J., 1986, CHEMOTHERAPY MALARIA, Vsecond; DIVO AA, 1988, ANTIMICROB AGENTS CH, V32, P1182, DOI 10.1128/AAC.32.8.1182; LEPERS JP, 1989, T ROY SOC TROP MED H, V83, P491, DOI 10.1016/0035-9203(89)90263-0; MONTAY G, 1984, ANTIMICROB AGENTS CH, V25, P463, DOI 10.1128/AAC.25.4.463; RIOU JF, 1986, BIOCHEMISTRY-US, V25, P1471, DOI 10.1021/bi00355a001; SALMON D, 1990, ANTIMICROB AGENTS CH, V34, P2327, DOI 10.1128/AAC.34.12.2327; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; WISE R, 1984, J ANTIMICROB CHEMOTH, V13, P59, DOI 10.1093/jac/13.suppl_B.59; WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581	10	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					874	875		10.7326/0003-4819-114-10-874	http://dx.doi.org/10.7326/0003-4819-114-10-874			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014948				2022-12-01	WOS:A1991FL65000007
J	KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ				KADUNCE, DP; BURR, R; GRESS, R; KANNER, R; LYON, JL; ZONE, JJ			CIGARETTE-SMOKING - RISK FACTOR FOR PREMATURE FACIAL WRINKLING	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-FLOW; SKIN; SMOKERS; FACE	Objective: To determine if cigarette smoking is a risk factor for the development of premature facial wrinkling. Design: Cross-sectional study. Setting: Smoking cessation clinic and community. Patients: Convenience sample of 132 adult smokers and nonsmokers in 1988. Measurements: A questionnaire was administered to quantify cigarette smoking and to obtain information about possibly confounding factors such as skin pigmentation, sun exposure, age, and sex. Wrinkling was assessed using photographs of the temple region, and a severity score based on predetermined criteria was assigned. A logistic regression model, which controlled for confounding variables, was developed to assess the risk for premature wrinkling in response to pack-years of smoking. Main Results: The prevalence of premature wrinkling was independently associated with sun exposure and pack-years of smoking. After controlling for age, sex, and sun exposure, premature wrinkling increased with increased pack-years of smoking. Heavy cigarette smokers (> 50 pack-years) were 4.7 times more likely to be wrinkled than nonsmokers (95% CI, 1.0 to 22.6; P value for trend = 0.05). Sun exposure of more than 50 000 lifetime hours also increased the risk of being excessively wrinkled 3.1-fold (CI, 1.2 to 7.1). When excessive sun exposure and cigarette smoking occurred together, the risk for developing excessive wrinkling was multiplicative (prevalence ratio of 12.0; CI, 1.5 to 530). Conclusion: Cigarette smoking is an independent risk factor for the development of premature wrinkling.			KADUNCE, DP (corresponding author), UNIV UTAH, HLTH SCI CTR,DEPT MED,DIV DERMATOL,ROOM 4B454, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.							BRESLOW N, 1978, BIOMETRICS, V34, P100, DOI 10.2307/2529594; BRESLOW NE, 1980, STATISTICAL METHODS; CHEN VL, 1986, J INVEST DERMATOL, V87, P334, DOI 10.1111/1523-1747.ep12524421; CRAIG S, 1985, PLAST RECONSTR SURG, V75, P842, DOI 10.1097/00006534-198506000-00015; DANIELL HW, 1971, ANN INTERN MED, V75, P873, DOI 10.7326/0003-4819-75-6-873; Fletcher C, 1976, NATURAL HIST CHRONIC; Gilchrest BA., 1984, SKIN AGING PROCESSES; GILCHREST BA, 1986, AGING SKIN; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P30; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MODEL D, 1985, BMJ-BRIT MED J, V291, P1760, DOI 10.1136/bmj.291.6511.1760; NIEWOEHNER D, 1986, CURRENT PULMONOLOGY, V7, P23; READ RC, 1984, AM J SURG, V148, P706, DOI 10.1016/0002-9610(84)90421-5; REES TD, 1984, PLAST RECONSTR SURG, V73, P911, DOI 10.1097/00006534-198406000-00009; REUS WF, 1984, BRIT J PLAST SURG, V37, P213, DOI 10.1016/0007-1226(84)90011-0; SCOTTO J, 1983, DHHS NIH832433 PUBL; SOFFER A, 1986, ARCH INTERN MED, V146, P1496, DOI 10.1001/archinte.146.8.1496; WAEBER B, 1984, AM J PHYSIOL, V247, pH895, DOI 10.1152/ajpheart.1984.247.6.H895; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1982, DHHS PHS8250179 PUBL, P21; 1986, EPILOGUE VER 3	22	170	180	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					840	844		10.7326/0003-4819-114-10-840	http://dx.doi.org/10.7326/0003-4819-114-10-840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014944				2022-12-01	WOS:A1991FL65000002
J	LEVINE, B; CHAISSON, RE				LEVINE, B; CHAISSON, RE			MYCOBACTERIUM-KANSASII - A CAUSE OF TREATABLE PULMONARY-DISEASE ASSOCIATED WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY SYNDROME; AVIUM COMPLEX INFECTION; SYNDROME AIDS; TUBERCULOSIS; INTRACELLULARE; THERAPY	Objective: To assess the clinical features and response to therapy of Mycobacterium kansasii infection in patients with human immunodeficiency virus (HIV) infection. Design: We reviewed the records of all patients with M. kansasii and HIV infection treated between January 1985 and June 1990. Setting: The Johns Hopkins Hospital, Baltimore, Maryland. Results: Nineteen patients with M. kansasii and HIV infection were identified; 14 patients had exclusive pulmonary infection, 3 patients had pulmonary and extrapulmonary infection, and 2 patients had exclusive extrapulmonary infection. At the time of diagnosis of M. kansasii infection, the median CD4+ lymphocyte count was 49 cells/mu-L (range, 0 to 198 cells/mu-L), and 16 of 19 patients had a previous diagnosis of the acquired immunodeficiency syndrome (AIDS). All 17 patients with pulmonary infection presented with fever and cough of at least 2 weeks duration. Chest radiographs showed either focal upper lobe infiltrates (n = 8) or diffuse interstitial infiltrates (n = 9); 9 patients also had thin-walled cavitary lesions. Nine patients with pulmonary M. kansasii infection were treated with antituberculosis chemotherapy, with resolution of fever and respiratory symptoms, improvement of radiographic infiltrates, and sputum conversion; 1 patient with M. kansasii osteomyelitis also responsed to antituberculosis therapy. Autopsies done on 3 treated patients did not reveal any evidence of M. kansasii infection. Nine patients did not receive any antituberculosis chemotherapy; 2 untreated patients developed progressive cavitary pulmonary disease and died from M. kansasii pneumonia. Conclusions: Mycobacterium kansasii causes serious and potentially life-threatening pulmonary disease in patients with advanced HIV-related immunosuppression. In contrast to previous reports, our findings indicate that disease produced by M. kansasii in patients with HIV infection is responsive to antituberculosis chemotherapy.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								AHN CH, 1982, AM REV RESPIR DIS, V125, P388; AHN CH, 1987, AM REV RESPIR DIS, V135, P10; [Anonymous], 1987, ANN INTERN MED, V106, P254, DOI 10.7326/0003-4819-106-2-254; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHAN J, 1984, ANN INTERN MED, V101, P400, DOI 10.7326/0003-4819-101-3-400_1; CHAPMAN JS, 1977, ATYPICAL MYCOBACTERI; FOURNIER AM, 1988, CHEST, V93, P772, DOI 10.1378/chest.93.4.772; GREENE JB, 1982, ANN INTERN MED, V97, P539, DOI 10.7326/0003-4819-97-4-539; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HIRASUNA JD, 1987, ANN INTERN MED, V107, P784, DOI 10.7326/0003-4819-107-5-784_1; HORSBURGH CR, 1989, AM REV RESPIR DIS, V139, P4, DOI 10.1164/ajrccm/139.1.4; JACOBSON MA, 1989, AM J CLIN PATHOL, V91, P236, DOI 10.1093/ajcp/91.2.236; PFUETZE KH, 1965, AM REV RESPIR DIS, V92, P470; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SANDERS WE, 1990, PRINCIPLES PRACTICE, P1914; SCHRAUFNAGEL DE, 1986, BRIT J DIS CHEST, V80, P131, DOI 10.1016/0007-0971(86)90033-1; SHERER R, 1986, ANN INTERN MED, V105, P710, DOI 10.7326/0003-4819-105-5-710; SNIDER DE, 1987, AM REV RESPIR DIS, V136, P492; TECSONTUMANG FT, 1984, ANN INTERN MED, V100, P461, DOI 10.7326/0003-4819-100-3-461_2; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; TSUKAMURA M, 1981, REV INFECT DIS, V3, P841; WALLACE JM, 1988, CHEST, V93, P926, DOI 10.1378/chest.93.5.926; WOLINSKY E, 1981, REV INFECT DIS, V3, P1025; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YOUNG LS, 1986, REV INFECT DIS, V8, P1024; YOUNG LS, 1988, J INFECT DIS, V157, P863, DOI 10.1093/infdis/157.5.863; 1987, MMWR, V36, pS3; 1981, AM REV RESPIR DIS, V123, P343; 1985, CTR DISEASE CONTROL, P165	32	100	100	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					861	868		10.7326/0003-4819-114-10-861	http://dx.doi.org/10.7326/0003-4819-114-10-861			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	1673053				2022-12-01	WOS:A1991FL65000005
J	LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS				LITAM, P; SWAN, F; CABANILLAS, F; TUCKER, SL; MCLAUGHLIN, P; HAGEMEISTER, FB; RODRIGUEZ, MA; VELASQUEZ, WS			PROGNOSTIC VALUE OF SERUM BETA-2 MICROGLOBULIN IN LOW-GRADE LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LACTATE-DEHYDROGENASE LEVELS; HL-A ANTIGENS; MALIGNANT-LYMPHOMA; MULTIPLE-MYELOMA; HODGKINS-DISEASE; CELL LYMPHOMAS; SMALL SUBUNIT; BETA-2-MICROGLOBULIN; BETA2-MICROGLOBULIN	Objective: To evaluate serum beta-2 microglobulin (beta-2M) and other prognostic indicators in previously untreated low-grade lymphoma. Design: Cohort study of 80 patients with uniformly treated low-grade lymphoma, followed for a median of 21 months. These 80 patients, all of whom had serum beta-2M drawn within 2 weeks before starting therapy, were derived from a cohort of 119 previously untreated patients entered into one of three clinical trials. Setting: Tertiary referral cancer center. Patients: Eight previously untreated stage I to IV patients (mean age, 55 years). Intervention: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-blemycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stage I and II received COP-bleomycin and radiotherapy. Measurements: Outcome was determined by assessing complete remission rate and time to treatment failure. Univariate and multivariate analyses were used. Results: The complete remission rate for patients with a beta-2M level of 3.0 mg/L or greater was 36% compared with 71% for those with a level of less than 3.0 mg/L. Using multivariate analysis that tested beta-2M as a continuous variable, it was selected as the most significant factor for complete response. The adjusted odds ratio was 0.285 (95% CI, 0.101 to 0.809). The Ann Arbor stage had marginal significance (adjusted odds ratio, 0.435; CI, 0.150 to 1.263). For time to treatment failure, beta-2M was the only variable retained in the multivariate model. At 42 months, no patient with a beta-2M level of 3.0 mg/L or greater was projected to be in remission as compared with 85% of patients with a beta-2M level of less than 3.0 mg/L. Conclusions: The serum beta-2M level is a good predictor of complete response and time to treatment failure. A large number of patients should be studied to clarify the role of other potentially independent variables such as stage and age.	UNIV TEXAS, MD ANDERSON CANCER CTR, 1515 HOLCOMBE BLVD, BOX 68, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Cabanillas, Fernando/0000-0001-9234-7893				ALEXANIAN R, 1985, AM J HEMATOL, V20, P345, DOI 10.1002/ajh.2830200405; AMLOT PL, 1979, EUR J CANCER, V15, P791, DOI 10.1016/0014-2964(79)90155-5; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BACH FH, 1976, NEW ENGL J MED, V295, P872, DOI 10.1056/NEJM197610142951606; BACH FH, 1976, NEW ENGL J MED, V295, P927, DOI 10.1056/NEJM197610212951705; BATAILLE R, 1983, BRIT J HAEMATOL, V55, P439, DOI 10.1111/j.1365-2141.1983.tb02158.x; BERGGARD I, 1968, J BIOL CHEM, V243, P4095; BODMER WF, 1981, TISSUE ANTIGENS, V17, P9; CARBONE PP, 1971, CANCER RES, V31, P1860; CHILD JA, 1980, CANCER-AM CANCER SOC, V45, P318, DOI 10.1002/1097-0142(19800115)45:2<318::AID-CNCR2820450220>3.0.CO;2-C; COX DR, 1972, J R STAT SOC B, V34, P187; CRESSWEL.P, 1974, P NATL ACAD SCI USA, V71, P2123, DOI 10.1073/pnas.71.5.2123; DIXON DO, 1987, J CLIN ONCOL, V5, P1670, DOI 10.1200/JCO.1987.5.10.1670; EVRIN PE, 1973, CLIN CHIM ACTA, V43, P183, DOI 10.1016/0009-8981(73)90449-X; FERRARIS AM, 1979, BLOOD, V54, P928; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203; GOSPODAROWICZ MK, 1984, INT J RADIAT ONCOL, V10, P489, DOI 10.1016/0360-3016(84)90028-2; GREY HM, 1973, J EXP MED, V138, P1608, DOI 10.1084/jem.138.6.1608; HAGBERG H, 1983, CANCER, V51, P2220, DOI 10.1002/1097-0142(19830615)51:12<2220::AID-CNCR2820511212>3.0.CO;2-A; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEGROS M, 1987, P AN M AM SOC CLIN, V6, P748; MALE DK, 1986, IMMUNOLOGY, P57; MCLAUGHLIN P, 1987, J CLIN ONCOL, V5, P867, DOI 10.1200/JCO.1987.5.6.867; MCLAUGHLIN P, 1990, 4TH P INT C MAL LYMP; MOLLER P, 1987, INT J CANCER, V40, P32, DOI 10.1002/ijc.2910400107; MOLLER P, 1986, IMMUNOLOGY, V59, P411; NILSSON K, 1974, TRANSPLANT REV, V21, P53; PARHAM P, 1979, J IMMUNOL, V123, P342; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; ROSENBERG SA, 1982, CANCER, V49, P2112; RUDDERS RA, 1979, CANCER, V43, P1643, DOI 10.1002/1097-0142(197905)43:5<1643::AID-CNCR2820430513>3.0.CO;2-J; SCHNEIDER RJ, 1980, CANCER, V46, P139, DOI 10.1002/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8; SHUSTER J, 1976, CLIN CHIM ACTA, V67, P307, DOI 10.1016/0009-8981(76)90339-9; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; SWAN F, 1988, BLOOD, V72, pA258; TROWSDALE J, 1980, J EXP MED, V152, pS11; VEZZONI MA, 1983, TUMORI, V69, P279, DOI 10.1177/030089168306900401; ZINKERNAGEL RM, 1979, ADV IMMUNOL, V27, P151	40	86	87	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1991	114	10					855	860		10.7326/0003-4819-114-10-855	http://dx.doi.org/10.7326/0003-4819-114-10-855			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL650	2014946				2022-12-01	WOS:A1991FL65000004
J	ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F				ARTIGAS, J; ARASTEH, K; AVERDUNK, R; BACHLER, B; HORNSCHEIDT, M; GROSSE, G; LAGE, M; NIEDOBITEK, F			HYALINE GLOBULES REACTING POSITIVELY WITH ZIDOVUDINE ANTIBODY IN BRAIN AND SPINAL-CORD OF AIDS PATIENTS	LANCET			English	Note							3'-AZIDO-3'-DEOXYTHYMIDINE; DIDEOXYNUCLEOSIDES	Histology of the central nervous system in nine AIDS patients who had been treated with zidovudine showed extracellular hyaline globules in the white matter of the brain and the spinal cord. In immunohistochemical studies with a battery of antibodies, the only positive reaction of these globules was with an antibody to zidovudine. High-performance liquid chromatography showed the presence of a zidovudine isomer in eluates of brain tissue from these patients.	AUGUSTE VIKTORIA KRANKENHAUS, DEPT MED, W-1000 BERLIN 41, GERMANY; AUGUSTE VIKTORIA KRANKENHAUS, DEPT CLIN BIOCHEM, W-1000 BERLIN 41, GERMANY		ARTIGAS, J (corresponding author), AUGUSTE VIKTORIA KRANKENHAUS, INST PATHOL, RUBENSTR 125, W-1000 BERLIN 41, GERMANY.							DAVTYAN DG, 1987, LANCET, V1, P919; ELLISON S, 1988, CLIN RES, V36, pA117; HAGLER DN, 1986, LANCET, V2, P1392; HARRIS PJ, 1988, NEW ENGL J MED, V318, P250, DOI 10.1056/NEJM198801283180412; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; SPEAR JB, 1988, ANN INTERN MED, V109, P76, DOI 10.7326/0003-4819-109-1-76; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925; YARCHOAN R, 1987, LANCET, V1, P132, DOI 10.1016/S0140-6736(87)91968-4; 1991, BIOCH ORGANIC COMPOU, P1204	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1127	1128		10.1016/0140-6736(91)92790-9	http://dx.doi.org/10.1016/0140-6736(91)92790-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1709247				2022-12-01	WOS:A1991FL12400007
J	EVERALL, IP; LUTHERT, PJ; LANTOS, PL				EVERALL, IP; LUTHERT, PJ; LANTOS, PL			NEURONAL LOSS IN THE FRONTAL-CORTEX IN HIV-INFECTION	LANCET			English	Article							IMMUNE-DEFICIENCY SYNDROME; ARBITRARY PARTICLES; AIDS; VIRUS; NUMBER; NEUROPATHOLOGY; ENCEPHALOPATHY; PATHOLOGY; PROTEIN; BRAINS	In an attempt to elucidate the cause and mechanism of the dementia and other neurological disorders that can occur in HIV-1 infection, we have quantitatively assessed neuronal populations, by means of a stereological technique (the disector), in the frontal cortex of patients with HIV infection. Eleven of sixty-five brains in the Medical Research Council Central AIDS Brain Bank were selected for study. The selected patients died without opportunistic infection or neoplasm affecting the brain; they had HIV encephalitis or minimal changes. We compared their neuronal counts with those of eight control subjects (seven died of systemic illness, one of pontine haemorrhage which did not affect the cerebral hemispheres). The neuronal numerical density was significantly lower in the HIV group than in the control group (mean [SD] 307 [46] vs 499 [113] x 10(2) per mm3; p < 0.001). This difference represents a loss of about 38%. There was no significant difference between the HIV subgroups, which suggests that neuronal loss occurs in cases of minor pathology as well as in HIV encephalitis. This finding contributes to the understanding of dementia in AIDS patients and has important implications for their future treatment.			EVERALL, IP (corresponding author), INST PSYCHIAT,DEPT NEUROPATHOL,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.			Luthert, Philip/0000-0001-7276-6898				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BUDKA H, 1989, ACTA NEUROPATHOL, V77, P225, DOI 10.1007/BF00687573; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CIARDI A, 1990, ACTA NEUROPATHOL, V81, P51, DOI 10.1007/BF00662637; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN LG, 1985, AIDS RES, V1, P447; EVERALL IP, 1991, IN PRESS NEUROPATHOL; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GUNDERSEN HJG, 1981, J MICROSC-OXFORD, V121, P65, DOI 10.1111/j.1365-2818.1981.tb01199.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LANG W, 1989, ACTA NEUROPATHOL, V77, P379, DOI 10.1007/BF00687372; MARIO M, 1990, AIDS, V4, P831; Michaels J, 1988, Immunodefic Rev, V1, P71; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; WILEY CA, IN PRESS ANN NEUROL	21	465	467	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1119	1121		10.1016/0140-6736(91)92786-2	http://dx.doi.org/10.1016/0140-6736(91)92786-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674013				2022-12-01	WOS:A1991FL12400003
J	HURWITZ, B; ASSERSON, T				HURWITZ, B; ASSERSON, T			TAX-EXEMPTION FOR SEVERE MENTAL IMPAIRMENT	LANCET			English	Editorial Material											HURWITZ, B (corresponding author), THE SURGERY,1 ASHBY GROVE,LONDON N1 3PR,ENGLAND.							1991, MENTAL IMPAIRMENT SE, P7; 1989, PLCO8912 DEP HLTH ME; 1990, PLCO907 DEP HLTH MEM	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1147	1148		10.1016/0140-6736(91)92803-A	http://dx.doi.org/10.1016/0140-6736(91)92803-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL124	1674026				2022-12-01	WOS:A1991FL12400017
J	JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM				JAYNE, DRW; DAVIES, MJ; FOX, CJV; BLACK, CM; LOCKWOOD, CM			TREATMENT OF SYSTEMIC VASCULITIS WITH POOLED INTRAVENOUS IMMUNOGLOBULIN	LANCET			English	Article							ANTINEUTROPHIL CYTOPLASM ANTIBODIES; GAMMA-GLOBULIN; KAWASAKI SYNDROME; AUTOANTIBODIES; NEUTROPHILS; DIAGNOSIS; DISEASE; INVIVO	The therapeutic effect of a course of high-dose, pooled, intravenous immunoglobulin (IVIg) on disease activity and circulating antineutrophil cytoplasm antibodies (ANCA) was investigated in 7 patients with systemic vasculitis. 5 had active disease despite conventional immunosuppression, and 2 had not received any treatment. All 7 had clinical improvement, which was sustained in 6 and transient in 1. The fall in ANCA concentrations to a mean of 51% of the pre-treatment values was maintained during follow-up. C-reactive protein concentration also dropped considerably. IVIg seemed to confer a useful therapeutic effect without adverse reaction.	IPSWICH HOSP,DEPT MED,IPSWICH,SUFFOLK,ENGLAND; NORTHAMPTON GEN HOSP,DEPT MED,NORTHAMPTON NN1 5BD,ENGLAND; ROYAL FREE HOSP,DEPT RHEUMATOL,LONDON,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	JAYNE, DRW (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Jayne, David/0000-0002-1712-0637	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTA M, 1989, BLOOD, V74, P326; CHALOPIN JM, 1984, EUR J IMMUNOL, V14, P470, DOI 10.1002/eji.1830140516; COHEN J, 1982, Q J MED, V51, P1; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GROTZ W, 1990, APMIS S19, V98, P54; HAYS WM, 1981, STATISTICS, P630; JAYNE DRW, 1989, CLIN NEPHROL, V32, P101; JORDAN SC, 1989, CLIN IMMUNOL IMMUNOP, V53, pS164, DOI 10.1016/0090-1229(89)90082-2; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; LEUNG DYM, 1989, LANCET, V2, P1298; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; PALLA R, 1986, CLIN NEPHROL, V26, P314; ROSSI F, 1991, CLIN EXP IMMUNOL, V83, P298; ROSSI F, 1989, IMMUNOL REV, V110, P215; SAVAGE COS, 1989, ARCH DIS CHILD, V64, P360, DOI 10.1136/adc.64.3.360; SAVAGE COS, 1987, LANCET, V1, P1389; SCHIFFERLI J, 1991, LANCET, V335, P457; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SULTAN Y, 1984, LANCET, V2, P765; VANDERWOUDE FJ, 1985, LANCET, V1, P425	23	258	266	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1137	1139		10.1016/0140-6736(91)92797-6	http://dx.doi.org/10.1016/0140-6736(91)92797-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674023				2022-12-01	WOS:A1991FL12400014
J	KRISTIANSEN, IS; EGGEN, AE; THELLE, DS				KRISTIANSEN, IS; EGGEN, AE; THELLE, DS			COST-EFFECTIVENESS OF INCREMENTAL PROGRAMS FOR LOWERING SERUM-CHOLESTEROL CONCENTRATION - IS INDIVIDUAL INTERVENTION WORTH WHILE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; PRIMARY-PREVENTION; SMOKING; THERAPY; HEALTH; TRIAL; MEN	Objective - To evaluate the relative cost effectiveness of various cholesterol lowering programmes. Design - Retrospective analysis. Setting - Norwegian cholesterol lowering programme in Norwegian male population aged 40-49 (n = 200 000), whose interventions comprise a population based promotion of healthier eating habits, dietary treatment (subjects with serum cholesterol concentration 6.0-7.9 mmol/l), and dietary and drug treatment combined (serum cholesterol concentration greater-than-or-equal-to 8.0 mmol/l). Main outcome measure - Marginal cost effectiveness ratios - that is, the ratio of net treatment costs (cost of treatment minus savings in treatment costs for coronary heart disease) to life years gained and to quality of life years (QALYs) saved. Results - The cost per life year gained over 20 years of a population based strategy was projected to be L12. For an individual strategy based on dietary treatment the cost was about L12 400 per life year gained and L111 600 if drugs were added for 50% of the subjects with serum cholesterol concentrations greater-than-or-equal-to 8.0 mmol/l. Conclusions - The results underline the importance of marginal cost effectiveness analyses for incremental programmes of health care. The calculations of QALYs, though speculative, indicate that individual intervention should be implemented cautiously and within more selected groups than currently recommended. Drugs should be reserved for subjects with genetic hypercholesterolaemia or who are otherwise at very high risk of arteriosclerotic disease.			KRISTIANSEN, IS (corresponding author), UNIV TROMSO,INST COMMUNITY MED,N-9000 TROMSO,NORWAY.		Thelle, Dag Steinar/ABD-1867-2020	Thelle, Dag Steinar/0000-0002-4417-5967				BJARTVEIT K, 1988, Tidsskrift for den Norske Laegeforening, V108, P2285; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; EGGEN A E, 1989, Tidsskrift for den Norske Laegeforening, V109, P857; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; GOLDMAN L, 1989, CIRCULATION, V80, P254, DOI 10.1161/01.CIR.80.2.254; HALL J P, 1988, Medical Journal of Australia, V148, P273; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1988, STAT MED, V7, P1109, DOI 10.1002/sim.4780071104; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; MARTENS LL, 1989, AM J MED S4A, V87, P54; OSTER G, 1986, AM J PUBLIC HEALTH, V76, P647, DOI 10.2105/AJPH.76.6.647; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; SALONEN JT, 1981, AM J EPIDEMIOL, V114, P81, DOI 10.1093/oxfordjournals.aje.a113177; SLATTEBREKK OV, 1990, STF81A90003 NORW I H; STEIN EA, 1989, AM J MED S4A, V87, P20; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; THURMER H, 1991, INT J RISK SOC MED, V1, P267; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Weinstein MC, 1980, CLIN DECISION ANAL; WESTLUND K, 1972, SCAND J CLIN IN S127, V30, P3; WILLIAMS A, 1985, BRIT MED J, V291, P326, DOI 10.1136/bmj.291.6491.326; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1988, ARCH INTERN MED, V148, P36; 1990, COST EFFECTIVENESS O; 1988, CARDIOVASCULAR DISEA; 1986, CAUSES DEATH 1985; 1984, JAMA-J AM MED ASSOC, V251, P365; 1984, JAMA-J AM MED ASSOC, V251, P351; 1988, EUR HEART J, V9, P571	36	64	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1119	1122		10.1136/bmj.302.6785.1119	http://dx.doi.org/10.1136/bmj.302.6785.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1904286	Green Published, Bronze			2022-12-01	WOS:A1991FL43900018
J	LITTLE, JM; AVRAMOVIC, J				LITTLE, JM; AVRAMOVIC, J			GALLSTONE FORMATION AFTER MAJOR ABDOMINAL-SURGERY	LANCET			English	Article							SLUDGE FORMATION; RISK-FACTORS; CHOLELITHIASIS; METABOLISM; COMPLICATION; VAGOTOMY; DISEASE	84 patients underwent multiple abdominal ultrasound examinations over a median of 36 months (range 6-140). 11 had gallstones at their first ultrasound examination, and were excluded from further analysis. Of the remaining 73 patients, 12 of 47 who underwent major abdominal surgery had gallstones within 14-36 months of operation, compared with 0 of 26 who did not undergo such surgery. The cumulative prevalence of new gallstones within 3 years of major surgery was 28%; no new gallstones were seen from 36 to up to 140 months postoperatively. By univariate and logistic regression analysis, age and major abdominal surgery were the only significant clinical determinants for the appearance of gallstones during follow-up. The findings of this retrospective study indicate that major abdominal surgery may accelerate the development of gallstones in some patients. If confirmed in a prospective study, it may be possible to define groups at high risk of gallstones after surgery and to institute prophylactic measures.	UNIV SYDNEY, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney	LITTLE, JM (corresponding author), WESTMEAD HOSP, DEPT SURG, WESTMEAD, NSW 2145, AUSTRALIA.							BENGMARK S, 1982, BILIARY TRACT, P270; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; COWIE AGA, 1972, BRIT J SURG, V59, P365, DOI 10.1002/bjs.1800590508; DEITEL M, 1987, SURG GYNECOL OBSTET, V164, P549; DOTY JE, 1985, ANN SURG, V201, P76, DOI 10.1097/00000658-198520110-00011; DUANE WC, 1976, J LIPID RES, V17, P211; GOSBINK BR, 1976, SEMIN RADIOL, V11, P185; HARRISON EC, 1978, AM HEART J, V95, P483, DOI 10.1016/0002-8703(78)90240-5; HAUTERS P, 1988, BRIT J SURG, V75, P899, DOI 10.1002/bjs.1800750923; HEATON KW, 1969, BMJ-BRIT MED J, V3, P494, DOI 10.1136/bmj.3.5669.494; IHASZ M, 1981, AM J SURG, V141, P48, DOI 10.1016/0002-9610(81)90010-6; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LINDSTROM CG, 1977, SCAND J GASTROENTERO, V12, P341, DOI 10.3109/00365527709180938; LORUSSO D, 1988, SURGERY, V103, P579; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MILLER MC, 1968, CAN MED ASSOC J, V98, P350; PITT HA, 1983, GASTROENTEROLOGY, V84, P1274; ROSLYN JJ, 1984, AM J SURG, V148, P58, DOI 10.1016/0002-9610(84)90289-7; SALEN G, 1975, GASTROENTEROLOGY, V69, P676; TOMPKINS RK, 1972, SURGERY, V71, P196	23	25	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1991	337	8750					1135	1137		10.1016/0140-6736(91)92796-5	http://dx.doi.org/10.1016/0140-6736(91)92796-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674022				2022-12-01	WOS:A1991FL12400013
J	SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW				SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW			RISK-FACTORS FOR STROKE IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							DIASTOLIC BLOOD-PRESSURE; CIGARETTE-SMOKING; VENTRICULAR HYPERTROPHY; MORTALITY; ALCOHOL; HYPERTENSION	Objective - To determine the risk factors for stroke in a cohort representative of middle aged British men. Design - Prospective study of a cohort of men followed up for eight years. Setting - General practices in 24 towns in England, Wales, and Scotland (the British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each town. Main outcome measure - Fatal and non-fatal strokes. Results - 110 of the men had at least one stroke; there were four times as many non-fatal as fatal strokes. The relative risk of stroke was 12.1 in men who had high blood pressure (systolic blood pressure greater-than-or-equal-to 160 mm Hg) and were current smokers compared with normotensive, non-smoking men. Diastolic blood pressure yielded no additional information, and former cigarette smokers had the same risk as men who had never smoked. Heavy alcohol intake was associated with a relative risk of stroke of 3.8 in men without previously diagnosed cardiovascular disease. Men with pre-existing ischaemic heart disease had an increased risk of stroke, but only when left ventricular hypertrophy on electrocardiography was also present. Conclusions - Systolic blood pressure, cigarette smoking, and left ventricular hypertrophy on electrocardiography in men with pre-existing ischaemic heart disease were found to be the major risk factors for stroke in middle aged British men. Heavy alcohol intake seemed to increase the risk of stroke in men without previously diagnosed cardiovascular disease. A large proportion of strokes should be preventable by controlling blood pressure and stopping smoking.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SS,SCOTLAND	Royal Infirmary of Edinburgh	SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BLACKWELDER WC, 1980, AM J MED, V68, P165; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P374; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; DALE S, 1988, STROKE; DAVEYSMITH G, 1990, J EPIDEMIOL COMMUNIT, V44, P257; DONNAN GA, 1989, LANCET, V2, P643; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; ISO H, 1989, NEW ENGL J MED, V324, P4; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; MACFARLANE PW, 1981, BRIT HEART J, V45, P402; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, J HYPERTENS, V4, pS14; MENOTTI A, 1989, J HYPERTENS, V7, P595, DOI 10.1097/00004872-198907000-00011; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; RUTAN GH, 1989, J CLIN EPIDEMIOL, V42, P663, DOI 10.1016/0895-4356(89)90010-3; SAUNDERS JB, 1981, LANCET, V2, P653; SHAPER AG, 1988, LANCET, V2, P1267; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAMLER J, 1989, HYPERTENSION S1, V13, P12; STOKES J, 1987, CIRCULATION, V75, P56; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; VANDENBAN GC, 1989, INT J EPIDEMIOL, V18, P95, DOI 10.1093/ije/18.1.95; WALKER M, 1984, JR COLL GEN PRACT, V34, P364; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P201; 1988, BMJ, V297, P126; 1988, BMJ, V296, P1565	31	169	170	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1111	1115		10.1136/bmj.302.6785.1111	http://dx.doi.org/10.1136/bmj.302.6785.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1828378	Bronze, Green Published			2022-12-01	WOS:A1991FL43900016
J	SHELDON, TA; SIMPSON, J				SHELDON, TA; SIMPSON, J			APPRAISAL OF A NEW SCHEME FOR PRENATAL SCREENING FOR DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; DECISION-ANALYSIS; PREGNANCY	Objective - To appraise a new method of prenatal screening for Down's syndrome based on maternal serum concentrations of alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin combined with maternal age - the "triple test". Design - Examination of the cost effectiveness of the triple test relative to screening only by maternal age over a range of population detection rates. Setting - Leicestershire Health Authority. Main outcome measures - Costs per affected fetus detected. Results - The triple test is more cost effective than screening only by maternal age for risk cut off points for amniocentesis, resulting in a detection rate over 45%. The most efficient detection rate is around 60-65%, for which the cost per case detected is around L29 000, though screening with higher detection rates is still likely to be cost beneficial. Conclusions - Prenatal screening for Down's syndrome based on the triple test should replace screening based only on maternal age. Individual women's preferences should be elicited by the use of structured decision analysis in order to maximise utility and so increase the benefits of the screening programme.	LEICESTERSHIRE DIST HLTH AUTHOR,LEICESTER LE1 6TY,ENGLAND		SHELDON, TA (corresponding author), UNIV LEEDS,DEPT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021	Sheldon, Trevor/0000-0002-7479-5913				CALLAN J, 1988, 42 CTR HLTH EC DISC; CARTMILL RS, 1991, IN PRESS J PERINATAL; DOUBILET P, 1985, MED CARE, V23, P648, DOI 10.1097/00005650-198505000-00021; DOWIE J, 1987, PROFESSIONAL JUDGMEN, P9; Drummond Michael, 1988, Br Med J (Clin Res Ed), V296, P566; FERGUSONSMITH M, 1987, SCREENING FETAL GENE; GILL M, 1987, SOC SCI MED, V24, P725, DOI 10.1016/0277-9536(87)90109-2; HAGARD S, 1976, BRIT MED J, V1, P753, DOI 10.1136/bmj.1.6012.753; HENDERSON JB, 1987, SCREENING FETAL GENE; MCGROTHER CW, 1990, J MENT DEFIC RES, V34, P49; McKeown Thomas, 1968, SCREENING MED CARE R; Pauker S P, 1987, Birth Defects Orig Artic Ser, V23, P151; PAUKER SP, 1977, YALE J BIOL MED, V50, P275; RICHARDS M, 1987, SCREENING FETAL GENE; SADOVNICK AD, 1981, AM J MED GENET, V10, P367, DOI 10.1002/ajmg.1320100409; SCHWARTZ WB, 1979, NEW ENGL J MED, V300, P556, DOI 10.1056/NEJM197903083001011; THORNTON JG, 1990, PRENATAL DIAGNOSIS P; Torrance GW, 1987, METHODS EC EVALUATIO; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1987, BAILLIERE CLIN OB GY, V1, P649, DOI 10.1016/S0950-3552(87)80010-X; Weinstein MC, 1980, CLIN DECISION ANAL; 1987, SCREENING FETAL GENE	22	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1133	1136		10.1136/bmj.302.6785.1133	http://dx.doi.org/10.1136/bmj.302.6785.1133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1710520	Green Published, Bronze			2022-12-01	WOS:A1991FL43900023
J	SORSCHER, EJ; HUANG, Z				SORSCHER, EJ; HUANG, Z			DIAGNOSIS OF GENETIC-DISEASE BY PRIMER-SPECIFIED RESTRICTION MAP MODIFICATION, WITH APPLICATION TO CYSTIC-FIBROSIS AND RETINITIS-PIGMENTOSA	LANCET			English	Article							ENZYMATICALLY AMPLIFIED DNA; OLIGONUCLEOTIDE PROBES; RHODOPSIN; MUTATION	Detection of small alterations or abnormalities in genomic DNA (eg, point mutations or small deletions) has become increasingly important in the diagnosis of genetic disease and polymorphism. When a mutation or polymorphism creates a new restriction endonuclease site, it can easily be identified by polymerase chain reaction (PCR) amplification of the DNA region of interest, followed by digestion with the restriction endonuclease. However, useful restriction sites are the exception, and a variety of specialised techniques have been developed to identify subtle DNA abnormalities. We have shown that where a DNA mutation does not create a useful novel restriction site, such a site can be introduced by PCR and specially chosen primers. The approach is simple and inexpensive and should be broadly applicable in the diagnosis of genetic polymorphism and mutation. The technique is illustrated here by the three base-pair deletion responsible for most cases of cystic fibrosis and by detection of the point mutation in the rhodopsin gene that has been associated with some cases of autosomal dominant retinitis pigmentosa.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	SORSCHER, EJ (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.			Sorscher, Eric J./0000-0001-9341-3354				[Anonymous], 1989, METABOLIC BASIS INHE, V34, P253; BALLABIO A, 1990, NATURE, V343, P220, DOI 10.1038/343220a0; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; Erlich HA, 1989, PCR TECHNOLOGY, P36; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P3606, DOI 10.1093/nar/17.9.3606; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR G, 1990, ANAL BIOCHEM, V186, P64, DOI 10.1016/0003-2697(90)90573-R	12	39	44	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1991	337	8750					1115	1118		10.1016/0140-6736(91)92785-Z	http://dx.doi.org/10.1016/0140-6736(91)92785-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL124	1674012				2022-12-01	WOS:A1991FL12400002
J	BITTLES, AH; MASON, WM; GREENE, J; RAO, NA				BITTLES, AH; MASON, WM; GREENE, J; RAO, NA			REPRODUCTIVE-BEHAVIOR AND HEALTH IN CONSANGUINEOUS MARRIAGES	SCIENCE			English	Article							SOUTH-INDIA; PARENTAL CONSANGUINITY; PREREPRODUCTIVE MORTALITY; GENETIC-DISEASE; TAMIL-NADU; CONGENITAL-ABNORMALITIES; PARNETAL CONSANGUINITY; POSTNATAL MORTALITY; FETAL GROWTH; JAPAN	In many regions of Asia and Africa, consanguineous marriages currently account for approximately 20 to 50% of all unions, and preliminary observations indicate that migrants from these areas continue to contract marriages with close relatives when resident in North America and Western Europe. Consanguinity is associated with increased gross fertility, due at least in part to younger maternal age at first livebirth. Morbidity and mortality also may be elevated, resulting in comparable numbers of surviving offspring in consanguineous and nonconsanguineous families. With advances in medicine and public health, genetic disorders will account for an increased proportion of disease worldwide. Predictably, this burden will fall more heavily on countries and communities in which consanguinity is strongly favored, as the result of the expression of deleterious recessive genes. However, studies conducted in such populations indicate that the adverse effects associated with inbreeding are experienced by a minority of families.	UNIV CALIF LOS ANGELES,SOCIOL,LOS ANGELES,CA 90024; UNIV MICHIGAN,CTR POPULAT STUDIES,ANN ARBOR,MI 48104; INDIAN INST SCI,BIOCHEM,BANGALORE 560012,KARNATAKA,INDIA	University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; Indian Institute of Science (IISC) - Bangalore	BITTLES, AH (corresponding author), UNIV LONDON KINGS COLL,LONDON WC2R 2LS,ENGLAND.			Bittles, Alan/0000-0002-8176-2730				AFZAL M, 1988, BEHAV GENET, V18, P583, DOI 10.1007/BF01082310; AGRAWAL N, 1984, BEHAV GENET, V14, P579, DOI 10.1007/BF01068128; ALAWADI SA, 1986, CLIN GENET, V29, P384; Ansari SA, 1978, INDIAN J MED RES, V68, P295; B K, 1979, IND J HERED, V11, P77; Barth F, 1954, SOUTHWEST J ANTHROP, V10, P164, DOI 10.1086/soutjanth.10.2.3628823; BASHI J, 1977, NATURE, V266, P440, DOI 10.1038/266440a0; BASSARAN N, 1988, CLIN GENET, V34, P339; Basu S K, 1975, J Popul Res, V2, P57; BEER AE, 1981, AM J OBSTET GYNECOL, V141, P987; BEMISS SM, 1858, T AM MED ASS, V11, P319; BENALLEGUE A, 1984, ARCH FR PEDIATR, V41, P435; Bittles A. H, 1988, HUMAN MATING PATTERN, P153; BITTLES AH, 1987, MAN, V22, P736, DOI 10.2307/2803361; BITTLES AH, 1988, ANN HUM BIOL, V15, P455, DOI 10.1080/03014468800000062; BITTLES AH, 1990, FERTILITY RESOURCES, P62; BOOK JA, 1957, ANN HUM GENET, V21, P191; BRATT CS, 1984, FAM LAW QUART, V18, P257; BUMPASS LL, 1978, DEMOGRAPHY, V15, P75, DOI 10.2307/2060491; BUMPASS LL, 1977, SOC BIOL, V24, P31, DOI 10.1080/19485565.1977.9988259; BUNDEY S, 1990, J EPIDEMIOL COMMUN H, V44, P130, DOI 10.1136/jech.44.2.130; Bundey S, 1991, Paediatr Perinat Epidemiol, V5, P101, DOI 10.1111/j.1365-3016.1991.tb00689.x; CALDWELL JC, 1988, CAUSES DEMOGRAPHIC C, P239; Carr D H, 1971, Adv Hum Genet, V2, P201; CHAKRABORTY R, 1977, HUM GENET, V36, P47, DOI 10.1007/BF00390435; CHALEBY K, 1987, BRIT J PSYCHIAT, V150, P547, DOI 10.1192/bjp.150.4.547; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; COLEMAN DA, 1980, HUM HERED, V30, P278, DOI 10.1159/000153144; COOK ROBERT, 1966, J TROP PEDIAT AFR CHILD HEALTH, V11, P95; DARR A, 1988, J MED GENET, V25, P186, DOI 10.1136/jmg.25.3.186; DARWIN F, 1887, LIFE LETT C DARWIN, V2, P309; Darwin George, 1875, J STAT SOC, V38, P344; DARWIN GH, 1875, J STAT ASS, V37, P153; DECOSTA C, 1986, MED J AUSTRALIA, V144, P721; DEVI ARR, 1987, J MED GENET, V24, P362, DOI 10.1136/jmg.24.6.362; DIAMOND JM, 1987, NATURE, V329, P487, DOI 10.1038/329487a0; DRONAMRAJU KR, 1963, ACTA GENET STAT MED, V13, P21; DRONAMRAJU KR, 1963, J GENET, V58, P387, DOI 10.1007/BF02986307; ELALFI S, 1969, J KWT MED ASS, V3, P227; EMERY AEH, 1990, PRINCIPLES PRACTICE, P3; FARAG TI, 1988, CLIN GENET, V33, P78; Fei Hsiao-eung, 1939, PEASANT LIFE CHINA, P50; FREIREMAIA N, 1968, EUGEN QUART, V15, P22, DOI 10.1080/19485565.1968.9987749; FREIREMAIA N, 1984, AM J MED GENET, V18, P391, DOI 10.1002/ajmg.1320180306; FREIREMAIA N, 1983, AM J MED GENET, V16, P331, DOI 10.1002/ajmg.1320160306; FREUNDLICH E, 1984, ISRAEL J MED SCI, V20, P1035; GEDDES WR, 1963, PEASANT LIFE COMMUNI, P28; GINTER EK, 1987, HUM GENET, P547; GOLDSCHMIDT E, 1960, ANN HUM GENET, V24, P191, DOI 10.1111/j.1469-1809.1960.tb01732.x; GORDON RR, 1988, BMJ-BRIT MED J, V297, P774, DOI 10.1136/bmj.297.6651.774; GOSWAMI HK, 1970, ACTA GENET MED GEMEL, V19, P486, DOI 10.1017/S112096230001489X; HAFEZ M, 1983, J MED GENET, V20, P58, DOI 10.1136/jmg.20.1.58; HALL JG, 1978, AM J MED GENET, V1, P417, DOI 10.1002/ajmg.1320010405; HAMAMY HA, 1989, HUM HERED, V39, P271, DOI 10.1159/000153871; HENDRICKS CH, 1955, OBSTET GYNECOL, V6, P592, DOI 10.1097/00006250-195512000-00003; HONEYMAN MM, 1987, ARCH DIS CHILD, V62, P231, DOI 10.1136/adc.62.3.231; IMAIZUMI Y, 1975, JPN J HUM GENET, V20, P91; IMAIZUMI Y, 1986, CLIN GENET, V30, P230; KABARITY A, 1981, HUM GENET, V57, P444, DOI 10.1007/BF00281704; KHLAT M, 1986, AM J MED GENET, V25, P299, DOI 10.1002/ajmg.1320250215; KHLAT M, 1988, AM J HUM GENET, V43, P188; KHLAT M, 1989, AM J PHYS ANTHROPOL, V80, P481, DOI 10.1002/ajpa.1330800407; Khlat M, 1984, J BIOSOC SCI, V16, P369; KHOURY MJ, 1987, AM J EPIDEMIOL, V125, P251, DOI 10.1093/oxfordjournals.aje.a114524; Krishan G, 1986, AM J PHYS ANTHROPOL, V70, P60; KULKARNI ML, 1990, J MED GENET, V27, P348, DOI 10.1136/jmg.27.6.348; KUMAR S, 1967, ANN HUM GENET, V31, P141, DOI 10.1111/j.1469-1809.1967.tb00545.x; LEBEL RR, 1983, AM J MED GENET, V15, P543, DOI 10.1002/ajmg.1320150404; Lesthaeghe Ron., 1989, REPROD SOCIAL ORG SU, P238; MAGNUS P, 1985, CLIN GENET, V28, P335; MARCALLO FA, 1964, ANN HUM GENET, V27, P203, DOI 10.1111/j.1469-1809.1963.tb00787.x; McKusick Victor., 1978, MED GENETIC STUDIES; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; NADERI S, 1979, OBSTET GYNECOL, V53, P195; NEEL JV, 1962, P NATL ACAD SCI USA, V48, P573, DOI 10.1073/pnas.48.4.573; NEEL JV, 1962, AM J HUM GENET, V48, P573; OBER CL, 1983, AM J HUM GENET, V35, P994; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V75, P477, DOI 10.1002/ajpa.1330750405; OBRIEN E, 1988, AM J PHYS ANTHROPOL, V77, P335, DOI 10.1002/ajpa.1330770306; OKSENBERG JR, 1984, FERTIL STERIL, V42, P389; PARISH WL, 1978, VILLAGE FAMILY CONT, P170; RAO NA, 1988, CLIN GENET, V34, P60; RAO PSS, 1977, SOC BIOL, V24, P281, DOI 10.1080/19485565.1977.9988298; RAO PSS, 1979, J MED GENET, V16, P24, DOI 10.1136/jmg.16.1.24; RAO PSS, 1977, ANN HUM GENET, V41, P87, DOI 10.1111/j.1469-1809.1977.tb01964.x; RAO PSSS, 1979, ANN HUM GENET, V42, P401, DOI 10.1111/j.1469-1809.1979.tb00672.x; REDDY PG, 1988, ANN HUM BIOL, V15, P263, DOI 10.1080/03014468800009731; REID RM, 1976, HUM BIOL, V48, P139; SAEDIWONG S, 1989, J ASIAN AFR STUD, V24, P247, DOI DOI 10.1177/002190968902400308; SAHA N, 1988, J BIOSOC SCI, V20, P333, DOI 10.1017/S0021932000006660; SANGHVI LD, 1966, EUGEN QUART, V13, P291, DOI 10.1080/19485565.1966.9987682; Sanghvi LD, 1956, ACTA GENET STAT MED, V6, P41; SAUGSTAD LF, 1977, ANN HUM GENET, V40, P481, DOI 10.1111/j.1469-1809.1977.tb01865.x; SCHORK MA, 1964, AM J HUM GENET, V16, P292; SCHULL WJ, 1970, AM J HUM GENET, V22, P239; SCHULL WJ, 1970, HUMANGENETIK, V9, P294, DOI 10.1007/BF00286995; SCHULL WJ, 1962, HUM BIOL, V34, P271; SCHULL WJ, 1972, AM J HUM GENET, V24, P425; SCHULL WJ, 1958, AM J HUM GENET, V10, P294; Schull WJ, 1965, EFFECTS INBREEDING J; SCOTTEMUAKPOR AB, 1974, AM J HUM GENET, V26, P674; SHAMI S A, 1982, Biologia (Lahore), V28, P1; SHAMI SA, 1989, J MED GENET, V26, P267, DOI 10.1136/jmg.26.4.267; SHAMI SA, 1990, ANN HUM BIOL, V17, P97, DOI 10.1080/03014469000000842; TANAKA K, 1964, P JPN ACAD, V40, P852, DOI 10.2183/pjab1945.40.852; Tanner R E, 1958, Eugen Rev, V49, P197; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; Tuncbilek E, 1989, Nufusbil Derg, V11, P35; WHYTE MK, 1984, URBAN LIFE CONT CHIN, P133; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; YADAV GC, 1988, J INHERIT METAB DIS, V11, P277, DOI 10.1007/BF01800370; 1989, STATE WORLDS CHILDRE, P94	112	236	237	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					789	794		10.1126/science.2028254	http://dx.doi.org/10.1126/science.2028254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL123	2028254				2022-12-01	WOS:A1991FL12300035
J	BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y				BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y			IDENTIFICATION OF A PEPTIDE SPECIFIC FOR APLYSIA SENSORY NEURONS BY PCR-BASED DIFFERENTIAL SCREENING	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; MECHANOAFFERENT NEURONS; SYNAPTIC CONNECTIONS; RESPONSE PROPERTIES; INNERVATING TAIL; FACILITATION; DISHABITUATION; SENSITIZATION; AMPLIFICATION; HABITUATION	In order to identify genes specific for the sensory neurons of Aplysia, a miniaturized differential screening method based on the polymerase chain reaction and applicable to small amounts of tissue was used. One messenger RNA was isolated that is expressed in every mechanoreceptor sensory cluster of the Aplysia central nervous system. This messenger RNA encodes a peptide that seems to function as an inhibitory cotransmitter. The peptide selectively inhibits certain postsynaptic cells but not others and thereby allows the sensory neurons to achieve target-specific synaptic actions.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	BRUNET, JF (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168 ST,NEW YORK,NY 10032, USA.			Brunet, Jean-Francois/0000-0002-1985-6103				BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P896, DOI 10.1152/jn.1980.43.4.896; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P5483, DOI 10.1073/pnas.84.15.5483; CROPPER EC, 1990, P NATL ACAD SCI USA, V87, P933, DOI 10.1073/pnas.87.3.933; DUBUC B, 1991, J EXP BIOL, V156, P315; ESKIN A, 1989, P NATL ACAD SCI USA, V86, P2458, DOI 10.1073/pnas.86.7.2458; FIORE L, 1980, NEUROBIOLOGY INVERTE, P20; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOKFELT T, 1987, EXPERIENTIA, V43, P768; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HOKFELT T, 1983, SCIENCE, V221, P286; KISTLER HB, 1985, J NEUROSCI, V5, P72; Maniatis T., 1982, MOL CLONING; PINSKER H, 1970, SCIENCE, V167, P1740, DOI 10.1126/science.167.3926.1740; RAYPORT SG, 1983, J NEUROPHYSIOL, V49, P864, DOI 10.1152/jn.1983.49.4.864; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOLTZ KP, 1987, SCIENCE, V235, P685; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	27	82	86	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					856	859		10.1126/science.1840700	http://dx.doi.org/10.1126/science.1840700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1840700				2022-12-01	WOS:A1991FL12300051
J	HOLLMANN, M; HARTLEY, M; HEINEMANN, S				HOLLMANN, M; HARTLEY, M; HEINEMANN, S			CA2+ PERMEABILITY OF KA-AMPA GATED GLUTAMATE RECEPTOR CHANNELS DEPENDS ON SUBUNIT COMPOSITION	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; EXCITATORY AMINO-ACIDS; XENOPUS-LAEVIS OOCYTES; ACTIVATED CHANNELS; DIVALENT-CATIONS; STRIATAL NEURONS; CHLORIDE CURRENT; CALCIUM; CULTURE	NMDA (N-methyl-D-aspartate) receptors and non-NMDA receptors represent the two major classes of ion channel-linked glutamate receptors. Unlike the NMDA receptor channels, non-NMDA receptor channels have usually been thought to conduct monovalent cations only. Non-NMDA receptor ion channels that can be gated by kainic acid (KA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) are formed by the glutamate receptor subunits GluR1, GluR2, and GluR3. These subunits were expressed in various combinations in Xenopus oocytes so that their permeability to divalent cations could be studied. At physiological resting potentials, KA and AMPA elicited inward calcium currents in oocytes expressing GluR1, GluR3, and GluR1 plus GluR3. In contrast, oocytes expressing GluR1 plus GluR2 or GluR3 plus GluR2 showed no such permeability. Thus, in neurons expressing certain KA-AMPA receptor subunits, glutamate may trigger calcium-dependent intracellular events by activating non-NMDA receptors.			HOLLMANN, M (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.			Hollmann, Michael/0000-0001-8000-7787	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28709-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, UNPUB; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1987, J NEUROSCI, V7, P3230; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; MONAGHAN DT, 1989, ANN REV PHARM TOXICO, V21, P165; MURPHY SN, 1989, J PHARMACOL EXP THER, V249, P184; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P1097, DOI 10.1152/jn.1989.61.6.1097; OGURA A, 1990, NEUROSCI RES, V9, P103, DOI 10.1016/0168-0102(90)90026-B; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; RANDLE JCR, 1988, MOL CELL BIOCHEM, V80, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275	35	1294	1320	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					851	853		10.1126/science.1709304	http://dx.doi.org/10.1126/science.1709304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709304				2022-12-01	WOS:A1991FL12300049
J	HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y				HOSHIJIMA, K; INOUE, K; HIGUCHI, I; SAKAMOTO, H; SHIMURA, Y			CONTROL OF DOUBLESEX ALTERNATIVE SPLICING BY TRANSFORMER AND TRANSFORMER-2 IN DROSOPHILA	SCIENCE			English	Article							CHROMOSOMALLY MALE DROSOPHILA; GENE-PRODUCT LEADS; SEX DETERMINATION; FEMALE DIFFERENTIATION; ECTOPIC EXPRESSION; RNA; MELANOGASTER; PROTEIN; ENCODES; LOCUS	Sex-specific alternative processing of doublesex (dsx) precursor messenger RNA (pre-mRNA) regulates somatic sexual differentiation in Drosophila melanogaster. Cotransfection analyses in which the dsx gene and the female-specific transformer (tra) and transformer-2 (tra-2) complementary DNAs were expressed in Drosophila Kc cells revealed that female-specific splicing of the dsx transcript was positively regulated by the products of the tra and tra-2 genes. Furthermore, analyses of mutant constructs of dsx showed that a portion of the female-specific exon sequence was required for regulation of dsx pre-messenger RNA splicing.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyoto University								AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1988, GENE DEV, V2, P477, DOI 10.1101/gad.2.4.477; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELOTE JM, 1982, P NATL ACAD SCI-BIOL, V79, P1568, DOI 10.1073/pnas.79.5.1568; BELOTE JM, 1989, DEV GENET, V10, P143, DOI 10.1002/dvg.1020100304; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HOSHIJIMA K, UNPUB; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NOTHIGER R, 1985, TRENDS GENET, V1, P209, DOI 10.1016/0168-9525(85)90082-4; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAIKI RK, 1988, SCIENCE, V239, P427; SCHUPBACH T, 1982, DEV BIOL, V89, P117, DOI 10.1016/0012-1606(82)90300-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	23	252	260	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					833	836		10.1126/science.1902987	http://dx.doi.org/10.1126/science.1902987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1902987				2022-12-01	WOS:A1991FL12300043
J	LAVORGNA, G; UEDA, H; CLOS, J; WU, C				LAVORGNA, G; UEDA, H; CLOS, J; WU, C			FTZ-F1, A STEROID-HORMONE RECEPTOR LIKE PROTEIN IMPLICATED IN THE ACTIVATION OF FUSHI-TARAZU	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; ESTROGEN-RECEPTOR; AMINO-ACIDS; GENE KNIRPS; SUPERFAMILY; DNA; SEGMENTATION; SEQUENCE; MEMBER; IDENTIFICATION	The Drosophila homeobox segmentation gene fushi tarazu (ftz) is expressed in a seven-stripe pattern during early embryogenesis. This characteristic pattern is largely specified by the zebra element located immediately upstream of the ftz transcriptional start site. The FTZ-F1 protein, one of multiple DNA binding factors that interacts with the zebra element, is implicated in the activation of ftz transcription, especially in stripes 1, 2, 3, and 6. An FTZ-F1 complementary DNA has been cloned by recognition site screening of a Drosophila expression library. The identity of the FTZ-F1 complementary DNA clone was confirmed by immunological cross-reaction with antibodies to FTZ-F1 and by sequence analysis of peptides from purified FTZ-F1 protein. The predicted amino acid sequence of FTZ-F1 revealed that the protein is a member of the nuclear hormone receptor superfamily. This finding raises the possibility that a hormonal ligand affects the expression of a homeobox segmentation gene early in embryonic development.	NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	LAVORGNA, G (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.		UEDA, Hitoshi/B-1455-2011; Lavorgna, Giovanni/AAN-2575-2020					AKAM M, 1987, DEVELOPMENT, V101, P1; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FEIGL G, 1989, NUCLEIC ACIDS RES, V17, P7167, DOI 10.1093/nar/17.18.7167; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOLLENBERG SM, 1985, NATURE, V318, P670; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LAVORGNA G, UNPUB; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; RICHARDS G, 1976, DEV BIOL, V54, P256, DOI 10.1016/0012-1606(76)90303-1; ROTHE M, 1989, EMBO J, V8, P3087, DOI 10.1002/j.1460-2075.1989.tb08460.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SEAGRAVES WA, 1990, GENE DEV, V4, P204; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	49	265	271	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					848	851		10.1126/science.1709303	http://dx.doi.org/10.1126/science.1709303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709303				2022-12-01	WOS:A1991FL12300048
J	MADSEN, EL; SINCLAIR, JL; GHIORSE, WC				MADSEN, EL; SINCLAIR, JL; GHIORSE, WC			INSITU BIODEGRADATION - MICROBIOLOGICAL PATTERNS IN A CONTAMINATED AQUIFER	SCIENCE			English	Article							DEEP SUBSURFACE SEDIMENTS; MICROBIAL ECOLOGY; ORGANIC-COMPOUNDS; WASTE SITE; BACTERIA; DEGRADATION; PROTOZOA; OKLAHOMA; WATER; FIELD	Conventional approaches for proving in situ biodegradation of organic pollutants in aquifers have severe limitations. In the approach described here, patterns in a comprehensive set of microbiological activity and distribution data were analyzed. Measurements were performed on sediment samples gathered at consistent depths in aquifer boreholes spanning a gradient of contaminant concentrations at a buried coal tar site. Microbial adaptation to polyaromatic hydrocarbons (PAHs) was demonstrated by mineralization of naphthalene and phenanthrene in samples from PAH-contaminated, but not adjacent pristine, zones. Furthermore, contaminant-stimulated in situ bacterial growth was indicated because enhanced numbers of protozoa and their bacterial prey were found exclusively in contaminated subsurface samples. The data suggest that many convergent lines of logically linked indirect evidence can effectively document in situ biodegradation of aquifer contaminants.			MADSEN, EL (corresponding author), CORNELL UNIV,DIV BIOL SCI,MICROBIOL SECT,ITHACA,NY 14853, USA.							ALEXANDER M, 1981, SCIENCE, V211, P132, DOI 10.1126/science.7444456; [Anonymous], 1984, PETROLEUM MICROBIOLO; BALKWILL DL, 1985, APPL ENVIRON MICROB, V50, P580, DOI 10.1128/AEM.50.3.580-588.1985; BORDEN RC, 1987, WATER RESOUR BULL, V23, P629; BROCK TD, 1988, BIOL MICROORGANISMS, P5; CHAPELLE FH, 1990, APPL ENVIRON MICROB, V56, P1865, DOI 10.1128/AEM.56.6.1865-1874.1990; CHIANG CY, 1989, GROUND WATER, V27, P823, DOI 10.1111/j.1745-6584.1989.tb01046.x; CLINE PV, 1985, WASTE MANAGE RES, V3, P351, DOI 10.1016/0734-242X(85)90128-4; CURDS CR, 1982, ANNU REV MICROBIOL, V36, P27, DOI 10.1146/annurev.mi.36.100182.000331; DAGLEY S, 1977, SURV PROG CHEM, V8, P121; EVANS WC, 1977, NATURE, V270, P17, DOI 10.1038/270017a0; FEDERLE TW, 1988, GROUND WATER, V26, P761, DOI 10.1111/j.1745-6584.1988.tb00427.x; Fenchel T., 2013, ECOLOGY OF PROTOZOA, DOI DOI 10.1007/978-3-662-25981-8; Floodgate G.D., 1984, PETROLEUM MICROBIOLO, P355; Foissner W., 1987, Progress in Protistology, V2, P69; FREDRICKSON JK, 1989, GEOMICROBIOL J, V7, P53, DOI 10.1080/01490458909377849; GHIORSE WC, 1988, ADV APPL MICROBIOL, V33, P107, DOI 10.1016/S0065-2164(08)70206-5; HARTWIG E, 1984, Senckenbergiana Maritima, V16, P121; Karl DM., 1986, METHODS SPECIAL APPL, V2, P85; KLECKA GM, 1990, GROUND WATER, V28, P534, DOI 10.1111/j.1745-6584.1990.tb01709.x; Kolwitz R., 1909, INT REV GES HYDROBIO, V2, P126; LEAHY JG, 1990, MICROBIOL REV, V54, P305, DOI 10.1128/MMBR.54.3.305-315.1990; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LEVINS SN, 1991, 1ST P INT S MICR DEE; MARTIN JP, 1980, LIGNIN BIODEGRADATIO, V1, P77; Moriarty F., 1988, ECOTOXICOLOGY STUDY; PIATT JF, 1990, AUK, V107, P387, DOI 10.2307/4087623; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; RAYMOND RL, 1976, APPL ENVIRON MICROB, V31, P522, DOI 10.1128/AEM.31.4.522-535.1976; RIDGWAY HF, 1990, APPL ENVIRON MICROB, V56, P3565, DOI 10.1128/AEM.56.11.3565-3575.1990; ROGERSON A, 1983, J GEN APPL MICROBIOL, V29, P41, DOI 10.2323/jgam.29.41; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; SINCLAIR JL, 1989, GEOMICROBIOL J, V7, P15, DOI 10.1080/01490458909377847; SINCLAIR JL, 1987, APPL ENVIRON MICROB, V53, P1157, DOI 10.1128/AEM.53.5.1157-1163.1987; SINCLAIR JL, 1991, 1ST P INT S MICR DEE; SPAIN JC, 1984, APPL ENVIRON MICROB, V48, P944, DOI 10.1128/AEM.48.5.944-950.1984; Stout J.D., 1980, Advances in Microbial Ecology, V4, P1; TAYLOR BB, P ENV RES C GROUNDWA; THOMAS JM, 1989, J IND MICROBIOL, V4, P109, DOI 10.1007/BF01569795; TRIBE H. T., 1961, Soil Science, V92, P61, DOI 10.1097/00010694-196107000-00009; VESTAL JR, 1984, PETROLEUM MICROBIOLO, P475; VILLAUME JF, 1984, HAZARDOUS TOXIC WAST, P362; WILSON JT, 1985, ENVIRON TOXICOL CHEM, V4, P721, DOI 10.1002/etc.5620040602; WILSON JT, 1983, GROUND WATER, V21, P134, DOI 10.1111/j.1745-6584.1983.tb00710.x; 1990, GROUND WATER, V28, P715	45	168	170	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					830	833		10.1126/science.2028258	http://dx.doi.org/10.1126/science.2028258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028258				2022-12-01	WOS:A1991FL12300042
J	MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A				MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A			HBV X-PROTEIN ALTERS THE DNA-BINDING SPECIFICITY OF CREB AND ATF-2 BY PROTEIN-PROTEIN INTERACTIONS	SCIENCE			English	Article							HEPATITIS-B VIRUS; LONG TERMINAL REPEAT; CYCLIC-AMP; RESPONSE ELEMENT; TRANS-ACTIVATION; VIRAL ENHANCERS; MAMMALIAN-CELLS; GENE; TRANSCRIPTION; TRANSACTIVATOR	The hepatitis B virus (HBV) X gene product trans-activates viral and cellular genes. The X protein (pX) does not bind independently to nucleic acids. The data presented here demonstrate that pX entered into a protein-protein complex with the cellular transcriptional factors CREB and ATF-2 and altered their DNA binding specificities. Although CREB and ATF-2 alone did not bind to the HBV enhancer element, a pX-CREB or pX-ATF-2 complex did bind to the HBV enhancer. Thus, the ability of pX to interact with cellular factors broadened the DNA binding specificity of these regulatory proteins and provides a mechanism for pX to participate in transcriptional regulation. This strategy of altered binding specificity may modify the repertoire of genes that can be regulated by transcriptional factors during viral infection.	UNIV COLORADO,SCH MED,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,CTR CANC,DENVER,CO 80262; UNIV COLORADO,SCH MED,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [P30-CA46934-02, CA33135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033135, P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FACTOR O, 1990, ONCOGENE, V5, P867; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GODING CR, 1989, VIROLOGY, V173, P363; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, IN PRESS MOL ENDOCRI; HOEFFLER JP, 1990, TRENDS ENDOCRINOL ME, V1, P151; HOEFFLER JP, UNPUB; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7144; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JAMEEL S, 1990, J VIROL, V64, P3963, DOI 10.1128/JVI.64.8.3963-3966.1990; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HG, UNPUB; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TOGNONI A, 1986, NUCLEIC ACIDS RES, V13, P7357; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WU J, 1990, CELL, V63, P673; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	404	420	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					842	844		10.1126/science.1827531	http://dx.doi.org/10.1126/science.1827531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1827531				2022-12-01	WOS:A1991FL12300046
J	MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM				MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM			EXPERIMENTAL-THERAPY OF HUMAN GLIOMA BY MEANS OF A GENETICALLY ENGINEERED VIRUS MUTANT	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; ACYCLOVIR-RESISTANT HERPES; ACQUIRED IMMUNODEFICIENCY SYNDROME; RADIATION-THERAPY; MALIGNANT GLIOMA; INFECTIONS; RADIOTHERAPY; FOSCARNET; GLIOBLASTOMA; THYMIDINE	Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.	HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,DEPT SURG NEUROSURG,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,DIV NEUROSURG,ANN ARBOR,MI 48109	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	MARTUZA, RL (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RRO5381] Funding Source: Medline; NIAID NIH HHS [R01-AI26126] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin F C, 1979, Adv Cancer Res, V30, P301, DOI 10.1016/S0065-230X(08)60900-8; BURDICK KH, 1964, CANCER, V17, P708, DOI 10.1002/1097-0142(196406)17:6<708::AID-CNCR2820170604>3.0.CO;2-3; CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4; CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; COEN DM, 1985, J VIROL, V53, P477, DOI 10.1128/JVI.53.2.477-488.1985; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FIELD HJ, 1978, J HYG-CAMBRIDGE, V81, P267, DOI 10.1017/S0022172400025109; FIELD HJ, 1980, ANTIMICROB AGENTS CH, V17, P209, DOI 10.1128/AAC.17.2.209; HIRSCH MS, 1983, NEW ENGL J MED, V309, P963; HIRSCH MS, 1983, NEW ENGL J MED, V309, P1034; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; JAMIESON AT, 1974, J GEN VIROL, V24, P465, DOI 10.1099/0022-1317-24-3-465; KIM TS, IN PRESS J NEUROSURG; Kobayashi H, 1979, Adv Cancer Res, V30, P279; LEE JK, 1990, NEUROSURGERY, V26, P598, DOI 10.1227/00006123-199004000-00007; LEVIN AL, 1989, CANC PRINCIPLES PRAC, V2, P1557; Luna L.G., 1968, MANUAL HISTOLOGIC ST, Vthird; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MEDHKOUR A, 1989, J NEUROSURG, V71, P545, DOI 10.3171/jns.1989.71.4.0545; MOORE A. E., 1960, PROGR EXPTL TUMOR RES, V1, P411; ONOYAMA Y, 1976, AM J ROENTGENOL, V126, P481, DOI 10.2214/ajr.126.3.481; PEARSON HE, 1956, P SOC EXP BIOL MED, V92, P551; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SALAZAR OM, 1979, INT J RADIAT ONCOL, V5, P1733, DOI 10.1016/0360-3016(79)90554-6; SAUTER C, 1978, CURRENT CHEMOTHERAPY, P1112; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; SIGEL MM, 1955, J IMMUNOL, V75, P386; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; TENSER RB, 1979, SCIENCE, V205, P915, DOI 10.1126/science.224454; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; YOULE MM, 1988, LANCET, V2, P341	36	738	812	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					854	856		10.1126/science.1851332	http://dx.doi.org/10.1126/science.1851332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851332				2022-12-01	WOS:A1991FL12300050
J	MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME				MCINTIRE, WS; WEMMER, DE; CHISTOSERDOV, A; LIDSTROM, ME			A NEW COFACTOR IN A PROKARYOTIC ENZYME - TRYPTOPHAN TRYPTOPHYLQUINONE AS THE REDOX PROSTHETIC GROUP IN METHYLAMINE DEHYDROGENASE	SCIENCE			English	Article							COVALENTLY BOUND PQQ; AMINO-ACID-SEQUENCE; PSEUDOMONAS SP-J; PYRROLOQUINOLINE QUINONE; PARACOCCUS-DENITRIFICANS; PYRIDOXO-QUINOPROTEIN; DIAMINE OXIDASE; BIOSYNTHESIS; PURIFICATION; TYROSINE	Methylamine dehydrogenase (MADH), an alpha-2-beta-2 enzyme from numerous methylotrophic soil bacteria, contains a novel quinonoid redox prosthetic group that is covalently bound to its small beta-subunit through two amino acyl residues. A comparison of the amino acid sequence deduced from the gene sequence of the small subunit for the enzyme from Methylobacterium extorquens AM1 with the published amino acid sequence obtained by the Edman degradation method, allowed the identification of the amino acyl constituents of the cofactor as two tryptophyl residues. This information was crucial for interpreting H-1 and C-13 nuclear magnetic resonance, and mass spectral data collected for the semicarbazide- and carboxymethyl-derivatized bis(tripeptidyl)-cofactor of MADH from bacterium W3A1. The cofactor is composed of two cross-linked tryptophyl residues. Although there are many possible isomers, only one is consistent with all the data: The first tryptophyl residue in the peptide sequence exists as an indole-6,7-dione, and is attached at its 4 position to the 2 position of the second, otherwise unmodified, indole side group. Contrary to earlier reports, the cofactor of MADH is not 2,7,9-tricarboxypyrroloquinoline quinone (PQQ), a derivative thereof, or pro-PQQ. This appears to be the only example of two cross-linked, modified amino acyl residues having a functional role in the active site of an enzyme, in the absence of other cofactors or metal ions.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; CALTECH, WM KECK LABS, PASADENA, CA 91125 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; California Institute of Technology	MCINTIRE, WS (corresponding author), DEPT VET AFFAIRS MED CTR, DIV MOLEC BIOL, SAN FRANCISCO, CA 94121 USA.				NHLBI NIH HHS [HL 16251] Funding Source: Medline; NIGMS NIH HHS [GM 36296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1989, PQQ AND QUINOPROTEINS, P145; AMEYAMA M, 1984, AGR BIOL CHEM TOKYO, V48, P561, DOI 10.1080/00021369.1984.10866184; ANTHONY C, 1989, PQQ AND QUINOPROTEINS, P1; BACKES G, UNPUB; CHISTOSERDOV AY, 1990, BIOCHEM BIOPH RES CO, V172, P211, DOI 10.1016/S0006-291X(05)80195-0; CLARK K, 1990, J AM CHEM SOC, V112, P6433, DOI 10.1021/ja00173a061; DAVIDSON VL, 1987, FEMS MICROBIOL LETT, V44, P121, DOI 10.1111/j.1574-6968.1987.tb02254.x; DEBEER R, 1980, BIOCHIM BIOPHYS ACTA, V622, P370, DOI 10.1016/0005-2795(80)90050-1; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; DRYHURST G, 1990, CHEM REV, V90, P795, DOI 10.1021/cr00103a007; DUINE J A, 1989, Biofactors, V2, P87; GALLOP PM, 1989, TRENDS BIOCHEM SCI, V14, P343, DOI 10.1016/0968-0004(89)90169-2; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GLATZ Z, 1987, BIOCHEM J, V242, P603, DOI 10.1042/bj2420603; GROEN BW, 1988, FEBS LETT, V237, P98, DOI 10.1016/0014-5793(88)80179-0; HARTMANN C, 1988, Biofactors, V1, P41; HARTMANN C, 1990, FEBS LETT, V261, P441, DOI 10.1016/0014-5793(90)80611-L; HARTMANN C, 1987, J BIOL CHEM, V262, P962; HAYWOOD GW, 1982, FEMS MICROBIOL LETT, V15, P79, DOI 10.1111/j.1574-6968.1982.tb00042.x; HOUCK DR, 1989, PQQ AND QUINOPROTEINS, P177; HOUCK DR, 1988, J AM CHEM SOC, V110, P6920, DOI 10.1021/ja00228a070; HUSAIN M, 1987, BIOCHEMISTRY-US, V26, P4139, DOI 10.1021/bi00387a059; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1987, J BACTERIOL, V169, P1712, DOI 10.1128/jb.169.4.1712-1717.1987; ISHII Y, 1983, J BIOCHEM, V93, P107, DOI 10.1093/oxfordjournals.jbchem.a134144; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JENKINS O, 1987, J GEN MICROBIOL, V133, P453; KARHUNEN E, 1990, FEBS LETT, V267, P6, DOI 10.1016/0014-5793(90)80273-L; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1983, BIOCHEMISTRY-US, V22, P3858, DOI 10.1021/bi00285a022; KENNEY WC, 1984, MICROBIAL GROWTH C1, P165; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; LARGE PJ, 1988, METHYLOTROPHY BIOTEC, P18; Lee E, UNPUB; LERCH K, 1982, J BIOL CHEM, V257, P6414; LOBENSTEINVERBEEK CL, 1984, FEBS LETT, V170, P305, DOI 10.1016/0014-5793(84)81333-2; Martin G. E., 1988, 2 DIMENSIONAL NMR ME; MATHEWS FS, COMMUNICATION; MATSUMOTO T, 1978, J BIOCHEM-TOKYO, V83, P1591, DOI 10.1093/oxfordjournals.jbchem.a132070; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P303, DOI 10.1016/0005-2744(78)90064-5; MATSUMOTO T, 1978, BIOCHIM BIOPHYS ACTA, V522, P291, DOI 10.1016/0005-2744(78)90063-3; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1986, BIOCHEM BIOPH RES CO, V141, P562, DOI 10.1016/S0006-291X(86)80210-8; MCINTIRE WS, 1987, APPL ENVIRON MICROB, V53, P2183, DOI 10.1128/AEM.53.9.2183-2188.1987; MICHAUDSORET I, 1990, BIOCHEM BIOPH RES CO, V172, P1122, DOI 10.1016/0006-291X(90)91563-8; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PENNINGS EJM, 1989, FEBS LETT, V255, P97, DOI 10.1016/0014-5793(89)81068-3; PRINCE RC, 1990, TRENDS BIOCHEM SCI, V15, P170, DOI 10.1016/0968-0004(90)90152-2; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RAPHALS P, 1990, SCIENCE, V249, P619, DOI 10.1126/science.2166338; ROBERTSON JG, 1989, J BIOL CHEM, V264, P19916; RODRIGUEZ EJ, 1989, J AM CHEM SOC, V111, P7947, DOI 10.1021/ja00202a041; RUCKER R, 1989, PQQ AND QUINOPROTEINS, P159; RUCKER RB, 1988, FASEB J, V2, P2252, DOI 10.1096/fasebj.2.7.3127264; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; VANDERMEER RA, 1986, FEBS LETT, V206, P111, DOI 10.1016/0014-5793(86)81350-3; VANDERMEER RA, 1989, FEBS LETT, V254, P99, DOI 10.1016/0014-5793(89)81017-8; VANDERMEER RA, 1989, FEBS LETT, V246, P109, DOI 10.1016/0014-5793(89)80263-7; VANDERMEER RA, 1987, FEBS LETT, V221, P299, DOI 10.1016/0014-5793(87)80944-4; VANKLEEF MAG, 1988, FEBS LETT, V237, P91, DOI 10.1016/0014-5793(88)80178-9; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; VELDINK GA, 1990, FEBS LETT, V270, P135, DOI 10.1016/0014-5793(90)81252-J; VELLIEUX FMD, 1989, FEBS LETT, V255, P460, DOI 10.1016/0014-5793(89)81145-7; VELLIEUX FMD, 1986, EUR J BIOCHEM, V154, P383, DOI 10.1111/j.1432-1033.1986.tb09409.x; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; Wuthrich K., 1986, NMR PROTEINS NUCL AC; 1990, MORB MORTAL WKLY REP, V39, P589; 1990, MORB MORTAL WKLY REP, V39, P789	74	341	345	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					817	824		10.1126/science.2028257	http://dx.doi.org/10.1126/science.2028257			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028257				2022-12-01	WOS:A1991FL12300039
J	MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL				MICHNICK, SW; ROSEN, MK; WANDLESS, TJ; KARPLUS, M; SCHREIBER, SL			SOLUTION STRUCTURE OF FKBP, A ROTAMASE ENZYME AND RECEPTOR FOR FK506 AND RAPAMYCIN	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC BINDING-PROTEIN; LAC REPRESSOR HEADPIECE; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; IMMUNOSUPPRESSANT FK506; CYCLOSPORIN-A; CONFORMATION; CYCLOPHILIN	Immunophilins, when complexed to immunosuppressive ligands, appear to inhibit signal transduction pathways that result in exocytosis and transcription. The solution structure of one of these, the human FK506 and rapamycin binding protein (FKBP), has been determined by nuclear magnetic resonance (NMR). FKBP has a previously unobserved antiparallel beta-sheet folding topology that results in a novel loop crossing and produces a large cavity lined by a conserved array of aromatic residues; this cavity serves as the rotamase active site and drug-binding pocket. There are other significant structural features (such as a protruding positively charged loop and an apparently flexible loop) that may be involved in the biological activity of FKBP.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030804, R01GM030804, R01GM038627, R37GM038627] Funding Source: NIH RePORTER; NCRR NIH HHS [I-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM-30804, GM-38627] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALBERS MW, IN PRESS BIOMED CHEM; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1991, ACCOUNTS CHEM RES, V24, P54; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHIRGADZE YN, 1987, ACTA CRYSTALLOGR A, V43, P405, DOI 10.1107/S0108767387099239; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; FISHER G, 1989, NATURE, V337, P476; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GOEBL MG, 1991, CELL, V64, P1051, DOI 10.1016/0092-8674(91)90258-Z; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; HULTSCH T, IN PRESS P NATL ACAD; JIN Y, UNPUB; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAPTEIN R, 1985, J MOL BIOL, V182, P179, DOI 10.1016/0022-2836(85)90036-1; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MORAS D, 1975, J BIOL CHEM, V250, P9137; NEUHAUS D, 1985, EUR J BIOCHEM, V151, P257, DOI 10.1111/j.1432-1033.1985.tb09096.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, IN PRESS COMPUTATION; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PTITSYN OB, 1980, Q REV BIOPHYS, V13, P339, DOI 10.1017/S0033583500001724; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; ROSEN MK, IN PRESS BIOCHEMISTR; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P601, DOI 10.1002/bip.360240402	42	291	303	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					836	839		10.1126/science.1709301	http://dx.doi.org/10.1126/science.1709301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709301				2022-12-01	WOS:A1991FL12300044
J	PAVLETICH, NP; PABO, CO				PAVLETICH, NP; PABO, CO			ZINC FINGER DNA RECOGNITION - CRYSTAL-STRUCTURE OF A ZIF268-DNA COMPLEX AT 2.1-A	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FUNCTIONAL REGIONS; BINDING DOMAINS; 5S-RNA GENE; PROTEIN; RESOLUTION; REPRESSOR; GROWTH; OPERATOR; KRUPPEL	The zinc finger DNA-binding motif occurs in many proteins that regulate eukaryotic gene expression. The crystal structure of a complex containing the three zinc fingers from Zif268 (a mouse immediate early protein) and a consensus DNA-binding site has been determined at 2.1 angstroms resolution and refined to a crystallographic R factor of 18.2 percent. In this complex, the zinc fingers bind in the major groove of B-DNA and wrap partway around the double helix. Each finger has a similar relation to the DNA and makes its primary contacts in a three-base pair subsite. Residues from the amino-terminal portion of an alpha-helix contact the bases, and most of the contacts are made with the guanine-rich strand of the DNA. This structure provides a framework for understanding how zinc fingers recognize DNA and suggests that this motif may provide a useful basis for the design of novel DNA-binding proteins.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	PAVLETICH, NP (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.		Wilson, Matthew H/K-3193-2013		NIGMS NIH HHS [GM-31471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS TH, 1988, CELL, V54, P353, DOI 10.1016/0092-8674(88)90198-5; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEMIS LT, 1988, MOL CELL BIOL, V8, P2125, DOI 10.1128/MCB.8.5.2125; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V21 MANUAL; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JACOBS G, 1990, New Biologist, V2, P583; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ONEIL KT, 1990, CELL, V249, P774; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, UNPUB; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; WANG JC, 1990, J BIOL CHEM, V265, P6513; 1979, SERC4 DAR LAB COLL C	45	1763	1919	3	191	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	1991	252	5007					809	817		10.1126/science.2028256	http://dx.doi.org/10.1126/science.2028256			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	2028256				2022-12-01	WOS:A1991FL12300038
J	UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT				UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT			INHIBITION OF PDGF BETA-RECEPTOR SIGNAL TRANSDUCTION BY COEXPRESSION OF A TRUNCATED RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; INSULIN-RECEPTORS; HUMAN-FIBROBLASTS; ACTIVATION; BINDING; PROTEIN	A mutated form of the platelet-derived growth factor (PDGF) beta-receptor lacking most of its cytoplasmic domain was tested for its ability to block wild-type PDGF receptor function. PDGF induced the formation of complexes consisting of wild-type and truncated receptors. Such complexes were defective in autophosphorylation. When truncated receptors were expressed in excess compared to wild-type receptors, stimulation by PDGF of receptor autophosphorylation, association of phosphatidylinositol-3 kinase with the receptor, and calcium mobilization were blocked. Thus, a truncated receptor can inactivate wild-type receptor function by forming ligand-dependent receptor complexes (probably heterodimers) that are incapable of mediating the early steps of signal transduction.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	UENO, H (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [P01 HL-43821, R01 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHU SHW, 1985, J CELL PHYSIOL, V124, P391, DOI 10.1002/jcp.1041240306; COLBERT H, UNPUB; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANTZ CN, 1985, EXP CELL RES, V158, P287, DOI 10.1016/0014-4827(85)90454-9; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, UNPUB; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	184	201	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					844	848		10.1126/science.1851331	http://dx.doi.org/10.1126/science.1851331			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851331				2022-12-01	WOS:A1991FL12300047
J	VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J				VANDUYNE, GD; STANDAERT, RF; KARPLUS, PA; SCHREIBER, SL; CLARDY, J			ATOMIC-STRUCTURE OF FKBP-FK506, AN IMMUNOPHILIN-IMMUNOSUPPRESSANT COMPLEX	SCIENCE			English	Article							PEPTIDYL-PROLYL ISOMERASE; PROTEIN; FK506	The structure of the human FK506 binding protein (FKBP), complexed with the immunosuppressant FK506, has been determined to 1.7 angstroms resolution by x-ray crystallography. The conformation of the protein changes little upon complexation, but the conformation of FK506 is markedly different in the bound and unbound forms. The drug's association with the protein involves five hydrogen bonds, a hydrophobic binding pocket lined with conserved aromatic residues, and an unusual carbonyl binding pocket. The nature of this complex has implications for the mechanism of rotamase catalysis and for the biological actions of FK506 and rapamycin.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT CHEM,BAKER LAB,ITHACA,NY 14853	Harvard University; Cornell University; Cornell University			Standaert, Robert F./AAI-1532-2021; Standaert, Robert F/D-9467-2013	Standaert, Robert F/0000-0002-5684-1322; Karplus, Paul/0000-0001-8725-6292	NATIONAL CANCER INSTITUTE [R01CA024487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24487] Funding Source: Medline; NIGMS NIH HHS [GM-38627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; FINDLAY JA, 1980, CAN J CHEM, V58, P579, DOI 10.1139/v80-090; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARUSO P, 1990, J AM CHEM SOC, V112, P9434, DOI 10.1021/ja00181a078; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; WANDLESS TJ, 1991, J AM CHEM SOC, V113, P2339, DOI 10.1021/ja00006a083	23	614	635	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					839	842		10.1126/science.1709302	http://dx.doi.org/10.1126/science.1709302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1709302				2022-12-01	WOS:A1991FL12300045
J	AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J				AHARONI, R; TEITELBAUM, D; ARNON, R; PURI, J			IMMUNOMODULATION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS BY ANTIBODIES TO THE ANTIGEN-IA COMPLEX	NATURE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; CLASS-II; T-CELLS; HISTOCOMPATIBILITY MOLECULES; IMMUNE-RESPONSE; PEPTIDE; BINDING; VACCINATION; RECOGNITION	AUTOIMMUNE diseases occur when T lymphocytes become activated on recognizing self antigen linked to the autologous class II molecule of the major histocompatibility complex (MHC) 1,2. The resulting complex of antigen MHC T-cell receptor could be a target for treatment of autoimmune diseases. Studies in which each component is blocked separately 3-10 might be limited by interference in non-relevant immune responses that either use the same set of T-cell-receptor V gene segments or are linked to the same MHC. We report here an attack by a specific antibody on the unique antigenic site formed by the binding of two components of the trimolecular complex, the autoantigen bound to the self MHC 11-14. We tested its effect in experimental allergic encephalomyelitis, an acute neurological autoimmune disease which is widely regarded as a model for autoimmune disorders 15-17 and which is mediated by CD4+ T cells recognizing myelin basic protein (BP), or its peptides, in association with self Ia 18,19. We made monoclonal antibodies which bound only the complex of BP and I-A(s). These antibodies blocked the proliferative response in vitro to the encephalitogenic determinant of BP and reduced the response to intact BP, without affecting the response to a nonrelevant antigen-purified protein derivative of tuberculin presented on syngeneic macrophages. They also inhibited experimental allergic encephalomyelitis in H-2s mice. Hence, antibodies directed specifically to the autoantigen-Ia complex, may offer a highly selective and effective treatment in autoimmune diseases.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; DEMOTZ S, 1989, 7TH P INT C IMM, P60; ESHHAR Z, 1980, J IMMUNOL, V124, P775; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FRITZ RB, 1985, J IMMUNOL, V134, P2328; HIRSHFELD H, 1970, FEBS LETT, V7, P317, DOI 10.1016/0014-5793(70)80193-4; HOHFELD R, 1989, ANN NEUROL, V25, P532; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; OFFNER H, 1986, CELL IMMUNOL, V100, P364, DOI 10.1016/0008-8749(86)90036-5; PATERSON PY, 1977, AUTOIMMUNITY, P644; PURI J, 1980, EUR J IMMUNOL, V10, P273, DOI 10.1002/eji.1830100410; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SRIRAM S, 1987, J IMMUNOL, V139, P1485; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; URBAN JL, 1989, CELL, V59, P257, DOI 10.1016/0092-8674(89)90288-2; URBAN JL, 1980, CELL, V10, P273; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	25	90	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					147	150		10.1038/351147a0	http://dx.doi.org/10.1038/351147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709449				2022-12-01	WOS:A1991FL03500051
J	AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH				AMANN, R; SPRINGER, N; LUDWIG, W; GORTZ, HD; SCHLEIFER, KH			IDENTIFICATION INSITU AND PHYLOGENY OF UNCULTURED BACTERIAL ENDOSYMBIONTS	NATURE			English	Article							PARAMECIUM-CAUDATUM; HOLOSPORA-ELEGANS; OBTUSA; PROBES; FORMS; CELLS; DNA	THE use of Koch's technique to isolate bacteria in pure cultures has enabled thousands of bacterial species to be characterized. But for the many microorganisms that have never been cultivated, DNA amplification in vitro using the polymerase chain reaction is now making their genes accessible 1-3. Here we use this technique to study bacteria of the genus Holospora, which live in ciliates 4 and whose phylogenetic relationship has remained unknown because they are impossible to cultivate. Species of Holospora are highly infectious 5-7 and live in the nuclei of their specific host cells: H. elegans and H. undulata infect micronuclei of Paramecium caudatum 8, whereas H. obtusa infects the macronucleus in other strains of the same host species 9; Holospora species have a common developmental cycle 10-13. We have amplified, cloned and sequenced gene fragments encoding ribosomal RNA of H. obtusa. The phylogenetic position of H. obtusa in the alpha-group of Proteobacteria was determined by 16S rRNA sequence analysis. The sequences were then used to design species- as well as genus-specific rRNA hybridization probes, which enabled us to detect and differentiate individual cells of the endosymbionts in situ. The large amount of rRNA in the cells indicates a high physiological activity of the endosymbionts in the host nuclei.	UNIV MUNSTER,INST ZOOL,W-4400 MUNSTER,GERMANY	University of Munster	AMANN, R (corresponding author), TECH UNIV MUNICH,LEHRSTUHL MIKROBIOL,ARCISSTR 21,W-8000 MUNICH 2,GERMANY.		Amann, Rudolf I/C-6534-2014	Amann, Rudolf I/0000-0002-0846-7372				AMANN RI, 1990, J BACTERIOL, V172, P762, DOI 10.1128/jb.172.2.762-770.1990; AMANN RI, 1990, APPL ENVIRON MICROB, V56, P1919, DOI 10.1128/AEM.56.6.1919-1925.1990; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELONG EF, 1989, SCIENCE, V243, P1360, DOI 10.1126/science.2466341; DRYDEN SC, 1990, NUCLEIC ACIDS RES, V18, P7267, DOI 10.1093/nar/18.24.7267; EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; FUJISHIMA M, 1990, ZOOL SCI, V7, P849; GIOVANNONI SJ, 1990, NATURE, V345, P60, DOI 10.1038/345060a0; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P720, DOI 10.1128/jb.170.2.720-726.1988; GORTZ HD, 1990, J BACTERIOL, V172, P5664; GORTZ HD, 1980, PROTISTOLOGICA, V16, P591; GORTZ HD, 1989, J GEN MICROBIOL, V135, P3079; GORTZ HD, 1986, INT REV CYTOL, V102, P169, DOI 10.1016/S0074-7696(08)61275-9; GROMOV BV, 1981, INT J SYST BACTERIOL, V31, P348, DOI 10.1099/00207713-31-3-348; Hafkine M. -W., 1890, ANN I PASTEUR, V4, P148; Holt, 1984, BERGEYS MANUAL SYSTE, P795; HORI H, 1979, P NATL ACAD SCI USA, V76, P381, DOI 10.1073/pnas.76.1.381; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OSSIPOV D V, 1975, Acta Protozoologica, V14, P263; PREER JR, 1984, INT J SYST BACTERIOL, V32, P140; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHMIDT HJ, 1987, MICROBIOS, V49, P189; SCHMIDT HJ, 1985, MICROBIOS, V4, P165; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782, DOI 10.1128/AEM.56.3.782-787.1990; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	287	295	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					161	164		10.1038/351161a0	http://dx.doi.org/10.1038/351161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709451				2022-12-01	WOS:A1991FL03500056
J	BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM				BARTOLOMEI, MS; ZEMEL, S; TILGHMAN, SM			PARENTAL IMPRINTING OF THE MOUSE H19 GENE	NATURE			English	Article							EXPRESSION; EVOLUTION; RNA	THE mouse H19 gene encodes one of the most abundant RNAs in the developing mouse embryo 1. It is expressed at the blastocyst stage of development, and accumulates to high levels in tissues of endodermal and mesodermal origin (H. Kim, unpublished result). After birth the gene is repressed in all tissues except skeletal muscle. It lacks a common open reading frame in the 2.5-kilobase RNA, but has considerable nucleotide sequence similarity between the genes of rodents and humans 2,3. Expression of the gene in transgenic mice results in late prenatal lethality, suggesting that the dosage of its gene product is strictly controlled 4. The H19 gene maps to the distal segment of mouse chromosome 7, in a region that is parentally imprinted 5, a process by which genes are differentially expressed on the maternal and paternal chromosomes. We have now used an RNase protection assay that can distinguish between H19 alleles in four subspecies of Mus, to demonstrate that the H19 gene is parentally imprinted, with the active copy derived from the mother. This assay will be of general use in assaying allele-specific gene expression.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	BARTOLOMEI, MS (corresponding author), PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BONHOMME F, 1984, BIOCHEM GENET, V22, P275, DOI 10.1007/BF00484229; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, IN PRESS GENES DEV; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVISSON MT, 1988, MOUSE NEWS LETT, V81, P12; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAMMER MF, 1989, P NATL ACAD SCI USA, V86, P3261, DOI 10.1073/pnas.86.9.3261; LYON MF, 1988, AM J HUM GENET, V42, P8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SEARLE AG, 1990, GENET RES, V56, P237, DOI 10.1017/S0016672300035333; SEARLE AG, 1985, ANEUPLOIDY ETIOLOGY, P363; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	23	969	997	0	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					153	155		10.1038/351153a0	http://dx.doi.org/10.1038/351153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709450				2022-12-01	WOS:A1991FL03500053
J	BINETRUY, B; SMEAL, T; KARIN, M				BINETRUY, B; SMEAL, T; KARIN, M			HA-RAS AUGMENTS C-JUN ACTIVITY AND STIMULATES PHOSPHORYLATION OF ITS ACTIVATION DOMAIN	NATURE			English	Article							TRANSCRIPTION FACTOR AP-1; PROTO-ONCOGENE; MOUSE FIBROBLASTS; GENE-EXPRESSION; TRANSFORMATION; INTERACTS; ENCODES; ELEMENT; PRODUCT; CELLS	Ha-Ras augments c-Jun-mediated transactivation by potentiating the activity of the c-Jun activation domain. Ha-Ras also causes a corresponding increase in phosphorylation of specific sites in that part of the c-Jun protein. A Ha-Ras-induced protein kinase cascade resulting in hyperphosphorylation of the c-Jun activation domain could explain how these oncoproteins cooperate to transform rat embryo fibroblasts.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, 0636, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009	Binetruy, Bernard/0000-0001-8012-7092; 				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DOTTO GP, 1985, NATURE, V318, P472; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCCORMICK F, 1989, ONCOGENES MOL ORIGIN, P125; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RADLER-POHL A, 1990, New Biologist, V2, P566; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YANG-YEN H-F, 1990, New Biologist, V2, P351; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	50	621	640	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					122	127		10.1038/351122a0	http://dx.doi.org/10.1038/351122a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903181				2022-12-01	WOS:A1991FL03500041
J	BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE				BRIDGES, ND; PERRY, SB; KEANE, JF; GOLDSTEIN, SAN; MANDELL, V; MAYER, JE; JONAS, RA; CASTENEDA, AR; LOCK, JE			PREOPERATIVE TRANSCATHETER CLOSURE OF CONGENITAL MUSCULAR VENTRICULAR SEPTAL-DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE; MULTIPLE	Background. Surgical repair of muscular ventricular septal defects, particularly those associated with complex heart lesions, carries a higher risk of reoperation and death than the repair of membranous defects. Closing a muscular defect through an incision in the systemic ventricle may cause late ventricular dysfunction. In a collaborative approach to this problem, we undertook preoperative transcatheter closure of muscular ventricular septal defects remote from the atrioventricular and semilunar valves, followed by the surgical repair of associated conditions. Methods. In 12 patients selected jointly by a cardiologist and a cardiac surgeon, we attempted preoperative transcatheter umbrella closure of 21 defects. Half the patients had associated complex heart lesions; the others had had pulmonary-artery banding to reduce the amount of left-to-right shunting. Half had severe ventricular septal deficiency. Results. All 21 defects were successfully closed without major complications. Subsequent cardiac surgery for associated conditions in 11 of the 12 patients resulted in a mean pulmonary-to-systemic flow ratio of 1.1, indicating minimal residual left-to-right shunting; 1 patient awaited surgical repair. No deaths, reoperations, or late complications have occurred after a follow-up of 7 to 20 months. Conclusions. A collaborative approach using transcatheter closure followed by the surgical repair of associated cardiac lesions may decrease rates of operative mortality, reoperation, and left ventricular dysfunction in patients with muscular ventricular septal defects.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT CARDIOVASC SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			miaoyue, chen/A-6575-2012; Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				Breckenridge I M, 1972, Ann Thorac Surg, V13, P128; BRIDGES ND, 1990, CIRCULATION, V82, P1681, DOI 10.1161/01.CIR.82.5.1681; Elliott L P, 1977, Circulation, V56, P1048; FELLOWS KE, 1977, CIRCULATION, V56, P485, DOI 10.1161/01.CIR.56.3.485; FOX KM, 1978, BRIT HEART J, V40, P141; FRIEDMAN WF, 1965, CIRCULATION, V32, P35, DOI 10.1161/01.CIR.32.1.35; GRIFFITHS SP, 1981, AM J CARDIOL, V48, P877, DOI 10.1016/0002-9149(81)90353-2; HANNA B, 1991, Journal of the American College of Cardiology, V17, p110A; KIRKLIN JK, 1980, J THORAC CARDIOVASC, V80, P458; KIRKLIN JW, 1986, CARDIAC SURG MORPHOL, P637; LOCK JE, 1988, CIRCULATION, V78, P361, DOI 10.1161/01.CIR.78.2.361; LOCK JE, 1989, CIRCULATION, V79, P1091, DOI 10.1161/01.CIR.79.5.1091; OLAUGHLIN MP, 1989, CATHETER CARDIO DIAG, V17, P175, DOI 10.1002/ccd.1810170311; RIZZOLI G, 1980, J THORAC CARDIOV SUR, V80, P494; RIZZOLI G, 1983, THORAC CARDIOV SURG, V31, P382, DOI 10.1055/s-2007-1022024; ROME JJ, 1990, CIRCULATION, V82, P751, DOI 10.1161/01.CIR.82.3.751; ROME JJ, 1988, CIRCULATION S2, V78, P291; SINGH AK, 1977, ANN SURG, V186, P577, DOI 10.1097/00000658-197711000-00006; TAYLOR JFN, 1971, BRIT HEART J, V33, P285; VANPRAAGH R, 1977, CIRCULATION, V56, P139, DOI 10.1161/01.CIR.56.2.139; VANPRAAGH R, 1978, HEART DISEASE INFANC, P68; WALDHAUSEN JA, 1964, SURGERY, V56, P868; ZAVANELLA C, 1977, ANN THORAC SURG, V24, P537, DOI 10.1016/S0003-4975(10)63453-4	23	116	124	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1312	1317		10.1056/NEJM199105093241903	http://dx.doi.org/10.1056/NEJM199105093241903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017227	Green Published			2022-12-01	WOS:A1991FK18600003
J	CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA				CHARNAS, LR; BERNARDINI, I; RADER, D; HOEG, JM; GAHL, WA			CLINICAL AND LABORATORY FINDINGS IN THE OCULOCEREBRORENAL SYNDROME OF LOWE, WITH SPECIAL REFERENCE TO GROWTH AND RENAL-FUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE CONCENTRATION; HIGH-DENSITY-LIPOPROTEIN; FANCONI SYNDROME; LENS EXAMINATION; CARNITINE; DISEASE; CYSTINOSIS; CHILDREN; PROGRESSION; DEFICIENCY	Background. The oculocerebrorenal syndrome of Lowe is an X-linked disorder whose clinical manifestations include congenital cataracts, mental retardation, and renal tubular dysfunction. We investigated growth, renal function, and serum chemistry values in patients with the oculocerebrorenal syndrome to determine the natural history of the disorder and its heterogeneity with respect to these characteristics. Methods. Twenty-three patients with the oculocerebrorenal syndrome, ranging in age from 4 months to 31 years, were examined. Height was compared with bone age. Renal function was assessed by measurements of proteinuria, urinary volume, and fractional excretions of potassium, phosphate, carnitine, and amino acids. Creatinine clearance was determined as a measure of glomerular function. Results. In the oculocerebrorenal syndrome, linear growth decreases after one year of age; bone age lies between chronologic age and height age. Renal dysfunction occurs in the first year of life, characterized by proteinuria (mean [+/- SD], 1.38 +/- 0.77 g of urinary protein per square meter of body-surface area per day; normal, less-than-or-equal-to 0.10), generalized aminoaciduria (mean, 686 +/- 505-mu-mol of urinary amino acid per kilogram of body weight per day; normal, 94 +/- 45), carnitine wasting (mean fractional excretion, 0.10 +/- 0.05; normal, 0.03 +/- 0.01), and phosphaturia progressing into the third decade. Urinary wasting of individual amino acids is milder than in cystinosis, and branched-chain amino acids are relatively spared. Reciprocal serum creatinine levels fall linearly with age, predicting renal failure in the fourth decade. Concentrations of the muscle enzymes creatine kinase, aspartate aminotransferase, and lactate dehydrogenase, as well as of total serum protein, serum alpha-2-globulin, and high-density lipoprotein cholesterol, are elevated. Conclusions. Renal glomerular deterioration is slowly progressive in the oculocerebrorenal syndrome. Renal tubular dysfunction begins early and persists; most patients require alkalinization therapy, and many benefit from supplemental potassium, phosphate, calcium, or carnitine. Serum enzyme elevations suggest muscle involvement in the oculocerebrorenal syndrome.	NICHHD,HUMAN GENET BRANCH,HUMAN BIOCHEM GENET SECT,BLDG 10,RM 9S242,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; NICHHD,HUMAN GENET BRANCH,NEUROGENET UNIT,BETHESDA,MD 20892; NHLBI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ABBASSI VALIOLLAH, 1968, AMER J DIS CHILD, V115, P145; ABITBOL C, 1990, J PEDIATR-US, V116, P243, DOI 10.1016/S0022-3476(05)82881-1; ADAMSON MD, 1989, SEMIN NEPHROL, V9, P147; ARBUS GS, 1981, PEDIATRICS, V67, P871; ATHREYA BH, 1983, ARTHRITIS RHEUM, V26, P728, DOI 10.1002/art.1780260605; ATTREE O, 1990, AM J HUM GENET SA244, V47; BANERJEE AK, 1982, IRISH J MED SCI, V15, P42; BERNARDINI I, 1985, J CLIN INVEST, V75, P1124, DOI 10.1172/JCI111806; BREMER HJ, 1981, DISTURBANCES AMINO A; CHARNAS L, 1988, NEUROPEDIATRICS, V19, P7, DOI 10.1055/s-2008-1052393; CHUTORIAN A, 1966, NEUROLOGY, V16, P115, DOI 10.1212/WNL.16.2_Part_1.115; CIBIS GW, 1986, OPHTHALMOLOGY, V93, P1041; DELLEMAN JW, 1977, J PEDIATR OPHTHALMOL, V14, P205; ELLIMAN D, 1983, J PEDIATR-US, V103, P1011, DOI 10.1016/S0022-3476(83)80759-8; FISHER DA, 1977, J CLIN ENDOCR METAB, V45, P191, DOI 10.1210/jcem-45-2-191; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1988, ANN INTERN MED, V109, P557, DOI 10.7326/0003-4819-109-7-557; GAHL WA, 1988, J CLIN INVEST, V81, P549, DOI 10.1172/JCI113353; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GARDNER RJM, 1976, J MED GENET, V13, P449, DOI 10.1136/jmg.13.6.449; GARZULY F, 1973, NEUROPADIATRIE, V4, P304, DOI 10.1055/s-0028-1091747; Gellis S S, 1972, Am J Dis Child, V124, P891; GINSBERG J, 1981, J PEDIAT OPHTH STRAB, V18, P16; GOBERNADO JM, 1984, ARCH NEUROL-CHICAGO, V41, P208, DOI 10.1001/archneur.1984.04050140106037; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORMAN LS, 1985, CLIN CHEM PRINCIPLES, P354; Haldane JBS, 1935, J GENET, V31, P317, DOI 10.1007/BF02982403; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HOEG JM, 1984, CLIN PHARMACOL THER, V36, P555, DOI 10.1038/clpt.1984.219; HOLTGREWE JL, 1986, J PEDIATR ORTHOPED, V6, P165, DOI 10.1097/01241398-198603000-00009; KIERAS FJ, 1984, BIOCHEM MED METAB B, V31, P201, DOI 10.1016/0006-2944(84)90024-3; KOHYAMA J, 1989, PEDIATR NEUROL, V5, P373, DOI 10.1016/0887-8994(89)90052-0; KORNFELD M, 1975, ARCH NEUROL-CHICAGO, V32, P103, DOI 10.1001/archneur.1975.00490440053008; LACHAUX A, 1986, ARCH FR PEDIATR, V43, P68; LEUMANN EP, 1978, HELV PAEDIATR ACTA, V33, P25; LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/archpedi.1952.02040060030004; MATIN MA, 1980, J MENT DEFIC RES, V24, P1; MCGARRY JD, 1976, J LIPID RES, V17, P277; PAPADOPOULOS NM, 1989, CLIN CHEM, V35, P2231; REBOUCHE CJ, 1983, MAYO CLIN PROC, V58, P533; REIMOLD EW, 1981, AM J DIS CHILD, V135, P1039, DOI 10.1001/archpedi.1981.02130350039013; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; ROSENBLATT D, 1974, J PEDIATR-US, V84, P924, DOI 10.1016/S0022-3476(74)80819-X; RUTHERFORD WE, 1977, KIDNEY INT, V11, P62, DOI 10.1038/ki.1977.8; SEPPALA R, 1990, LAB INVEST, V63, P197; SILVER DN, 1987, J CLIN INVEST, V79, P282, DOI 10.1172/JCI112795; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TRIPATHI RC, 1986, OPHTHALMOLOGY, V93, P1046; WADELIUS C, 1989, AM J HUM GENET, V44, P241; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WITZLEBEN CL, 1968, AM J MED, V44, P319, DOI 10.1016/0002-9343(68)90163-0; YAMASHINA I, 1983, MOL CELL BIOCHEM, V52, P107; YOSHIDA R, 1982, BIOCHEM BIOPH RES CO, V107, P1144; 1980, NIH81527 NAT HEART L	55	84	88	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1318	1325		10.1056/NEJM199105093241904	http://dx.doi.org/10.1056/NEJM199105093241904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017228				2022-12-01	WOS:A1991FK18600004
J	DIFRANCESCO, D; TORTORA, P				DIFRANCESCO, D; TORTORA, P			DIRECT ACTIVATION OF CARDIAC-PACEMAKER CHANNELS BY INTRACELLULAR CYCLIC-AMP	NATURE			English	Article							SINO-ATRIAL NODE; DEPENDENT PROTEIN-KINASE; CURRENT IF; PHOSPHORYLATION; MYOCYTES; MODULATION; NEURONS; HEART; ACETYLCHOLINE; CONDUCTANCE	CYCLIC AMP acts as a second messenger in the modulation of several ion channels 1-9 that are typically controlled by a phosphorylation process 10. In cardiac pacemaker cells, adrenaline and acetylcholine regulate the hyperpolarization-activated current (i(f)), but in opposite ways; this current is involved in the generation and modulation of pacemaker activity 11. These actions are mediated by cAMP and underlie control of spontaneous rate by neurotransmitters 12-17. Whether the cAMP modulation of i(f) is mediated by channel phosphorylation is, however, still unknown. Here we investigate the action of cAMP on i(f) in excised patches of cardiac pacemaker cells and find that cAMP activates i(f) by a mechanism independent of phosphorylation, involving a direct interaction with the channels at their cytoplasmic side. Cyclic AMP activates i(f) by shifting its activation curve to more positive voltages, in agreement with whole-cell results. This is the first evidence of an ion channel whose gating is dually regulated by voltage and direct cAMP binding.			DIFRANCESCO, D (corresponding author), UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,VIA CELORIA 26,I-20133 MILAN,ITALY.		DiFrancesco, Dario/G-8408-2017	DiFrancesco, Dario/0000-0002-7322-1790; Tortora, Paolo/0000-0001-5234-601X				BOBKER DH, 1989, NEURON, V2, P1535, DOI 10.1016/0896-6273(89)90041-X; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; CHANG F, 1990, BIOPHYS J, V57, pA141; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P477, DOI 10.1113/jphysiol.1988.sp017343; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1985, PROG BIOPHYS MOL BIO, V46, P163, DOI 10.1016/0079-6107(85)90008-2; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; JAYNES LW, 1986, NATURE, V317, P61; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PAPE HC, 1989, NATURE, V340, P715, DOI 10.1038/340715a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0; TERESAKI WL, 1977, J BIOL CHEM, V252, P1041; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; TSIEN RW, 1974, J GEN PHYSIOL, V64, P293, DOI 10.1085/jgp.64.3.293; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	30	655	668	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					145	147		10.1038/351145a0	http://dx.doi.org/10.1038/351145a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1709448				2022-12-01	WOS:A1991FL03500050
J	EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM				EZEKOWITZ, RAB; WILLIAMS, DJ; KOZIEL, H; ARMSTRONG, MYK; WARNER, A; RICHARDS, FF; ROSE, RM			UPTAKE OF PNEUMOCYSTIS-CARINII MEDIATED BY THE MACROPHAGE MANNOSE RECEPTOR	NATURE			English	Article							INVITRO; ZYMOSAN; PHAGOCYTOSIS	HUMAN exposure to Pneumocystis carinii is common 1,2 but, in the absence of acquired 3 or genetic 4 dysfunction of either cellular or humoral immunity, exposure rarely leads to illness. Although alveolar macrophages can degrade P. carinii 5,6, macrophage receptors involved in P. carinii recognition have not been clearly defined. Characterization of a predominant surface glycoprotein of the high mannose type 7,8 led us to investigate the role of the macrophage mannose receptor in this process. We report here that binding and uptake of cultured rat P. carinii by human and rat alveolar macrophages is reduced by 90% in the presence of competitive inhibitors of mannose receptor activity and by adherence of alveolar macrophages to mannan-coated surfaces. Further, only those COS cells transfected with the human macrophage mannose receptor complementary DNA that express surface mannose receptors bind and ingest P. carinii. These studies establish that the macrophage mannose receptor is sufficient for uptake of P. carinii and emphasize the role of the alveolar macrophage in first-line host defence against P. carinii.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MACARTHUR CTR MOLE PARASITOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT INTERNAL MED, PULM & CRIT CARE SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV PULM & CRIT CARE MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT RESP BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	EZEKOWITZ, RAB (corresponding author), CHILDRENS HOSP MED CTR, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA.							ARMSTRONG MYK, 1989, J PROTOZOOL, V36, pS24, DOI 10.1111/j.1550-7408.1989.tb05816.x; BERTON G, 1983, IMMUNOLOGY, V49, P705; EZEKOWITZ RAB, 1985, J CLIN INVEST, V76, P2368, DOI 10.1172/JCI112249; EZEKOWITZ RAB, 1988, J CELL SCI, P121; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; EZEKOWITZ RAB, 1989, NAT IMMUN, P15; HARMSEN AG, 1990, J EXP MED, V172, P937, DOI 10.1084/jem.172.3.937; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; MASUR H, 1978, J EXP MED, V147, P157, DOI 10.1084/jem.147.1.157; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MEUWISSEN JHET, 1977, J INFECT DIS, V136, P43, DOI 10.1093/infdis/136.1.43; MURRAY JF, 1987, AM REV RESPIR DIS, V135, P504; NAKAMURA Y, 1989, J PROTOZOOL, V36, pS58, DOI 10.1111/j.1550-7408.1989.tb05832.x; PIFER LL, 1978, PEDIATRICS, V61, P35; POTTRATZ ST, 1990, J CLIN INVEST, V86, P1678, DOI 10.1172/JCI114891; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; RADDING JA, 1989, INFECT IMMUN, V57, P2149, DOI 10.1128/IAI.57.7.2149-2157.1989; SHELLITO J, 1990, J CLIN INVEST, V85, P1686, DOI 10.1172/JCI114621; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VONBEHREN LA, 1978, AM REV RESPIR DIS, V118, P1051	21	374	379	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1991	351	6322					155	158		10.1038/351155a0	http://dx.doi.org/10.1038/351155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903183				2022-12-01	WOS:A1991FL03500054
J	GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F				GRISSO, JA; KELSEY, JL; STROM, BL; CHIU, GY; MAISLIN, G; OBRIEN, LA; HOFFMAN, S; KAPLAN, F			RISK-FACTORS FOR FALLS AS A CAUSE OF HIP FRACTURE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; NHANES-I; OSTEOPOROSIS; WEIGHT; FEMUR; ESTROGENS	Background. Although even in the elderly most falls are not associated with fractures, over 90 percent of hip fractures are the result of a fall. Few studies have assessed whether the risk factors for falls are also important risk factors for hip fracture. Methods. To examine the importance of risk factors for falls in the epidemiology of hip fracture, we performed a case-control study of 174 women (median age, 80 years) admitted with a first hip fracture to 1 of 30 hospitals in New York and Philadelphia. Controls, matched to the case patients according to age and hospital, were selected from general surgical and orthopedic surgical hospital services. Information was obtained by direct interview. Results. As measured by the odds ratio, increased risks for hip fracture were associated with lower-limb dysfunction (odds ratio = 1.7; 95 percent confidence interval, 1.1 to 2.8), visual impairment (odds ratio = 5.1; 95 percent confidence interval, 1.9 to 13.9), previous stroke (odds ratio = 2.0; 95 percent confidence interval, 1.0 to 4.0), Parkinson's disease (odds ratio = 9.4; 95 percent confidence interval, 1.2 to 76.1), and use of long-acting barbiturates (odds ratio = 5.2; 95 percent confidence interval, 0.6 to 45.0). Of the controls, 44 (25 percent) had had a recent fall. The case patients were more likely than these controls to have fallen from a standing height or higher (odds ratio = 2.4; 95 percent confidence interval, 1.0 to 5.7). Of those with hip fracture the younger patients (< 75 years old) were more likely than the older ones (greater-than-or-equal-to 75 years old) to have fallen on a hard surface (odds ratio = 1.9; 95 percent confidence interval, 1.04 to 3.7). Conclusions. A number of factors that have been identified as risk factors for falls are also associated with hip fracture, including lower-limb dysfunction, neurologic conditions, barbiturate use, and visual impairment. Given the prevalence of these problems among the elderly, who are at highest risk, programs to prevent hip fracture should include measures to prevent falls in addition to measures to slow bone loss.	COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; HOSP UNIV PENN,DEPT ORTHOPED,PHILADELPHIA,PA 19104	Columbia University; University of Pennsylvania; Pennsylvania Medicine	GRISSO, JA (corresponding author), UNIV PENN,SCH MED,CLIN EPIDEMIOL UNIT,GEN INTERNAL MED SECT,317R NURSING EDUC BLDG,420 SERV DR,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035409] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR35409] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALFFRAM PER-AXEL, 1964, ACTA ORTHOPAED SCAND SUPPL, V65, P1; [Anonymous], 1982, EPIDEMIOLOGIC RES; BASTOW MD, 1983, LANCET, V1, P143; BRESLOW NE, 1980, IARC SCI PUBL, V32, P373; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; CLARK ANG, 1968, GERONTOL CLIN, V10, P257, DOI 10.1159/000245191; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; FELSON DT, 1988, AM J EPIDEMIOL, V128, P1102; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; FLOREY CDV, 1970, J CHRON DIS, V23, P93; HERZOG AR, 1988, J GERONTOL, V43, pS200, DOI 10.1093/geronj/43.6.S200; HUTCHINSON TA, 1979, LANCET, V2, P705; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAYE JM, 1990, GERONTOLOGIST, V30, P100, DOI 10.1093/geront/30.1.100; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOLLER WC, 1989, CLIN NEUROPHARMACOL, V12, P98; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623-199072050-00008; MELTON LJ, 1987, OSTEOPOROTIC SYNDROM, P45; MICOZZI MS, 1986, AM J CLIN NUTR, V44, P725, DOI 10.1093/ajcn/44.6.725; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Schlesselman J.J., 1982, CASE CONTROL STUDIES; TAGGART HM, 1988, J AM GERIATR SOC, V36, P1006, DOI 10.1111/j.1532-5415.1988.tb04367.x; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WALLACE RB, 1987, PHS881214 DEP HLTH H, P423; WILLIAMS AR, 1982, OBSTET GYNECOL, V60, P695; WOOTTON R, 1979, CLIN SCI, V57, P93, DOI 10.1042/cs0570093; Wootton R, 1982, Age Ageing, V11, P160, DOI 10.1093/ageing/11.3.160; WYSHAK G, 1981, J GERONTOL, V36, P424, DOI 10.1093/geronj/36.4.424; [No title captured]	41	644	665	1	42	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1326	1331		10.1056/NEJM199105093241905	http://dx.doi.org/10.1056/NEJM199105093241905			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK186	2017229				2022-12-01	WOS:A1991FK18600005
J	HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG				HANDFORD, PA; MAYHEW, M; BARON, M; WINSHIP, PR; CAMPBELL, ID; BROWNLEE, GG			KEY RESIDUES INVOLVED IN CALCIUM-BINDING MOTIFS IN EGF-LIKE DOMAINS	NATURE			English	Article							BETA-HYDROXYASPARTIC ACID; EPIDERMAL GROWTH-FACTOR; HUMAN FACTOR-IX; NUCLEOTIDE-SEQUENCE; PROTEIN; GENE; HOMOLOGY; REPEATS; SITE	MANY extracellular proteins with diverse functions contain domains similar to epidermal growth factor (EGF), a number of which have a consensus Asp/Asn, Asp/Asn, Asp*/Asn*, Tyr/Phe (where the asterisk denotes a beta-hydroxylated residue) 1. These include the coagulation factors IX and X, proteins with two EGF-like domains, the first of which contains the consensus residues 2. The first EGF-like domain of human factor IX contains a calcium-binding site, which is believed to be responsible for one of the high-affinity sites detected in this protein 3. Similar results have been obtained for bovine factor X 4. We have now used protein engineering and H-1-NMR techniques to investigate the importance of individual consensus residues for ligand binding. Measurement of a calcium-dependent Tyr 69 shift 3 in the isolated first EGF-like domain from human factor IX demonstrates that Asp 47, Asp 49, and Asp 64 are directly involved in this binding. Gln 50, whose importance has previously been overlooked, is also involved in this binding. Two mutations 5 in this domain, Asp 47 --> Glu, and Asp 64 --> Asn, present in patients with haemophilia B, reduce calcium binding to the domain > 4-fold and > 1,000-fold, respectively. Furthermore, the defective calcium binding of Asn 64 can be partially rescued by the compensatory mutation Gln 50 --> Glu. This latter mutation, when introduced singly more than doubles the affinity of the domain for calcium. This study thus defines residues involved in a new type of calcium-binding site and provides strong circumstantial evidence for calcium-binding motifs in many extracellular proteins, including the developmentally important proteins of Drosophila, notch, delta and crumbs 1,6-8.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3RE,ENGLAND; UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3RE,ENGLAND	University of Oxford; University of Oxford	HANDFORD, PA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.							BARON M, 1990, THESIS U OXFORD; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERNLUND P, 1983, J BIOL CHEM, V258, P2509; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; JAENICKE R, 1989, PROTEIN STRUCTURE PR, P208; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NISHIMURA H, 1989, THROMB HAEMOSTASIS, V62, P17; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	22	273	276	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					164	167		10.1038/351164a0	http://dx.doi.org/10.1038/351164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030732				2022-12-01	WOS:A1991FL03500057
J	KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R				KOOPMAN, P; GUBBAY, J; VIVIAN, N; GOODFELLOW, P; LOVELLBADGE, R			MALE DEVELOPMENT OF CHROMOSOMALLY FEMALE MICE TRANSGENIC FOR SRY	NATURE			English	Article							TESTIS-DETERMINING GENE; SEX-REVERSED MICE; Y-CHROMOSOME; MOUSE; DUPLICATION; EXPRESSION	The initiation of male development in mammals requires one or more genes on the Y chromosome. A recently isolated gene, termed SRY in humans and Sry in mouse, has many of the genetic and biological properties expected of a Y-located testis-determining gene. It is now shown that Sry on a 14-kilobase genomic DNA fragment is sufficient to induce testis differentiation and subsequent male development when introduced into chromosomally female mouse embryos.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,LONDON WC2A 3PX,ENGLAND	MRC National Institute for Medical Research; Cancer Research UK			Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BETA P, 1990, NATURE, V348, P448; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1988, DEVELOPMENT, V102, P443; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; EICHER EM, 1988, PHILOS T R SOC B, V322, P109, DOI 10.1098/rstb.1988.0118; EICHER EM, 1980, CYTOGENET CELL GENET, V28, P104, DOI 10.1159/000131518; ELLIS NA, 1989, NATURE, V337, P81, DOI 10.1038/337081a0; FORD CE, 1959, LANCET, V1, P711; FREDGA K, 1988, PHILOS T R SOC B, V322, P83, DOI 10.1098/rstb.1988.0116; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1990, DEVELOPMENT, V109, P647; Hogan B., 1986, MANIPULATING MOUSE E; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JAGER RJ, 1990, HUM GENET, V85, P666; Josso N., 1981, Mechanisms of sex differentiation in animals and man., P165; JOST A, 1988, PHILOS T ROY SOC B, V322, P55, DOI 10.1098/rstb.1988.0113; Jost A., 1973, Recent Progress Hormone Res, V29, P1; Jost A, 1947, ARCH ANAT MICR MORPH, P271; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P153; Maniatis T., 1982, MOL CLONING; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCLAREN A, 1982, NATURE, V300, P446, DOI 10.1038/300446a0; MCLAREN A, 1988, PHILOS T ROY SOC B, V322, P3, DOI 10.1098/rstb.1988.0109; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; PALMER SJ, 1991, DEVELOPMENT, V111, P1017; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6646; SCHERER G, 1989, HUM GENET, V81, P291; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; WELSHONS W. J., 1959, PROC NATL ACAD SCI, V45, P560, DOI 10.1073/pnas.45.4.560; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; [No title captured]	42	1678	1763	1	123	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					117	121		10.1038/351117a0	http://dx.doi.org/10.1038/351117a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	2030730				2022-12-01	WOS:A1991FL03500040
J	ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S				ROSSI, G; JIANG, Y; NEWMAN, AP; FERRONOVICK, S			DEPENDENCE OF YPT1 AND SEC4 MEMBRANE ATTACHMENT ON BET2	NATURE			English	Article							RAS PROTEINS; YEAST; SECRETION; BINDING; SUPPRESSION; MUTANTS; GENES	MANY small GTP-binding proteins are synthesized as soluble proteins that are post-translationally modified as a prerequisite for membrane attachment 1. Ypt1 and Sec4 are homologous Raslike GTP-binding proteins that have been proposed to regulate the specificity of vesicular traffic at different stages of the secretory pathway by cycling on and off membranes 2-6. Here we show that BET2, initially identified as a gene required for transport from endoplasmic reticulum to Golgi apparatus in yeast 7, encodes a factor that is needed for the membrane attachment of Ypt1 and Sec4. DNA sequence analysis has revealed that Bet2 is homologous to Dpr1 (Ram1), an essential component of a protein prenyltransferase that modifies Ras 8, enabling it to attach to membranes 9,10. We propose that Bet2 modifies Ypt1 and Sec4 in an analogous manner.	YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GROESCH ME, 1990, J CELL BIOL, V111, P45, DOI 10.1083/jcb.111.1.45; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; PETERSENBJORN S, 1990, YEAST, V6, P345, DOI 10.1002/yea.320060407; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUOHOLA H, 1988, J CELL BIOL, V107, P1456; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	25	103	106	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					158	161		10.1038/351158a0	http://dx.doi.org/10.1038/351158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903184				2022-12-01	WOS:A1991FL03500055
J	SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P				SWAT, W; IGNATOWICZ, L; VONBOEHMER, H; KISIELOW, P			CLONAL DELETION OF IMMATURE CD4+8+ THYMOCYTES IN SUSPENSION-CULTURE BY EXTRATHYMIC ANTIGEN-PRESENTING CELLS	NATURE			English	Article							TRANSGENIC MICE; T-CELLS; TOLERANCE; RECEPTOR; THYMUS	ONE mechanism ensuring self tolerance of T cells is the clonal deletion of thymocytes bearing alpha-beta T-cell receptors 1-4. The stage of thymocyte development at which the interaction with antigen-presenting cells (APCs) leads to deletion, however, has not been determined directly. Indirect evidence suggests that intrathymic APCs induce deletion of CD4+8+ thymocytes 3-6 (which die by apoptosis 7) but deletion at less 8 and more mature 9 developmental stages has also been implied. It is also not clear if clonal elimination of thymocytes can be triggered by peripheral antigens carried on extrathymic APCs migrating through the thymus 10. Here we show antigen-specific induction of apoptosis in CD4+8+ thymocytes cultured in suspension, by thymic as well as splenic APCs. Thus the recognition of antigen by CD4+8+ thymocytes may lead to deletion, suggesting that this is the central mechanism of tolerance induction, which is not limited by the antigen-presenting ability of the thymic stroma.	POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,UL CZERSKA 12,PL-53114 WROCLAW,POLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences								CEREDIG R, 1983, J EXP MED, V158, P1654, DOI 10.1084/jem.158.5.1654; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LONGO DL, 1980, NATURE, V287, P44, DOI 10.1038/287044a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1988, NATURE, V335, P174, DOI 10.1038/335174a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	18	268	269	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1991	351	6322					150	153		10.1038/351150a0	http://dx.doi.org/10.1038/351150a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL035	1903182				2022-12-01	WOS:A1991FL03500052
J	VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A				VANHOOFT, IMS; GROBBEE, DE; DERKX, FHM; DELEEUW, PW; SCHALEKAMP, MADH; HOFMAN, A			RENAL HEMODYNAMICS AND THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM IN NORMOTENSIVE SUBJECTS WITH HYPERTENSIVE AND NORMOTENSIVE PARENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CALCIUM ENTRY BLOCKADE; BLOOD-PRESSURE; RESPONSES; PLASMA; RADIOIMMUNOASSAY; TRANSPLANTATION; PREDICTION; PRORENIN; FAILURE	Background and Methods. The kidney is important in blood-pressure regulation, but its role in the development of essential hypertension is still subject to debate. We compared renal hemodynamics, measured in terms of the clearance of para-aminohippuric acid and inulin, and the characteristics of the renin-angiotensin-aldosterone system in three groups of normotensive subjects at different degrees of risk for hypertension: 41 subjects with two normotensive parents, 52 with one normotensive and one hypertensive parent, and 61 with two hypertensive parents. The subjects ranged in age from 7 to 32 years. Results. The mean renal blood flow was lower in the subjects with two hypertensive parents than in those with two normotensive parents (mean difference [+/- SE], 198 +/- 61 ml per minute per 1.73 m2 of body-surface area; P = 0.002). Moreover, both the filtration fraction and renal vascular resistance were higher in the subjects with two hypertensive parents (filtration fraction: mean difference, 3.0 +/- 1.1 percentage points; P = 0.006; renal vascular resistance: mean difference, 2.7 +/- 0.8 mm Hg per deciliter per minute per 1.73 m2; P = 0.006). The subjects with two hypertensive parents had lower plasma concentrations of renin (mean difference, 3.3 +/- 1.6 mU per liter; P = 0.03) and aldosterone (mean difference, 111 +/- 36 pmol per liter; P = 0.003) than those with two normotensive parents. The differences could not be explained by the small differences in blood pressure between the groups. The values in the subjects with one hypertensive and one normotensive parent fell between those for the other two groups. Conclusions. Renal vasoconstriction is increased and renin and aldosterone secretion is decreased in young persons at risk for hypertension. These findings support the hypothesis that alterations in renal hemodynamics occur at an early stage in the development of familial hypertension.	ERASMUS UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS; ZUIDERZIEKENHUIS, DEPT INTERNAL MED, ROTTERDAM, NETHERLANDS; ERASMUS UNIV, HOSP DIJKZIGT, DEPT INTERNAL MED 1, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC			Grobbee, Diederick/C-7651-2014; de Leeuw, Peter W./J-4552-2016	Grobbee, Diederick/0000-0003-4472-4468; de Leeuw, Peter W./0000-0002-4949-5812				BELLO CT, 1965, AM J MED SCI, V250, P24, DOI 10.1097/00000441-196507000-00005; BERGER EY, 1948, J CLIN INVEST, V27, P710, DOI 10.1172/JCI102020; BIANCHI G, 1983, KIDNEY INT, V23, P870, DOI 10.1038/ki.1983.109; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BIANCHI G, 1979, LANCET, V1, P173, DOI 10.1016/S0140-6736(79)90577-4; BLACKSHEAR JL, 1987, HYPERTENSION, V9, P384, DOI 10.1161/01.HYP.9.4.384; BROWN JJ, 1976, LANCET, V1, P1217; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; De Leeuw P. W., 1981, HYPERTENSION YOUNG O, P57; DELEEUW PW, 1987, ACTA MED SCAND S, V622, P5; DERKX FHM, 1983, HYPERTENSION, V5, P244, DOI 10.1161/01.HYP.5.2.244; DERKX FHM, 1987, J CLIN ENDOCR METAB, V65, P349, DOI 10.1210/jcem-65-2-349; DLUHY RG, 1988, J CARDIOVASC PHARM, V12, pS149; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; GUIDI E, 1985, NEPHRON, V41, P14, DOI 10.1159/000183539; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; GUYTON AC, 1984, NETH J MED, V27, P117; HARRAP SB, 1986, J HYPERTENS, V4, pS249; HOFMAN A, 1980, EPIDEMIOLOGY ARTERIA, V8, P99; Hollenberg N K, 1970, Trans Assoc Am Physicians, V83, P93; HOLLENBERG NK, 1978, MEDICINE, V57, P167, DOI 10.1097/00005792-197803000-00004; HOLLENBERG NK, 1986, AM J MED, V81, P412, DOI 10.1016/0002-9343(86)90291-3; HOLLENBERG NK, 1981, HYPERTENSION, V3, P11, DOI 10.1161/01.HYP.3.1.11; LIJNEN PJ, 1978, CLIN CHIM ACTA, V88, P403, DOI 10.1016/0009-8981(78)90447-3; LONDON GM, 1988, AM J HYPERTENS, V1, pS127, DOI 10.1093/ajh/1.3.127S; LOWENSTEIN J, 1967, CIRCULATION, V35, P250, DOI 10.1161/01.CIR.35.2.250; MALVANO R, 1976, J NUCL BIOL MED, V20, P37; MESSERLI FH, 1978, CIRCULATION, V58, P441, DOI 10.1161/01.CIR.58.3.441; MONTANARI A, 1988, HYPERTENSION, V12, P498, DOI 10.1161/01.HYP.12.5.498; REUBI FC, 1978, AM J MED, V64, P556, DOI 10.1016/0002-9343(78)90573-9; SCHALEKAMP MA, 1970, CLIN SCI, V38, P101, DOI 10.1042/cs0380101; SHOBACK DM, 1983, J CLIN INVEST, V72, P2115, DOI 10.1172/JCI111176; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; UNEDA S, 1984, J HYPERTENS       S3, V2, P437; VANHOOFT IM, 1988, J HYPERTENS, V6, pS594, DOI 10.1097/00004872-198812040-00186; VANHOOFT IMS, 1988, INT J EPIDEMIOL, V17, P228, DOI 10.1093/ije/17.1.228; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001	38	135	136	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1991	324	19					1305	1311		10.1056/NEJM199105093241902	http://dx.doi.org/10.1056/NEJM199105093241902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK186	2017226				2022-12-01	WOS:A1991FK18600002
J	BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH				BENFIELD, DG; FLAKSMAN, RJ; LIN, TH; KANTAK, AD; KOKOMOOR, FW; VOLLMAN, JH			TEACHING INTUBATION SKILLS USING NEWLY DECEASED INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This prospective study was designed to (1) test the hypothesis that the majority of families of newly dead infants in a tertiary neonatal intensive care unit would consent to their infants' being intubated for teaching purposes, (2) determine factors related to family consent, and (3) determine the effects of participation on resident physicians and respiratory therapists. Family consent for intubation was requested following 44 (80%) of the 55 deaths that occurred during the 10-month study period. Of these requests, 32 (73%) were granted. Proportionately more white than black families consented and consent was positively related to autopsy permission. Fifty-three (75%) of 71 trainees completed a mailed questionnaire after their first intubation experience. Although each respondent found the experience helpful, many reported mixed feelings categorized as doubt about participating, apprehension and discomfort, respect for the body, appreciation for the opportunity, a sense of achievement, and feelings of comfort knowing that consent had been obtained. These findings confirm our initial hypothesis and suggest that (1) newly dead infants can be a valuable resource for teaching intubation skills, and (2) others considering a similar approach need to be aware of and sensitive to trainees' feelings.	CHILDRENS HOSP MED CTR,NEONATOL INTENS CARE UNIT,AKRON,OH 44308; AKRON REG PERINATAL CTR,AKRON,OH; NORTHEASTERN OHIO UNIV,COLL MED,DEPT PEDIAT,ROOTSTOWN,OH 44272	Northeast Ohio Medical University (NEOMED)	BENFIELD, DG (corresponding author), CHILDRENS HOSP MED CTR,DEPT PEDIAT,DIV NEONATOL,281 LOCUST ST,AKRON,OH 44308, USA.							BRANDT AM, 1978, HASTINGS CTR REP, V8, P28; Crawford T, 1987, Physician Exec, V13, P25; FELDMAN DS, 1986, STATVIEW 512 PLUS PR; Fox Renee, 1979, ESSAYS MED SOCIOLOGY, P51; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ORLOWSKI JP, 1989, NEW ENGL J MED, V320, P396; TOCHEN ML, 1979, J PEDIATR-US, V95, P1050, DOI 10.1016/S0022-3476(79)80309-1	8	48	48	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2360	2363		10.1001/jama.265.18.2360	http://dx.doi.org/10.1001/jama.265.18.2360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016832				2022-12-01	WOS:A1991FJ95500030
J	LAWRENCE, RA				LAWRENCE, RA			CORTICOSTEROID EFFECT ON LACTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PREDNISOLONE; MILK				LAWRENCE, RA (corresponding author), UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14642, USA.							Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; Dembinski T. C., 1987, The mammary gland. Development, regulation, and function., P355; LAWRENCE RA, 1989, BREASTFEEDING GUIDE, P256; MCKENZIE SA, 1975, ARCH DIS CHILD, V50, P894, DOI 10.1136/adc.50.11.894; Neville M. C., 1983, Lactation. Physiology, nutrition, and breast-feeding, P141; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; SIETSEMA WK, 1989, INT J CLIN PHARM TH, V27, P179; TAUBER U, 1984, INT J CLIN PHARM TH, V22, P48	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016840				2022-12-01	WOS:A1991FJ95500041
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LICENSING OF G-CSF AND GM-CSF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-01	WOS:A1991FJ95500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SCIENTIFIC-DATA SOUGHT ON HEALTH CLAIMS ON FOODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-01	WOS:A1991FJ95500008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NUTRITION LABELING AND EDUCATION ACT OF 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1990, JAMA-J AM MED ASSOC, V263, P2995	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2315	2315						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	1707990				2022-12-01	WOS:A1991FJ95500007
J	PEARSON, JW				PEARSON, JW			ENDOCERVICAL BRUSH FOR PAPANICOLAU SMEARS - ADVERSE-EFFECTS OR CONTRAINDICATIONS TO USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											PEARSON, JW (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							BOON ME, 1989, ACTA CYTOL, V33, P843; DOTTERS DJ, 1988, AM J OBSTET GYNECOL, V159, P814, DOI 10.1016/S0002-9378(88)80143-1; WEITZMAN GA, 1988, J REPROD MED, V33, P677	3	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1991	265	18					2409	2409						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ955	2016841				2022-12-01	WOS:A1991FJ95500042
J	HELMAN, CG				HELMAN, CG			LIMITS OF BIO-MEDICAL EXPLANATION	LANCET			English	Article							DISORDERS				HELMAN, CG (corresponding author), UNIV COLL & MIDDLESEX SCH MED, WHITTINGTON HOSP, DEPT PRIMARY HLTH CARE, HIGHGATE HILL, LONDON N19 5NF, ENGLAND.							BRABIN L, 1985, AM J EPIDEMIOL, V122, P725, DOI 10.1093/oxfordjournals.aje.a114155; COOPER JE, 1969, AM J PSYCHIAT, V125, P21, DOI 10.1176/ajp.125.10S.21; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; ELLIOTTBINNS CP, 1986, J ROY COLL GEN PRACT, V36, P542; Goffman E., 1961, ENCOUNTERS 2 STUDIES; Good B J, 1977, Cult Med Psychiatry, V1, P25, DOI 10.1007/BF00114809; Greeley A. M., 1978, MED ANTHROPOL, V2, P31, DOI [10.1080/01459740.1978.9986961, DOI 10.1080/01459740.1978.9986961]; Helman C G, 1981, J R Coll Gen Pract, V31, P548; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; HELMAN CG, 1981, SOC SCI MED-MED ANTH, V15, P521, DOI 10.1016/0160-7987(81)90026-0; HELMAN CG, 1985, CULT MED PSYCHIAT, V9, P1; Helman CG, 1990, CULTURE HLTH ILLNESS; HELMAN CG, 1988, ANTHR TODAY, V14, P14; Kark S. L., 1981, PRACTICE COMMUNITY O; Keesing R. M., 1981, CULTURAL ANTHR; Kleinman A., 1981, PATIENTS HEALERS CON; Lock M, 1988, BIOMEDICINE EXAMINED; MULL JD, 1988, SOC SCI MED, V27, P53, DOI 10.1016/0277-9536(88)90163-3; OBrien B., 1984, PATTERNS EUROPEAN DI; Payer Lynn, 1989, MED CULTURE; PEACOCK J, 1986, ANTHR LENS; PICHOT P, 1982, PSYCHOL MED, V12, P475, DOI 10.1017/S0033291700055586; SKULTANS V, 1970, MAN, V5, P639, DOI 10.2307/2799108; Stacey M., 1988, SOCIOLOGY HLTH HEALI; VAYDA E, 1982, ARCH SURG-CHICAGO, V117, P846; WEISS MG, 1988, SOC SCI MED, V27, P5, DOI 10.1016/0277-9536(88)90159-1	26	21	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1080	1083		10.1016/0140-6736(91)91720-F	http://dx.doi.org/10.1016/0140-6736(91)91720-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673506				2022-12-01	WOS:A1991FK20400017
J	KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK				KAUFMAN, LD; GRUBER, BL; GREGERSEN, PK			CLINICAL FOLLOW-UP AND IMMUNOGENETIC STUDIES OF 32 PATIENTS WITH EOSINOPHILIA-MYALGIA-SYNDROME	LANCET			English	Article								31 patients with L-tryptophan-associated eosinophilia-myalgia syndrome (EMS) that developed during the United States outbreak in 1989 were followed up prospectively at a university hospital outpatient rheumatology clinic for 16 to 24 months from the onset of their illness. Another patient with EMS associated with L-tryptophan in 1988 was followed up for 30 months. 93% of the 28 survivors from the 1989 cohort continue to have symptoms affecting 1-4 organ systems (median 3) and 3 have died, so the disorder produces considerable morbidity and mortality. The chronic sequelae most often associated with long-term disability are sclerodermatous skin thickening (54%), sensorimotor polyneuropathy (61%), proximal myopathy (36%), and severe episodic myalgias (64%). Thrombocytopenia developed in 1 patient. HLA-class II typing revealed a non-significant trend towards an association with HLA-DR4. Early therapy with corticosteroids did not seem to prevent the development of chronic manifestations.	CORNELL UNIV, N SHORE UNIV HOSP,COLL MED,DEPT MED,DIV MOLEC MED, MANHASSET, NY 11030 USA	Cornell University; Northwell Health; North Shore University Hospital	KAUFMAN, LD (corresponding author), SUNY STONY BROOK, HLTH SCI CTR T16040, DEPT MED, DIV ALLERGY RHEUMATOL & CLIN IMMUNOL, STONY BROOK, NY 11794 USA.							BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CROFFORD LJ, 1990, J CLIN INVEST, V86, P1757, DOI 10.1172/JCI114902; EIDSON M, 1990, LANCET, V335, P645, DOI 10.1016/0140-6736(90)90421-Z; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1990, J RHEUMATOL, V17, P795; KAUFMAN LD, 1990, MEDICINE, V69, P187, DOI 10.1097/00005792-199007000-00001; KAUFMAN LD, 1990, J AM ACAD DERMATOL, V23, P1063, DOI 10.1016/0190-9622(90)70334-E; KAUFMAN LD, IN PRESS RHEUM DIS C; KILBOURNE EM, 1983, NEW ENGL J MED, V309, P1408, DOI 10.1056/NEJM198312083092302; LAKHANPAL S, 1988, SEMIN ARTHRITIS RHEU, V17, P221, DOI 10.1016/0049-0172(88)90008-X; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MEDSGER TA, 1968, ARTHRITIS RHEUM-US, V11, P554, DOI 10.1002/art.1780110405; SEIDMAN RJ, 1991, J NEUROPATH EXP NEUR, V50, P49, DOI 10.1097/00005072-199101000-00004; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; TAZELAAR HD, 1990, CHEST, V97, P1032, DOI 10.1378/chest.97.5.1032; TSOKOS GC, 1981, ARCH INTERN MED, V246, P766; VARGA J, 1990, SEMIN ARTHRITIS RHEU, V19, P313, DOI 10.1016/0049-0172(90)90069-R; VICARIO JL, 1982, LANCET, V1, P276; 1989, MMWR, V38, P765	20	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 4	1991	337	8749					1071	1074		10.1016/0140-6736(91)91717-9	http://dx.doi.org/10.1016/0140-6736(91)91717-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673503				2022-12-01	WOS:A1991FK20400014
J	MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC				MAGOS, AL; BAUMANN, R; LOCKWOOD, GM; TURNBULL, AC			EXPERIENCE WITH THE 1ST 250 ENDOMETRIAL RESECTIONS FOR MENORRHAGIA	LANCET			English	Article							ND-YAG LASER; ABLATION; SURGERY	234 patients with menorrhagia were treated hysteroscopically by transcervical resection of the endometrium (TCRE) instead of hysterectomy. 250 procedures were performed under general anaesthesia (63%) or under sedation plus local anaesthesia (38%). The endometrium was excised either totally (91%) or partially (9%) in all but one case, and 56 (22%) of the patients underwent simultaneous resection of submucous fibroids. Surgical time (range 10-100 min) varied with the gynaecologist's experience. 479 ml was the average volume of uterine irrigant absorbed by the patient. Blood loss was usually slight. Operative complications were uncommon, but 4 (2%) women sustained a uterine perforation (without serious sequelae), 7 (3%) absorbed more than 2 litres of fluid, and 1 required tamponade to control postoperative bleeding. Hospital stay was short and full recovery usual by 1-2 weeks. Menstrual symtoms improved in over 90% of the patients throughout the follow-up of up to 2 1/2 years; 27-42% of the women became amenorrhoeic at some time after total TCRE. Results were best in women > 35 years of age, but was not influenced by the presence of fibroids or pretreatment dysmenorrhoea. 10 (4%) women later underwent hysterectomy. Hysteroscopy 3 and 12 months after surgery revealed a small, fibrotic uterine cavity in the majority.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND	University of Oxford	MAGOS, AL (corresponding author), ROYAL FREE HOSP,ACAD DEPT OBSTET & GYNAECOL,LONDON NW3 2QG,ENGLAND.							ASHERMAN JG, 1950, J OBSTET GYN BRIT EM, V57, P892; BAGGISH MS, 1988, AM J OBSTET GYNECOL, V159, P287, DOI 10.1016/S0002-9378(88)80069-3; BAUMANN R, 1990, BRIT MED J, V300, P304, DOI 10.1136/bmj.300.6720.304; DANIELL JF, 1986, COLP GYNECOL LAS SUR, V2, P43; DAVIS JA, 1989, BRIT J OBSTET GYNAEC, V96, P928, DOI 10.1111/j.1471-0528.1989.tb03347.x; DECHERNEY A, 1983, OBSTET GYNECOL, V61, P392; GIMPELSON RJ, 1988, J REPROD MED, V33, P872; GOLDFARB HA, 1990, OBSTET GYNECOL, V76, P833, DOI 10.1097/00006250-199011000-00022; GOLDRATH MH, 1981, AM J OBSTET GYNECOL, V140, P14, DOI 10.1016/0002-9378(81)90251-9; GOLDRATH MH, 1990, J REPROD MED, V35, P91; GOLDRATH MH, 1986, GYNAECOLOGICAL LASER, P253; GORDON AG, 1989, BAILLIERE CLIN OB GY, V3, P429, DOI 10.1016/S0950-3552(89)80003-3; LOCKWOOD M, 1990, BRIT J OBSTET GYNAEC, V97, P656, DOI 10.1111/j.1471-0528.1990.tb02562.x; LOMANO JM, 1986, J REPROD MED, V31, P148; LOMANO JM, 1988, AM J OBSTET GYNECOL, V159, P152, DOI 10.1016/0002-9378(88)90512-1; MAGOS AL, 1990, LANCET, V335, P44, DOI 10.1016/0140-6736(90)90165-2; MAGOS AL, 1989, LANCET, V2, P925; MAGOS AL, 1989, BRIT MED J, V298, P1209, DOI 10.1136/bmj.298.6682.1209; MAGOS AL, 1990, ADV REP END, V2, P97; NEUWIRTH RS, 1978, AM J OBSTET GYNECOL, V131, P91, DOI 10.1016/0002-9378(78)90481-7; PERRY CP, 1990, J GYNECOL SURG, V6, P199, DOI 10.1089/gyn.1990.6.199; PHIPPS JH, 1990, OBSTET GYNECOL, V76, P876, DOI 10.1097/00006250-199011000-00032; PHIPPS JH, 1990, LANCET, V335, P374, DOI 10.1016/0140-6736(90)90207-L; TOWNSEND DE, 1990, OBSTET GYNECOL, V76, P310; VANCAILLIE TG, 1989, OBSTET GYNECOL, V74, P425	25	248	253	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1991	337	8749					1074	1078		10.1016/0140-6736(91)91718-A	http://dx.doi.org/10.1016/0140-6736(91)91718-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK204	1673504				2022-12-01	WOS:A1991FK20400015
J	PHILP, I; MAWHINNEY, S; MUTCH, WJ				PHILP, I; MAWHINNEY, S; MUTCH, WJ			SETTING STANDARDS FOR LONG-TERM CARE OF THE ELDERLY IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,GERIATR MED,DUNDEE DD1 9SY,SCOTLAND	University of Dundee				philp, ian/0000-0002-3972-6496				DENHAM M, 1989, CARE ELDERLY, V1, P855; DONALDSON C, 1988, AGE AGEING, V17, P379, DOI 10.1093/ageing/17.6.379; Kane RA, 1987, LONG TERM CARE PRINC; PHILP I, IN PRESS INT J GERIA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1056	1056		10.1136/bmj.302.6784.1056	http://dx.doi.org/10.1136/bmj.302.6784.1056			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903665	Green Published, Bronze			2022-12-01	WOS:A1991FK56300023
J	SURTEES, SJ; STOCKTON, MG; GIETZEN, TW				SURTEES, SJ; STOCKTON, MG; GIETZEN, TW			ALLERGY TO PENICILLIN - FABLE OR FACT	BRITISH MEDICAL JOURNAL			English	Article							SKIN	Objective - To assess whether, on the basis of one blood test, penicillin allergy might be excluded sufficiently for general practitioners to give oral penicillin to patients claiming a history of penicillin allergy. Design - Prospective study of patients referred by general practioners. Setting - Outpatient allergy clinic in a district general hospital. Patients - 175 referred patients who gave a history of immediate type reaction to penicillin, of whom 144 attended as requested and 132 completed the investigations. Main outcome measures - History and examination, serum radioallergosorbent test to phenoxymethyl-penicillin and benzylpenicillin, and oral challenge with penicillin. Results - Of 132 patients, four were confirmed to have penicillin allergy by the radioallergosorbent test and 128 had an oral penicillin challenge without ill effect. Conclusions - Most patients who gave a history of penicillin allergy are not so allergic, and their actual allergic state should be substantiated whenever feasible. For patients reporting minor or vague reactions negative findings with a radioallergosorbent test to phenoxymethylpenicillin and benzylpenicillin provide sufficient evidence to give oral penicillin safely.			SURTEES, SJ (corresponding author), DIST GEN HOSP,DEPT CLIN CHEM,EASTBOURNE BN21 2UD,E SUSSEX,ENGLAND.							BEELEY L, 1984, BRIT MED J, V288, P511, DOI 10.1136/bmj.288.6416.511-a; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; FOX AM, 1965, BMJ-BRIT MED J, V2, P206, DOI 10.1136/bmj.2.5455.206; HOLGATE ST, 1988, BRIT MED J, V296, P1213, DOI 10.1136/bmj.296.6631.1213; JARISCH R, 1981, CLIN ALLERGY, V11, P155, DOI 10.1111/j.1365-2222.1981.tb01579.x; KIRK CR, 1988, BRIT MED J, V296, P1236, DOI 10.1136/bmj.296.6631.1236; MYERS PC, 1985, BRIT MED J, V291, P450; OSWALD NTA, 1983, BRIT MED J, V287, P265, DOI 10.1136/bmj.287.6387.265; Pearce S. J., 1982, ADVERSE DRUG REACT, V94, P344; SIMMONDS J, 1978, BRIT MED J, V2, P1404, DOI 10.1136/bmj.2.6149.1404; SMITH AG, 1989, ADVERSE DRUG REACT, V134, P500; Sorensen H T, 1986, Scand J Prim Health Care, V4, P252	12	65	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1991	302	6784					1051	1052		10.1136/bmj.302.6784.1051	http://dx.doi.org/10.1136/bmj.302.6784.1051			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK563	1903664	Green Published, Bronze			2022-12-01	WOS:A1991FK56300021
J	CHAPDELAINE, Y; BONEN, L				CHAPDELAINE, Y; BONEN, L			THE WHEAT MITOCHONDRIAL GENE FOR SUBUNIT-I OF THE NADH DEHYDROGENASE COMPLEX - A TRANSSPLICING MODEL FOR THIS GENE-IN-PIECES	CELL			English	Article							REVEALS EXTENSIVE HOMOLOGIES; RNA SECONDARY STRUCTURE; PLANT-MITOCHONDRIA; RIBOSOMAL PROTEIN-S12; MARCHANTIA-POLYMORPHA; SEQUENCE-ANALYSIS; READING FRAME; DNA-SEQUENCE; INTRONS; CHLOROPLAST	The nad1 gene encoding subunit I of the respiratory chain NADH dehydrogenase is fragmented into five unique-copy coding segments that are scattered over at least 40 kb and interspersed with other genes in the wheat mitochondrial genome. The nad1 segments are flanked by sequences with group II intron features, and transcript analysis demonstrates the presence of correctly spliced mRNAs. RNA editing occurs at sites asymmetrically distributed along the wheat nad1 coding region, and the initiation codon is created by RNA editing. The unusual organization of the wheat nad1 gene is attributed to mitochondrial DNA rearrangements within introns, and a trans-splicing model involving secondary structural interactions between group II-like intron pieces is proposed for its expression.			CHAPDELAINE, Y (corresponding author), UNIV OTTAWA,DEPT BIOL,OTTAWA K1N 6N5,ONTARIO,CANADA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BONEN L, 1980, NUCLEIC ACIDS RES, V8, P319, DOI 10.1093/nar/8.2.319; BONEN L, 1988, GENE, V73, P47, DOI 10.1016/0378-1119(88)90311-3; BONEN L, 1984, EMBO J, V3, P2531, DOI 10.1002/j.1460-2075.1984.tb02168.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; DANDEKAR T, 1990, NUCLEIC ACIDS RES, V18, P4719, DOI 10.1093/nar/18.16.4719; FUKUZAWA H, 1986, FEBS LETT, V198, P11, DOI 10.1016/0014-5793(86)81174-7; GELIEBTER J, 1986, P NATL ACAD SCI USA, V83, P3371, DOI 10.1073/pnas.83.10.3371; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HERRIN DL, 1988, J BIOL CHEM, V262, P14601; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P10025, DOI 10.1093/nar/16.21.10025; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LANG BF, 1985, J MOL BIOL, V184, P353, DOI 10.1016/0022-2836(85)90286-4; LEJEUNE B, 1988, VARIABILITE GENETIQU, P201; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, COMPR TREAT, V15, P229; MAKAROFF CA, 1987, NUCLEIC ACIDS RES, V15, P5141, DOI 10.1093/nar/15.13.5141; Maniatis T., 1982, MOL CLONING; MATSUBAYASHI T, 1987, MOL GEN GENET, V210, P385, DOI 10.1007/BF00327187; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; PALMER JD, 1990, TRENDS GENET, V6, P115, DOI 10.1016/0168-9525(90)90125-P; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMELZER C, 1986, CELL, V46, P57; SMALL I, 1989, CELL, V58, P69, DOI 10.1016/0092-8674(89)90403-0; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WILSON AJ, 1984, PLANT CELL REP, V3, P237, DOI 10.1007/BF00269301; WISSINGER B, 1991, CELL, V65; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	179	188	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					465	472		10.1016/0092-8674(91)90464-A	http://dx.doi.org/10.1016/0092-8674(91)90464-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902143				2022-12-01	WOS:A1991FK18200013
J	CHAPMAN, KB; BOEKE, JD				CHAPMAN, KB; BOEKE, JD			ISOLATION AND CHARACTERIZATION OF THE GENE ENCODING YEAST DEBRANCHING ENZYME	CELL			English	Article							PRE-MESSENGER RNA; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; SPLICING INVITRO; TY ELEMENTS; INTRON; DNA; INTERMEDIATE; SEQUENCES; MUTANTS	Using a genetic screen aimed at identifying cellular factors involved in Ty1 transposition, we have identified a mutation in a host gene that reduces Ty1 transposition frequency. The mutant, dbr1, is also defective in the process of intron turnover. In dbr1 cells, excised introns derived from a variety of pre-mRNAs are remarkably stable and accumulate to levels exceeding that of the corresponding mRNA. The stable excised introns accumulate in the form of a lariat that is missing the linear sequences 3' of the branchpoint. The DBR1 gene has been isolated by complementation of the transposition phenotype. DBR1 is shown to encode debranching enzyme, an RNA processing activity that hydrolyzes the 2'-5' phosphodiester linkage at the branchpoint of excised intron lariats. In Saccharomyces cerevisiae, debranching enzyme plays a requisite role in the rapid turnover of excised introns, yet its function is not essential for viability.			CHAPMAN, KB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCI NIH HHS [ET32 CA09139] Funding Source: Medline; NIGMS NIH HHS [GM-36481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENAS J, 1987, J BIOL CHEM, V262, P4274; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1989, MOBILE DNA; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FLAVELL A, 1985, NATURE, V316, P574, DOI 10.1038/316574a0; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SHARP PA, 1987, COLD SPRING HARB SYM, V52, P277, DOI 10.1101/SQB.1987.052.01.033; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WESSLER SR, 1989, GENE, V82, P127, DOI 10.1016/0378-1119(89)90037-1; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553	34	184	188	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					483	492		10.1016/0092-8674(91)90466-C	http://dx.doi.org/10.1016/0092-8674(91)90466-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850323				2022-12-01	WOS:A1991FK18200015
J	DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB				DAVIS, S; LU, ML; LO, SH; LIN, S; BUTLER, JA; DRUKER, BJ; ROBERTS, TM; AN, Q; CHEN, LB			PRESENCE OF AN SH2 DOMAIN IN THE ACTIN-BINDING PROTEIN TENSIN	SCIENCE			English	Article							SMOOTH-MUSCLE VINCULIN; PHOSPHOLIPASE C-II; TYROSINE KINASES; FOCAL ADHESIONS; ALPHA-ACTININ; SARCOMA-VIRUS; CELLS; PHOSPHORYLATION; SIMILARITY; INVITRO	The molecular cloning of the complementary DNA coding for a 90-kilodalton fragment of tensin, an actin-binding component of focal contacts and other submembraneous cytoskeletal structures, is reported. The derived amino acid sequence revealed the presence of a Src homology 2 (SH2) domain. This domain is shared by a number of signal transduction proteins including nonreceptor tyrosine kinases such as Abl, Fps, Src, and Src family members, the transforming protein Crk, phospholipase C-gamma-l, PI-3 (phosphatidylinositol) kinase, and guanosine triphosphatase-activating protein (GAP). Like the SH2 domain found in Src, Crk, and Abl, the SH2 domain of tensin bound specifically to a number of phosphotyrosine-containing proteins from v-src-transformed cells. Tensin was also found to be phosphorylated on tyrosine residues. These findings suggest that by possessing both actin-binding and phosphotyrosine-binding activities and being itself a target for tyrosine kinases, tensin may link signal transduction pathways with the cytoskeleton.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT BIOPHYS,BALTIMORE,MD 21218	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Johns Hopkins University				Druker, Brian/0000-0001-8331-8206	NIGMS NIH HHS [GM 22289, GM 38318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038318, R01GM022289] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Burridge K, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P587; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTLER JAV, UNPUB; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS RR, 1984, J BIOL CHEM, V259, P3916; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; KELLIE S, 1985, EXP CELL RES, V160, P259, DOI 10.1016/0014-4827(85)90174-0; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P669; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LIN S, 1989, SPRINGER SERIES BIOP, V3, P341; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; Marston F. A. O., 1987, DNA CLONING, P59; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; RISINGER M A, 1988, Journal of Cell Biology, V107, p256A; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SMITH DB, 1990, CURRENT PROTOCOLS MO; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085; WILKINS JA, 1987, J CELL BIOL, V106, pA130	42	217	218	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					712	715		10.1126/science.1708917	http://dx.doi.org/10.1126/science.1708917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708917				2022-12-01	WOS:A1991FK18500051
J	DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP				DOE, CQ; CHULAGRAFF, Q; WRIGHT, DM; SCOTT, MP			THE PROSPERO GENE SPECIFIES CELL FATES IN THE DROSOPHILA CENTRAL-NERVOUS-SYSTEM	CELL			English	Article							ACHAETE-SCUTE COMPLEX; EMBRYONIC-DEVELOPMENT; NEURONAL DEVELOPMENT; GLIAL PATHWAYS; AXON PATHWAYS; GROWTH CONES; PROTEIN; NEUROGENESIS; EXPRESSION; LOCALIZATION	The molecular mechanisms used to generate neuronal diversity are largely unknown. To identify genes controlling cell fate in the Drosophila central nervous system, we screened for mutations that alter expression of homeobox genes in the developing central nervous system (indicating changes in cell fates). We also screened "enhancer trap" lines to identify genes expressed in neuronal stem cells (neuroblasts). The prospero gene was discovered in both screens. Prospero is expressed in a subset of neuroblasts, sensory neuron precursors, and identified glial precursors. It is not expressed in neurons. Neuroblasts lacking prospero function generate abnormal cell lineages, producing incorrectly specified progeny that differentiate into neurons showing axon pathfinding defects. Prospero is therefore a novel type of gene expressed in neuroblasts and known to specify neuronal fate.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	DOE, CQ (corresponding author), UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801, USA.				PHS HHS [18163, 27056] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1991, IN PRESS ANN REV NEU, V14; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; Doe C Q, 1990, Semin Cell Biol, V1, P211; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOE CQ, 1991, IN PRESS DETERMINANT; ENGELS WR, 1986, FOCUS, V8, P6; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUFF R, 1989, DEV BIOL, V134, P146, DOI 10.1016/0012-1606(89)90085-7; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1989, J NEUROSCI, V9, P2421; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROBERTSON HM, 1988, GENETICS, V118, P461; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; Sambrook J., 1989, MOL CLONING LAB MANU; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5	49	392	397	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					451	464		10.1016/0092-8674(91)90463-9	http://dx.doi.org/10.1016/0092-8674(91)90463-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673362				2022-12-01	WOS:A1991FK18200012
J	DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L				DONADIO, S; STAVER, MJ; MCALPINE, JB; SWANSON, SJ; KATZ, L			MODULAR ORGANIZATION OF GENES REQUIRED FOR COMPLEX POLYKETIDE BIOSYNTHESIS	SCIENCE			English	Article							FATTY-ACID SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA STREPTOMYCES; ERYTHROMYCIN RESISTANCE; MACROLIDE BIOSYNTHESIS; ANTIBIOTICS; SEQUENCE; CLONING; CDNA	In Saccharopolyspora erythraea, the genes that govern synthesis of the polyketide portion of the macrolide antibiotic erythromycin are organized in six repeated units that encode fatty acid synthase (FAS)-like activities. Each repeated unit is designated a module, and two modules are contained in a single open reading frame. A model for the synthesis of this complex polyketide is proposed, where each module encodes a functional synthase unit and each synthase unit participates specifically in one of the six FAS-like elongation steps required for formation of the polyketide. In addition, genetic organization and biochemical order of events appear to be colinear. Evidence for the model is provided by construction of a selected mutant and by isolation of a polyketide of predicted structure.	ABBOTT LABS,BIOACT MICROBIAL METABOLITE PROJECT,N CHICAGO,IL 60064	Abbott Laboratories	DONADIO, S (corresponding author), ABBOTT LABS,DEPT CORP MOLEC BIOL,N CHICAGO,IL 60064, USA.							BALTZ RH, 1988, ANNU REV MICROBIOL, V42, P547; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BIRCH AJ, 1953, AUST J CHEM, V6, P360, DOI 10.1071/CH9530360; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CHIRALA SS, 1989, J BIOL CHEM, V264, P3750; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWITT JP, 1985, J BACTERIOL, V164, P969, DOI 10.1128/JB.164.2.969-971.1985; DONADIO S, IN PRESS GENE; HALE RS, 1987, FEBS LETT, V224, P133, DOI 10.1016/0014-5793(87)80436-2; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUBER MLB, 1990, ANTIMICROB AGENTS CH, V34, P1535, DOI 10.1128/AAC.34.8.1535; KINOSHITA K, 1988, J CHEM SOC CHEM COMM, V943; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; MACNEIL DJ, 1990, J CELL BIOL A S, V14, P92; Maniatis T., 1982, MOL CLONING; MARTIN JR, 1968, BIOCHEMISTRY-US, V7, P1728, DOI 10.1021/bi00845a016; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; OMURA S, 1984, MACROLIDE ANTIBIOTIC, P199; RICHARDSON MA, 1990, J BACTERIOL, V172, P3790, DOI 10.1128/jb.172.7.3790-3798.1990; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAVER MJ, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; UCHIYAMA H, 1985, GENE, V38, P103, DOI 10.1016/0378-1119(85)90208-2; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; WEBER JM, 1988, GENE, V68, P173, DOI 10.1016/0378-1119(88)90019-4; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	39	758	830	1	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					675	679		10.1126/science.2024119	http://dx.doi.org/10.1126/science.2024119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024119				2022-12-01	WOS:A1991FK18500039
J	DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH				DU, XP; PLOW, EF; FRELINGER, AL; OTOOLE, TE; LOFTUS, JC; GINSBERG, MH			LIGANDS ACTIVATE INTEGRIN ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA)	CELL			English	Article							ARG-GLY-ASP; FUNCTION-ASSOCIATED ANTIGEN-1; IIB-GLYCOPROTEIN-IIIA; AMINO-ACID SEQUENCES; CELL-BINDING DOMAIN; SYNTHETIC PEPTIDES; GLANZMANNS THROMBASTHENIA; FIBRONECTIN RECEPTOR; RECOGNITION SIGNAL; ADHESIVE PROTEINS	Integrin alpha-IIb-beta-3 (platelet GPIIb-IIIa) binds fibrinogen via recognition sequences such as Arg-Gly-Asp (RGD). Fibrinogen binding requires agonist activation of platelets, whereas the binding of short synthetic RGD peptides does not. We now find that RGD peptide binding leads to changes in alpha-IIb-beta-3 that are associated with acquisition of high affinity fibrinogen-binding function (activation) and subsequent platelet aggregation. The structural specificities for peptide activation and for inhibition of ligand binding are similar, indicating that both are consequences of occupancy of the same site(s) on alpha-IIb-beta-3. Thus, the RGD sequence is a trigger of high affinity ligand binding to alpha-IIb-beta-3, and certain RGD-mimetics are partial agonists as well as competitive antagonists of integrin function.			DU, XP (corresponding author), Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.		O'Toole, Timothy/I-4172-2013	Frelinger, Andrew/0000-0002-6871-7441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039150, R01HL028235, P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28235, HL-39150, HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COHEN I, 1989, BLOOD, V73, P1880; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1980, BLOOD, V55, P169; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1987, J BIOL CHEM, V262, P5437; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAM SCT, 1987, J BIOL CHEM, V262, P947; LASH JW, 1987, DEV BIOL, V123, P411, DOI 10.1016/0012-1606(87)90399-X; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MARGUERIE GA, 1982, J BIOL CHEM, V257, P1872; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEERSCHKE EI, 1981, BLOOD, V57, P663; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMS PJ, 1990, IN PRESS J BIOL CHEM; STEINER B, 1989, J BIOL CHEM, V264, P13102; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WOODS VL, 1986, J BIOL CHEM, V261, P5242; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; ZAMARRON C, 1990, THROMB HAEMOSTASIS, V64, P41	66	472	479	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					409	416		10.1016/0092-8674(91)90458-B	http://dx.doi.org/10.1016/0092-8674(91)90458-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018974				2022-12-01	WOS:A1991FK18200007
J	FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL				FERGUSON, BM; BREWER, BJ; REYNOLDS, AE; FANGMAN, WL			A YEAST ORIGIN OF REPLICATION IS ACTIVATED LATE IN S-PHASE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME-REPLICATION; DNA; SEQUENCES; GENES; ORGANIZATION; PLASMIDS; TIME	The mechanism that causes large regions of eukaryotic chromosomes to remain unreplicated until late in S phase is not understood. We have found that 67 kb of telomere-adjacent DNA at the right end of chromosome V in S. cerevisiae is replicated late in S phase. An ARS element in this region, ARS501, was shown by two-dimensional gel analysis to be an active origin of replication. Kinetic analyses indicate that the rate of replication fork movement within this late region is similar to that in early replicating regions. Therefore, the delayed replication of the region is a consequence of late origin activation. The results also support the idea that the pattern of interspersed early and late replication along the chromosomes of higher eukaryotes is a consequence of the temporal regulation of origin activation.	UNIV WASHINGTON,DEPT GENET SK-50,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Reynolds, Ann/B-7324-2013	Reynolds, Ann/0000-0002-2881-6955	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18926] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BREWER BJ, 1988, CANCER CELL, V6, P229; CALDERON IL, 1983, CURR GENET, V7, P93, DOI 10.1007/BF00365632; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; HINNEBUSCH AG, 1983, J BIOL CHEM, V258, P5238; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLINGSWORTH NM, 1988, THESIS U WASHINGTON; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON DA, 1984, EMBO J, V3, P1837; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; MAINE GT, 1984, MOL CELL BIOL, V4, P86, DOI 10.1128/MCB.4.1.86; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MANIATIS T, 1908, MOL CLONING; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; SITNEY K, 1987, THESIS U CALIFORNIA; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; THRASHBINGHAM C, 1989, MOL CELL BIOL, V9, P809, DOI 10.1128/MCB.9.2.809; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257	38	184	188	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					507	515		10.1016/0092-8674(91)90468-E	http://dx.doi.org/10.1016/0092-8674(91)90468-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018976				2022-12-01	WOS:A1991FK18200017
J	FRANK, LG; GLICKMAN, SE; LICHT, P				FRANK, LG; GLICKMAN, SE; LICHT, P			FATAL SIBLING AGGRESSION, PRECOCIAL DEVELOPMENT, AND ANDROGENS IN NEONATAL SPOTTED HYENAS	SCIENCE			English	Article							CROCUTA-CROCUTA; SOCIAL-ORGANIZATION	Fatal neonatal sibling aggression is common in predatory birds but has not been previously reported in wild mammals. Spotted hyena females are strongly masculinized, both anatomically and behaviorally, apparently by high levels of androgens during ontogeny. Neonates display elevated androgen levels, precocial motor development, and fully erupted front teeth. Litters are usually twins, and siblings fight violently at birth, apparently leading to the death of one sibling in same-sex litters, whereas in mixed-sex litters both siblings usually survive.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	FRANK, LG (corresponding author), UNIV CALIF BERKELEY, DEPT PSYCHOL, BERKELEY, CA 94720 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039917] Funding Source: NIH RePORTER; NIMH NIH HHS [MH39917] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BEKOFF M, 1981, AGGRESSIVE BEHAV, V7, P225, DOI 10.1002/1098-2337(1981)7:3<225::AID-AB2480070306>3.0.CO;2-I; FRANK LG, 1986, ANIM BEHAV, V34, P1510, DOI 10.1016/S0003-3472(86)80221-4; FRANK LG, 1990, J ZOOL, V221, P308, DOI 10.1111/j.1469-7998.1990.tb04001.x; FRANK LG, 1986, ANIM BEHAV, V34, P1500, DOI 10.1016/S0003-3472(86)80220-2; FRANK LG, UNPUB; Fraser D, 1990, J Reprod Fertil Suppl, V40, P355; GLICKMAN SE, 1987, P NATL ACAD SCI USA, V84, P3444, DOI 10.1073/pnas.84.10.3444; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; GOULD SJ, 1981, NAT HIST, V90, P16; HOFER H, 1989, 5TH INT THER C ROM; Kranendonk H.J., 1983, Zoologische Garten, V53, P339; KRUUK H, 1972, SPOTTED HYENA; LICHT P, 1982, BIOL REPROD, V27, P411, DOI 10.1095/biolreprod27.2.411; LINDEQUE M, 1982, J REPROD FERTIL, V65, P405; LINDEQUE M, 1986, J REPROD FERTIL, V78, P211; MACPHERSON AH, 1969, CAN WILDL REP SER, V8; MATTHEWS L. HARRISON, 1939, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P1; MILLS MGL, 1990, KALAHARI HYAENAS, P138; MOCK DW, 1990, AM SCI, V78, P438; PARKER GA, 1989, AM NAT, V133, P846, DOI 10.1086/284956; Pournelle G. H., 1965, Journal of Mammalogy, V46, P503, DOI 10.2307/1377649; Rieger I., 1981, MAMMALIAN SPECIES, V150, P1; SMALE L, 1989, 5TH INT THER C ROM; TILSON RL, 1984, ANIM BEHAV, V32, P715, DOI 10.1016/S0003-3472(84)80147-5	24	133	138	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					702	704		10.1126/science.2024122	http://dx.doi.org/10.1126/science.2024122			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024122				2022-12-01	WOS:A1991FK18500047
J	FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW				FUNGLEUNG, WP; SCHILHAM, MW; RAHEMTULLA, A; KUNDIG, TM; VOLLENWEIDER, M; POTTER, J; VANEWIJK, W; MAK, TW			CD8 IS NEEDED FOR DEVELOPMENT OF CYTOTOXIC T-CELLS BUT NOT HELPER T-CELLS	CELL			English	Article							MLSA-ENCODED ANTIGENS; STEM-CELLS; HOMOLOGOUS RECOMBINATION; TYROSINE PHOSPHORYLATION; PLURIPOTENTIAL CELLS; SURFACE EXPRESSION; TRANSGENIC MICE; KINASE P56LCK; MOUSE EMBRYOS; LYMPHOCYTES-T	A mutant mouse strain without CD8 (Lyt-2 and Lyt-3) expression on the cell surface has been generated by disrupting the Lyt-2 gene using embryonic stem cell technology. In these mice, CD8+ T lymphocytes are not present in peripheral lymphoid organs, but the CD4+ T lymphocyte population seems to be unaltered. Cytotoxic response of T lymphocytes from these mice against alloantigens and viral antigens is dramatically decreased. Proliferative response against alloantigens and in vivo help to B lymphocytes, however, are not affected. These data suggest that CD8 is necessary for the maturation and positive selection of class I MHC restricted cytotoxic T lymphocytes but is not required on any of the intermediate thymocyte populations (CD8+CD4-TcR- or CD4+CD8+TcR(low)) during the development of functional class II MHC restricted helper T cells.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8006 ZURICH, SWITZERLAND; ERASMUS UNIV, DEPT IMMUNOL, 3000 DR ROTTERDAM, NETHERLANDS	University of Toronto; University of Toronto; University of Zurich; Erasmus University Rotterdam	FUNGLEUNG, WP (corresponding author), UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA.		Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRADLEY A, 1987, PRODUCTION ANALCHIMA; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HIRSCH MS, 1968, J EXP MED, V128, P121, DOI 10.1084/jem.128.1.121; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOSZINOWSKI U, 1975, EUR J IMMUNOL, V5, P245, DOI 10.1002/eji.1830050405; LEDBETTER JA, 1981, J EXP MED, V153, P1503, DOI 10.1084/jem.153.6.1503; LIAW CW, 1986, J IMMUNOL, V137, P1037; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; NAKAUCHI H, 1987, P NATL ACAD SCI USA, V84, P4210, DOI 10.1073/pnas.84.12.4210; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; RUDD CE, 1989, IMMUNOL REV, V111, P225, DOI 10.1111/j.1600-065X.1989.tb00548.x; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SCHILHAM MW, 1986, J IMMUNOL, V137, P2748; SCHMIDTULLRICH R, 1990, INT IMMUNOL, V2, P247, DOI 10.1093/intimm/2.3.247; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOTT DW, 1970, CLIN EXP IMMUNOL, V6, P313; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.iy.05.040187.003101; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WALKER ID, 1984, IMMUNOL REV, V82, P47, DOI 10.1111/j.1600-065X.1984.tb01117.x; WALKER ID, 1984, EUR J IMMUNOL, V14, P906, DOI 10.1002/eji.1830141009; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	51	482	499	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					443	449		10.1016/0092-8674(91)90462-8	http://dx.doi.org/10.1016/0092-8674(91)90462-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1673361				2022-12-01	WOS:A1991FK18200011
J	KARA, CJ; GLIMCHER, LH				KARA, CJ; GLIMCHER, LH			INVIVO FOOTPRINTING OF MHC CLASS-II GENES - BARE PROMOTERS IN THE BARE LYMPHOCYTE SYNDROME	SCIENCE			English	Article							DR-ALPHA GENE; B-CELL VARIANT; HLA-DR; NUCLEOTIDE-SEQUENCE; CHAIN GENE; EXPRESSION; BINDING; PROTEIN; ENHANCER; HYBRIDS	Major histocompatibility complex (MHC) class II genes are coordinately regulated and show tissue-specific expression. With the use of in vivo footprinting, common promoter sites in these genes were found to be occupied only in cells that expressed the genes, in spite of the presence of the promoter binding proteins. In vivo analysis of mutant cell lines that exhibited coordinate loss of class II MHC expression, including several from individuals with bare lymphocyte syndrome, revealed two in vivo phenotypes. One suggests a defect in gene activation, whereas the other suggests a defect in promoter accessibility.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI021163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21163] Funding Source: Medline; NIGMS NIH HHS [GM36864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACCOLLA RS, 1985, P NATL ACAD SCI USA, V82, P5145, DOI 10.1073/pnas.82.15.5145; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1989, J IMMUNOL, V142, P1005; DAS HK, 1983, P NATL ACAD SCI-BIOL, V80, P3543, DOI 10.1073/pnas.80.12.3543; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; FINN PW, 1990, EMBO J, V9, P1543, DOI 10.1002/j.1460-2075.1990.tb08273.x; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLADSTONE P, 1980, SOMAT CELL GENET, V6, P285, DOI 10.1007/BF01538802; Griscelli C, 1989, Immunodefic Rev, V1, P135; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; KARA C, UNPUB; KOBR M, 1990, MOL CELL BIOL, V10, P965, DOI 10.1128/MCB.10.3.965; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SHERMAN PA, 1987, P NATL ACAD SCI USA, V84, P4254, DOI 10.1073/pnas.84.12.4254; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X	29	175	176	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					709	712		10.1126/science.1902592	http://dx.doi.org/10.1126/science.1902592			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902592				2022-12-01	WOS:A1991FK18500050
J	KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M				KEATING, M; ATKINSON, D; DUNN, C; TIMOTHY, K; VINCENT, GM; LEPPERT, M			LINKAGE OF A CARDIAC-ARRHYTHMIA, THE LONG QT SYNDROME, AND THE HARVEY RAS-1 GENE	SCIENCE			English	Article							ANIRIDIA-WILMS TUMOR; CANCER-PATIENTS; LOCALIZATION; C-HA-RAS1; ONCOGENE; PROTEINS; PRODUCT; LOCUS; CELLS	Genetic factors contribute to heart disease. In this study, linkage analyses have been performed in a family that is predisposed to sudden death from cardiac arrhythmias, the long QT syndrome (LQT). A DNA marker at the Harvey ras-1 locus (H-ras-1) was linked to LQT with a logarithm of the likelihood ratio for linkage (lod score) of 16.44 at theta = 0, which confirms the genetic basis of this trait and localizes this gene to the short arm of chromosome 11. As no recombination was observed between LQT and H-ras-1, and there is a physiological rationale for its involvement in this disease, ras becomes a candidate for the disease locus.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84132; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84143; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	KEATING, M (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,DIV CARDIOL,SALT LAKE CITY,UT 84132, USA.							Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; DAUSSET J, 1986, PRESSE MED, V15, P1801; DEMARTINVILLE B, 1983, NATURE, V305, P641, DOI 10.1038/305641a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GIUFFRE RM, 1990, AM J HUM GENET, V47; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HUERRE C, 1983, NATURE, V305, P638, DOI 10.1038/305638a0; ITOH S, 1962, CLIN PEDIATR PHILADE, V21, P20; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KEATING MT, UNPUB; KLINGER HP, 1989, CYTOGENET CELL GENET, V51, P740; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; MCKUSICK VA, 1908, MENDELIAN INHERITANC; MELKI J, 1987, CYTOGENET CELL GENET, V40, P775; ROMANO C, 1965, LANCET, V1, P658; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SCHWARTZ P J, 1989, Journal of the American College of Cardiology, V13, p20A; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; VINCENT GM, 1989, CIRCULATION S2, V80, P654; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEITKAMP LR, 1989, CYTOGENET CELL GENET, V51, P1106; WEITKAMP LR, 1985, CYTOGENET CELL GENET, V40, P775; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	34	442	457	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					704	706		10.1126/science.1673802	http://dx.doi.org/10.1126/science.1673802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1673802				2022-12-01	WOS:A1991FK18500048
J	KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL				KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL			PROTECTION AGAINST MALARIA BY VACCINATION WITH SPOROZOITE SURFACE PROTEIN-2 PLUS CS PROTEIN	SCIENCE			English	Article							CIRCUMSPOROZOITE PROTEIN; MONOCLONAL-ANTIBODIES; PLASMODIUM-YOELII; MAMMALIAN-CELLS; MURINE MALARIA; EXPRESSION; EFFICIENT; VACCINES; ANTIGENS; SYSTEM	The circumsporozoite (CS) protein has been the target for development of malaria sporozoite vaccines for a decade. However, immunization with subunit vaccines based on the CS protein has never given the complete protection found after immunization with irradiated sporozoites. BALB/c mice immunized with irradiated Plasmodium yoelii sporozoites produced antibodies and cytotoxic T cells against a 140-kilodalton protein, sporozoite surface protein 2 (SSP2). Mice immunized with P815 cells that had been transfected with either SSP2 or CS genes were partially protected, and those immunized with a mixture of SSP2 and CS transfectants were completely protected against malaria. These studies emphasize the importance of vaccine delivery systems in achieving protection and define a multi-antigen sporozoite vaccine.	USN,MED RES INST,MALARIA PROGRAM,BETHESDA,MD 20889; NIH,PARASIT DIS LAB,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; [Anonymous], COMMUNICATION; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLYDE DF, 1973, AM J MED SCI, V266, P160; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; HAMMERLING GJ, 1979, J EXP MED, V150, P108, DOI 10.1084/jem.150.1.108; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; KHUSMITH S, UNPUB; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1987, P NATL ACAD SCI USA, V84, P8647, DOI 10.1073/pnas.84.23.8647; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; Rieckmann K H, 1979, Bull World Health Organ, V57 Suppl 1, P261; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; Sedegah M., 1988, Technological Advances in Vaccine Development  (Proceedings of a Genentech, Ortho, Smith Kline & French-UCLA Symposium, 30 Jan.-6 Feb. 1988, Park City, Utah, USA)., P295; SEDEGAH M, 1990, B WORLD HEALTH ORGAN, V68, P109; SEDEGAH M, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591	33	181	189	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					715	718		10.1126/science.1827210	http://dx.doi.org/10.1126/science.1827210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1827210				2022-12-01	WOS:A1991FK18500052
J	KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG				KIM, HK; KIM, JW; ZILBERSTEIN, A; MARGOLIS, B; KIM, JG; SCHLESSINGER, J; RHEE, SG			PDGF STIMULATION OF INOSITOL PHOSPHOLIPID HYDROLYSIS REQUIRES PLC-GAMMA-1 PHOSPHORYLATION ON TYROSINE RESIDUES 783 AND 1254	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-GAMMA; FACTOR RECEPTOR; KINASES INVIVO; BOVINE BRAIN; SUBSTRATE; CALCIUM; INVITRO	PDGF binding to its receptor promotes the association with and stimulates the phosphorylation of PLC-gamma-1 at tyrosine and serine residues. Also, PDGF induces an increase in the hydrolysis of inositol phospholipids by PLC. How PDGF activates PLC was investigated by substituting phenylalanine for tyrosine at PLC-gamma-1 phosphorylation sites 771, 783, and 1254 and expressing the mutant enzymes in NIH 3T3 cells. Phenylalanine substitution at Tyr-783 completely blocked the activation of PLC by PDGF, whereas mutation at Tyr-1254 inhibited and mutation at Tyr-771 enhanced the response. Like the wild type, PLC-gamma-1 substituted with phenylalanine at Tyr-783 became associated with the PDGF receptor and underwent phosphorylation at serine residues in response to PDGF. These results suggest that PLC-gamma-1 is the PLC isozyme that mediates PDGF-induced inositol phospholipid hydrolysis, that phosphorylation on Tyr-783 is essential for PLC-gamma-1 activation. These results provide direct evidence that growth factor receptors activate the function of intracellular protein by tyrosine phosphorylation.	NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892; RORER BIOTECHNOL INC,KING OF PRUSSIA,PA 19406; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); New York University	KIM, HK (corresponding author), NHLBI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.bi.56.070187.004313; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KIM JW, 1990, J BIOL CHEM, V265, P3940; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	33	530	539	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					435	441		10.1016/0092-8674(91)90461-7	http://dx.doi.org/10.1016/0092-8674(91)90461-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1708307				2022-12-01	WOS:A1991FK18200010
J	KISS, T; MARSHALLSAY, C; FILIPOWICZ, W				KISS, T; MARSHALLSAY, C; FILIPOWICZ, W			ALTERATION OF THE RNA-POLYMERASE SPECIFICITY OF U3 SNRNA GENES DURING EVOLUTION AND INVITRO	CELL			English	Article							SMALL NUCLEAR RNAS; C-MYC GENE; III PROMOTER; TATA BOX; TRANSCRIPTION; COMPONENTS; SEQUENCES; BINDING; PLANTS; VIRUS	We present evidence that the genes encoding U3 snRNA in plants are transcribed by RNA polymerase III (pol III) and not by RNA polymerase II (pol II) as in vertebrates or lower eukaryotes. The U3 gene is the only known example of a gene transcribed by different polymerases in different organisms. It is possible to convert the plant U3 gene into a functional pol II-transcribed gene by manipulating the spacing between the promoter elements and inserting a pol II-specific termination signal. Pol II-transcribed U3 RNA, containing the 5'-terminal cap different from that present in the wild-type counterpart, is packaged in transfected protoplasts into U3 snRNP precipitable with anti-fibrillarin antibodies. These findings provide further evidence for the common ancestry of the pol II and pol III transcription systems, and indicate that promoter diversification in some genes has occurred relatively recently.			KISS, T (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; CHANDRASEKHARAPPA SC, 1983, J CELL PHYSIOL, V117, P169, DOI 10.1002/jcp.1041170206; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; EPSTEIN P, 1984, BIOCHEMISTRY-US, V23, P5421, DOI 10.1021/bi00318a007; FILIPOWICZ W, 1990, MOL BIOL REP, V14, P125, DOI 10.1007/BF00360443; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOUY M, 1989, MOL BIOL EVOL, V6, P109; GUILTINAN MJ, 1988, EUR J CELL BIOL, V46, P547; GUPTA S, 1990, J BIOL CHEM, V265, P19137; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HELLUNGLARSEN P, 1980, BIOCHIM BIOPHYS ACTA, V609, P201, DOI 10.1016/0005-2787(80)90213-0; HELLUNGLARSEN P, 1981, BIOCHEM BIOPH RES CO, V99, P1303, DOI 10.1016/0006-291X(81)90761-0; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1985, EUR J BIOCHEM, V152, P259, DOI 10.1111/j.1432-1033.1985.tb09192.x; KISS T, 1990, NUCLEIC ACIDS RES, V18, P1941, DOI 10.1093/nar/18.8.1941; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MARSHALLSAY C, 1990, NUCLEIC ACIDS RES, V18, P3451; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MEMET S, 1988, J BIOL CHEM, V263, P10048; MUHLBACH HP, 1979, NATURE, V278, P185, DOI 10.1038/278185a0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; REDDY R, 1990, NUCLEIC ACIDS RES, V18, P2231, DOI 10.1093/nar/18.suppl.2231; REDDY R, 1988, NUCLEIC ACIDS RES, V16, pR71, DOI 10.1093/nar/16.suppl.r71; REDDY R, 1981, J BIOL CHEM, V16, P8452; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SZKUKALEK A, 1990, NUCLEIC ACIDS RES, V18, P1295, DOI 10.1093/nar/18.5.1295; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1989, EMBO J, V8, P3875, DOI 10.1002/j.1460-2075.1989.tb08566.x; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3459; WISE JA, 1981, J BIOL CHEM, V256, P956	52	98	104	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					517	526		10.1016/0092-8674(91)90469-F	http://dx.doi.org/10.1016/0092-8674(91)90469-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1826860				2022-12-01	WOS:A1991FK18200018
J	KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T				KOCH, CA; ANDERSON, D; MORAN, MF; ELLIS, C; PAWSON, T			SH2 AND SH3 DOMAINS - ELEMENTS THAT CONTROL INTERACTIONS OF CYTOPLASMIC SIGNALING PROTEINS	SCIENCE			English	Article							ROUS-SARCOMA VIRUS; GROWTH-FACTOR RECEPTOR; AMINO-TERMINAL DOMAIN; TYROSINE KINASE GENE; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL KINASE; SRC GENE; PDGF RECEPTOR; EGF RECEPTOR; REGULATES INTERACTIONS	Src homology (SH) regions 2 and 3 are noncatalytic domains that are conserved among a series of cytoplasmic signaling proteins regulated by receptor protein-tyrosine kinases, including phospholipase C-gamma, Ras GTPase (guanosine triphosphatase)-activating protein, and Src-like tyrosine kinases. The SH2 domains of these signaling proteins bind tyrosine phosphorylated polypeptides, implicated in normal signaling and cellular transformation. Tyrosine phosphorylation acts as a switch to induce the binding of SH2 domains, thereby mediating the formation of heteromeric protein complexes at or near the plasma membrane. The formation of these complexes is likely to control the activation of signal transduction pathways by tyrosine kinases. The SH3 domain is a distinct motif that, together with SH2, may modulate interactions with the cytoskeleton and membrane. Some signaling and transforming proteins contain SH2 and SH3 domains unattached to any known catalytic element. These noncatalytic proteins may serve as adaptors to link tyrosine kinases to specific target proteins. These observations suggest that SH2 and SH3 domains participate in the control of intracellular responses to growth factor stimulation.	UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013; Moran, Michael/GYD-3631-2022					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1987, J VIROL, V61, P1893, DOI 10.1128/JVI.61.6.1893-1900.1987; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO J, 1988, NATURE, V343, P377; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, COMMUNICATION; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1990, ANNU REV BIOCHEM, V61, P121; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM JW, 1990, J BIOL CHEM, V265, P3940; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH C, UNPUB; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KRIZ R, 1990, CIBA F SYMP, V150, P112; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTSU M, COMMUNICATION; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PELICCI G, COMMUNICATION; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REICHMAN CT, COMMUNICATION; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROTTAPEL R, IN PRESS MOL CELL BI; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	131	1859	1969	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					668	674		10.1126/science.1708916	http://dx.doi.org/10.1126/science.1708916			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1708916				2022-12-01	WOS:A1991FK18500038
J	LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG				LERNER, RA; BENKOVIC, SJ; SCHULTZ, PG			AT THE CROSSROADS OF CHEMISTRY AND IMMUNOLOGY - CATALYTIC ANTIBODIES	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; CLAISEN REARRANGEMENT; ENZYMIC CATALYSIS; COMBINING SITES; BINDING-ENERGY; NOBEL LECTURE; SPECIFICITY; GENERATION; AMIDE; HYDROLYSIS	Immunochemistry has historically focused on the nature of antigenicity and antibody-antigen recognition. However, in the last 5 years, the field of immunochemistry has taken a new direction. With the aid of mechanistic and synthetic chemistry, the vast network of molecules and cells of the immune system has been tapped to produce antibodies with a new function - catalytic antibodies. Because antibodies can be generated that selectively bind almost any molecule of interest, this new technology offers the potential to tailor-make highly selective catalysts for applications in biology, chemistry, and medicine. In addition, catalytic antibodies provide fundamental insight into important aspects of biological catalysis, including the importance of transition-state stabilization, proximity effects, general acid and base catalysts, electrophilic and nucleophilic catalysis, and strain.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	Scripps Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California Berkeley	LERNER, RA (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.							ARATA Y, 1990, J SYNTH ORG CHEM JPN, V6, P482; ARMSTRONG RW, 1989, J AM CHEM SOC, V111, P7530, DOI 10.1021/ja00201a038; BALAN A, 1988, J CHEM SOC CHEM COMM, P106, DOI 10.1039/c39880000106; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BARTLETT P, 1983, BIOCHEMISTRY-US, V22, P4168; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; BLACKBURN GF, IN PRESS ANAL CHEM; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P7246, DOI 10.1021/bi00397a008; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; CARTER EA, 1987, J CHEM PHYS, V86, P862, DOI 10.1063/1.452287; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; COCHRAN AG, 1990, J AM CHEM SOC, V112, P9414, DOI 10.1021/ja00181a065; COCHRAN AG, 1988, J AM CHEM SOC, V110, P7888, DOI 10.1021/ja00231a056; COCHRAN AG, UNPUB; CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P1009, DOI 10.1002/anie.198810093; CRAM DJ, 1987, PRIX NOBEL, P129; CRAM DJ, 1987, PRIX NOBEL, P105; DAFFRON A, 1971, BIOCHEM BIOPH RES CO, V52, P779; DANISHEVSKY S, UNPUB; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DURFOR CN, 1988, J AM CHEM SOC, V110, P8713, DOI 10.1021/ja00234a032; ESCHENMOSER A, 1989, 25TH EUCHEM C STER B; GOODMAN JW, 1985, ANTIGEN, V3; HERMES JD, 1987, COLD SPRING HARB SYM, V52, P597, DOI 10.1101/SQB.1987.052.01.068; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HILVERT D, UNPUB; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; INAGAMI T, 1969, J BIOCHEM, V65, P809, DOI 10.1093/oxfordjournals.jbchem.a129081; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; JACKSON DY, IN PRESS J AM CHEM S; JACKSON DY, IN PRESS P NATL ACAD; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1989, THESIS U CALIFORNIA; JACOBSEN JL, UNPUB; JANDA K, UNPUB; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1990, J AM CHEM SOC, V112, P8886, DOI 10.1021/ja00180a035; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, 1988, J AM CHEM SOC, V110, P4835, DOI 10.1021/ja00222a056; JANJIC N, 1989, J AM CHEM SOC, V111, P6374, DOI 10.1021/ja00198a058; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KAISER ET, 1984, SCIENCE, V226, P505, DOI 10.1126/science.6238407; KEINAN E, 1990, PURE APPL CHEM, V62, P2013, DOI 10.1351/pac199062102013; KHORANA HG, 1968, P INT C BIOCH, V7, P17; KITAZUME T, IN PRESS J AM CHEM S; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOSHLAND DE, 1973, SCI AM, V229, P52, DOI 10.1038/scientificamerican1073-52; KRAFT GA, 1989, ANNU REP MED CHEM, V25, P299; LANDSTEINER K, 1944, SPECIFICITY SEROLOGI; Lavallee D. K., 1988, MOL STRUCT ENERG, V9, P279; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LERNER RA, 1984, ADV IMMUNOL, V36, P1, DOI 10.1016/S0065-2776(08)60898-6; LERNER RA, UNPUB; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; MARTIN JT, IN PRESS CIBA F S; MERRIFIELD RB, 1985, ANGEW CHEM INT EDIT, V24, P799, DOI 10.1002/anie.198507993; NAKAYAMA GR, IN PRESS CIBA F S; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; Nisonoff A, 1975, ANTIBODY MOL; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PAULING L, 1948, Am Sci, V36, P51; Pauling L, 1944, J AM CHEM SOC, V66, P784, DOI 10.1021/ja01233a039; POCKER Y, 1977, J AM CHEM SOC, V99, P2276, DOI 10.1021/ja00449a042; POLLACK SJ, 1987, COLD SPRING HARB SYM, V52, P97, DOI 10.1101/SQB.1987.052.01.014; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POLLACK SJ, 1988, SCIENCE, V242, P1038, DOI 10.1126/science.3194752; POLLACK SJ, 1989, J AM CHEM SOC, V111, P1929, DOI 10.1021/ja00187a085; POLLACK SJ, 1988, METHOD ENZYMOL, V178, P551; PRESSMAN D, 1968, STRUCTURAL BASES ANT; RASO W, 1975, BIOCHEMISTRY-US, V14, P584; ROSTER MJ, 1988, SCIENCE, V241, P1200; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SEEBACH D, 1990, ANGEW CHEM INT EDIT, V29, P1320, DOI 10.1002/anie.199013201; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; SHOKAT KM, 1990, ANGEW CHEM INT EDIT, V29, P1296, DOI 10.1002/anie.199012961; SHOKAT KM, 1988, ANGEW CHEM INT EDIT, V27, P1172, DOI 10.1002/anie.198811721; SHOKAT R, IN PRESS CIBA F S; SUDHIR P, 1989, SCIENCE, V244, P1158; TAWFIK DS, 1990, BIOCHEMISTRY-US, V29, P9916, DOI 10.1021/bi00494a023; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; WESTHEIMER FH, 1962, ADV ENZYMOL, V24, P456; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Woolley D., 1952, STUDY ANTIMETABOLITE; ZERNER B, 1964, J AM CHEM SOC, V86, P3674, DOI 10.1021/ja01072a016	102	653	698	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					659	667		10.1126/science.2024118	http://dx.doi.org/10.1126/science.2024118			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024118				2022-12-01	WOS:A1991FK18500037
J	LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR				LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR			DIRECT INTERACTION BETWEEN SP1 AND THE BPV ENHANCER E2-PROTEIN MEDIATES SYNERGISTIC ACTIVATION OF TRANSCRIPTION	CELL			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; DNA-BINDING PROTEINS; CARBOXY-TERMINAL DOMAIN; LONG CONTROL REGION; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; GENE-EXPRESSION; MAMMALIAN-CELLS; E2 PROTEIN; PROMOTER	The physical interaction of heterologous site-specific DNA-binding proteins is an important theme in eukaryotic transcriptional regulation. In this paper, we show that the cellular transcription factor Sp1 and the BPV-1 (bovine papillomavirus type 1) enhancer protein E2 activate transcription synergistically from two papilloma viral promoters and a series of synthetic promoter constructs in transient transfection experiments. Furthermore, Sp1 can target E2 to a promoter region even in the absence of a specific E2 DNA-binding motif. Biochemical experiments establish that Sp1 enhances E2 binding to its sites and that the two proteins form a specific complex. Sp1 sequesters distally bound E2 to the promoter region by formation of stable DNA loops, visualized by electron microscopy. These experiments substantiate the notion that enhancer binding proteins are targeted to promoter regions by direct interaction with proteins that bind proximal to the transcriptional start site.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	LI, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HERMONAT PL, 1987, J VIROL, V61, P3889, DOI 10.1128/JVI.61.12.3889-3895.1987; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KNIGHT J, 1981, IN PRESS P NATL ACAD; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOSKALUK C, 1987, P NATL ACAD SCI USA, V84, P1215, DOI 10.1073/pnas.84.5.1215; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; PRAKASH SS, 1988, J VIROL, V62, P3608, DOI 10.1128/JVI.62.10.3608-3613.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBBINS P, 1985, EUKARYOTIC TRANSCRIP, P41; ROBBINS PD, 1986, MOL CELL BIOL, V6, P1283, DOI 10.1128/MCB.6.4.1283; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SPALHOLZ BA, 1988, J VIROL, V62, P2128; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SU W, 1991, IN PRESS GENES DEV; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VAILLANCOURT P, 1990, J VIROL, V64, P3927, DOI 10.1128/JVI.64.8.3927-3937.1990; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	70	301	304	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					493	505		10.1016/0092-8674(91)90467-D	http://dx.doi.org/10.1016/0092-8674(91)90467-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850324				2022-12-01	WOS:A1991FK18200016
J	MALINOW, R				MALINOW, R			TRANSMISSION BETWEEN PAIRS OF HIPPOCAMPAL SLICE NEURONS - QUANTAL LEVELS, OSCILLATIONS, AND LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RELEASE; INDUCTION; EFFICACY; INVITRO	Long-term potentiation (LTP) of synaptic transmission after coincident pre- and postsynaptic activity is considered a cellular model of changes underlying learning and memory. In intact tissue, LTP has been observed only between populations of neurons, making analysis of mechanisms difficult. Transmission between individual pre- and postsynaptic hippocampal cells was studied, suggesting quantal amplitude distributions with little variability in quantal size. LTP between such pairs is manifested by large, persistent, and synapse-specific potentiation with a shift in amplitude distribution that suggests presynaptic changes. Oscillations in amplitude of transmission, apparently of presynaptic origin, are common and can be triggered by LTP.	STANFORD UNIV, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University	MALINOW, R (corresponding author), UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T, 1988, LONG TERM POTENTIATI; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MEIRI H, 1978, J PHYSIOL-LONDON, V278, P513, DOI 10.1113/jphysiol.1978.sp012321; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PAWSON PA, 1989, PROC R SOC SER B-BIO, V237, P489, DOI 10.1098/rspb.1989.0061; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SILVERMAN V, 1986, DENSITY ESTIMATE STA; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	197	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					722	724		10.1126/science.1850871	http://dx.doi.org/10.1126/science.1850871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1850871				2022-12-01	WOS:A1991FK18500054
J	MITTNACHT, S; WEINBERG, RA				MITTNACHT, S; WEINBERG, RA			G1/S PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS ASSOCIATED WITH AN ALTERED AFFINITY FOR THE NUCLEAR COMPARTMENT	CELL			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; CELL-CYCLE; ENCODED PROTEIN; RB GENE; PRODUCT; EXPRESSION; CHROMOSOME-13	Hyperphosphorylation of the retinoblastoma protein (pRB) is assumed to be a regulatory event leading to the inactivation of its growth-repressing functions. We demonstrate a functional alteration linked to the phosphorylation status of the protein. The un- or under-phosphorylated species are tightly associated with the nuclear structure. The association is resistant to digestion with nucleases, and release requires elevated salt concentrations. In contrast, the hyperphosphorylated species are eluted under hypotonic buffer conditions. The conversion from low salt-resistant to low salt-extractable pRB occurs with transition through the G1/S boundary of the cell cycle and thus parallels the reported onset of pRB phosphorylation. The ability to form a tight nuclear association is impaired in several naturally occuring pRB mutants, all of which show alterations within the binding region for viral oncoproteins. We suggest that the tight nuclear interaction is essential for the growth-regulating functions of pRB and may be preempted by viral oncoproteins.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	MITTNACHT, S (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139, USA.				NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COMMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; GRAND RJA, 1989, ONCOGENE, V4, P1291; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUBERMAN JA, 1987, CELL, V48, P7, DOI 10.1016/0092-8674(87)90347-3; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOPS AD, 1988, CELL, V55, P857, DOI 10.1016/0092-8674(88)90141-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISSMANN PT, 1989, ONCOGENE, V4, P839; RYGAARD K, 1990, CANCER RES, V50, P5312; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; VAUGHN JP, 1990, NUCLEIC ACIDS RES, V18, P1965, DOI 10.1093/nar/18.8.1965; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1988, ONCOGENE, V3, P471	71	325	328	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					381	393		10.1016/0092-8674(91)90456-9	http://dx.doi.org/10.1016/0092-8674(91)90456-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	2018973				2022-12-01	WOS:A1991FK18200005
J	PRENDERGAST, GC; LAWE, D; ZIFF, EB				PRENDERGAST, GC; LAWE, D; ZIFF, EB			ASSOCIATION OF MYN, THE MURINE HOMOLOG OF MAX, WITH C-MYC STIMULATES METHYLATION-SENSITIVE DNA-BINDING AND RAS COTRANSFORMATION	CELL			English	Article							MAJOR LATE PROMOTER; CASEIN KINASE-II; LEUCINE ZIPPER; TRANSCRIPTION FACTOR; EARLY REGION-1A; CELLS; PROTEINS; ONCOGENE; FOS; TRANSFORMATION	Myn, a novel murine approximately 18 kd basic/helix-loop-helix/"leucine zipper" (B/HLH/LZ) protein, forms a specific DNA-binding complex with the c-Myc oncoprotein through the HLH/LZ motif in both proteins. c-Myc/Myn recognizes a c-Myc-binding site (GACCACGTGGTC) with higher affinity than either protein by itself. CpG methylation of the recognition site greatly inhibits DNA binding, suggesting that DNA methylation may regulate the c-Myc/Myn complex in vivo. In 3T3 fibroblasts, Myn mRNA levels are induced several-fold by serum with delayed early kinetics, suggesting regulation by immediate-early gene products. Coexpression of Myn in a myc/ras rat embryo fibroblast focus formation assay specifically augmented c-myc transforming activity. We suggest that interaction of Myn with c-Myc stabilizes sequence-specific DNA binding in vivo.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	PRENDERGAST, GC (corresponding author), NYU MED CTR,KAPLAN CANC CTR,HOWARD HUGHES MED INST,MSB 397,NEW YORK,NY 10016, USA.			Ziff, Edward/0000-0001-7389-8649				BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROUCH DH, 1990, ONCOGENE, V5, P433; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GIBSON TJ, 1990, DNA MAP SEQ, V1, P3; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES PA, 1986, CANCER RES, V46, P461; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KERKHOFF E, 1991, IN PRESS P NATL ACAD; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MULLER R, 1987, ONCOGENE RES, V2, P19; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, IN PRESS EMBO J; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	63	572	580	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					395	407		10.1016/0092-8674(91)90457-A	http://dx.doi.org/10.1016/0092-8674(91)90457-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1840505				2022-12-01	WOS:A1991FK18200006
J	SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ				SHUFORD, W; RAFF, HV; FINLEY, JW; ESSELSTYN, J; HARRIS, LJ			EFFECT OF LIGHT CHAIN V-REGION DUPLICATION ON IGG OLIGOMERIZATION AND INVIVO EFFICACY	SCIENCE			English	Article							COMPLEMENT; IMMUNOGLOBULIN; ACTIVATION; ANTIBODIES; PROTECTION; PROTEINS	A human immunoglobulin G1 (IgG1) antibody oligomer was isolated from a transfected myeloma cell line that produced a monoclonal antibody to group B streptococci. Compared to the IgG1 monomer, the oligomer was significantly more effective at protecting neonatal rats from infection in vivo. The oligomer was also shown to cross the placenta and to be stable in neonatal rats. Immunochemical analysis and complementary DNA sequencing showed that the transfected cell line produced two distinct kappa light chains: a normal light chain (L(n)) with a molecular mass of 25 kilodaltons and a 37-kilodalton species (L37), the domain composition of which was variable-variable-constant (V-V-C). Cotransfection of vectors encoding the heavy chain and L37 resulted in production of oligomeric IgG.	BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT MOLEC IMMUNOL,SEATTLE,WA 98121; BRISTOL MYERS,SQUIBB PHARMACEUT RES INST,DEPT IMMUNE SCI,SEATTLE,WA 98121	Bristol-Myers Squibb; Bristol-Myers Squibb								CHIEN NC, 1989, P NATL ACAD SCI USA, V86, P5532, DOI 10.1073/pnas.86.14.5532; DAMERVAL C, 1987, ELECTROPHORESIS, V8, P158, DOI 10.1002/elps.1150080308; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; ENGVALL E, 1972, J IMMUNOL, V109, P129; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; HAMES BD, 1981, GEL ELECTROPHORESIS, P30; HARLOW E, 1988, ANTIBODIES LAB MANUA, P391; JESKE DJ, 1984, FUNDAMENTAL IMMUNOLO, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN TR, 1988, J INFECT DIS, V157, P91, DOI 10.1093/infdis/157.1.91; MORRISON SL, 1989, ADV IMMUNOL, V44, P65; RAFF HV, 1988, J EXP MED, V168, P905, DOI 10.1084/jem.168.3.905; RAFF HV, 1990, J INFECT DIS, V163, P346; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P308; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; SHIGEOKA AO, 1984, J INFECT DIS, V150, P63, DOI 10.1093/infdis/150.1.63; SHUFORD W, UNPUB; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SMITH VH, UNPUB; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162	21	16	23	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					724	727		10.1126/science.1902593	http://dx.doi.org/10.1126/science.1902593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1902593				2022-12-01	WOS:A1991FK18500055
J	SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B				SIDRANSKY, D; VONESCHENBACH, A; TSAI, YC; JONES, P; SUMMERHAYES, I; MARSHALL, F; PAUL, M; GREEN, P; HAMILTON, SR; FROST, P; VOGELSTEIN, B			IDENTIFICATION OF P53 GENE-MUTATIONS IN BLADDER CANCERS AND URINE SAMPLES	SCIENCE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RAS ONCOGENE; SHORT ARM; TRANSFORMATION; DNA; CHROMOSOME-11; CARCINOMA; ANTIONCOGENES; COOPERATION	Although bladder cancers are very common, little is known about their molecular pathogenesis. In this study, invasive bladder cancers were evaluated for the presence of gene mutations in the p53 suppressor gene. Of 18 tumors evaluated, 11 (61 percent) were found to have genetic alterations of p53. The alterations included ten point mutations resulting in single amino acid substitutions, and one 24-base pair deletion. In all but one case, the mutations were associated with chromosome 17p allelic deletions, leaving the cells with only mutant forms of the p53 gene product. Through the use of the polymerase chain reaction and oligomer-specific hybridization, p53 mutations were identified in 1 to 7 percent of the cells within the urine sediment of each of three patients tested. The p53 mutations are the first genetic alterations demonstrated to occur in a high proportion of primary invasive bladder cancers. Detection of such mutations ex vivo has clinical implications for monitoring individuals whose tumor cells are shed extracorporeally.	JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT UROL,HOUSTON,TX 77054; UNIV SO CALIF,KENNETH J NORRIS COMPREHENS CANC CTR,LOS ANGELES,CA 90033; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; JOHNS HOPKINS UNIV,DEPT UROL,BALTIMORE,MD 21215; JOHNS HOPKINS UNIV,DEPT PATHOL,BALTIMORE,MD 21231; MD ANDERSON HOSP & TUMOR INST,DEPT CELL BIOL,HOUSTON,TX 77054	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009071, R01CA043460, R37CA043460, R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [CA49758, CA43460, CA09071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; Badalament R A, 1988, Semin Urol, V6, P22; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, IN PRESS NUCLEAR PRO; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COON JM, COMMUNICATION; DEITCH AD, 1990, J UROLOGY, V143, P700, DOI 10.1016/S0022-5347(17)40064-4; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DELSENNO L, 1989, J UROLOGY, V142, P146; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOOT NC, 1958, CANCER BRUSSELS, V11, P137; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GIBAS Z, 1984, CANCER RES, V44, P1257; HANSEN MF, 1987, CANCER RES, V47, P5518; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1985, ACTA CYTOL, V29, P810; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASKUS JR, 1988, UROL RES, V6, P341; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MUNROE DG, 1988, ONCOGENE, V2, P621; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; NEAL DE, 1985, LANCET, V1, P366; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAGHAVAN D, 1990, NEW ENGL J MED, V322, P1129, DOI 10.1056/NEJM199004193221607; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SIDRANSKY D, UNPUB; SPEISSL B, 1982, UICC INT UNION CANCE; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSAI YC, 1990, CANCER RES, V50, P40; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WEINBERG RA, 1989, CANCER RES, V49, P3713	54	838	868	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					706	709		10.1126/science.2024123	http://dx.doi.org/10.1126/science.2024123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024123				2022-12-01	WOS:A1991FK18500049
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			A PROTEIN-CONDUCTING CHANNEL IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; NUCLEAR-ENVELOPE PERMEABILITY; IMMUNOGLOBULIN LIGHT-CHAINS; NASCENT POLYPEPTIDES; ROUGH MICROSOMES; MEMBRANE; TRANSLOCATION; SEQUENCE; PREPROLACTIN; RECEPTOR	The existence of a protein-conducting channel in the endoplasmic reticulum membrane was demonstrated by electrophysiological techniques. Pancreatic rough microsome (RM) vesicles were fused to one side (cis) of a planar lipid bilayer separating two aqueous compartments of 50 mM salt. This exposed the cytoplasmic surface of the RMs, with its attached ribosomes, to the cis chamber. Addition of 100-mu-M puromycin to the cis side caused a large increase in membrane conductance, presumably the result of puromycin-induced clearance of nascent protein chains from the lumen of protein-conducting channels. When puromycin was added at low concentrations (0.33-mu-M), single channels of 220 pS were observed. These closed when the salt concentration was raised to levels at which ribosomes detach from the membrane (150-400 mM), indicating that the attached ribosome keeps the channel in an open conformation. A mechanism for a complete cycle of opening and closing of the protein-conducting channel is suggested.			SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224				ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193, DOI DOI 10.1007/978-1-4684-3330-2_16; BRECHER AS, 1969, BIOCHEM J, V112, P335, DOI 10.1042/bj1120335; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CORNELL DG, 1989, BIOCHEMISTRY-US, V28, P2789, DOI 10.1021/bi00433a008; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HERSH LB, 1981, J NEUROCHEM, V36, P1594, DOI 10.1111/j.1471-4159.1981.tb00605.x; HEYER EJ, 1976, J GEN PHYSIOL, V67, P703, DOI 10.1085/jgp.67.6.703; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JIANG LW, 1986, J CELL BIOL, V102, P853, DOI 10.1083/jcb.102.3.853; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAKE JA, 1985, ANNU REV BIOCHEM, V54, P507, DOI 10.1146/annurev.biochem.54.1.507; MARCHAIS D, 1979, J PHYSIOL-LONDON, V297, P9, DOI 10.1113/jphysiol.1979.sp013025; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MILSTEIN C, 1972, NATURE-NEW BIOL, V239, P117, DOI 10.1038/newbio239117a0; MUELLER P, 1963, J PHYS CHEM-US, V67, P534, DOI 10.1021/j100796a529; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MUELLER P, 1969, LABORATORY TECHNIQUE, P141; MULLINS LJ, 1959, J GEN PHYSIOL, V42, P817, DOI 10.1085/jgp.42.4.817; NESMEYANOVA MA, 1989, FEBS LETT, V257, P203, DOI 10.1016/0014-5793(89)81534-0; NILES WD, 1987, J GEN PHYSIOL, V90, P703, DOI 10.1085/jgp.90.5.703; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PERARA E, 1985, J CELL BIOL, V101, P2292, DOI 10.1083/jcb.101.6.2292; Pestka S, 1974, Methods Enzymol, V30, P261; PETERS R, 1983, J BIOL CHEM, V258, P1427; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; SABATINI DD, 1970, J CELL BIOL, V45, P146, DOI 10.1083/jcb.45.1.146; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SCHWARZ W, 1977, BIOPHYS J, V20, P343, DOI 10.1016/S0006-3495(77)85554-9; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; SIUTAMANGANO P, 1981, J BIOL CHEM, V256, P2094; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; SUSZKIW JB, 1970, BIOCHEMISTRY-US, V9, P4008, DOI 10.1021/bi00822a021; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANHELDEN D, 1977, NATURE, V269, P711, DOI 10.1038/269711a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2; YAMAMOTO Y, 1990, BIOCHEMISTRY-US, V29, P8998, DOI 10.1021/bi00490a017; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	72	526	545	3	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					371	380		10.1016/0092-8674(91)90455-8	http://dx.doi.org/10.1016/0092-8674(91)90455-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1902142				2022-12-01	WOS:A1991FK18200004
J	STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL				STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL			LATE ENDOSOMES DERIVE FROM EARLY ENDOSOMES BY MATURATION	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTOR; HEPATOMA-CELL LINE; HUMAN ASIALOTRANSFERRIN TYPE-3; ASIALOGLYCOPROTEIN RECEPTOR; IMMUNOELECTRON MICROSCOPY; LYSOSOMAL-ENZYME; RAT HEPATOCYTES; TRANSFERRIN RECEPTORS; FREE SYSTEM	Endocytosed proteins destined for degradation in lysosomes are targeted mainly to early endosomes following uptake. Late endosomes are the major site for entry of newly synthesized lysosomal hydrolases via the cation-independent mannose 6-phosphate receptor into the degradative pathway. No consensus exists as to the mechanism of transport from early to late endosomes. We used asialoorosomucoid and transferrin to label selected parts of the degradative and receptor-recycling pathways, respectively, in the human hepatoma cell line HepG2. Intracellular mixing of sequentially endocytosed I-125- and HRP-labeled ligands was monitored by using 3,3'-diaminobenzidine-mediated density perturbation. The entire endocytic pathway of asialoorosomucoid, except for the lysosomes, remained fully accessible to subsequently endocytosed transferrin conjugated to HRP with unchanged kinetics. These results together with immunoelectron microscopic data support a model in which early endosomes gradually mature into late endosomes.	ST LOUIS CHILDRENS HOSP, DEPT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINKRODT DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	STOORVOGEL, W (corresponding author), STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.							AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BRETSCHER MS, 1984, CELL, V38, P3, DOI 10.1016/0092-8674(84)90519-1; BRIDGES K, 1982, P NATL ACAD SCI-BIOL, V79, P350, DOI 10.1073/pnas.79.2.350; CIECHANOVER A, 1983, CELL, V32, P267, DOI 10.1016/0092-8674(83)90517-2; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REGOECZI E, 1985, EXP CELL RES, V160, P1, DOI 10.1016/0014-4827(85)90230-7; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, IN PRESS J CELL BIOL; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WARD DM, 1989, J BIOL CHEM, V264, P8164; WATTS C, 1984, EMBO J, V3, P1965, DOI 10.1002/j.1460-2075.1984.tb02077.x; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375	56	257	260	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					417	427		10.1016/0092-8674(91)90459-C	http://dx.doi.org/10.1016/0092-8674(91)90459-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850321				2022-12-01	WOS:A1991FK18200008
J	SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL				SULLIVAN, SJ; MAKI, T; BORLAND, KM; MAHONEY, MD; SOLOMON, BA; MULLER, TE; MONACO, AP; CHICK, WL			BIOHYBRID ARTIFICIAL PANCREAS - LONG-TERM IMPLANTATION STUDIES IN DIABETIC, PANCREATECTOMIZED DOGS	SCIENCE			English	Article							ISLET XENOGRAFT SURVIVAL; BIOARTIFICIAL PANCREAS; ENDOCRINE PANCREAS; CAPILLARY UNITS; TRANSPLANTATION; CULTURE; MOUSE; SERUM; CELLS; MICE	Diabetic complications such as neuropathy, retinopathy, and renal and cardiovascular disease continue to pose major health risks for diabetic patients. Consequently, much effort has focused on approaches that could replace conventional insulin therapy and provide more precise regulation of blood glucose levels. The biohybrid perfused artificial pancreas was designed to incorporate islet tissue and a selectively permeable membrane that isolates this tissue from the immune system of the recipient. Biohybrid pancreas devices containing canine islet allografts were implanted in ten pancreatectomized dogs requiring 18 to 32 units of injected insulin daily. These implants resulted in good control of fasting glucose levels in six of these animals without further exogenous insulin for periods of up to 5 months.	NEW ENGLAND DEACONESS HOSP, BROOKLINE, MA 02212 USA; HARVARD UNIV, SCH MED, DIV ORGAN TRANSPLANTAT, BROOKLINE, MA 02212 USA; WR GRACE & CO CONN, DIV RES, LEXINGTON, MA 02173 USA	Harvard University	SULLIVAN, SJ (corresponding author), BIOHYBRID TECHNOL INC, 910 TURNPIKE RD, SHREWSBURY, MA 01545 USA.							AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; BONNEVIENIELSEN V, 1983, ENDOCRINOLOGY, V112, P1049, DOI 10.1210/endo-112-3-1049; BORLAND KM, UNPUB; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHICK WL, 1975, SCIENCE, V187, P847, DOI 10.1126/science.187.4179.847; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; GOTOH M, 1988, TRANSPLANT P, V20, P997; HALL FF, 1970, AM J CLIN PATHOL, V53, P627; JONSSON S, 1974, EUR J IMMUNOL, V4, P29, DOI 10.1002/eji.1830040108; KAVAI M, 1989, TRANSPL P, V21, P2709; KRAEGEN EW, 1981, HORM METAB RES, V13, P365, DOI 10.1055/s-2007-1019271; KUPIECWEGLINSKI JW, 1988, TRANSPLANTATION, V46, P785, DOI 10.1097/00007890-198812000-00001; LIKE AA, 1978, LAB INVEST, V38, P470; MAKI T, IN PRESS; MAKI T, 1990, 16TH ANN M AM SOC TR; Michaels A.S., 1971, U.S. Patent, Patent No. [3,615,024, 3615024]; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; REACH G, 1984, DIABETES, V33, P752, DOI 10.2337/diabetes.33.8.752; REACH G, 1984, BIOMED BIOCHIM ACTA, V43, P569; RICORDI C, 1988, TRANSPLANTATION, V45, P994, DOI 10.1097/00007890-198805000-00035; SCHARP DW, 1989, INT HDB PANCREAS TRA, P455; SELAWRY HP, 1984, DIABETES, V33, P405, DOI 10.2337/diabetes.33.4.405; SOELDNER JS, 1971, DIABETES MELLITUS DI, V3, P107; SORENSEN JT, 1982, DIABETES CARE, V5, P148, DOI 10.2337/diacare.5.3.148; SULLIVAN FP, 1987, TRANSPLANTATION, V44, P465, DOI 10.1097/00007890-198710000-00001; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; SWOPE SL, 1984, P NATL ACAD SCI-BIOL, V81, P1822, DOI 10.1073/pnas.81.6.1822; TZE WJ, 1983, DIABETES, V32, P1185, DOI 10.2337/diabetes.32.12.1185; TZE WJ, 1980, DIABETOLOGIA, V19, P541; WARNOCK GL, 1988, DIABETES, V37, P467, DOI 10.2337/diabetes.37.4.467; 1989, DIABETES, V38; 1990, TRANSPLANT P, V22	32	181	210	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					718	721		10.1126/science.2024124	http://dx.doi.org/10.1126/science.2024124			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024124				2022-12-01	WOS:A1991FK18500053
J	TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M				TOMIE, T; SHIMIZU, H; MAJIMA, T; YAMADA, M; KANAYAMA, T; KONDO, H; YANO, M; ONO, M			3-DIMENSIONAL READOUT OF FLASH X-RAY IMAGES OF LIVING SPERM IN WATER BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article								The imaging of living specimens in water by x-ray microscopy can be greatly enhanced with the use of an intense flash x-ray source and sophisticated technologies for reading x-ray images. A subpicosecond x-ray pulse from a laser-produced plasma was used to record the x-ray image of living sea urchin sperm in an x-ray resist. The resist relief was visualized at high resolution by atomic-force microscopy. Internal structure of the sperm head was evident, and the carbon density in a flagellum was estimated from the relief height.	NIKON INC,TSUKUBA LAB,TSUKUBA,IBARAKI 30026,JAPAN	Nikon Corporation	TOMIE, T (corresponding author), ELECTROTECH LAB,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN RD, 1968, J CELL BIOL, V37, P825, DOI 10.1083/jcb.37.3.825; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Cheng P.C., 1987, XRAY MICROSCOPY INST, P65; EASON RW, 1985, ANN REPORT; FEDER R, 1985, SCIENCE, V227, P63, DOI 10.1126/science.3964958; FEDER R, 1977, SCIENCE, V197, P259, DOI 10.1126/science.406670; GIUDICE G, 1987, SEA URCHIN EMBRYO, P23; JACOBSEN C, 1988, XRAY MICROSCOPY, V2, P253; KIRZ J, 1984, XRAY MICROSCOPY, P262; LONDON RA, 1989, APPL OPTICS, V28, P3397, DOI 10.1364/AO.28.003397; ROSSER RJ, 1987, APPL OPTICS, V26, P4313, DOI 10.1364/AO.26.004313; SAYRE D, 1988, XRAY MICROSCOPY, V2; SOLEM JC, 1986, J OPT SOC AM B, V3, P1551, DOI 10.1364/JOSAB.3.001551; 1990, INT C XRAY MICROSCOP	14	80	81	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					691	693		10.1126/science.2024121	http://dx.doi.org/10.1126/science.2024121			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	2024121				2022-12-01	WOS:A1991FK18500043
J	WISSINGER, B; SCHUSTER, W; BRENNICKE, A				WISSINGER, B; SCHUSTER, W; BRENNICKE, A			TRANS SPLICING IN OENOTHERA MITOCHONDRIA - NAD1-MESSENGER RNAS ARE EDITED IN EXON AND TRANSSPLICING GROUP-II INTRON SEQUENCES	CELL			English	Article							GENE ORGANIZATION; PLANT-MITOCHONDRIA; NUCLEOTIDE-SEQUENCE; WHEAT MITOCHONDRIA; RIBOSOMAL-PROTEIN; CHLOROPLAST DNA; CDNA LIBRARIES; EXPRESSION; GENOME; SUBUNIT	The complete NADH dehydrogenase subunit 1 (nad1) ORF in Oenothera mitochondria is encoded by five exons. These exons are located in three distant locations of the mitochondrial genome. One genomic region encodes exon a, the second encodes exons b and c, and the third specifies exons d and e. Cis-splicing group II introns separate exons b and c and d and e, while trans-splicing reactions are required to link exons a and b and c and d. The two parts of the group II intron sequences involved in these trans-splicing events can be aligned in domain IV. Exon sequences and the maturase-related ORF in intron d/e are edited by numerous C to U alterations in the mRNA. Two RNA editing events in the trans-splicing intron a/b improve conservation of the secondary structure in the stem of domain VI. RNA editing in intron sequences may thus be required for the trans-splicing reaction.			WISSINGER, B (corresponding author), INST GENBIOL FORSCHUNG,IHNESTR 63,W-1000 BERLIN 33,GERMANY.							ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BRENNICKE A, 1980, PLANT PHYSIOL, V65, P1207, DOI 10.1104/pp.65.6.1207; BURGER G, 1985, ACHIEVEMENTS PERSPEC, V2, P305; CHAPDELAINE Y, 1991, CELL, V65; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1987, EMBO J, V6, P29, DOI 10.1002/j.1460-2075.1987.tb04714.x; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMATTINA L, 1989, FEBS LETT, V258, P79, DOI 10.1016/0014-5793(89)81620-5; LEAVER CJ, 1982, ANNU REV PLANT PHYS, V33, P373, DOI 10.1146/annurev.pp.33.060182.002105; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, BIOCH PLANTS COMPREH, V15, P229; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; RUTLEDGE RG, 1988, GENE, V68, P151, DOI 10.1016/0378-1119(88)90607-5; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHUSTER W, 1987, MOL GEN GENET, V210, P44, DOI 10.1007/BF00337757; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1988, PLANT SCI, V54, P1, DOI 10.1016/0168-9452(88)90049-0; SCHUSTER W, 1988, THESIS U TUBINGEN GE; SCHUSTER W, 1988, PLANT MOL BIOL PRACT, P79; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1984, P NATL ACAD SCI-BIOL, V81, P1946, DOI 10.1073/pnas.81.7.1946; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WARD BL, 1981, CELL, V25, P793, DOI 10.1016/0092-8674(81)90187-2; WISSINGER B, 1990, MOL GEN GENET, V224, P389, DOI 10.1007/BF00262433; WISSINGER B, 1988, MOL GEN GENET, V212, P56, DOI 10.1007/BF00322444; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	167	172	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					473	482		10.1016/0092-8674(91)90465-B	http://dx.doi.org/10.1016/0092-8674(91)90465-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850322				2022-12-01	WOS:A1991FK18200014
J	BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P				BENJAMIN, RJ; MADRIGAL, JA; PARHAM, P			PEPTIDE BINDING TO EMPTY HLA-B27 MOLECULES OF VIABLE HUMAN-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ANKYLOSING-SPONDYLITIS; MONOCLONAL-ANTIBODIES; ANTIGEN; HLA; ASSOCIATION; RECOGNITION; MUTAGENESIS; CHAINS; VIRUS	INTRACELLULAR binding of antigenic peptides by polymorphic class I major histocompatibility complex molecules creates the ligands recognized by receptors of CD8+ T cells 1. Previously described in vitro assays of peptide binding to class I molecules have been limited by either the low proportion of accessible binding sites or the lack of allelic specificity 2-6. Here we describe a system in which the human class I molecule HLA-B27 binds considerable amounts of an influenza peptide with precise allelic discrimination. Binding requires viable cells, is stimulated by gamma-interferon and is inhibited by brefeldin A. Our results are consistent with the presence of fairly stable 'empty' HLA-B27 molecules at the cell surface. By contrast, analysis of the binding of a second influenza peptide indicates that empty HLA-Aw68 molecules are relatively short-lived. We speculate that HLA-B27 might bind extracellular peptides in vivo and that this property could underlie its association with autoimmune disease.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	BENJAMIN, RJ (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BREWERTON DA, 1973, LANCET, V1, P904; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MCMICHAEL AJ, 1980, HUM IMMUNOL, V1, P121, DOI 10.1016/0198-8859(80)90099-3; MCMICHAEL AJ, 1986, J EXP MED, V164, P1397, DOI 10.1084/jem.164.5.1397; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1987, J EXP MED, V166, P283, DOI 10.1084/jem.166.1.283; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WAYS JP, 1983, BIOCHEM J, V216, P423, DOI 10.1042/bj2160423; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	35	149	150	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					74	77		10.1038/351074a0	http://dx.doi.org/10.1038/351074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027387				2022-12-01	WOS:A1991FK19300064
J	BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L				BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L			NEONATAL HERPES-SIMPLEX VIRUS-INFECTION IN RELATION TO ASYMPTOMATIC MATERNAL INFECTION AT THE TIME OF LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCOPROTEIN-G; WESTERN BLOT; DELIVERY; TYPE-2; ANTIBODIES; CULTURES; RISK; HISTORY; MOTHERS; INFANTS	Background and Methods. To define the risk factors associated with neonatal acquisition of herpes simplex virus (HSV) infection, we prospectively obtained HSV cultures from the cervis and external genitalia of 15,923 pregnant women in early labor who were without symptoms or signs of genital HSV infection. Follow-up of the women with positive cultures for HSV and their HSV-exposed infants included serologic tests and serial cultures for HSV. Results. HSV was isolated from 56 of the women (0.35 percent), 18 of whom (35 percent) had serologic evidence of a recently acquired, subclinical first episode of genital HSV infection, and 34 of whom (65 percent) had reactivation of HSV. Neonatal HSV developed in 6 of 18 infants (33 percent) born to the women with a first episode of genital HSV, and in 1 of 34 infants (3 percent) born to the women with reactivation of HSV (P < 0.01); neonatal HSV also occurred in three of the infants born to the 15,867 women with negative cultures. Neonatal HSV-2 occurred in 1 of 4 infants born to mothers seronegative at delivery for both HSV-1 and HSV-2, in 4 of 12 infants exposed to HSV-2 whose mothers had only HSV-1 antibodies at delivery, and in none of the infants born to 31 women who were HSV-2-seropositive. An increased risk of neonatal HSV was associated with exposure to viral shredding from the cervix and the use of fetal-scalp electrodes. Conclusions. Of the asymptomatic women who shed HSV in early labor, about a third have recently acquired genital HSV, and their infants are 10 times more likely to have neonatal HSV than those of women with asymptomatic reactivation of HSV. The presence of maternal antibodies specific to HSV-2 but not HSV-1 appears to reduce the neonatal transmission of HSV-2. Further studies are necessary to determine whether screening and prophylactic treatment are warranted for infants of HSV-2-seronegative mothers who shed HSV-1 or HSV-2 in early labor.	CHILDRENS HOSP MED CTR, SEATTLE, WA USA; UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BROWN, ZA (corresponding author), UNIV WASHINGTON, DEPT OBSTET & GYNECOL, RH-20, SEATTLE, WA 98195 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BROWN ZA, 1987, PEDIATR INFECT DIS J, V6, P1057; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; FORSGREN M, 1990, SCAND J INFECT DIS, P37; GUTMAN LT, 1986, J INFECT DIS, V154, P415, DOI 10.1093/infdis/154.3.415; HANKINS GDV, 1984, AM J OBSTET GYNECOL, V150, P100, DOI 10.1016/S0002-9378(84)80119-2; KEYSERLING HH, 1983, INFECT DIS, P636; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; SIMKOVICH JW, 1988, AM J OBSTET GYNECOL, V158, P588, DOI 10.1016/0002-9378(88)90034-8; STAGNO S, 1985, NEW ENGL J MED, V313, P1327, DOI 10.1056/NEJM198511213132105; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; SULLIVANBOLYAI J, 1983, JAMA-J AM MED ASSOC, V250, P3059, DOI 10.1001/jama.250.22.3059; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; YEAGER AS, 1984, PEDIATRICS, V73, P188; [No title captured]	27	316	323	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1247	1252		10.1056/NEJM199105023241804	http://dx.doi.org/10.1056/NEJM199105023241804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1849612				2022-12-01	WOS:A1991FJ82300004
J	LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B				LUBS, MLE; BAUER, MS; FORMAS, ME; DJOKIC, B			LISCH NODULES IN NEUROFIBROMATOSIS TYPE-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VONRECKLINGHAUSEN NEUROFIBROMATOSIS; IRIS HAMARTOMATA		MIAMI CHILDRENS HOSP, MIAMI, FL 33155 USA; UNIV MIAMI, SCH MED, DEPT PEDIAT, DIV GENET, MIAMI, FL 33152 USA	University of Miami								[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CAWTHON, 1990, CELL, V62, P609; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHARLES SJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1571, DOI 10.1001/archopht.1989.01070020649012; CROWE FW, 1956, CLIN PATHOLOGICAL GE, V146, P153; FLUELER U, 1986, NEUROPEDIATRICS, V17, P183, DOI 10.1055/s-2008-1052525; GOODMAN LA, 1954, J AM STAT ASSOC, V49, P732, DOI 10.2307/2281536; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Kendall M., 1955, RANK CORRELATION MET; LEWIS RA, 1984, OPHTHALMOLOGY, V91, P929; LEWIS RA, 1981, OPHTHALMOLOGY, V88, P348; Lisch K, 1937, Z AUGENHEILKD, V93, P137; LITTLER M, 1990, J MED GENET, V27, P307, DOI 10.1136/jmg.27.5.307; MURPHY E A, 1973, Birth Defects Original Article Series, V9, P19; Riccardi V, 1986, NEUROFIBROMATOSIS PH, P29; Riccardi V M, 1981, Adv Neurol, V29, P1; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WAARDENBURG PJ, 1918, NED TIJDSCHR GENEES, V2, P1453; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WARD K, 1990, AM J HUM GENET, V46, P943; ZEHAVI C, 1986, CLIN GENET, V29, P51	23	96	100	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1264	1266		10.1056/NEJM199105023241807	http://dx.doi.org/10.1056/NEJM199105023241807			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1901624				2022-12-01	WOS:A1991FJ82300007
J	LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL				LUESCHER, IF; ROMERO, P; CEROTTINI, JC; MARYANSKI, JL			SPECIFIC BINDING OF ANTIGENIC PEPTIDES TO CELL-ASSOCIATED MHC CLASS-I MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOLYTIC T-CELLS; IMMUNOGENIC PEPTIDES; RECOGNITION; HLA; CAPACITY; GENE	T LYMPHOCYTES recognize antigen in the form of peptides that associate with specific alleles of class I or class II major histocompatibility (MHC) molecules 1,2. By contrast with the clear MHC allele-specific binding of peptides to purified class II molecules 3-6 purified solubilized class I molecules either bind relatively poorly 7 or show degenerate specificity 8-11. Using photoaffinity labelling, we demonstrate here the specific interaction of peptides with cell-associated MHC class I molecules and show that this involves metabolically active processes.			LUESCHER, IF (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Maryanski, Janet/G-3161-2013					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAYLEY H, 1984, AZIDES NITRENES REAC, P434; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; CHOPPIN J, 1990, J EXP MED, V172, P889, DOI 10.1084/jem.172.3.889; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1990, J BIOL CHEM, V265, P11177; LUESCHER IF, 1988, P NATL ACAD SCI USA, V85, P871, DOI 10.1073/pnas.85.3.871; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1987, NATURE, V330, P660, DOI 10.1038/330660a0; MARYANSKI JL, 1986, J IMMUNOL, V136, P4340; MARYANSKI JL, 1988, J EXP MED, V167, P1391, DOI 10.1084/jem.167.4.1391; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PALA P, 1988, J IMMUNOL, V141, P2289; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAEFFER EB, 1989, P NATL ACAD SCI USA, V86, P4649, DOI 10.1073/pnas.86.12.4649; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; Schwartz R H, 1986, Adv Immunol, V38, P31, DOI 10.1016/S0065-2776(08)60006-1; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VANBLEEK GM, 1990, NATURE, V348, P213	32	60	75	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					72	74		10.1038/351072a0	http://dx.doi.org/10.1038/351072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027386				2022-12-01	WOS:A1991FK19300063
J	MEYRAND, P; SIMMERS, J; MOULINS, M				MEYRAND, P; SIMMERS, J; MOULINS, M			CONSTRUCTION OF A PATTERN-GENERATING CIRCUIT WITH NEURONS OF DIFFERENT NETWORKS	NATURE			English	Article								RHYTHMIC motor behaviours are generated within the central nervous system by neuronal circuits called central pattern generators (CPG) 1. Although a CPG can produce several forms of the same behaviour 2-5 and several circuits may interact to generate different behaviours 6, it is generally assumed that a given CPG consists of a predefined assemblage of neurons that is functionally distinguishable from other circuits. However, recent studies on the stomatogastric nervous system of crustacea have suggested that CPGs may not be immutable functional entities 7-10. We now report that under an identified neuromodulatory stimulus, the CPG that produces swallowing-like behaviour of the foregut in lobsters is constructed de novo from neurons belonging to other CPGs. Consequently neurons operating independently as members of different circuits may be reconfigured into a new pattern-generating circuit that operates differently from the original circuits. This not only challenges the concept of the CPG being a discrete functional entity, but also demonstrates that a modulatory input can specify an appropriate CPG from a pool of individual neurons of diverse origins.	UNIV BORDEAUX 1,CNRS,NEUROBIOL & PHYSIOL COMPAREES LAB,PL DR PEYNEAU,F-33120 ARCACHON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux								CAZALETS JR, 1990, J NEUROSCI, V10, P448; CAZALETS JR, 1990, J NEUROSCI, V10, P458; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DICKINSON PS, 1990, NATURE, V344, P155, DOI 10.1038/344155a0; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; HOOPER SL, 1989, SCIENCE, V244, P1587, DOI 10.1126/science.2740903; MARDER E, 1988, NATURE, V335, P296, DOI 10.1038/335296a0; MEYRAND P, 1988, SOC NEUR ABSTR, V14; Nagy F., 1987, P205; ROBERTSON RM, 1979, PROC R SOC SER B-BIO, V206, P235, DOI 10.1098/rspb.1979.0103; Selverston A.I., 1987, CRUSTACEAN STOMATOGA; STEIN PSG, 1988, NEUROBIOLOGY VERTEBR, P201; WEIMANN JM, 1991, J NEUROPHYSIOL, V65, P111, DOI 10.1152/jn.1991.65.1.111; [No title captured]	14	179	179	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					60	63		10.1038/351060a0	http://dx.doi.org/10.1038/351060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	2027383				2022-12-01	WOS:A1991FK19300059
J	NAUMANN, D; HELM, D; LABISCHINSKI, H				NAUMANN, D; HELM, D; LABISCHINSKI, H			MICROBIOLOGICAL CHARACTERIZATIONS BY FT-IR SPECTROSCOPY	NATURE			English	Article								Infrared signals of microorganisms are highly specific fingerprint-like patterns that can be used for probing the identity of microorganisms. The simplicity and versatility of Fourier-transform infrared spectroscopy (FT-IR) makes it a versatile technique for rapid differentiation, classification, identification and large-scale screening at the subspecies level.			NAUMANN, D (corresponding author), BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,NORDUFER 20,W-1000 BERLIN 65,GERMANY.							HELM D, 1991, J GEN MICROBIOL, V137, P69, DOI 10.1099/00221287-137-1-69; NAUMANN D, 1988, J MOL STRUCT, V174, P165, DOI 10.1016/0022-2860(88)80152-2; NAUMANN D, 1988, MIKROCHIM ACTA, V1, P373, DOI 10.1007/BF01205910; NAUMANN D, IN PRESS MODERN TECH; THRELKELD CH, 1982, J FOOD SCI, V47, P1222, DOI 10.1111/j.1365-2621.1982.tb07652.x	5	751	784	8	149	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					81	82		10.1038/351081a0	http://dx.doi.org/10.1038/351081a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1902911				2022-12-01	WOS:A1991FK19300066
J	OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC				OKANO, Y; EISENSMITH, RC; GUTTLER, F; LICHTERKONECKI, U; KONECKI, DS; TREFZ, FK; DASOVICH, M; WANG, T; HENRIKSEN, K; LOU, H; WOO, SLC			MOLECULAR-BASIS OF PHENOTYPIC HETEROGENEITY IN PHENYLKETONURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; PRENATAL-DIAGNOSIS; LINKAGE DISEQUILIBRIUM; MAMMALIAN-CELLS; DNA; GENE; MUTATION; LOCUS; HYPERPHENYLALANINEMIA; SUBSTITUTION	Background. Phenylketonuria is a metabolic disorder that results from a deficiency of the hepatic enzyme phenylalanine hydroxylase. Its clinical phenotype varies widely, and to date more than 10 mutations in the phenylalanine hydroxylase gene have been identified in persons with the disorder. We attempted to relate the clinical phenotype of patients to their genotype. Methods. We studied 258 patients with phenylketonuria from Denmark and Germany for the presence of eight mutations previously found in patients from these countries. The in vitro activity of the enzymes associated with these mutations was determined by expression analysis in heterologous mammalian cells. The level of activity was then used to predict the in vivo level of phenylalanine hydroxylase activity in patients with various combinations of mutant phenylalanine hydroxylase alleles. Results. The eight mutations involved 64 percent of all mutant phenylalanine hydroxylase alleles in the patients. Expression analysis showed that these mutant enzymes produced from 0 to 50 percent of normal enzyme activity. The predicted level of phenylalanine hydroxylase activity correlated strongly with the pretreatment serum level of phenylalanine (r = 0.91, P < 0.001 in the Danish patients and r = 0.74, P < 0.001 in the German patients), phenylalanine tolerance in the Danish patients (r = 0.84, P < 0.001), and the serum phenylalanine level measured after standardized oral protein loading in the German patients (r = 0.84, P < 0.001). Conclusions. Our results strongly support the hypothesis that there is a molecular basis for phenotypic heterogeneity in phenylketonuria. The establishment of genotype will therefore aid in the prediction of biochemical and clinical phenotypes in patients with this disease.	BAYLOR UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BAYLOR UNIV, INST MOLEC GENET, HOUSTON, TX 77030 USA; JOHN F KENNEDY INST, GLOSTRUP, DENMARK; UNIV HEIDELBERG, KINDERKLIN, W-6900 HEIDELBERG, GERMANY	Baylor College of Medicine; Baylor University; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor University; Ruprecht Karls University Heidelberg					NICHD NIH HHS [HD-17711] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017711, R01HD017711] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABADIE V, 1989, GENOMICS, V5, P936, DOI 10.1016/0888-7543(89)90137-7; BARTHOLOME K, 1975, PEDIATR RES, V9, P899, DOI 10.1203/00006450-197509120-00006; BLASKOVICS ME, 1974, ARCH DIS CHILD, V49, P835, DOI 10.1136/adc.49.11.835; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DILELLA AG, 1987, METHOD ENZYMOL, V152, P447; DILELLA AG, 1988, LANCET, V1, P497; DILELLA AG, 1987, NATURE, V327, P333, DOI 10.1038/327333a0; DILELLA AG, 1986, NATURE, V322, P799, DOI 10.1038/322799a0; DWORNICZAK B, 1989, HUM GENET, V84, P95, DOI 10.1007/BF00210683; GUTTLER F, 1987, J PEDIATR-US, V110, P68, DOI 10.1016/S0022-3476(87)80290-1; GUTTLER F, 1980, ACTA PAEDIATR SCAND, P1; JERVIS GA, 1947, J BIOL CHEM, V169, P651; JOHN SWM, 1990, AM J HUM GENET, V46, P970; JOHN SWM, 1989, AM J HUM GENET, V45, P905; KANG ES, 1970, PEDIATRICS, V45, P83; KAUFMAN S, 1975, PEDIATR RES, V9, P632, DOI 10.1203/00006450-197508000-00004; Kaufman S., 1976, ADV NEUROCHEM, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDLEY FD, 1986, NEW ENGL J MED, V314, P1276, DOI 10.1056/NEJM198605153142002; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LEDLEY FD, 1985, SCIENCE, V228, P77, DOI 10.1126/science.3856322; LICHTERKONECKI U, 1988, HUM GENET, V78, P347, DOI 10.1007/BF00291733; LICHTERKONECKI U, 1988, BIOCHEMISTRY-US, V27, P2881, DOI 10.1021/bi00408a032; LIDSKY AS, 1985, LANCET, V1, P549; LIDSKY AS, 1985, AM J HUM GENET, V37, P619; LYONNET S, 1989, AM J HUM GENET, V44, P511; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MCCAMAN MW, 1962, J LAB CLIN MED, V59, P885; MOORE S, 1958, ANAL CHEM, V30, P1185, DOI 10.1021/ac60139a005; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; OKANO Y, 1991, GENOMICS, V9, P96, DOI 10.1016/0888-7543(91)90225-4; OKANO Y, 1990, AM J HUM GENET, V46, P919; OKANO Y, 1990, AM J HUM GENET, V46, P18; OKANO Y, IN PRESS EUR J PEDIA; THOMPSON GN, 1990, J CLIN INVEST, V86, P317, DOI 10.1172/JCI114701; TREFZ FK, 1981, J INHERIT METAB DIS, V4, P101, DOI 10.1007/BF02263611; TREFZ FK, 1979, CLIN CHIM ACTA, V99, P211, DOI 10.1016/0009-8981(79)90264-X; WOO SLC, 1988, AM J HUM GENET, V43, P781; WOO SLC, 1983, NATURE, V306, P151, DOI 10.1038/306151a0; [No title captured]; 1990, SOMAT CELL MOLEC GEN, V16, P885	41	223	226	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1232	1238		10.1056/NEJM199105023241802	http://dx.doi.org/10.1056/NEJM199105023241802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	2014036				2022-12-01	WOS:A1991FJ82300002
J	STEPHENS, LR; HUGHES, KT; IRVINE, RF				STEPHENS, LR; HUGHES, KT; IRVINE, RF			PATHWAY OF PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE SYNTHESIS IN ACTIVATED NEUTROPHILS	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; INOSITOL PHOSPHATES; BOVINE BRAIN; 4,5-BISPHOSPHATE; IDENTIFICATION; 4-PHOSPHATE; POLYPHOSPHOINOSITIDE; PHOSPHODIESTERASE; TRANSFORMATION; TRISPHOSPHATE	Neutrophils activated by the formyl peptide f-Met-LeuPhe transiently accumulate a small subset of highly polar inositol lipids. A similar family of lipids also appear in many other cells in response to a range of growth factors and activated oncogenes, and are presumed to be the direct or indirect products of 3-phosphatidylinositol kinase. The structures of these lipids are shown to be phosphatidylinositol 3-phosphate, phosphatidylinositol-(3,4)bisphosphate and phosphatidylinositol-(3,4,5)trisphosphate, and we present evidence that in intact neutrophils a phosphatidyl-inositol-(4,5)bisphosphate-3-kinase seems to be the focal point through which agonists stimulate the formation of 3-phosphorylated inositol lipids.	AMERSHAM INT PLC,CARDIFF CF4 7YT,WALES		STEPHENS, LR (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE RES STN,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.			stephens, len/0000-0002-2771-3487				ALLEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277; ASCOLI M, 1990, J BIOL CHEM, V265, P1718; Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENNETT JP, 1982, BIOCHEM J, V208, P801, DOI 10.1042/bj2080801; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; ENDOMANN G, 1990, J BIOL CHEM, V265, P396; GEE NS, 1988, BIOCHEM J, V253, P777, DOI 10.1042/bj2530777; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; IRVINE RF, 1978, BIOCHEM J, V176, P475, DOI 10.1042/bj1760475; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PALMER FBSC, 1981, J LIPID RES, V22, P1296; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIM SS, 1990, J BIOL CHEM, V265, P10367; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; Stephens LR, 1990, METHODS INOSITIDE RE, P9; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; TOMLINSON R, 1961, J BIOL CHEM, V236, P1902; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	50	437	449	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					33	39		10.1038/351033a0	http://dx.doi.org/10.1038/351033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851250				2022-12-01	WOS:A1991FK19300049
J	WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR				WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR			MUTANT ALPHA-SUBUNITS OF GI2 INHIBIT CYCLIC-AMP ACCUMULATION	NATURE			English	Article							BINDING REGULATORY COMPONENT; ADENYLATE-CYCLASE; G-PROTEINS; MUTATIONS; MEMBRANES; RECEPTOR; SITE; IDENTIFICATION; DISSOCIATION; STIMULATION	ONE or more of three G(i) proteins, G(i1-3), mediates hormonal inhibition of adenylyl cyclase 1-3. Whether this inhibition is mediated by the alpha or by the beta-gamma-subunits of G(i) proteins is unclear 1,2. Mutations inhibiting the intrinsic GTPase activity of another G protein, the stimulatory regulator of adenylyl cyclase (G(s)), constitutively activate it by replacing either of two conserved amino acids in its alpha-subunit (alpha-s) 4-7. These mutations create the gsp oncogene which is found in human pituitary and thyroid tumours 5,8. In a second group of human endocrine tumours, somatic mutations in the alpha-subunit of G(i2) replace a residue cognate to one of those affected by gsp mutations 8. This implies that the mutations convert the alpha-i2 gene into a dominantly acting oncogene, called gip2 (ref. 8), and that the mutant alpha-i2 subunits are constitutively active. We have therefore assessed cyclic AMP accumulation in cultured cells which stably or transiently express exogenous wild-type alpha-i2 complementary DNA or either of two mutant alpha-i2 cDNAs. The results show that putatively oncogenic mutations in alpha-i2 constitutively activate the protein's ability to inhibit cAMP accumulation.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV NICE, FAC SCI, CNRS, CTR BIOCHIM, F-06034 NICE, FRANCE	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				Wong, Yung Hou/0000-0002-0123-7697				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; EVANS T, 1987, J BIOL CHEM, V262, P176; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P3178; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1986, J BIOL CHEM, V261, P5215; KATADA T, 1984, J BIOL CHEM, V259, P3578; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	30	250	251	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1991	351	6321					63	65		10.1038/351063a0	http://dx.doi.org/10.1038/351063a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851251				2022-12-01	WOS:A1991FK19300060
J	ARANA, GW				ARANA, GW			DEXAMETHASONE SUPPRESSION TEST IN THE DIAGNOSIS OF DEPRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PSYCHIATRY; UTILITY				ARANA, GW (corresponding author), MED UNIV S CAROLINA,CHARLESTON,SC 29425, USA.							ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193; ARANA GW, 1988, AM J PSYCHIAT, V145, P707; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; GLASSMAN AH, 1987, AM J PSYCHIAT, V144, P1253	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2253	2254						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH877	2013959				2022-12-01	WOS:A1991FH87700042
J	BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM				BACHORIK, PS; CLOEY, TA; FINNEY, CA; LOWRY, DR; BECKER, DM			LIPOPROTEIN-CHOLESTEROL ANALYSIS DURING SCREENING - ACCURACY AND RELIABILITY	ANNALS OF INTERNAL MEDICINE			English	Article							PROGRAM; PRECISION; PLASMA	Objective: To evaluate the accuracy and reliability of lipoprotein-cholesterol measurements obtained during screening. Design: Cross-sectional study. Participants: From November 1989 to January 1990, 154 adults were screened. Measurements: Split venous samples from fasting participants were analyzed for total cholesterol, triglyceride, and high-density-lipoprotein (HDL) cholesterol with screening and standardized laboratory methods. Low-density-lipoprotein (LDL)-cholesterol levels were calculated using the Friedewald equation. Split venous samples from nonfasting participants were analyzed for total cholesterol. Capillary blood samples were analyzed for total cholesterol with the screening method. Main Results: Total cholesterol measurements in screening venous blood samples were 5.4% and 3.8% lower than the laboratory values in samples from fasting and nonfasting participants, respectively. Triglyceride and HDL-cholesterol values in venous samples obtained from fasting participants were, on average, 9.8% and 11.2% lower than the respective laboratory measurements. Screening HDL-cholesterol values varied, differing from the laboratory values by as much as 40% in 95% of participants. In fasting participants, total cholesterol in capillary samples averaged 5.5% higher than in venous samples; in nonfasting participants the capillary samples were 3.1% higher. Screening for either total cholesterol or LDL cholesterol identified 93% of the persons with LDL-cholesterol values of 3.36 mmol/L (130 mg/dL) or higher. Conclusions: Total cholesterol can be reliably measured in samples from fasting or nonfasting persons. The values in capillary blood samples were slightly higher than those in venous samples. Screening HDL-cholesterol values were too variable to establish the HDL-cholesterol level reliably. Participants with high LDL-cholesterol levels were identified as accurately by measuring total cholesterol only when compared with calculating the LDL-cholesterol level from total cholesterol, triglyceride, and HDL-cholesterol concentrations.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University								[Anonymous], 1977, CLIN CHEM, V23, P60; BACHORIK PS, 1989, CLIN CHEM, V35, P1734; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; CLOEY T, 1990, JAMA-J AM MED ASSOC, V263, P2788, DOI 10.1001/jama.263.20.2788; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GREENLAND P, 1987, AM J PUBLIC HEALTH, V77, P73, DOI 10.2105/AJPH.77.1.73; HAVAS S, 1989, AM J PREV MED, V5, P337, DOI 10.1016/S0749-3797(18)31054-7; KOCH TR, 1987, CLIN CHEM, V33, P2262; KWITEROVICH PO, 1986, CIRCULATION, V73, P30; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; SNEDECOR GW, 1968, STATISTICAL METHODS, P56; WARNICK GR, 1978, J LIPID RES, V19, P65; WONES RG, 1989, PUBLIC HEALTH REP, V104, P425; 1984, JAMA-J AM MED ASSOC, V251, P1196; 1989, NIH893045 US DEP HLT	17	26	26	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					741	747		10.7326/0003-4819-114-9-741	http://dx.doi.org/10.7326/0003-4819-114-9-741			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012356				2022-12-01	WOS:A1991FJ11700006
J	BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP				BRUNS, FJ; ADLER, S; FRALEY, DS; SEGEL, DP			SUSTAINED REMISSION OF MEMBRANOUS GLOMERULONEPHRITIS AFTER CYCLOPHOSPHAMIDE AND PREDNISONE	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; FOLLOW-UP; UNTREATED PATIENTS; NEPHROTIC SYNDROME; NATURAL-HISTORY; RENAL-FUNCTION; NEPHROPATHY; CHLORAMBUCIL; ADULTS; METHYLPREDNISOLONE	Objective: To determine the effect of cyclophosphamide and prednisone on progressive renal failure and on nephrotic features in patients with membranous glomerulonephritis. Design: Prospective, nonrandomized time series. Setting: Outpatient clinic at a university medical center. Patients: Eleven consecutive patients with biopsy-proven membranous glomerulonephritis and rising plasma creatinine levels over at least 6 months. Intervention: Cyclophosphamide and prednisone in ten patients and cyclophosphamide alone in one patient. Measurements and Main Results: In ten patients treated with both agents, the median plasma creatinine rose 53-mu-mol/L (0.6 mg/dL) over the months before treatment from 141 to 194-mu-mol/L (1.6 to 2.2 mg/dL) (95% CI, 27 to 141-mu-mol/L; P = 0.002). After combined therapy for 6 months, the median plasma creatinine fell to 133-mu-mol/L (1.5 mg/dL) for a median decline of 62-mu-mol/L (0.7 mg/dL) (CI, 44 to 150-mu-mol/L; P = 0.006). Pretreatment plasma creatinine levels, which ranged from 159 to 371-mu-mol/L (1.8 to 4.2 mg/dL), decreased in the ten patients by 6 months and remained stable in seven of the eight patients followed 24 to 54 months after therapy was completed. The median urine protein excretion decreased by 9.6 g/d with 12 months of therapy in the ten patients from 11.9 to 2.3 g/d (CI, 6.0 to 15.1 g/d; P < 0.001). The median plasma albumin rose by 14 g/L from 24 to 38 g/L (CI, 11 to 19 g/L; P < 0.001). The median plasma cholesterol fell by 3.26-mu-mol/L (140 mg/dL) from 10.45 to 6.52-mu-mol/L (405 to 252 mg/dL) (CI, 1.42 to 7.16-mu-mol/L; P = 0.01). One patient who had a relapse 30 months after completing therapy responded to re-treatment with renal function and nephrotic variables returning toward normal. The eleventh patient received cyclophosphamide alone and had a course similar to that of the combined therapy group. Conclusion: Cyclophosphamide plus prednisone can promote prolonged remissions in membranous glomerulonephritis even when renal function is already declining.	UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BRUNS, FJ (corresponding author), MONTEFIORE UNIV HOSP, 3459 5TH AVE, PITTSBURGH, PA 15213 USA.							BAILAR JC, 1984, NEW ENGL J MED, V311, P156, DOI 10.1056/NEJM198407193110306; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BLACK DAK, 1970, BRIT MED J, V3, P421, DOI 10.1136/bmj.3.5720.421; BRUNS FJ, 1989, AM J MED, V86, P400, DOI 10.1016/0002-9343(89)90336-7; CAMERON JS, 1979, KIDNEY INT, V15, P88; CAMERON JS, 1982, AM J KIDNEY DIS, V1, P371; CATTRAN D, 1984, 9TH P INT C NEPHR A, V74; CATTRAN DC, 1989, NEW ENGL J MED, V320, P210, DOI 10.1056/NEJM198901263200403; COGGINS CH, 1979, NEW ENGL J MED, V301, P1301; DAVISON AM, 1984, CLIN NEPHROL, V22, P61; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DONADIO JV, 1974, KIDNEY INT, V6, P431, DOI 10.1038/ki.1974.129; Ehrenreich T., 1968, PATHOL ANNU, V3, P145; EVANOFF GV, 1987, ARCH INTERN MED, V147, P492, DOI 10.1001/archinte.147.3.492; FRANKLIN WA, 1973, KIDNEY INT, V4, P36, DOI 10.1038/ki.1973.78; GARTNER HV, 1974, NEPHRON, V13, P288, DOI 10.1159/000180405; GLASSOCK RJ, 1982, AM J KIDNEY DIS, V1, P376, DOI 10.1016/S0272-6386(82)80011-5; HONKANEN E, 1986, CLIN NEPHROL, V25, P122; IDELSON BA, 1977, ARCH INTERN MED, V137, P891, DOI 10.1001/archinte.137.7.891; LAVORI PW, 1983, NEW ENGL J MED, V309, P1291, DOI 10.1056/NEJM198311243092105; LOUIS TA, 1984, NEW ENGL J MED, V310, P24, DOI 10.1056/NEJM198401053100106; MANOS J, 1982, CLIN NEPHROL, V18, P286; MATHIESON PW, 1988, LANCET, V2, P869; MOSES LE, 1985, NEW ENGL J MED, V312, P890, DOI 10.1056/NEJM198504043121405; NOEL LH, 1979, AM J MED, V66, P82, DOI 10.1016/0002-9343(79)90486-8; PIERIDES AM, 1977, Q J MED, V46, P163; PONTICELLI C, 1989, NEW ENGL J MED, V320, P8, DOI 10.1056/NEJM198901053200102; PONTICELLI C, 1984, NEW ENGL J MED, V310, P946, DOI 10.1056/NEJM198404123101503; Ponticelli C, 1987, Adv Nephrol Necker Hosp, V16, P195; RANDALL RE, 1970, AM SOC NEPHROL, V4, P65; RELMAN AS, 1989, NEW ENGL J MED, V320, P248, DOI 10.1056/NEJM198901263200411; RYAN BF, 1985, MINITAB HDB, P292; SUKI WN, 1981, AM J NEPHROL, V1, P11, DOI 10.1159/000166481; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; TILLER DJ, 1981, 8TH P INT C NEPHR, P345; TU WH, 1984, NEPHRON, V36, P118, DOI 10.1159/000183130; WEST ML, 1987, KIDNEY INT, V32, P579, DOI 10.1038/ki.1987.247	37	72	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					725	730		10.7326/0003-4819-114-9-725	http://dx.doi.org/10.7326/0003-4819-114-9-725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012353				2022-12-01	WOS:A1991FJ11700003
J	EZZAT, S; STROM, C; MELMED, S				EZZAT, S; STROM, C; MELMED, S			COLON POLYPS IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Note							GROWTH		UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,DIV ENDOCRINOL & METAB,B-131, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041906, R01DK034824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41906, DK 34824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNNER JE, 1990, CLIN ENDOCRINOL, V32, P65, DOI 10.1111/j.1365-2265.1990.tb03751.x; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; EZZAT S, 1991, J CLIN ENDOCR METAB, V72, P245, DOI 10.1210/jcem-72-2-245; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KLEIN I, 1982, ANN INTERN MED, V97, P27, DOI 10.7326/0003-4819-97-1-27; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; MOON HD, 1950, CANCER RES, V10, P297; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1806, DOI 10.1210/endo-120-5-1806; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541	10	80	81	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					754	755		10.7326/0003-4819-114-9-754	http://dx.doi.org/10.7326/0003-4819-114-9-754			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012357				2022-12-01	WOS:A1991FJ11700008
J	MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG				MANN, SJ; JAMES, GD; WANG, RS; PICKERING, TG			ELEVATION OF AMBULATORY SYSTOLIC BLOOD-PRESSURE IN HYPERTENSIVE SMOKERS - A CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CIGARETTE-SMOKING; EXERCISE	Although smoking raises blood pressure, the office blood pressure measurements of smokers are the same as, or lower than, those of nonsmokers. To resolve this paradox, we compared the office and 24-hour ambulatory blood pressures of 59 untreated hypertensive smokers with 118 nonsmoking hypertensives matched for age, sex, and race. The office blood pressures of the smoking and nonsmoking groups were 141/93 and 142/93 mm Hg, respectively. The awake ambulatory systolic blood pressure was significantly higher in the smokers (145 vs 140 mm Hg). This difference was greater among patients over the age of 50 years (153 vs 142 mm Hg), and absent among patients under 50 years (140 vs 139 mm Hg). Blood pressures during sleep did not differ between the two groups (121/76 vs 123/77 mm Hg). We conclude that, among white hypertensives above the age of 50 years, smokers maintain a higher daytime ambulatory systolic blood pressure than nonsmokers even though blood pressure measured in the office is similar.	CORNELL UNIV,MED CTR,NEW YORK HOSP,CTR CARDIOVASC & HYPERTENS,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital			Mann, Samuel J./AAI-5510-2020					BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; BERGLUND G, 1975, ACTA MED SCAND, V198, P291; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; CELLINA GU, 1975, AM HEART J, V89, P18, DOI 10.1016/0002-8703(75)90004-6; DEVEREUX RB, 1988, AM HEART J, V116, P1124, DOI 10.1016/0002-8703(88)90176-7; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; GOFIN R, 1982, ISRAEL J MED SCI, V18, P1217; GOLDBOURT U, 1977, AM J EPIDEMIOL, V105, P75, DOI 10.1093/oxfordjournals.aje.a112358; GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8; GREEN MS, 1986, AM HEART J, V111, P932, DOI 10.1016/0002-8703(86)90645-9; GREENE SB, 1977, J CHRON DIS, V30, P401, DOI 10.1016/0021-9681(77)90034-0; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; HIGGINS MW, 1967, AM J EPIDEMIOL, V86, P60, DOI 10.1093/oxfordjournals.aje.a120734; JAMES GD, 1988, HYPERTENSION, V11, P545, DOI 10.1161/01.HYP.11.6.545; JENKINS CD, 1968, CIRCULATION, V38, P1140, DOI 10.1161/01.CIR.38.6.1140; LEVENSON J, 1987, ARTERIOSCLEROSIS, V7, P572, DOI 10.1161/01.ATV.7.6.572; LORENTSEN E, 1972, CIRCULATION, V46, P257, DOI 10.1161/01.CIR.46.2.257; MANN SJ, 1989, AM J MED, V86, P79, DOI 10.1016/0002-9343(89)90137-X; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; SPOHR U, 1979, ATHEROSCLEROSIS, V33, P271, DOI 10.1016/0021-9150(79)90179-5; THOMAS CB, 1956, ANN INTERN MED, V44, P874, DOI 10.7326/0003-4819-44-5-874; THULESIUS O, 1978, ANGIOLOGY, V29, P374, DOI 10.1177/000331977802900504; 1964, PUBLICATION US PHS, V1130	24	199	208	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2226	2228		10.1001/jama.265.17.2226	http://dx.doi.org/10.1001/jama.265.17.2226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013955				2022-12-01	WOS:A1991FH87700035
J	MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE				MOORE, RD; KESSLER, H; RICHMAN, DD; FLEXNER, C; CHAISSON, RE			NON-HODGKINS-LYMPHOMA IN PATIENTS WITH ADVANCED HIV-INFECTION TREATED WITH ZIDOVUDINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPSTEIN-BARR VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; KAPOSIS SARCOMA; INSITU HYBRIDIZATION; SAN-FRANCISCO; AIDS; MALIGNANCIES; TRENDS; MEN	We wished to determine the incidence of human immunodeficiency virus-related high-grade non-Hodgkin's lymphoma (NHL) and identify factors associated with the development of NHL in patients receiving zidovudine. Data are from a 2-year prospective, observational, multisite study of 1030 patients with the acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex who received zidovudine. Non-Hodgkin's lymphoma developed in 24 (2.3%) of 1030 patients who received zidovudine during 1463 person-years of follow-up (rate, 1.6 per 100 person-years of therapy). The relative hazard for development of NHL was stable throughout 2 years of therapy, with the risk of developing NHL 0.8% for each additional 6 months of therapy. Factors associated with development of NHL were a prior diagnosis of Kaposi's sarcoma, herpes simplex virus infection, or lower mean neutrophil count. Less strongly associated was a prior diagnosis of oral hairy leukoplakia or homosexual transmission of HIV. By Cox proportional hazards analysis, a prior diagnosis of Kaposi's sarcoma, cytomegalovirus disease, or oral hairy leukoplakia was most strongly associated with development of NHL. Our study demonstrates a relatively high incidence of NHL in patients with advanced human immunodeficiency virus disease who are undergoing antiretroviral therapy and suggests possible risk factors for development of NHL.	UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; VET ADM MED CTR,SAN DIEGO,CA 92161; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT MED,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT IMMUNOL MICROBIOL,CHICAGO,IL 60612	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Johns Hopkins University; Rush University; Rush University								BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERNSTEIN L, 1989, CANCER RES, V49, P466; DREW WL, 1988, LANCET, V1, P66; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; HOLMBERG SD, 1988, LANCET, V2, P746; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; KRUEGER GRF, 1989, ANTICANCER RES, V9, P1457; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, IN PRESS ARCH INTERN; MURRAY RS, 1987, ANN NEUROL, V22, P155; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RABKIN CS, 1990, LANCET, V336, P248, DOI 10.1016/0140-6736(90)91775-6; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; 1990, COMPREHENSIVE INFORM, P48; 1991, PHYSICIANS DESK REFE, P790; 1985, MMWR, V34, P373	22	82	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2208	2211		10.1001/jama.265.17.2208	http://dx.doi.org/10.1001/jama.265.17.2208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013953				2022-12-01	WOS:A1991FH87700032
J	PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR				PIPER, JM; RAY, WA; DAUGHERTY, JR; GRIFFIN, MR			CORTICOSTEROID USE AND PEPTIC-ULCER DISEASE - ROLE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS	ANNALS OF INTERNAL MEDICINE			English	Article							GASTRIC-ULCER; ADRENOCORTICOSTEROID THERAPY; ASPIRIN; ASSOCIATION; PREVENTION; SECRETION	Objective: To estimate the relative risk for peptic ulcer disease that is associated with the use of oral corticosteroids. Design: A nested case-control study. Setting: Tennessee Medicaid program. Participants: The case patients (n = 1415) were hospitalized between 1984 and 1986 for gastric or duodenal ulcer or for upper gastrointestinal hemorrhage of unknown cause. The controls (n = 7063) were randomly selected from Medicaid enrollees not meeting the study criteria for inclusion as case patients. Measurements and Main Results: The estimated relative risk for the development of peptic ulcer disease among current users of oral corticosteroids was 2.0 (95% CI, 1.3 to 3.0). However, the risk was increased only in those who concurrently received nonsteroidal anti-inflammatory drugs (NSAIDS); these persons had an estimated relative risk associated with current corticosteroid use of 4.4 (CI, 2.0 to 9.7). In contrast, the estimated relative risk for those corticosteroid users not receiving corticosteroids and NSAIDs had a risk for peptic ulcer disease that was 15 times greater than that of nonusers of either drug. Conclusion: Discrepant findings among earlier studies regarding steroids and the risk for peptic ulcer disease could in part be due to differences in the use of NSAIDs among study participants. The high risk for peptic ulcer disease associated with combined use of NSAIDs and corticosteroids indicates the need to prescribe this drug combination cautiously.			PIPER, JM (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT PREVENT MED, MED CTR N A-1112, NASHVILLE, TN 37232 USA.				FDA HHS [FD-U-000073] Funding Source: Medline	FDA HHS		BECK JC, 1950, CAN MED ASSOC J, V62, P423; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; CONN HO, 1976, NEW ENGL J MED, V294, P473, DOI 10.1056/NEJM197602262940905; DAVIS TA, 1952, JAMA-J AM MED ASSOC, V150, P31, DOI 10.1001/jama.1952.63680010004008c; DEAN AG, 1988, AM J EPIDEMIOL, V127, P654, DOI 10.1093/oxfordjournals.aje.a114840; DELANEY JP, 1979, GASTROENTEROLOGY, V76, P913; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GRAHAM DY, 1988, LANCET, V2, P1277; GRAY SJ, 1951, JAMA-J AM MED ASSOC, V147, P1529, DOI 10.1001/jama.1951.03670330021007; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWLEY CJ, 1990, BMJ-BRIT MED J, V300, P278; JANOWITZ HD, 1958, GASTROENTEROLOGY, V34, P11; KAHN DS, 1961, AM J PATHOL, V38, P177; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P379; LANZA FL, 1989, SCAND J GASTROENTERO, V24, P24, DOI 10.3109/00365528909091171; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MALONE DE, 1986, BRIT J RHEUMATOL, V25, P342; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; MCINTOSH JH, 1985, GUT, V26, P789, DOI 10.1136/gut.26.8.789; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MOE AE, 1952, GASTROENTEROLOGY, V20, P343; PAYNE CD, 1986, GLIM SYSTEM RELEASE; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROBERT A, 1964, ARCH PATHOL, V77, P407; SEINO S, 1978, GUT, V19, P10, DOI 10.1136/gut.19.1.10; SELLING JA, 1987, ANN INTERN MED, V106, P368, DOI 10.7326/0003-4819-106-3-368; SOMERVILLE K, 1986, LANCET, V1, P462; SPIRO HM, 1983, NEW ENGL J MED, V309, P45, DOI 10.1056/NEJM198307073090110; SPIRO HM, 1950, J LAB CLIN MED, V35, P899; STRUM WB, 1986, ANN INTERN MED, V105, P757, DOI 10.7326/0003-4819-105-5-757; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; 1985, CLIN MODIFICATION, V2	35	425	433	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					735	740		10.7326/0003-4819-114-9-735	http://dx.doi.org/10.7326/0003-4819-114-9-735			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	2012355				2022-12-01	WOS:A1991FJ11700005
J	RAUB, WF				RAUB, WF			COMBINATION THERAPY MOST BENEFICIAL AGAINST RECTAL-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P709	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-01	WOS:A1991FH87700008
J	RAUB, WF				RAUB, WF			TRANSGENIC MICE ALLOW RAPID TESTING OF AGENTS THAT REVERSE MULTIDRUG RESISTANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, P NATL ACAD SCI USA, V88, P547	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-01	WOS:A1991FH87700007
J	RAUB, WF				RAUB, WF			LONG-TERM PROPHYLAXIS EFFECTIVE AGAINST RECURRENT URINARY-TRACT INFECTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, WF (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, REV INFECT DIS, V13, P77	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1991	265	17					2173	2173		10.1001/jama.265.17.2173	http://dx.doi.org/10.1001/jama.265.17.2173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH877	2013940				2022-12-01	WOS:A1991FH87700006
J	SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM				SCHULMAN, KA; LYNN, LA; GLICK, HA; EISENBERG, JM			COST-EFFECTIVENESS OF LOW-DOSE ZIDOVUDINE THERAPY FOR ASYMPTOMATIC PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE; AIDS	We did a cost-effectiveness analysis of zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. The incremental direct medical costs of zidovudine therapy were determined, and data on the effects of therapy were derived from the report of the Acquired Immunodeficiency Syndrome (AIDS) Clinical Trials Group Protocol 019. Zidovudine therapy has an annual incremental cost of $2653 per person. The cost per year of life saved ranges between $6553 and $70 526, depending on which epidemiologic model of potential long-term zidovudine effect is used (in sensitivity analyses, the cost per year of life saved ranges between $2649 and $250 546). Although expensive, zidovudine therapy has the potential to yield a substantial survival benefit to patients. The cost effectiveness of zidovudine therapy compares favorably with that of other common medical therapies.	UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HILTS PJ, 1989, NY TIMES        0819, pA1; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; SCITOVSKY AA, 1990, PUBLIC HLTH REP, V102, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WINKENWERDER W, 1989, NEW ENGL J MED, V320, P1598, DOI 10.1056/NEJM198906153202406; 1982, MANUAL LABORATORY WO; 1990, MMWR, V39, P20; 1988, PUBLIC HLTH REP S1, V103, P35; 1989, MONTHLY VITAL STATIS, V37, P1; 1989, NY TIMES        0820, pE22; 1990, HIV AIDS SURVEILLANC, P1; 1989, ACTG 019 QUESTIONS A; 1989, JAMA-J AM MED ASSOC, V261, P75	21	114	114	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1991	114	9					798	802		10.7326/0003-4819-114-9-798	http://dx.doi.org/10.7326/0003-4819-114-9-798			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ117	1672806				2022-12-01	WOS:A1991FJ11700012
J	BRAHAMS, D				BRAHAMS, D			HYPOGLYCEMIA AND INTENT	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030		10.1016/0140-6736(91)92679-V	http://dx.doi.org/10.1016/0140-6736(91)92679-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673179				2022-12-01	WOS:A1991FJ13500018
J	CUMMINS, D; HEUSCHKEL, R; DAVIES, SC				CUMMINS, D; HEUSCHKEL, R; DAVIES, SC			PENICILLIN PROPHYLAXIS IN CHILDREN WITH SICKLE-CELL DISEASE IN BRENT	BRITISH MEDICAL JOURNAL			English	Article							ORAL PENICILLIN; ANEMIA; INFECTION	Objective-To assess compliance with oral penicillin prophylaxis in children with sickle cell disease and identify possible reasons for poor compliance. Design-Closed questionnaires given to parents of children with sickle cell disease and general practitioners in Brent. Urine samples from 23 children were tested for penicillin. Setting-Paediatric haematology clinic, Central Middlesex Hospital, and general practices in Brent. Subjects-50 children (aged less-than-or-equal-to 16) attending clinic with sickle cell disease over six months (33 HbSS, 12 HbSC, five HbS beta-thalassaemia). 30 general practitioners: 15 with the greatest number of patients with sickle cell disease on the Brent register; 15 selected randomly from family practitioner committee's list. Main outcome measures-Reported compliance with and awareness of importance of penicillin prophylaxis. Results of urine tests for penicillin. Results-31 parents claimed that their children received penicillin every day and 19 that they received it most days (greater-than-or-equal-to 5 days a week). Penicillin was detected in only 10 of 23 urine samples tested. Parents and doctors seemed not to appreciate the importance of treatment: only eight parents were aware of the risk of death if penicillin were discontinued, and 16 doctors were unaware that regular penicillin prophylaxis prevents pneumococcal septicaemia and death in these children. Conclusions-Education for families with children with sickle cell disease must be improved. Specialised information and training are needed for doctors working in areas with a high prevalence of the disorder.	CENT MIDDLESEX HOSP,DEPT HAEMATOL,LONDON NW10 7NS,ENGLAND	Imperial College London								BARRETTCONNOR E, 1971, MEDICINE, V50, P97, DOI 10.1097/00005792-197103000-00002; BROWN AK, 1989, PEDIATRICS, V83, P897; BROZOVIC M, 1984, J CLIN PATHOL, V37, P1321, DOI 10.1136/jcp.37.12.1321; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; FRANKLIN IM, 1988, BRIT MED J, V296, P592, DOI 10.1136/bmj.296.6622.592; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GORDIS L, 1969, J PEDIATR-US, V75, P957, DOI 10.1016/S0022-3476(69)80332-X; GORDIS L, 1969, PEDIATRICS, V43, P173; Grove D.C., 1955, ASSAY METHODS ANTIBI, P14; JOHN AB, 1984, BRIT MED J, V288, P1567, DOI 10.1136/bmj.288.6430.1567; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; POWARS D, 1987, AM J DIS CHILD, V141, P250, DOI 10.1001/archpedi.1987.04460030028017; Prashar Usha, 1985, SICKLE CELL ANAEMIA; ROBINSON MG, 1966, NEW ENGL J MED, V274, P1006, DOI 10.1056/NEJM196605052741806; ROWLEY PT, 1978, NEW YORK STATE J MED, V78, P42; 1986, LANCET, V2, P1432	16	34	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					989	990		10.1136/bmj.302.6783.989	http://dx.doi.org/10.1136/bmj.302.6783.989			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039895	Green Published, Bronze			2022-12-01	WOS:A1991FJ50800016
J	LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML				LAMMIE, PJ; HITCH, WL; ALLEN, EMW; HIGHTOWER, W; EBERHARD, ML			MATERNAL FILARIAL INFECTION AS RISK FACTOR FOR INFECTION IN CHILDREN	LANCET			English	Note							BRUGIA-PAHANGI; ANTIGENS; RESPONSES; PARASITE; JIRDS	Familial clustering of filarial infection was investigated through random house-to-house surveys of 643 individuals in Leogane, Haiti, an area with endemic Bancroftian filariasis. Children of infected mothers were 2.4 to 2.9 times more likely to be infected than were those of amicrofilaraemic mothers. Filarial-specific cellular responsiveness in amicrofilaraemic children born to infected mothers was lower than that in amicrofilaraemic children born to amicrofilaraemic mothers. No effect of paternal infection status was seen. The findings show that maternal infection is a risk factor for filarial infection in children and is associated with altered parasite-specific immune reactivity.			LAMMIE, PJ (corresponding author), CTR DIS CONTROL, CTR INFECT DIS,DIV PARASIT DIS,PARASIT DIS BRANCH, F13, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.				PHS HHS [YO2-00005-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		FRANKENBURG S, 1988, J IMMUNOL METHODS, V112, P177, DOI 10.1016/0022-1759(88)90355-9; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; LAMMIE PJ, 1988, AM J TROP MED HYG, V38, P125, DOI 10.4269/ajtmh.1988.38.125; LAMMIE PJ, 1983, J IMMUNOL, V130, P1386; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; Ottesen E A, 1984, Trans R Soc Trop Med Hyg, V78 Suppl, P9, DOI 10.1016/0035-9203(84)90309-2; OTTESEN EA, 1981, ACTA TROP, V38, P205; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; RACCURT CP, 1988, T ROY SOC TROP MED H, V82, P721, DOI 10.1016/0035-9203(88)90214-3; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862	10	93	93	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1991	337	8748					1005	1006		10.1016/0140-6736(91)92661-K	http://dx.doi.org/10.1016/0140-6736(91)92661-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673168				2022-12-01	WOS:A1991FJ13500005
J	TUCK, MW; CRICK, RP				TUCK, MW; CRICK, RP			EFFICIENCY OF REFERRAL FOR SUSPECTED GLAUCOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the efficiency of referral for suspected glaucoma to general practitioners and consultants by optometrists. Design-A prospective survey covering 5% of all sight tests performed by optometrists in England and Wales over six months, with analysis of referred patients. Setting-241 optometrists' practices in areas representative of England and Wales in socio-economic terms. Subjects-Of 275 600 people attending for a sight test, 1505 were referred with suspected glaucoma (0.9% of those aged over 40). Outcomes were recorded for 1228 patients, 1103 (90%) of whom attended for examination by a consultant ophthalmologist (8% on a private basis). The analysis was confined to the 704 cases in which the information on diagnosis was received directly from a consultant or general practitioner. Main outcome measures-Diagnoses reported by consultant ophthalmologists. Waiting times before an appointment for examination by a consultant ophthalmologist. Results-Glaucoma was confirmed in 283 of the 704 referred patients, and another 222 patients were considered to require further monitoring. In all, 112 (41%) of 275 confirmed cases of glaucoma were in patients with intraocular pressures greater-than-or-equal-to 30 mm Hg. At all levels of intraocular pressure the accuracy of referral was greater when the optometrist also recorded the presence of suspicious optic discs or loss of visual field, or both; but only 331 (47%) out of the 704 referred patients had been tested with a field screener. The median waiting time for an NHS clinic appointment was nine weeks. Almost a 10th of confirmed cases of glaucoma were in people in a high risk category for glaucoma who had to wait at least 14 weeks for an appointment. Conclusions-Closer cooperation, especially at the local level, among consultants, general practitioners, and optometrists is needed to improve testing and referral for suspected glaucoma. Optometrists should be encouraged to perform all the three main tests-ophthalmoscopy, tonometry, and perimetry-in patients before referral and to report precisely on reasons for referral to help prioritisation. The optometrist's referral letter to the general practitioner should always be passed on to the consultant. Similarly, the diagnosis should always be reported back to the optometrist.	UNIV LONDON KINGS COLL HOSP,INT GLAUCOMA ASSOC,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								Brittain G P, 1988, Health Trends, V20, P43; CLEARKIN L, 1983, T OPHTHAL SOC UK, V103, P284; CRICK RP, 1982, DISPENSING OPTICIAN, V34, P192; GILLIE RF, 1982, OPHTHALMIC OPT, V22, P586; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; HOWIE JGR, 1982, BRIT MED J, V285, P1009, DOI 10.1136/bmj.285.6347.1009-a; KLJAKOVIC M, 1985, BRIT MED J, V290, P1043, DOI 10.1136/bmj.290.6474.1043; MACKEAN M, 1982, BRIT MED J, V285, P1093; PORT MJA, 1988, OPHTHAL PHYSL OPT, V8, P323, DOI 10.1016/0275-5408(88)90182-2; PORT MJA, 1989, OPHTHAL PHYSL OPT, V9, P31, DOI 10.1111/j.1475-1313.1989.tb00801.x; PORT MJA, 1989, BCO SURVEY MED REFER; STEINMANN WC, 1982, BMJ-BRIT MED J, V285, P1091, DOI 10.1136/bmj.285.6348.1091; TUCK M, 1990, OPTICIAN, V191, P16; TUCK M, 1989, HLTH TRENDS, V21, P131; TUCK M, 1990, OPTICIAN, V199, P24; TUCK MW, 1991, OPHTHAL PHYSL OPT, V11, P22, DOI 10.1111/j.1475-1313.1991.tb00190.x; VOGEL R, 1990, BRIT J OPHTHALMOL, V74, P3, DOI 10.1136/bjo.74.1.3; WILSON R, 1982, ARCH OPHTHALMOL-CHIC, V100, P737, DOI 10.1001/archopht.1982.01030030741002	19	44	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1991	302	6783					998	1000		10.1136/bmj.302.6783.998	http://dx.doi.org/10.1136/bmj.302.6783.998			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ508	2039899	Bronze, Green Published			2022-12-01	WOS:A1991FJ50800020
J	[Anonymous]				[Anonymous]			HIV IN CHILDREN	LANCET			English	Editorial Material																		HONIGSBAUM N, 1991, HIV AIDS CHILDREN; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1991, LANCET, V337, P253	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1991	337	8748					1030	1030						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ135	1673180				2022-12-01	WOS:A1991FJ13500019
J	AAMODT, EJ; CHUNG, MA; MCGHEE, JD				AAMODT, EJ; CHUNG, MA; MCGHEE, JD			SPATIAL CONTROL OF GUT-SPECIFIC GENE-EXPRESSION DURING CAENORHABDITIS-ELEGANS DEVELOPMENT	SCIENCE			English	Article							TRANSGENIC NEMATODES; CELL; TRANSFORMATION; LINEAGE; FUSION; EMBRYO	The nematode Caenorhabditis elegans was transformed with constructs containing upstream deletions of the gut-specific ges-1 carboxylesterase gene. With particular deletions, ges-1 was expressed, not as normally in the gut, but rather in muscle cells of the pharynx (which belong to a sister lineage of the gut) or in body wall muscle and hypodermal cells (which belong to a cousin lineage of the gut). These observations suggest that gut-specific gene expression in C. elegans involves not only gut-specific activators but also multiple repressors that are present in particular nongut lineages.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary				McGhee, James/0000-0001-7266-7275				AAMODT EJ, UNPUB; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DEAROLF CR, 1989, GENE DEV, V3, P384, DOI 10.1101/gad.3.3.384; DEPPE U, 1978, P NATL ACAD SCI USA, V75, P376, DOI 10.1073/pnas.75.1.376; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; FIRE A, 1989, EMBO J, V8, P3419, DOI 10.1002/j.1460-2075.1989.tb08506.x; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FRANKS RR, 1988, GENE DEV, V2, P1, DOI 10.1101/gad.2.1.1; GOODBOURN S, 1990, BIOCHIM BIOPHYS ACTA, V1032, P53, DOI 10.1016/0304-419X(90)90012-P; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOUGHEVANS BR, 1990, DEVELOPMENT, V110, P41; JEFFERSON RA, 1987, J MOL BIOL, V193, P41, DOI 10.1016/0022-2836(87)90624-3; MCGHEE JD, 1990, GENETICS, V125, P505; MELLO CC, COMMUNICATION; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SPIETH J, 1988, DEV BIOL, V130, P285, DOI 10.1016/0012-1606(88)90434-4; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; STROEHER VL, UNPUB; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	23	84	90	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					579	582		10.1126/science.2020855	http://dx.doi.org/10.1126/science.2020855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020855				2022-12-01	WOS:A1991FJ12700052
J	BRILLIANT, MH; GONDO, Y; EICHER, EM				BRILLIANT, MH; GONDO, Y; EICHER, EM			DIRECT MOLECULAR-IDENTIFICATION OF THE MOUSE PINK-EYED UNSTABLE MUTATION BY GENOME SCANNING	SCIENCE			English	Article							RECOMBINANT-INBRED STRAINS; COAT-COLOR MUTATION; HUMAN DNA; MICE; GENE; CHROMOSOME-7; PROVIRUS; LINKAGE; RATES; LOCUS	DNA sequences associated with the mouse pink-eyed unstable mutation were identified in the absence of closely linked molecular markers and without prior knowledge of the encoded gene product. This was accomplished by "genome scanning," a technique in which high-resolution Southern blots of genomic DNAs were hybridized to a dispersed and moderately repetitive DNA sequence. In this assay, pink-eyed unstable DNA was distinguished from the DNA of wild-type and revertant mice by enhanced hybridization to one of several hundred resolved fragments. The fragments showing enhanced hybridization in pink-eyed unstable DNA was cloned and found to lie within a DNA duplication that is located close to, or within, the pink-eyed dilution locus. The duplication associated with the mouse pink-eyed unstable mutation may mediate the high reversion frequency characteristic of this mutation.	JACKSON LAB,BAR HARBOR,ME 04609	Jackson Laboratory	BRILLIANT, MH (corresponding author), FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111, USA.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489	NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05529] Funding Source: Medline; NIGMS NIH HHS [GM43840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BAILEY DW, 1971, TRANSPLANTATION, V11, P325, DOI 10.1097/00007890-197103000-00013; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; BURT DW, 1984, NUCLEIC ACIDS RES, V12, P8579, DOI 10.1093/nar/12.22.8579; COPELAND NG, 1983, CELL, V33, P379, DOI 10.1016/0092-8674(83)90419-1; DEOL MS, 1983, J EMBRYOL EXP MORPH, V78, P291; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONDO Y, UNPUB; Haldane JBS, 1915, J GENET, V5, P133, DOI 10.1007/BF02985370; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNOBLER R L, 1984, Experimental and Clinical Immunogenetics, V1, P217; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MINTZ B, 1970, CONTROL MECHANISMS E, P15; ORKIN SH, 1986, CELL, V47, P854; PHILLIPS JS, 1977, MOUSE NEWS LETT, V56, P38; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHLAGER G, 1967, GENETICS, V57, P319; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; SILVER J, 1986, P NATL ACAD SCI USA, V83, P1423, DOI 10.1073/pnas.83.5.1423; SILVERS WK, 1979, COAT COLORS MICE, P90; SOUTHERN EM, 1975, J MOL BIOL, V98, P5503; Sturtevant AH, 1925, GENETICS, V10, P117; TARTOF KD, 1988, GENETICS, V120, P1; Taylor B. A., 1978, ORIGINS INBRED MICE, P423, DOI [10.1016/B978-0-12-507850-4.50032-9, DOI 10.1016/B978-0-12-507850-4.50032-9]; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; WHITNEY JB, 1982, J HERED, V73, P12, DOI 10.1093/oxfordjournals.jhered.a109567; WOLFE HG, 1963, 11TH P INT C GEN, P251	31	114	115	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					566	569		10.1126/science.1673574	http://dx.doi.org/10.1126/science.1673574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1673574				2022-12-01	WOS:A1991FJ12700047
J	DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM				DULCEY, CS; GEORGER, JH; KRAUTHAMER, V; STENGER, DA; FARE, TL; CALVERT, JM			DEEP UV PHOTOCHEMISTRY OF CHEMISORBED MONOLAYERS - PATTERNED COPLANAR MOLECULAR ASSEMBLIES	SCIENCE			English	Article							GOLD	Deep ultraviolet (UV) irradiation is shown to modify organosilane self-assembled monolayer (SAM) films by a photocleavage mechanism, which renders the surface amenable to further SAM modification. Patterned UV exposure creates alternating regions of intact SAM film and hydrophilic, reactive sites. The exposed regions can undergo a second chemisorption reaction to produce an assembly of SAMs in the same molecular plane with similar substrate attachment chemistry. The UV-patterned films are used as a template for selective buildup of fluorophores, metals, and biological cells.	USN,RES LAB,CTR BIOMOLEC SCI & ENGN,CODE 6090,WASHINGTON,DC 20375; GEOCENTERS INC,FT WASHINGTON,MD 20744; US FDA,CTR DEVICES & RADIOL HLTH,ROCKVILLE,MD 20857	United States Department of Defense; United States Navy; Naval Research Laboratory; US Food & Drug Administration (FDA)								Benson S., 1976, THERMOCHEMICAL KINET; BIEDLER JL, 1973, CANCER RES, V33, P2643; DOUB DL, 1947, J AM CHEM SOC, V69, P2714; KALLURY KMR, 1988, ANAL CHEM, V60, P169, DOI 10.1021/ac00153a014; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; LAIBINIS PE, 1989, SCIENCE, V245, P845, DOI 10.1126/science.245.4920.845; LAND DP, 1990, REV SCI INSTRUM, V61, P1674, DOI 10.1063/1.1141131; POLYMEROPOULOS EE, 1978, J CHEM PHYS, V69, P1836, DOI 10.1063/1.436844; ROBERTS G, 1990, LANGMUIR BLODGETT FI, pCH7; SCHNUR JM, Patent No. 7182123; SRINIVASAN R, 1989, CHEM REV, V89, P1303, DOI 10.1021/cr00096a003; STENGER DA, Patent No. 7598194; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; WALSH R, 1981, ACCOUNTS CHEM RES, V14, P246, DOI 10.1021/ar00068a004; WASSERMAN SR, 1989, J MATER RES, V4, P886, DOI 10.1557/JMR.1989.0886; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; Zisman WA., 1964, ADV CHEM SER	17	489	538	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					551	554		10.1126/science.2020853	http://dx.doi.org/10.1126/science.2020853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020853				2022-12-01	WOS:A1991FJ12700042
J	EISEN, JS				EISEN, JS			DETERMINATION OF PRIMARY MOTONEURON IDENTITY IN DEVELOPING ZEBRAFISH EMBRYOS	SCIENCE			English	Article							GROWTH CONES; LINEAGE	The developmental determination of primary motoneurons was investigated by transplanting identified motoneurons in embryonic zebrafish to new spinal cord positions. Some cells moved from the new positions in which they were placed back to their original positions, thus it was difficult to evaluate whether they were determined. Among cells that remained in their new positions, those transplanted about 1 hour before axogenesis developed axonal trajectories that were appropriate for their original soma positions, whereas those transplanted 2 to 3 hours before axogenesis developed morphologies appropriate for their new soma positions. These results suggest that motoneuronal identity is determined before axogenesis.			EISEN, JS (corresponding author), UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403, USA.				NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS23915] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS023915, R01NS023915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVEREZ IS, IN PRESS DEVELOPMENT; EISEN J, UNPUB; EISEN JS, 1990, J NEUROSCI, V10, P34; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; HANNEMAN E, 1988, DEVELOPMENT, V103, P49; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; KANDEL ER, 1976, CELLULAR BASIS BEHAV, P211; Kimble J., 1979, Cell lineage, stem cells and cell determination. (Proc. Internat. Workshop on cell lineage, stem cells and cell determination, Seillac, France, 20-24 May 1979. - Inserm Symposium No.10), P59; KIMMEL CB, 1990, MOL APPROACHES SUPRA, P137; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANCEJONES C, 1988, DEV BIOL, V126, P408, DOI 10.1016/0012-1606(88)90150-9; PIKE SH, 1990, J NEUROSCI, V10, P44; SANES DH, 1989, NEURON, V2, P1237, DOI 10.1016/0896-6273(89)90308-5; STENT GS, 1985, PHILOS T R SOC B, V312, P3, DOI 10.1098/rstb.1985.0174; WESTERFIELD M, 1988, MESSAGE MIND, P110	17	106	107	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					569	572		10.1126/science.1708527	http://dx.doi.org/10.1126/science.1708527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708527				2022-12-01	WOS:A1991FJ12700048
J	HAN, JW; MCCORMICK, F; MACARA, IG				HAN, JW; MCCORMICK, F; MACARA, IG			REGULATION OF RAS-GAP AND THE NEUROFIBROMATOSIS-1 GENE-PRODUCT BY EICOSANOIDS	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN	Ras-GAP (GTPase activating protein) is a regulatory protein that stimulates the intrinsic guanosine triphosphatase (GTPase) activity of the proto-oncogene product p21ras. A domain of the neurofibromatosis gene product (NF1) that has sequence similarity to the catalytic domain of Ras-GAP and to yeast IRA gene products also has a specific stimulatory activity toward p21ras GTPase. Arachidonic acid and phosphatidic acid inactivate GAP, but no agents have been identified that stimulate GAP and thereby switch p21ras off. With the use of recombinant Ha-c-Ras and Ras-GAP, NF1, and GAP catalytic domains, it was found that prostaglandins PGF2-alpha and PGA2 stimulated Ras-GAP and that prostacyclin PGI2 inhibited Ras-GAP. The stimulatory effect of PGF2-alpha was saturable and structure-specific and competed with the inhibitory effect of arachidonic acid. Arachidonic acid also inhibited the catalytic activity of NF1, but prostaglandins were not stimulatory. These results suggest a mechanism for the allosteric control of Ras function through the modulation of arachidonate metabolism.	CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608		HAN, JW (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOPHYS,CTR ENVIRONM HLTH SCI,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [R01CA038888] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT A, 1979, PRACTICAL APPLICATIO, P149; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALLENBECK R, 1990, J BIOL CHEM, V265, P21922; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOORE PK, 1985, PROSTANOIDS PHARM PH, P32; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	26	101	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					576	579		10.1126/science.1902323	http://dx.doi.org/10.1126/science.1902323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1902323				2022-12-01	WOS:A1991FJ12700051
J	LIU, SC; DERICK, LH; ZHAI, S; PALEK, J				LIU, SC; DERICK, LH; ZHAI, S; PALEK, J			UNCOUPLING OF THE SPECTRIN-BASED SKELETON FROM THE LIPID BILAYER IN SICKLED RED-CELLS	SCIENCE			English	Article							HUMAN-ERYTHROCYTES; MEMBRANE SKELETON; ATP DEPLETION; FREE VESICLES; CATION; RELEASE; SODIUM; PHOSPHATIDYLCHOLINE; TRANSFORMATION	The distribution of spectrin and band 3 in deoxygenated reversibly sickled cells was visualized by immunofluorescence and immunoelectron microscopy. Antibodies against band 3, the major lipid-associated transmembrane protein, labeled the entire cell body, including the entire length of the long protruding spicule, whereas antibodies against spectrin labeled only the cell body and the base region of the spicules. The results suggest that the formation of long spicules during sickling is associated with a continuous polymerization of hemoglobin S polymers, presumably through gaps in the spectrin-actin meshwork, and a subsequent uncoupling of the lipid bilayer from the submembrane skeleton.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT MED,BOSTON,MA 02135	Tufts University; Tufts University	LIU, SC (corresponding author), TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02135, USA.				NHLBI NIH HHS [HL-15157-7, HL-37462, HL-27215] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462, P60HL015157, R01HL027215, R37HL027215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1982, NATURE, V295, P612, DOI 10.1038/295612a0; BERKOWITZ LR, 1985, AM J PHYSIOL, V249, pC208, DOI 10.1152/ajpcell.1985.249.3.C208; BERTLES JF, 1969, BLOOD-J HEMATOL, V33, P884, DOI 10.1182/blood.V33.6.884.884; BOOKCHIN RM, 1981, J PHYSIOL-LONDON, V312, P265, DOI 10.1113/jphysiol.1981.sp013628; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; CANESSA M, 1987, BLOOD, V70, P1861; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; FRANCK PFH, 1983, J BIOL CHEM, V258, P8435; JENSEN WN, 1970, SEMIN HEMATOL, V7, P409; JOINER CH, 1986, J CLIN INVEST, V78, P1487, DOI 10.1172/JCI112740; JOINER CH, 1988, BLOOD CELLS, V13, P339; LIU SC, 1989, EUR J CELL BIOL, V49, P358; Liu Shun-Wei, UNPUB; LUTZ HU, 1977, J CELL BIOL, V73, P548, DOI 10.1083/jcb.73.3.548; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; MOHANDAS N, 1986, BLOOD, V68, P450; OTT P, 1981, BIOCHIM BIOPHYS ACTA, V641, P79, DOI 10.1016/0005-2736(81)90570-8; PALEK J, 1978, ERYTHROCYTE MEMBRANE, P75; RIS H, 1985, J CELL BIOL, V100, P1474, DOI 10.1083/jcb.100.5.1474; RUMSBY MG, 1977, BIOCHEM SOC T, V5, P126, DOI 10.1042/bst0050126; TOSTESON DC, 1952, J CLIN INVEST, V31, P406, DOI 10.1172/JCI102623; WAGNER GM, 1986, J LAB CLIN MED, V108, P315	24	67	67	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					574	576		10.1126/science.2020854	http://dx.doi.org/10.1126/science.2020854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	2020854				2022-12-01	WOS:A1991FJ12700050
J	LOTURCO, JJ; KRIEGSTEIN, AR				LOTURCO, JJ; KRIEGSTEIN, AR			CLUSTERS OF COUPLED NEUROBLASTS IN EMBRYONIC NEOCORTEX	SCIENCE			English	Article							GAP JUNCTIONAL COMMUNICATION; MAMMALIAN CEREBRAL-CORTEX; SINGLE-CHANNEL CURRENTS; FETAL MONKEY NEOCORTEX; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; CORTICAL-NEURONS; MIGRATION; TRANSPLANTATION; GUIDANCE	The neocortex of the brain develops from a simple germinal layer into a complex multilayer structure. To investigate cellular interactions during early neocortical development, whole-cell patch clamp recordings were made from neuroblasts in the ventricular zone of fetal rats. During early corticogenesis, neuroblasts are physiologically coupled by gap junctions into clusters of 15 to 90 cells. The coupled cells form columns within the ventricular zone and, by virtue of their membership in clusters, have low apparent membrane resistances and generate large responses to the inhibitory neurotransmitter gamma-aminobutyric acid. As neuronal migration out of the ventricular zone progresses, the number of cells within the clusters decreases. These clusters allow direct cell to cell interaction at the earliest stages of corticogenesis.			LOTURCO, JJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROSURG,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021223, P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS12151, NS07280, NS21223] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BARFIELD J A, 1990, Society for Neuroscience Abstracts, V16, P1272; BERRY M, 1965, J ANAT, V99, P691; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLANTON MG, 1990, P NATL ACAD SCI USA, V87, P8027, DOI 10.1073/pnas.87.20.8027; CONNORS BW, 1984, J NEUROSCI, V4, P1324; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GOODALL H, 1984, J EMBRYOL EXP MORPH, V79, P53; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; JENSEN KF, 1984, P NATL ACAD SCI-BIOL, V81, P964, DOI 10.1073/pnas.81.3.964; JONES EG, 1975, SCIENCE, V190, P572, DOI 10.1126/science.810887; KAZNOWSKI CE, 1990, SOC NEUR ABSTR, V16, P1272; KRIEGSTEIN A R, 1990, Society for Neuroscience Abstracts, V16, P57; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; LOTURCO JJ, IN PRESS J NEUROSCI; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; Miller M, 1988, DEV MATURATION CEREB, V7, P133; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PETERS A, 1975, J ANAT EMBRYOL, V141, P3; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; RAKIC P, 1975, BRAIN MECHANISMS MEN, P3; ROBERTSON JD, 1963, J CELL BIOL, V19, P201, DOI 10.1083/jcb.19.1.201; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781	41	277	279	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					563	566		10.1126/science.1850552	http://dx.doi.org/10.1126/science.1850552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850552				2022-12-01	WOS:A1991FJ12700046
J	NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E				NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E			INDUCTION BY NGF OF MEIOTIC MATURATION OF XENOPUS OOCYTES EXPRESSING THE TRK PROTOONCOGENE PRODUCT	SCIENCE			English	Article							BIOCHEMICAL-CHARACTERIZATION; RECEPTOR; PROTEINS; ACTIVATION; SEQUENCES	The effect of nerve growth factor (NGF) was assessed in Xenopus oocytes expressing the human trk proto-oncogene product, p140prototrk. Oocytes injected with trk messenger RNA expressed polypeptides recognized by antibodies to the trk gene product. Exposure of these oocytes to nanomolar amounts of NGF resulted in specific surface binding of I-125-labeled NGF, tyrosine phosphorylation of p140prototrk, and meiotic maturation, as determined by germinal vesicle breakdown and maturation promoting factor (p34cdc2) kinase activation. Thus the trk proto-oncogene product can act as a receptor for NGF in a functionally productive manner.	NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Parada, luis F/B-9400-2014; Nebreda, Angel Rodriguez/R-9594-2019					ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SMITH LD, 1989, DEVELOPMENT, V107, P685; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	27	119	122	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					558	560		10.1126/science.1850550	http://dx.doi.org/10.1126/science.1850550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850550				2022-12-01	WOS:A1991FJ12700044
J	SHAPIRO, BM				SHAPIRO, BM			THE CONTROL OF OXIDANT STRESS AT FERTILIZATION	SCIENCE			English	Article							SEA-URCHIN EGGS; PROTEIN CROSS-LINKING; GUANYLATE-CYCLASE; ACROSOME REACTION; INTRACELLULAR-PH; STRONGYLOCENTROTUS-PURPURATUS; EXTRACELLULAR-MATRIX; SPERM; MEMBRANE; ENVELOPE	Metazoan eggs alter their coats after fertilization to protect the early embryo. In sea urchins, this modification consists of a rapid, coordinated set of noncovalent macromolecular assembly steps that are stabilized by protein cross-linking. The sea urchin egg uses an oxidative cross-linking reaction that requires hydrogen peroxide and a secreted peroxidase and thus faces the challenge of oxidant stress at the beginning of its development. Protection from the deleterious effects of this oxidative mechanism is afforded by regulation of the production and utilization of oxidizing species. This regulation requires a specific protein kinase C-activated oxidase and ovothiol, an intracellular antioxidant.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle								BACKSTROM S, 1959, EXP CELL RES, V18, P347, DOI 10.1016/0014-4827(59)90013-8; BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; CHANDLER DE, 1986, CELL TISSUE RES, V246, P153; CHANDLER DE, 1980, J CELL BIOL, V84, P618, DOI 10.1083/jcb.84.3.618; CHRISTEN R, 1983, J BIOL CHEM, V258, P5392; CHRISTEN R, 1982, J BIOL CHEM, V257, P4881; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; DARSZON A, 1984, EUR J BIOCHEM, V144, P515, DOI 10.1111/j.1432-1033.1984.tb08496.x; DEITS T, 1984, J BIOL CHEM, V259, P3525; DEITS T, 1985, J BIOL CHEM, V260, P7882; DEITS TL, 1986, J BIOL CHEM, V261, P2159; DUBE F, 1985, CELL, V40, P657, DOI 10.1016/0092-8674(85)90214-4; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; EPEL D, 1969, EXP CELL RES, V58, P312, DOI 10.1016/0014-4827(69)90510-2; Epel D., 1978, Current Topics in Developmental Biology, V12, P185, DOI 10.1016/S0070-2153(08)60597-9; FAHEY RC, 1976, BIOCHIM BIOPHYS ACTA, V437, P445, DOI 10.1016/0304-4165(76)90013-1; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FOERDER CA, 1978, P NATL ACAD SCI USA, V75, P3183, DOI 10.1073/pnas.75.7.3183; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; HALL HG, 1978, CELL, V15, P343, DOI 10.1016/0092-8674(78)90003-X; Harvey EN, 1910, J EXP ZOOL, V8, P355, DOI 10.1002/jez.1400080402; HEINECKE JW, 1989, P NATL ACAD SCI USA, V86, P1259, DOI 10.1073/pnas.86.4.1259; HEINECKE JW, 1990, J BIOL CHEM, V265, P7717; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; HOLLER TP, 1990, BIOCHEMISTRY-US, V29, P1953, DOI 10.1021/bi00459a042; ISONO N, 1968, EXP CELL RES, V50, P616, DOI 10.1016/0014-4827(68)90423-0; Isono N., 1963, Journal of the Faculty of Science Tokyo University Zoology, V10, P67; JAFFE LA, 1976, NATURE, V261, P68, DOI 10.1038/261068a0; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JAFFE LA, 1985, DEV BIOL, V99, P265; KAMEL LC, 1985, LIPIDS, V20, P350, DOI 10.1007/BF02534201; KAY E, 1982, CELL, V29, P867, DOI 10.1016/0092-8674(82)90448-2; KAY ES, 1987, DEV BIOL, V121, P325, DOI 10.1016/0012-1606(87)90168-0; KAY ES, 1985, BIOL FERTILIZATION, V3, P45; KLEBANOFF SJ, 1979, J EXP MED, V149, P938, DOI 10.1084/jem.149.4.938; KRANE SM, 1960, BIOCHIM BIOPHYS ACTA, V43, P369, DOI 10.1016/0006-3002(60)90461-3; LALLIER R, 1971, EXPERIENTIA, V27, P1323, DOI 10.1007/BF02136716; LALLIER R A, 1970, Experimental Cell Research, V63, P460; LASER H., 1939, PROC ROY SOC [LONDON] SER B, V126, P539, DOI 10.1098/rspb.1939.0007; LEE HC, 1983, DEV BIOL, V95, P31, DOI 10.1016/0012-1606(83)90004-0; LEE HC, 1986, J BIOL CHEM, V261, P6026; PALUMBO A, 1982, TETRAHEDRON LETT, V23, P3207, DOI 10.1016/S0040-4039(00)88597-4; PALUMBO A, 1984, COMP BIOCHEM PHYS B, V78, P81, DOI 10.1016/0305-0491(84)90149-4; PETASNE RG, 1987, NATURE, V325, P516, DOI 10.1038/325516a0; RUNNSTROM J, 1966, ADV MORPHOL, V5, P231; SCHACKMANN RW, 1984, J BIOL CHEM, V259, P3914; SCHATTEN H, 1988, CELL BIOL FERTILIZAT; SCHULZ S, 1989, FASEB J, V3, P2026, DOI 10.1096/fasebj.3.9.2568301; SHAPIRO B M, 1988, Biofactors, V1, P85; SHAPIRO BM, 1987, CELL, V49, P293, DOI 10.1016/0092-8674(87)90276-5; SHAPIRO BM, 1988, CELL BIOL FERTILIZAT, P251; Shearer C, 1922, P R SOC LOND B-CONTA, V93, P213, DOI 10.1098/rspb.1922.0016; Sies H., 1985, OXIDATIVE STRESS; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SOMERS CE, 1989, DEV BIOL, V131, P226, DOI 10.1016/S0012-1606(89)80054-5; SOMERS CE, IN PRESS J BIOL CHEM; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TRIMMER JS, 1986, ANNU REV CELL BIOL, V2, P1; TURNER E, 1986, J BIOL CHEM, V261, P3056; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043; TURNER E, 1988, RESPIRATORY BURST IT, P385; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; VANBAALE.C, 1966, NATURE, V211, P951; VERON M, 1977, CELL, V10, P321, DOI 10.1016/0092-8674(77)90226-4; Warburg O, 1908, H-S Z PHYSIOL CHEM, V57, P1, DOI 10.1515/bchm2.1908.57.1-2.1; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WEIDMAN PJ, 1987, J BIOL CHEM, V262, P15076; WEIDMAN PJ, 1985, J CELL BIOL, V100, P938, DOI 10.1083/jcb.100.3.938; WEIDMAN PJ, 1987, J CELL BIOL, V105, P561, DOI 10.1083/jcb.105.1.561; WHITAKER MJ, 1982, QUANT REV BIOPHYS, V15, P4; WHITAKER MJ, 1985, FERTILIZATION RESPON, V3, P168; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203	80	132	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					533	536		10.1126/science.1850548	http://dx.doi.org/10.1126/science.1850548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850548				2022-12-01	WOS:A1991FJ12700037
J	YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y				YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y			OPC-21268, AN ORALLY EFFECTIVE, NONPEPTIDE VASOPRESSIN-VI RECEPTOR ANTAGONIST	SCIENCE			English	Article							ARGININE-VASOPRESSIN; ADENYLATE-CYCLASE; RAT; MEMBRANES; RESPONSES; HORMONE	An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been identified. This compound selectively antagonized binding to the V1 subtype of the vasopressin receptor in a competitive manner. In vivo, the compound acted as a specific antagonist of arginine vasopressin (AVP)-induced vasoconstriction. After oral administration in conscious rats, the compound also antagonized pressor responses to AVP. OPC-21268 can be used to study the physiological role of AVP and may be therapeutically useful in the treatment of hypertension and congestive heart failure.			YAMAMURA, Y (corresponding author), OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 2,46310 KAGASUNO KAWAUCHI CHO,TOKUSHIMA 77101,JAPAN.							ANDERSON WA, 1963, BIOCHIM BIOPHYS ACTA, V67, P674; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOCKAERT J, 1973, J BIOL CHEM, V248, P5922; GILLESPIE JS, 1967, BRIT J PHARM CHEMOTH, V30, P78, DOI 10.1111/j.1476-5381.1967.tb02114.x; KNAPE JTA, 1988, ARCH INT PHARMACOD T, V291, P142; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING M, 1981, J MED CHEM, V24, P701, DOI 10.1021/jm00138a012; MANNING M, 1977, J MED CHEM, V20, P1228, DOI 10.1021/jm00219a026; MANNING M, 1989, J LAB CLIN MED, V114, P617; NAKAHARA T, 1978, J BIOL CHEM, V253, P3211; NAKAMURA T, 1983, J BIOL CHEM, V258, P9283; SAWYER WH, 1981, SCIENCE, V212, P49, DOI 10.1126/science.7209515; TOLBERT MEM, 1980, J BIOL CHEM, V255, P1938; YAMAMURA Y, UNPUB	15	303	317	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					572	574		10.1126/science.1850553	http://dx.doi.org/10.1126/science.1850553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850553				2022-12-01	WOS:A1991FJ12700049
J	YAN, H; SCHLESSINGER, J; CHAO, MV				YAN, H; SCHLESSINGER, J; CHAO, MV			CHIMERIC NGF-EGF RECEPTORS DEFINE DOMAINS RESPONSIBLE FOR NEURONAL DIFFERENTIATION	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; STIMULATION; INDUCTION; MUTANTS	To determine the domains of the low-affinity nerve growth factor (NGF) receptor required for appropriate signal transduction, a series of hybrid receptors were constructed that consisted of the extracellular ligand-binding domain of the human epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and cytoplasmic domains of the human low-affinity NGF receptor (NGFR). Transfection of these chimeric receptors into rat pheochromocytoma PC12 cells resulted in appropriate cell surface expression. Biological activity mediated by the EGF-NGF chimeric receptor was assayed by the induction of neurite outgrowth in response to EGF in stably transfected cells. Furthermore, the chimeric receptor mediated nuclear signaling, as evidenced by the specific induction of transin messenger RNA, an NGF-responsive gene. Neurite outgrowth was not observed with chimeric receptors that contained the transmembrane domain from the EGFR, suggesting that the membrane-spanning region and cytoplasmic domain of the low-affinity NGFR are necessary for signal transduction.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	YAN, H (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.			Chao, Moses/0000-0002-6969-3744				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Berg M.D., UNPUB; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P4730; HOSANG M, 1985, J BIOL CHEM, V260, P655; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; POLLOCK D, 1990, NEUROSCIENCE, V10, P2626; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YAN H, UNPUB	27	111	118	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					561	563		10.1126/science.1850551	http://dx.doi.org/10.1126/science.1850551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850551				2022-12-01	WOS:A1991FJ12700045
J	YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU				YOUNG, LS; DUNSTAN, HM; WITTE, PR; SMITH, TP; OTTONELLO, S; SPRAGUE, KU			A CLASS-III TRANSCRIPTION FACTOR COMPOSED OF RNA	SCIENCE			English	Article							POLYMERASE-III; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; PURIFICATION; RECOGNITION; COMPLEXES; SEQUENCES; REQUIRES; REGION; SIGNAL	It is generally assumed that the machinery that transcribes genes is composed entirely of polypeptides. However, in vitro transcription by silkworm RNA polymerase III requires a transcription factor that is not a polypeptide. This component, TFIIIR, is distinct from the previously identified transcription components: RNA polymerase III, and the accessory factors TFIIIA, TFIIIB, TFIIIC, and TFIIID. The newly discovered TFIIIR is a macromolecule that appears to be composed of RNA. It is resistant to heat, detergent, phenol, protease, and deoxyribonuclease, but it is sensitive to alkali and ribonuclease.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA; UNIV PARMA, INST SCI BIOCHIM, I-43100 PARMA, ITALY	University of Oregon; University of Oregon; University of Oregon; University of Parma					NIGMS NIH HHS [GM 32851, GM 07413, GM 25388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388, R01GM032851] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CIECHANOVER A, 1985, P NATL ACAD SCI USA, V82, P1341, DOI 10.1073/pnas.82.5.1341; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DUNSTAN H, UNPUB; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HEINS JN, 1967, J BIOL CHEM, V242, P1016; HUANG DD, 1984, SCIENCE, V225, P1482, DOI 10.1126/science.6206568; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KLEKAMP MS, 1987, J BIOL CHEM, V262, P7878; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; MORTON DG, 1982, MOL CELL BIOL, V2, P1524, DOI 10.1128/MCB.2.12.1524; MOWRY KL, 1988, TRENDS BIOCHEM SCI, V13, P447, DOI 10.1016/0968-0004(88)90220-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PACE NR, 1987, MOL BIOL RNA NEW PER, P17; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROMANIUK PJ, 1988, MOL BIOL RNA, P123; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SMITH TW, UNPUB; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; SPRAGUE KU, 1987, RNA POLYM REGULATION, P195; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUZUKI Y, 1974, J MOL BIOL, V88, P393, DOI 10.1016/0022-2836(74)90490-2; TANIUCHI H, 1966, J BIOL CHEM, V241, P4366; TOMIZAWA J, 1987, MOL BIOL RNA NEW PER, P249; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WILSON ET, 1985, J MOL BIOL, V183, P153, DOI 10.1016/0022-2836(85)90209-8; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOUNG LS, 1991, MOL CELL BIOL, V11, P1382, DOI 10.1128/MCB.11.3.1382; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	43	48	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					542	546		10.1126/science.1708526	http://dx.doi.org/10.1126/science.1708526			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1708526				2022-12-01	WOS:A1991FJ12700039
J	BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL				BACHELERIE, F; ALCAMI, J; ARENZANASEISDEDOS, F; VIRELIZIER, JL			HIV ENHANCER ACTIVITY PERPETUATED BY NF-KAPPA-B INDUCTION ON INFECTION OF MONOCYTES	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; GENE-EXPRESSION; ALPHA; TRANSCRIPTION; INTERLEUKIN-1; ACTIVATION; MITOGENS	PERMISSIVENESS to replication of human immunodeficiency virus (HIV) differs in T lymphocytes and macrophages. In T cells, HIV transcription is poorly detected in vivo 1. Cloned, normal T lymphocytes show very little, if any, basal activity of the HIV enhancer and low nuclear expression of NF-kappa-B 2, a potent transcriptional activator of the HIV enhancer 3-5. In contrast, fixed tissue macrophages express detectable HIV proteins, indicating permanent virus transcription 6. One explanation for the perpetuation of virus infection in macrophages could be sustained nuclear NF-kappa-B expression. However, the U937 monocytic cell line, which is fully permissive to HIV replication, is known to express only low levels of nuclear NF-kappa-B 7. We show here that chronic HIV infection results in both induction of a nuclear factor with antigenic properties indistinguishable from those of NF-kappa-B and permanently increased HIV enhancer activity. This phenomenon, which is independent of tumour necrosis factor, is associated with HIV replication, and is thus likely to explain at least in part the perpetuation of HIV infection in monocytes.	INST PASTEUR,UNITE IMMUNOL VIRALE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Alcami, Pepe/T-2242-2018; BACHELERIE, FRANCOISE/F-8823-2013; Arenzana-Seisdedos, Fernando/E-5835-2016	Alcami, Pepe/0000-0003-0023-7377; BACHELERIE, FRANCOISE/0000-0002-0399-3277; 				BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; DU EJ, 1990, P NATL ACAD SCI USA, V86, P5974; GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001; GHOSH R, 1990, CELL, V62, P1019; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRIFFIN G, 1990, NATURE, V343, P219, DOI 10.1038/343219a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HAASE AT, 1984, METHOD VIROL, V7, P189; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISRAEL N, 1989, J IMMUNOL, V143, P3956; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WANG Y, 1987, J EXP MED, V166, P625, DOI 10.1084/jem.166.3.625	26	179	182	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					709	712		10.1038/350709a0	http://dx.doi.org/10.1038/350709a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023633				2022-12-01	WOS:A1991FJ13000061
J	CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I				CLARKE, R; DALY, L; ROBINSON, K; NAUGHTEN, E; CAHALANE, S; FOWLER, B; GRAHAM, I			HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTATHIONINE BETA-SYNTHASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ENDOTHELIAL-CELL INJURY; LOW-DENSITY LIPOPROTEIN; CONTAINING AMINO-ACIDS; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE; FAMILY HISTORY; FOLIC-ACID	Background. Hyperhomocysteinemia arising from impaired methionine metabolism, probably usually due to a deficiency of cystathionine beta-synthase, is associated with premature cerebral, peripheral, and possibly coronary vascular disease. Both the strength of this association and its independence of other risk factors for cardiovascular disease are uncertain. We studied the extent to which the association could be explained by heterozygous cystathionine beta-synthase deficiency. Methods. We first established a diagnostic criterion for hyperhomocysteinemia by comparing peak serum levels of homocysteine after a standard methionine-loading test in 25 obligate heterozygotes with respect to cystathionine beta-synthase deficiency (whose children were known to be homozygous for homocystinuria due to this enzyme defect) with the levels in 27 unrelated age- and sex-matched normal subjects. A level of 24.0-mu-mol per liter or more was 92 percent sensitive and 100 percent specific in distinguishing the two groups. The peak serum homocysteine levels in these normal subjects were then compared with those in 123 patients whose vascular disease had been diagnosed before they were 55 years of age. Results. Hyperhomocysteinemia was detected in 16 of 38 patients with cerebrovascular disease (42 percent), 7 of 25 with peripheral vascular disease (28 percent), and 18 of 60 with coronary vascular disease (30 percent), but in none of the 27 normal subjects. After adjustment for the effects of conventional risk factors, the lower 95 percent confidence limit for the odds ratio for vascular disease among the patients with hyperhomocysteinemia, as compared with the normal subjects, was 3.2. The geometric-mean peak serum homocysteine level was 1.33 times higher in the patients with vascular disease than in the normal subjects (P = 0.002). The presence of cystathionine beta-synthase deficiency was confirmed in 18 of 23 patients with vascular disease who had hyperhomocysteinemia. Conclusions. Hyperhomocysteinemia is an independent risk factor for vascular disease, including coronary disease, and in most instances is probably due to cystathionine beta-synthase deficiency.	ADELAIDE HOSP,DEPT CARDIOL,PETER ST,DUBLIN 8,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT MED,DUBLIN 2,IRELAND; CHILDRENS HOSP,NATL SCREENING CTR METAB DIS,DUBLIN,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT COMMUNITY MED & EPIDEMIOL,DUBLIN 4,IRELAND; ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 1HA,LANCS,ENGLAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; University College Dublin; Royal Manchester Children's Hospital								USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; BERG K, 1989, ARTERIOSCLEROSIS S, V9, P50; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1984, STROKE, V15, P1012, DOI 10.1161/01.STR.15.6.1012; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; BRATTSTROM LE, 1985, METABOLISM, V34, P1073, DOI 10.1016/0026-0495(85)90082-4; BRESLOW NE, 1980, IARC SCI PUBL, V32, P124; CAREY MC, 1968, AM J MED, V45, P26, DOI 10.1016/0002-9343(68)90004-1; FOWLER B, 1978, J CLIN INVEST, V61, P645, DOI 10.1172/JCI108976; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; FRIMPTER GW, 1961, J BIOL CHEM, V236, pPC51; GOLDBOURT U, 1986, ARTERIOSCLEROSIS, V6, P357, DOI 10.1161/01.ATV.6.4.357; GRAEBER JE, 1982, PEDIATR RES, V16, P490, DOI 10.1203/00006450-198206000-00018; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1977, HYPERTENSION PHYSIOP, P880; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P2047, DOI 10.1073/pnas.83.7.2047; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; MYERS RH, 1989, 2ND P INT C PREV CAR, pA376; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; OLSZEWSKI AJ, 1988, ATHEROSCLEROSIS, V69, P109, DOI 10.1016/0021-9150(88)90003-2; PANGANAMALA RV, 1986, PROSTAG LEUKOTR ESS, V22, P349, DOI 10.1016/0262-1746(86)90145-9; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; ROBINSON K, 1990, CDNA12834ENC OFF OFF; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROSENMAN RH, 1976, AM J CARDIOL, V37, P903, DOI 10.1016/0002-9149(76)90117-X; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SOLBERG LA, 1983, ARTERIOSCLEROSIS, V3, P187, DOI 10.1161/01.ATV.3.3.187; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1983, METABOLISM, V32, P363, DOI 10.1016/0026-0495(83)90045-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950; 1981, NIH822035 DEP HLTH H	49	1866	1955	0	51	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1149	1155		10.1056/NEJM199104253241701	http://dx.doi.org/10.1056/NEJM199104253241701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011158				2022-12-01	WOS:A1991FH57200001
J	HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV				HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV			HIGH-AFFINITY NGF BINDING REQUIRES COEXPRESSION OF THE TRK PROTOONCOGENE AND THE LOW-AFFINITY NGF RECEPTOR	NATURE			English	Article							NERVE GROWTH-FACTOR; PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NEURO-BLASTOMA; HUMAN-MELANOMA CELLS; NEUROTROPHIC FACTOR; RAT PHEOCHROMOCYTOMA; MOLECULAR-CLONING; GENE-TRANSFER; EXPRESSION; BRAIN	Nerve growth factor (NGF) interacts with two different low-affinity receptors that can be distinguished by affinity crosslinking. Reconstitution experiments by membrane fusion and transient transfection into heterologous cells indicate that high-affinity NGF binding requires coexpression and binding to both the low-affinity NGF receptor and the tyrosine kinase trk gene product. These studies reveal a new growth factor receptor-mediated mechanism of cellular differentiation involving trk and the low-affinity NGF receptor.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC EMBRYOL GRP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HEMPSTEAD, BL (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DEPT CELL BIOL & ANAT, DIV HEMATOL ONCOL, 1300 YORK AVE, NEW YORK, NY 10021 USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Berg M.D., UNPUB; BERND P, 1984, J BIOL CHEM, V259, P5509; BLOCK T, 1983, J NEUROCHEM, V40, P1654, DOI 10.1111/j.1471-4159.1983.tb08139.x; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURTON J, 1990, P NATL ACAD SCI USA, V87, P7329, DOI 10.1073/pnas.87.18.7329; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; GROB PM, 1985, J BIOL CHEM, V260, P8044; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HOSANG M, 1985, J BIOL CHEM, V260, P655; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, IN PRESS SCIENCE; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLENDER EJ, 1980, J BIOL CHEM, V255, P9338; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VALE RD, 1982, J CELL BIOL, V94, P710, DOI 10.1083/jcb.94.3.710; Volonte C, 1990, GROWTH FACTORS, V2, P321; WALDEMAN TA, 1990, ANNU REV BIOCHEM, V58, P875; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAN H, IN PRESS SCIENCE; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	79	1129	1154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1991	350	6320					678	683		10.1038/350678a0	http://dx.doi.org/10.1038/350678a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1850821				2022-12-01	WOS:A1991FJ13000050
J	PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ				PARK, JK; ROSENSTEIN, YJ; REMOLDODONNELL, E; BIERER, BE; ROSEN, FS; BURAKOFF, SJ			ENHANCEMENT OF T-CELL ACTIVATION BY THE CD43 MOLECULE WHOSE EXPRESSION IS DEFECTIVE IN WISKOTT-ALDRICH SYNDROME	NATURE			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODY; SIALOPHORIN CD43; HUMAN-LEUKOCYTES; LEUKOSIALIN; PROLIFERATION; ANTIGEN; CD2; PHOSPHORYLATION; RECEPTOR	CD43 (sialophorin, leukosialin, leukocyte large sialoglycoprotein), a heavily sialylated molecule found on most leukocytes and platelets, was initially identified as a major glycoprotein of mouse, rat and human T cells 1-8. CD43 expression is defective on the T cells of males with the Wiskott-Aldrich syndrome, an X chromosome-linked recessive immunodeficiency disorder 9. Affected males are susceptible to opportunistic infections and do not respond to polysaccharide antigens, reflecting defects in cytotoxic and helper T-cell functions. Anti-CD43 monoclonal antibodies have a modest costimulatory effect on T cells, natural killer cells, B cells and monocytes 10-14, and one such antibody has been shown to activate T cells directly 15. To investigate a possible physiological role for CD43, a complementary DNA encoding the human protein 16,17 was introduced into an antigen-responsive murine T-cell hybridoma 18. We observed that CD43 enhances the antigen-specific activation of T cells and that the intracellular domain of CD43, which is hyperphosphorylated during T-cell activation 19-21, is required for this function. We also found that antigen-presenting cells can bind specifically to immobilized purified CD43 and that the binding can be inhibited by liposomes containing CD43 as well as by anti-CD43 monoclonal antibodies.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SCH MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PARK, JK (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Bierer, Barbara/0000-0001-6448-8170				AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BEYERS AD, 1989, IMMUNOL REV, V111, P59, DOI 10.1111/j.1600-065X.1989.tb00542.x; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CHATILA TA, 1988, J IMMUNOL, V140, P4308; GAHMBERG CG, 1976, J CELL BIOL, V68, P642, DOI 10.1083/jcb.68.3.642; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARKMAN R, 1981, LANCET, V2, P1387; PILLER V, 1989, J BIOL CHEM, V264, P18824; POTTER H, 1987, CURRENT PROTOCOLS MO; REMOLDODONNELL E, 1987, BLOOD, V70, P104; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VARGASCORTES M, 1988, SCAND J IMMUNOL, V27, P661, DOI 10.1111/j.1365-3083.1988.tb02399.x; WIKEN M, 1989, SCAND J IMMUNOL, V29, P363, DOI 10.1111/j.1365-3083.1989.tb01135.x	26	138	141	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					706	709		10.1038/350706a0	http://dx.doi.org/10.1038/350706a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023632				2022-12-01	WOS:A1991FJ13000060
J	RAMACHANDRAN, VS; GREGORY, RL				RAMACHANDRAN, VS; GREGORY, RL			PERCEPTUAL FILLING IN OF ARTIFICIALLY INDUCED SCOTOMAS IN HUMAN VISION	NATURE			English	Article							APPARENT MOTION; VISUAL AREAS; COLOR; CONTOURS; FORM	PATIENTS with scotomas or blind-spots in their visual field 1-5 resulting from damage to the visual pathways often report that the pattern from the rest of the visual field 'fills in' to occupy the scotoma. Here we describe a novel technique for generating an artificial perceptual scotoma which enabled us to study the spatial and temporal characteristics of this filling-in process. A homogeneous grey square subtending 1.5-degrees was displayed against a background of twinkling two-dimensional noise of equal mean luminance (Fig. 1). On steady eccentric fixation for 10 s the square vanished and was filled in by the twinkling noise from the surround. Using this display we found that 'filling in' is an active visual process that probably involves creating an actual neural representation of the surround rather than merely ignoring the absence of information from the scotoma; filling in can occur separately for colour and texture, suggesting separate mechanisms; the filling-in process does not completely suppress information from the scotoma, even after an image has faded completely from consciousness it can nevertheless contribute to motion perception; and the process can be strongly influenced by illusory contours.	UNIV BRISTOL,DEPT PSYCHOL,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	RAMACHANDRAN, VS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL 0109,LA JOLLA,CA 92092, USA.							ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BENDER MB, 1946, ARCH NEURO PSYCHIATR, V55, P627, DOI 10.1001/archneurpsyc.1946.02300170075008; Brewster D., 1832, LETT NATURAL MAGIC; CRANE HD, 1983, SCIENCE, P1078; FINKEL LH, 1989, J NEUROSCI, V9, P3188; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSSBERG S, 1985, PSYCHOL REV, V92, P173, DOI 10.1037/0033-295X.92.2.173; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Kaniza G., 1979, ORG VISION; KRAUSKOPF J, 1961, AM J PSYCHOL, V80, P632; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; POGGIO T, 1985, NATURE, V138, P645; POPPEL E, 1986, NATURE, V320, P523, DOI 10.1038/320523a0; RAMACHANDRAN VS, 1990, PERCEPTION, V19, P273; RAMACHANDRAN VS, 1990, AI AND THE EYE, P21; RAMACHANDRAN VS, 1986, PERCEPT PSYCHOPHYS, V39, P361, DOI 10.3758/BF03203005; RAMACHANDRAN VS, 1985, PERCEPTION, V14, P127, DOI 10.1068/p140127; RAMACHANDRAN VS, 1987, NATURE, V328, P645, DOI 10.1038/328645a0; RAMACHANDRAN VS, IN PRESS ARTFUL BRAI; RAMACHANDRAN VS, 1987, 11TH EUR C VIS PERC; RAMACHANDRAN VS, SOC NEUR ABSTR, V15, P624; Rock I., 1983, LOGIC PERCEPTION; SERGENT J, 1988, BRAIN, V3, P347; Shepard R. N., 1981, PERCEPTUAL ORG, P279; Teuber H.L., 1966, BRAIN CONSCIOUS EXPE, P182; TROXLER D, 1804, OPHTHALMOLOGISCHE 2, V1, P1; VANESSEN DC, 1979, ANNU REV NEUROSCI, V2, P227, DOI 10.1146/annurev.ne.02.030179.001303; VONDERHEYDT RE, 1978, SCIENCE, V224, P1260; WEISZCRANTZ IL, 1961, CURRENTPROBLEMS ANIM, P30; Yarbus A. L., 1967, EYE MOVEMENTS VISION; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	31	330	335	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					699	702		10.1038/350699a0	http://dx.doi.org/10.1038/350699a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FJ130	2023631				2022-12-01	WOS:A1991FJ13000058
J	SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL				SCHUMACHER, TNM; DEBRUIJN, MLH; VERNIE, LN; KAST, WM; MELIEF, CJM; NEEFJES, JJ; PLOEGH, HL			PEPTIDE SELECTION BY MHC CLASS-I MOLECULES	NATURE			English	Article							TOXIC LYMPHOCYTES-T; H-2-DEFICIENT LYMPHOMA VARIANTS; ASSOCIATION; DETERMINANT; RECOGNIZE; PROTEINS; CELLS; HLA	SYNTHETIC peptides have been used to sensitize target cells and thereby screen for epitopes recognized by T cells 1-7. Most epitopes of cytotoxic T lymphocytes can be mimicked by synthetic peptides of 12-15 amino acids 8. Although in specific cases, truncations of peptides improves sensitization of target cells 8,9, no optimum length for binding to major histocompatibility complex (MHC) class I molecules has been defined. We have now analysed synthetic peptide captured by empty MHC class I molecules of the mutant cell line RMA-S. We found that class I molecules preferentially bound short peptides (nine amino acids) and selectively bound these peptides even when they were a minor component in a mixture of longer peptides. These results may help to explain the difference in size restriction of T-cell epitopes between experiments with synthetic peptides and those with naturally processed peptides 10-12.	NETHERLANDS CANC INST,DEPT IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	SCHUMACHER, TNM (corresponding author), NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Schumacher, Ton/Y-2432-2019; Neefjes, Jacques J.C./H-8780-2017	Schumacher, Ton/0000-0003-0517-8804; Neefjes, Jacques J.C./0000-0001-6763-2211; Kast, W Martin/0000-0003-2321-3159				BJORKMAN PJ, 1990, REV BIOCH, V59, P253; ELLIOTT T, 1990, NATURE, V348, P195, DOI 10.1038/348195a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOTCH F, 1988, J EXP MED, V186, P2057; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KAST WM, IN PRESS P NATN ACAD; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARYANSKI JL, 1986, NATURE, V324, P578, DOI 10.1038/324578a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; PHILLIPS DR, 1970, BIOCHEM BIOPH RES CO, V40, P284, DOI 10.1016/0006-291X(70)91007-7; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213	26	276	305	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					703	706		10.1038/350703a0	http://dx.doi.org/10.1038/350703a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1708852				2022-12-01	WOS:A1991FJ13000059
J	SONIES, BC; DALAKAS, MC				SONIES, BC; DALAKAS, MC			DYSPHAGIA IN PATIENTS WITH THE POSTPOLIO SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROMUSCULAR SYMPTOMS; OLD POLIOMYELITIS	Background and Methods. Dysphagia may develop in some patients many years after an attack of acute paralytic poliomyelitis. To identify clinical or subclinical signs of oropharyngeal dysfunction, we examined 32 patients (mean age, 48.9 years) with the post-polio syndrome (defined by new weakness in the limbs). Of the 32 patients, 14 had symptoms of new swallowing difficulties, and 18 were asymptomatic in this respect; 12 had a history of bulbar involvement during acute poliomyelitis. Swallowing function was assessed objectively by ultrasonography, videofluoroscopy, and an oral motor index score for 10 components of oral function. Results. All but 1 of the 32 patients, regardless of whether they had new symptoms or previous bulbar involvement, had some abnormality on detailed testing of oropharyngeal function; only 2 patients had any signs of aspiration. The mean oral motor index score (a quantitative measure of oral sensorimotor function) in the patients was higher than that in age-matched normal subjects (P < 0.001). Videofluoroscopy showed abnormalities of varying severity, including unilateral bolus transport through the pharynx, pooling in the valleculae or pyriform sinuses, delayed pharyngeal constriction, and impaired tongue movements. On ultrasonography, the mean (+/- SD) duration of wet swallows was significantly longer in the symptomatic patients than in the asymptomatic patients (2.67 +/- 0.70 vs. 1.65 +/- 0.42 seconds). The four patients who were reexamined two years later had objective signs of worsening oropharyngeal function and corresponding new symptoms. Conclusions. In patients with the post-polio syndrome, the bulbar muscles often have clinical or subclinical signs of dysfunction. These abnormalities suggest that in bulbar neurons there is a slowly progressive deterioration similar to that in the muscles of the limbs.	NINCDS,NEUROMUSCULAR DIS SECT,RM 4N248,BLDG 10,BETHESDA,MD 20892; WARREN G MAGNUSON CLIN CTR,DEPT REHABIL MED,SPEECH PATHOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								BAKER AB, 1950, ARCH NEURO PSYCHIATR, V63, P257, DOI 10.1001/archneurpsyc.1950.02310200065007; BODIAN D, 1949, POLIOMYELITIS PAPERS, P62; BOSMA JF, 1976, PHYSL ORAL TISSUES, V2, P78; BROWN S, 1987, RES CLIN ASPECTS LAT, V23, P83; BUCHHOLZ D, 1987, RES CLIN ASPECTS LAT, V23, P55; CASHMAN NR, 1987, NEW ENGL J MED, V317, P7, DOI 10.1056/NEJM198707023170102; DALAKAS M, 1990, Current Opinion in Rheumatology, V2, P901; DALAKAS MC, 1984, REV INFECT DIS, V6, pS562; DALAKAS MC, 1986, NEW ENGL J MED, V314, P959, DOI 10.1056/NEJM198604103141505; DALAKAS MC, 1986, EUR NEUROL, V25, P381, DOI 10.1159/000116038; DALAKAS MC, 1988, NEUROLOGY, V38, P99, DOI 10.1212/WNL.38.1.99; DALAKAS MC, 1988, ADV CONT NEUROLOGY, V29, P51; DALAKAS MC, 1984, MIAMI S F, P73; DALAKAS MC, 1990, POSTPOLIO SYNDROME, P31; DALAKAS MC, 1987, RES CLIN ASPECTS LAT, V23, P241; Darley F.L., 1975, MOTOR SPEECH DISORDE; Groher M, 1984, DYSPHAGIA DIAGNOSIS; HALSTEAD LS, 1987, RES CLIN ASPECTS LAT, V23; Logemann JA., 1986, DYSPHAGIA, V1, P34, DOI 10.1007/bf02408238; LOGEMANN JA, 1985, EVALUATION TREATMENT; LOGEMANN JA, 1983, MANUAL VIDEO FLUOROG; MUNSAAT TL, 1987, RES CLIN ASPECTS LAT, V23, P329; MUNSAT TL, 1990, POSTPOLIO SYNDROME; PEZESHKPOUR GH, 1988, ARCH NEUROL-CHICAGO, V45, P505, DOI 10.1001/archneur.1988.00520290033010; RAVITS J, 1990, MUSCLE NERVE, V13, P667, DOI 10.1002/mus.880130802; SHAWKER TH, 1984, ULTRASOUND ANN, P237; Sonies B C, 1988, Dysphagia, V3, P1, DOI 10.1007/BF02406274; SONIES BC, 1988, OTOLARYNG CLIN N AM, V21, P637; SONIES BC, 1987, DYSPHAGIA, V1, P178	29	61	61	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1162	1167		10.1056/NEJM199104253241703	http://dx.doi.org/10.1056/NEJM199104253241703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011159	Bronze			2022-12-01	WOS:A1991FH57200003
J	WARING, DA; KENYON, C				WARING, DA; KENYON, C			REGULATION OF CELLULAR RESPONSIVENESS TO INDUCTIVE SIGNALS IN THE DEVELOPING C-ELEGANS NERVOUS-SYSTEM	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE; LINEAGES; HOMEOBOX	IN Caenorhabditis elegans, cell-cell communication is required to form a simple pattern of sensory ray neurons and cuticular structures (alae). The C. elegans pal-1 gene initiates one developmental pathway (ray lineages) simply by blocking a cell-cell interaction that induces an alternative pathway 1. Here we show by mosaic analysis that pal-1+ acts by preventing specific cells from responding to inductive signals. The results indicate that although cell signals play a critical role in generating this pattern, they do not provide spatial information. Instead, signals are sent to many, if not all, of the precursor cells, and the ability to respond is spatially restricted. This patterning strategy thus differs from many well known models for pattern formation in which localized inductive signals influence a subset of cells within a field. We find that pal-1 encodes a homeodomain protein and so is likely to regulate transcription. The pal-1+ protein could block the response to cell signals either by repressing genes involved in signal transduction or by acting directly on downstream genes in a way that neutralizes the effects of the intercellular signals. Genetic experiments indicate that one candidate for such a downstream gene is the Antennapedia-like homeotic selector gene mab-5.			WARING, DA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q	14	51	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					712	715		10.1038/350712a0	http://dx.doi.org/10.1038/350712a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023634				2022-12-01	WOS:A1991FJ13000062
J	YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI				YOUNG, S; LESOUEF, PN; GEELHOED, GC; STICK, SM; CHIR, B; TURNER, KJ; LANDAU, LI			THE INFLUENCE OF A FAMILY HISTORY OF ASTHMA AND PARENTAL SMOKING ON AIRWAY RESPONSIVENESS IN EARLY INFANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL RESPONSIVENESS; INHALED HISTAMINE; CHILDHOOD ASTHMA; NEWBORN-INFANTS; ATOPIC DISEASE; REACTIVITY; IGE; CHILDREN; ALLERGY	Background. Airway responsiveness to inhaled nonspecific bronchoconstrictive agents has been demonstrated in normal, healthy infants. However, it is unknown whether airway responsiveness is present from birth or if it develops as a result of subsequent insults to the respiratory tract. To investigate this question, we assessed airway responsiveness in 63 normal infants at a mean age of 4 1/2 weeks. Methods. Respiratory function was measured with use of the partial forced expiratory flow-volume technique to determine the maximal flow at functional residual capacity (V(maxFRC)). The infants inhaled nebulized histamine at sequentially doubled concentrations (0.125 to 8.0 g per liter), until a concentration was reached at which the V(maxFRC) fell by 40 percent from the base-line value (PC40) or until a concentration of 8.0 g per liter was reached. We also assessed maternal serum levels of IgE, cord-serum levels of IgE, the infants' skin reactivity to several allergens, and the parents' responsiveness to histamine and obtained family histories of asthma and smoking. Results. Airway responsiveness was increased in infants with a family history of asthma (n = 19; median PC40, 0.78 g per liter; 95 percent confidence interval, 0.44 to 1.15; P < 0.01), parental smoking (n = 13; median PC40, 0.52 g per liter; 95 percent confidence interval, 0.43 to 5.40; P < 0.05), or both (n = 20; median PC40, 0.69 g per liter; 95 percent confidence interval, 0.37 to 2.10; P < 0.05), as compared with the infants with no family history of asthma or smoking. The infants with no family history of asthma or smoking had a median PC40 of 2.75 g per liter (95 percent confidence interval, 1.48 to 4.00). No significant relations were detected between the immunologic variables and the PC40 in the infants. Conclusions. This study indicates that airway responsiveness can be present early in life and suggests that a family history of asthma or parental smoking contributes to elevated levels of airway responsiveness at an early age.	PRINCESS MARGARET HOSP,CLIN IMMUNOL RES UNIT,PERTH,WA 6001,AUSTRALIA		YOUNG, S (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,POB D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014; Stick, Stephen/AAA-5945-2021; Stick, Stephen/O-5683-2014; Stick, Stephen/GZG-7584-2022	Stick, Stephen/0000-0002-5386-8482; Le Souef, Peter/0000-0003-0930-1654				BENSON MK, 1977, J APPL PHYSIOL, V43, P643, DOI 10.1152/jappl.1977.43.4.643; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; CADE JF, 1971, LANCET, V2, P186; CAMPBELL MJ, 1989, STATISTICS CONFIDENC, P71; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; DEKOCK MA, 1966, J APPL PHYSIOL, V21, P185, DOI 10.1152/jappl.1966.21.1.185; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; GARDNER MJ, 1989, CONFIDENCE INTERVAL; GELLER DE, 1988, PEDIATR PULM, V4, P90, DOI 10.1002/ppul.1950040206; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; GERRARD JW, 1974, J PEDIATR, V5, P660; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; ORGEL HA, 1977, ANN ALLERGY, V39, P161; PRENDIVILLE A, 1987, THORAX, V42, P92, DOI 10.1136/thx.42.2.92; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; Schwartz M, 1952, ACTA ALLERGOL S2, V5, P1; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SILVERMAN M, 1985, NEONATAL PEDIATRIC R, P161; STICK S M, 1990, American Review of Respiratory Disease, V141, pA283; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220, DOI 10.1152/jappl.1982.53.5.1220; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TEPPER RS, 1987, J APPL PHYSIOL, V62, P1155, DOI 10.1152/jappl.1987.62.3.1155; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; TURNER KJ, 1981, CLIN EXP IMMUNOL, V43, P458; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZAR JH, 1974, BIOSTAT ANAL, P109; [No title captured]	34	349	354	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	1991	324	17					1168	1173		10.1056/NEJM199104253241704	http://dx.doi.org/10.1056/NEJM199104253241704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH572	2011160				2022-12-01	WOS:A1991FH57200004
J	ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM				ZAHLER, AM; WILLIAMSON, JR; CECH, TR; PRESCOTT, DM			INHIBITION OF TELOMERASE BY G-QUARTET DNA STRUCTURES	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA; RIBONUCLEOPROTEIN; OXYTRICHA; REPEATS; ENZYME; MODEL	THE ends or telomeres of the linear chromosomes of eukaryotes are composed of tandem repeats of short DNA sequences, one strand being rich in guanine (G strand) and the complementary strand in cytosine 1,2. Telomere synthesis involves the addition of telomeric repeats to the G strand by telomere terminal transferase (telomerase) 3-6. Telomeric G-strand DNAs from a variety of organisms adopt compact structures 7, the most stable of which is explained by the formation of G-quartets 8,9. Here we investigate the capacity of the different folded forms of telomeric DNA to serve as primers for the Oxytricha nova telomerase in vitro. Formation of the K+-stabilized G-quartet structure in a primer inhibits its use by telomerase. Furthermore, the octanucleotide T4G4, which does not fold, is a better primer than (T4G4)2, which can form a foldback structure 7-10. We conclude that telomerase does not require any folding of its DNA primer. Folding of telomeric DNA into G-quartet structures seems to influence the extent of telomere elongation in vitro and might therefore act as a negative regulator of elongation in vivo.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder			Williamson, James R/B-2891-2009; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X; Zahler, Alan/0000-0003-0027-1647				BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; Klobutcher L.A., 1986, P111; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1990, THESIS U COLORADO; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	21	998	1044	5	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	1991	350	6320					718	720		10.1038/350718a0	http://dx.doi.org/10.1038/350718a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	2023635				2022-12-01	WOS:A1991FJ13000064
J	BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV				BALDWIN, DC; HUGHES, PH; CONARD, SE; STORR, CL; SHEEHAN, DV			SUBSTANCE USE AMONG SENIOR MEDICAL-STUDENTS - A SURVEY OF 23 MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; RELIABILITY	Senior students at 23 regionally distributed medical schools received an anonymous questionnaire designed to examine current and prior use of tobacco, alcohol, and nine other drugs. The overall response rate was 67% (N = 2046). Substance use prevalence rates during the 30 days preceding the survey included alcohol, 87.5%; marijuana, 10.0%; cigarettes, 10.0%; cocaine, 2.8%; tranquilizers, 2.3%; opiates other than heroin, 1.1%; psychedelics other than LSD (lysergic acid diethylamide), 0.6%; amphetamines, 0.3%; barbiturates, 0.2%; LSD, 0.1%; and heroin, 0.0%. Compared with national, age-related comparison groups, senior medical students reported less use of all substances during the past 30 days and the past 12 months, except for alcohol, tranquilizers, and psychedelics other than LSD. Substantial new drug use after entry into medical school was reported only for tranquilizers. Seven students (0.2%) admitted to current dependence on a substance other than tobacco, four of these implicating marijuana. Thirty-three students (1.6%) believed that they currently needed help for substance abuse. Only 25.7% were aware of any policy on substance abuse at their own school.	UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, TAMPA, FL 33620 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA	State University System of Florida; University of South Florida; University of Texas System; University of Texas Dallas	BALDWIN, DC (corresponding author), AMER MED ASSOC, DIV MED EDUC RES & INFORMAT, 515 N STATE ST, CHICAGO, IL 60610 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050				BACHMAN JG, 1990, J HEALTH SOC BEHAV, V31, P173, DOI 10.2307/2137171; BORKMAN T, 1986, ALCOHOL HEALTH RES W, V10, P54; CLARK DC, 1987, JAMA-J AM MED ASSOC, V257, P2921, DOI 10.1001/jama.257.21.2921; COLLINS J, 1989, NATIONAL ADOLESCENT; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1986, JAMA-J AM MED ASSOC, V256, P1545, DOI 10.1001/jama.1986.03380120015003; CROWLEY AE, 1987, JAMA-J AM MED ASSOC, V258, P1013, DOI 10.1001/jama.258.8.1013; JOHNSTON LD, 1985, STUDYING DRUG USE, P117; JOHNSTON LD, 1989, ADM891638US DEP HLTH; KING FW, 1970, AM PSYCHOL, V25, P982, DOI 10.1037/h0029859; LUETGERT MJ, 1973, INT J ADDICT, V8, P683, DOI 10.3109/10826087309057494; MADDUX JF, 1986, AM J PSYCHIAT, V143, P187; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; OMALLEY PM, 1983, INT J ADDICT, V18, P805, DOI 10.3109/10826088309033049; ROWLEY BD, 1988, J MED EDUC, V63, P759; SCHWARTZ RH, 1990, ARCH INTERN MED, V150, P883, DOI 10.1001/archinte.150.4.883; SINGLE E, 1975, J DRUG ISSUES, V5, P426, DOI 10.1177/002204267500500411	18	103	106	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2074	2078		10.1001/jama.265.16.2074	http://dx.doi.org/10.1001/jama.265.16.2074			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013926				2022-12-01	WOS:A1991FG90700023
J	HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV				HUGHES, PH; CONARD, SE; BALDWIN, DC; STORR, CL; SHEEHAN, DV			RESIDENT PHYSICIAN SUBSTANCE USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STUDENTS	A national survey was conducted to determine patterns of drug use among 3000 American resident physicians. Sixty percent (1785) of the residents surveyed responded. This report evaluates the prevalence of drug use among the respondents, when they initiated drug use, and their reasons for current use. Substance use rates are compared with other studies of resident physicians and with a sample of their nonphysician age peers surveyed the same year. Heavy substance use patterns were not observed among resident physicians. They had significantly lower rates of use for most psychoactive substances than their peers in the general population but did report higher rates of past-month use of alcohol and benzodiazepines. A sizable minority began using benzodiazepines and prescription opiates during their residency years - the stage in physicians' training when they first receive prescribing privileges. Current users of benzodiazepines and opiates used these drugs primarily for self-treatment rather than recreation. These two substances are often associated with impairment at later stages in the physician's career.	JAMES A HALEY VET ADM MED CTR, TAMPA, FL 33612 USA; UNIV TEXAS, HLTH SCI CTR, DEPT FAMILY & COMMUNITY MED, DALLAS, TX 75235 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; University of Texas System; University of Texas Dallas; American Medical Association	HUGHES, PH (corresponding author), UNIV S FLORIDA, DEPT PSYCHIAT & BEHAV MED, CTR STUDY IMPAIRED PROFESS, 3515 E FLETCHER AVE, TAMPA, FL 33613 USA.		Sheehan, David V/L-6879-2013	Sheehan, David V/0000-0002-5118-7050	NIDA NIH HHS [1 R01 DA04877] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CLARK AW, 1988, J MED EDUC, V63, P44; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; CONARD S, 1989, AM J PSYCHIAT, V146, P382; CROWLEY AE, 1988, JAMA-J AM MED ASSOC, V260, P1049, DOI 10.1001/jama.1988.03410080019002; JOHNSTON L, 1989, ADM891638 DEP HLTH H; KORAN LM, 1988, WESTERN J MED, V148, P97; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1984, J HEALTH SOC BEHAV, V25, P34, DOI 10.2307/2136703; REUBEN DB, 1990, JAMA-J AM MED ASSOC, V263, P958, DOI 10.1001/jama.263.7.958; SETHI BB, 1980, ACTA PSYCHIAT SCAND, V62, P447, DOI 10.1111/j.1600-0447.1980.tb00633.x; SINGH G, 1981, INDIAN J MED RES, V73, P594; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; 1985, RES MONOGRAPH, V57	13	89	90	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2069	2073		10.1001/jama.265.16.2069	http://dx.doi.org/10.1001/jama.265.16.2069			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013925				2022-12-01	WOS:A1991FG90700022
J	KROBER, MS; STRACENER, CE; BASS, JW				KROBER, MS; STRACENER, CE; BASS, JW			DECREASED MEASLES ANTIBODY-RESPONSE AFTER MEASLES-MUMPS-RUBELLA VACCINE IN INFANTS WITH COLDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTERFERON-PRODUCTION	We examined the possibility that the common cold or afebrile upper respiratory tract infection might interfere with successful immunization in children who receive standard measles-mumps-rubella vaccine. Infants 15 to 18 months of age presenting at our well-child clinics for routine examination and immunizations were divided into two groups. Those infants with a history and physical findings of upper respiratory tract infection were compared with healthy control group infants who did not have upper respiratory tract infections, and who did not have a history of upper respiratory tract infection symptoms within the previous month. Both groups were studied for their serologic response to measles-mumps-rubella vaccination. Prevaccination serum samples were obtained prior to vaccine administration and postvaccination serum samples were obtained 6 to 8 weeks later. Measles antibody was measured in these serum samples by an indirect fluorescein-tagged antibody test. Ten (21%) of 47 infants with colds failed to develop measles antibody, while only one (2%) of 51 well infants failed to develop antibody. We conclude that infants with colds have a significant seroconversion failure rate associated with measles vaccine administration and that this may be the cause of some primary measles vaccine failures.	TRIPLER ARMY MED CTR,DEPT PEDIAT,HONOLULU,HI 96859	United States Department of Defense; United States Army	KROBER, MS (corresponding author), MADIGAN ARMY MED CTR,DEPT PEDIAT,BOX 295,TACOMA,WA 98431, USA.							BRUNELL PA, 1990, PEDIATRICS, V83, P474; CHESHIK SG, 1988, PEDIATRIIA, V9, P10; DESMYTER J, 1968, PROG MED VIROL, V10, P268; GRIFFIN DE, 1990, J INFECT DIS, V161, P449, DOI 10.1093/infdis/161.3.449; Grimes D E, 1989, J Pediatr Health Care, V3, P187, DOI 10.1016/0891-5245(89)90082-5; HALL CB, 1981, ANN INTERN MED, V94, P53, DOI 10.7326/0003-4819-94-1-53; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; IZBICKY A, 1977, J HYG EPID MICROB IM, V21, P191; MARKOWITZ L, 1990, PEDIATR INFECT DIS J, V9, P530; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MIRCHAMSY H, 1969, J GEN VIROL, V4, P413; NAKAYAMA T, 1988, J INFECT DIS, V158, P1386, DOI 10.1093/infdis/158.6.1386; NDKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; RAY CG, 1967, J PEDIATR, V72, P27; TOLCHIN D, 1973, J PEDIATR-US, V83, P890, DOI 10.1016/S0022-3476(73)80401-9; WHEELOCK EF, 1964, LANCET, V2, P382	18	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2095	2096		10.1001/jama.265.16.2095	http://dx.doi.org/10.1001/jama.265.16.2095			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013930				2022-12-01	WOS:A1991FG90700027
J	MASON, JO				MASON, JO			UNITED-STATES-PUBLIC-HEALTH-SERVICES STRATEGIC PLAN TO ELIMINATE CHILDHOOD LEAD-POISONING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service	MASON, JO (corresponding author), US DEPT HHS,WASHINGTON,DC 20201, USA.							1988, NATURE EXTENT CHILDH; 1990, NEW ENGL J MED, V322, P83	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2049	2049						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG907	2013918				2022-12-01	WOS:A1991FG90700004
J	SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR				SELBY, JV; NEWMAN, B; QUIROGA, J; CHRISTIAN, JC; AUSTIN, MA; FABSITZ, RR			CONCORDANCE FOR DYSLIPIDEMIC HYPERTENSION IN MALE TWINS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; INSULIN; PREVALENCE	Sixty cases of dyslipidemic hypertension were identified in the 1028 middle-aged, white, male twin participants in the first examination of the National Heart, Lung, and Blood Institute Twin Study (1969 to 1973). The prevalence of dyslipidemic hypertension was similar by zygosity but proband concordance was three times greater in monozygotic than dizygotic twins (0.44 [seven concordant and 18 discordant pairs] vs 0.14 [two concordant and 24 discordant pairs]), suggesting a genetic effect on the condition. Low high-density lipoprotein cholesterol level was the most common lipid abnormality in concordant pairs. Mortality from ischemic heart disease was significantly higher in individuals with dyslipidemic hypertension. Obesity and glucose intolerance were closely associated with the syndrome. Moreover, within the 18 discordant monozygotic twin pairs, the twins with dyslipidemic hypertension had gained significantly more weight as adults and were significantly heavier than their unaffected cotwins. Thus, although genetic factors may influence development of dyslipidemic hypertension, nongenetic, potentially modifiable aspects of obesity are also closely related to expression of this clinically important syndrome.	VET AFFAIRS MED CTR,DEPT MED,LONG BEACH,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,DEPT EPIDEMIOL,BERKELEY,CA 94720; INDIANA UNIV,SCH MED,DEPT MED GENET,INDIANAPOLIS,IN 46202; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; NHLBI,CLIN GENET & EPIDEMIOL BRANCH,BETHESDA,MD 20892	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Berkeley; Indiana University System; Indiana University-Purdue University Indianapolis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SELBY, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM,DIV RES,NO CALIF REG,3451 PIEDMONT AVE,OAKLAND,CA 94611, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055026] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC55026] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; COX NJ, 1989, DIABETES, V38, P653, DOI 10.2337/diabetes.38.5.653; CRIQUI MH, 1986, CIRCULATION, V73, P40; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; FABSITZ RR, 1978, BEHAV GENET, V8, P15, DOI 10.1007/BF01067701; FEINLEIB M, 1970, ACTA GENET MED GEMEL, V19, P243, DOI 10.1017/S1120962300025592; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; FUH MMT, 1987, ARCH INTERN MED, V147, P1035, DOI 10.1001/archinte.147.6.1035; HUNT SC, 1989, ARTERIOSCLEROSIS, V9, P335, DOI 10.1161/01.ATV.9.3.335; JABLON S, 1967, AM J HUM GENET, V19, P133; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; LEE ET, 1980, STATISTICAL METHODS; MACMAHON SW, 1985, ARTERIOSCLEROSIS, V5, P391, DOI 10.1161/01.ATV.5.4.391; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NEUFELD HN, 1983, CIRCULATION, V67, P943, DOI 10.1161/01.CIR.67.5.943; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; NEWMAN B, 1990, AM J PUBLIC HEALTH, V80, P675, DOI 10.2105/AJPH.80.6.675; PERMUTT MA, 1990, DIABETES CARE, V13, P364, DOI 10.2337/diacare.13.3.364; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REED T, IN PRESS J CLIN EPID; ROHLFING JJ, 1986, WESTERN J MED, V145, P210; SHIEH SM, 1987, ATHEROSCLEROSIS, V67, P49, DOI 10.1016/0021-9150(87)90264-4; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	25	87	88	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1991	265	16					2079	2084		10.1001/jama.265.16.2079	http://dx.doi.org/10.1001/jama.265.16.2079			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG907	2013927				2022-12-01	WOS:A1991FG90700024
J	ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK				ALLAN, LD; COOK, A; SULLIVAN, I; SHARLAND, GK			HYPOPLASTIC LEFT HEART SYNDROME - EFFECTS OF FETAL ECHOCARDIOGRAPHY ON BIRTH PREVALENCE	LANCET			English	Article							DISEASE	Hypoplastic left heart syndrome was diagnosed prenatally and confirmed in 105 fetuses since 1983 at a regional referral centre. An increased detection rate since 1988 is probably related to increased experience in the use of a four-chamber view of the fetal heart during routine obstetric ultrasound scanning. When the diagnosis was made sufficiently early, most parents chose to terminate the pregnancy after the prognosis and surgical options were explained. By contrast, after an increase in the mid 1980s, since 1988 there has been a striking fall in the number of newborn babies with hypoplastic left heart syndrome treated at a supraregional referral centre. More widespread use of four-chamber cardiac screening during routine fetal ultrasonography may reduce the number of newborn babies with hypoplastic left heart syndrome-a factor which should be taken into account when the likely requirements for neonatal cardiac transplantation facilities are calculated.	GUYS HOSP,DEPT PATHOL,LONDON SE1 9RT,ENGLAND; HOSP SICK CHILDREN,DEPT PAEDIAT CARDIOL,LONDON WC1N 3JH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ALLAN, LD (corresponding author), GUYS HOSP,DEPT PERINATAL CARDIOL,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.			Cook, Andrew/0000-0001-5079-7546				ALLAN LD, 1989, INT J CARDIOL, V25, P341, DOI 10.1016/0167-5273(89)90226-X; ALLAN LD, 1984, BRIT HEART J, V52, P542; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CULLEN S, 1990, BRIT HEART J, V64, P90; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; JONAS R, 1990, AUG CARD SOC AUSTR N; MELIONES JN, 1990, CIRCULATION, V82, P151; MURDISON KA, 1990, CIRCULATION, V82, P199; PAHL E, 1990, J PEDIATR, V116, P117	11	62	63	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					959	961		10.1016/0140-6736(91)91582-F	http://dx.doi.org/10.1016/0140-6736(91)91582-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678041				2022-12-01	WOS:A1991FH13100015
J	CHAPMAN, S; WOODWARD, S				CHAPMAN, S; WOODWARD, S			AUSTRALIAN COURT RULES THAT PASSIVE SMOKING CAUSES LUNG-CANCER, ASTHMA ATTACKS, AND RESPIRATORY-DISEASE	BRITISH MEDICAL JOURNAL			English	Editorial Material									ACT SMOKING & HLTH,SURREY HILLS 2010,AUSTRALIA		CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD 2145,AUSTRALIA.							BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; CHAPMAN S, 1980, BRIT MED J, V281, P1187, DOI 10.1136/bmj.281.6249.1187; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; Chapman S, 1984, MEDIA INFORMATION AU, V31, P47; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; WINSTANLEY M, 1989, TOBACCO AUSTR FACTS; WOODWARD SD, 1990, MED J AUSTRALIA, V153, P682, DOI 10.5694/j.1326-5377.1990.tb126321.x; 1987, EFFECTS PASSIVE SMOK; 1978, STUDY PUBLIC ATTITUD, V1	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					943	945		10.1136/bmj.302.6782.943	http://dx.doi.org/10.1136/bmj.302.6782.943			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032037	Green Published, Bronze			2022-12-01	WOS:A1991FH48700022
J	FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K				FRANKLIN, RCG; SPIEGELHALTER, DJ; MACARTNEY, FJ; BULL, K			EVALUATION OF A DIAGNOSTIC ALGORITHM FOR HEART-DISEASE IN NEONATES	BRITISH MEDICAL JOURNAL			English	Article							EXPERT SYSTEMS; CHEST PAIN; EMERGENCY; PROTOCOL; INFANTS	Objective-To develop, test, and validate an algorithm for diagnosing disease in neonates during an over the telephone referral to a specialist cardiac centre. Design-A draft algorithm requiring only data available to a referring paediatrician was generated. This was modified in the light of a retrospective review of case records. A questionnaire to elicit all the data required by the algorithm was then generated. There followed a prospective three phase evaluation during consecutive over the telephone referrals. This consisted of (a) a conventional phase with unstructured referral consultations, (b) a phase with referrals structured around the questionnaire but independent of the algorithm, and (c) a validation phase with the algorithm (and its previous errors) available during the referral consultation. Setting-59 paediatric centres in south east England and a central specialist paediatric cardiology unit. Patients-Consecutive neonates (aged < 31 days) referred with suspected heart disease. The retrospective review was of records of 174 neonates from 1979. In the prospective evaluation (1987-90) the conventional phase comprised 71 neonates (over 5.5 months), the structured phase 203 neonates (over 14 months), and the validation phase 195 neonates (over 12 months). Main outcome measures-Diagnostic accuracy (assigning patients to the correct diagnostic category (out of 27)), of the referring paediatrician, the specialist after the referral consultation, and the algorithm as compared with the definitive diagnosis by echocardiography at the specialist centre, and score for the appropriateness of management in transit. Results-Simply structuring the consultation by questionnaire (that is, proceeding from the conventional phase to the structured phase) improved the diagnostic accuracy of both paediatricians (from 34% (24/71 cases) to 48% (97/203) correct) and specialists (from 54% (38/71 cases) to 64% (130/203) correct). The algorithm (structured phase) would have been even more accurate (78% (158/203 cases); p < 0.01). Management scores in the structured phase were also better than in the conventional phase (80% (162/203 cases) upsilon-58% (41/71) appropriate; p < 0.01). Management scores would have improved to 91% appropriate (185/203; p < 0.001) had the algorithmic diagnoses dictated management. The superiority of the algorithm was maintained but not bettered in the validation phase. Conclusions-Applying the algorithm should reduce the morbidity and mortality of neonates with critical heart disease by aiding clinicians in therapeutic decisions for in transit care.	HOSP SICK CHILDREN,PAEDIAT CARDIOL,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit								ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BOVE EL, 1983, ARCH DIS CHILD, V58, P137, DOI 10.1136/adc.58.2.137; Breimann L, 1984, CLASSIFICATION REGRE; COOK DH, 1978, CAN J PUBLIC HEALTH, V69, P297; DANFORD DA, 1986, J AM COLL CARDIOL, V8, P1125, DOI 10.1016/S0735-1097(86)80391-6; FRANKLIN RCG, 1989, INT J CLIN MONIT COM, V6, P157, DOI 10.1007/BF01721028; FRANKLIN RCG, IN PRESS J THORAC CA; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; LAURITZEN SL, 1988, J ROY STAT SOC B MET, V50, P157; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; REALE A, 1908, COMPUT BIOMED RES, V1, P533; ROETHLINGSBURGE.FJ, 1939, MANAGEMENT WORKER; RUBAY J, 1988, CIRCULATION, V78, P1; SCHWARTZ WB, 1987, NEW ENGL J MED, V316, P685, DOI 10.1056/NEJM198703123161109; TEACH RL, 1981, COMPUT BIOMED RES, V14, P542, DOI 10.1016/0010-4809(81)90012-4; WARBURTON D, 1981, ARCH DIS CHILD, V56, P94, DOI 10.1136/adc.56.2.94; WARNER HR, 1961, JAMA-J AM MED ASSOC, V177, P177, DOI 10.1001/jama.1961.03040290005002; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	19	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					935	939		10.1136/bmj.302.6782.935	http://dx.doi.org/10.1136/bmj.302.6782.935			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032035	Green Published, Bronze			2022-12-01	WOS:A1991FH48700017
J	HANSPAL, RS; FISHER, K				HANSPAL, RS; FISHER, K			ASSESSMENT OF COGNITIVE AND PSYCHOMOTOR FUNCTION AND REHABILITATION OF ELDERLY PEOPLE WITH PROSTHESES	BRITISH MEDICAL JOURNAL			English	Article									HAROLD WOOD HOSP,NE THAMES REG DISABLEMENT SERV CTR,ROMFORD,ESSEX,ENGLAND		HANSPAL, RS (corresponding author), ROYAL NATL ORTHOPAED HOSP,DISABLEMENT SERV CTR,REHABIL UNIT,STANMORE,MIDDX,ENGLAND.							GUTTMAN L, 1952, MEASUREMENT PREDICTI; NIE N, 1976, STATISTICAL PACKAGE; Pattie A., 1979, MANUAL CLIFTON ASSES; VITALI M, 1986, AMPUTATIONS PROSTHES	4	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					940	940		10.1136/bmj.302.6782.940	http://dx.doi.org/10.1136/bmj.302.6782.940			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FH487	2032036	Green Published, Bronze			2022-12-01	WOS:A1991FH48700020
J	KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG				KEATING, JN; TRIMBLE, KC; MULCAHY, F; SCOTT, JM; WEIR, DG			EVIDENCE OF BRAIN METHYLTRANSFERASE INHIBITION AND EARLY BRAIN INVOLVEMENT IN HIV-POSITIVE PATIENTS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; COMBINED DEGENERATION; S-ADENOSYLMETHIONINE; L-HOMOCYSTEINE; L-METHIONINE; DEFICIENCY; ADENOSINE; AIDS	The myelopathy associated with human immunodeficiency virus (HIV) infection closely resembles that in subacute combined degeneration, a disorder of vitamin B-12 metabolism. To investigate whether the disorders share a pathogenetic mechanism, S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were measured in the cerebrospinal fluid (CSF) of 20 HIV-seropositive patients and 30 HIV-negative patients who were undergoing lumbar puncture for other medical reasons. The HIV-seropositive patients had significantly lower CSF concentrations of SAM (mean 77 [SD 25] vs 131 [35] nmol/l; p < 0.001) and significantly higher concentrations of SAH (30.5 [6.8] vs 19.0 [7.1] nmol/l; p < 0.001) than the controls. There was therefore a significant difference between the groups in the SAM/SAH (methylation) ratio (HIV 2.7 [1.0] vs control 7.6 [3.4]; p < 0.001). There were no correlations between SAM or SAH concentrations or methylation ratio and age or sex in both groups, or serum B-12 and folate concentrations, CSF folate, serum or CSF methylmalonic acid, risk factors, body mass index, specific drug treatment received, or disease stage in the HIV group. This finding suggests that HIV affects the brain from a very early stage of the infection. We suggest that, as in the pig, the CSF methylation ratio closely reflects that in the brain. In HIV-infected patients a reduced brain methylation ratio would inhibit methyltransferase enzymes, which would lead to hypomethylation in the central nervous system and ultimately to neurological lesions. In a pig model of subacute combined degeneration and in vitamin-B-12-deficient human beings, the primary cause of the low methylation ratio is impaired recycling of SAH back to SAM, a process which requires vitamin-B-12-dependent methionine synthase. The HIV patients in this study were vitamin B-12 and folate replete, which suggests a different cause for the low methylation ratio.	ST JAMES HOSP, MED SCH BLDG, DUBLIN 8, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT CLIN MED, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin								BARNES DM, 1987, SCIENCE, V235, P1574, DOI 10.1126/science.3103218; BEACH RS, 1988, JAMA-J AM MED ASSOC, V259, P519, DOI 10.1001/jama.1988.03720040017014; BOUDES P, 1990, LANCET, V335, P1401, DOI 10.1016/0140-6736(90)91279-J; DEFERRA F, 1984, CANCER RES, V44, P2297; DELAHABA G, 1959, J BIOL CHEM, V234, P603; EPSTEIN L G, 1984, AIDS Research, V1, P447; GHARIB A, 1982, J NEUROCHEM, V38, P810, DOI 10.1111/j.1471-4159.1982.tb08702.x; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HERBERT V, 1990, AM J HEMATOL, V34, P132, DOI 10.1002/ajh.2830340210; Herbert V, 1961, FED PROC, V20, P453; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HYLAND K, 1988, NEUROLOGY, V38, P459, DOI 10.1212/WNL.38.3.459; KELLEHER BP, 1990, MED LAB SCI, V47, P90; KUTZBACH C, 1967, BIOCHIM BIOPHYS ACTA, V139, P217, DOI 10.1016/0005-2744(67)90140-4; LAYZER RB, 1978, NEUROLOGY, V28, P504, DOI 10.1212/WNL.28.5.504; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; MOLLOY A M, 1986, P505; MOLLOY AM, 1990, BIOMED CHROMATOGR, V4, P257, DOI 10.1002/bmc.1130040611; MOLLOY AM, 1989, CHEM BIOL PTERIDINES, P881; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; SCOTT JM, 1974, AM J MED TECHNOL, V40, P125; SCOTT JM, 1981, LANCET, V2, P334; SURTEES R, 1990, LANCET, V335, P619, DOI 10.1016/0140-6736(90)90409-X; SURTEES R, 1990, J NEUROL NEUROSUR PS, V53, P569, DOI 10.1136/jnnp.53.7.569; WAGNER J, 1986, ANAL BIOCHEM, V154, P604, DOI 10.1016/0003-2697(86)90036-9; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x; WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987	31	65	65	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1991	337	8747					935	939		10.1016/0140-6736(91)91570-K	http://dx.doi.org/10.1016/0140-6736(91)91570-K			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678030				2022-12-01	WOS:A1991FH13100003
J	KEMP, AM; SIBERT, JR				KEMP, AM; SIBERT, JR			OUTCOME IN CHILDREN WHO NEARLY DROWN - A BRITISH-ISLES STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the outcome in nearly drowned children in the British Isles and identify factors that might predict a poor prognosis. Design-Study of drowned and of nearly drowned children aged less-than-or-equal-to 14. Information on nearly drowned children admitted to hospital obtained from consultant paediatricians returning monthly notification cards through the British Paediatric Surveillance Unit. Information on drowned children obtained from Office of Population Censuses and Surveys and other national epidemiological offices. Setting-British Isles, 1988 and 1989. Subjects-330 children who had confirmed submersion incidents. 142 died before admission to hospital and 188 children were admitted after nearly drowning. Main outcome measures-Death, full recovery, or degree of handicap after near drowning and signs on admission to hospital. Results-All of the children who were conscious on admission fully recovered. Of the 64 children unconscious on admission, 31 had normally reactive pupils and all but three (all of whom had severe pre-existing neurological disease) recovered fully. Of the 33 children with fixed dilated pupils on admission, 10 fully recovered, 13 died, and 10 had severe neurological deficit. Spontaneous respiratory effect on admission was associated with normal survival. Pupils that remained dilated six hours after admission and fits continuing 24 hours after admission predicted a poor outcome. Conclusion-Children can survive normally after near drowning in the British Isles, particularly if they have been hypothermic. Resuscitation should not be abandoned in nearly drowned children until they have been rewarmed.	UNIV COLL CARDIFF,LLANDOUGH HOSP,COLL MED,DEPT CHILD HLTH,CARDIFF CF6 1XX,S GLAM,WALES	Cardiff University								CONN AW, 1984, CAN ANAESTH SOC J, V31, pS38, DOI 10.1007/BF03007034; FRATES RC, 1981, AM J DIS CHILD, V135, P1006, DOI 10.1001/archpedi.1981.02130350010004; FREWEN TC, 1985, J PEDIATR-US, V106, P615, DOI 10.1016/S0022-3476(85)80085-8; GOLDEN F, 1980, BR J HOSP MED, V23, P373; HARRIES M, 1986, BMJ, V293, P123; MODELL JH, 1976, CHEST, V70, P231, DOI 10.1378/chest.70.2.231; MODELL JH, 1981, CRIT CARE MED, V9, P351; OCARROLL PW, 1988, JAMA-J AM MED ASSOC, V260, P380, DOI 10.1001/jama.260.3.380; ORLOWSKI JP, 1988, JAMA-J AM MED ASSOC, V26, P390; PEARN J, 1977, LANCET, V1, P7; PEARN J, 1985, BRIT MED J, V291, P1447, DOI 10.1136/bmj.291.6507.1447; PEARN JH, 1979, MED J AUSTRALIA, V1, P463, DOI 10.5694/j.1326-5377.1979.tb127044.x; PEARN JH, 1979, PEDIATRICS, V64, P187; PETERSON B, 1977, PEDIATRICS, V59, P364; RAMEY CA, 1987, J APPL PHYSIOL, V63, P665, DOI 10.1152/jappl.1987.63.2.665; 1989, DEATHS CAUSE 1988 RE	16	44	44	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					931	933		10.1136/bmj.302.6782.931	http://dx.doi.org/10.1136/bmj.302.6782.931			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032033	Green Published, Bronze			2022-12-01	WOS:A1991FH48700015
J	KENNEDY, A; SCHON, F				KENNEDY, A; SCHON, F			EPILEPSY - DISAPPEARING LESIONS APPEARING IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							CT LESIONS; COMPUTED-TOMOGRAPHY; CYSTICERCOSIS; SEIZURES; INDIA; SCAN	Objective-Investigation of spontaneously resolving lesions associated with epilepsy. Design-Observational study during one year. Setting-One neurology department. Patients-4 cases in patients (one of Indian parents, one African, one white English, and one Afro-Caribbean) resident in the United Kingdom, who presented with transient epilepsy. Main outcome measures-Findings on computed tomography and on screening for infections. Results-In all four cases a small mass lesion in one cerebral hemisphere was observed on computed tomography, which resolved after 9, 4, 3 and 1.5 months respectively without surgery. Conclusions-The number of cases seen in one year suggests that the lesions may be more common in the United Kingdom than previously recognised and that research into their cause is warranted.	ATKINSON MORLEYS HOSP,DEPT NEUROL,LONDON SW20 0NE,ENGLAND									AHUJA GK, 1989, J NEUROL NEUROSUR PS, V52, P915, DOI 10.1136/jnnp.52.7.915; BANSAL BC, 1989, J NEUROL NEUROSUR PS, V52, P1185, DOI 10.1136/jnnp.52.10.1185; CHANDY MJ, 1989, LANCET, V1, P390, DOI 10.1016/S0140-6736(89)91771-6; DEBEYL DZ, 1985, J NEUROL NEUROSUR PS, V48, P187, DOI 10.1136/jnnp.48.2.187; FEINSTEIN A, 1990, J NEUROL NEUROSUR PS, V53, P244, DOI 10.1136/jnnp.53.3.244; GOULATIA RK, 1987, EPILEPSIA, V28, P523, DOI 10.1111/j.1528-1157.1987.tb03682.x; MINGUETTI G, 1983, J NEUROL NEUROSUR PS, V46, P936, DOI 10.1136/jnnp.46.10.936; RAJSHEKHAR V, 1990, J NEUROL NEUROSUR PS, V53, P818, DOI 10.1136/jnnp.53.9.818-a; WADIA RS, 1987, J NEUROL NEUROSUR PS, V50, P1298, DOI 10.1136/jnnp.50.10.1298	9	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					933	935		10.1136/bmj.302.6782.933	http://dx.doi.org/10.1136/bmj.302.6782.933			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032034	Bronze, Green Published			2022-12-01	WOS:A1991FH48700016
J	OSTLERE, LS; LANGTRY, JAA				OSTLERE, LS; LANGTRY, JAA			ALLERGY TO SPIRAMYCIN DURING PROPHYLACTIC TREATMENT OF FETAL TOXOPLASMOSIS	BRITISH MEDICAL JOURNAL			English	Letter											OSTLERE, LS (corresponding author), WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND.							DAFFOS F, 1988, NEW ENGL J MED, V318, P281; DESCOTERS J, 1988, J ANTIMICROBIAL C SB, P207; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; GALLAND MC, 1987, THERAPIE, V42, P227; HOHFELD P, 1989, J PEDIATR, V115, P765; 1990, LANCET, V336, P346	6	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					970	970		10.1136/bmj.302.6782.970	http://dx.doi.org/10.1136/bmj.302.6782.970			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	2032060	Bronze, Green Published			2022-12-01	WOS:A1991FH48700071
J	STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN				STUART, AG; WREN, C; SHARPLES, PM; HUNTER, S; HEY, EN			HYPOPLASTIC LEFT HEART SYNDROME - MORE POTENTIAL TRANSPLANT RECIPIENTS THAN SUITABLE DONORS	LANCET			English	Article							ORTHOTOPIC CARDIAC TRANSPLANTATION; ANENCEPHALIC INFANTS; ORGAN DONORS; EXPERIENCE; DEATH	Neonatal cardiac transplantation offers the prospect of survival for babies with hypoplastic left heart syndrome-but only if suitable donors are available. In a retrospective survey in the Northern health region of England and Wales, the likely need for neonatal cardiac transplantation far outweighed the potential availability of donors. Over 8 years (1983-90) hypoplastic left heart syndrome was identified in 38 newborn babies and in 9 fetuses in utero. Of 41 live births (including 3 diagnosed prenatally) 31 would have been candidates for a cardiac transplant, but only 4 suitable donors could be identified (3 with anencephaly born alive during the same period and 1 who died between 1979 and 1986 after a head injury). Analysis of all infant deaths in 1987-89 revealed only 3 potential donors from 426 deaths in the 3 years. Although more widespread antenatal diagnosis may lead to fewer liveborn babies with hypoplastic left heart syndrome, these findings indicate that an alternative source of donors needs to be identified before neonatal cardiac transplantation can be widely used in the treatment of this disorder.	FREEMAN RD HOSP,DEPT PAEDIAT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle Freeman Hospital; Newcastle University - UK				Stuart, Alan Graham/0000-0003-2789-2216				BAILEY LL, 1988, ANN SURG, V208, P279, DOI 10.1097/00000658-198809000-00004; BAILEY LL, 1990, PEDIATR CLIN N AM, V37, P137; Bailey LL., 1984, HEART TRANSPLANT, V3, P265; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; DAVID TJ, 1983, J MED GENET, V20, P338, DOI 10.1136/jmg.20.5.338; HARRISON MR, 1986, LANCET, V2, P1383; HOLZGREVE W, 1987, NEW ENGL J MED, V326, P1069; LLOYD TR, 1989, AM HEART J, V117, P1337, DOI 10.1016/0002-8703(89)90416-X; MAVROUDIS C, 1989, J THORAC CARDIOV SUR, V97, P389; MAVROUDIS C, 1988, J THORAC CARDIOV SUR, V96, P912; MEDEARIS DN, 1989, NEW ENGL J MED, V321, P391, DOI 10.1056/NEJM198908103210610; MORRIS CD, 1990, PEDIATRICS, V85, P977; NORWOOD WI, 1981, J THORAC CARDIOV SUR, V82, P511; PEABODY JL, 1989, NEW ENGL J MED, V321, P344, DOI 10.1056/NEJM198908103210602; PIGOTT JD, 1988, ANN THORAC SURG, V45, P122; SHEWMON DA, 1988, HASTINGS CENT REP, V18, P11, DOI 10.2307/3562217; STILLER CR, 1988, TRANSPL P, V20, P1; TRUOG RD, 1989, NEW ENGL J MED, V321, P388, DOI 10.1056/NEJM198908103210609; TUCKER WY, 1990, J THORAC CARDIOV SUR, V99, P885; 1988, C MED ROYAL COLLEGES	20	21	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1991	337	8747					957	959		10.1016/0140-6736(91)91581-E	http://dx.doi.org/10.1016/0140-6736(91)91581-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH131	1678040				2022-12-01	WOS:A1991FH13100014
J	BEEN, MD; PERROTTA, AT				BEEN, MD; PERROTTA, AT			GROUP-I INTRON SELF-SPLICING WITH ADENOSINE - EVIDENCE FOR A SINGLE NUCLEOSIDE-BINDING SITE	SCIENCE			English	Article							TETRAHYMENA PRE-RRNA; BIOLOGICAL CATALYSIS; SECONDARY STRUCTURE; RNA; SEQUENCE; MITOCHONDRIA; RIBOZYME; IVS	For self-splicing of Tetrahymena ribosomal RNA precursor, guanosine binding is required for 5' splice-site cleavage and exon ligation. Whether these two reactions use the same or different guanosine-binding sites has been debated. A double mutation in a previously identified guanosine-binding site within the intron resulted in preference for adenosine (or adenosine triphosphate) as the substrate for cleavage at the 5' splice site. However, splicing was blocked in the exon ligation step. Blockage was reversed by a change from guanine to adenine at the 3' splice site. These results indicate that a single determinant specifies nucleoside binding for both steps of splicing. Furthermore, it suggests that RNA could form an active site specific for adenosine triphosphate.			BEEN, MD (corresponding author), DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; GARRIGA G, 1984, CELL, V39, P631, DOI 10.1016/0092-8674(84)90470-7; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1988, EMBO J, V7, P3531, DOI 10.1002/j.1460-2075.1988.tb03229.x; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PERROTTA AJ, UNPUB; PRICE JV, 1988, GENE DEV, V2, P1439, DOI 10.1101/gad.2.11.1439; TANNER NK, 1987, BIOCHEMISTRY-US, V26, P3330, DOI 10.1021/bi00386a013; VANDERHORST G, 1987, EMBO J, V6, P2139, DOI 10.1002/j.1460-2075.1987.tb02481.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	20	105	108	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					434	437		10.1126/science.2017681	http://dx.doi.org/10.1126/science.2017681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017681				2022-12-01	WOS:A1991FH10300041
J	BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW				BELL, LR; HORABIN, JI; SCHEDL, P; CLINE, TW			POSITIVE AUTOREGULATION OF SEX-LETHAL BY ALTERNATIVE SPLICING MAINTAINS THE FEMALE DETERMINED STATE IN DROSOPHILA	CELL			English	Article								Sex-lethal is a binary switch gene that controls all aspects of Drosophila sexual dimorphism. It must be active in females and inactive in males. The on/off regulation reflects alternative RNA splicing in which full-length proteins are produced only in females. Here we investigate the role of Sxl in maintaining sexual pathway commitments. By ectopic expression of a female Sxl cDNA in transgenic male flies, we show that Sxl protein induces a rapid switch from male- to female-specific splicing. The ectopically expressed Sxl protein will trans-activate an endogenous wild-type Sxl gene. This establishes a feedback loop in which Sxl proteins induce their own synthesis by directing the female-specific splicing of Sxl transcripts. We conclude that the female determined state is maintained by Sxl through positive autoregulation, while the male determined state is maintained by default.	PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA	Princeton University								BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, IN PRESS GENES DEV; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1988, GENETICS, V119, P829; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; ERICKSON JW, 1991, IN PRESS SCIENCE; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEHRING WJ, 1973, DEV SYSTEMS INSECTS, V2; GERGEN JP, 1987, GENETICS, V117, P477; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LINDALEY D, 1985, DROS INFORM SERV, V62, P1; Lindsley D.L., 1990, Drosophila Information Service, V68, P1; LINDSLEY DL, 1986, DROS INF SERV, V64, P1; LINDSLEY DL, 1987, DROS INFORM SERV, V65, P1; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; MAINE EM, 1985, COLD SPRING HARB SYM, V50, P595, DOI 10.1101/SQB.1985.050.01.072; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MULLER H. J., 1932, Proceedings. 6th Int. Congr. Genet., V1, P213; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; OLIVER B, 1990, GENETICS, V125, P535; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SALZ HK, 1989, GENE DEV, V3, P708, DOI 10.1101/gad.3.5.708; SALZ HK, 1987, GENETICS, V117, P221; SANCHEZ L, 1982, ROUX ARCH DEV BIOL, V191, P211, DOI 10.1007/BF00848339; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SCHUPBACH T, 1985, GENETICS, V109, P529; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STEINMANNZWICKY M, 1989, CELL, V57, P157, DOI 10.1016/0092-8674(89)90181-5; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; ZUSMAN SB, 1987, GENETICS, V115, P725	49	282	289	2	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					229	239		10.1016/0092-8674(91)90157-T	http://dx.doi.org/10.1016/0092-8674(91)90157-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015624				2022-12-01	WOS:A1991FH09200006
J	CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG				CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG			PROTEIN DNA CROSS-LINKING DEMONSTRATES STEPWISE ATP-DEPENDENT ASSEMBLY OF T4-DNA POLYMERASE AND ITS ACCESSORY PROTEINS ON THE PRIMER-TEMPLATE	CELL			English	Article								T4 DNA polymerase, the 44/62 and 45 polymerase accessory proteins, and 32 single-stranded DNA-binding protein catalyze ATP-dependent DNA synthesis. Using DNA primers with cross-linkable residues at specific positions, we obtained structural data that reveal how these proteins assemble on the primer-template. With the nonhydrolyzable ATP analog ATP-gamma-S, assembly of the 44/62 and 45 proteins on the primer requires 32 protein but not polymerase. ATP hydrolysis changes the position and intensity of cross-linking to each of the accessory proteins and allows cross-linking of polymerase. Our data indicate that the initial binding of the three accessory proteins and ATP to a 32 protein-covered primer-template is followed by ATP hydrolysis, binding of polymerase, and movement of the accessory proteins to yield a complex capable of processive DNA synthesis.	PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	CAPSON, TL (corresponding author), NIDDKD, NUCL ACID BIOCHEM SECT, BIOCHEM PHARMACOL LAB, BLDG 8, ROOM 2A-15, BETHESDA, MD 20892 USA.				NIGMS NIH HHS [GM 12011, GM 13306] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Bayley H, 1977, Methods Enzymol, V46, P69; BAYLEY H, 1983, LABORATORY TECHNIQUE, V12; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DISSINGER S, 1990, J BIOL CHEM, V265, P7662; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P6455, DOI 10.1093/nar/15.16.6455; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; JARVIS TC, 1990, UCLA SYM BI, V127, P261; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MUNN M, 1986, THESIS U CALIFORNIA; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; RUSH J, 1989, J BIOL CHEM, V264, P10943; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WOLD MS, 1989, J BIOL CHEM, V264, P2801	42	91	91	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					249	258		10.1016/0092-8674(91)90159-V	http://dx.doi.org/10.1016/0092-8674(91)90159-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849797				2022-12-01	WOS:A1991FH09200008
J	COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM				COOKE, MP; ABRAHAM, KM; FORBUSH, KA; PERLMUTTER, RM			REGULATION OF T-CELL RECEPTOR SIGNALING BY A SRC FAMILY PROTEIN-TYROSINE KINASE (P59FYN)	CELL			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; CD4 RECEPTOR; ACTIVATION; EXPRESSION; COMPLEX; PHOSPHORYLATION; POLYPEPTIDE; GENE; IDENTIFICATION	Engagement of the clonotypic antigen receptor (TCR) on T lymphocytes provokes an activation response leading to cell proliferation and lymphokine secretion. To examine the molecular basis of T cell signaling, we generated transgenic animals in which a lymphocyte-specific nonreceptor protein-tyrosine kinase p59fyn(T) is 20-fold overexpressed in developing T lineage cells. Thymocytes from these mice, analyzed using both cellular and biochemical assays, were remarkably hyperstimulable. Moreover, the responsiveness of normal thymocytes to TCR-derived signals correlated well with the extent to which p59fyn was expressed in these cells. Overexpression of a catalytically inactive form of p59fyn substantially inhibited TCR-mediated activation in otherwise normal thymocytes. These effects are unique to p59fyn; overexpression of a closely related T cell-specific tyrosine kinase, p56lck, elicits dramatically different phenotypes. Our results suggest that p59fyn is a critically important component of the TCR signal transduction apparatus.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	COOKE, MP (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA09537, CA45682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009537, R01CA045682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, IN PRESS P NATL ACAD; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JUNE CH, 1990, J IMMUNOL, V144, P1591; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mishell B.B., 1980, SELECTED METHODS CEL; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Sambrook J., 1989, MOL CLONING LAB MANU; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SCHWARTZ RH, 1990, SCIENCE, V248, P1342; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLIAMS AF, 1982, SCIENCE, V216, P696, DOI 10.1126/science.6177036; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	53	436	443	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					281	291		10.1016/0092-8674(91)90162-R	http://dx.doi.org/10.1016/0092-8674(91)90162-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015626				2022-12-01	WOS:A1991FH09200011
J	FINCH, EA; TURNER, TJ; GOLDIN, SM				FINCH, EA; TURNER, TJ; GOLDIN, SM			CALCIUM AS A COAGONIST OF INOSITOL 1,4,5-TRISPHOSPHATE INDUCED CALCIUM RELEASE	SCIENCE			English	Article							CARDIAC PURKINJE-CELL; SARCOPLASMIC-RETICULUM; SUPERFUSION SYSTEM; TRISPHOSPHATE; RECEPTOR; CHANNELS; NUCLEOTIDES; MICROSOMES; ACTIVATION; VESICLES	Inositol 1,4,5-trisphosphate (IP3)-induced calcium release from intracellular stores is a regulator of cytosolic-free calcium levels. The subsecond kinetics and regulation of IP3-induced calcium-45 release from synaptosome-derived microsomal vesicles were resolved by rapid superfusion. Extravesicular calcium acted as a coagonist, potentiating the transient IP3-induced release of calcium-45. Thus, rapid elevation of cytosolic calcium levels may trigger IP3-induced calcium release in vivo. Extravesicular calcium also produced a more slowly developing, reversible inhibition of IP3-induced calcium-45 release. Sequential positive and negative feedback regulation by calcium of IP3-induced calcium release may contribute to transients and oscillations of cytosolic-free calcium in vivo.	HARVARD UNIV, SCH MED, DEPT NEUROBIOL, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; CAMBRIDGE NEUROSCI RES INC, CAMBRIDGE, MA 02139 USA	Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School				Turner, Timothy/0000-0001-9770-2647	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035423] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35423] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, UNPUB; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GARCIA AM, 1984, J GEN PHYSIOL, V83, P819, DOI 10.1085/jgp.83.6.819; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JEAN T, 1986, J BIOL CHEM, V261, P6414; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PEARCE LB, 1988, BIOCHEMISTRY-US, V27, P4396, DOI 10.1021/bi00412a029; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; SHAH J, 1987, BRAIN RES, V419, P1, DOI 10.1016/0006-8993(87)90562-2; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; TURNER TJ, 1989, BIOCHEMISTRY-US, V28, P586, DOI 10.1021/bi00428a026; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Whittaker VP, 1969, HDB NEUROCHEMISTRY, VII, P327, DOI DOI 10.1007/978-1-4899-7321-4_14	35	788	795	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1991	252	5004					443	446		10.1126/science.2017683	http://dx.doi.org/10.1126/science.2017683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017683				2022-12-01	WOS:A1991FH10300044
J	HUANG, J; SCHNEIDER, RJ				HUANG, J; SCHNEIDER, RJ			ADENOVIRUS INHIBITION OF CELLULAR PROTEIN-SYNTHESIS INVOLVES INACTIVATION OF CAP-BINDING PROTEIN	CELL			English	Article							DOUBLE-STRANDED-RNA; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; 5' NONTRANSLATED REGION; MESSENGER-RNA; INITIATION-FACTOR; VAI-RNA; TRIPARTITE LEADER; TRANSLATIONAL CONTROL; INFECTED CELLS; GENE-EXPRESSION	Adenovirus (Ad) infection results in a marked inhibition of cellular protein synthesis that initiates during the late phase of the viral infectious cycle. We show that the mechanism used for suppression of cellular protein synthesis during cell cycle progression is exploited by Ad to repress host and enhance late viral mRNA translation. Discrimination between cellular and late Ad mRNAs and inhibition of host protein synthesis are shown to involve viral-mediated underphosphorylation of cap-binding protein (CBP) and subsequent inactivation of CBP complex, a large enzymatic complex required for cap-dependent mRNA translation. Late Ad mRNAs, like those of poliovirus, possess the unique ability to translate independent of a normal cap recognition process and do not require the activity of CBP complex. Inhibition of cellular translation by these two viruses is quite similar, except that whereas CBP complex is proteolytically degraded by poliovirus, it is functionally inactivated by Ad.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	HUANG, J (corresponding author), NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [R01CA042357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CHERNEY CS, 1979, J VIROL, V5, P533; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DERY I, 1987, TRANSLATIONAL REGULA; DOLPH PJ, 1988, J VIROL, V62, P2059, DOI 10.1128/JVI.62.6.2059-2066.1988; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FLINT SJ, 1984, COMPR VIROL, V19, P297; GINSBERG HS, 1984, J GEN VIROL, V36, P59; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUANG JT, 1990, P NATL ACAD SCI USA, V87, P7115, DOI 10.1073/pnas.87.18.7115; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMALLEY RP, 1989, VIROLOGY, V168, P112, DOI 10.1016/0042-6822(89)90409-1; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETTERSSON U, 1978, CELL, V12, P741; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SCHNEIDER RJ, 1984, CELL, V37, P291, DOI 10.1016/0092-8674(84)90325-8; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SEN GC, 1983, J GEN VIROL, V64, P2213, DOI 10.1099/0022-1317-64-10-2213; SIEKIERKA J, 1985, P NATL ACAD SCI USA, V82, P1959, DOI 10.1073/pnas.82.7.1959; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG Y, 1989, J BIOL CHEM, V264, P10679; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	64	153	161	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					271	280		10.1016/0092-8674(91)90161-Q	http://dx.doi.org/10.1016/0092-8674(91)90161-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849798				2022-12-01	WOS:A1991FH09200010
J	HUGIN, AW; VACCHIO, MS; MORSE, HC				HUGIN, AW; VACCHIO, MS; MORSE, HC			A VIRUS-ENCODED SUPERANTIGEN IN A RETROVIRUS-INDUCED IMMUNODEFICIENCY SYNDROME OF MICE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MURINE LEUKEMIA VIRUSES; T-CELLS; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES; CLONAL DELETION; C57BL/6 MICE; I-E; MLS; RECEPTOR	The development of an immunodeficiency syndrome of mice caused by a replication-defective murine leukemia virus (MuLV) is paradoxically associated with a rapid activation and proliferation of CD4+ T cells that are dependent on the presence of B cells. The responses of normal spleen cells to B cell lines that express the defective virus indicated that these lines express a cell surface determinant that shares "superantigenic" properties with some microbial antigens and Mls-like self antigens. This antigen elicited a potent proliferative response that was dependent on the presence of CD4+ T cells and was associated with selective expansion of cells bearing V-beta-5. This response was markedly inhibited by a monoclonal antibody specific for the MuLV gag-encoded p30 antigen.	NIAID,IMMUNOPATHOL LAB,BLDG 7,ROOM 304,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Morse, Herbert/0000-0002-9331-3705	NIAID NIH HHS [N01-AI-72622] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1987, J EXP MED, V166, P1150, DOI 10.1084/jem.166.4.1150; ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ABE R, 1988, IMMUNOL TODAY, V9, P230, DOI 10.1016/0167-5699(88)91221-2; ABRIGNANI S, 1990, P NATL ACAD SCI USA, V87, P6136, DOI 10.1073/pnas.87.16.6136; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CERNY A, UNPUB; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHATTOPADHYAY SK, UNPUB; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; CHEUNG SC, 1991, J VIROL, V65, P823, DOI 10.1128/JVI.65.2.823-828.1991; CHEUNG SC, 1991, J IMMUNOL, V146, P121; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; COLE BC, 1989, J IMMUNOL, V142, P4131; COLE BC, 1990, J IMMUNOL, V144, P425; COLE BC, 1990, J IMMUNOL, V144, P20; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HAMELINBOURASSA D, 1989, IMMUNOGENETICS, V30, P266, DOI 10.1007/BF02421330; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1990, J VIROL, V64, P5764, DOI 10.1128/JVI.64.12.5764-5772.1990; HUGIN AW, UNPUB; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1988, J IMMUNOGENET, V15, P161; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; KROWKA J, 1990, J IMMUNOL, V144, P2535; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; LIAO NS, 1990, J IMMUNOL, V144, P844; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAKINO M, 1990, J IMMUNOL, V144, P4347; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MORSE HC, 1989, J IMMUNOL, V143, P844; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; NAIR MPN, 1988, P NATL ACAD SCI USA, V85, P6498, DOI 10.1073/pnas.85.17.6498; NORTON SD, 1990, J IMMUNOL, V144, P2089; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PECK AB, 1977, NATURE, V266, P840, DOI 10.1038/266840a0; PITHA PM, 1988, J IMMUNOL, V141, P3611; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; ROSENBERG AS, 1991, TRANSPLANT P, V23, P167; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SICILIANO RF, 1989, J IMMUNOL, V142, P1506; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943	63	209	220	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					424	427		10.1126/science.1850169	http://dx.doi.org/10.1126/science.1850169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1850169				2022-12-01	WOS:A1991FH10300038
J	LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y				LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y			ENGRAFTMENT AND DEVELOPMENT OF HUMAN T-CELLS AND B-CELLS IN MICE AFTER BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; COMBINED IMMUNE-DEFICIENCY; RED-BLOOD-CELLS; SCID-HU MOUSE; SOYBEAN AGGLUTININ; RESISTANCE; SUSCEPTIBILITY; RECIPIENTS; ALLOGRAFTS; GRAFTS	A model for human lymphocyte ontogeny has been developed in a normal mouse. Human bone marrow, depleted of mature T and B lymphocytes, and bone marrow from mice with severe combined immunodeficiency were transplanted into lethally irradiated BALB/c mice. Human B and T cells were first detected 2 to 4 months after transplantation and persisted for at least 6 months. Most human thymocytes (30 to 50 percent of total thymocytes) were CD3+ CD4+ CD8+. Human immunoglobulin was detected in some chimeras, and a human antibody response to dinitrophenol could be generated after primary and secondary immunization.	WEIZMANN INST SCI,DEPT BIOPHYS,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT PEDIAT,IL-62621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center			Lapidot, Tsvee/A-1812-2010; Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945				KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KEEVER CA, 1989, BLOOD, V73, P1340; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; LAPIDOT T, 1989, BLOOD, V73, P2025; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; OREILLY RJ, 1986, PRIMARY IMMUNODEFICI, P301; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; REISNER Y, 1981, LANCET, V2, P327; RONNINGEN KS, 1989, HUM IMMUNOL, V26, P215; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZ E, 1987, J IMMUNOL, V138, P460; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; VANBEKKUM DW, 1985, BONE MARROW TRANSPL, P311	18	87	102	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					427	431		10.1126/science.1826797	http://dx.doi.org/10.1126/science.1826797			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1826797				2022-12-01	WOS:A1991FH10300039
J	MALIM, MH; CULLEN, BR				MALIM, MH; CULLEN, BR			HIV-1 STRUCTURAL GENE-EXPRESSION REQUIRES THE BINDING OF MULTIPLE REV MONOMERS TO THE VIRAL RRE - IMPLICATIONS FOR HIV-1 LATENCY	CELL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; ESCHERICHIA-COLI; TRANS-ACTIVATOR; MESSENGER-RNA; PROTEIN; SEQUENCE; INVITRO; PURIFICATION; RECOGNITION; POLYMERASE	Expression of the structural proteins of HIV-1 requires the direct interaction of the viral Rev trans-activator with its cis-acting RNA target sequence, the Rev response element or RRE. Here, we demonstrate that this specific RNA-binding event is, as expected, mediated by the conserved arginine-rich motif of Rev. However, we also show that amino acid residues located proximal to this basic domain that are critical for in vivo Rev function are dispensable for sequence-specific binding to the RRE. Instead, these sequences are required for the multimerization of Rev on the viral RRE target sequence. The observation that Rev function requires the sequential binding of multiple Rev molecules to the RRE provides a biochemical explanation for the observed threshold effect for Rev function in vivo and suggests a molecular model for the high incidence of latent infection by HIV-1.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University	MALIM, MH (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.			Malim, Michael/0000-0002-7699-2064				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; JAKOBOVITS A, 1990, EMBO J, V9, P1165, DOI 10.1002/j.1460-2075.1990.tb08223.x; JONES K A, 1989, New Biologist, V1, P127; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NALIN CM, 1990, P NATL ACAD SCI USA, V87, P7593, DOI 10.1073/pnas.87.19.7593; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILEY LS, 1990, P NATL ACAD SCI USA, V87, P7497, DOI 10.1073/pnas.87.19.7497; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	37	355	362	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					241	248		10.1016/0092-8674(91)90158-U	http://dx.doi.org/10.1016/0092-8674(91)90158-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015625				2022-12-01	WOS:A1991FH09200007
J	NEARING, BD; HUANG, AH; VERRIER, RL				NEARING, BD; HUANG, AH; VERRIER, RL			DYNAMIC TRACKING OF CARDIAC VULNERABILITY BY COMPLEX DEMODULATION OF THE T-WAVE	SCIENCE			English	Article							SYMPATHETIC NERVOUS-SYSTEM; VENTRICULAR-FIBRILLATION; MYOCARDIAL ISCHEMIA; NEURAL ACTIVITY; ALTERNATION; REPERFUSION; ARRHYTHMIAS; MECHANISMS; HEART	A link is found between T wave alternans and vulnerability to ventricular fibrillation, and a new approach is provided for quantification of susceptibility to malignant arrhythmias. Complex demodulation reveals that alternation of the electrocardiogram is concentrated during the first half of the T wave, coinciding with the vulnerable period of the cardiac cycle. During myocardial ischemia and reperfusion, there are marked increases in the degree of T wave alternans that parallel the established time course of changes in vulnerability. The influence of the sympathetic nervous system in arrhythmogenesis is also accurately detected. Ultimately, complex demodulation of the electrocardiogram could provide a technique for identification and management of individuals at risk for sudden cardiac death.			VERRIER, RL (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20007, USA.		Verrier, Richard L/H-3083-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033567] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM DR, 1984, J ELECTROCARDIOL, V17, P209, DOI 10.1016/S0022-0736(84)80057-6; Bloomfield P., 1976, FOURIER ANAL TIME SE; CARSON DL, 1986, CARDIOVASC RES, V20, P521, DOI 10.1093/cvr/20.7.521; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, CIRC RES, V66, P525, DOI 10.1161/01.RES.66.2.525; CORBALAN R, 1976, AM HEART J, V92, P223, DOI 10.1016/S0002-8703(76)80258-X; CORR PB, 1986, HEART CARDIOVASCULAR, pCH58; ELSHERIF N, 1988, CIRC RES, V63, P286, DOI 10.1161/01.RES.63.2.286; FRIEHLING TD, 1985, AM J CARDIOL, V55, P1339, DOI 10.1016/0002-9149(85)90500-4; GUEVARA MR, 1981, SCIENCE, V214, P1350, DOI 10.1126/science.7313693; HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44; LOMBARDI F, 1983, AM HEART J, V105, P958, DOI 10.1016/0002-8703(83)90397-6; LOWN B, 1976, NEW ENGL J MED, V294, P1165; Oppenheim A.V., 1975, DIGIT SIGNAL PROCESS; PRIORI SG, 1990, CIRCULATION, V81, P1911, DOI 10.1161/01.CIR.81.6.1911; RITZENBERG AL, 1984, NATURE, V307, P159, DOI 10.1038/307159a0; ROSEN MR, 1990, CARDIAC ELECTROPHYSI, pCH34; ROZANSKI JJ, 1982, PACE, V5, P359, DOI 10.1111/j.1540-8159.1982.tb02243.x; RUSSELL DC, 1979, BRIT HEART J, V42, P88; SCHWARTZ PJ, 1977, CIRC RES, V41, P51, DOI 10.1161/01.RES.41.1.51; SCHWARTZ PJ, 1975, AM HEART J, V89, P45, DOI 10.1016/0002-8703(75)90008-3; SCHWARTZ PJ, 1985, AM HEART J, V109, P399, DOI 10.1016/0002-8703(85)90626-X; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, pCH37; SHIN SJ, 1989, IEEE T BIO-MED ENG, V36, P274; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; SMITH JM, 1990, CARDIAC ELECTROPHYSI, pCH25; SURAWICZ B, 1985, J AM COLL CARDIOL, V5, pB43, DOI 10.1016/S0735-1097(85)80526-X; VERRIER RL, 1986, EUR HEART J, V7, P13; VERRIER RL, 1978, AM J PHYSIOL, V234, pH592, DOI 10.1152/ajpheart.1978.234.5.H592; ZIPES DP, 1990, CARDIAC ELECTROPHYSI, pCH36; 1990, AM J PHYSL, V259; 1985, PUBL NIH, V8623	33	252	271	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					437	440		10.1126/science.2017682	http://dx.doi.org/10.1126/science.2017682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017682				2022-12-01	WOS:A1991FH10300042
J	OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H				OHASHI, PS; OEHEN, S; BUERKI, K; PIRCHER, H; OHASHI, CT; ODERMATT, B; MALISSEN, B; ZINKERNAGEL, RM; HENGARTNER, H			ABLATION OF TOLERANCE AND INDUCTION OF DIABETES BY VIRUS-INFECTION IN VIRAL-ANTIGEN TRANSGENIC MICE	CELL			English	Article								To address the mechanisms of tolerance to extrathymic proteins, we have generated transgenic mice expressing the lymphocytic choriomeningitis viral (LCMV) glycoprotein (GP) in the beta-islet cells of the pancreas. The fate of LCMV GP-specific T cells was followed by breeding the GP transgenic mice with T cell receptor transgenic mice, specific for LCMV and H-2D(b). These studies suggest that "peripheral tolerance" of self-reactive T cells does not involve clonal deletion, clonal anergy, or a decrease in the density of T cell receptors or accessory molecules. Instead, this model indicates that self-reactive cytotoxic T cells may remain functionally unresponsive, owing to a lack of appropriate T cell activation. Infection of transgenic mice with LCMV readily abolishes peripheral unresponsiveness to the self LCMV GP antigen, resulting in a CD8+ T cell-mediated diabetes. These data suggest that similar mechanisms may operate in several so-called "T cell-mediated autoimmune diseases."	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND; CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Novartis; Sandoz; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	OHASHI, PS (corresponding author), UNIV HOSP ZURICH, INST PATHOL, DEPT EXPTL PATHOL, CH-8091 ZURICH, SWITZERLAND.		Malissen, Bernard/AAK-4659-2020	Malissen, Bernard/0000-0003-1340-9342; Ohashi, Pamela S./0000-0003-2915-9317				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1981, P NATL ACAD SCI-BIOL, V78, P6456, DOI 10.1073/pnas.78.10.6456; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BURKLY LC, 1990, SCIENCE, V248, P1364, DOI 10.1126/science.1694042; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FAUSTMAN D, 1980, J EXP MED, V151, P1563, DOI 10.1084/jem.151.6.1563; FERRICK DA, 1990, IMMUNOL REV, V118, P257, DOI 10.1111/j.1600-065X.1990.tb00819.x; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1990, ANNU REV CELL BIOL, V6, P493, DOI 10.1146/annurev.cellbio.6.1.493; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; Hogan B., 1986, MANIPULATING MOUSE E; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LIKE AA, 1982, SCIENCE, V216, P644, DOI 10.1126/science.7041259; LINDAHL P, 1973, P NATL ACAD SCI USA, V70, P2785, DOI 10.1073/pnas.70.10.2785; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MILLER BJ, 1988, J IMMUNOL, V140, P52; MILLER J, 1990, J IMMUNOL, V144, P334; MILLER JFA, 1989, IMMUNOLOGY, V1, P137; MOMBURG F, 1986, J IMMUNOL, V136, P940; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MOSKOPHIDIS D, 1991, IN PRESS J VIROL; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NAGATA M, 1989, J IMMUNOL, V143, P1155; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PIRCHER H, 1987, EUR J IMMUNOL, V17, P1843, DOI 10.1002/eji.1830171226; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PUJOLBORRELL R, 1987, NATURE, V326, P304, DOI 10.1038/326304a0; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; ROSA F, 1984, IMMUNOL TODAY, V5, P261, DOI 10.1016/0167-5699(84)90135-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; WOOD PJ, 1987, J IMMUNOL, V139, P3236; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	75	1087	1093	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					305	317		10.1016/0092-8674(91)90164-T	http://dx.doi.org/10.1016/0092-8674(91)90164-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901764				2022-12-01	WOS:A1991FH09200013
J	OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H				OLDSTONE, MBA; NERENBERG, M; SOUTHERN, P; PRICE, J; LEWICKI, H			VIRUS-INFECTION TRIGGERS INSULIN-DEPENDENT DIABETES-MELLITUS IN A TRANSGENIC MODEL - ROLE OF ANTI-SELF (VIRUS) IMMUNE-RESPONSE	CELL			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PANCREATIC BETA-CELLS; COXSACKIE-B-VIRUS; CLASS-II MHC; DIFFERENTIATED FUNCTIONS; AUTOIMMUNE-DISEASE; PROTEIN-STRUCTURE; CROSS-REACTIVITY; MICE; EXPRESSION	We investigated the potential association between viruses and insulin-dependent (type 1) diabetes (IDDM) by developing a transgenic mouse model. By inserting into these mice a unique viral protein that was then expressed as a self-antigen in the pancreatic islets of Langerhans, we could study the effect on that expressed antigen alone, or in concert with an induced antiviral (i.e., autoimmune) response manifested later in life in causing IDDM. Our results indicate that a viral gene introduced as early as an animal's egg stage, incorporated into the germline, and expressed in islet cells does not produce tolerance when the host is exposed to the same virus later in life. We observed that the induced anti-self (viral) CTL response leads to selective and progressive damage of beta-cells, resulting in IDDM.			OLDSTONE, MBA (corresponding author), SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,VIROL SERV,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NIAID NIH HHS [AI-09484] Funding Source: Medline; NIA NIH HHS [AG-04342] Funding Source: Medline; NINDS NIH HHS [NS-01330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BAEKKESKOV S, 1990, CURR TOP MICROBIOL, V164, P1; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BOTTAZZO GF, 1983, LANCET, V2, P1115; BUCHMEIER MJ, 1981, VIROLOGY, V113, P73, DOI 10.1016/0042-6822(81)90137-9; BUCHMEIER MJ, 1979, VIROLOGY, V99, P111, DOI 10.1016/0042-6822(79)90042-4; BUCHMEIER MJ, 1978, VIROLOGY, V89, P133, DOI 10.1016/0042-6822(78)90047-8; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DOLSTONE MBA, 1990, J EXP MED, V171, P2077; DOLSTONE MBA, 1989, SCI AM, V260, P42; DYRBERG T, 1990, CURR TOP MICROBIOL, V156, P1; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Gamble D R, 1980, Epidemiol Rev, V2, P49; GLADISCH R, 1976, Z KARDIOL, V65, P837; HAMAFURA T, 1988, DIABETES, V37, P204; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B., 1986, MANIPULATING MOUSE E; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; HULTQUIST G, 1973, UPSALA J MED SCI, V78, P139, DOI 10.3109/03009737309178618; JENSON AB, 1984, PROG MED VIROL, V29, P197; JENSON AB, 1980, LANCET, V2, P354; KING ML, 1983, LANCET, V1, P1397; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; KLAVINSKIS LS, 1989, J VIROL, V63, P4311, DOI 10.1128/JVI.63.10.4311-4316.1989; KLAVINSKIS LS, 1989, VIROLOGY, V168, P232, DOI 10.1016/0042-6822(89)90262-6; KLAVINSKIS LS, 1987, J GEN VIROL, V68, P1867, DOI 10.1099/0022-1317-68-7-1867; KOEVARY S, 1983, SCIENCE, V220, P727, DOI 10.1126/science.6836309; LERNER RA, 1971, SCIENCE, V173, P60, DOI 10.1126/science.173.3991.60; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOHR JM, 1990, LANCET, P644; Maniatis T., 1982, MOL CLONING; MENSER MA, 1978, LANCET, V1, P57; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; OLDSTONE MBA, 1984, SCIENCE, V224, P1440, DOI 10.1126/science.6203172; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1985, VIROLOGY, V142, P158, DOI 10.1016/0042-6822(85)90430-1; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1980, J IMMUNOL, V124, P831; OLDSTONE MBA, 1982, SCIENCE, V218, P1125, DOI 10.1126/science.7146898; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1983, VIROLOGY, V127, P426, DOI 10.1016/0042-6822(83)90155-1; OLDSTONE MBA, 1978, UCLA S MOL CELLULAR, V9, P43; PAK CY, 1988, LANCET, V2, P1; PATTERSON K, 1981, LANCET, V1, P1048; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SISSONS JGP, 1980, P NATL ACAD SCI-BIOL, V77, P559, DOI 10.1073/pnas.77.1.559; SOUTHERN PJ, 1987, VIROLOGY, V157, P145, DOI 10.1016/0042-6822(87)90323-0; SOUTHERN PJ, 1986, VACCINES 86 MODERN A, P239; THOMSON G, 1988, AM J HUM GENET, V43, P799; TISHON A, 1988, J IMMUNOL, V140, P1280; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; UNGER R H, 1985, P1018; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WRIGHT KE, 1990, VIROLOGY, V177, P175, DOI 10.1016/0042-6822(90)90471-3; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; [No title captured]	64	681	689	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					319	331		10.1016/0092-8674(91)90165-U	http://dx.doi.org/10.1016/0092-8674(91)90165-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1901765				2022-12-01	WOS:A1991FH09200014
J	PFALLER, R; SMYTHE, C; NEWPORT, JW				PFALLER, R; SMYTHE, C; NEWPORT, JW			ASSEMBLY DISASSEMBLY OF THE NUCLEAR-ENVELOPE MEMBRANE - CELL-CYCLE DEPENDENT BINDING OF NUCLEAR-MEMBRANE VESICLES TO CHROMATIN INVITRO	CELL			English	Article							XENOPUS CDC2 PROTEIN; CHROMOSOME CONDENSATION; GOLGI-APPARATUS; FREE SYSTEM; COMPONENT; MITOSIS; LAMINA; LAEVIS; KINASE; MATURATION	Dissociation and association of membranes with chromatin at the beginning and end of mitosis are critical in controlling nuclear dynamics during these stages of the cell cycle. Employing purified membrane and cytosolic fractions from Xenopus eggs, a simple assay was developed for the reversible binding of nuclear membrane vesicles to chromatin. We have shown, using phosphatase and kinase inhibitors, that membrane-chromatin association is regulated by a phosphatase/kinase system. In interphase, the balance in this system favors dephosphorylation, possibly of a membrane receptor, which then mediates chromatin binding. At mitosis the membrane receptor is phosphorylated, causing release of chromatin-bound membrane. Purified MPF kinase does not directly cause membranes to dissociate from chromatin. Rather, binding of membranes to chromatin at mitosis appears to be regulated indirectly by MPF through its action on a phosphatase/kinase system that directly modulates the phosphorylation state of a nuclear membrane component.			PFALLER, R (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, R01GM033523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33523-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHALY N, 1984, J CELL BIOL, V99, P661, DOI 10.1083/jcb.99.2.661; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOERING V, 1990, EMBO (European Molecular Biology Organization) Journal, V9, P4073; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; FIELDS AP, 1988, J CELL BIOL, V107, P833, DOI 10.1083/jcb.107.3.833; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V339, P287; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; PADAN R, 1990, J BIOL CHEM, V265, P7808; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	46	119	119	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					209	217		10.1016/0092-8674(91)90155-R	http://dx.doi.org/10.1016/0092-8674(91)90155-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849796				2022-12-01	WOS:A1991FH09200004
J	REDDY, P; HAHN, S				REDDY, P; HAHN, S			DOMINANT NEGATIVE MUTATIONS IN YEAST TFIID DEFINE A BIPARTITE DNA-BINDING REGION	CELL			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION-FACTOR; UPSTREAM ACTIVATION SITE; TATA-BOX; SACCHAROMYCES-CEREVISIAE; CYC1 GENE; HAP1 ACTIVATOR; S-CEREVISIAE; PROTEIN; SEQUENCES	Genetic analysis showed that the conserved C-terminal 180 amino acids of yeast TFIID contain all the essential functions for growth of yeast and response to acidic transcriptional activation signals. A genetic screen was used to identify functionally important residues within this C-terminal region. Five dominant TFIID mutations were isolated that had lost the ability to bind DNA. Four of these mutations were single amino acid substitutions in the most N-terminal of two 66-67 amino acid repeats in TFIID. Analogous mutations made in the most C-terminal repeat all failed to bind DNA and inhibited growth of cells, suggesting that the DNA-binding function of TFIID is partitioned between the two repeated regions. Overproduction of wild-type TFIID rescued the dominance of the TFIID mutants, suggesting that the mutant proteins are dominant because they compete with wild-type TFIID for binding to one or more essential transcription factors.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	REDDY, P (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.			Hahn, Steven/0000-0001-7240-2533				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAIO X, 1990, GENE, V88, P107; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAWGA F, 1985, P NATL ACAD SCI USA, V82, P8557; OGDEN JE, 1986, MOL CELL BIOL, V6, P4335, DOI 10.1128/MCB.6.12.4335; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIKORSKI RS, 1989, GENETICS, V122, P19; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	45	120	121	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					349	357		10.1016/0092-8674(91)90168-X	http://dx.doi.org/10.1016/0092-8674(91)90168-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	2015629				2022-12-01	WOS:A1991FH09200017
J	ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG				ROSENFELD, MA; SIEGFRIED, W; YOSHIMURA, K; YONEYAMA, K; FUKAYAMA, M; STIER, LE; PAAKKO, PK; GILARDI, P; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; JALLAT, S; PAVIRANI, A; LECOCQ, JP; CRYSTAL, RG			ADENOVIRUS-MEDIATED TRANSFER OF A RECOMBINANT ALPHA-L-ANTITRYPSIN GENE TO THE LUNG EPITHELIUM INVIVO	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; INSITU HYBRIDIZATION; DNA; ALPHA-1-ANTITRYPSIN; IDENTIFICATION; EXPRESSION; CELLS; INDIVIDUALS; TYPE-5; ASSAY	The respiratory epithelium is a potential site for somatic gene therapy for the common hereditary disorders alpha-1-antitrypsin (alpha-1AT) deficiency and cystic fibrosis. A replication-deficient adenoviral vector (Ad-alpha-1AT) containing an adenovirus major late promoter and a recombinant human alpha-1AT gene was used to infect epithelial cells of the cotton rat respiratory tract in vitro and in vivo. Freshly isolated tracheobronchial epithelial cells infected with Ad-alpha-1AT contained human alpha-1AT messenger RNA transcripts and synthesized and secreted human alpha-1AT. After in vivo intratracheal administration of Ad-alpha-1AT to these rats, human alpha-1AT messenger RNA was observed in the respiratory epithelium, human alpha-1AT was synthesized and secreted by lung tissue, and human alpha-1AT was detected in the epithelial lining fluid for at least 1 week.	NHLBI,PULM BRANCH,BETHESDA,MD 20892; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Transgene SA								BALLAY A, 1985, EMBO J, V4, P3861, DOI 10.1002/j.1460-2075.1985.tb04158.x; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; CHANOCK RM, 1966, JAMA-J AM MED ASSOC, V195, P151; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Evans MJ, 1989, LUNG CELL BIOL, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILARDI P, 1990, FEBS LETT, V267, P60, DOI 10.1016/0014-5793(90)80287-S; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAJAHMAD Y, 1986, J VIROL, V57, P267, DOI 10.1128/JVI.57.1.267-274.1986; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORWITZ MS, 1990, VIROLOGY, P01679; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; MASSARO GD, 1989, LUNG CELL BIOL, P81; MICHALSKI JP, 1985, J IMMUNOL METHODS, V83, P101, DOI 10.1016/0022-1759(85)90063-8; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORNEX JF, 1986, J CLIN INVEST, V77, P1952, DOI 10.1172/JCI112524; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; Strauss SE, 1984, ADENOVIRUSES, P451; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704	40	696	1198	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					431	434		10.1126/science.2017680	http://dx.doi.org/10.1126/science.2017680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017680				2022-12-01	WOS:A1991FH10300040
J	SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B				SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B			DOWN-REGULATION OF T-CELL RECEPTORS ON SELF-REACTIVE T-CELLS AS A NOVEL MECHANISM FOR EXTRATHYMIC TOLERANCE INDUCTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREATIC BETA-CELLS; CLASS-II MHC; CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; ANTIGENS; EXPRESSION; MOLECULES; GENES	By generating two types of transgenic mice we have investigated how extrathymic events can contribute to self tolerance. The major histocompatibility complex class I gene K(b) was expressed under the control of the glial fibrillary acidic protein promoter in cells of neuroectodermal origin outside the thymus. These mice were tolerant to K(b). When crossed to transgenic mice expressing a K(b)-specific T cell receptor (TCR), clonotype+, CD8+CD4- mature T cells could be detected in normal numbers in the thymus of the double-transgenic mice but were strongly reduced in spleen and lymph nodes in comparison with TCR single-transgenic mice. After isolation of clonotype negative splenic T cells and activation in vitro, reappearance of the clonotype+, CD8+CD4- cells was observed. These results indicate that down-regulation of TCR and CD8 molecules on the antigen-specific T cells is a novel mechanism, by which peripheral tolerance to this antigen can occur.	CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	SCHONRICH, G (corresponding author), GERMAN CANC RES CTR,INST IMMUNOL & GENET,IM NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		; Malissen, Bernard/AAK-4659-2020	Kalinke, Ulrich/0000-0003-0503-9564; Malissen, Bernard/0000-0003-1340-9342; Malissen, Marie/0000-0003-2331-1445; Schmitt-Verhulst, Anne-Marie/0000-0002-1296-2739; Schonrich, Gunther/0000-0002-5346-5704				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALBERT F, 1982, IMMUNOGENETICS, V76, P533; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRADBURY M, 1981, TRENDS NEUROSCI, V4, P100, DOI 10.1016/0166-2236(81)90032-1; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BURNET FM, 1959, CLONAL SELECTION THE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COWING C, 1985, IMMUNOL TODAY, V6, P72, DOI 10.1016/0167-5699(85)90018-0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; HAFLER DA, 1987, IMMUNOL REV, V100, P307, DOI 10.1111/j.1600-065X.1987.tb00537.x; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; Hogan B., 1986, MANIPULATING MOUSE E; HUA C, 1986, J IMMUNOL, V136, P1937; HUE I, 1990, J IMMUNOL, V144, P4410; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; KOURILSKY P, 1987, P NATL ACAD SCI USA, V84, P3400, DOI 10.1073/pnas.84.10.3400; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; KUHLMANNKRIEG S, 1988, DEV BRAIN RES, V39, P269, DOI 10.1016/0165-3806(88)90031-4; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; KYEWSKI BA, 1984, NATURE, V308, P196, DOI 10.1038/308196a0; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; Maniatis T, 1989, DECONTAMINATION DILU; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; Miller J F, 1989, Autoimmunity, V4, P299, DOI 10.3109/08916938909014706; MIYADA CG, 1985, P NATL ACAD SCI USA, V82, P2890, DOI 10.1073/pnas.82.9.2890; MOMBURG F, 1989, J IMMUNOL, V142, P352; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1989, IMMUNOL TODAY, V10, P17, DOI 10.1016/0167-5699(89)90060-1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROTTER J, 1989, DEV BRAIN RES, V46, P115, DOI 10.1016/0165-3806(89)90148-X; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x	60	520	523	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					293	304		10.1016/0092-8674(91)90163-S	http://dx.doi.org/10.1016/0092-8674(91)90163-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849799				2022-12-01	WOS:A1991FH09200012
J	SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL				SHEN, L; CHEN, ZW; MILLER, MD; STALLARD, V; MAZZARA, GP; PANICALI, DL; LETVIN, NL			RECOMBINANT VIRUS-VACCINE INDUCED SIV-SPECIFIC CD8+ CYTOTOXIC LYMPHOCYTES-T	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; AIDS; CELLS; PROTECTION; INDIVIDUALS; REPLICATION; INFECTION; SEQUENCE; INVITRO; MACAQUE	Evidence indicates that cytotoxic T lymphocytes (CTLs) may be important in containing the spread of the human immunodeficiency virus (HIV) in the infected host. Although the use of recombinant viruses has been proposed as an approach to elicit protective immunity against HIV, the ability of recombinant viral constructs to elicit CD8+ CTL responses in higher primates has never been demonstrated. A live recombinant virus, vaccinia-simian immunodeficiency virus of macaques (SIV(mac)), was used to determine whether such a genetically restricted, T lymphocyte-mediated antiviral response could be generated in a primate. Vaccinia-SIV(mac) vaccination elicited an SIV(mac) Gag-specific, CD8+ CTL response in rhesus monkeys. These CTLs recognized a peptide fragment that spans residues 171 to 195 of the Gag protein. The rhesus monkey major histocompatibility complex (MHC) class I gene product restricting this CTL response was defined. Both the vaccinated and SIV(mac)-infected monkeys that shared this MHC class I gene product developed CTLs with the same Gag epitope specificity. These findings support the use of recombinant virus vaccines for the prevention of HIV infections in humans.	HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772; APPL BIOTECHNOL INC,CAMBRIDGE,MA 02142	Harvard University					NCI NIH HHS [CA50139] Funding Source: Medline; NIAID NIH HHS [AI26507, AI20729] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020729, R01AI020729] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ada GF, 1990, SEMIN VIROL SER, V1, P3; BENNINK JR, 1984, NATURE, V311, P578, DOI 10.1038/311578a0; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; EARL PL, 1986, SCIENCE, V234, P728, DOI 10.1126/science.3490689; FRANCHINI G, 1987, NATURE, V328, P539, DOI 10.1038/328539a0; KANNAGI M, 1985, P NATL ACAD SCI USA, V82, P7053, DOI 10.1073/pnas.82.20.7053; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; MAZZARA G, UNPUB; MCLAUGHLINTAYLOR E, 1988, J GEN VIROL, V69, P1731, DOI 10.1099/0022-1317-69-7-1731; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLER MD, IN PRESS VACCINES 91; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; ROOK AH, 1987, J IMMUNOL, V138, P1064; Shen L., UNPUB; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WATANABE M, 1990, J VIROL, V64, P656, DOI 10.1128/JVI.64.2.656-663.1990; YAMAMOTO H, 1990, J IMMUNOL, V145, P3740; YAMAMOTO H, 1990, J IMMUNOL, V144, P3385; ZAGURY D, 1988, NATURE, V332, P728, DOI 10.1038/332728a0; ZARLING JM, 1987, J IMMUNOL, V139, P988	30	90	94	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					440	443		10.1126/science.1708168	http://dx.doi.org/10.1126/science.1708168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1708168				2022-12-01	WOS:A1991FH10300043
J	STAMATOYANNOPOULOS, G				STAMATOYANNOPOULOS, G			HUMAN HEMOGLOBIN SWITCHING	SCIENCE			English	Editorial Material							BETA-GLOBIN GENE; DOMINANT CONTROL REGION; TRANSGENIC MICE; EXPRESSION				STAMATOYANNOPOULOS, G (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.							BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RYAN TM, 1989, P NATL ACAD SCI USA, V86, P37, DOI 10.1073/pnas.86.1.37; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; SPANGLER EA, 1990, NUCLEIC ACIDS RES, V18, P7093, DOI 10.1093/nar/18.23.7093; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2	17	53	53	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					383	383		10.1126/science.2017679	http://dx.doi.org/10.1126/science.2017679			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	2017679				2022-12-01	WOS:A1991FH10300029
J	WULCZYN, FG; KAHMANN, R				WULCZYN, FG; KAHMANN, R			TRANSLATIONAL STIMULATION - RNA SEQUENCE AND STRUCTURE REQUIREMENTS FOR BINDING OF COM PROTEIN	CELL			English	Article								Translation of the bacteriophage Mu mom gene is positively regulated by the phage Com protein. We report here that purified Com protein specifically stimulates mom gene expression in vitro. Furthermore, Com is shown to bind a site in the mom translational initiation region (TIR) in a sequence-specific manner. In vitro RNA footprint experiments have been used to define the Com-binding site and to study mRNA secondary structure in the mom TIR. Com binding is shown to correlate with a conformational change in the mom TIR both in vivo and in vitro. The role of secondary structure was further examined by testing the effects of mutations in the TIR on translation and stimulation. The results support a model for translational stimulation in which Com binding induces a conformational change in the mom mRNA, thereby enhancing ribosome binding.			WULCZYN, FG (corresponding author), BERLIN GMBH, INST GENBIOL FORSCH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.							AIBA H, 1981, J BIOL CHEM, V256, P1905; ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BETZ JL, 1976, J MOL BIOL, V105, P293, DOI 10.1016/0022-2836(76)90113-3; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRALLA J, 1974, NATURE, V248, P204, DOI 10.1038/248204a0; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HATTMAN S, 1987, GENE, V55, P345, DOI 10.1016/0378-1119(87)90295-2; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHMANN R, 1985, GENE, V39, P61, DOI 10.1016/0378-1119(85)90108-8; KAHMANN R, 1982, COLD SPRING HARB SYM, V47, P639; LEACH D, 1979, MOL GEN GENET, V172, P179, DOI 10.1007/BF00268280; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MAYFORD M, 1989, EMBO J, V8, P4307, DOI 10.1002/j.1460-2075.1989.tb08617.x; MCMULLIN TW, 1990, MOL CELL BIOL, V10, P4590, DOI 10.1128/MCB.10.9.4590; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; STERN S, 1988, METHOD ENZYMOL, V164, P481; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TOUSSAINT A, 1976, VIROLOGY, V70, P17, DOI 10.1016/0042-6822(76)90232-4; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; WULCZYN FG, 1989, CELL, V57, P1201, DOI 10.1016/0092-8674(89)90057-3; WULCZYN FG, 1987, GENE, V51, P139, DOI 10.1016/0378-1119(87)90302-7; WULCZYN FG, 1990, NATO ASI SERIES H, V49, P285; WYCKOFF E, 1986, GENE, V43, P281, DOI 10.1016/0378-1119(86)90217-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	56	58	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					259	269		10.1016/0092-8674(91)90160-Z	http://dx.doi.org/10.1016/0092-8674(91)90160-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1826635				2022-12-01	WOS:A1991FH09200009
J	ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH				ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH			ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-RENIN; WORK SITE; ALDOSTERONE; ANGIOTENSIN; SECRETION; SYSTEM	Background. To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program. Methods. Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race. Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups. Results. Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile. During 8.3 years of follow-up, there were 27 myocardial infarctions. As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3). The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group. The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers. Conclusions. In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,CTR CARDIOVASC,NEW YORK,NY 10021	Cornell University	ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Sealey, Jean/A-9562-2009	Cohen, Hillel/0000-0002-4524-0898	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; COX DR, 1972, J R STAT SOC B, V34, P187; FREIS ED, 1973, AM J MED, V255, P275; GAVRAS H, 1971, LANCET, V2, P19; GAVRAS H, 1977, ARCH INTERN MED, V137, P155; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; KAPLAN NM, 1976, ANN INTERN MED, V84, P639, DOI 10.7326/0003-4819-84-6-639; KAPLAN NM, 1975, JAMA-J AM MED ASSOC, V231, P167, DOI 10.1001/jama.231.2.167; LARAGH JH, 1972, AM J MED, V52, P633, DOI 10.1016/0002-9343(72)90054-X; LARAGH JH, 1973, AM J MED, V55, P261, DOI 10.1016/0002-9343(73)90128-9; LARAGH JH, 1960, JAMA-J AM MED ASSOC, V174, P293, DOI 10.1001/jama.1960.63030030007014; Laragh JH, 1990, HYPERTENSION PATHOPH, P1329; LEDINGHAM JM, 1990, HYPERTENSION PATHOPH, P33; MEADE TW, 1983, CLIN SCI, V64, P273, DOI 10.1042/cs0640273; MEYER P, 1990, HYPERTENSION PATHOPH, P541; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; SEALEY JE, 1981, CLIN BIOCHEM, V14, P273, DOI 10.1016/S0009-9120(81)91000-6; Sealey JE, 1990, HYPERTENSION PATHOPH, P1443; SHAPIRO R, 1976, J LAB CLIN MED, V88, P222; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; Winternitz M C, 1940, Yale J Biol Med, V12, P623; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, BMJ, V291, P97	30	687	694	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1098	1104		10.1056/NEJM199104183241605	http://dx.doi.org/10.1056/NEJM199104183241605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1759997				2022-12-01	WOS:A1991FG91200005
J	CHEN, JH; SEEMAN, NC				CHEN, JH; SEEMAN, NC			SYNTHESIS FROM DNA OF A MOLECULE WITH THE CONNECTIVITY OF A CUBE	NATURE			English	Article							NUCLEIC-ACID JUNCTIONS; DESIGN	A PRINCIPAL goal of biotechnology is the assembly of novel biomaterials for analytical, industrial and therapeutic purposes. The advent of stable immobile nucleic acid branched junctions 1-4 makes DNA a good candidate for building frameworks to which proteins or other functional molecules can be attached and thereby juxtaposed 5-7. The addition of single-stranded 'sticky' ends 8 to branched DNA molecules converts them into macromolecular valence clusters that can be ligated together 1. The edges of these frameworks are double-helical DNA, and the vertices correspond to the branch points of junctions. Here, we report the construction from DNA of a covalently closed cube-like molecular complex containing twelve equal-length double-helical edges arranged about eight vertices. Each of the six 'faces' of the object is a single-stranded cyclic molecule, doubly catenated to four neighbouring strands, and each vertex is connected by an edge to three others. Each edge contains a unique restriction site for analytical purposes. This is the first construction of a closed polyhedral object from DNA.			CHEN, JH (corresponding author), NYU,DEPT CHEM,NEW YORK,NY 10003, USA.		Chen, Junghuei/B-5217-2011					CARUTHERS MH, 1981, CHEM ENZYMATIC SYNTH, P71; CHEN JH, 1989, J AM CHEM SOC, V111, P6402, DOI 10.1021/ja00198a063; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; HOPFIELD JJ, 1988, SCIENCE, V241, P817, DOI 10.1126/science.241.4867.817; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; ROBINSON BH, 1987, PROTEIN ENG, V1, P295, DOI 10.1093/protein/1.4.295; SEEMAN NC, 1988, J BIOMOL STRUCT DYN, V5, P997, DOI 10.1080/07391102.1988.10506445; SEEMAN NC, 1983, BIOPHYS J, V44, P201, DOI 10.1016/S0006-3495(83)84292-1; SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9; SEEMAN NC, 1990, J BIOMOL STRUCT DYN, V8, P573, DOI 10.1080/07391102.1990.10507829; SEEMAN NC, 1985, J BIOMOL STRUCT DYN, V3, P11, DOI 10.1080/07391102.1985.10508395; WANG JC, 1979, P NATL ACAD SCI USA, V76, P200, DOI 10.1073/pnas.76.1.200; Wells A.F., 1977, 3 DIMENSIONAL NETS P; [No title captured]	15	1024	1090	10	350	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					631	633		10.1038/350631a0	http://dx.doi.org/10.1038/350631a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017259				2022-12-01	WOS:A1991FH11200067
J	HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R				HSIAO, K; MEINER, Z; KAHANA, E; CASS, C; KAHANA, I; AVRAHAMI, D; SCARLATO, G; ABRAMSKY, O; PRUSINER, SB; GABIZON, R			MUTATION OF THE PRION PROTEIN IN LIBYAN JEWS WITH CREUTZFELDT-JAKOB DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERSTMANN-STRAUSSLER SYNDROME; SCRAPIE INCUBATION-TIME; HUNTINGTONS-DISEASE; GENE; POLYMORPHISM; LINKAGE; ANTICIPATION; ISRAEL	Background. Creutzfeldt-Jakob disease is a transmissible neurodegenerative disorder that occurs more than 100 times more frequently among Libyan Jews than in the worldwide population. We examined 11 patients with the disease - 10 Libyan Jews from Israel and 1 Libyan Jews from Italy - to determine whether abnormalities of the prion protein could be detected in them. Abnormal forms of this host-encoded protein are the predominant if not sole components of the transmissible agent that causes the disease. Methods. The prion-protein open-reading frame in peripheral-leukocyte DNA from the Italian patient was amplified with the polymerase chain reaction and sequenced. Allele-specific oligonucleotide hybridization was used to assess a prion-protein codon 200 lysine mutation in the 10 Israeli patients and 37 control subjects. Results. The prion-protein sequence in DNA from the Italian patient revealed a single nucleotide change (G --> A) at the first position of codon 200 that resulted in a substitution of lysine for glutamate. This substitution was detected in all 10 Israeli patients, 8 of whom had a positive family history of Creutzfeldt-Jakob disease. One patient was homozygous for the lysine mutation, and her clinical course did not differ from that of the patients heterozygous for the mutation. The lysine mutation was not found in one Moroccan Jew from Israel with Creutzfeldt-Jakob disease. Conclusions. The codon 200 lysine mutation of the prion-protein gene is consistently present among Libyan Jews with Creutzfeldt-Jakob disease, strongly supporting a genetic pathogenesis of their illness. The similarity of the clinical courses of the patient homozygous for this mutation and the patients heterozygous for it argues that familial Creutzfeldt-Jakob disease is a true dominant disorder.	HADASSAH UNIV HOSP,DEPT NEUROL,EIN KAREM,IL-91120 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,ASHQELON,ISRAEL; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; BARZILAI GOVT HOSP,ASHQELON,ISRAEL; UNIV MILAN,OSPED MAGGIORE POLICLIN,IST CLIN NEUROL,I-20122 MILAN,ITALY	Hebrew University of Jerusalem; Ben Gurion University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ben Gurion University; Barzilai Medical Center; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Cass, Carol E/F-5861-2010	Kahana, Esther/0000-0002-3863-3271	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014069, P50NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008967, P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG-08967, AG-02132] Funding Source: Medline; NINDS NIH HHS [NS-14069] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPERS M, 1970, AM J TROP MED HYG, V19, P133, DOI 10.4269/ajtmh.1970.19.133; ALTER M, 1974, SCIENCE, V186, P848; ALTER M, 1976, SCIENCE, V192, P428, DOI 10.1126/science.192.4238.428-b; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BOCKMAN JM, 1985, NEW ENGL J MED, V312, P73, DOI 10.1056/NEJM198501103120202; BOCKMAN JM, 1987, ANN NEUROL, V21, P589, DOI 10.1002/ana.410210611; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DICKINSON AG, 1969, GENET RES, V13, P213, DOI 10.1017/S0016672300002895; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; Gajdusek D C, 1972, J Clin Pathol Suppl (R Coll Pathol), V6, P78, DOI 10.1136/jcp.25.Suppl_6.78; GOLDBERG H, 1979, SLOW TRANSMISSIBLE D, V1, P195; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; HERZBERG L, 1974, SCIENCE, V186, P848, DOI 10.1126/science.186.4166.848; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; HSIAO K, 1989, ANN NEUROL, V26, P137; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, IN PRESS NEUROLOGY; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; KAHANA E, 1974, SCIENCE, V183, P90, DOI 10.1126/science.183.4120.90; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASTERS CL, 1979, SLOW TRANSMISSIBLE D, V1, P143; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1989, LANCET, V1, P51; PARRY HB, 1983, SCRAPIE DIS SHEEP, P31; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P42, DOI 10.1159/000110134; RIDLEY RM, 1988, J MED GENET, V25, P589, DOI 10.1136/jmg.25.9.589; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WILESMITH JW, 1988, VET REC, V123, P638	40	237	239	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1091	1097		10.1056/NEJM199104183241604	http://dx.doi.org/10.1056/NEJM199104183241604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008182				2022-12-01	WOS:A1991FG91200004
J	LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN				LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN			EXPRESSION OF BLOOD-GROUP ANTIGEN-A - A FAVORABLE PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-BLADDER; CARCINOMA; ABH; GLYCOSYLATION; ANTIBODIES; RECEPTOR; TUMORS	Background. New prognostic factors are needed to guide the treatment of patients with non-small-cell lung cancer. We evaluated the prognostic value of altered expression of ABH blood-group antigens, which has been implicated in the multistep process of carcinogenesis and tumor progression. Methods. The presence of blood-group antigens was assessed immunohistochemically in paraffin-embedded tumor samples from 164 patients who underwent curative surgery for non-small-cell lung cancer from 1980 through 1982. Monoclonal antibodies were used to detect the A and B antigens, and Ulex europaeus agglutinin I to detect H antigen. Results. Survival of the 28 patients with blood type A or AB who had primary tumors negative for blood-group antigen A was significantly shorter than that of the 43 patients with antigen A-positive tumors (P < 0.001) and of the 93 patients with blood type B or O (P =0.002). The respective median survival times were 15, 71, and 39 months. Disease progressed significantly earlier in the 28 patients with tumors negative for blood-group antigen A than in the antigen A-positive patients (P < 0.001). Expression of blood-group antigen B or H in tumor cells did not correlate with survival. Cox proportional-hazards regression analysis showed that expression of blood-group antigen A in tumor cells added significantly to the prediction of overall survival provided by other known prognostic factors among the patients with blood type A or AB (P = 0.004). Conclusions. Expression of blood-group antigen A in tumor cells is an important favorable prognostic factor in patients with non-small-cell lung cancer. This variable needs to be considered in the design of future trials of therapy.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC SURG, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LEE, JS (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED ONCOL, BOX 80, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA045746] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11672, CA-45746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; BLACK MM, 1956, AM J CLIN PATHOL, V26, P250; CAREY TE, 1987, OTOLARYNG HEAD NECK, V96, P221, DOI 10.1177/019459988709600301; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DABELSTEEN E, 1988, APMIS, V96, P813, DOI 10.1111/j.1699-0463.1988.tb00948.x; DABELSTEEN E, 1974, ACTA PATH MICRO IM A, VA 82, P431; DAVIDSOHN I, 1973, ARCH PATHOL, V95, P132; DAVIDSOHN I, 1972, AM J CLIN PATHOL, V57, P715; DAVIDSOHN I, 1969, AM J PATHOL, V57, P307; FINKELSTEIN DM, 1986, J CLIN ONCOL, V4, P702, DOI 10.1200/JCO.1986.4.5.702; FUJIOKA T, 1986, UROL INT, V41, P397, DOI 10.1159/000281242; GIBLETT ER, 1983, HEMATOLOGY, P1491; GOOI HC, 1985, BIOSCIENCE REP, V5, P83; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HIROHASHI S, 1984, J NATL CANCER I, V72, P1299; HONG WK, 1989, P AN M AM SOC CLIN, V8, P167; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; JUHL BR, 1986, CANCER, V58, P1184; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; LEE JS, 1989, P AN M AM SOC CLIN, V8, P226; LIMAS C, 1979, CANCER, V44, P2099, DOI 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO;2-I; MACKENZIE IC, 1977, ACTA PATH MICRO IM A, V85, P49; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NARUKE, 1989, J THORAC CARDIOV SUR, V97, P350; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; ORNTOFT TF, 1987, CANCER, V60, P2641, DOI 10.1002/1097-0142(19871201)60:11<2641::AID-CNCR2820601112>3.0.CO;2-5; SCHOENTAG R, 1984, CANCER, V53, P503, DOI 10.1002/1097-0142(19840201)53:3<503::AID-CNCR2820530323>3.0.CO;2-J; Snedecor G.W., 1980, STAT METHODS, V7; SUMMERS JL, 1983, CANCER RES, V43, P934; YARDEN Y, 1985, J BIOL CHEM, V260, P315	34	205	215	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1084	1090		10.1056/NEJM199104183241603	http://dx.doi.org/10.1056/NEJM199104183241603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1848917				2022-12-01	WOS:A1991FG91200003
J	LEVINSKY, NG; RETTIG, RA				LEVINSKY, NG; RETTIG, RA			THE MEDICARE END-STAGE RENAL-DISEASE PROGRAM - A REPORT FROM THE INSTITUTE-OF-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NATL ACAD SCI,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	LEVINSKY, NG (corresponding author), BOSTON UNIV,MED CTR,BOSTON,MA 02118, USA.							EVANS RW, 1981, JAMA-J AM MED ASSOC, V245, P487, DOI 10.1001/jama.245.5.487; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GARCIA JR, 1990, STAFFING DIALYSIS UN; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, PRICE DIALYSIS HOSPI; HELD PJ, 1990, MORTALITY PRICE DIAL; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; Lohr KN, 1990, MEDICARE STRATEGY QU, V2; RENNIE D, 1981, NEW ENGL J MED, V304, P351, DOI 10.1056/NEJM198102053040609; RETTIG RA, IN PRESS KIDNEY FAIL; 1990, 1990 NAT I DIAB DIG; 1990, UNITED NETWORK ORGAN; 1990, HLTH CARE FINANCING; 1990, DISTRIBUTION ORGANS	14	63	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1143	1148		10.1056/NEJM199104183241628	http://dx.doi.org/10.1056/NEJM199104183241628			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	2008193	Bronze			2022-12-01	WOS:A1991FG91200027
J	ORMEROD, W				ORMEROD, W			SCIENCE AND SECRECY	NATURE			English	Editorial Material											ORMEROD, W (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							MOLLOY JO, 1971, J PROTOZOOL, V18, P157, DOI 10.1111/j.1550-7408.1971.tb03298.x	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					551	552		10.1038/350551a0	http://dx.doi.org/10.1038/350551a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017252				2022-12-01	WOS:A1991FH11200024
J	PYLE, AM; CECH, TR				PYLE, AM; CECH, TR			RIBOZYME RECOGNITION OF RNA BY TERTIARY INTERACTIONS WITH SPECIFIC RIBOSE 2'-OH GROUPS	NATURE			English	Article							TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; KINETICS; BINDING; TEMPERATURE; SUBSTRATE; SELECTION	SHORTENED forms of the group I intron from Tetrahymena catalyse sequence-specific cleavage of exogenous oligonucleotide substrates 1, 2. The association between RNA enzyme (ribozyme) and substrate is mediated by pairing between an internal guide sequence on the ribozyme and a complementary sequence on the substrate 1, 3, 4. RNA substrates and cleavage products associate with a binding energy greater than that of base-pairing by approximately 4 kcal-mol-1 (at 42-degrees-C), whereas DNA associates with an energy around that expected for base-pairing 5-9. It has been proposed that the difference in binding affinity is due to specific 2'-OH groups on an RNA substrate forming stabilizing tertiary interactions with the core of the ribozxyme, or that the RNA.RNA helix formed upon association of an RNA substrate and the ribozyme might be more stable than an RNA.DNA helix of the same sequence 6. To differentiate between these two models, chimaeric oligonucleotides containing deoxynucleotide residues at successive positions along the chain were synthesized, and their equilibrium binding constants for association with the ribozyme were measured directly by a new gel electrophoresis technique 5. We report here that most of the extra binding energy can be accounted for by discrete RNA-ribozyme interactions, the 2'-OH group on the sugar residue three nucleotides from the cleavage site contributing the most interaction energy. Thus, in addition to the well documented binding of RNA to RNA by base-pairing 10-14, 2'-OH groups within a duplex can also mediate association between RNA molecules.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEEN MD, 1987, CELL, V50, P951, DOI 10.1016/0092-8674(87)90522-8; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DAHM SC, 1990, BIOCHIMIE, V72, P819, DOI 10.1016/0300-9084(90)90191-I; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DIX DB, 1986, J BIOL CHEM, V261, P112; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NELSON JW, 1982, BIOCHEMISTRY-US, V21, P5289, DOI 10.1021/bi00264a026; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TURNER DH, 1987, J AM CHEM SOC, V109, P3783, DOI 10.1021/ja00246a047; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WU T, 1989, NUCLEIC ACIDS RES, V9, P3501; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	31	184	189	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					628	631		10.1038/350628a0	http://dx.doi.org/10.1038/350628a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1708111				2022-12-01	WOS:A1991FH11200066
J	REGNIER, FE				REGNIER, FE			PERFUSION CHROMATOGRAPHY	NATURE			English	Article							LIQUID-CHROMATOGRAPHY; PROTEINS	Perfusion chromatography is a technique based on fluid dynamics for reducing stagnant mobile phase mass transfer in liquid chromatography. This is achieved by using supports with large pores that allow mobile phase to flow through particles.			REGNIER, FE (corresponding author), PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907, USA.							AFEYAN N, 1991, IN PRESS J CHROMATOG; AFEYAN N, 1989, 595661 US PAT APPL; AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; DONE JN, 1972, J CHROMATOGR SCI, V10, P606, DOI 10.1093/chromsci/10.10.606; Giddings J.C., 1965, DYNAMICS CHROMATOGRA; HORVATH C, 1976, J CHROMATOGR, V126, P401, DOI 10.1016/S0021-9673(01)84088-7; PEARSON JD, 1984, HIGH PERFORMANCE LIQ; REGNIER FE, 1987, CHROMATOGRAPHIA, V24, P241, DOI 10.1007/BF02688486; REGNIER FE, 1991, CHROMATOGRAPHY, pCH14; SNYDER LR, 1969, J CHROMATOGR SCI, V7, P352, DOI 10.1093/chromsci/7.6.352; THEVENON G, 1989, J CHROMATOGR, V476, P499, DOI 10.1016/S0021-9673(01)93894-4; TWEETEN KA, 1986, J CHROMATOGR, V359, P111, DOI 10.1016/0021-9673(86)80066-8; YANG Y, 1990, 469956 US PAT APPL	13	137	141	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					634	635		10.1038/350634a0	http://dx.doi.org/10.1038/350634a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017260				2022-12-01	WOS:A1991FH11200068
J	RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A				RIVIERE, Y; BLANK, V; KOURILSKY, P; ISRAEL, A			PROCESSING OF THE PRECURSOR OF NF-KAPPA-B BY THE HIV-1 PROTEASE DURING ACUTE INFECTION	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; BINDING; EXPRESSION	TRANSCRIPTION of the human immunodeficiency virus type-1 (HIV-1) genome is regulated in part by cellular factors and is stimulated by activation of latently infected T cells. T-cell activation also correlates with the induction of the factor NF-kappa-B which binds to two adjacent sites in the HIV-1 long terminal repeat 1. This factor consists of two DNA-binding subunits of relative molecular mass 50,000 (50K) associated with two 65K subunits. It is located in the nucleus in mature B cells, but is present in other cell types as an inactive cytoplasmic complex 2, 3. External stimuli, including those that activate T cells, result in nuclear translocation of active NF-kappa-B. The cloning of the complementary DNA for the 50K subunit 4,5 helped to identify an exclusively cytoplasmic 105K precursor (p105) (V.B., P.K. and A.I., manuscript submitted). The expression of active NF-kappa-B might therefore also be regulated by the extent of processing of p105. Because HIV-1 requires active NF-kappa-B for efficient transcription 1, we tested the effect of HIV-1 infection on the processing of the human 105K precursor. We show here that the HIV-1 protease can process p105 and increases levels of active nuclear NF-kappa-B complex.	INST PASTEUR,UNITE BIOL MOLEC GENE,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE VIROL & IMMUNOL CELLULAIRE,CNRS,URA 1157,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, GENE DEV, V3, P1689; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hirel PH, 1990, ANTIVIR CHEM CHEMOTH, V1, P9, DOI 10.1177/095632029000100103; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; LAURENT AG, 1989, J VIROL, V63, P4074, DOI 10.1128/JVI.63.9.4074-4078.1989; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; SKALKA AM, 1989, CELL, V56, P911, DOI 10.1016/0092-8674(89)90621-1; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	13	165	167	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					625	626		10.1038/350625a0	http://dx.doi.org/10.1038/350625a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017258				2022-12-01	WOS:A1991FH11200064
J	SILVER, ML; PARKER, KC; WILEY, DC				SILVER, ML; PARKER, KC; WILEY, DC			RECONSTITUTION BY MHC-RESTRICTED PEPTIDES OF HLA-A2 HEAVY-CHAIN WITH BETA-2-MICROGLOBULIN, INVITRO	NATURE			English	Article							TOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGENS; ASSOCIATION; MOLECULES; EPITOPES; BINDING	CYTOTOXIC T lymphocytes kill virally infected cells when they detect antigenic fragments presented by class I major histocompatibility complex (MHC) antigens (HLA in humans). The crystal structures of HLA-A2 and HLA-Aw68 reveal that peptide-antigen forms an integral part of the HLA structure, being retained in a prominent groove even after purification and crystallization 1-3. Here we report that the heavy chain and beta-2-microglobulin of HLA-A2, after separation and fractionation in denaturants, reassemble efficiently under renaturing conditions only in the presence of MHC-restricted 4 peptides. A complex of heavy chain, beta-2-microglobulin, and viral peptide in the ratio 1:1:1 is formed in up to 46% yield. Reconstitution is not stimulated by either of two peptides not restricted to HLA-A2. The reconstituted complex of HLA-A2 and the influenza virus (B/Lee/40) nucleoprotein peptide, Np (85-94), crystallizes under conditions previously used to crystallize HLA-A2 (ref. 5). Peptide-linked folding and assembly suggests mechanisms for the unusual capacity of HLA to bind many peptides of diverse sequence.	HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University				Parker, Kenneth/0000-0002-6282-2478				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BOUILLOT M, 1989, NATURE, V339, P473, DOI 10.1038/339473a0; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BUSHKIN Y, 1984, MOL IMMUNOL, V21, P821, DOI 10.1016/0161-5890(84)90135-4; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CARRENO BM, 1990, P NATL ACAD SCI USA, V87, P3420, DOI 10.1073/pnas.87.9.3420; CHEN BP, 1990, J EXP MED, V172, P931, DOI 10.1084/jem.172.3.931; CHEN BP, 1989, NATURE, V337, P743, DOI 10.1038/337743a0; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FRELINGER JA, 1990, J EXP MED, V172, P827, DOI 10.1084/jem.172.3.827; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOTCH FM, 1987, NATURE, V326, P882; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; PARHAM P, 1978, NATURE, V276, P397, DOI 10.1038/276397a0; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; SAPER MA, IN PRESS J MOL BIOL; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TURNER MJ, 1975, J BIOL CHEM, V250, P4512; ZINKERNAGEL RM, 1974, NATURE, V251, P548	24	110	117	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					619	622		10.1038/350619a0	http://dx.doi.org/10.1038/350619a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	2017257				2022-12-01	WOS:A1991FH11200062
J	STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR				STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR			SOMATOTROPH HYPOPLASIA AND DWARFISM IN TRANSGENIC MICE EXPRESSING A NON-PHOSPHORYLATABLE CREB MUTANT	NATURE			English	Article							HORMONE-RELEASING FACTOR; NUCLEAR FACTOR CREB; SOMATOSTATIN GENE; PITUITARY; TRANSCRIPTION; HYPERPLASIA; BINDING; PROTEIN; CELLS	MOST of the transcriptional effects of cyclic AMP are mediated by the cAMP response element binding protein (CREB) 1, 2. After activation of cAMP-dependent protein kinase A, the catalytic subunits of this enzyme apparently mediate the phosphorylation and activation of CREB 3, 4. As cAMP serves as a mitogenic signal for anterior pituitary somatotrophic cells 5, we investigated whether CREB similarly regulates proliferation of these cells. We prepared transgenic mice expressing a transcriptionally inactive mutant of CREB (CREBM1), which cannot be phosphorylated, in cells of the anterior pituitary. If CREB activity is required for proliferation, the overexpressed mutant protein would effectively compete with wild-type CREB activity and thereby block the response to cAMP. As predicted, the CREBM1 transgenic mice exhibited a dwarf phenotype with atrophied pituitary glands markedly deficient in somatotroph but not other cell types. We conclude that transcriptional activation of CREB is necessary for the normal development of a highly restricted cell type, and that environmental cues, possibly provided by the hypothalamic growth hormone-releasing factor, are necessary for population of the pituitary by somatotrophic cells.	UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOMED SCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037	University of California System; University of California San Diego; Salk Institute	STRUTHERS, RS (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BILLESTRUP N, 1987, MOL ENDOCRINOL, V1, P300, DOI 10.1210/mend-1-4-300; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORELLI E, 1989, NATURE, V339, P593; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; 1986, MANIPULATING MOUSE E	21	266	268	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					622	624		10.1038/350622a0	http://dx.doi.org/10.1038/350622a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1826763				2022-12-01	WOS:A1991FH11200063
J	BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL				BURCHFIELD, DJ; LUCAS, VW; ABRAMS, RM; MILLER, RL; DEVANE, CL			DISPOSITION AND PHARMACODYNAMICS OF METHAMPHETAMINE IN PREGNANT SHEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-FLOW; AMPHETAMINE; HEMORRHAGE; COCAINE; HYPERTENSION; PERFORMANCE; ABUSE	To determine the placental transfer of methamphetamine, its subsequent fetal disposition, and its hemodynamic effects, we administered methamphetamine intravenously to 15 pregnant ewes 3 days after placement of maternal and fetal vascular catheters. Methamphetamine crossed the placenta within 30 seconds of its administration. Although the ewes had higher peak concentrations, the fetuses' longer elimination half-life ultimately led to higher fetal than maternal methamphetamine concentrations. The ratio of fetal tissue to plasma drug concentration 2 hours after administration was highest in the lung, followed by the placenta, kidney, intestine, liver, brain, and heart. Methamphetamine caused a 54% to 63% rise in maternal blood pressure, a 20% to 37% increase in fetal blood pressure, and a drop in fetal oxyhemoglobin saturation and arterial pH. We conclude that methamphetamine, in doses at or below what is commonly abused, has effects that could be detrimental to the health of the mother and her fetus.	UNIV FLORIDA, DEPT OBSTET & GYNECOL, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PHARM PRACTICE, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, DEPT PSYCHIAT, GAINESVILLE, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	BURCHFIELD, DJ (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT PEDIAT, DIV NEONATOL, BOX J-296, GAINESVILLE, FL 32610 USA.		DeVane, Lindsay/B-6645-2012		NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005170] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05170] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Abrams R M, 1985, Alcohol Drug Res, V6, P361; ANGGARD E, 1970, EUR J CLIN PHARMACOL, V3, P3, DOI 10.1007/BF00560284; BECKETT AH, 1965, J PHARM PHARMACOL, VS 17, pS109, DOI 10.1111/j.2042-7158.1965.tb07757.x; BOST RO, 1989, J ANAL TOXICOL, V13, P300, DOI 10.1093/jat/13.5.300; BRINKMAN CR, 1984, MATERNAL FETAL MED P, P679; BROWNE JCM, 1953, J OBSTET GYN BRIT EM, V60, P141; BURCHFIELD DJ, 1987, PEDIATR RES, V21, pA256, DOI 10.1203/00006450-198704010-00532; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHYNN KY, 1975, JAMA-J AM MED ASSOC, V233, P55; FARRELL BM, 1983, J CHROMATOGR, V272, P111, DOI 10.1016/S0378-4347(00)86108-3; GARRIOTT J C, 1973, Journal of Forensic Sciences, V18, P434; GOODMAN SJ, 1970, J AMER MED ASSOC, V212, P480, DOI 10.1001/jama.1970.03170160068021; HALL JN, 1988, TRENDS PATTERNS METH; KANE FJ, 1969, J AMER MED ASSOC, V210, P556, DOI 10.1001/jama.1969.03160290108032; Lees M M, 1967, J Obstet Gynaecol Br Commonw, V74, P319; LITTLE BB, 1988, OBSTET GYNECOL, V72, P541; MAYER SE, 1980, PHARMACOL BASIS THER, P56; METCALFE J, 1974, Progress in Cardiovascular Diseases, V16, P363, DOI 10.1016/0033-0620(74)90028-0; NAEYE RL, 1979, AM J OBSTET GYNECOL, V133, P8, DOI 10.1016/0002-9378(79)90402-2; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; PASTERNAK JF, 1983, NEUROLOGY, V33, P559; PIPKIN FB, 1985, PHYSL DEV FETUS NEWB, P699; REYNOLDS ML, 1979, EARLY HUM DEV, V3, P163, DOI 10.1016/0378-3782(79)90005-7; RUBLER S, 1977, AM J CARDIOL, V40, P534, DOI 10.1016/0002-9149(77)90068-6; SZETO HH, 1982, ANNU REV PHARMACOL, V22, P221, DOI 10.1146/annurev.pa.22.040182.001253; TALLEDO OD, 1968, AM J OBSTET GYNECOL, V100, P218, DOI 10.1016/S0002-9378(15)33724-8; WEINER N, 1980, PHARMACOL BASIS THER, P138; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; ZUSPAN FP, 1964, AM J OBSTET GYNECOL, V90, P88; 1990, NIDA CAPSULES, P1	30	61	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1968	1973		10.1001/jama.265.15.1968	http://dx.doi.org/10.1001/jama.265.15.1968			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008026				2022-12-01	WOS:A1991FF76800022
J	HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH				HUNT, RC; BRYAN, DM; BRINKLEY, VS; WHITLEY, TW; BENSON, NH			INABILITY TO ASSESS BREATH SOUNDS DURING AIR MEDICAL TRANSPORT BY HELICOPTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								This study assessed the capabilities of a traditional and an amplified stethoscope used by flight nurses to assess breath sounds during air medical transport in an MBB BO-105 helicopter. We developed a normal breath sound model using a prerecorded tape of breath sounds interspersed with segments without breath sounds; the recorder had been placed in the chest wall of a resuscitation training manikin. Flight nurses completed control listening sessions in a quiet environment and experimental sessions during flight using a traditional stethoscope for half of the sessions and an amplified stethoscope for the remaining half. In the quiet environment, flight nurses accurately reported the presence or absence of breath sounds in 110 (92%) of 120 trials. During helicopter flight, none of the flight nurses heard breath sounds during any of the recorded segments with either the traditional stethoscope or the amplified stethoscope. We conclude that flight nurses are unable to hear normal breath sounds using a traditional or amplified stethoscope during flight in a medically configured MBB BO-105 helicopter. Improved stethoscopes, innovative methods of listening, and reduction of aircraft noise are potential solutions to the problems of breath sound assessment during air medical transport.	PITT CTY MEM HOSP,EASTCARE EMERGENCY AIR MED SERV,GREENVILLE,NC		HUNT, RC (corresponding author), E CAROLINA UNIV,SCH MED,DEPT EMERGENCY MED,MOYE BLVD,GREENVILLE,NC 27858, USA.							BISHOP LC, 1990, JAMA-J AM MED ASSOC, V263, P233, DOI 10.1001/jama.1990.03440020067017; COLLETT HM, 1990, J AIR MED TRANSP JUL, P20; DICK T, 1986, JEMS, V11, P77; GASAWAY DC, 1986, AVIAT SPACE ENVIR MD, V57, P103; HARMS T, 1990, J AIR MED TRANSP OCT, P76; HUNT RC, 1990, 1990 ROCK MOUNT C EM; PASIC TB, 1985, ARCH OTOLARYNGOL, V111, P507; WILKINS RL, 1988, LUNG SOUNDS PRACTICA; 1990, J AIR MED TRANSP MAR, P6	9	46	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1982	1984		10.1001/jama.265.15.1982	http://dx.doi.org/10.1001/jama.265.15.1982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008028				2022-12-01	WOS:A1991FF76800025
J	KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S				KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S			HEPATITIS-B AND HEPATITIS-C VIRUSES AND THEIR INTERACTION IN THE ORIGIN OF HEPATOCELLULAR-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC NON-A; ANTIBODIES; PREVALENCE; SMOKING	Serum taken from patients in a case-control study in Athens, Greece, was used to examine the interactive roles of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the origin of hepatocellular carcinoma (HCC). An enzyme immunoassay for anti-HCV was used to test serum taken from 185 cases with HCC, 35 cases with metastatic liver cancer (MLC), and 432 hospital controls. Weakly positive anti-HCV results were more strongly related to MLC than to HCC, implying that these anti-HCV results are false positive. By contrast, strongly positive anti-HCV results were significantly related to HCC (relative risk [RR], 6.3), whereas no significant association was evident for MLC (RR, 0.6). The association of anti-HCV with HCC was substantially higher among subjects whose radioimmunoassay was positive for hepatitis B surface antigen (RR, 20.0) than among those whose radioimmunoassay was negative for this marker (RR, 4.8). These findings indicate that HCV infection has an interactive role in the origin of HCC.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; IPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE	Harvard University; Harvard T.H. Chan School of Public Health; Athens Medical School; National & Kapodistrian University of Athens								ALTER H, 1989, 1ST P INT S HEP C VI, P25; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; GRAY JJ, 1990, LANCET, V335, P609, DOI 10.1016/0140-6736(90)90398-O; GRAY JJ, 1989, SERODIAG IMMUN INF D, V3, P389, DOI 10.1016/0888-0786(89)90057-7; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MORGANCAPNER P, 1988, LANCET, V1, P1397; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PURCELL RH, 1989, CANCER DETECT PREV, V14, P203; SIMONETTI RG, 1989, LANCET, V2, P1338; TRICHOPOULOS D, 1987, INT J CANCER, V39, P45, DOI 10.1002/ijc.2910390109; TRICHOPOULOS D, 1978, LANCET, V2, P1217; WREGHITT TG, 1990, LANCET, P789; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; 1988, IARC SCI PUBL, V44, P207	24	201	201	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1974	1976		10.1001/jama.265.15.1974	http://dx.doi.org/10.1001/jama.265.15.1974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1848908				2022-12-01	WOS:A1991FF76800023
J	STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF				STREISSGUTH, AP; AASE, JM; CLARREN, SK; RANDELS, SP; LADUE, RA; SMITH, DF			FETAL ALCOHOL SYNDROME IN ADOLESCENTS AND ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL ALCOHOL; FOLLOW-UP; EXPOSURE; INFANCY	Fetal alcohol syndrome is a specific recognizable pattern of malformation. Manifestations in 61 adolescents and adults suffering from alcohol teratogenesis are presented. After puberty, the faces of patients with fetal alcohol syndrome or fetal alcohol effects were not as distinctive. Patients tended to remain short and microcephalic, although their weight was somewhat closer to the mean. The average IQ was 68, but the range of IQ scores widely varied. Average academic functioning was at the second- to fourth-grade levels, with arithmetic deficits most characteristic. Maladaptive behaviors such as poor judgment, distractibility, and difficulty perceiving social cues were common. Family environments were remarkably unstable. Fetal alcohol syndrome is not just a childhood disorder; there is a predictable long-term progression of the disorder into adulthood, in which maladaptive behaviors present the greatest challenge to management.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, CTR CHILD DEV MENTAL RETARDAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, INST ALCOHOLISM & DRUG ABUSE, SEATTLE, WA 98195 USA; UNIV VANCOUVER, DEPT PEDIAT, VANCOUVER, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	STREISSGUTH, AP (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI, GG-20, 2707 NE BLAKELEY, SEATTLE, WA 98195 USA.				NIAAA NIH HHS [AA01455] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA001455, R37AA001455] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aase JM, 1990, DIAGNOSTIC DYSMORPHO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; CLARREN SK, 1990, ALCOHOL CLIN EXP RES, V14, P674, DOI 10.1111/j.1530-0277.1990.tb01226.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1063, DOI 10.1056/NEJM197805112981906; DEHAENE P, 1977, REV ALCOOL, V23, P145; Dorris Michael, 1989, BROKEN CORD; DRISCOLL CD, 1990, NEUROTOXICOL TERATOL, V12, P231, DOI 10.1016/0892-0362(90)90094-S; GRAY J K, 1990, Alcoholism Clinical and Experimental Research, V14, P294; Grossman H. J., 1983, CLASSIFICATION MENTA; HALL JG, 1989, HDB NORMAL PHYSICAL; HANSON JW, 1978, J PEDIATR-US, V92, P457, DOI 10.1016/S0022-3476(78)80449-1; HARRIS JC, 1988, YOUNG PERSON DOWN SY, P35; IOSUB S, 1981, ALCOHOL CLIN EXP RES, V5, P523; JASTAK S, 1984, MANUAL WIDE RANGE AC; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; Lemoine P., 1968, OUEST MED THER DRUG, P476; LITTLE BB, 1990, AM J DIS CHILD, V144, P1142, DOI 10.1001/archpedi.1990.02150340088030; MAJEWSKI F, 1988, INT CONGR SER, V805, P837; MAY PA, 1983, SOC BIOL, V30, P374; RILEY EP, 1990, ALCOHOL CLIN EXP RES, V14, P670, DOI 10.1111/j.1530-0277.1990.tb01225.x; ROBINSON GC, 1987, CAN MED ASSOC J, V137, P203; SAMPSON PD, 1989, NEUROTOXICOL TERATOL, V11, P477, DOI 10.1016/0892-0362(89)90025-1; SAVAGE DD, 1989, ALCOHOL CLIN EXP RES, V13, P588, DOI 10.1111/j.1530-0277.1989.tb00382.x; Smith, 1982, RECOGNIZABLE PATTERN; SPARROW SS, 1984, MANUAL VINELAND; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1984, J AM ACAD CHILD PSY, V23, P465, DOI 10.1016/S0002-7138(09)60326-5; STREISSGUTH AP, 1989, NEUROTOXICOL TERATOL, V11, P493, DOI 10.1016/0892-0362(89)90026-3; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1978, ALCOHOL CLIN EXP RES, V2, P165, DOI 10.1111/j.1530-0277.1978.tb04717.x; STREISSGUTH AP, 1990, ALCOHOL CLIN EXP RES, V14, P662, DOI 10.1111/j.1530-0277.1990.tb01224.x; STREISSGUTH AP, 1989, ANN NY ACAD SCI, V562, P145, DOI 10.1111/j.1749-6632.1989.tb21013.x; Wechsler D, 1981, ADULT INTELLIGENCE S; Wechsler D, 1974, WECHSLER ADULT INTEL; WEST JR, 1986, ALCOHOL BRAIN DEV; 1976, MONTHLY VITAL STATIS, V25; 1981, FDA DRUG B, V2, P10	39	574	577	2	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1961	1967		10.1001/jama.265.15.1961	http://dx.doi.org/10.1001/jama.265.15.1961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	2008025				2022-12-01	WOS:A1991FF76800021
J	KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH				KORENMAN, J; BAKER, B; WAGGONER, J; EVERHART, JE; DIBISCEGLIE, AM; HOOFNAGLE, JH			LONG-TERM REMISSION OF CHRONIC HEPATITIS-B AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							VIRUS-INFECTION; CONTROLLED TRIAL; E-ANTIGEN; HOMOSEXUAL MEN; HBSAG; ANTIBODY; FOLLOW	Objective: To evaluate whether remissions of chronic hepatitis B induced by alpha-interferon therapy are of long duration. Design: Cohort study. Setting: Clinical Center of the National Institutes of Health, a tertiary referral center. Patients: Sixty-four patients with chronic hepatitis B were treated with alpha-interferon between 1984 and 1986. Main Outcome Measures: Patients were followed with frequent examinations and determinations of serum liver biochemical tests and hepatitis B virus (HBV) markers including hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA using blot hybridization and polymerase chain reaction. Results: Among 64 patients with chronic hepatitis B who were treated with alpha-interferon, 23 (36%) responded to treatment with loss of HBeAg and improvement in serum aminotransferases. All 23 have been followed for 3 to 7 years (mean, 4.3 years). During follow-up, 3 of 23 patients relapsed, with reappearance of HBeAg and abnormal serum aminotransferases, all within 1 year of therapy. The remaining 20 patients continued to have no detectable HBeAg or HBV DNA (using blot hybridization) in serum and to be asymptomatic for liver disease, although 3 had minimal elevations in serum aminotransferases. Thirteen patients (65%) became negative for HBsAg between 0.2 and 6 years (mean, 3 years) after loss of HBeAg. Although no patient had HBV DNA that was detectable by blot hybridization, the 7 patients who remained HBsAg positive all had HBV DNA in serum detected by polymerase chain reaction, but only 2 of 13 HBsAg-negative patients had viral genome using this method. Testing sequential samples indicated that HBV DNA detected by polymerase chain reaction usually disappeared at or around the time that test results for HBsAg became negative. Conclusions: Remissions in chronic hepatitis B induced by alpha-interferon are of long duration and are followed, in most patients, by the loss of HBsAg and all evidence of residual virus replication.	NIDDKD, DIV DIGEST DIS & NUTR,BLDG 31,ROOM 9A23, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALEXANDER GJM, 1987, LANCET, V2, P66; BROOK MG, 1989, GUT, V30, P1116, DOI 10.1136/gut.30.8.1116; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARMAN WF, 1989, LANCET, V2, P588; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DOOLEY JS, 1986, GASTROENTEROLOGY, V90, P150, DOI 10.1016/0016-5085(86)90087-9; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989; KASSIANIDES C, 1988, VIRAL HEPATITIS LIVE, P840; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; MOESTRUP T, 1986, BRIT MED J, V292, P854, DOI 10.1136/bmj.292.6524.854; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; SAMPLINER RE, 1979, AM J MED SCI, V277, P17, DOI 10.1097/00000441-197901000-00002; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; Ticehurst JR, 1989, DIAGNOSTIC PROCEDURE, P957	22	359	360	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					629	634		10.7326/0003-4819-114-8-629	http://dx.doi.org/10.7326/0003-4819-114-8-629			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003708				2022-12-01	WOS:A1991FG03100003
J	STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR				STECKELBERG, JM; MURPHY, JG; BALLARD, D; BAILEY, K; TAJIK, AJ; TALIERCIO, CP; GIULIANI, ER; WILSON, WR			EMBOLI IN INFECTIVE ENDOCARDITIS - THE PROGNOSTIC VALUE OF ECHOCARDIOGRAPHY	ANNALS OF INTERNAL MEDICINE			English	Article							DIMENSIONAL ECHOCARDIOGRAPHY; BACTERIAL-ENDOCARDITIS; VALVE-REPLACEMENT; VEGETATION SIZE	Objective: To determine whether vegetations visualized on two-dimensional echocardiography are an independent risk factor for the development of subsequent emboli in patients with infective endocarditis and to assess the timing of emboli relative to the initiation of antimicrobial therapy. Design: Investigator-blinded, retrospective incidence cohort study. Setting: Tertiary referral center. Patients: Patients with left-sided native valve infective endocarditis who had two-dimensional echocardiography within 72 hours of beginning antimicrobial therapy. Measurements and Main Results: The crude incidence rate of first embolic events in patients receiving antimicrobial therapy was 6.2 per 1000 patient-days (95% CI, 4.2 to 9.2). The rates in patients with and without vegetations were 7.1 and 4.9 per 1000 patient-days, respectively (incidence rate ratio, 1.4; 95% CI, 0.6 to 3.3). The relation between vegetations and risk for emboli was microorganism-dependent: Stratified incidence rate ratios were 6.9 (95% CI, 1.1 to 42.5; P < 0.05) and 1.0 (95% CI, 0.2 to 3.9) for viridans streptococcal and Staphylococcus aureus endocarditis, respectively. The rate of first embolic events diminished over time (P < 0.001), falling from 13 per 1000 patient-days during the first week of therapy to less than 1.2 per 1000 patient-days after completion of the second week of therapy. Conclusions: Overall, the presence of vegetations on echocardiography was not associated with a significantly higher risk for embolus in patients with left-sided native valve infective endocarditis. The relative risk for embolic events associated with echocardiographically visualized vegetations may be microorganism-dependent, with a significantly increased risk seen only in patients with viridans streptococcal infection. The rate of embolic events declines with time after initiation of antimicrobial treatment.			STECKELBERG, JM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BAIN RJI, 1987, J ANTIMICROB CHEMOTH, V20, P17, DOI 10.1093/jac/20.suppl_A.17; BRANDENBURG RO, 1983, J AM COLL CARDIOL, V1, P280, DOI 10.1016/S0735-1097(83)80029-1; BUDA AJ, 1986, AM HEART J, V112, P1291, DOI 10.1016/0002-8703(86)90362-5; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS RS, 1980, AM J MED, V69, P57, DOI 10.1016/0002-9343(80)90500-8; EGEBLAD H, 1979, EUR J CARDIOL, V10, P369; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LUTAS EM, 1986, AM HEART J, V112, P107, DOI 10.1016/0002-8703(86)90687-3; MANOLIS AS, 1988, ARCH INTERN MED, V148, P2461, DOI 10.1001/archinte.148.11.2461; MARTIN RP, 1980, AM J CARDIOL, V46, P379, DOI 10.1016/0002-9149(80)90004-1; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; OBRIEN JT, 1984, AM HEART J, V108, P386, DOI 10.1016/0002-8703(84)90630-6; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; ROY P, 1976, CIRCULATION, V53, P474, DOI 10.1161/01.CIR.53.3.474; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; STEWART JA, 1980, CIRCULATION, V61, P374, DOI 10.1161/01.CIR.61.2.374; STULZ P, 1989, J CARDIOVASC SURG, V30, P20; TAJIK AJ, 1978, MAYO CLIN PROC, V53, P271; WANN LS, 1979, CIRCULATION, V60, P728, DOI 10.1161/01.CIR.60.4.728	19	274	283	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1991	114	8					635	640		10.7326/0003-4819-114-8-635	http://dx.doi.org/10.7326/0003-4819-114-8-635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG031	2003709				2022-12-01	WOS:A1991FG03100004
J	AKHRAS, F; JACKSON, G				AKHRAS, F; JACKSON, G			RAISED EXERCISE DIASTOLIC BLOOD-PRESSURE AS INDICATOR OF ISCHEMIC LEFT-VENTRICULAR DYSFUNCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; 2-DIMENSIONAL ECHOCARDIOGRAPHY	91 (16.8%) of 541 consecutive patients investigated for chest pain or after recent uncomplicated myocardial infarction had a rise in diastolic blood pressure (DBP) of more than 15 mm Hg during a symptom-limited treadmill test. 63 also had electrocardiographic evidence of ischaemia, but 28 did not have 1 mm ST segment depression, of whom 24 had angiographic evidence of more than 70% stenosis of two or more major coronary arteries. 55 of these 91 patients underwent coronary artery bypass surgery; repeat angiography in 22 at 12 months showed an improved left ventricular ejection fraction in 18 who had a normal postoperative DBP response, but no change in ejection fraction in the 4 who still had an abnormal rise in DBP on exercise. Exercise-induced ischaemia may cause a reversible fall in cardiac output that sometimes leads to reflex vasoconstriction and a rise in DBP before a fall in systolic blood pressure or ECG evidence of ST segment depression. An abnormal DBP response to exercise may identify some patients at high risk of myocardial infarction who might otherwise have false-negative exercise tests.	GUYS HOSP,DEPT CARDIOL,LONDON SE1 9RT,ENGLAND; LEWISHAM HOSP,DEPT CARDIOL,LONDON SE13 6LH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust								AKHRAS F, 1985, BRIT HEART J, V53, P598; AKHRAS F, 1988, J AM COLL CARDIOL, V11, P102; BOUCHARD RJ, 1971, CIRCULATION, V44, P1072, DOI 10.1161/01.CIR.44.6.1072; BRUCE R A, 1969, Progress in Cardiovascular Diseases, V11, P371, DOI 10.1016/0033-0620(69)90027-9; ELLESTAD MH, 1986, STRESS TESTING PRINC, P86; FOLLAND ED, 1979, CIRCULATION, V60, P760, DOI 10.1161/01.CIR.60.4.760; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SHEPS DS, 1979, AM J CARDIOL, V43, P708, DOI 10.1016/0002-9149(79)90067-5; WEINER DA, 1982, AM J CARDIOL, V49, P1627, DOI 10.1016/0002-9149(82)90238-7; WOLTHUIS RA, 1977, CIRCULATION, V55, P153, DOI 10.1161/01.CIR.55.1.153	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					899	900		10.1016/0140-6736(91)90216-C	http://dx.doi.org/10.1016/0140-6736(91)90216-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672979				2022-12-01	WOS:A1991FG04800014
J	ANDERSON, JB; GRANT, JBF				ANDERSON, JB; GRANT, JBF			POSTOPERATIVE RETENTION OF URINE - A PROSPECTIVE URODYNAMIC STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORPHINE; INHIBITION; ANALGESIA; DETRUSOR; NALOXONE; REFLEX	Objective-To investigate the cause of post-operative retention of urine in elderly men. Design-Prospective study. Setting-Northern General Hospital, Sheffield. Patients-32 consecutive men (median age 73, range 55-85) referred to the urology department who were unable to pass urine either within 48 hours after operation and required catheterisation (23) or after removal of a catheter inserted at the initial operation (nine). Intervention-Intermittent self catheterisation. Main outcome measures-Urological investigation by medium fill and voiding cystometry within four weeks after operation, and minimum follow up three months thereafter. Results-6 patients resumed normal voiding before urodynamic assessment, three proceeded straight to prostatectomy, and one was unfit for self catheterisation. Of 22 men who underwent urodynamic investigation, only five had bladder outflow obstruction, who subsequently had successful prostatectomy; 15 showed either a low pressure-low flow system (seven) or complete detrusor failure (eight) and two showed pelvic parasympathetic nerve damage. With intermittent self catheterisation spontaneous voiding returned in all but one man within a median of 8 weeks (range 6-32 weeks). Recovery of bladder function took significantly longer in men with detrusor failure than in those with an underactive bladder (median 10 weeks (range 6-32 weeks) upsilon-median 8 weeks (range 6-8 weeks); p = 0.05). Three months later all patients had re-established their own normal voiding pattern with minimal residual urine on ultrasonography and satisfactory flow rates. Conclusions-Postoperative urinary retention in elderly men is not an indication for prostatectomy; a normal pattern of micturition can be re-established by intermittent self catheterisation in most men.	NO GEN HOSP, DEPT UROL, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	Northern General Hospital								CAMPBELL ED, 1972, DIS COLON RECTUM, V15, P69, DOI 10.1007/BF02587676; Craigen A A, 1969, J R Coll Gen Pract, V18, P226; DOYLE PT, 1976, BRIT J UROL, V48, P329, DOI 10.1111/j.1464-410X.1976.tb06645.x; DRAY A, 1984, J PHARMACOL EXP THER, V231, P254; DRAY A, 1988, ANESTHESIOLOGY, V68, P323, DOI 10.1097/00000542-198803000-00001; DURANT PAC, 1988, ANESTHESIOLOGY, V68, P325, DOI 10.1097/00000542-198803000-00002; ELLIS H, 1987, LECTURE NOTES GENERA, P362; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; GOSLING JA, 1977, J UROLOGY, V118, P302, DOI 10.1016/S0022-5347(17)57981-1; HASKELL DL, 1974, ARCH SURG-CHICAGO, V109, P378; HISAMITSU T, 1984, BRAIN RES, V298, P51, DOI 10.1016/0006-8993(84)91146-6; HODSMAN NBA, 1988, BRIT J SURG, V75, P212, DOI 10.1002/bjs.1800750307; LEVENTHAL A, 1978, Surgery Gynecology and Obstetrics, V146, P347; MARSHALL V, 1988, CLIN SCI SURGEONS, P552; MITCHELL JP, 1986, HAMILTON BAILEYS EME, P507; MURRAY KHA, 1982, BRIT J UROL, V54, P638, DOI 10.1111/j.1464-410X.1982.tb13614.x; PETERSEN TK, 1982, BRIT J ANAESTH, V54, P1175, DOI 10.1093/bja/54.11.1175; PETROS JG, 1990, AM J SURG, V159, P374, DOI 10.1016/S0002-9610(05)81274-7; SANDYK R, 1986, UROLOGY, V27, P79, DOI 10.1016/0090-4295(86)90215-3; STALLARD S, 1988, BRIT J SURG, V75, P1141, DOI 10.1002/bjs.1800751128; TAMMELA T, 1986, SCAND J UROL NEPHROL, V20, P197, DOI 10.3109/00365598609024494; TREIGER P, 1950, AM J SURG, V80, P195, DOI 10.1016/0002-9610(50)90529-0; VAIDYANATHAN S, 1981, J UROLOGY, V126, P500, DOI 10.1016/S0022-5347(17)54596-6; VIRTANEN R, 1982, ACTA ANAESTH SCAND, V26, P297, DOI 10.1111/j.1399-6576.1982.tb01770.x; WALTS LF, 1985, CLIN ORTHOP RELAT R, V194, P280; 1990, BR J OBSTET GYNAE S6, V97	26	39	42	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1991	302	6781					894	896		10.1136/bmj.302.6781.894	http://dx.doi.org/10.1136/bmj.302.6781.894			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1709058	Green Published, Bronze			2022-12-01	WOS:A1991FG42100028
J	BRAVERMAN, AS				BRAVERMAN, AS			MEDICAL ONCOLOGY IN THE 1990S	LANCET			English	Editorial Material											BRAVERMAN, AS (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 55,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625	2	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					901	902		10.1016/0140-6736(91)90218-E	http://dx.doi.org/10.1016/0140-6736(91)90218-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672980				2022-12-01	WOS:A1991FG04800015
J	CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV				CERVERA, R; RAMIREZ, G; FERNANDEZSOLA, J; DCRUZ, D; CASADEMONT, J; GRAU, JM; ASHERSON, RA; KHAMASHTA, MA; URBANOMARQUEZ, A; HUGHES, GRV			ANTIBODIES TO ENDOTHELIAL-CELLS IN DERMATOMYOSITIS - ASSOCIATION WITH INTERSTITIAL LUNG-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									ST THOMAS HOSP,RAYNE INST,LUPUS ARTHRIT RES UNIT,LONDON SE1 7EH,ENGLAND; HOSP CLIN BARCELONA,DEPT INTERNAL MED,MUSCLE RES UNIT,BARCELONA,SPAIN	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Barcelona; Hospital Clinic de Barcelona			Casademont, Jordi/A-6828-2010; SOLA, JOAQUIM FERNANDEZ/K-3991-2019; Casademont, Jordi/GPK-8669-2022	Casademont, Jordi/0000-0002-8100-1827; SOLA, JOAQUIM FERNANDEZ/0000-0002-3218-0582; Casademont, Jordi/0000-0002-8100-1827				ARSURA EL, 1988, SEMIN ARTHRITIS RHEU, V18, P29, DOI 10.1016/0049-0172(88)90032-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; ROSENBAUM J, 1988, CLIN EXP IMMUNOL, V72, P450	5	49	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	881		10.1136/bmj.302.6781.880-a	http://dx.doi.org/10.1136/bmj.302.6781.880-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025728	Bronze, Green Published			2022-12-01	WOS:A1991FG42100023
J	CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J				CLEMENS, JD; VANLOON, F; SACK, DA; RAO, MR; AHMED, F; CHAKRABORTY, J; KAY, BA; KHAN, MR; YUNUS, M; HARRIS, JR; SVENNERHOLM, AM; HOLMGREN, J			BIOTYPE AS DETERMINANT OF NATURAL IMMUNIZING EFFECT OF CHOLERA	LANCET			English	Note							VACCINES; BANGLADESH	To test the hypothesis that clinical Vibrio cholerae O1 infections protect against recurrent cholera, treated cholera episodes in a rural Bangladesh population of 188 153 people who were followed between 1985 and 1988 were analysed. Of the 2214 people with initial episodes of cholera, 7 had a second episode. The incidence of cholera was 61% lower in subjects who had had an earlier episode than in those without such an episode. Whereas initial episodes of classical cholera were associated with complete protection against subsequent cholera, initial episodes of El Tor cholera were associated with negligible protection.	INT CTR DIARRHOEL DIS RES,DHAKA,BANGLADESH; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; CTR DIS CONTROL,ENTER INFECT BRANCH,ATLANTA,GA 30333; UNIV MARYLAND,CTR VACCINE DEV,BALTIMORE,MD 21201; GOTHENBURG UNIV,DEPT MED MICROBIOL,S-41124 GOTHENBURG,SWEDEN	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore; University of Gothenburg	CLEMENS, JD (corresponding author), NICHHD,PREVENT RES PROGRAM,EXECUT PLAZA N BLDG,ROOM 640,BETHESDA,MD 20892, USA.			Harris, Jeffrey/0000-0001-8728-7195				CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, LANCET, V1, P1375; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Le vine MM, 1981, ACUTE ENTERIC INFECT, P443; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; ROTHMAN KJ, 1986, MODERN EPIDEMIOL; Ruzicka LT, 1978, DEMOGRAPHIC SURVEILL, V2; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; WOODWARD WE, 1971, J INFECT DIS, V123, P61, DOI 10.1093/infdis/123.1.61	10	52	52	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					883	884		10.1016/0140-6736(91)90207-6	http://dx.doi.org/10.1016/0140-6736(91)90207-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672971				2022-12-01	WOS:A1991FG04800006
J	MADEN, A; SWINTON, M; GUNN, J				MADEN, A; SWINTON, M; GUNN, J			DRUG-DEPENDENCE IN PRISONERS	BRITISH MEDICAL JOURNAL			English	Article											MADEN, A (corresponding author), INST PSYCHIAT,DEPT FORENS PSYCHIAT,LONDON SE5 8AF,ENGLAND.							CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; Home Office, 1988, PUNISHMENT CUSTODY C; MADEN A, 1990, BRIT MED J, V301, P1133, DOI 10.1136/bmj.301.6761.1133; 1988, POLICY STATEMENT THR	4	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					880	880		10.1136/bmj.302.6781.880	http://dx.doi.org/10.1136/bmj.302.6781.880			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	2025727	Bronze, Green Published			2022-12-01	WOS:A1991FG42100022
J	NEIL, HAW				NEIL, HAW			CHOLESTEROL SCREENING AND LIFE ASSURANCE	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD LIPID CONCENTRATIONS; DEATH; RISK	Objectives-To examine how insurance companies assess proposals for life assurance from applicants with raised cholesterol concentrations and to determine the excess mortality rating applied. Design-Survey of 49 companies underwriting term life assurance. Setting-United Kingdom. Subjects-Four fictional men aged 30 seeking 20 year term policies paying benefit only on death. Two had total cholesterol concentrations of 6.4 and 8.1 mmol/l but no other cardiovascular risk factors; one was overweight, hypertensive, smoked 20 cigarettes daily, and had a total cholesterol concentration of 8.1 mmol/l; and one had possible familial hypercholesterolaemia and a total cholesterol concentration of 10.7 mmol/l after treatment. Main outcome measure-Percentage excess mortality rating. Results-All companies used explicit criteria to assess the mortality risk associated with hyperlipidaemias, and 47 companies applied the same criteria to men and women. No excess mortality rating was imposed on an applicant with a total cholesterol concentration of 6.4 mmol/l, but a small excess was applied to an applicant with a concentration of 8.1 mmol/l (median excess 50%, range 0-75%). When multiple cardiovascular risk factors were present the same concentration of 8.1 mmol/l resulted in a substantial excess (median 135%, range 50-200%). A smaller but more variable excess was applied to an applicant with possible familial hypercholesterolaemia (median 75%, range 0-200%). Conclusions-Despite considerable differences among companies in the excess mortality ratings applied, increases in term life assurance premiums are likely to be restricted to patients with severe hypercholesterolaemia, in particular those with familial hypercholesterolaemia. In the absence of other cardiovascular risk factors milder hypercholesterolaemia is unlikely to result in higher premiums.			NEIL, HAW (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							Brackenridge R. D. C., 1985, MED SELECTION LIFE R; DURRINGTON PN, 1989, HYPERLIPIDAEMIA DIAG, P103; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; MARTEAU TM, 1990, BRIT MED J, V301, P26, DOI 10.1136/bmj.301.6742.26; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; SLACK J, 1969, LANCET, V2, P1380; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; 1988, EUR HEART J, V9, P571	11	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					891	893		10.1136/bmj.302.6781.891	http://dx.doi.org/10.1136/bmj.302.6781.891			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	2025730	Green Published, Bronze			2022-12-01	WOS:A1991FG42100027
J	OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M				OCONNOR, DW; POLLITT, PA; BROOK, CPB; REISS, BB; ROTH, M			DOES EARLY INTERVENTION REDUCE THE NUMBER OF ELDERLY PEOPLE WITH DEMENTIA ADMITTED TO INSTITUTIONS FOR LONG-TERM CARE	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL STATE; COMMUNITY; SERVICES; VALIDITY	Objective-To test whether early diagnosis and practical help reduce the number of elderly people with dementia admitted to institutions. Design-Controlled trial of effect of help from a multidisciplinary team on admission rates of people with dementia. Setting-Seven general practices in Cambridge. Subjects-2889 subjects aged 75 and over, of whom 159 were identified as having dementia with a two stage community survey. Eighty six subjects were referred for extra help if they or their supporters wished. The other 73 subjects had access to the usual services and served as controls. Intervention-Subjects and families in the action group were offered a wide range of help, including financial benefits, physical aids, home helps, respite admissions, practical advice, and psychiatric assessments. Main outcome measure-Permanent admission to long term care within two years after diagnosis. Results-Early intervention did not affect admission rates in subjects who lived with supporters. By contrast, nine of the 14 (64%) subjects with moderate or severe dementia living alone were admitted in the action group in the study's second year compared with only one of 13 (8%) controls (p = 0.004). Conclusions-Some people with moderate or severe dementia who lived alone and were at serious risk may have been identified earlier by the resource team. Without the team these people would not have become known to the responsible authorities until families, neighbours, and wardens became unable to cope. The study was conducted during the team's formative period, however, and greater experience might have allowed some subjects to remain at home for longer.	HUGHES HALL PROJECT LATER LIFE,CAMBRIDGE CB1 2EW,ENGLAND	University of Cambridge				O'Connor, Daniel/0000-0003-0188-1340				ASKHAM J, 1990, DEMENTIA HOME CARE; BLENKNER M, 1971, SOC CASEWORK-JCSW, V52, P483, DOI 10.1177/104438947105200801; BOAS JW, 1971, BRIT J RADIOL, V44, P122; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Challis D, 1986, CASE MANAGEMENT COMM; Challis D., 1990, CASE MANAGEMENT SOCI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilleard CJ, 1984, LIVING DEMENTIA COMM; GODBER C, 1977, AGE AGEING, V6, P100; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P203, DOI 10.1002/gps.930040405; OCONNOR DW, 1989, J PSYCHIAT RES, V23, P87, DOI 10.1016/0022-3956(89)90021-6; OCONNOR DW, 1989, ACTA PSYCHIAT SCAND, V79, P190, DOI 10.1111/j.1600-0447.1989.tb08587.x; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OCONNOR DW, 1990, ACTA PSYCHIAT SCAND, V81, P78, DOI 10.1111/j.1600-0447.1990.tb06453.x; OCONNOR DW, 1989, INT J GERIATR PSYCH, V4, P339, DOI 10.1002/gps.930040607; OPIT LJ, 1977, BRIT MED J, V1, P30, DOI 10.1136/bmj.1.6052.30; Pollitt PA, 1989, AGEING SOC, V9, P261; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; 1987, DIAGNOSTIC STATISTIC; 1989, CARING PEOPLE	21	66	66	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					871	875		10.1136/bmj.302.6781.871	http://dx.doi.org/10.1136/bmj.302.6781.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FG421	1902752	Bronze, Green Published			2022-12-01	WOS:A1991FG42100019
J	PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD				PACKER, GJ; GORING, CC; GAYNER, AD; CRAXFORD, AD			AUDIT OF ANKLE INJURIES IN AN ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the treatment of ankle injuries in an accident and emergency department could be improved by an audit of existing treatment and the creation and use of a protocol. Design-The study consisted of three parts: a review of the current treatment and published reports on treatment, the formation of a protocol, and a study of treatment after introducing the protocol. Setting-Accident and emergency department of a district general hospital. Patients-550 patients attending the department with ankle injuries over four months. Results-The review of treatment showed that patients with fractures were detected and treated adequately, but most had radiography. Patients with ligamentous injuries may have been undertreated. After introducing the protocol the number of patients undergoing radiography was reduced from 205 (80%) to 186 (70%) (0.0027 < p < 0.01). In 87% of the notes reviewed the protocol had been completed. Sixty six patients with ligamentous injuries were reviewed in the department or soft tissue clinic compared with 20 before the protocol was introduced. There was a 53% reduction in inappropriate referrals to the fracture clinic (13 before upsilon nine after). Conclusions-Using a protocol can, at little expense, improve the treatment of ankle injuries and reduce the cost of radiology in an accident and emergency department. Implication-Treatment of other conditions may be improved by introducing a protocol.			PACKER, GJ (corresponding author), N TYNESIDE GEN HOSP,N SHIELDS NE29 8NH,TYNE & WEAR,ENGLAND.							BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; 1990, LANCET, V335, P1313	3	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1991	302	6781					885	887		10.1136/bmj.302.6781.885	http://dx.doi.org/10.1136/bmj.302.6781.885			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG421	1902753	Bronze, Green Published			2022-12-01	WOS:A1991FG42100025
J	SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P				SCHATTENKERK, JKME; VANGOOL, T; VANKETEL, RJ; BARTELSMAN, JFWM; KUIKEN, CL; TERPSTRA, WJ; REISS, P			CLINICAL-SIGNIFICANCE OF SMALL-INTESTINAL MICROSPORIDIOSIS IN HIV-1-INFECTED INDIVIDUALS	LANCET			English	Article							AIDS; PATIENT	To assess the importance of microsporidiosis of the small intestine in the pathogenesis of chronic diarrhoea in HIV-1-infected individuals, duodenal biopsy samples from the following three patient groups were prospectively evaluated for bacterial, viral, and parasitic pathogens by standard methods, and for microsporidia by light microscopy: 55 consecutive HIV-1-antibody-positive subjects with unexplained diarrhoea of at least 3 weeks duration (group A); 38 HIV-1-seropositive subjects without diarrhoea (group B) who consecutively underwent upper gastrointestinal endoscopy for various reasons; and 7 patients without known risk factors for HIV infection with chronic unexplained diarrhoea (group C). In groups A and B most subjects had had previous AIDS-defining opportunistic infections and the median peripheral blood CD4 lymphocyte count was less than 0.1 X 10(9)/l. Microsporidia were detected as the single pathogen in 15 of the group A compared with 1 (in whom diarrhoea subsequently developed) of the group B patients (p = 0.001) and none of the group C patients. With the exception of 4 of the group A patients, no other intestinal pathogens were identified in any of the patients. The median peripheral blood CD4 count was significantly lower in patients with detectable microsporidia than in those without microsporidiosis (0.03 X 10(9)/l vs 0.06 X 10(9)/l; p = 0.03); in all patients with microsporidiosis, the CD4 count was equal to or less than 0.1 X 10(9)/l. 13 patients with microsporidiosis were treated with metronidazole, in 10 of whom treatment led to a substantial improvement or disappearance of diarrhoea within days of starting therapy, but did not result in eradication of the parasite in the 5 patients who underwent repeat biopsy. The findings suggest that small-intestinal microsporidiosis is an important cause of chronic unexplained diarrhoea in HIV-1-infected individuals with pronounced cellular immune deficiency. This infection should therefore be added to the list of AIDS-defining opportunistic infections.	ROYAL TROP INST,DEPT INTERNAL MED,AMSTERDAM,NETHERLANDS; ROYAL TROP INST,NH SWELLENGREBEL LAB TROP HYG,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT MED MICROBIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,NATL AIDS THERAPY EVALUAT CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam			Van Gool, Tom/H-6750-2012					Bryan R. T., 1990, Principles and practice of infectious diseases., P2130; CALI A, 1990, J PROTOZOOL, V37, P145, DOI 10.1111/j.1550-7408.1990.tb05885.x; CROWE S, 1990, 6TH INT C AIDS SAN F, V3, P217; CURRY A, 1988, J CLIN PATHOL, V41, P477, DOI 10.1136/jcp.41.4.477-b; DESPORTES I, 1985, J PROTOZOOL, V32, P250; FRIEDBERG DN, 1990, ARCH OPHTHALMOL-CHIC, V108, P504, DOI 10.1001/archopht.1990.01070060052047; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; OIRENSTEIN JM, 1990, HUM PATHOL, V21, P475; ORENSTEIN J, 1990, 6TH INT C AIDS SAN F, V1, P252; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; Soave R., 1990, Principles and practice of infectious diseases., P2122; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; Van Reken DE, 1990, PRINCIPLES PRACTICE, P398; VANGOOL T, 1990, LANCET, V336, P697, DOI 10.1016/0140-6736(90)92198-Q; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; 1990, MMWR, V39, P188; 1987, MMWR S1, V36, pS3	18	158	159	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					895	898		10.1016/0140-6736(91)90215-B	http://dx.doi.org/10.1016/0140-6736(91)90215-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672978				2022-12-01	WOS:A1991FG04800013
J	TULPPALA, M; VIINIKKA, L; YLIKORKALA, O				TULPPALA, M; VIINIKKA, L; YLIKORKALA, O			THROMBOXANE DOMINANCE AND PROSTACYCLIN DEFICIENCY IN HABITUAL ABORTION	LANCET			English	Article							RECURRENT ABORTION; PREGNANCY; WOMEN	To evaluate the significance of vasoactive prostanoids in habitual abortion, we measured urinary excretion of prostacyclin metabolites (6-keto-PGF1-alpha and 2,3-dinor-6-keto-PGF1-alpha) and of thromboxane A2 metabolites (TxB2 and 2,3-dinor-TxB2) during 25 pregnancies in 22 women with recurrent spontaneous abortion (RSA). The control group were 16 pregnant women with no history of abortion. Ultrasound examination at first follow-up appointment showed a living fetus in 23 pregnancies of women with RSA. 9 of these pregnancies ended in abortion; 14 continued to term as did all the pregnancies in the control group. Compared with controls, women with RSA had a lower (p < 0.05) ratio of prostacyclin to thromboxane between weeks 4 and 7 of gestation and a lower (p < 0.01) output of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11. Women whose pregnancies ended in abortion had higher (p < 0.05) output of 2,3-dinor-TxB2 between weeks 4 and 7 of gestation and lower (p < 0.01) excretion of 2,3-dinor-6-keto-PGF1-alpha between weeks 8 and 11 compared with women whose pregnancies proceeded to term. We conclude that deficiency of vasodilatory prostacyclin may be a factor in habitual abortion.	UNIV CENT HOSP HELSINKI,DEP OBSTET & GYNAECOL 1,SF-00290 HELSINKI,FINLAND; UNIV CENT HOSP HELSINKI,CHILDRENS HOSP,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	TULPPALA, M (corresponding author), UNIV CENT HOSP HELSINKI,DEPT OBSTET & GYNAECOL 2,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CASEY ML, 1986, SEMIN PERINATOL, V10, P270; DECASTELLARNAU C, 1988, EUR J OBSTET GYN R B, V29, P173, DOI 10.1016/0028-2243(88)90145-1; FRIEDMAN SA, 1988, OBSTET GYNECOL, V71, P122; GOLAN A, 1989, FERTIL STERIL, V51, P747; HILL JA, 1990, AM J REPROD IMMUNOL, V22, P33, DOI 10.1111/j.1600-0897.1990.tb01029.x; JOGEE M, 1983, BRIT J OBSTET GYNAEC, V90, P247, DOI 10.1111/j.1471-0528.1983.tb08618.x; MCNEELY MJ, 1988, FERTIL STERIL, V50, P1; MCPARLAND P, 1990, LANCET, V335, P1552, DOI 10.1016/0140-6736(90)91377-M; NOORT WA, 1990, EUR J OBSTET GYN R B, V35, P15, DOI 10.1016/0028-2243(90)90137-P; PARISI VM, 1986, SEMIN PERINATOL, V10, P288; PORTNOI MF, 1988, OBSTET GYNECOL, V72, P31; REGAN L, 1990, LANCET, V336, P1141, DOI 10.1016/0140-6736(90)92765-A; Rushton DI, 1988, EARLY PREGNANCY LOSS, P149; SCOTT JR, 1987, OBSTET GYNECOL, V70, P645; STIRRAT GM, 1990, LANCET, V336, P728, DOI 10.1016/0140-6736(90)92215-4; WALLENBURG HCS, 1986, LANCET, V1, P1; WALSH SW, 1990, SEMIN PERINATOL, V14, P152; YLIKORKALA O, 1986, J CLIN ENDOCR METAB, V63, P1307, DOI 10.1210/jcem-63-6-1307; YLIKORKALA O, 1985, AM J OBSTET GYNECOL, V152, P318, DOI 10.1016/S0002-9378(85)80221-0	19	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					879	881		10.1016/0140-6736(91)90205-4	http://dx.doi.org/10.1016/0140-6736(91)90205-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672969				2022-12-01	WOS:A1991FG04800004
J	WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF				WAKABAYASHI, A; BRENNER, M; KAYALEH, RA; BERNS, MW; BARKER, SJ; RICE, SJ; TADIR, Y; DELLABELLA, L; WILSON, AF			THORACOSCOPIC CARBON-DIOXIDE LASER TREATMENT OF BULLOUS EMPHYSEMA	LANCET			English	Note							DRAINAGE; BULLAE	A new technique of thoracoscopic laser ablation of pulmonary bullae suitable for patients with multiple bullae and diffuse emphysema was developed and assessed in 22 patients. 20 of 22 patients survived. Pre-operative and postoperative functional evaluation is available for the 11 patients followed up for more than a month; at 1 to 3 months postoperatively there were increases in FVC (mean 2.0 litres pre-operatively to 2.7 litres postoperatively, p < 0.001), in FEV1 (0.74 to 1.06 litres, p = 0.01), and in maximum exercise treadmill times (5.4 min to 8.0 min, p < 0.01). Postoperative air leaks lasted a mean of 13 days and usually resolved spontaneously. Other complications were bleeding (1 patient) and unilateral acute lung injury (1 patient). These early results suggest that selected patients with diffuse emphysema and pulmonary bullae may benefit from thoracoscopic carbon dioxide laser ablation.	UNIV CALIF IRVINE,IRVINE MED CTR,DEPT SURG,DIV PULM & CRIT CARE MED,101 CITY DR S,ORANGE,CA 92668; BECKMAN LASER INST & MED CLIN,IRVINE,CA; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT PULM & CRIT CARE MED,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT RADIOL,ORANGE,CA 92668; UNIV CALIF IRVINE,IRVINE MED CTR,DEPT ANESTHESIA,ORANGE,CA 92668	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine				Berns, Michael/0000-0002-9640-2885				BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; FITZGERALD MX, 1974, J THORAC CARDIOV SUR, V68, P566; Gaensler E A, 1986, J Thorac Imaging, V1, P75, DOI 10.1097/00005382-198603000-00009; GUNSTENSEN J, 1973, J THORAC CARDIOV SUR, V65, P920; HEAD JR, 1948, J THORAC CARDIOVASC, V40, P443; LAROS CD, 1986, J THORAC CARDIOV SUR, V91, P63; MACARTHUR AM, 1977, THORAX, V32, P668, DOI 10.1136/thx.32.6.668; OBRIEN CJ, 1986, AUST NZ J SURG, V56, P241, DOI 10.1111/j.1445-2197.1986.tb06142.x; VENN GE, 1988, THORAX, V43, P998, DOI 10.1136/thx.43.12.998; WAKABAYASHI A, 1990, ANN THORAC SURG, V50, P786	10	120	122	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1991	337	8746					881	883		10.1016/0140-6736(91)90206-5	http://dx.doi.org/10.1016/0140-6736(91)90206-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG048	1672970	Green Submitted			2022-12-01	WOS:A1991FG04800005
J	CHISAKA, O; CAPECCHI, MR				CHISAKA, O; CAPECCHI, MR			REGIONALLY RESTRICTED DEVELOPMENTAL DEFECTS RESULTING FROM TARGETED DISRUPTION OF THE MOUSE HOMEOBOX GENE HOX-1.5	NATURE			English	Article							DROSOPHILA HOMEOTIC GENES; NEURAL CREST CELLS; MOLECULAR-GENETICS; DNA-SEQUENCE; STEM-CELLS; EXPRESSION; COMPLEX; ANTENNAPEDIA; EMBRYO; MURINE	Gene targeting in mouse embryo-derived stem cells has been used to disrupt the homeobox gene hox-1.5. Mice heterozygous at the hox-1.5 locus appear normal, whereas hox-1.5-/hox-1.5- mice die at or shortly after birth. These homozygotes are athymic, aparathyroid, have reduced thyroid and submaxillary tissue and exhibit a wide range of throat abnormalities. In addition, they often feature defects of the heart and arteries as well as craniofacial abnormalities. These deficiencies are remarkably similar to the pathology of the human congenital disorder DiGeorge's syndrome.			CHISAKA, O (corresponding author), UNIV UTAH,SCH MED,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1987, DEVELOPMENT, V101, P1; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BOCKMAN DE, 1989, ANAT RECORD, V225, P209, DOI 10.1002/ar.1092250306; BOCKMAN DE, 1984, SCIENCE, V223, P498, DOI 10.1126/science.6606851; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; COULY G, 1988, DEVELOPMENT, V103, P101; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FAINSOD A, 1987, DEV BIOL, V124, P125, DOI 10.1016/0012-1606(87)90465-9; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREENBERG F, 1988, AM J HUM GENET, V43, P605; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; HOLLAND PWH, 1988, GENE DEV, V2, P773, DOI 10.1101/gad.2.7.773; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAUFMAN TC, 1980, GENETICS, V94, P115; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; LEDOUARIN NM, 1980, NEURAL CREST; LELEIVRE CS, 1975, J EMBRYOL EXP MORPH, V34, P125; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN GR, 1987, NATURE, V325, P21, DOI 10.1038/325021b0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V38, P675, DOI 10.1016/0092-8674(84)90262-9; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P916; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NODEN DM, 1975, DEV BIOL, V42, P106, DOI 10.1016/0012-1606(75)90318-8; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PULTZ MA, 1988, GENE DEV, V2, P901, DOI 10.1101/gad.2.7.901; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1984, P NATL ACAD SCI USA, V81, P3115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	48	741	754	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					473	479		10.1038/350473a0	http://dx.doi.org/10.1038/350473a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1673020				2022-12-01	WOS:A1991FG14300041
J	EWBANK, JJ; CREIGHTON, TE				EWBANK, JJ; CREIGHTON, TE			THE MOLTEN GLOBULE PROTEIN CONFORMATION PROBED BY DISULFIDE BONDS	NATURE			English	Article							ALPHA-LACTALBUMIN; STATE	THE molten globule is a compact protein conformation that has a secondary structure content like that of the native protein, but poorly defined tertiary structure. It is a stable state for a few proteins under particular conditions 1 and could be a ubiquitous kinetic intermediate in protein folding 2. The extent to which native interactions, above the level of the secondary structure, are preserved in this conformation is not so far known. Here we report that alpha-lactalbumin can adopt a molten globule conformation when one of its four disulphide bonds is reduced. In this state, the three other disulphide bonds rearrange spontaneously, at the same rate as when the protein is fully unfolded, to a number of different disulphide bond isomers that tend to maintain the molten globule conformation. That the molten globule state is compatible with a variety of disulphide bond pairings suggests that it is unlikely to be stabilized by many specific tertiary interactions.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; CREIGHTON TE, 1977, J MOL BIOL, V113, P313, DOI 10.1016/0022-2836(77)90144-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; HOLLECKER M, 1989, PROTEIN STRUCTURE PR, P145; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IYER KS, 1973, J BIOL CHEM, V248, P707; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; PFEIL W, 1986, FEBS LETT, V198, P287, DOI 10.1016/0014-5793(86)80422-7; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAO KR, 1989, BIOCHEM BIOPH RES CO, V163, P1390, DOI 10.1016/0006-291X(89)91133-9; SHECHTER Y, 1973, BIOCHEMISTRY-US, V12, P3407, DOI 10.1021/bi00742a007; THOMPSON MP, 1988, BIOCHEM BIOPH RES CO, V157, P944, DOI 10.1016/S0006-291X(88)80965-3	18	139	140	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					518	520		10.1038/350518a0	http://dx.doi.org/10.1038/350518a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1901628				2022-12-01	WOS:A1991FG14300057
J	GARCIA, JV; MILLER, AD				GARCIA, JV; MILLER, AD			SERINE PHOSPHORYLATION-INDEPENDENT DOWN-REGULATION OF CELL-SURFACE CD4 BY NEF	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HTLV-III; T-CELLS; PROTEIN; PATHOGENESIS; MODULATION; TYPE-1	A DECLINE in the T-cell population usually marks the onset of progressive immunological disease in individuals infected with the human immunodeficiency virus (HIV). Because CD4+ cells help to coordinate efficient immune responses, some of the defects in the immune function in advanced cases of AIDS may be explained by the disappearance of these cells. Therefore, an understanding of the mechanisms used by HIV to induce the reduction of CD4+ cells is important. Here we use a Moloney murine leukaemia virus-based retroviral vector in order to express the nef gene of HIV-1 in three lymphocytic cell lines expressing CD4. In all cases we find that cell-surface CD4 expression is inversely related to nef expression. However, nef does not alter steady-state levels of CD4 RNA or CD4 protein. Also, nef can downregulate a CD4 triple mutant (Ser --> Ala) that is neither phosphorylated nor down-regulated by phorbol esters, indicating that nef is acting by a different mechanism.			GARCIA, JV (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104, USA.			Miller, Dusty/0000-0002-3736-3660				ACRES RB, 1986, J BIOL CHEM, V261, P6210; AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GALLO RC, 1990, J ACQ IMMUN DEF SYND, V3, P380; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HASELTINE WA, 1990, RETROVIRUS BIOL HUMA; HOXIE JA, 1986, J IMMUNOL, V137, P1194; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PAVLAKIS G N, 1990, New Biologist, V2, P20; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; TEMIN HM, 1980, COLD SPRING HARB SYM, V44, P773, DOI 10.1101/SQB.1980.044.01.083; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980	18	704	717	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					508	511		10.1038/350508a0	http://dx.doi.org/10.1038/350508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014052				2022-12-01	WOS:A1991FG14300054
J	GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR				GJERTSON, DW; TERASAKI, PI; TAKEMOTO, S; MICKEY, MR			NATIONAL ALLOCATION OF CADAVERIC KIDNEYS BY HLA MATCHING - PROJECTED EFFECT ON OUTCOME AND COSTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURVIVAL	Background. Although receiving a cadaveric kidney matched at the HLA-A, B, and DR loci enhances graft survival in cyclosporine-treated patients, the value of a national system of kidney allocation based on HLA matching, with the attendant increased likelihood of better matching, is still questioned. Some fear that the costs of a national system are unjustified when only a small fraction of donors would exactly match any of the 16,000 potential recipients anyway. We estimated the effect on graft survival of the use of HLA matching for all allocations of cadaveric kidneys in the United States. Methods. The graft-survival rates in five mutually exclusive groups of transplants with increasing numbers of HLA mismatches were estimated by partitioning the data for 22,190 first-time recipients of cadaveric kidneys. Overall graft survival was projected as a weighted average with use of the percentages of transplants in the hierarchical groups in recipient waiting pools of various sizes. We compared the benefits and costs of HLA matching in a national system with those of introducing cyclosporine, which was projected to enhance graft survival by 7 percentage points at 10 years. Results. Sharing kidneys nationally on the basis of hierarchical HLA matching was estimated to enhance graft survival by an additional 5 percentage points at 10 years. The anticipated five-year cost of national allocation of kidneys by HLA matching for 7000 recipients, including consideration of the costs of graft removal and dialysis after transplant rejection, would be $6.5 million less than the cost of using cyclosporine alone. Conclusions. The use of an HLA allocation system will not add to the cost of renal transplantation, but it will improve the long-term results to the same extent as cyclosporine. We propose the initiation of a national kidney-sharing system based on hierarchical levels of HLA matches.	UNIV CALIF LOS ANGELES,TISSUE TYPING LAB,950 VET AVE,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					PHS HHS [2375] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cook D J, 1987, Clin Transpl, P277; EVANS RW, 1988, TRANSPL P, V20, P49; GILKS WR, 1987, TRANSPLANTATION, V43, P669, DOI 10.1097/00007890-198705000-00013; Gjertson D W, 1989, Clin Transpl, P353; HELD PJ, 1990, 16TH ANN SCI M AM SO; MANNINEN DL, 1991, TRANSPLANT P, V23, P1312; McClelland J, 1989, Clin Transpl, P471; MICKEY MR, 1989, TRANSPLANTATION, V47, P401; OPELZ G, 1988, NEW ENGL J MED, V318, P1289, DOI 10.1056/NEJM198805193182001; Persijn G G, 1988, Clin Transpl, P237; PFAFF WW, 1989, TRANSPL P, V21, P1405; STARZL TE, 1987, JAMA-J AM MED ASSOC, V257, P3073, DOI 10.1001/jama.257.22.3073; Takemoto S, 1989, Clin Transpl, P463; TAKEMOTO S, 1991, TRANSPLANT P, V23, P1318; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033; TERASAKI P, 1989, TRANSPLANT P, V21, P615; 1990, NIH90583 PUBL	17	83	84	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1032	1036		10.1056/NEJM199104113241505	http://dx.doi.org/10.1056/NEJM199104113241505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	2005940	Bronze			2022-12-01	WOS:A1991FF77100005
J	LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E				LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E			SUBCELLULAR PATTERNS OF CALCIUM RELEASE DETERMINED BY G-PROTEIN-SPECIFIC RESIDUES OF MUSCARINIC RECEPTORS	NATURE			English	Article							SUBTYPES; CELL; HYDROLYSIS	CALCIUM release from intracellular stores is a point of convergence for a variety of receptors involved in cell signalling 1. Consequently, the mechanism(s) by which cells differentiate between individual receptor signals is central to transmembrane communication 2-5. There are significant differences in timing and magnitude of Ca2+ release stimulated by the m2 and m3 muscarinic acetylcholine receptors 6-11. The m2 receptors couple to a pertussis toxin-sensitive G protein to activate phosphatidyl inositol hydrolysis weakly and to stimulate small, delayed and oscillatory chloride currents. In contrast, m3 receptors potently activate phosphatidyl inositol hydrolysis and stimulate large, rapid and transient chloride currents by a pertussis toxin-insensitive G protein pathway. Using confocal microscopy, we now show that the m2- and m3-coupled Ca2+ release pathways can also be spatially distinguished. At submaximal acetylcholine concentrations, both receptors stimulated pulses of Ca2+ release from discrete foci in random, periodic and frequently bursting patterns of activity. But maximal stimulation of m2 receptors increased the number of focal release sites, whereas m3 receptors invariably evoked a Ca2+ wave propagating rapidly just beneath the plasma membrane surface. Analysis of pertussis toxin sensitivity and hybrid m2-m3 muscarinic acetylcholine receptors confirmed that these Ca2+ release patterns represent distinct cell signalling pathways.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	LECHLEITER, J (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHARMACOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1989, TRENDS PHARM SCI S4, V10, P34; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792	15	153	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					505	508		10.1038/350505a0	http://dx.doi.org/10.1038/350505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1849616				2022-12-01	WOS:A1991FG14300053
J	MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA				MCHEYZERWILLIAMS, MG; NOSSAL, GJV; LALOR, PA			MOLECULAR CHARACTERIZATION OF SINGLE MEMORY B-CELLS	NATURE			English	Article							SOMATIC MUTATION; IMMUNE-RESPONSE; ANTIBODY REPERTOIRE; MOUSE; HYPERMUTATION; GENERATION; ANTIGEN; MICE; DNA; NP	PRIMARY antigenic exposure results in an initial antibody response and the T cell-dependent induction of B-cell memory 1,2. Memory B-cell differentiation is characterized by somatic hypermutation in antibody variable region genes (V) and selection of B cells expressing high-affinity variants of this antigen receptor 3-5. Despite our current understanding of B-cell memory 6-8, the origin of memory B cells and the regulation of their differentiation remain elusive. This is largely due to the difficulties in observing and purifying this minor component of the immunized spleen. Further, molecular characterization of memory B cells requires hybridoma formation which restricts analyses to only those clones capable of fusion and does not allow isolation of cells in a normal physiological state. We have therefore developed a unique system which allows isolation and unambiguous enumeration of IgG1+ memory B cells, based on six-parameter flow cytometry, secretion of antibody in clonal cultures and analysis of clonally expressed V genes using the polymerase chain reaction 9. Here we report that single IgG1+ antigen-binding B cells from an early secondary immune response proliferate in lipopolysaccharide-driven microcultures and produce antigen-specific IgG1 antibodies. Individual B-cell clones in these cultures express somatically mutated heavy chain V genes, confirming their designation as memory B cells. Although isolated memory B cells undergo extensive proliferation in vitro, V gene sequence analysis of their individual progeny shows that further hypermutation does not occur.			MCHEYZERWILLIAMS, MG (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.							ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; GRAY D, 1990, CURR TOP MICROBIOL, V159, P1; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LALOR PA, 1990, EUR J IMMUNOL, V20, P485, DOI 10.1002/eji.1830200305; LALOR PA, 1989, EUR J IMMUNOL, V19, P501, DOI 10.1002/eji.1830190314; LEBECQUE SG, IN PRESS J EXP MED; LEVY NS, 1989, J EXP MED, V169, P2007, DOI 10.1084/jem.169.6.2007; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MANSER T, 1990, IMMUNOL TODAY, V11, P305, DOI 10.1016/0167-5699(90)90124-R; MCHEYZERWILLIAMS MG, 1989, EUR J IMMUNOL, V19, P2025, DOI 10.1002/eji.1830191109; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P6350, DOI 10.1073/pnas.79.20.6350; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; TAO W, 1990, J IMMUNOL, V145, P3216; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	30	135	136	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					502	505		10.1038/350502a0	http://dx.doi.org/10.1038/350502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014051				2022-12-01	WOS:A1991FG14300052
J	MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM				MCKINNEY, RE; MAHA, MA; CONNOR, EM; FEINBERG, J; SCOTT, GB; WULFSOHN, M; MCINTOSH, K; BORKOWSKY, W; MODLIN, JF; WEINTRUB, P; ODONNELL, K; GELBER, RD; ROGERS, GK; LEHRMAN, SN; WILFERT, CM			A MULTICENTER TRIAL OF ORAL ZIDOVUDINE IN CHILDREN WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; INFECTION; AZT; SURVIVAL; TYPE-1	Background and Methods. Zidovudine has been shown to be an effective antiretroviral treatment in adults with human immunodeficiency virus (HIV) infection. We examined the safety of zidovudine and the tolerance of and therapeutic response to the drug in 88 children with advanced HIV disease. During a 24-week outpatient trial, zidovudine (180 mg per square meter of body-surface area per dose) was given by mouth every six hours and serial measurements were made of clinical, immunologic, and virologic indexes. Children who completed 24 weeks of treatment were permitted to continue receiving zidovudine. Results. Of the 88 children (mean age, 3.9 years; range, 4 months to 11 years), 61 completed the initial 24-week trial, and 49 continued to receive zidovudine for up to 90 weeks (median follow-up, 56 weeks). The patients generally tolerated zidovudine well. One or more episodes of hematologic toxicity occurred in 54 children (61 percent) - anemia (hemoglobin level, < 75 g per liter) in 23 children (26 percent) and neutropenia (neutrophil count, < 0.75 X 10(9) per liter) in 42 (48 percent). Many of these abnormalities resolved spontaneously, but 30 children required transfusions or a modification of the dose of zidovudine. Only three children had to stop receiving the drug because of hematologic toxicity. Kaplan-Meier analysis demonstrated that the probability of survival was 0.89 after 24 weeks and 0.79 after 52 weeks. There was marked improvement in weight gain, cognitive function (mainly in children < 3 years old), serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebrospinal fluid cultures negative for HIV. CD4+ lymphocyte counts (mean at base line, 0.263 X 10(9) per liter) improved during the first 12 weeks, although the improvement was not sustained through the 24th week. Conclusions. Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease. The resultant clinical, immunologic, and virologic improvements in children are similar to those reported with zidovudine in adults.	BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709; NEW JERSEY CHILDRENS HOSP,NEWARK,NJ; NIAID,DIV AIDS,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL 33152; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; NYU,SCH MED,DEPT PEDIAT,NEW YORK,NY 10003; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Burroughs Wellcome Fund; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Miami; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; New York University; Johns Hopkins University	MCKINNEY, RE (corresponding author), DUKE UNIV,MED CTR,SCH MED,DEPT PEDIAT,BOX 3461,DURHAM,NC 27710, USA.			feinberg, judith/0000-0003-4206-7214				BALIS FM, 1989, J PEDIATR-US, V114, P880, DOI 10.1016/S0022-3476(89)80158-1; BALIS FM, 1989, ANN INTERN MED, V110, P279, DOI 10.7326/0003-4819-110-4-279; CHAISSON RE, 1988, ARCH INTERN MED, V148, P2151, DOI 10.1001/archinte.148.10.2151; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; MCKINNEY RE, 1990, J PEDIATR-US, V116, P640, DOI 10.1016/S0022-3476(05)81619-1; MICHALSKI FJ, 1989, YALE J BIOL MED, V62, P93; PARKS WP, 1988, J ACQ IMMUN DEF SYND, V1, P125; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; ROWE PC, 1987, H LANE HDB MANUAL PE, P325; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR S, V36, pS1; 1969, BAYLEY SCALES INFANT; 1989, MMWR, V38, P1; 1972, MCCARTHY SCALES CHIL	23	199	202	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	1991	324	15					1018	1025		10.1056/NEJM199104113241503	http://dx.doi.org/10.1056/NEJM199104113241503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF771	1672443				2022-12-01	WOS:A1991FF77100003
J	MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A				MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A			A NOVEL CYCLIN ENCODED BY A BCL1-LINKED CANDIDATE ONCOGENE	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MESSENGER-RNA; GENE; AMPLIFICATION; DIVISION; KINETICS; MEIOSIS; BCL-1	WE have previously identified a candidate oncogene (PRAD1 or D11S287E) on chromosome 11q13 which is clonally rearranged with the parathyroid hormone locus in a subset of benign parathyroid tumours 1,2. We now report that a cloned human placental PRAD1 complementary DNA encodes a protein of 295 amino acids with sequence similarities to the cyclins. Cyclins can form a complex with and activate p34 cdc2 protein kinase, thereby regulating progress through the cell cycle (reviewed in refs 3-5). PRAD1 messenger RNA levels vary dramatically across the cell cycle in HeLa cells. Addition of the PRAD1 protein to interphase clam embryo lysates containing inactive p34cdc2 kinase and lacking endogenous cyclins allows it to be isolated using beads bearing p13suc1, a yeast protein that binds cdc2 and related kinases with high affinity and coprecipitates kinase-associated proteins. Addition of PRAD1 also induces phosphorylation of histone H1, a preferred substrate of cdc2. These data suggest that PRAD1 encodes a novel cyclin whose overexpression may play an important part in the development of various tumours with abnormalities in 11q13.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019	Bloom, Theodora/0000-0002-0222-4177				ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Battey, 1986, BASIC METHODS MOL BI; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THEILLET C, 1990, ONCOGENE, V5, P147; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431	33	1285	1350	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					512	515		10.1038/350512a0	http://dx.doi.org/10.1038/350512a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1826542				2022-12-01	WOS:A1991FG14300055
J	RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM				RITTER, AM; LEWIN, GR; KREMER, NE; MENDELL, LM			REQUIREMENT FOR NERVE GROWTH-FACTOR IN THE DEVELOPMENT OF MYELINATED NOCICEPTORS INVIVO	NATURE			English	Article							HAIRY SKIN; RAT; MECHANORECEPTORS; RECEPTOR; SURVIVAL	IN adult animals, sensory neurons innervating the skin are phenotypically diverse 1-3. We have now investigated whether nerve growth factor (NGF) has a physiological role in the development of this diversity. We gave antisera against NGF to rats from postnatal day 1 (PND 1) to adulthood (5 weeks). We found a virtually complete depletion of high threshold mechanoreceptors conducting in the A-delta range (2-13 m s-1) in the sural nerve. This afferent type, normally present in large numbers, appeared to have been replaced by D-hair afferents, sensitive mechanoreceptors which normally are relatively rare. NGF deprivation had this effect only in early postnatal life; treatment from postnatal day 14 to adulthood had no effect. We conclude that the presence of NGF postnatally in skin is necessary for the proper phenotypic development of A-delta cutaneous nociceptors.	SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lewin, Gary R/B-8028-2011	Lewin, Gary/0000-0002-2890-6352; Mendell, Lorne/0000-0003-1540-8837				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; Burgess PR, 1973, HDB SENSORY PHYSIOLO, VII, P29; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; FITZGERALD M, 1987, J PHYSIOL-LONDON, V383, P79; FITZGERALD MI, 1966, J COMP NEUROL, V126, P37, DOI 10.1002/cne.901260103; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HANDWERKER HO, 1985, DEV ORG PROCESSING S, P289; HORCH KW, 1977, J INVEST DERMATOL, V69, P75, DOI 10.1111/1523-1747.ep12497887; HULSEBOSCH CE, 1987, J COMP NEUROL, V259, P445, DOI 10.1002/cne.902590310; KOERBER HR, 1988, J NEUROPHYSIOL, V60, P1584, DOI 10.1152/jn.1988.60.5.1584; KRUGER L, 1981, J COMP NEUROL, V198, P137, DOI 10.1002/cne.901980112; LEWIN GR, 1989, J PHYSIOL-LONDON, V412, pP26; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; LYNN B, 1988, NEUROSCI LETT, V85, P71, DOI 10.1016/0304-3940(88)90431-4; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; YIP HK, 1984, J NEUROSCI, V4, P2986	17	140	141	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					500	502		10.1038/350500a0	http://dx.doi.org/10.1038/350500a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	2014050				2022-12-01	WOS:A1991FG14300051
J	TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH				TAYLOR, SJ; CHAE, HZ; RHEE, SG; EXTON, JH			ACTIVATION OF THE BETA-1 ISOZYME OF PHOSPHOLIPASE-C BY ALPHA-SUBUNITS OF THE GQ CLASS OF G-PROTEINS	NATURE			English	Article							BOVINE BRAIN; TYROSINE PHOSPHORYLATION	MANY hormones, neurotransmitters and growth factors, on binding to G protein-coupled receptors or receptors possessing tyrosine kinase activity, increase intracellular levels of the second messengers inositol 1,4,5-trisphophate and 1,2-diacylglycerol. This is due to activation of phosphoinositide-specific phospholipase(s) C (PLC), the isozymes of which are classified into groups, alpha, beta, gamma and delta (refs 1, 2). The beta, gamma and delta-groups themselves contain PLC isozymes which have both common and unique structural domains 3. Only the gamma-1 isozyme has been implicated in a signal transduction mechanism 4. This involves association with, and tyrosine phosphorylation by, the ligand-bound epidermal growth factor and platelet-derived growth factor receptors 5-7, probably by means of the PLC-gamma-1-specific src homology (SH2) domain 8. Because EGF receptor-mediated tyrosine phosphorylation of PLC-gamma-1 stimulates catalytic activity in vitro 9 and G proteins have been implicated in the activation of PLC 10, we investigated which PLC isozymes are subject to G protein regulation. We have purified 11 an activated G protein alpha-subunit that stimulates partially purified phospholipase C and now report that this G protein specifically activates the beta-1 isozyme, but not the gamma-1 and delta-1 isozymes of phospholipase C. We also show that this protein is related to the G(q) class of G protein alpha-subunits 12.	VANDERBILT UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA; NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA	Howard Hughes Medical Institute; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; KRIZ R, 1990, CIBA F SYMP, V150, P112; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; RATH HM, 1990, J BIOL CHEM, V265, P3080; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; ULLRICH A, 1990, J CELL, V61, P203; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568	30	762	766	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1991	350	6318					516	518		10.1038/350516a0	http://dx.doi.org/10.1038/350516a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1707501				2022-12-01	WOS:A1991FG14300056
J	BARONDESS, JA				BARONDESS, JA			THE RISK OF CONTRACTING HIV-INFECTION IN THE COURSE OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BARONDESS, JA (corresponding author), NEW YORK ACAD MED,2 E 103RD ST,NEW YORK,NY 10029, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1872	1873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005738				2022-12-01	WOS:A1991FE86200031
J	GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT				GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT			POSSIBLE HEALTH-CARE PROFESSIONAL-TO-PATIENT HIV TRANSMISSION - DENTISTS REACTIONS TO A CENTERS-FOR-DISEASE-CONTROL REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On July 27, 1990, the Centers for Disease Control reported possible transmission of the human immunodeficiency virus (HIV) from a dentist to a patient as a result of patient care. We surveyed a random national probability sample of 300 dentists with a 26-item survey in August and September 1990 to assess reactions to the report (response rate, 59%). Respondents tended not to believe the report (mean was 3.2, median 3.0, where 1 indicated "do not believe" and 7 indicated "believe"). Our sample also tended to believe that transmission of HIV from dentists to patients was unlikely in the future (mean was 2.0, median 2.0, where 1 indicated "not at all likely" and 7 indicated "very likely"). Fifty-one percent of our sample recommended that dentists infected with HIV should discontinue practice, while 38% recommended continuing practice with changes in procedures. Seventy-four percent believed patients should be told if their dentist was infected with HIV. In summary, dentists doubted the possibility of dentist-to-patient transmission of HIV and did not believe the Centers for Disease Control case report, but they did believe infected dentists should refrain from clinical work or modify their practice.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GERBERT, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT DENT PUBL HLTH & HYG,DIV BEHAV SCI,707 PARNASUS,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1987, BAND PLAYED POLITICS; Babbie ER, 1973, SURVEY RES METHODS, P165; BLAND A, 1990, AIDS ALERT, V5, P161; BREO DL, 1990, JAMA-J AM MED ASSOC, V264, P1464, DOI 10.1001/jama.264.11.1464; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P1079; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; RELMAN AS, 1987, SEARCH MODERN HIPPOC, P198; 1991, MMWR, V40, P33; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2S, V36, pS1; 1986, FACTS AIDS DENTAL TE; 1990, MMWR, V39, P489; 1991, MMWR, V40, P21	14	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1845	1848		10.1001/jama.265.14.1845	http://dx.doi.org/10.1001/jama.265.14.1845			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848643				2022-12-01	WOS:A1991FE86200025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CORRECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Correction, Addition																		NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P847, DOI 10.1001/jama.265.7.847	1	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1802	1802		10.1001/jama.265.14.1802	http://dx.doi.org/10.1001/jama.265.14.1802			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848642				2022-12-01	WOS:A1991FE86200004
J	NOVELLO, AC				NOVELLO, AC			WOMEN AND HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1805	1805						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	2005724				2022-12-01	WOS:A1991FE86200005
J	BUCHANAN, CR; PREECE, MA; MILNER, RDG				BUCHANAN, CR; PREECE, MA; MILNER, RDG			MORTALITY, NEOPLASIA, AND CREUTZFELDT-JAKOB DISEASE IN PATIENTS TREATED WITH HUMAN PITUITARY GROWTH-HORMONE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							DIABETES-INSIPIDUS; TURNERS SYNDROME; THERAPY; CHILDREN; TUMORS; LEUKEMIA; EXPERIENCE; DEFICIENCY; RECURRENCE; CHILDHOOD	Objective-To determine the cause of death and incidence of neoplasia in patients treated with human pituitary growth hormone. Design-A long term cohort study established to receive details of death certification and tumour registrations through the Office of Population Censuses and Surveys and NHS central register. Patients-All patients (1246 male, 662 female) treated for short stature with pituitary growth hormone under the Medical Research Council working party and health services human growth hormone committee. Main outcome measures-Death or development of neoplasia. Results-110 patients died (68 male, 42 female; aged 0.9-57 years) from 1972 to 1990. Fifty three deaths were from neoplasia responsible for growth hormone deficiency (27 craniopharyngioma, 24 other intracranial tumour, two leukaemia); two from histiocytosis X; and 13 from pituitary insufficiency. Six patients died of Creutzfeldt-Jakob disease, six of other neurological disorders, and eight of acute infection. Other deaths were apparently unrelated to growth hormone deficiency or its treatment. Seventeen tumours (in 16 patients) were identified during or after growth hormone treatment. Four were in patients with previous intracranial neoplasia and two were after cranial irradiation. Thirteen were intracranial, the others being Hodgkin's lymphoma, osteosarcoma, carcinoma of colon, and basal cell carcinoma. Conclusions-Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death. Growth hormone treatment probably did not contribute to new tumour development. Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom. This cohort must remain under long term review.	INST CHILD HLTH,DEPT GROWTH & DEV,LONDON WC1N 1EH,ENGLAND; SHEFFIELD UNIV,CHILDRENS HOSP,DEPT PAEDIAT,SHEFFIELD S10 2TH,ENGLAND	University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield								ARSLANIAN SA, 1985, AM J DIS CHILD, V139, P347, DOI 10.1001/archpedi.1985.02140060029020; BROWN P, 1985, NEW ENGL J MED, V313, P728, DOI 10.1056/NEJM198509193131205; BROWN P, 1988, NEUROLOGY, V38, P1135, DOI 10.1212/WNL.38.7.1135; BUCHANAN CR, 1987, ARCH DIS CHILD, V62, P912, DOI 10.1136/adc.62.9.912; CLAYTON PE, 1988, LANCET, V1, P642; CLAYTON PE, 1987, LANCET, V1, P711; COCHIUS JI, 1990, AUST NZ J MED, V20, P592, DOI 10.1111/j.1445-5994.1990.tb01322.x; DELEMARREVANDEWAAL HA, 1988, LANCET, V1, P1159; FARWELL J, 1984, J NEURO-ONCOL, V2, P371; FISHER DA, 1988, LANCET, V1, P1159; FRISCH H, 1988, LANCET, V1, P1335; GOUJARD J, 1988, INT J EPIDEMIOL, V17, P423, DOI 10.1093/ije/17.2.423; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; MILNER RDG, 1979, CLIN ENDOCRINOL, V11, P15, DOI 10.1111/j.1365-2265.1979.tb03043.x; MILNER RDG, 1987, ARCH DIS CHILD, V62, P776, DOI 10.1136/adc.62.8.776; NW MI, 1988, NEUROLOGY, V38, P1133; POWELLJACKSON J, 1985, LANCET, V2, P244; PREECE MA, 1986, NEUROPATH APPL NEURO, V12, P509, DOI 10.1111/j.1365-2990.1986.tb00061.x; PREECE MA, 1986, IMMUNOLOGICAL ASPECT, P9; RABEN MS, 1958, J CLIN ENDOCR METAB, V18, P901, DOI 10.1210/jcem-18-8-901; REDMAN GP, 1988, LANCET, V1, P1335; RODENS KP, 1987, ACTA ENDOCR-COP    S, V283, P188; SHERWOOD MC, 1986, ARCH DIS CHILD, V61, P1222, DOI 10.1136/adc.61.12.1222; STAHNKE N, 1989, EUR J PEDIATR, V148, P591, DOI 10.1007/BF00441506; STANDEN GR, 1989, AM J HEMATOL, V31, P280, DOI 10.1002/ajh.2830310413; STANHOPE R, 1989, BRIT J HOSP MED, V41, P490; TANNER JM, 1971, ARCH DIS CHILD, V46, P745, DOI 10.1136/adc.46.250.745; WATANABE S, 1988, LANCET, V1, P1159; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x; WHITEHEAD HM, 1989, ULSTER MED J, V58, P153; 1986, ANN NEUROL, V19, P75; 1986, MORTALITY STATIS DH2	32	108	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					824	828		10.1136/bmj.302.6780.824	http://dx.doi.org/10.1136/bmj.302.6780.824			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025705	Bronze, Green Published			2022-12-01	WOS:A1991FF37700025
J	FROST, CD; LAW, MR; WALD, NJ				FROST, CD; LAW, MR; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .2. ANALYSIS OF OBSERVATIONAL DATA WITHIN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							URINARY SODIUM; POTASSIUM; VARIABILITY; EXCRETION; MEN; ASSOCIATION; CATIONS	Objective-To determine whether the estimates of the size of the association between blood pressure and sodium intake derived from studies of individuals within populations can be quantitatively reconciled with our estimates derived from comparisons of the average blood pressure and sodium intake between different populations. Design-Examination of data from 14 published studies that correlated blood pressure recordings in individuals against measurements of their 24 hour sodium intake (within population studies). Main outcome measure-Comparison of observed differences in blood pressure per 100 mmol/24 h difference in sodium intake in each within population study with predicted differences calculated from the between population data, after allowing for the underestimation of the true association of blood pressure with sodium intake caused by the large day to day variation in 24 hour sodium intake within individuals. Results-The underestimation bias inherent in the within population studies reduced the regression slope of blood pressure on single measures of 24 hour sodium intake to between a half and a quarter of the true value (for example, in one study from 6.0 to 2.4 mm Hg/100 mmol/24 h). Estimates from between population comparisons of the regression slope of blood pressure on sodium intake, after adjustment to take this underestimation bias into account, were similar to the values actually observed in the within population studies. Conclusion-The within population studies confirm our estimates from between population comparisons of the magnitude of the association between blood pressure and sodium intake.	ST BARTHOLOMEWS HOSP,COLL MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					[Anonymous], 1988, BMJ, V297, P319; ARMITAGE P, 1987, STATISTICAL METHODS; BULPITT CJ, 1986, J CHRON DIS, V39, P211, DOI 10.1016/0021-9681(86)90026-3; CONNOR SL, 1984, CIRCULATION, V70, P76, DOI 10.1161/01.CIR.70.1.76; ELLIOTT P, 1988, J HUM HYPERTENS, V2, P89; Joossens J. V., 1980, EPIDEMIOLOGY ARTERIA, P45; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LISHENG L, 1987, J HYPERTENS, V5, P331, DOI 10.1097/00004872-198706000-00011; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LUFT FC, 1986, AM J KIDNEY DIS, V7, P375, DOI 10.1016/S0272-6386(86)80085-3; SIANI A, 1989, HYPERTENSION, V13, P38, DOI 10.1161/01.HYP.13.1.38; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; STAESSEN J, 1983, AM J EPIDEMIOL, V117, P676, DOI 10.1093/oxfordjournals.aje.a113601; STRAZZULLO P, 1983, EUR HEART J, V4, P608, DOI 10.1093/oxfordjournals.eurheartj.a061532; WATT GCM, 1982, J EPIDEMIOL COMMUN H, V36, P197, DOI 10.1136/jech.36.3.197; 1989, J HUM HYPERTENSION, V3, P279	19	169	171	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					815	818		10.1136/bmj.302.6780.815	http://dx.doi.org/10.1136/bmj.302.6780.815			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025704	Bronze, Green Published			2022-12-01	WOS:A1991FF37700021
J	HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG				HENNIGAN, TW; FRANKS, PJ; HOCKEN, DB; ALLENMERSH, TG			INFLUENCE OF UNDERGRADUATE TEACHING ON MEDICAL-STUDENTS ATTITUDES TO RECTAL EXAMINATION	BRITISH MEDICAL JOURNAL			English	Article											HENNIGAN, TW (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181				HENNIGAN TW, 1990, BRIT MED J, V301, P478, DOI 10.1136/bmj.301.6750.478; [No title captured]	2	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1991	302	6780					829	829		10.1136/bmj.302.6780.829	http://dx.doi.org/10.1136/bmj.302.6780.829			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF377	2025707	Green Published, Bronze			2022-12-01	WOS:A1991FF37700027
J	IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S				IWAKI, Y; STARZL, TE; YAGIHASHI, A; TANIWAKI, S; ABUELMAGD, K; TZAKIS, A; FUNG, J; TODO, S			REPLACEMENT OF DONOR LYMPHOID-TISSUE IN SMALL-BOWEL TRANSPLANTS	LANCET			English	Note								The presence of recipient lymphocytes in grafts is thought to equate with rejection. Thus, we wished to follow the fate of lymphocytes after transplant of the small bowel. Three complete small-bowel transplants, two with the liver from the same donor also transplanted, were done successfully. Patients were immunosuppressed with FK 506. 5 to 11% of lymphocytes in the recipients' peripheral blood were of donor origin during the early postoperative period when there were no clinical signs of graft-versus-host disease. However, donor cells were no longer detectable after 12 to 54 days. Serial biopsy specimens of the grafted small bowel showed progressive replacement of lymphocytes in the lamina propria by those of the recipient's HLA phenotype. Lymphoid repopulation was complete after 10 to 12 weeks but the epithelial cells of the intestine remained those of the donor. The patients are on enteral alimentation after 5, 6, and 8 months with histopathologically normal or nearly normal intestines. Re-examination of assumptions about the rejection of intestinal grafts and strategies for its prevention are required following these observations.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT SURG,3601 5TH AVE,5C FALK CLIN,PITTSBURGH,PA 15213, USA.		FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARK CLI, 1990, TRANSPLANT P, V22, P2460; FUNG JJ, 1989, CLIN TRANSPLANT, V3, P316; FUNG JJ, 1985, HUM IMMUNOL, V14, P287, DOI 10.1016/0198-8859(85)90236-8; GOUW ASH, 1987, TRANSPLANTATION, V43, P291, DOI 10.1097/00007890-198702000-00025; GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A; MARKUS PM, IN PRESS TRANSPLANTA; MONCHIK GJ, 1971, SURGERY, V70, P693; MURASE N, IN PRESS SURGERY; STARZL TE, 1962, AM J SURG, V103, P219, DOI 10.1016/0002-9610(62)90491-9; TZAKIS AG, 1991, TRANSPLANT P, V23, P924	10	156	158	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					818	819		10.1016/0140-6736(91)92517-6	http://dx.doi.org/10.1016/0140-6736(91)92517-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1707470	Green Accepted			2022-12-01	WOS:A1991FF22800005
J	LAW, MR; FROST, CD; WALD, NJ				LAW, MR; FROST, CD; WALD, NJ			BY HOW MUCH DOES DIETARY SALT REDUCTION LOWER BLOOD-PRESSURE .1. ANALYSIS OF OBSERVATIONAL DATA AMONG POPULATIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SODIUM-INTAKE; 24-HOUR EXCRETION; RISK-FACTORS; HYPERTENSION; POTASSIUM; CULTURE; DISEASE; BELGIUM; CATIONS; MILTON	Objective-To estimate the quantitative relation between blood pressure and sodium intake. Design-Data were analysed from published reports of blood pressure and sodium intake for 24 different communities (47 000 people) throughout the world. Main outcome measure-Difference in blood pressure for a 100 mmol/24 h difference in sodium intake. Allowance was made for differences in blood pressure between economically developed and undeveloped communities to minimise overestimation of the association through confounding with other determinants of blood pressure. Results-Blood pressure was higher on average in the developed communities, but the association with sodium intake was similar in both types of community. A difference in sodium intake of 100 mmol/24 h was associated with an average difference in systolic blood pressure that ranged from 5 mm Hg at age 15-19 years to 10 mm Hg at age 60-69. The differences in diastolic blood pressure were about half as great. The standard deviation of blood pressure increased with sodium intake implying that the association of blood pressure with sodium intake in individuals was related to the initial blood pressure-the higher the blood pressure the greater the expected reduction in blood pressure for the same reduction in sodium intake. For example, at age 60-69 the estimated systolic blood pressure reduction in response to a 100 mmol/24 h reduction in sodium intake was on average 10 mm Hg but varied from 6 mm Hg for those on the fifth blood pressure centile to 15 mm Hg for those on the 95th centile. Conclusions-The association of blood pressure with sodium intake is substantially larger than is generally appreciated and increases with age and initial blood pressure.			LAW, MR (corresponding author), ST BARTHOLOMEWS HOSP, COLL MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					BAILEY K V, 1961, Trop Geogr Med, V13, P216; BAILEY KV, 1963, BRIT MED J, P775, DOI 10.1136/bmj.2.5360.775; BARNES R, 1965, Med J Aust, V1, P611; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DAWBER THOMAS R., 1967, P255; ELLIOTT P, 1988, BRIT MED J, V297, P319; FODOR JG, 1980, EPIDEMIOLOGY ARTERIA, P353; FROMENT A, 1979, REV EPIDEMIOL SANTE, V27, P437; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRIM CE, 1980, J CHRON DIS, V33, P87, DOI 10.1016/0021-9681(80)90032-6; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; KESTELOOT H, 1980, EUR J CARDIOL, V11, P169; KESTELOOT H, 1987, HYPERTENSION, V9, P654, DOI 10.1161/01.HYP.9.6.654; KESTELOOT H, 1984, ANN CLIN RES, V16, P72; KOMACHI Y, 1971, JPN CIRCULATION J, V35, P189, DOI 10.1253/jcj.35.189; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE MR, 1986, BMJ-BRIT MED J, V293, P266, DOI 10.1136/bmj.293.6541.266-b; LOWENSTEIN F, 1961, LANCET, V1, P389; LUFT FC, 1988, J CARDIOVASC PHARM, V12, pS49; MADDOCKS I., 1965, Papua and New Guinea Medical Journal, V8, P17; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MORSE WR, 1937, LANCET, V1, P966; MOSER M, 1959, AM J CARDIOL, V4, P727, DOI 10.1016/0002-9149(59)90122-5; OLIVER WJ, 1975, CIRCULATION, V52, P146, DOI 10.1161/01.CIR.52.1.146; PAGE LB, 1974, CIRCULATION, V49, P1132, DOI 10.1161/01.CIR.49.6.1132; PAGE LB, 1981, AM J CLIN NUTR, V34, P527, DOI 10.1093/ajcn/34.4.527; PRIOR IAM, 1968, NEW ENGL J MED, V279, P515, DOI 10.1056/NEJM196809052791004; SASAKI N, 1962, JPN HEART J, V3, P313; SCHNECKLOTH RE, 1962, AM HEART J, V63, P607, DOI 10.1016/0002-8703(62)90005-4; SIMMONS D, 1986, J EPIDEMIOL COMMUN H, V40, P188, DOI 10.1136/jech.40.2.188; SIMPSON FO, 1978, NEW ZEAL MED J, V87, P379; SIMPSON FO, 1982, NEW ZEAL MED J, V95, P873; STAESSEN J, 1981, J EPIDEMIOL COMMUN H, V35, P256, DOI 10.1136/jech.35.4.256; STAMLER J, 1976, JAMA-J AM MED ASSOC, V235, P2299, DOI 10.1001/jama.235.21.2299; TSENG WP, 1967, AM J EPIDEMIOL, V86, P513, DOI 10.1093/oxfordjournals.aje.a120762; TUOMILEHTO J, 1981, ACTA CARDIOL, V36, P83; 1989, J HUMAN HYPERTENSION, V3, P279	41	339	345	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1991	302	6780					811	815		10.1136/bmj.302.6780.811	http://dx.doi.org/10.1136/bmj.302.6780.811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF377	2025703	Bronze, Green Published			2022-12-01	WOS:A1991FF37700020
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			POSTMENOPAUSAL ESTROGEN AND CARDIOPROTECTION	LANCET			English	Editorial Material							ESTROGEN USE; MORTALITY; DISEASE; THERAPY; WOMEN				VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BUSH TL, 1985, EPIDEMIOL REV, V7, P80, DOI 10.1093/oxfordjournals.epirev.a036287; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; DAVIS ME, 1964, CLIN OBSTET GYNECOL, V7, P558; GAMBRELL RD, 1982, ACTA OBSTET GYNECO S, V106, P37; KNOPP RH, 1988, OBSTET GYNECOL, V72, pS23; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDIN BEC, 1990, LANCET, V336, P1327, DOI 10.1016/0140-6736(90)93018-K; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEVENSON JC, 1990, LANCET, V336, P1121, DOI 10.1016/0140-6736(90)92590-E; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; WEINSTEIN MC, 1980, NEW ENGL J MED, V303, P308, DOI 10.1056/NEJM198008073030604; WILSON RA, 1963, J AM GERIATR SOC, V11, P347, DOI 10.1111/j.1532-5415.1963.tb00068.x; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1977, BRIT MED J, V1, P862	19	32	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					833	834		10.1016/0140-6736(91)92526-8	http://dx.doi.org/10.1016/0140-6736(91)92526-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672923				2022-12-01	WOS:A1991FF22800014
J	YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ				YEUNG, ST; YOONG, C; SPINK, J; GALBRAITH, A; SMITH, PJ			FUNCTIONAL MYOCARDIAL IMPAIRMENT IN CHILDREN TREATED WITH ANTHRACYCLINES FOR CANCER	LANCET			English	Article							DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN; CARDIOMYOPATHY	A non-invasive exercise method was used to look for myocardial damage in apparently normal children who had received moderate doses of anthracyclines for treatment of cancer. 19 children (mean [SD] age 10.6 [4.3] years) who had received anthracyclines (mean total dose 230 [119] mg/m2) and 10 who had received other cytotoxic drugs (mean age 13.3 [4.9] years) were selected from 263 children attending routine follow-up examinations. They underwent measurement of heart rate, blood pressure, and left ventricular dimensions by echocardiography before and after exercise on a bicycle for a maximum of 10 min. All 29 were in remission. All the subjects showed normal fractional shortening (FS = left ventricular end-diastolic minus end-systolic diameter as a percentage of the end-diastolic diameter) at rest, but the increase in FS on exercise was significantly lower in the children who had received anthracyclines than in those who had not (3 [16]% vs 23 [17]%; p < 0.05). This difference remained significant after adjustment for age and drug exposure. However, there were no significant differences between the groups in the adjusted mean percentage changes on exercise in heart rate or systolic or diastolic blood pressure. Disease type had no effect on the cardiological indices. Thus, many children who have received anthracyclines may have suffered subclinical myocardial damage. Post-exercise echocardiography seems a useful noninvasive method for detecting such damage. Long-term cardiological follow-up of these patients is needed.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD,AUSTRALIA; PRINCE CHARLES HOSP,CHERMSIDE,QLD,AUSTRALIA	University of Queensland; Royal Children's Hospital Brisbane; Prince Charles Hospital								BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BLUM RH, 1975, CANCER CHEMOTH REP 3, V6, P247; BRISTOW MR, 1981, AM HEART J, V102, P709, DOI 10.1016/0002-8703(81)90096-X; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; DEARTH J, 1984, MED PEDIATR ONCOL, V12, P54, DOI 10.1002/mpo.2950120113; HAUSDORF G, 1988, BRIT HEART J, V60, P309; MARCHANDISE B, 1989, AM HEART J, V118, P92, DOI 10.1016/0002-8703(89)90077-X; PRAGA C, 1979, CANCER TREAT REP, V63, P827; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1982, SEMIN ONCOL, V9, P23	10	82	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					816	818		10.1016/0140-6736(91)92516-5	http://dx.doi.org/10.1016/0140-6736(91)92516-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672914				2022-12-01	WOS:A1991FF22800004
J	[Anonymous]				[Anonymous]			THE HIV CATCH-22	LANCET			English	Editorial Material																		ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; RILEY VC, 1991, LANCET, V337, P183, DOI 10.1016/0140-6736(91)90853-H; 1990, LANCET, V336, P1501; 1990, LANCET, V335, P821	5	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1991	337	8745					843	843						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF228	1672926				2022-12-01	WOS:A1991FF22800018
J	BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI				BARDWELL, VJ; WICKENS, M; BIENROTH, S; KELLER, W; SPROAT, BS; LAMOND, AI			SITE-DIRECTED RIBOSE METHYLATION IDENTIFIES 2'-OH GROUPS IN POLYADENYLATION SUBSTRATES CRITICAL FOR AAUAAA RECOGNITION AND POLY(A) ADDITION	CELL			English	Article							RNA INTERACTIONS; CLEAVAGE; INVITRO; POLYMERASE; SNRNP; OLIGONUCLEOTIDES; SEQUENCE	The importance of sugar contacts for the sequence-specific recognition that occurs during polyadenylation of mRNAs was investigated with chemically synthesized substrates containing 2'-O-CH3 groups at selected riboses. An RNA (5'-CUGCAAUAAACAAGUUAA-3') with 2'-O-CH3 ribose at each nucleotide except for the AAUAAA sequence and 3'-terminal adenosine was efficiently polyadenylated in vitro. Methylation of single riboses within AAUAAA inhibited both poly(A) addition and binding of the specificity factor, but the magnitude of inhibition varied greatly at different nucleotides. Nucleotides that showed sensitivity to base substitutions did not necessarily show sensitivity to ribose methylation, and vice versa. The data indicate that the specificity factor interacts with AAUAAA through RNA-protein contacts involving essential recognition of both sugars and bases at different nucleotide positions.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Basel; European Molecular Biology Laboratory (EMBL)				Lamond, Angus/0000-0001-6204-6045	NIGMS NIH HHS [GM31892, GM00521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031892, K04GM000521, R37GM031892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BOBST AM, 1969, J MOL BIOL, V46, P221, DOI 10.1016/0022-2836(69)90418-5; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HINGERTY B, 1974, BIOCHEM BIOPH RES CO, V61, P875, DOI 10.1016/0006-291X(74)90237-X; HOLMES KC, 1980, TRENDS BIOCHEM SCI, V5, P4, DOI 10.1016/S0968-0004(80)80066-1; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; LESLIE AGW, 1978, J MOL BIOL, V119, P399, DOI 10.1016/0022-2836(78)90222-X; Maniatis T., 1982, MOL CLONING; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; WAHLE E, 1991, IN PRESS J BIOL CHEM; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGLEY PL, 1990, MOL CELL BIOL, V10, P1705, DOI 10.1128/MCB.10.4.1705; ZARKOWER D, 1987, EMBO J, V6, P177, DOI 10.1002/j.1460-2075.1987.tb04736.x; ZMUDZKA B, 1969, BIOCHEM BIOPH RES CO, V37, P895, DOI 10.1016/0006-291X(69)90215-0	28	60	60	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					125	133		10.1016/0092-8674(91)90414-T	http://dx.doi.org/10.1016/0092-8674(91)90414-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1901516				2022-12-01	WOS:A1991FF77300015
J	BIGIANI, AR; ROPER, SD				BIGIANI, AR; ROPER, SD			MEDIATION OF RESPONSES TO CALCIUM IN TASTE CELLS BY MODULATION OF A POTASSIUM CONDUCTANCE	SCIENCE			English	Article							RECEPTOR-CELLS; MEMBRANE-PROPERTIES; K+ CHANNELS; TRANSDUCTION; MUDPUPPY; SOUR	Calcium salts are strong taste stimuli in vertebrate animals. However, the chemosensory transduction mechanisms for calcium are not known. In taste buds of Necturus maculosus (mud puppy), calcium evokes depolarizing receptor potentials by acting extracellularly on the apical ends of taste cells to block a resting potassium conductance. Therefore, divalent cations elicit receptor potentials in taste cells by modulating a potassium conductance rather than by permeating the cell membrane, the mechanism utilized by monovalent cations such as sodium and potassium ions.	UNIV COLORADO,HLTH SCI CTR,ROCKY MT TASTE & SMELL CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BIGIANI, AR (corresponding author), COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523, USA.		Bigiani, Albertino/G-3024-2015	Bigiani, Albertino/0000-0001-6987-488X; Roper, Stephen/0000-0001-6049-8320	NIA NIH HHS [5 RO1 AG06557] Funding Source: Medline; NINDS NIH HHS [2 RO1 NS24107, 2 POI NS 20486] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024107, P01NS020486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006557] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; AKAIKE N, 1976, J PHYSIOL-LONDON, V254, P87, DOI 10.1113/jphysiol.1976.sp011223; ARMSTRONG CM, 1986, J GEN PHYSIOL, V87, P817, DOI 10.1085/jgp.87.5.817; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; AVENET P, 1987, J MEMBRANE BIOL, V95, P265, DOI 10.1007/BF01869488; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; JUNGE D, 1970, COMP BIOCHEM PHYSIOL, V35, P623, DOI 10.1016/0010-406X(70)90979-5; KINNAMON SC, 1987, J PHYSIOL-LONDON, V383, P601; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1989, ANN NY ACAD SCI, V560, P112, DOI 10.1111/j.1749-6632.1989.tb24085.x; KINNAMON SC, 1988, CHEM SENSES, V13, P115, DOI 10.1093/chemse/13.1.115; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KITADA Y, 1978, JPN J PHYSIOL, V28, P413; KURIHARA K, 1989, BIOSIGNAL RANSDUCTIO, P181; MCPHEETERS M, 1985, CHEM SENSES, V10, P341, DOI 10.1093/chemse/10.3.341; Moncrieff R.W., 1967, CHEM SENSES, V3rd; ROPER SD, 1989, J MEMBRANE BIOL, V109, P29, DOI 10.1007/BF01870788; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SAND O, 1986, ACTA PHYSIOL SCAND, V126, P173, DOI 10.1111/j.1748-1716.1986.tb07803.x; SATO T, 1980, PROG NEUROBIOL, V14, P25, DOI 10.1016/0301-0082(80)90003-9; SCHIFFMAN SS, 1990, CHEM SENSES, V15, P129, DOI 10.1093/chemse/15.1.129; SPIELMAN AI, 1989, BRAIN RES, V503, P326, DOI 10.1016/0006-8993(89)91684-3; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; VANDEMORTEL JBJ, 1990, BIOCHIM BIOPHYS ACTA, V1026, P220, DOI 10.1016/0005-2736(90)90067-X	25	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					126	128		10.1126/science.2011748	http://dx.doi.org/10.1126/science.2011748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011748				2022-12-01	WOS:A1991FE95200050
J	BUCK, L; AXEL, R				BUCK, L; AXEL, R			A NOVEL MULTIGENE FAMILY MAY ENCODE ODORANT RECEPTORS - A MOLECULAR-BASIS FOR ODOR RECOGNITION	CELL			English	Article							SENSITIVE ADENYLATE-CYCLASE; TROUT OLFACTORY ROSETTES; BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SPATIAL-DISTRIBUTION; BINDING-SPECIFICITY; LIGAND-BINDING; GENES; CILIA; IDENTIFICATION	The mammalian olfactory system can recognize and discriminate a large number of different odorant molecules. The detection of chemically distinct odorants presumably results from the association of odorous ligands with specific receptors on olfactory sensory neurons. To address the problem of olfactory perception at a molecular level, we have cloned and characterized 18 different members of an extremely large multigene family that encodes seven transmembrane domain proteins whose expression is restricted to the olfactory epithelium. The members of this novel gene family are likely to encode a diverse family of odorant receptors.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BUCK, L (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Axel, Richard/0000-0002-3141-4076	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 23767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoore JE., 1982, FRAGRANCE CHEM SCI S, P27; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRONSHTEIN AA, 1977, TSITOLOGIYA+, V19, P33; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; EGEL R, 1981, NATURE, V290, P191, DOI 10.1038/290191a0; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MOULTON DG, 1967, PHYSIOL REV, V47, P1, DOI 10.1152/physrev.1967.47.1.1; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; RHEIN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4412, DOI 10.1073/pnas.77.8.4412; RUSHTON W A, 1955, J Physiol, V129, P41; RUSHTON WAH, 1965, J PHYSIOL-LONDON, V176, P24, DOI 10.1113/jphysiol.1965.sp007532; Sambrook J., 1989, MOL CLONING LAB MANU; SHEPHERD GM, 1985, TASTE OLFACTION CENT, P307; SICARD G, 1985, BRAIN RES, V326, P203, DOI 10.1016/0006-8993(85)90029-0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; THOMMESEN G, 1978, ACTA PHYSIOL SCAND, V102, P205, DOI 10.1111/j.1748-1716.1978.tb06064.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPLOEG L, 1991, GENE REARRANGEMENT, P51; WALD G, 1955, J GEN PHYSIOL, V38, P623, DOI 10.1085/jgp.38.5.623	44	3432	3638	24	499	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					175	187		10.1016/0092-8674(91)90418-X	http://dx.doi.org/10.1016/0092-8674(91)90418-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1840504	Bronze			2022-12-01	WOS:A1991FF77300019
J	CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM				CHO, KWY; MORITA, EA; WRIGHT, CVE; DEROBERTIS, EM			OVEREXPRESSION OF A HOMEODOMAIN PROTEIN CONFERS AXIS-FORMING ACTIVITY TO UNCOMMITTED XENOPUS EMBRYONIC-CELLS	CELL			English	Article							RETINOIC ACID; GROWTH-FACTORS; HOMEOBOX GENE; MESODERM; INDUCTION; LAEVIS; IDENTIFICATION; SPECIFICITY; DROSOPHILA; ORGANIZER	The anteroposterior character of mesoderm induced by a peptide growth factor (XTC-MIF) was tested by transplantation into host Xenopus gastrulae. Both retinoic acid and a homeodomain protein were able to override the anteriorizing effect of the growth factor. Microinjection of a posteriorly expressed homeobox mRNA can respecify anteroposterior identity, transforming head mesoderm into tail-inducing mesoderm. Unexpectedly, overexpression of XIHbox 6 protein in the transplanted cells, without addition of growth factors, caused the formation of tail-like structures. The cells overexpressing XIHbox 6 were able to recruit cells from the host into the secondary axis. The results suggest that vertebrate homeodomain proteins are part of the biochemical pathway leading to the generation of the body axis.			CHO, KWY (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-06] Funding Source: Medline; NIGMS NIH HHS [GM-07104, GM08243] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA AR, 1989, NATURE, V341, P33; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEVELOPMENT, V107, P229; DALE L, 1987, DEVELOPMENT, V100, P279; DEROBERTIS EM, 1990, SCI AM, V263, P46, DOI 10.1038/scientificamerican0790-46; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; GURDON JB, 1987, DEVELOPMENT, V99, P285; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARVEY RP, 1986, EMBO J, V5, P1237, DOI 10.1002/j.1460-2075.1986.tb04352.x; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOLTFRETER J, 1955, ANAL DEV; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES EA, 1987, DEVELOPMENT, V101, P557; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; Nieuwkoop P. D., 1969, ROUX ARCH ENTW MECH, V162, P34; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROSA F, 1988, SCIENCE, V239, P782; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; SPEMANN H, 1918, ROUX ARCH ENTW MECH, V43, P448; Spemann H., 1938, EMBRYONIC DEV INDUCT; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1989, DEVELOPMENT, V106, P691; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	47	93	95	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					55	64		10.1016/0092-8674(91)90407-P	http://dx.doi.org/10.1016/0092-8674(91)90407-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672833	Bronze			2022-12-01	WOS:A1991FF77300008
J	DEISS, LP; KIMCHI, A				DEISS, LP; KIMCHI, A			A GENETIC TOOL USED TO IDENTIFY THIOREDOXIN AS A MEDIATOR OF A GROWTH INHIBITORY SIGNAL	SCIENCE			English	Article							TUMOR SUPPRESSOR GENES; EPSTEIN-BARR VIRUS; C-MYC SUPPRESSION; INTERFERON-GAMMA; TRANSFORMED PHENOTYPE; NECROSIS FACTOR; CDNA LIBRARIES; EXPRESSION; CLONING; CELLS	Loss of sensitivity to growth inhibitory polypeptides is likely to be one of the events that participates in the formation of some tumors and might be caused by inactivation or loss of the genetic elements that transduce these extracellular signals. The isolation of such a gene was achieved by randomly inactivating genes by an anti-sense complementary DNA expression library followed by direct selection for growth in the presence of an inhibitory polypeptide. Thus, a gene whose inactivation conveyed growth resistance to interferon-gamma (IFN-gamma) was isolated. Sequence analysis showed complete identity with human thioredoxin, a dithiol reducing agent, implicated here in the IFN-gamma-mediated growth arrest of HeLa cells.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN JM, 1990, P NATL ACAD SCI USA, V87, P5026, DOI 10.1073/pnas.87.13.5026; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DEISS LP, UNPUB; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DRINKWATER NR, 1986, P NATL ACAD SCI USA, V83, P3402, DOI 10.1073/pnas.83.10.3402; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1988, ONCOGENE, V2, P485; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINDLAY CA, 1989, CELL, V57, P1083; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; IJZERMANS JNM, 1989, IMMUNOBIOLOGY, V179, P456, DOI 10.1016/S0171-2985(89)80049-X; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P521; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STEG P S, 1988, Cancer Research, V48, P6550; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	53	185	203	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					117	120		10.1126/science.1901424	http://dx.doi.org/10.1126/science.1901424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1901424				2022-12-01	WOS:A1991FE95200047
J	ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT				ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT			CDNA CLONING OF A NOVEL 85KD PROTEIN THAT HAS SH2 DOMAINS AND REGULATES BINDING OF PI3-KINASE TO THE PDGF BETA-RECEPTOR	CELL			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; TRANSFORMATION; ASSOCIATION; ACTIVATION; ELEMENTS	Using immobilized PDGF receptor as an affinity reagent, we purified an 85 kd protein (p85) from cell lysates and we cloned its cDNA. The protein contains an SH3 domain and two SH2 domains that are homologous to domains found in several receptor-associated enzymes. Recombinant p85 overexpressed in mammalian cells inhibited the binding of endogenous p85 and a 110 kd protein to the receptor and also blocked the association of PI3-kinase activity with the receptor. Experiments with receptor mutants and with short peptides derived from the kinase insert region of the PDGF receptor showed that the recombinant p85 binds to a well-defined phosphotyrosine-containing sequence of the receptor. p85 appears to be the subunit of PI3-kinase that links the enzyme to the ligand-activated receptor.	UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; NEW YORK MED COLL,DEPT ANAT & CELL BIOL,VALHALLA,NY 10595	University of California System; University of California San Francisco; New York Medical College	ESCOBEDO, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; PHS HHS [K11-H102410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER LC, 1990, J BIOL CHEM, V265, P19704; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P362; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1988, ONCOGENE, V3, P491; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Summers MD, 1987, MANUAL METHODS BACUL; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	516	540	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					75	82		10.1016/0092-8674(91)90409-R	http://dx.doi.org/10.1016/0092-8674(91)90409-R			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849460	Bronze			2022-12-01	WOS:A1991FF77300010
J	GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI				GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI			A CYCLIN-B HOMOLOG IN SACCHAROMYCES-CEREVISIAE - CHRONIC ACTIVATION OF THE CDC28 PROTEIN-KINASE BY CYCLIN PREVENTS EXIT FROM MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; COMPONENT; PRODUCT; MPF	A cyclin B homolog was identified in Saccharomyces cerevisiae using degenerate oligonucleotides and the polymerase chain reaction. The protein, designated Scb1, has a high degree of similarity with B-type cyclins from organisms ranging from fission yeast to human. Levels of SCB1 mRNA and protein were found to be periodic through the cell cycle, with maximum accumulation late, most likely in the G2 interval. Deletion of the gene was found not to be lethal, and subsequently other B-type cyclins have been found in yeast functionally redundant with Scb1. A mutant allele of SCB1 that removes an amino-terminal fragment of the encoded protein thought to be required for efficient degradation during mitosis confers a mitotic arrest phenotype. This arrest can be reversed by inactivation of the Cdc28 protein kinase, suggesting that cyclin-mediated arrest results from persistent protein kinase activation.			GHIARA, JB (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, MB-7, LA JOLLA, CA 92037 USA.		Richardson, Helena E/A-8080-2013	Richardson, Helena E/0000-0003-3852-4953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038328, R37GM038328, R01GM043487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38328, GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GLOTZER M, 1991, NATURE, V349, P32; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; Maniatis T., 1982, MOL CLONING; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RICHARDSON HE, 1989, CELL, V59, P127; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	72	277	280	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					163	174		10.1016/0092-8674(91)90417-W	http://dx.doi.org/10.1016/0092-8674(91)90417-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849458	Bronze			2022-12-01	WOS:A1991FF77300018
J	GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD				GOLDSCHMIDTCLERMONT, M; CHOQUET, Y; GIRARDBASCOU, J; MICHEL, F; SCHIRMERRAHIRE, M; ROCHAIX, JD			A SMALL CHLOROPLAST RNA MAY BE REQUIRED FOR TRANSSPLICING IN CHLAMYDOMONAS-REINHARDTII	CELL			English	Article							NUCLEAR; INTRONS; GENE; DNA; TRANSFORMATION; MUTATIONS; STABILITY	In C. reinhardtii, the mature psaA mRNA is assembled by a process involving trans-splicing of three separate transcripts encoded at three widely scattered loci of the chloroplast genome. At least one additional chloroplast locus (tscA) is required for trans-splicing of exons 1 and 2. We have mapped this gene by transformation of a deletion mutant with a particle gun. The 0.7 kb region of the chloroplast genome that is sufficient to rescue tscA function has been subjected to insertion mutagenesis, showing that it does not contain significant open reading frames. We suggest from these experiments that the products of the tscA gene may be a small chloroplast RNA that acts in trans in the first trans-splicing reaction of psaA. A model for the mode of action of this RNA is presented, in which the characteristic structure of group II introns is assembled from three separate transcripts.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND; INST BIOL PHYS CHIM,F-75005 PARIS,FRANCE; CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	GOLDSCHMIDTCLERMONT, M (corresponding author), UNIV GENEVA,DEPT PLANT BIOL,30 QUAI E ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.		Choquet, Yves/M-5533-2019; Choquet, Yves/ABE-3084-2020; Rochaix, Jean-David/ABC-5243-2020	Choquet, Yves/0000-0003-4760-3397; 				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLOWERS AD, 1989, PLANT CELL, V1, P123, DOI 10.1105/tpc.1.1.123; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRIN DL, 1988, J BIOL CHEM, V263, P14601; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOHCHI T, 1988, NUCLEIC ACIDS RES, V16, P1025; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; OZEKI H, 1987, COLD SPRING HARB SYM, V52, P791, DOI 10.1101/SQB.1987.052.01.088; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROITGRUND C, 1990, CURR GENET, V17, P147, DOI 10.1007/BF00312860; SAMBROOK KJ, 1989, MOL CLONING LABORATO; ZUMBRUNN G, 1989, TECHNIQUE, V1, P204	30	148	155	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					135	143		10.1016/0092-8674(91)90415-U	http://dx.doi.org/10.1016/0092-8674(91)90415-U			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707343				2022-12-01	WOS:A1991FF77300016
J	GU, H; KITAMURA, D; RAJEWSKY, K				GU, H; KITAMURA, D; RAJEWSKY, K			B-CELL DEVELOPMENT REGULATED BY GENE REARRANGEMENT - ARREST OF MATURATION BY MEMBRANE-BOUND D-MU PROTEIN AND SELECTION OF DH ELEMENT READING FRAMES	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAINS; PRE-B; LIGHT-CHAIN; TRANSGENIC MICE; STEM-CELLS; VH-GENE; SEGMENTS; REGION; LOCUS; MOUSE	In productively rearranged murine V(H)-D(H)-J(H) genes (encoding immunoglobulin heavy chain variable regions), the D(H) elements are preferentially used in one particular reading frame (RF1), although the recombination breakpoints at the D(H)-J(H) border vary. Despite this variability, the bias of RF usage is not due to cellular selection by antigen but is quantitatively established at the stage of D(H)-J(H) rearrangement: RF3 is counterselected on the basis of stop codons. RF2 allows the expression of a truncated-mu-chain (D-mu-protein) from most D(H)-J(H) joints. Using B cells in which the membrane exon of the mu-chain is disrupted by homologous recombination on one of the two homologous chromosomes, we obtain evidence that membrane-bound D-mu-signals arrest of differentiation, presumably by preventing V(H)-D(H)J(H) joining. In addition to RF3 and RF2 counterselection, promotion of D(H)-J(H) joining in areas of sequence homology further enforces RF1 usage.			GU, H (corresponding author), UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY.							ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EILAT D, 1988, J IMMUNOL, V141, P1745; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; KAARTINEN M, 1985, IMMUNOL TODAY, V6, P324, DOI 10.1016/0167-5699(85)90127-6; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LANGMAN RE, 1987, MOL IMMUNOL, V24, P675, DOI 10.1016/0161-5890(87)90050-2; MARION TN, 1990, J IMMUNOL, V145, P2322; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER AM, 1990, SCIENCE, V250, P820; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RATHBUN G, 1989, IMMUNOGLOBULIN GENES; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUKADA S, 1990, J IMMUNOL, V144, P4053; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	35	213	215	2	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					47	54		10.1016/0092-8674(91)90406-O	http://dx.doi.org/10.1016/0092-8674(91)90406-O			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013094				2022-12-01	WOS:A1991FF77300007
J	GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P				GUNTHERT, U; HOFMANN, M; RUDY, W; REBER, S; ZOLLER, M; HAUSSMANN, I; MATZKU, S; WENZEL, A; PONTA, H; HERRLICH, P			A NEW VARIANT OF GLYCOPROTEIN CD44 CONFERS METASTATIC POTENTIAL TO RAT CARCINOMA-CELLS	CELL			English	Article							INHIBITS EXPERIMENTAL METASTASIS; LYMPHOCYTE HOMING RECEPTOR; HUMAN-TUMOR CELLS; MONOCLONAL-ANTIBODIES; HIGH ENDOTHELIUM; MELANOMA-CELLS; SURFACE GLYCOPROTEINS; PLASMINOGEN-ACTIVATOR; EXPRESSION; GENE	Using a monoclonal antibody (MAb1.1ASML) raised against a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML, cDNA clones have been isolated that encode glycoproteins with partial homology to CD44, a presumed adhesion molecule. In one of the clones, pMeta-1, the epitope marks an additional extracellular domain of 162 amino acids inserted into the rat CD44 protein between amino acid positions 223 and 247 (by analogy to human and murine CD44). The new variants are expressed only in the metastasizing cell lines of two rat tumors, the pancreatic carcinoma BSp73 and the mammary adenocarcinoma 13762NF; they are not expressed in the nonmetastasizing tumor cell lines nor in most normal rat tissues. Overexpression of pMeta-1 in the nonmetastasizing BSp73AS cells suffices to establish full metastatic behavior.	GERMAN CANC RES CTR,INST RADIOL & PATHOPHYSIOL,W-6900 HEIDELBERG 1,GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,W-7500 KARLSRUHE 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology	GUNTHERT, U (corresponding author), UNIV KARLSRUHE,INST GENET,W-7500 KARLSRUHE 1,GERMANY.		Hofmann-Apitius, Martin/E-6123-2018	Hofmann-Apitius, Martin/0000-0001-9012-6720				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; CARR I, 1981, Invasion and Metastasis, V1, P34; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1989, CANCER RES, V49, P5323; DENNING SM, 1990, J IMMUNOL, V144, P7; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FRISCH SM, 1990, ONCOGENE, V5, P75; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GARBISA S, 1987, CANCER RES, V47, P1523; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HUET S, 1989, J IMMUNOL, V143, P798; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KANSAS GS, 1989, J IMMUNOL, V142, P3050; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY J, 1990, EXP CELL RES, V187, P224, DOI 10.1016/0014-4827(90)90085-O; MATZKU S, 1983, INVAS METAST, V3, P109; MATZKU S, 1989, CANCER RES, V49, P1294; MATZKU S, 1984, CANCER IMMUNOL IMMUN, V17, P106, DOI 10.1007/BF00200045; MCCARTHY JB, 1988, J NATL CANCER I, V80, P108, DOI 10.1093/jnci/80.2.108; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RAZ A, 1989, CANCER RES, V49, P3489; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; REICH R, 1988, CANCER RES, V48, P3307; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WONG YC, 1990, BIOCHEM BIOPH RES CO, V166, P984, DOI 10.1016/0006-291X(90)90908-6; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	65	1626	1717	1	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					13	24		10.1016/0092-8674(91)90403-L	http://dx.doi.org/10.1016/0092-8674(91)90403-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707342	Bronze			2022-12-01	WOS:A1991FF77300004
J	KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV				KOLLER, KJ; LOWE, DG; BENNETT, GL; MINAMINO, N; KANGAWA, K; MATSUO, H; GOEDDEL, DV			SELECTIVE ACTIVATION OF THE B-NATRIURETIC PEPTIDE RECEPTOR BY C-TYPE NATRIURETIC PEPTIDE (CNP)	SCIENCE			English	Article							GUANYLATE-CYCLASE; SEQUENCE-ANALYSIS; ATRIAL; BRAIN; PRECURSOR; CLONING; BINDING; PLASMA	The natriuretic peptides are hormones that can stimulate natriuretic, diuretic, and vasorelaxant activity in vivo, presumably through the activation of two known cell surface receptor guanylyl cyclases (ANPR-A and ANPR-B). Although atrial natriuretic peptide (ANP) and, to a lesser extent, brain natriuretic peptide (BNP) are efficient activators of the ANPR-A guanylyl cyclase, neither hormone can significantly stimulate ANPR-B. A member of this hormone family, C-type natriuretic peptide (CNP), potently and selectively activated the human ANPR-B guanylyl cyclase. CNP does not increase guanosine 3',5'-monophosphate accumulation in cells expressing human ANPR-A. The affinity of CNP for ANPR-B is 50- or 500-fold higher than ANP or BNP, respectively. This ligand-receptor pair may be involved in the regulation of fluid homeostasis by the central nervous system.	GENENTECH INC,DEPT IMMUNOL RES & ASSAY TECHNOL,S SAN FRANCISCO,CA 94080; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN; MIYAZAKI MED COLL,DEPT BIOCHEM,MIYAZAKI 88916,JAPAN	Roche Holding; Genentech; National Cerebral & Cardiovascular Center - Japan; University of Miyazaki	KOLLER, KJ (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080, USA.							ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ANANDSRIVASTAVA MB, 1987, J BIOL CHEM, V262, P4931; BAXTER JD, 1988, BIO-TECHNOL, V6, P529, DOI 10.1038/nbt0588-529; BOVY PR, 1990, MED RES REV, V10, P115, DOI 10.1002/med.2610100105; CHABOT JG, 1990, CURRENT ASPECTS NEUR, V1, pCH2; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1990, BIOCHEM BIOPH RES CO, V170, P201, DOI 10.1016/0006-291X(90)91260-Y; HIRATA M, 1989, BIOCHIM BIOPHYS ACTA, V1010, P346, DOI 10.1016/0167-4889(89)90060-8; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; KAMBAYASHI Y, 1990, FEBS LETT, V259, P341, DOI 10.1016/0014-5793(90)80043-I; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLER KP, UNPUB; LOWE DA, UNPUB; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1990, NUCLEIC ACIDS RES, V18, P3412, DOI 10.1093/nar/18.11.3412; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; MCGREGOR A, 1990, J CLIN ENDOCR METAB, V70, P1103, DOI 10.1210/jcem-70-4-1103; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; MINAMINO N, UNPUB; MIYATA A, 1985, BIOCHEM BIOPH RES CO, V129, P248, DOI 10.1016/0006-291X(85)91429-9; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SONG DL, 1988, FEBS LETT, V232, P125, DOI 10.1016/0014-5793(88)80400-9; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; WILCOX JD, UNPUB	31	728	753	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					120	123		10.1126/science.1672777	http://dx.doi.org/10.1126/science.1672777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	1672777				2022-12-01	WOS:A1991FE95200048
J	LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D				LECHLEITER, J; GIRARD, S; PERALTA, E; CLAPHAM, D			SPIRAL CALCIUM WAVE-PROPAGATION AND ANNIHILATION IN XENOPUS-LAEVIS OOCYTES	SCIENCE			English	Article							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; RELEASE; ACTIVATION; CURVATURE; MODEL	Intracellular calcium (Ca2+) is a ubiquitous second messenger. Information is encoded in the magnitude, frequency, and spatial organization of changes in the concentration of cytosolic free Ca2+. Regenerative spiral waves of release of free Ca2+ were observed by confocal microscopy in Xenopus laevis oocytes expressing muscarinic acetylcholine receptor subtypes. This pattern of Ca2+ activity is characteristic of an intracellular milieu that behaves as a regenerative excitable medium. The minimal critical radius for propagation of focal Ca2+ waves (10.4 micrometers) and the effective diffusion constant for the excitation signal (2.3 x 10(-6) square centimeters per second) were estimated from measurements of velocity and curvature of circular wavefronts expanding from foci. By modeling Ca2+ release with cellular automata, the absolute refractory period for Ca2+ stores (4.7 seconds) was determined. Other phenomena expected of an excitable medium, such as wave propagation of undiminished amplitude and annihilation of colliding wavefronts, were observed.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Mayo Clinic; Harvard University			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				BACKX PH, 1989, J GEN PHYSIOL, V93, P963, DOI 10.1085/jgp.93.5.963; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1989, PROC R SOC SER B-BIO, V238, P235, DOI 10.1098/rspb.1989.0079; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CHEEK TR, 1989, J CELL SCI, V93, P211; DASCAL N, 1990, FEBS LETT, V267, P22, DOI 10.1016/0014-5793(90)80278-Q; DELISLE S, 1990, J BIOL CHEM, V265, P11726; FOERSTER P, 1989, P NATL ACAD SCI USA, V86, P6831, DOI 10.1073/pnas.86.18.6831; FOERSTER P, 1988, SCIENCE, V241, P685, DOI 10.1126/science.241.4866.685; GERHARDT M, 1990, SCIENCE, V247, P1563, DOI 10.1126/science.2321017; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HARKINS A B, 1991, Biophysical Journal, V59, p240A; KEENER JP, 1986, PHYSICA D, V21, P307, DOI 10.1016/0167-2789(86)90007-2; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, IN PRESS NATURE; MARKUS M, 1990, NATURE, V347, P56, DOI 10.1038/347056a0; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; Winfree A., 1987, TIME BREAKS; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINFREE AT, 1990, ANN NY ACAD SCI, V591, P190; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	32	610	624	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					123	126		10.1126/science.2011747	http://dx.doi.org/10.1126/science.2011747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011747				2022-12-01	WOS:A1991FE95200049
J	LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS				LEONE, A; FLATOW, U; KING, CR; SANDEEN, MA; MARGULIES, IMK; LIOTTA, LA; STEEG, PS			REDUCED TUMOR-INCIDENCE, METASTATIC POTENTIAL, AND CYTOKINE RESPONSIVENESS OF NM23-TRANSFECTED MELANOMA-CELLS	CELL			English	Article							GENE; NM23; DROSOPHILA; PROTEIN	Reduced expression of the nm23 gene in certain rodent model systems and human breast tumors has been correlated with high tumor metastatic potential. To investigate the functional effects of nm23 expression, we have transfected a constitutive murine nm23-1 expression construct into highly metastatic K-1735 TK murine melanoma cells. TK clones expressing the exogenous nm23-1 construct exhibited a reduced incidence of primary tumor formation, significant reductions in tumor metastatic potential independent of tumor cell growth, and altered responses to the cytokine transforming growth factor-beta-1 in soft agar colonization assays, compared with control-transfected TK clones. In contrast, nm23-1-transfected TK clones exhibited no significant differences in intrinsic tumor cell growth, i.e., primary tumor size in vivo, anchorage-dependent growth rate in vitro, and anchorage-independent colony formation in soft agar in vitro. The data demonstrate a suppressive effect of nm23 on several aspects of the cancer process, including tumor metastasis.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21740; MOLEC ONCOL INC,GAITHERSBURG,MD 20878	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LEONE, A (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.		leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAROLF CR, 1988, DEV BIOL, V129, P169; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALEBIC T, 1988, CLIN EXP METASTAS, V6, P301, DOI 10.1007/BF01753577; KIKKAWA S, 1991, IN PRESS J BIOL CHEM; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; ROSENBERG SA, 1987, SURGICAL TREATMENT M; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWARZ LC, 1988, CANCER RES, V48, P6999; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	23	575	614	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					25	35		10.1016/0092-8674(91)90404-M	http://dx.doi.org/10.1016/0092-8674(91)90404-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013093	Bronze			2022-12-01	WOS:A1991FF77300005
J	NEWMAN, A; NORMAN, C				NEWMAN, A; NORMAN, C			MUTATIONS IN YEAST U5 SNRNA ALTER THE SPECIFICITY OF 5' SPLICE-SITE CLEAVAGE	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER RNA; U1 SNRNA; HOST STRAINS; TACTAAC BOX; PROTEIN; DNA; IDENTIFICATION; REQUIREMENTS; RECOGNITION	Recognition of 5' splice sites in pre-mRNA splicing is achieved in part by base pairing with U1 snRNA. We have used interactive suppression in the yeast Saccharomyces cerevisiae to look for other factors involved in 5' splice-site recognition. This approach identified an extragenic suppressor that activates a cryptic 5' splice site. The suppressor is a gene for U5 snRNA (snR7) with a single base mutation in a strictly conserved 9 base sequence. This suggests that U5 snRNA can play a part in determining the position of 5' splice-site cleavage. Consistent with this, we have been able to isolate other mutations in the 9 base element in U5 snRNA that specifically activate a second cryptic 5' splice site nearby.			NEWMAN, A (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; Green MR, 1989, CURR OPIN CELL BIOL, V1, P519, DOI 10.1016/0955-0674(89)90014-8; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUTENBERGER JA, 1987, GENE ANAL TECH, V4, P87, DOI 10.1016/0735-0651(87)90001-X; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; Miller JH., 1972, EXPT MOL GENETICS; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PERELMAN D, 1990, MOL CELL BIOL, V10, P3284, DOI 10.1128/MCB.10.6.3284; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; VIJAYRAGHAVAN U, 1989, NUCLEIC ACIDS MOL BI, V3, P197; WHITTAKER E, 1990, P NATL ACAD SCI USA, V87, P2216, DOI 10.1073/pnas.87.6.2216; WINKELMANN G, 1989, EMBO J, V8, P3105, DOI 10.1002/j.1460-2075.1989.tb08462.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	47	188	208	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					115	123		10.1016/0092-8674(91)90413-S	http://dx.doi.org/10.1016/0092-8674(91)90413-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013092	Bronze			2022-12-01	WOS:A1991FF77300014
J	OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD				OTSU, M; HILES, I; GOUT, I; FRY, MJ; RUIZLARREA, F; PANAYOTOU, G; THOMPSON, A; DHAND, R; HSUAN, J; TOTTY, N; SMITH, AD; MORGAN, SJ; COURTNEIDGE, SA; PARKER, PJ; WATERFIELD, MD			CHARACTERIZATION OF 2 85KD PROTEINS THAT ASSOCIATE WITH RECEPTOR TYROSINE KINASES, MIDDLE-T/PP60C-SRC COMPLEXES, AND PI3-KINASE	CELL			English	Article							MIDDLE-T-ANTIGEN; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-II; PHOSPHATIDYLINOSITOL KINASE; PDGF RECEPTOR; SEQUENCE-ANALYSIS; MESSENGER-RNAS; BOVINE BRAIN; INOSITOL 3-PHOSPHATE; HEMATOPOIETIC-CELLS	Affinity-purified bovine brain phosphatidylinositol 3-kinase (PI3-kinase) contains two major proteins of 85 and 110 kd. Amino acid sequence analysis and cDNA cloning reveals two related 85 kd proteins (p85-alpha and p85-beta), which both contain one SH3 and two SH2 regions (src homology regions). When expressed, these 85 kd proteins bind to and are substrates for tyrosine-phosphorylated receptor kinases and the polyoma virus middle-T antigen/pp60c-src complex, but lack PI3-kinase activity. However, an antiserum raised against p85-beta immunoprecipitates PI3-kinase activity. The active PI3-kinase complex containing p85-alpha or p85-beta and the 110 kd protein binds to PDGF but not EGF receptors. p85-alpha and p85-beta may mediate specific PI3-kinase interactions with a subset of tyrosine kinases.	UNIV COLL & MIDDLX SCH MED,DEPT CHEM PATHOL,LONDON,ENGLAND; EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	University of London; University College London; European Molecular Biology Laboratory (EMBL)	OTSU, M (corresponding author), LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON,ENGLAND.		Hsuan, Justin/C-8825-2009; Parker, Peter j/D-5192-2013	Hsuan, Justin/0000-0001-6083-7564; Fry, Michael/0000-0001-8518-1370; parker, peter/0000-0002-6218-2933; Ruiz Larrea, Fernanda/0000-0001-5610-7745				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P294; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COHEN B, 1990, MOL CELL BIOL, V87, P4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSTOVA J, 1989, NUCLEIC ACIDS RES, V17, P1427, DOI 10.1093/nar/17.4.1427; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACDONALD ML, 1985, P NATL ACAD SCI USA, V82, P3993, DOI 10.1073/pnas.82.12.3993; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P499, DOI 10.1093/nar/12.1Part2.499; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STOCKWELL PA, 1987, COMPUT APPL BIOSCI, V3, P37; SUGANO S, 1985, MOL CELL BIOL, V5, P2399, DOI 10.1128/MCB.5.9.2399; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; Summers MD, 1987, MANUAL METHODS BACUL; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; THOMPSON DM, 1985, J BIOL CHEM, V260, P8824; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1984, EMBO J, V3, P361, DOI 10.1002/j.1460-2075.1984.tb01812.x; ULUG ET, 1990, J VIROL, V64, P3995; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	114	733	823	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					91	104		10.1016/0092-8674(91)90411-Q	http://dx.doi.org/10.1016/0092-8674(91)90411-Q			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1707345	Bronze			2022-12-01	WOS:A1991FF77300012
J	PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J				PAIN, B; WOODS, CM; SAEZ, J; FLICKINGER, T; RAINES, M; PEYROL, S; MOSCOVICI, C; MOSCOVICI, MG; KUNG, HJ; JURDIC, P; LAZARIDES, E; SAMARUT, J			EGF-R AS A HEMATOPOIETIC GROWTH-FACTOR RECEPTOR - THE C-ERBB PRODUCT IS PRESENT IN CHICKEN ERYTHROCYTIC PROGENITORS AND CONTROLS THEIR SELF-RENEWAL	CELL			English	Article							THYROID-HORMONE RECEPTOR; AVIAN-LEUKOSIS VIRUS; TARGET-CELLS; ERYTHROBLASTOSIS; EXPRESSION; ACTIVATION; ONCOGENE; PROTEIN; INVITRO; DIFFERENTIATION	c-erbB, encoding the EGF receptor (EGF-R), was originally identified as the cellular homolog of a chicken leukemia oncogene. In humans, EGF-R is distributed widely except in hemopoietic tissues, and its amplification is associated with epidermal and glial malignancies. Here we show that c-erbB is present in normal chicken erythrocytic progenitors and transmits the mitogenic signal induced by TGF-alpha. Cells that contain high affinity EGF-R are at approximately the BFU-E stage, and their long-term renewal can be induced by TGF-alpha. Upon addition of insulin and erythropoietin, they can be induced to terminally differentiate into red cells. We previously demonstrated that v-erbA blocks differentiation of chicken erythrocytic progenitors but does not abrogate their growth factor dependence for proliferation. These data indicate that proliferation and differentiation are not necessarily coupled in these cells. They also demonstrate a direct role of c-erbB in the control of self-renewal of normal chicken erythrocytic progenitors and could account for the predominant leukemogenic potential of the chicken erbB gene.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; HOP DEBROUSSE, INSERM, F-69005 Lyon, FRANCE; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; PASTEUR INST, Lyon, FRANCE; VET ADM MED CTR, TUMOR VIROL LAB, GAINESVILLE, FL 32601 USA	California Institute of Technology; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	PAIN, B (corresponding author), ECOLE NORMALE SUPER LYON, INRA, CNRS, BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE.		Kung, Hsing-Jien/C-7651-2013; Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444	NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NCI NIH HHS [CA39207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN TD, 1990, COLONY STIMULATING F, P1; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BERNIER M, 1986, ENDOCRINOLOGY, V118, P2254, DOI 10.1210/endo-118-6-2254; BEUG H, 1982, J CELL PHYSIOL, P195; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.bi.56.070187.004313; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GLINEUR C, 1989, ONCOGENE, V4, P1247; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; ISCOVE N, 1990, NATURE, V347, P126, DOI 10.1038/347126a0; KAZIMIERCZAK J, 1986, CELL TISSUE RES, V245, P487; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MAIHLE NJ, 1991, IN PRESS P NATL ACAD; MILLER M, 1990, ONCOGENE, V5, P1125; MURA CV, 1981, J BIOL CHEM, V256, P9767; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NILSEN TW, 1985, JCELL, V41, P7149; PAIN B, 1990, New Biologist, V2, P284; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAMARUT J, 1908, J CELL PHYSL, V105, P553; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	40	93	96	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					37	46		10.1016/0092-8674(91)90405-N	http://dx.doi.org/10.1016/0092-8674(91)90405-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1672832	Bronze			2022-12-01	WOS:A1991FF77300006
J	SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B				SHARP, KA; NICHOLLS, A; FINE, RF; HONIG, B			RECONCILING THE MAGNITUDE OF THE MICROSCOPIC AND MACROSCOPIC HYDROPHOBIC EFFECTS	SCIENCE			English	Article							FREE-ENERGY; SURFACE; DEPENDENCE; AREA	The magnitude of the hydrophobic effect, as measured from the surface area dependence of the solubilities of hydrocarbons in water, is generally thought to be about 25 calories per mole per square angstrom (cal mol-1 angstrom-2). However, the surface tension at a hydrocarbon-water interface, which is a "macroscopic" measure of the hydrophobic effect, is almost-equal-to 72 cal mol-1 angstrom-2. In an attempt to reconcile these values, alkane solubility data have been reevaluated to account for solute-solvent size differences, leading to a revised "microscopic" hydrophobic effect of 47 cal mol-1 angstrom-2. This value, when used in a simple geometric model for the curvature dependence of the hydrophobic effect, predicts a macroscopic alkane-water surface tension that is close to the macroscopic value.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168 ST, NEW YORK, NY 10032 USA; BIOSYM TECHNOL INC, SAN DIEGO, CA 92121 USA	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030518, R01GM041371, R37GM030518] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30518, GM41371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1907, PHYSICAL CHEM SURFAC; AVEYARD R, 1965, J COLLOID INTERF SCI, V20, P2255; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BENNAIM A, 1978, J PHYS CHEM-US, V82, P792, DOI 10.1021/j100496a008; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BUFF FP, 1965, PHYS REV LETT, V15, P621, DOI 10.1103/PhysRevLett.15.621; CHOI DS, 1970, J CHEM PHYS, V53, P2608, DOI 10.1063/1.1674378; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DEYOUNG LR, 1990, J PHYS CHEM-US, V94, P801, DOI 10.1021/j100365a054; DILL KA, 1990, SCIENCE, V250, P297, DOI 10.1126/science.2218535; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINE R, UNPUB; Flory PJ, 1941, J CHEM PHYS, V9, P660, DOI 10.1063/1.1750971; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; HERMANN RB, 1977, P NATL ACAD SCI USA, V74, P4144, DOI 10.1073/pnas.74.10.4144; HILDEBRAND JH, 1947, J CHEM PHYS, V15, P225, DOI 10.1063/1.1746484; Huggins ML, 1941, J CHEM PHYS, V9, P440, DOI 10.1063/1.1750930; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; MANSOORI GA, 1971, J CHEM PHYS, V54, P1523, DOI 10.1063/1.1675048; MCAULIFFE C, 1966, J PHYS CHEM-US, V70, P1267, DOI 10.1021/j100876a049; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; NICHOLLS A, UNPUB; PIEROTTI RA, 1965, J PHYS CHEM-US, V69, P281, DOI 10.1021/j100885a043; POSTMA JPM, 1982, FARADAY SYMP CHEM S, P55, DOI 10.1039/fs9821700055; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; TANFORD C, 1979, P NATL ACAD SCI USA, V76, P4175, DOI 10.1073/pnas.76.9.4175; TANFORD C, 1980, HYDROPHOBIC EFFECT; TOLMAN RC, 1949, J CHEM PHYS, V17, P333, DOI 10.1063/1.1747247	31	482	488	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1991	252	5002					106	109		10.1126/science.2011744	http://dx.doi.org/10.1126/science.2011744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011744				2022-12-01	WOS:A1991FE95200043
J	SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J				SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J			CLONING OF PI3 KINASE ASSOCIATED P85 UTILIZING A NOVEL METHOD FOR EXPRESSION CLONING OF TARGET PROTEINS FOR RECEPTOR TYROSINE KINASES	CELL			English	Article							PHOSPHOLIPASE C-II; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; CATALYTIC DOMAINS; PHOSPHORYLATION; TRANSFORMATION; ELEMENTS	A novel method has been developed to allow cloning of protein targets for receptors with tyrosine kinase activity. By utilizing the carboxy-terminal tail of EGF receptor (EGFR) as a probe to screen lambda-gt11 expression libraries, several EGFR-binding proteins have been cloned; two have been analyzed and contain unique SH2 and SH3 domains. One gene (GRB-1) has been fully sequenced, is expressed in various tissues and cell lines, and has a molecular mass of 85 kd. Interestingly, GRB-1 encodes the human counterpart of the PI3 kinase-associated protein p85. Advantages of this technique include the ease of cloning tyrosine kinase receptor targets present at low levels and the ability to identify proteins that are related in their capacity to bind activated receptors but contain no significant DNA sequence homology. This method, termed CORT (for cloning of receptor targets), offers a general approach for the identification and cloning of various receptor targets.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	SKOLNIK, EY (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; 	NIDDK NIH HHS [DK01927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001927] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS G, 1990, EMBO J, V9, P4375; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OTSU M, 1991, CELL; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V335, P90; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; [No title captured]	42	595	645	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					83	90		10.1016/0092-8674(91)90410-Z	http://dx.doi.org/10.1016/0092-8674(91)90410-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849461	Bronze			2022-12-01	WOS:A1991FF77300011
J	SUBBIAH, S				SUBBIAH, S			LOW-RESOLUTION REAL-SPACE ENVELOPES - AN APPROACH TO THE ABINITIO MACROMOLECULAR PHASE PROBLEM	SCIENCE			English	Article							INFORMATION-THEORY; MAXIMUM-ENTROPY; CRYSTALLOGRAPHY; REFINEMENT; CRYSTAL; IMAGES	An ab initio approach to the phase problem in macromolecular x-ray crystallography is described. A random gas of hard-sphere point scatterers is allowed to condense under the constraint of the solvent fraction and the restraint of the observed Fourier amplitude data. Two applications to real macromolecular examples are discussed. This method produces an approximate outline of the bulk solvent regions and thus yields a low-resolution picture of the unit cell that can be extended to higher resolutions in special cases, such as through the use of molecular replacement or of noncrystallographic symmetry-based phase extension.			SUBBIAH, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041455, R37GM041455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1986, P NATL ACAD SCI USA, V83, P5489, DOI 10.1073/pnas.83.15.5489; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRICOGNE G, 1984, ACTA CRYSTALLOGR A, V40, P410, DOI 10.1107/S0108767384000866; BRICOGNE G, 1982, COMPUTATIONAL CRYSTA, P258; BRITTEN PL, 1982, ACTA CRYSTALLOGR A, V38, P12; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLLINS DM, 1982, NATURE, V298, P49, DOI 10.1038/298049a0; COXETER HSM, 1961, INTRO GEOMETRY, P404; FLAHERTY KM, UNPUB; HAUPTMAN HA, 1972, CRYSTAL STRUCTURE DE; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARLE J, 1986, SCIENCE, V232, P837, DOI 10.1126/science.232.4752.837; KARLE J, 1950, ACTA CRYSTALLOGR, V3, P181, DOI 10.1107/S0365110X50000446; KARLE J, 1989, ACTA CRYSTALLOGR A, V45, P765, DOI 10.1107/S0108767389007403; KARLE J, 1980, INT J QUANTUM CHEM, V7, P357; KEEN DA, 1990, NATURE, V344, P423, DOI 10.1038/344423a0; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P515, DOI 10.1107/S0365110X58001456; KLUG A, 1958, ACTA CRYSTALLOGR A, V40, P11; LIPSCOMB WN, 1949, ACTA CRYSTALLOGR, V2, P193, DOI 10.1107/S0365110X49000515; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; MONDRAGON A, 1989, J MOL BIOL, V205, P189, DOI 10.1016/0022-2836(89)90375-6; NARAYAN R, 1982, ACTA CRYSTALLOGR A, V38, P122, DOI 10.1107/S0567739482000229; NAVAZA J, 1985, ACTA CRYSTALLOGR A, V41, P222; Patterson AL, 1934, PHYS REV, V46, P0372, DOI 10.1103/PhysRev.46.372; PIRO OE, 1983, ACTA CRYSTALLOGR A, V39, P61, DOI 10.1107/S0108767383000094; PODJARNY AD, 1987, ANNU REV BIOPHYS BIO, V16, P351; POST B, 1979, ACTA CRYSTALLOGR A, V35, P17, DOI 10.1107/S0567739479000048; PRINCE E, 1988, ACTA CRYSTALLOGR A, V44, P218; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SEMENOVSKAYA SV, 1985, ACTA CRYSTALLOGR A, V41, P268, DOI 10.1107/S0108767385000563; SHEN W, 1987, NATURE, V329, P232, DOI 10.1038/329232a0; SUBBIAH S, UNPUB; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; THAYER M, IN PRESS J MOL BIOL; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WILKINS SW, 1983, ACTA CRYSTALLOGR A, V39, P47, DOI 10.1107/S0108767383000082; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813	39	35	38	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					128	133		10.1126/science.2011749	http://dx.doi.org/10.1126/science.2011749			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011749				2022-12-01	WOS:A1991FE95200051
J	SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K				SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K			THE ROLE OF CDC28 AND CYCLINS DURING MITOSIS IN THE BUDDING YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							CELL-DIVISION CYCLE; P34CDC2 PROTEIN-KINASE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; MITOTIC CONTROL; MESSENGER-RNA; COMPONENT	cdc28-1N is a conditional allele that has normal G1 (Start) function but confers a mitotic defect. We have isolated seven genes that in high dosage suppress the growth defect of cdc28-1N cells but not of Start-defective cdc28-4 cells. Three of these (CLB1, CLB2, and CLB4) encode proteins strongly homologous to G2-specific B-type cyclins. Another gene, CLB3, was cloned using PCR. CLB1 and CLB2 encode a pair of closely related proteins; CLB3 and CLB4 encode a second pair. Neither CLB1 nor CLB2 is essential; however, disruption of both is lethal and causes a mitotic defect. Furthermore, the double mutant cdc28-1N clb2::LEU2 is nonviable, whereas cdc28-4 clb2::LEU2 is viable, suggesting that the cdc28-1N protein may be defective in its interaction with B-type cyclins. Our results are consistent with CDC28 function being required in both G1 and mitosis. Its mitotic role, we believe, involves interaction with a family of at least four G2-specific cyclins.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory	SURANA, U (corresponding author), RES INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Surana, Uttam/H-1142-2011	Nasmyth, Kim/0000-0001-7030-4403; Surana, Uttam/0000-0002-4785-6514				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CARTER LA, 1978, EXP CELL RES, V112, P15; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOEBL M, 1988, CELL, V54, P739; GORDON CN, 1977, J CELL SCI, V24, P81; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTIG A, 1981, CURR GENET, V4, P29, DOI 10.1007/BF00376783; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T., 1982, MOL CLONING; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WEINERT T, 1989, J CELL SCI, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064	64	428	440	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					145	161		10.1016/0092-8674(91)90416-V	http://dx.doi.org/10.1016/0092-8674(91)90416-V			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849457	Bronze			2022-12-01	WOS:A1991FF77300017
J	VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM				VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM			DEVELOPMENTAL ABNORMALITIES IN TRANSGENIC MICE EXPRESSING A SIALIC-ACID SPECIFIC 9-O-ACETYLESTERASE	CELL			English	Article							INFLUENZA-C VIRUS; MELANOMA-ASSOCIATED GANGLIOSIDE; DE-ORTHO-ACETYLATION; CELL-SURFACE; O-ACETYLATION; MEMBRANE-FUSION; GERMINAL CELLS; RAT RETINA; LOW-PH; HEMAGGLUTININ	9-O-acetylation of sialic acids is tissue specific and developmentally regulated. We have selectively destroyed these O-acetyl groups during murine embryogenesis by expressing the 9-O-acetyl-sialic acid-specific esterase of influenza C. DNA constructs driven by the metallothionein promoter arrested development at the 2-cell stage and gave a markedly decreased yield of live mice. A similar construct driven by the phenylethanolamine-N-methyltransferase promoter did not cause this block, but gave transgenic mice with selective expression of esterase in the retina and the adrenal gland. These organs showed variable abnormalities in organization, while all other tissues examined appeared normal. The ganglioside 9-O-acetyl-G(D3) was selectively destroyed in target tissues. Thus, 9-O-acetylated sialic acids may play an role in murine development at the 2-cell stage and in certain differentiated tissues.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	VARKI, A (corresponding author), UNIV CALIF SAN DIEGO, SAN DIEGO CANC CTR, LA JOLLA, CA 92093 USA.		Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035880, R37GM032373, R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [CA23100] Funding Source: Medline; NIGMS NIH HHS [GM35880, GM32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BECH K, 1969, ACTA PATHOL MIC SC, V76, P391; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BOUHOURS D, 1983, J BIOL CHEM, V258, P299; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHANEY W, 1986, J BIOL CHEM, V261, P551; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1989, J BIOL CHEM, V264, P3409; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DEKAN G, 1990, AM J PATHOL, V137, P913; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELS MC, 1989, VIROLOGY, V170, P346, DOI 10.1016/0042-6822(89)90394-2; FARQUHAR MG, 1991, IN PRESS INTRACELLUL; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FORMANOWSKI F, 1990, J GEN VIROL, V71, P1181, DOI 10.1099/0022-1317-71-5-1181; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GENDEL S, 1983, J BACTERIOL, V156, P148, DOI 10.1128/JB.156.1.148-154.1983; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; Hogan B., 1986, MANIPULATING MOUSE E; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KORNFELD S, 1982, CIBA F SYMP, V92, P138; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MENDEZOTERO R, 1988, J NEUROSCI, V8, P564; MONK M, 1987, MAMMALIAN DEV; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORRISON TG, 1989, VIROLOGY, V171, P10, DOI 10.1016/0042-6822(89)90505-9; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NISHIMURA H, 1988, J GEN VIROL, V69, P2545, DOI 10.1099/0022-1317-69-10-2545; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0; REID PE, 1984, HISTOCHEM J, V16, P235, DOI 10.1007/BF01003608; REITMAN ML, 1982, J BIOL CHEM, V257, P357; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; Rutishauser U, 1990, Adv Exp Med Biol, V265, P179; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SCHACHTER H, 1988, BIOCHIMIE, V70, P1701, DOI 10.1016/0300-9084(88)90309-4; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SERONFERRE M, 1981, ANNU REV PHYSIOL, V43, P141, DOI 10.1146/annurev.ph.43.030181.001041; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEVENS ME, 1989, EXP CELL RES, V183, P319, DOI 10.1016/0014-4827(89)90392-3; THEILER K, 1974, Z ANAT ENTWICKLUNGS, V144, P195, DOI 10.1007/BF00519775; THURIN J, 1985, J BIOL CHEM, V260, P4556; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; VARKI A, 1983, J BIOL CHEM, V258, P2465; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; WARING H, 1936, J MICROSC SCI, V78, P329; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	82	124	124	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					65	74		10.1016/0092-8674(91)90408-Q	http://dx.doi.org/10.1016/0092-8674(91)90408-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1826463	Bronze			2022-12-01	WOS:A1991FF77300009
J	VOS, JC; SASKER, M; STUNNENBERG, HG				VOS, JC; SASKER, M; STUNNENBERG, HG			PROMOTER MELTING BY A STAGE-SPECIFIC VACCINIA VIRUS TRANSCRIPTION FACTOR IS INDEPENDENT OF THE PRESENCE OF RNA-POLYMERASE	CELL			English	Article							ACCURATE TRANSCRIPTION; GENE-TRANSCRIPTION; INITIATION-FACTOR; SOLUBLE EXTRACT; DNA-REPLICATION; PURIFICATION; PROTEIN; INVITRO; REQUIREMENT; MECHANISM	Fractionation of an extract prepared from HeLa cells infected with vaccinia virus resulted in the separation of factors involved in vaccinia virus intermediate transcription. Two activities, VITF-A and VITF-B, in addition to the viral RNA polymerase are necessary and sufficient to direct intermediate transcription in vitro. VITF-B confers intermediate promoter specificity to an early-specific extract prepared from virus particles. A committed complex between VITF-B and the template can sequester VITF-A and RNA polymerase into a preinitiation complex. VITF-B is further able to melt the promoter at the start site of transcription. Open complex formation is stimulated by ATP. In contrast to prokaryotic and eukaryotic pol III transcription, promoter melting is independent of the presence of RNA polymerase.			VOS, JC (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Vos, J. Chris/0000-0003-3737-9942				BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; HOODADHINGRA U, 1989, J VIROL, V63, P714, DOI 10.1128/JVI.63.2.714-729.1989; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHMITT JFC, 1988, J VIROL, V62, P1889, DOI 10.1128/JVI.62.6.1889-1897.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHWER B, 1988, EMBO J, V7, P1183, DOI 10.1002/j.1460-2075.1988.tb02929.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WRIGHT CF, 1989, J VIROL, V63, P4224, DOI 10.1128/JVI.63.10.4224-4233.1989; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	40	45	45	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					105	113		10.1016/0092-8674(91)90412-R	http://dx.doi.org/10.1016/0092-8674(91)90412-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	2013091	Bronze			2022-12-01	WOS:A1991FF77300013
J	WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB				WEBER, JM; LEUNG, JO; SWANSON, SJ; IDLER, KB; MCALPINE, JB			AN ERYTHROMYCIN DERIVATIVE PRODUCED BY TARGETED GENE DISRUPTION IN SACCHAROPOLYSPORA-ERYTHRAEA	SCIENCE			English	Article							RAT MAMMARY-GLAND; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; MYCOBACTERIUM-AVIUM; NUCLEOTIDE-SEQUENCE; INVITRO ACTIVITIES; BIOSYNTHESIS; CLONING; IDENTIFICATION; HYDROLASE	Derivatives of erythromycin with modifications at their C-6 position are generally sought for their increased stability at acid pH, which in turn may confer improved pharmacological properties. A recombinant mutant of the erythromycin-producing bacterium, Saccharopolyspora erythraea, produced an erythromycin derivative, 6-deoxyerythromycin A, that could not be obtained readily by chemical synthesis. This product resulted from targeted disruption of the gene, designated eryF (systematic nomenclature, CYP107), that apparently codes for the cytochrome P450, 6-deoxyerythronolide B (DEB) hydroxylase, which converts DEB to erythronolide B (EB). Enzymes normally acting on EB can process the alternative substrate DEB to form the biologically active erythromycin derivative lacking the C-6 hydroxyl group.	ABBOTT LABS,ANTIINFECT RES,ABBOTT PK,IL 60064; ABBOTT LABS,CORP MOLEC BIOL,ABBOTT PK,IL 60064	Abbott Laboratories; Abbott Laboratories	WEBER, JM (corresponding author), ABBOTT LABS,DEPT 451-R5,BIOPROC DEV,N CHICAGO,IL 60064, USA.		Weber, J. Mark/AAF-5739-2020					Corcoran JW, 1981, ANTIBIOTICS, P132; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; FERNANDES PB, 1989, ANTIMICROB AGENTS CH, V33, P1531, DOI 10.1128/AAC.33.9.1531; FERNANDES PB, 1986, ANTIMICROB AGENTS CH, V30, P865, DOI 10.1128/AAC.30.6.865; HARDY DJ, 1988, ANTIMICROB AGENTS CH, V32, P1710, DOI 10.1128/AAC.32.11.1710; HARDY DR, UNPUB; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HOPWOOD DA, 1989, GENETICS MOL BIOL IN, P12; ISHIZAKI T, 1989, J BACTERIOL, V171, P596, DOI 10.1128/jb.171.1.596-601.1989; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KIRST HA, 1989, ANTIMICROB AGENTS CH, V33, P1413, DOI 10.1128/AAC.33.9.1413; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; MCALPINE JR, UNPUB; NAGGERT J, 1987, BIOCHEM J, V243, P597, DOI 10.1042/bj2430597; NAIK S, 1989, ANTIMICROB AGENTS CH, V33, P1614, DOI 10.1128/AAC.33.9.1614; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RINEHART KL, 1977, PURE APPL CHEM, V49, P1361, DOI 10.1351/pac197749091361; SAFFORD R, 1987, BIOCHEMISTRY-US, V26, P1358, DOI 10.1021/bi00379a023; SAKAKIBARA H, 1984, MACROLIDE ANTIBIOTIC, P85; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SHAFIEE A, 1987, BIOCHEMISTRY-US, V26, P6204, DOI 10.1021/bi00393a037; SHIER WT, 1969, BIOCHEMISTRY-US, V63, P198; SWANSON RN, UNPUB; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WEBER JM, 1989, GENE, V75, P235, DOI 10.1016/0378-1119(89)90269-2; ZALKIN H, 1988, J BIOL CHEM, V263, P1595	34	138	156	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1991	252	5002					114	117		10.1126/science.2011746	http://dx.doi.org/10.1126/science.2011746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FE952	2011746				2022-12-01	WOS:A1991FE95200046
J	BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM				BRADDOCK, M; THORBURN, AM; KINGSMAN, AJ; KINGSMAN, SM			BLOCKING OF TAT-DEPENDENT HIV-1 RNA MODIFICATION BY AN INHIBITOR OF RNA POLYMERASE-II PROCESSIVITY	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATION; UNWINDING ACTIVITY; MAMMALIAN-CELLS; EXPRESSION; ELONGATION; PROTEIN	HUMAN immunodeficiency virus gene expression is regulated transcriptionally and post-transcriptionally 1-4 by the virally encoded tat protein (Tat). Tat functions through an RNA target sequence located in the untranslated region at the 5' end of viral transcripts 5-8. In Xenopus oocytes, translation of RNA containing the target sequence is specifically activated by Tat. This activation only occurs if the RNA is injected into the nucleus, and might be due to a Tat-dependent, nucleus-specific chemical modification of the RNA which somehow facilitates translation 8. Here we demonstrate that Tat activation of its target RNA in the nucleus involves a Tat-dependent covalent modification. The modified RNA is competent for translation after reinjection into either the nucleus or the cytoplasm in the absence of Tat. Furthermore, we find that the nucleoside analogue 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, which inhibits processivity of RNA polymerase II (ref. 9), blocks this Tat-dependent modification.	DEPT BIOCHEM,VIRUS MOLEC BIOL GRP,S PARKS RD,OXFORD OX1 3QU,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND	University of Oxford								BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; KIMMELMAN M, 1989, CELL, V59, P687; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693	23	48	49	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					439	441		10.1038/350439a0	http://dx.doi.org/10.1038/350439a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011194				2022-12-01	WOS:A1991FF04200056
J	BRESSAC, B; KEW, M; WANDS, J; OZTURK, M				BRESSAC, B; KEW, M; WANDS, J; OZTURK, M			SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA	NATURE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; LIVER; DNA; ESTABLISHMENT	HEPATOCELLULAR carcinoma (HCC) is a prevalent cancer in sub-Saharan Africa and eastern Asia 1. Hepatitis B virus and aflatoxins are risk factors for HCC 2, but the molecular mechanism of human hepatocellular carcinogenesis is largely unknown 3. Abnormalities in the structure and expression of the tumour-suppressor gene p53 are frequent in HCC cell lines 4, and allelic losses from chromosome 17p have been found in HCCs from China 5 and Japan 6. Here we report on allelic deletions from chromosome 17p and mutations of the p53 gene found in 50% of primary HCCs from southern Africa. Four of five mutations detected were G --> T substitutions, with clustering at codon 249. This mutation specificity could reflect exposure to a specific carcinogen, one candidate being aflatoxin B1 (ref. 7), a food contaminant in Africa 8, which is both a mutagen that induces G to T substitution 9 and a liver-specific carcinogen 10.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,MGH E,149 13TH ST,BOSTON,MA 02129; UNIV WITWATERSRAND,PARKTOWN 2193,SOUTH AFRICA	Harvard University; Massachusetts General Hospital; University of Witwatersrand			Paillerets, Brigitte Bressac-de/D-8954-2018; ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; OZTURK, MEHMET/0000-0002-6092-9706				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOSCH FX, 1989, LIVER CELL CARCINOMA, P3; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHIBA I, 1990, ONCOGENE, V5, P1603; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; FUJIMORI M, 1991, CANCER RES, V51, P89; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; MAKLIN D, 1990, SCIENCE, V250, P1233; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NEWBERNE PM, 1969, CANCER RES, V29, P236; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SLAGLE BL, 1991, CANCER RES, V51, P49; VANRENSBURG SJ, 1985, BRIT J CANCER, V51, P713, DOI 10.1038/bjc.1985.107; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YANG SS, 1990, CANCER RES, V50, pS5658; YEH FS, 1989, CANCER RES, V49, P2506	29	1265	1304	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					429	431		10.1038/350429a0	http://dx.doi.org/10.1038/350429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1672732				2022-12-01	WOS:A1991FF04200052
J	BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H				BURKE, GL; SPRAFKA, JM; FOLSOM, AR; HAHN, LP; LUEPKER, RV; BLACKBURN, H			TRENDS IN SERUM-CHOLESTEROL LEVELS FROM 1980 TO 1987 - THE MINNESOTA HEART SURVEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE RISK-FACTORS; 2 NATIONAL SURVEYS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DEATH; PERSPECTIVE; PREVALENCE; MORTALITY	Background and Methods. We assessed community trends in the awareness, treatment, and control of hypercholesterolemia (defined as a serum cholesterol level greater-than-or-equal-to 6.21 mmol per liter [240 mg per deciliter]) during the 1980s in the Minneapolis-St. Paul (Twin Cities) metropolitan area. Twin Cities residents 25 to 74 years old participated in independent, cross-sectional, population-based surveys of risk factors for cardiovascular disease in 1980-1982 (n = 3365) and 1985-1987 (n = 4545). Results. Mean serum total cholesterol levels, as adjusted for age, decreased significantly (P < 0.01) from 1980-1982 to 1985-1987 in men (from 5.30 mmol per liter [205 mg per deciliter] to 5.16 mmol per liter [200 mg per deciliter]) and women (from 5.19 mmol per liter [201 mg per deciliter] to 5.04 mmol per liter [195 mg per deciliter]). The prevalence of hypercholesterolemia as adjusted for age decreased significantly (P < 0.05) in men (17.8 to 15.1 percent) and women (17.1 to 13.6 percent). The ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was unchanged during this period, because of a concurrent decline in the level of HDL cholesterol. Participants with hypercholesterolemia in the 1985-1987 survey were more likely than those in the 1980-1982 survey to be aware of their condition (32.6 vs. 25.4 percent), to be treated with lipid-lowering agents (4.3 vs. 1.9 percent), and to have their condition controlled (1.9 vs. 0.3 percent). Among those who reported treatment by a physician for hyperlipidemia, changes were observed in the type of treatment recommended. A significant increase (P < 0.05) was noted from 1980-1982 to 1985-1987 in the percentage of men being treated for hyperlipidemia with lipid-lowering medication (5.2 vs. 11.6 percent) and with exercise programs (10.3 vs. 20.1 percent). In women being treated for hyperlipidemia, a nonsignificant increase was noted in the use of lipid-lowering medication (8.2 vs. 13.9 percent), and a significant increase (P < 0.05) was observed in the number of exercise prescriptions (4.1 vs. 12.0 percent). Conclusions. We found a substantial decline in the prevalence of hypercholesterolemia in the Twin Cities between 1980-1982 and 1985-1987 that may be attributed to changes in lifestyle, such as diet and exercise, and to a lesser extent to more aggressive intervention with lipid-lowering drugs by physicians.	UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	BURKE, GL (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.				PHS HHS [R01-23727] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; GILLUM RF, 1984, AM J MED, V76, P1055, DOI 10.1016/0002-9343(84)90857-X; GRAVES KL, 1990, CIRCULATION, V82, P347; GRUNDY SM, 1985, ARTERIOSCLEROSIS, V72, pA1135; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P2087, DOI 10.1001/jama.253.14.2087; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KEYS A, 1970, CIRCULATION S1, V41, P162; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; LUEPKER RV, 1985, J CHRON DIS, V38, P671, DOI 10.1016/0021-9681(85)90021-9; MARTIN MJ, 1986, LANCET, V2, P933; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3527, DOI 10.1001/jama.258.24.3527; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TIKKANEN MJ, 1987, CIRCULATION, V76, P529, DOI 10.1161/01.CIR.76.3.529; TYROLER HA, 1971, ARCH INTERN MED, V128, P907, DOI 10.1001/archinte.128.6.907; 1979, J CHRON DIS, V32, P609; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1985, SAS USERS GUIDE BASI; 1984, JAMA-J AM MED ASSOC, V251, P365; 1987, JAMA-J AM MED ASSOC, V257, P937; 1974, DHEW NIH75628 NAT HE; 1979, PREV MED, V8, P612	29	66	66	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					941	946		10.1056/NEJM199104043241402	http://dx.doi.org/10.1056/NEJM199104043241402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	2002818				2022-12-01	WOS:A1991FE37600002
J	CASTILLA, A; PRIETO, J; FAUSTO, N				CASTILLA, A; PRIETO, J; FAUSTO, N			TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-ALPHA IN CHRONIC LIVER-DISEASE - EFFECTS OF INTERFERON ALFA THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEPATITIS-B; FACTOR-BETA; EXTRACELLULAR-MATRIX; COLLAGEN FORMATION; CONTROLLED TRIAL; RAT HEPATOCYTES; DNA-SYNTHESIS; DISSE SPACE; ITO CELL; FIBROSIS	Background. Cirrhosis is a diffuse process of hepatic fibrosis and regenerative nodule formation of unknown pathogenesis. Transforming growth factor (TGF) beta-1 induces the production of extracellular matrix proteins by liver cells and has been implicated in the pathogenesis of hepatic fibrosis in laboratory animals. TGF-alpha is a hepatocyte mitogen that participates in liver regeneration. Methods. Using Northern blot analysis, we studied the expression of TGF-beta-1 messenger RNA (mRNA) in liver specimens from 42 patients with chronic hepatitis and cirrhosis and 12 subjects with either normal or fatty livers. The results were correlated with measurements of procollagen Type I mRNA in liver tissue, procollagen Type III peptide in serum, and the degree of histologic injury. We also investigated whether TGF-alpha mRNA would be detectable in biopsy specimens of livers with proliferative activity. Results. TGF-beta-1 mRNA expression correlated closely with the expression of procollagen Type I mRNA (r = 0.94) and serum procollagen Type III peptide (r = 0.89) and with the histologic activity index (r = 0.73). All patients with increased fibrogenic activity (serum procollagen Type III peptide level, > 11.9-mu-g per liter) had increased levels of TGF-beta-1 mRNA (2 to 14 times the levels in the control group or in patients with normal fibrogenic activity), and both TGF-alpha and H3 histone (a marker of DNA synthesis) mRNAs were detectable in patients with regenerative nodules. Six of eight patients with hepatitis C treated with interferon alfa for one year had sustained clinical responses with normalization of serum procollagen Type III peptide and aminotransferase activity. All these patients had normal levels of TGF-beta-1 mRNA in liver specimens obtained at the end of the year. Conclusions. TGF-beta-1 may have an important role in the pathogenesis of fibrosis in patients with chronic liver disease, and TGF-alpha expression may be associated with liver regeneration in these patients.	UNIV NAVARRA,UNIV CLIN,CTR BIOMED RES,DEPT INTERNAL MED,PAMPLONA,SPAIN; BROWN UNIV,DEPT PATHOL & LAB MED,DIV BIOL & MED,PROVIDENCE,RI 02912	University of Navarra; Brown University			Yang, Chen/G-1379-2010	Prieto, Jesus/0000-0002-1091-9593	NATIONAL CANCER INSTITUTE [R01CA023226, R01CA035249, R37CA023226] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35249, CA-23226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNONI G, 1990, GASTROENTEROLOGY, V98, P197, DOI 10.1016/0016-5085(90)91310-3; ARMENDARIZBORUNDA J, 1990, FASEB J, V4, P215, DOI 10.1096/fasebj.4.2.2298342; BIAGINI G, 1989, J HEPATOL, V8, P115, DOI 10.1016/0168-8278(89)90170-0; Bissell D.M., 1990, HEPATOLOGY TXB LIVER, P424; BISSELL DM, 1990, HEPATOLOGY, V11, P488, DOI 10.1002/hep.1840110322; BISSELL M, 1990, PROGR LIVER DISEASES, V9, P143; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brouwer A, 1988, LIVER BIOL PATHOBIOL, P665; CAMPS J, 1989, Journal of Hepatology, V9, pS17, DOI 10.1016/0168-8278(89)90210-9; CARR BI, 1986, CANCER RES, V46, P2330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CONN HO, 1987, DIS LIVER, P725; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; CZAJA MJ, 1989, HEPATOLOGY, V10, P795, DOI 10.1002/hep.1840100508; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FAUSTO N, 1989, LAB INVEST, V60, P4; FRENCH SW, 1988, AM J PATHOL, V132, P73; GEERTS A, 1987, CIRRHOSIS LIVER METH, P83; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; HAHN EG, 1987, CIRRHOSIS LIVER METH, P63; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; HORN T, 1986, J HEPATOL, V3, P333, DOI 10.1016/S0168-8278(86)80486-X; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IRABURU M, 1989, J MED VIROL, V27, P39, DOI 10.1002/jmv.1890270109; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MAK KM, 1984, GASTROENTEROLOGY, V87, P188; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MCMAHON JB, 1986, CANCER RES, V46, P4665; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MILANI S, 1990, AM J PATHOL, V137, P59; MINATO Y, 1983, HEPATOLOGY, V3, P559; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; NAKATSUKASA H, 1990, LAB INVEST, V63, P171; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; OKANOUE T, 1983, ARCH PATHOL LAB MED, V107, P459; PRIETO J, 1989, HEPATOLOGY, V9, P720, DOI 10.1002/hep.1840090511; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROJKIND M, 1988, LIVER BIOL PATHOBIOL, P1269; RUWART MJ, 1989, HEPATOLOGY, V10, P801, DOI 10.1002/hep.1840100509; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERLOCK S, 1989, DISEASES LIVER BILIA, P410; THOMSON BJ, 1987, LANCET, V1, P539; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119; ZERN MA, 1990, CONNECTIVE TISSUE HL, P99	55	666	680	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					933	940		10.1056/NEJM199104043241401	http://dx.doi.org/10.1056/NEJM199104043241401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE376	1900574				2022-12-01	WOS:A1991FE37600001
J	CURRAN, WJ				CURRAN, WJ			SCIENTIFIC AND COMMERCIAL DEVELOPMENT OF HUMAN CELL-LINES - ISSUES OF PROPERTY, ETHICS, AND CONFLICT-OF-INTEREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		MOORE F, 1964, GIVE TAKE DEV TISSUE; Owens James Franklin, 1987, Med Trial Tech Q, V33, P335; PARKER PM, 1989, J LEGAL MED, V10, P357, DOI 10.1080/01947648909513576; WAGNER AB, 1987, COMPUT HIGH TECHNOL, V3, P231; 1987, NEW DEV BIOTECHNOLOG, V1	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 4	1991	324	14					998	1000		10.1056/NEJM199104043241419	http://dx.doi.org/10.1056/NEJM199104043241419			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	FE376	2002828				2022-12-01	WOS:A1991FE37600031
J	FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD				FLANAGAN, PM; KELLEHER, RJ; SAYRE, MH; TSCHOCHNER, H; KORNBERG, RD			A MEDIATOR REQUIRED FOR ACTIVATION OF RNA POLYMERASE-II TRANSCRIPTION INVITRO	NATURE			English	Article							PREINITIATION COMPLEX; GAL4 DERIVATIVES; FACTOR ATF; YEAST; GENE; INITIATION; MECHANISM; BINDING; PROMOTERS; INTERACTS	ACTIVATOR proteins bind to enhancer DNA elements and stimulate the initiation of transcription. It has been proposed 1-3 that activators contact general initiation factors at a promoter, and evidence for such direct interaction has been obtained 4-10. Studies of transcription in vitro, however, have suggested that activators might function through an intermediary molecule(s) distinct from the general factors. In the first of these studies 11,12, we exploited the finding that one activator could inhibit transcription stimulated by a second activator (activator interference or 'squelching') 13-15. This inhibition, which is attributed to competition between the activators for a common target factor, could not be relieved by addition of a large excess of general initiation factors, suggesting that the target for which activators compete is distinct from these factors. Similar conclusions came from the observation that TFIID's expressed from cloned genes 16-18 fail to replace partially purified 'natural' TFIID fractions in supporting activation, evidently because they lacked some component present in the impure fractions. While these lines of evidence for a novel 'mediator' of activation were negative, we also showed that a partially purified fraction from yeast would reverse activator interference 12. This positive effect of a presumptive mediator provided an assay for its activity, but its role in activation was still only inferred. We now present direct evidence for a mediator which is required for stimulation of transcription in vitro by the activators GAL4-VP16 and GCN4, but which has no effect on transcription in the absence of activator protein.			FLANAGAN, PM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,FAIRCHILD CTR,DEPT CELL BIOL,STANFORD,CA 94305, USA.							BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1988, CELL, V52, P303, DOI 10.1016/S0092-8674(88)80020-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KORNBERG RD, 1989, GENE REGULATION AIDS, P9; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	27	296	308	3	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					436	438		10.1038/350436a0	http://dx.doi.org/10.1038/350436a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011193				2022-12-01	WOS:A1991FF04200055
J	HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC				HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC			MUTATIONAL HOTSPOT IN THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS	NATURE			English	Article							DNA; EXPOSURE	HUMAN hepatocellular carcinomas (HCC) from patients in Qidong, an area of high incidence in China, in which both hepatitis B virus and aflatoxin B1 are risk factors 1, were analysed for mutations in p53, a putative tumour-suppressor gene. Eight of the 16 HCC had a point mutation at the third base position of codon 249. The G --> T transversion in seven HCC DNA samples and the G --> C transversion in the other HCC are consistent with mutations caused by aflatoxin B1 in mutagenesis experiments 2,3. No mutations were found in exons 5, 6, 8 or the remainder of exon 7. These results contrast with p53 mutations previously reported in carcinomas and sarcomas of human lung, colon, oesophagus and breast; these are primarily scattered over four of the five evolutionarily conserved domains, which include codon 249 (refs 4-9). We suggest that the mutant p53 protein may be responsible for a selective clonal expansion of hepatocytes during carcinogenesis.	NCI,DIV CANC ETIOL,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; CHINESE ACAD MED SCI,INST CANC,BEIJING,PEOPLES R CHINA; QIDONG LIVER CANC INST,JIANGSU,PEOPLES R CHINA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Chinese Academy of Medical Sciences - Peking Union Medical College								AUTRUP H, 1984, CHEM-BIOL INTERACT, V50, P15, DOI 10.1016/0009-2797(84)90128-5; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1978, P NATL ACAD SCI USA, V75, P2003, DOI 10.1073/pnas.75.4.2003; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LECHNER JF, 1989, CANCER DETECT PREV, V14, P239; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SAMBAMURTI K, 1988, GENETICS, V120, P863; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Sun T., 1986, DIET NUTRITION CANCE, P225; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WINBERG G, 1980, NUCLEIC ACIDS RES, V8, P253, DOI 10.1093/nar/8.2.253; WOGAN GN, 1989, ENVIRON HEALTH PERSP, V81, P9, DOI 10.2307/3430797; WOGAN GN, 1985, ENVIRON HEALTH PERSP, V62, P5, DOI 10.2307/3430088	25	1455	1520	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					427	428		10.1038/350427a0	http://dx.doi.org/10.1038/350427a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849234				2022-12-01	WOS:A1991FF04200051
J	KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K				KAECH, S; COVIC, L; WYSS, A; BALLMERHOFER, K			ASSOCIATION OF P60C-SRC WITH POLYOMA-VIRUS MIDDLE-T-ANTIGEN ABROGATING MITOSIS-SPECIFIC ACTIVATION	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSFORMING PROTEIN; REGULATORY DOMAIN; PP60C-SRC; SITES; KINASE; GENE; PRODUCT; INVIVO	POLYOMA middle-T antigen is required for tumorigenesis in animals and for viral transformation of a variety of cells in culture (reviewed in ref. 1). Middle-T associates with and thereby activates p60c-src, a cellular tyrosine kinase homologous to the oncogene product of Rous sarcoma virus 2,3. Activation of p60c-src by middle-T is accompanied both by dephosphorylation of tyrosine 527, a site which negatively regulates src kinase activity (reviewed in refs 4-6) and by autophosphorylation on tyrosine 416 (refs 7-10). Phosphoprotein p60c-src is subject to cell cycle-specific regulation. It is most active during mitosis and repressed in interphase 11. Here we report that mitotic p60c-src is dephosphorylated at tyrosine 527. We also show that in cells expressing middle-T, src kinase activity is high both in mitosis and during interphase. An oncogenic mutant src protein, p60c-src(527F), where tyrosine 527 is substituted by phenylalanine, is also highly active in all phases of the cell cycle.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research				Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990	27	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					431	433		10.1038/350431a0	http://dx.doi.org/10.1038/350431a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1707141				2022-12-01	WOS:A1991FF04200053
J	KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K				KITAMURA, D; ROES, J; KUHN, R; RAJEWSKY, K			A B-CELL-DEFICIENT MOUSE BY TARGETED DISRUPTION OF THE MEMBRANE EXON OF THE IMMUNOGLOBULIN MU-CHAIN GENE	NATURE			English	Article							PRE-B; MONOCLONAL-ANTIBODY; LYMPHOCYTES-B; HEAVY-CHAINS; LIGHT-CHAIN; BONE-MARROW; STEM-CELLS; REARRANGEMENT; LAMBDA-5; LOCUS	OF the various classes of antibodies that B lymphocytes can produce, class M (IgM) is the first to be expressed on the membrane of the developing cells. Pre-B cells, the precursors of B-lymphocytes, produce the heavy chain of IgM (mu-chain), but not light chains 1. Recent data suggest that pre-B cells express mu-chains on the membrane together with the 'surrogate' light chains lambda-5 and VpreB (refs 2-7). This complex could control pre-B-cell differentiation, in particular the rearrangement of the light-chain genes 8. We have now assessed the importance of the membrane form of the mu-chain in B-cell development by generating mice lacking this chain. We disrupted one of the membrane exons of the gene encoding the mu-chain constant region by gene targeting 9 in mouse embryonic stem cells 10. From these cells we derived mice heterozygous or homozygous for the mutation. B-cell development in the heterozygous mice seemed to be normal, but in homozygous animals B cells were absent, their development already being arrested at the stage of pre-B-cell maturation.	UNIV COLOGNE,INST GENET,WEYERTAL 121,W-5000 COLOGNE 41,GERMANY	University of Cologne			Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Roes, Jurgen/0000-0003-3235-2345				CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Coffman R L, 1982, Immunol Rev, V69, P5; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1033; COOPER MD, 1989, IMMUNOGLOBULIN GENES, P1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRUTZMANN R, 1981, THEISIS U COLOGNE; Guise J. W., 1989, Immunoglobulin genes., P275; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	29	1535	1604	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					423	426		10.1038/350423a0	http://dx.doi.org/10.1038/350423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1901381				2022-12-01	WOS:A1991FF04200050
J	MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S				MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY-DNA OF A BRAIN CALCIUM-CHANNEL	NATURE			English	Article							SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; CEREBELLAR SLICES; MESSENGER-RNAS; MUTANT MICE; ALPHA-1-SUBUNIT; MODULATION; CURRENTS; SEQUENCE; NEURONS	The primary structure of a voltage-dependent calcium channel from rabbit brain has been deduced by cloning and sequencing the complementary DNA. Calcium channel activity expressed from the cDNA is dramatically increased by coexpression of the alpha-2 and beta-subunits, known to be associated with the dihydropyridine receptor. This channel is a high voltage-activated calcium channel that is insensitive both to nifedipine and to omega-conotoxin. We suggest that it is expressed predominantly in cerebellar Purkinje cells and granule cells.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; UNIV SAARLAND, FAK MED, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY; NATL INST BASIC BIOL, DIV BEHAV & NEUROBIOL, OKAZAKI, AICHI 444, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN	Kyoto University; Kyoto University; Saarland University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University			Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014; Nakai, Junichi/GQZ-6415-2022	Furuichi, Teiichi/0000-0002-9676-1888; Imoto, Keiji/0000-0002-2861-5985				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERTOLINO M, 1990, FASEB J, V4, pA1202; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOLL W, 1985, NEUROSCI LETT, V56, P335, DOI 10.1016/0304-3940(85)90265-4; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BRADLEY P, 1978, BRAIN RES, V142, P135, DOI 10.1016/0006-8993(78)90182-8; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CREPEL F, 1984, J PHYSIOL-LONDON, V346, P111, DOI 10.1113/jphysiol.1984.sp015010; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HIRANO A, 1975, J NEUROPATH EXP NEUR, V34, P1, DOI 10.1097/00005072-197501000-00001; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NUMA S, 1986, ANN NY ACAD SCI, V479, P338, DOI 10.1111/j.1749-6632.1986.tb15580.x; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PURVES D, 1985, PRINCIPLES NEURAL DE; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; REGAN LJ, 1989, ANN NY ACAD SCI, V560, P121, DOI 10.1111/j.1749-6632.1989.tb24088.x; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAH D W Y, 1989, Society for Neuroscience Abstracts, V15, P823; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4	37	766	792	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					398	402		10.1038/350398a0	http://dx.doi.org/10.1038/350398a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849233				2022-12-01	WOS:A1991FF04200040
J	PERROTTA, AT; BEEN, MD				PERROTTA, AT; BEEN, MD			A PSEUDOKNOT-LIKE STRUCTURE REQUIRED FOR EFFICIENT SELF-CLEAVAGE OF HEPATITIS DELTA-VIRUS RNA	NATURE			English	Article							GENOME; SITE	HEPATITIS delta virus genomic and antigenomic RNAs contain a self-cleavage site hypothesized to function in processing the viral RNA during replication 1-3. Self-cleavage requires only a divalent cation 1-3 and is mediated at the genomic site by a sequence of less than 85 nucleotides 4. We propose that the genomic self-cleaving sequence element 4 and a corresponding sequence from the antigenomic RNA could generate related secondary structures. The region of the antigenomic sequence, predicted from the proposed structure, was synthesized and shown to be sufficient for self-cleavage. Evidence for two stems which form a tertiary interaction was obtained by site-specific mutagenesis of the antigenomic sequence. Efficient self-cleavage in 10 M formamide or 5 M urea, also a property of the genomic sequence 5, was dependent on base-pairing in both stems. But in the absence of denaturants, the stem distal to the site of cleavage was not required, suggesting that the tertiary interaction stabilizes the structure required for self-cleavage.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; PFEIJ CWA, 1990, TRENDS BIOCHEM SCI, V15, P143; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; VEIRIA J, 1987, METHOD ENZYMOL, V154, P3; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	14	300	346	2	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					434	436		10.1038/350434a0	http://dx.doi.org/10.1038/350434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011192				2022-12-01	WOS:A1991FF04200054
J	SPEAKMAN, JR; RACEY, PA				SPEAKMAN, JR; RACEY, PA			NO COST OF ECHOLOCATION FOR BATS IN FLIGHT	NATURE			English	Article							PTEROPUS-GOULDII; GAS-EXCHANGE; METABOLISM; PHYSIOLOGY	ECHOLOCATION has evolved in relatively few animal species 1. One constraint may be the high cost of producing pulses, the echoes of which can be detected over useful distances 2. The energy cost of echolocation in a small (6 g) insectivorous bat, when hanging at rest, was recently measured at 0.067 Joules per pulse 3, implying a mean cost for echolocation in flight of 9.5 x basal metabolic rate (range 7 to 12x). Because flight is very costly 4, whether the costs of echolocation and flying are additive is an important question. We measured the energy costs of flight in two species of small echolocating Microchiroptera using a novel combination of respirometry and doubly-labelled water 5. Flight energy expenditure (adjusted for body mass) was not significantly different between echolocating bats and non-echolocating bats and birds. The low cost of echolocation for flying vertebrates may have been a significant factor favouring its evolution in these groups.			SPEAKMAN, JR (corresponding author), UNIV ABERDEEN,DEPT ZOOL,ABERDEEN AB9 2TN,SCOTLAND.		Speakman, John R./A-9494-2008	Speakman, John R./0000-0002-2457-1823				BERNSTEIN MH, 1973, J EXP BIOL, V58, P401; BUTLER PJ, 1977, J EXP BIOL, V77, P7; CARPENTER RE, 1985, J EXP BIOL, V114, P619; CARPENTER RE, 1986, J EXP BIOL, V120, P79; COLLINS BG, 1978, PHYSL ZOOL, V52, P165; DAWKINS R, 1908, BIND WATCHMAKER; FLINT EN, 1984, AUK, V101, P288, DOI 10.1093/auk/101.2.288; GESSAMAN JA, 1980, COMP BIOCHEM PHYS A, V65, P273, DOI 10.1016/0300-9629(80)90030-4; GESSAMAN JA, 1988, CONDOR, V90, P662, DOI 10.2307/1368356; GESSAMAN JA, 1988, PHYSIOL ZOOL, V61, P507, DOI 10.1086/physzool.61.6.30156159; GOULD E, 1964, J EXP ZOOL, V156, P19, DOI 10.1002/jez.1401560103; HEALY S, 1990, EVOLUTION, V44, P339, DOI 10.1111/j.1558-5646.1990.tb05203.x; HUDSON DM, 1973, J EXP BIOL, V103, P121; LE FEBVRE EUGENE A., 1964, AUK, V81, P403; LIFSON N, 1966, J THEOR BIOL, V12, P46, DOI 10.1016/0022-5193(66)90185-8; MASMAN D, 1984, THESIS U GRONINGEN; NACTIGALL PE, 1988, ANIMAL SONAR PROCESS; PETTIGREW JD, 1986, SCIENCE, V231, P1304, DOI 10.1126/science.3945827; Racey PA, 1987, S ZOOL SOC LOND, V57, P107; ROTHE HJ, 1987, J COMP PHYSIOL B, V157, P99, DOI 10.1007/BF00702734; SPEAKMAN JR, 1988, PHYSIOL ZOOL, V61, P514, DOI 10.1086/physzool.61.6.30156160; SPEAKMAN JR, 1989, J COMP PHYSIOL A, V165, P679, DOI 10.1007/BF00610999; THOMAS SP, 1981, J EXP BIOL, V94, P231; THOMAS SP, 1975, J EXP BIOL, V63, P273; TORREBUENO JR, 1978, J EXP BIOL, V75, P223; TUCKER VA, 1972, AM J PHYSIOL, V222, P237, DOI 10.1152/ajplegacy.1972.222.2.237; TUCKER VA, 1968, J EXP BIOL, V48, P67; [No title captured]	28	175	178	4	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					421	423		10.1038/350421a0	http://dx.doi.org/10.1038/350421a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	2011191				2022-12-01	WOS:A1991FF04200049
J	BURKHART, J				BURKHART, J			AMA-RPS INSTRUMENTAL IN ACHIEVING NEW MATERNITY LEAVE POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1756	1756						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002585				2022-12-01	WOS:A1991FD65900036
J	CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N				CIESIELSKI, SD; SEED, JR; ESPOSITO, DH; HUNTER, N			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG NORTH-CAROLINA MIGRANT FARM-WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY TUBERCULOSIS; BCG VACCINATION; SKIN-TEST; INFECTION; PRISON; SENSITIVITY; REACTIVITY; COMMUNITY; SHELTERS; FEATURES	Although tuberculosis (TB) has been recognized as a significant health problem of migrant farm workers, the nature and extent of the problem have been poorly defined. We report the first population-based study of TB in a random sample of farm workers (n = 543) and the first use of recall antigens in an epidemiologic study of TB. Purified protein derivative positivity ranged from 33% in Hispanics to 54% in US-born blacks and 76% in Haitians. Active tubercular disease occurred in 3.6% of US-born blacks and 0.47% of Hispanics. Among US-born blacks, risk factors associated with farm work were most significant. Blacks born in the United States also had the highest prevalence of anergy. The use of recall antigens made possible a better description of the epidemiology of TB by excluding false negatives and clarifying associations between infection and risk factors. We conclude that TB among farm workers represents a serious public health problem with previously unrecognized risk factors. Additional resources for migrant health care, improvements in health care access, and fundamental changes in the system of migrant labor are all necessary to reduce the transmission of TB.	N CAROLINA STATE LAB PUBL HLTH,DIV LAB SERV,MICROBIOL BRANCH,RALEIGH,NC; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	CIESIELSKI, SD (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT PARASITOL & LAB PRACTICE,CHAPEL HILL,NC 27599, USA.							ABELES H, 1970, AM REV RESPIR DIS, V101, P706; American Thoracic Society, 1981, AM REV RESPIR DIS, V124, P356; [Anonymous], 1988, MMWR, V36, P817; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BATTERSHILL JH, 1980, CHEST, V77, P188, DOI 10.1378/chest.77.2.188; BHATNAGAR R, 1977, AM REV RESPIR DIS, V115, P207; BLEIKER MA, 1983, TUBERCLE, V64, P255, DOI 10.1016/0041-3879(83)90022-3; BONANNO G, 1983, DRUG ALCOHOL DEPEN, V12, P189, DOI 10.1016/0376-8716(83)90044-3; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHAPARAS SD, 1982, CRIT REV MICROBIOL, V9, P193; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P1; HERSHFIELD L, 1977, CHEST, V76, P805; HOLDEN M, 1971, NEW ENGL J MED, V285, P1506, DOI 10.1056/NEJM197112302852704; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; JONCAS JH, 1975, CAN MED ASSOC J, V113, P127; Kent PT, 1985, GUIDE LEVEL 3 LAB; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; KIRKPATRICK CH, 1964, J EXP MED, V119, P727, DOI 10.1084/jem.119.5.727; MCKEOWN T, 1976, ROLE MED; MCMURRAY DN, 1978, AM REV RESPIR DIS, V118, P827; MORLAND B, 1982, ACTA PHARMACOL TOX, V50, P221; NASH DR, 1980, CHEST, V77, P32, DOI 10.1378/chest.77.1.32; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; PEREZSTABLE EJ, 1986, AM J PUBLIC HEALTH, V76, P643, DOI 10.2105/AJPH.76.6.643; PIO A, 1976, B OFIC SANIT PANAM, V80, P281; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; ROSE CE, 1979, AM REV RESPIR DIS, V119, P603; RUST GS, 1990, AM J PUBLIC HEALTH, V80, P1213, DOI 10.2105/AJPH.80.10.1213; SALIMUDDIN A, 1985, TUBERCLE, V66, P133; SHAH BV, 1986, SURVEY DATA ANAL SOF; SHANNON DC, 1966, NEW ENGL J MED, V275, P690, DOI 10.1056/NEJM196609292751302; SHOTLAND J, 1989, FULL FIELDS EMPTY CU; SLUTKIN G, 1986, PUBLIC HEALTH REP, V101, P481; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007; TERRIS M, 1948, AM J PUBLIC HEALTH, V38, P1061; TRACHTMAN L, 1978, JAMA-J AM MED ASSOC, V240, P739, DOI 10.1001/jama.1978.03290080029014; WATSON H, 1984, ARIZ MED, V41, P665; WEBER DJ, 1989, SOUTHERN MED J, V82, P1204, DOI 10.1097/00007611-198910000-00003; ZEITZ SJ, 1974, J ALLERGY CLIN IMMUN, V53, P20, DOI 10.1016/0091-6749(74)90095-5; 1979, TUBERCLE, V60, P191; 1987, MMWR, V36, P212; 1988, MMWR, V37, P517; 1987, MMWR, V36, P785; 1982, TUBERCULOSIS US 1979; 1987, MMWR, V36, P493; 1985, ALCOHOL ALCOHOLISM, V20, P89; 1989, MMWR, V38, P236; 1982, MMWR, V31, P237; 1987, MMWR, V36, P257; 1987, MMWR, V36, P795; 1977, RECOMMENDATIONS COUN; 1986, 1985 TUBERCULOSIS ST; 1987, MMWR, V34, P429; 1986, JAMA-J AM MED ASSOC, V256, P977; 1989, MMWR, V38, P313; 1961, RECOMMENDATIONS REPO; 1985, TUBERCULOSIS MIGRANT; 1989, MMWR, V38, pS3; 1987, MMWR, V36, P77	63	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1715	1719		10.1001/jama.265.13.1715	http://dx.doi.org/10.1001/jama.265.13.1715			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD659	2002573				2022-12-01	WOS:A1991FD65900028
J	CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J				CONNOR, E; BAGARAZZI, M; MCSHERRY, G; HOLLAND, B; BOLAND, M; DENNY, T; OLESKE, J			CLINICAL AND LABORATORY CORRELATES OF PNEUMOCYSTIS-CARINII PNEUMONIA IN CHILDREN INFECTED WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; PROGNOSTIC FACTORS; LIFE EXPECTANCY; SURVIVAL; DISEASE; AIDS	The case histories of 27 children with Pneumocystis carinii pneumonia (PCP) who were followed up in the AIDS Program at the Children's Hospital of New Jersey, Newark, are reviewed. The mean and median age at PCP diagnosis were 10.8 and 7.7 months, respectively. All of the children had other clinical evidence of infection with the human immunodeficiency virus that was documented prior to the diagnosis of PCP or found at the time of PCP diagnosis. Most patients who presented to the hospital were acutely ill, and complications of treatment occurred in 70%. Overall, 89% of the patients died and 70% survived for less than 6 months after diagnosis of PCP. Median survival after the diagnosis of PCP was only 2.0 months and the median life span of children with PCP was only 14.4 months. Only 40% of children with PCP had CD4 lymphocyte counts at or below the threshold for institution of PCP prophylaxis in adults of 200 X 10(6) cells/L (200 cells/mm3).	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PEDIAT,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	CONNOR, E (corresponding author), CHILDRENS HOSP NEW JERSEY,DEPT PEDIAT,AIDS PROGRAM,15 S 9TH ST,NEWARK,NJ 07107, USA.		Bagarazzi, Mark L/AAU-1383-2021; Oleske, James/C-1951-2016	Oleske, James/0000-0003-2305-5605; Denny, Thomas/0000-0002-7364-8276	NIAID NIH HHS [1 U01 AI25883-01] Funding Source: Medline; PHS HHS [U64/CCU202219-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025883] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DENNY TN, 1990, PEDIATR RES, V27, P155; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MCCULLOUGH PC, 1986, RESPIRATION, V50, P286, DOI 10.1159/000194940; MCSHERRY G, 1988, 28TH INT C ANT AG CH; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; RUBINSTEIN A, 1986, J PEDIATR-US, V108, P498, DOI 10.1016/S0022-3476(86)80822-8; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1989, MMWR S5, V38, P1; 1987, MMWR, V36, P225	25	53	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1693	1697		10.1001/jama.265.13.1693	http://dx.doi.org/10.1001/jama.265.13.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672168				2022-12-01	WOS:A1991FD65900024
J	GILSTRAP, LC				GILSTRAP, LC			ELECTIVE APPENDECTOMY DURING ABDOMINAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GILSTRAP, LC (corresponding author), UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DALLAS,TX 75235, USA.							PARSONS AK, 1986, OBSTET GYNECOL, V68, P479; WATERS EG, 1977, OBSTET GYNECOL, V50, P511; WESTERMANN C, 1986, SURG GYNECOL OBSTET, V162, P307	3	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002579				2022-12-01	WOS:A1991FD65900034
J	GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW				GWINN, M; PAPPAIOANOU, M; GEORGE, JR; HANNON, WH; WASSER, SC; REDUS, MA; HOFF, R; GRADY, GF; WILLOUGHBY, A; NOVELLO, AC; PETERSEN, LR; DONDERO, TJ; CURRAN, JW			PREVALENCE OF HIV-INFECTION IN CHILDBEARING WOMEN IN THE UNITED-STATES - SURVEILLANCE USING NEWBORN BLOOD-SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; AIDS; SEROPREVALENCE; INFANTS	A national, population-based survey was initiated in 1988 to measure the prevalence of human immunodeficiency virus (HIV) infection in women giving birth to infants in the United States. Following standardized procedures, residual dried-blood specimens collected on filter paper for newborn metabolic screening were tested anonymously in state public health laboratories for maternal antibody to HIV. As of September 1990, annual survey data were available from 38 states and the District of Columbia. The highest HIV seroprevalence rates were observed in New York (5.8 per 1000), the District of Columbia (5.5 per 1000), New Jersey (4.9 per 1000), and Florida (4.5 per 1000). Nationwide, an estimated 1.5 per 1000 women giving birth to infants in 1989 were infected with HIV. Assuming a perinatal transmission rate of 30%, we estimate that approximately 1800 newborns acquired HIV infection during one 12-month period. Preventing transmission of HIV infection to women and infants is an urgent public health priority.	CTR DIS CONTROL,CTR ENVIRONM HLTH & INJURY CONTROL,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333; MASSACHUSETTS DEPT HLTH,BOSTON,MA; NICHHD,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	GWINN, M (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-49,ATLANTA,GA 30333, USA.							ANDIMAN WA, 1989, SEMIN PERINATOL, V13, P16; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; GRANT CM, 1990, 6TH INT C AIDS SAN F; GWINN M, 1990, 6TH INT C AIDS SAN F; HARDY LM, 1991, HIV SCREENING PREGNA; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; Hummel R. F., 1990, AIDS and Public Policy Journal, V5, P68; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MITCHELL JL, 1989, J NATL MED ASSOC, V81, P841; MOFENSON LM, 1989, 5TH INT AIDS C MONTR; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P113; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; PIZZO PA, 1990, PEDIATR INFECT DIS J, V9, P690, DOI 10.1097/00006454-199010000-00002; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SELIK RM, 1989, AIDS GYNECOLOGY CLIN, V1, P33; STRICOF RL, 1989, 5TH ANN NAT PED AIDS; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; 1989, CURRENT POPULATI P25, V1018; 1988, MMWR, V37, P341; 1988, ACOG TECHNICAL B, V123; 1990, MONTHLY VITAL STAT R, V38, P1; 1989, MMWR SS7, V38, P1; 1990, HIV AIDS SURVEILLANC, P1; 1988, MMWR, V37, P351; 1987, MMWR, V36, P509; 1988, MMWR, V37, P1	31	247	250	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1704	1708		10.1001/jama.265.13.1704	http://dx.doi.org/10.1001/jama.265.13.1704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002571				2022-12-01	WOS:A1991FD65900026
J	KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L				KOVACS, A; FREDERICK, T; CHURCH, J; ELLER, A; OXTOBY, M; MASCOLA, L			CD4 LYMPHOCYTE-T COUNTS AND PNEUMOCYSTIS-CARINII PNEUMONIA IN PEDIATRIC HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN; CHEMOPROPHYLAXIS; RATIO	The relationship between CD4 T-lymphocyte counts and infection with the human immunodeficiency virus (HIV) is retrospectively investigated for 266 HIV-infected and uninfected children who were born to infected women, including 39 with Pneumocystis carinii pneumonia (PCP), in a population-based surveillance study. Of 21 perinatally HIV-infected children with PCP only 10 (48%) had CD4 T-lymphocyte counts that were less than 500 X 10(6) cells/L (500 cells/mm3), compared with all 18 who were infected via blood transfusions or clotting factors. Among 68 children who were 1 year or younger, 18 (90%) of 20 PCP cases had CD4 T-lymphocyte counts that were less than 1500 X 10(6) cells/L (1500 cells/mm3) compared with only five (10%) of 48 children who did not have the acquired immunodeficiency syndrome (odds ratio, 77.4; 95% confidence interval, 19.7 to 313.4). The mean CD4 T-lymphocyte count was lower for the 39 PCP cases when compared with the 188 children who were at different stages of HIV infection and did not have the acquired immunodeficiency syndrome (AIDS) independent of age. The majority of perinatally HIV-infected children with PCP were 6 months or younger and 50% were previously unknown to be infected. Thus, HIV-positive children should be identified early and followed closely. CD4 T-lymphocyte counts may be useful in monitoring HIV-positive children and determining when to begin PCP prophylaxis.	LOS ANGELES CTY DEPT HLTH SERV,PEDIAT AIDS SURVEILLANCE STUDY,LOS ANGELES,CA; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; CTR DIS CONTROL,ATLANTA,GA 30333; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California; Centers for Disease Control & Prevention - USA; University of Southern California	KOVACS, A (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PATHOL,PEDIAT PAVIL,1129 N STATE S,ROOM 3D14,LOS ANGELES,CA 90033, USA.				PHS HHS [U64-CCU903273-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; DENNY TN, 1990, PEDIATR RES, V27, P155; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; HSU H, 1990, 30TH ICAAC ATL; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; KOVACS JA, 1989, J INFECT DIS, V160, P882, DOI 10.1093/infdis/160.5.882; LEIBOVITZ E, 1990, NEW ENGL J MED, V323, P531, DOI 10.1056/NEJM199008233230807; MASUR H, 1989, ANN INTERN MED, V111, P813, DOI 10.7326/0003-4819-111-10-813; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; SANDERSLAUFER D, 1990, PEDIATR RES, V27, P183; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VERNON DD, 1988, PEDIATRICS, V82, P223; YANASE Y, 1986, PEDIATR RES, V20, P1147, DOI 10.1203/00006450-198611000-00017; 1987, MMWR, V36, P225; 1987, MMWR, V36, P235; 1989, MMWR S5, V38, pS1; 1987, MMWR S15, V36, pS1	24	43	43	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1698	1703						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1672169				2022-12-01	WOS:A1991FD65900025
J	MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN				MCNEIL, JG; BRUNDAGE, JF; GARDNER, LI; WANN, ZF; RENZULLO, PO; REDFIELD, RR; BURKE, DS; MILLER, RN			TRENDS OF HIV SEROCONVERSION AMONG YOUNG-ADULTS IN THE UNITED-STATES-ARMY, 1985 TO 1989	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HTLV-III; INFECTION; AIDS; MEN; ANTIBODIES; TESTS	Because soldiers in the US Army are recurrently tested for the presence of antibody to the human immunodeficiency virus (HIV), HIV seroconversion rates can be directly measured. From November 1985 through October 1989, 429 HIV seroconversions were detected among 718 780 soldiers who contributed 1 088 447 person-years of follow-up time (HIV seroconversion rate, 0.39 per 1000 person-years). Period-specific seroconversion rates declined significantly, from 0.49 per 1000 person-years (November 1985 through October 1987) to 0.33 per 1000 person-years (November 1987 through October 1988) to 0.29 per 1000 person-years (November 1988 through October 1989). The HIV seroconversion risk among active-duty soldiers was significantly associated with race/ethnic group, age, gender, and marital status. Based on these trends, we estimate that approximately 220 soldiers (95% confidence interval, 160 to 297 soldiers) were infected with HIV during 1989 and 1990, with potentially fewer in future years.	SRA TECHNOL, ALEXANDRIA, VA USA; WALTER REED ARMY MED CTR, DIV RETROVIROL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	MCNEIL, JG (corresponding author), WALTER REED ARMY MED CTR, DEPT EPIDEMIOL, DIV PREVENT MED, WASHINGTON, DC 20307 USA.		Brundage, John/Q-9244-2019	/0000-0002-5704-8094				Breslow N.E., 1987, STATISTICAL METHODS, V2, P133; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BURKE DS, 1986, JAMA-J AM MED ASSOC, V256, P347, DOI 10.1001/jama.256.3.347; BURKE DS, 1989, CLIN LAB MED, V9, P369, DOI 10.1016/S0272-2712(18)30609-7; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77; DODD RY, 1988, 4TH INT C AIDS STOCK, V2, P347; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GARLAND FC, 1989, JAMA-J AM MED ASSOC, V262, P3161, DOI 10.1001/jama.262.22.3161; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HERBOLD JR, 1986, MIL MED, V151, P623; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KELLEY PW, 1987, AIDS ACQUIRED IMMUNE, P67; MCNEIL JG, 1989, NEW ENGL J MED, V320, P1581, DOI 10.1056/NEJM198906153202403; MCNEIL JG, 1989, 5TH INT C AIDS OTT, V1, P158; MCNEIL JG, 1990, 6TH INT C AIDS SAN F, V1, P265; PETRICCIANI JC, 1985, ANN INTERN MED, V103, P726, DOI 10.7326/0003-4819-103-5-726; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; 1990, MMWR, V39, P81; 1990, EGRET VERSION 25; 1990, MMWR, V39, P110; 1983, HIV AIDS SURVEILLANC	29	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1709	1714		10.1001/jama.265.13.1709	http://dx.doi.org/10.1001/jama.265.13.1709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002572				2022-12-01	WOS:A1991FD65900027
J	MULLIN, GE				MULLIN, GE			FOOD ALLERGY AND IRRITABLE-BOWEL-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HYPERSENSITIVITY		NIAID,MUCOSAL IMMUN SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	MULLIN, GE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.		Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788				BENTLEY SJ, 1983, LANCET, V2, P295; JOHANSSON SGO, 1984, ANN ALLERGY, V53, P665; JONES AV, 1982, LANCET, V2, P115; PETITPIERRE M, 1985, ANN ALLERGY, V54, P538; ZWETCHKENBAUM JF, 1988, ANN ALLERGY, V60, P1	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1736	1736						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	2002578				2022-12-01	WOS:A1991FD65900033
J	RAUB, W				RAUB, W			INTERFERON-GAMMA PREVENTS INFECTION IN CHRONIC GRANULOMATOUS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, NEW ENGL J MED, V324, P509	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-01	WOS:A1991FD65900006
J	RAUB, W				RAUB, W			TAMOXIFEN FOUND TO LOWER GROWTH-FACTOR LEVELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, J NATL CANCER I, V82, P1693	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-01	WOS:A1991FD65900004
J	RAUB, W				RAUB, W			PREDICTORS OF TYPE-II DIABETES IDENTIFIED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1990, ANN INTERN MED, V113, P909	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-01	WOS:A1991FD65900005
J	RAUB, W				RAUB, W			THERAPY APPEARS SAFE, EFFECTIVE AGAINST SPONTANEOUS ANIMAL TUMORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RAUB, W (corresponding author), NIH,BLDG 31,ROOM 2B23,BETHESDA,MD 20892, USA.							1991, J NATL CANCER I, V83, P18	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	1991	265	13					1633	1633						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD659	1900541				2022-12-01	WOS:A1991FD65900003
J	KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW				KERNAN, WN; HORWITZ, RI; BRASS, LM; VISCOLI, CM; TAYLOR, KJW			A PROGNOSTIC SYSTEM FOR TRANSIENT ISCHEMIA OR MINOR STROKE	ANNALS OF INTERNAL MEDICINE			English	Article							CEREBRAL INFARCTION; SURVIVAL; RECURRENCE; SCORE	Objective: To build a prognostic system for patients with carotid transient ischemic attack or minor stroke. Design: Inception cohort study with 2-year follow-up. Setting: Urban community teaching hospital. Patients: Eligible patients (n = 142), identified on a carotid ultrasound roster, had been hospitalized between 1984 and 1987 within 30 days of a first carotid transient ischemic attack or minor stroke. Measurements: Stroke or death within 2 years. Main Results: Three factors were associated with stroke or death: age of more than 65 years, diabetes, and hypertension. Based on regression coefficients, age of more than 65 years was assigned 3 points; diabetes, 3 points; and hypertension, 2 points. An initial prognostic system comprised risk groups 1 (0 points), 2 (1 to 5 points), and 3 (6 to 8 points). Outcome rates in the three groups were 2%, 31%, and 54% (P < 0.0001), respectively. In an independent test sample, the corresponding outcome rates for the initial system were 12%, 21%, and 31% (P = 0.04). A final prognostic system, including two additional predictors (coronary heart disease [1 point] and the distinction between stroke and transient ischemic attack for the baseline event [2 points]), comprised risk groups 1 (0 to 2 points), 2 (3 to 6 points), and 3 (7 to 11 points). Corresponding outcome rates were 3%, 27%, and 48% (P < 0.001) in the original cohort and 10%, 21%, and 59% (P < 0.001) in the test cohort. Conclusion: For selected patients with carotid transient ischemia or minor stroke, five clinical features can be combined to stratify effectively the risk for a subsequent stroke or death.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University								ABUZEID HAH, 1978, ARCH NEUROL-CHICAGO, V35, P121, DOI 10.1001/archneur.1978.00500270003001; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BRITTON M, 1980, ACTA MED SCAND, V207, P37; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CHAMBERS BR, 1987, NEUROLOGY, V37, P221, DOI 10.1212/WNL.37.2.221; DAVID N J, 1960, J Chronic Dis, V11, P394, DOI 10.1016/0021-9681(60)90045-X; DENNIS MS, 1989, STROKE, V20, P1494, DOI 10.1161/01.STR.20.11.1494; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FULLERTON KJ, 1988, Q J MED, V66, P147; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HOWARD G, 1989, J CLIN EPIDEMIOL, V42, P45, DOI 10.1016/0895-4356(89)90024-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLYHAYES M, 1988, ARCH PHYS MED REHAB, V69, P415; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C; MARSHALL J, 1959, BMJ-BRIT MED J, V1, P1614, DOI 10.1136/bmj.1.5138.1614; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MIAH K, 1983, J CHRON DIS, V36, P279, DOI 10.1016/0021-9681(83)90063-2; MOORE DJ, 1985, J VASC SURG, V2, P654, DOI 10.1067/mva.1985.avs0020654; OLSSON T, 1990, DIABETOLOGIA, V33, P244, DOI 10.1007/BF00404803; RABKIN SW, 1978, ANN INTERN MED, V89, P15, DOI 10.7326/0003-4819-89-1-15; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; TAYLOR KJ, 1988, CLIN APPLICATIONS DO, V6, P120; WADE DT, 1985, Q J MED, V56, P601; WADE DT, 1984, AGE AGEING, V13, P76, DOI 10.1093/ageing/13.2.76; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1984, BMDP USERS GUIDE CON; 1988, SAS LANGUAGE GUIDE P	30	57	62	2	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					552	557		10.7326/0003-4819-114-7-552	http://dx.doi.org/10.7326/0003-4819-114-7-552			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001088				2022-12-01	WOS:A1991FD66100005
J	ROSE, EH; ALEDORT, LM				ROSE, EH; ALEDORT, LM			NASAL SPRAY DESMOPRESSIN (DDAVP) FOR MILD HEMOPHILIA-A AND VONWILLEBRAND DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							BIOLOGICAL RESPONSE; VASOPRESSIN; INTRANASAL; HYPONATREMIA; SEIZURES	Objective: To evaluate the effect of a nasal spray preparation of desmopressin (DDAVP) on levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as the length of bleeding time in patients with mild hemophilia A and von Willebrand disease; to determine whether effective hemostatic levels can be attained; and to compare the effect of this spray with that of standard intravenous desmopressin treatment. Design: Before-and-after trial in patients known to respond to intravenous desmopressin. Setting: Regional, comprehensive, hemophilia diagnosis and treatment center. Patients: A total of 22 patients, including 11 patients with von Willebrand disease, 8 patients with mild hemophilia A, and 3 symptomatic hemophilia carriers. Interventions: Patients were infused with desmopressin, 0.3-mu-g/kg body weight. At least 1 week later, they were taught to self-administer desmopressin nasal spray, 150-mu-g to each nostril. Measurements: In patients with hemophilia, the level of factor VIII activity was measured; in patients with von Willebrand disease, levels of factor VIII activity, ristocetin cofactor activity, and von Willebrand antigen as well as bleeding time were measured before and after each administration of desmopressin. Main Results: Desmopressin, when administered intravenously or intranasally, elevated levels of factor VIII, ristocetin cofactor, and von Willebrand antigen in both mildly hemophiliac patients and patients with von Willebrand disease when compared with baseline measures (P < 0.05). Factor VIII levels adequate for hemostasis were achieved by 82% of the hemophiliac patients. An abnormal bleeding time was corrected in the majority (62%) of patients with von Willebrand disease. Conclusion: A nasal spray preparation of desmopressin apparently was effective both in treating bleeding episodes and when used prophylactically for minor surgical procedures in several patients.	CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [MCB-360001-04-01] Funding Source: Medline; NHLBI NIH HHS [HL-30567-02] Funding Source: Medline; PHS HHS [000217-01-2] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL030567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DELAFUENTE B, 1985, ANN INTERN MED, V103, P6, DOI 10.7326/0003-4819-103-1-6; DESIO L, 1985, THROMB HAEMOSTASIS, V54, P387; HARRIS AS, 1988, J PHARM SCI-US, V77, P337, DOI 10.1002/jps.2600770412; HARRIS AS, 1986, J PHARM SCI, V75, P1085, DOI 10.1002/jps.2600751113; Heinisch O., 1963, SAMPLING TECHNIQUES, V7, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; KOHLER M, 1984, KLIN WOCHENSCHR, V62, P543, DOI 10.1007/BF01727749; KOHLER M, 1986, THROMB HAEMOSTASIS, V55, P108; LETHAGEN S, 1990, BLUT, V60, P187, DOI 10.1007/BF01720274; LETHAGEN S, 1987, THROMB HAEMOSTASIS, V58, P1033; MANNUCCI PM, 1977, LANCET, V1, P869; MANNUCCI PM, 1987, THROMB HAEMOSTASIS, V58, P1037; MARIANA G, 1984, CLIN LAB HAEMATOL, V6, P229; SHEPHERD LL, 1989, J PEDIATR-US, V114, P470, DOI 10.1016/S0022-3476(89)80575-X; SMITH TJ, 1989, AM J HEMATOL, V31, P199, DOI 10.1002/ajh.2830310310; WARRIER AI, 1983, J PEDIATR-US, V102, P228, DOI 10.1016/S0022-3476(83)80526-5; [No title captured]	16	94	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					563	568		10.7326/0003-4819-114-7-563	http://dx.doi.org/10.7326/0003-4819-114-7-563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	1900403				2022-12-01	WOS:A1991FD66100007
J	TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU				TALPAZ, M; KANTARJIAN, H; KURZROCK, R; TRUJILLO, JM; GUTTERMAN, JU			INTERFERON-ALPHA PRODUCES SUSTAINED CYTOGENETIC RESPONSES IN CHRONIC MYELOGENOUS LEUKEMIA - PHILADELPHIA CHROMOSOME-POSITIVE PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INTERFERON; GRANULOCYTIC-LEUKEMIA; CULTURE REVEALS; REMISSION; THERAPY; CANCER	Objectives: To evaluate the frequency and the course of complete cytogenetic responses in interferon-alpha (IFN-alpha)-treated patients with chronic myelogenous leukemia. Design: Two prospective trials in consecutive patients. Setting: A major tertiary cancer center. Patients: Ninety-six consecutive patients with chronic myelogenous leukemia with disease duration of less than 1 year. Intervention: Patients received partially pure IFN-alpha intramuscularly, from 3 to 9 million U/d (51 patients) or recombinant IFN-alpha-2a (Roferon, Hoffmann-LaRoche, Inc., Nutley, New Jersey), 5 million U/m2 body surface area daily (45 patients). Measurements: Hematologic and cytogenetic tests were administered. Main Results: Seventy of the patients (73%) achieved hematologic remission (95% CI, 63% to 81%), and 18 (19%) had complete suppression of the Philadelphia chromosome on at least one cytogenetic test. A complete cytogenetic response was induced in 7 of 51 or 14% (CI, 6% to 26%) of the patients treated with the partially pure IFN-alpha and in 11 of 45 or 24% (CI, 13% to 40%) of the patients treated with recombinant IFN-alpha-2a. The difference in complete cytogenetic response between the two groups was 10.7% (CI, -5% to 26%; P > 0.2). Eleven patients had durable, ongoing, complete cytogenetic responses from 6 to more than 45 months (median, more than 30 months). Conclusion: This study was the first to show sustained, complete cytogenetic responses in a subset of patients with chronic myelogenous leukemia treated with single-agent therapy. The nature of this remission, that is, whether it depends on continuous therapy, requires further study.			TALPAZ, M (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT CLIN IMMUNOL & BIOL THERAPY, BOX 41, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.			Talpaz, Moshe/0000-0003-3361-3981				ARTHUR CK, 1988, BLOOD, V71, P1179; CHAMPLIN RE, 1985, BLOOD, V65, P1039; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CUNNINGHAM I, 1979, BLOOD, V53, P375; DUBE ID, 1984, BLOOD, V63, P1172; ERNSTOFF MS, 1984, AM J MED, V76, P593, DOI 10.1016/0002-9343(84)90282-1; GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P192, DOI 10.1200/JCO.1985.3.2.192; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1269, DOI 10.1056/NEJM198105213042105; KURZROCK R, 1987, BLOOD, V70, P943; LEE MS, 1988, BLOOD, V72, P893; MAEDA S, 1980, P NATL ACAD SCI-BIOL, V77, P7010, DOI 10.1073/pnas.77.12.7010; MCGLAVE PB, 1984, BLOOD, V63, P219; MORRA E, 1987, ASCO P, V6, P145; NIEDERLE N, 1987, SEMIN ONCOL, V14, P29; QUESADA JR, 1983, CANCER RES, V43, P940; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; SINGER JW, 1980, BLOOD, V56, P356; SOKAL JE, 1988, BLOOD, V72, P294; SPECK B, 1984, LANCET, V1, P665; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TALPAZ M, 1983, BLOOD, V62, P689; TRUJILLO JM, 1979, BLOOD, V53, P695; WILLIAMS CKO, 1981, ONCOLOGY, V38, P356, DOI 10.1159/000225587	26	425	428	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1991	114	7					532	538		10.7326/0003-4819-114-7-532	http://dx.doi.org/10.7326/0003-4819-114-7-532			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD661	2001086				2022-12-01	WOS:A1991FD66100002
J	ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA				ANDERSON, DC; BLOWER, AL; PACKER, JMV; GANGULI, LA			PREVENTING NEEDLESTICK INJURIES	BRITISH MEDICAL JOURNAL			English	Article							HIV INFECTION; SEROCONVERSION; DEVICE; NURSE; RISK		HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND; HOPE HOSP,DEPT MED MICROBIOL,SALFORD M6 8HD,LANCS,ENGLAND; SALFORD AREA HLTH AUTHOR,DEPT PUBL HLTH MED,ECCLES M3O 0NJ,ENGLAND		ANDERSON, DC (corresponding author), HOPE HOSP,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.							BESSENT RG, 1987, BRIT MED J, V295, P307, DOI 10.1136/bmj.295.6593.307; Centers for Disease Control reports include, 1988, MMWR, V37, P229; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GIOANNINI P, 1988, EUR J EPIDEMIOL, V4, P119, DOI 10.1007/BF00152703; GOLDWTER PN, 1987, INFECT CONT HOSP EP, V10, P21; GREEN ST, 1986, LANCET, V1, P1096; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; KENNEDY DA, 1988, J HOSP INFECT, V12, P315, DOI 10.1016/0195-6701(88)90074-6; KRASINSKI K, 1987, INFECT CONT HOSP EP, V8, P59, DOI 10.1017/S0195941700067084; MARCUS R, 1988, NEW ENGL J MED, V319, P1117; NEISSONVERNANT C, 1986, LANCET, V2, P814; NIXON AD, 1986, LANCET, V1, P888; OKSENHENDLER E, 1986, NEW ENGL J MED, V315, P582; RAMSEY KM, 1988, CLIN RES, V36, pA1; RIBNER BS, 1987, INFECT CONT HOSP EP, V8, P63, DOI 10.1017/S0195941700067096; STRICOF RL, 1986, NEW ENGL J MED, V314, P1115; 1984, LANCET, V2, P1376; 1983, MMWR, V32, P450; 1987, MMWR, V36, P285; 1990, GUIDANCE CLIN HLTH C; 1990, HIV CAUSATIVE AGENTS; 1987, MMWR, V36, P4; 1990, CODE PRACTICE SAFE U; 1990, BMJ, V300, P766; 1986, LAVHTLV 3 CAUSATIVE, P6	26	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					769	770		10.1136/bmj.302.6779.769	http://dx.doi.org/10.1136/bmj.302.6779.769			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2043216	Green Published, Bronze			2022-12-01	WOS:A1991FF22900028
J	FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM				FIRTH, HV; BOYD, PA; CHAMBERLAIN, P; MACKENZIE, IZ; LINDENBAUM, RH; HUSON, SM			SEVERE LIMB ABNORMALITIES AFTER CHORION VILLUS SAMPLING AT 56-66 DAYS GESTATION	LANCET			English	Note								Among 289 pregnancies in which chorion villus sampling (CVS) was carried out at 56-66 days' gestation, 5 babies with severe limb abnormalities were subsequently identified. 4 had oromandibular-limb hypogenesis syndromes, and the other had a terminal transverse limb reduction defect. This high incidence raises the possibility that CVS was an aetiological factor for these developmental anomalies.	JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND		FIRTH, HV (corresponding author), CHURCHILL HOSP,DEPT MED GENET,OXFORD OX3 7LJ,ENGLAND.							BOUWESBAVINCK JN, 1986, AM J MED GENET, V23, P903, DOI 10.1002/ajmg.1320230405; BOYD PA, 1990, PRENATAL DIAG, V10, P437, DOI 10.1002/pd.1970100705; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P666; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; JONES KL, 1988, SMITHS RECOGNISABLE, P588; RHOADS GG, 1989, NEW ENGL J MED, V320, P609, DOI 10.1056/NEJM198903093201001; WEBSTER WS, 1988, TERATOLOGY, V38, pA199; 1990, MB34 OFF POP CENS SU; 1991, MB35 OFF POP CENS SU	11	270	280	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					762	763		10.1016/0140-6736(91)91374-4	http://dx.doi.org/10.1016/0140-6736(91)91374-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672394				2022-12-01	WOS:A1991FD88400006
J	JICK, H; JICK, SS; DERBY, LE				JICK, H; JICK, SS; DERBY, LE			VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the extent of agreement between clinical information recorded on surgery computers of selected general practitioners and similar information in manual records of letters received from hospital consultants and kept in the general practitioners' files. Design-Hospital consultants' letters in the manual records of selected general practitioners were photocopied and the consultants' clinical diagnoses were compared with diagnoses recorded on computer. Setting-General practices in the United Kingdom using computers provided by VAMP Health for recording clinical information. Subjects-2491 patients who received one of three non-steroidal anti-inflammatory drugs and who attended 58 practices whose computer recorded data were considered after a preliminary review to be of satisfactory quality. Results-Among 1191 patients for whom consultants' letters were forwarded a clinical diagnosis reflecting the diagnosis noted on a consultant letter was present on the computer record for 1038 (87%). Conclusion-Clinical information available on the computer records of the general practitioners who participated in this study is satisfactory for many clinical studies.			JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.			Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992	FDA HHS [FD-U-000071-09] Funding Source: Medline	FDA HHS		FINDLAY GH, 1982, LANCET, V2, P95; JICK H, 1984, PHARMACOTHERAPY, V4, P99; JICK H, 1990, PHARMACOTHERAPY, V10, P395; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; SKEGG DCG, 1977, LANCET, V2, P475; TILSON H H, 1989, Journal of Clinical Research and Drug Development, V3, P39; WEST R, 1988, AM J PREVENTIVE ME S, P25	7	722	723	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					766	768		10.1136/bmj.302.6779.766	http://dx.doi.org/10.1136/bmj.302.6779.766			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021768	Green Published, Bronze			2022-12-01	WOS:A1991FF22900027
J	JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG				JOHNSEN, R; BERNERSEN, B; STRAUME, B; FORDE, OH; BOSTAD, L; BURHOL, PG			PREVALENCES OF ENDOSCOPIC AND HISTOLOGICAL-FINDINGS IN SUBJECTS WITH AND WITHOUT DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							PEPTIC-ULCER DISEASE; CHRONIC GASTRITIS; DUODENAL-ULCER; BIOPSY SPECIMENS; WORKING PARTY; DIAGNOSIS; SYMPTOMS; GASTRODUODENITIS; VOLUNTEERS; MANAGEMENT	Objective-To examine the association between dyspeptic symptoms and endoscopic and histological diagnoses. Design-Cross sectional study of people with dyspepsia and controls matched for age and sex identified by questionnaire survey of all inhabitants aged 20 to 69. Endoscopy and histological examination was performed with the examiner blind to whether or not the patient had dyspepsia. Setting-Population based survey in Sorreisa, Norway. Subjects-All people with dyspepsia and age and sex matched people without dyspepsia were offered endoscopy. A total of 309 people with dyspepsia and 310 without dyspepsia underwent endoscopy, giving 273 matched pairs. Main outcome measures-Prevalences of endoscopic and histological diagnoses made according to internationally accepted standards. Results-In all, 1802 of 2027 (88.9%) people returned the questionnaire. Of the 163 subjects who refused endoscopy, 114 were controls. Of five endoscopic and four histological diagnoses only peptic ulcer disease, endoscopic duodenitis, and active chronic gastritis were diagnosed significantly more often in people with dyspepsia. In all, 30% to 50% of the diagnoses of mucosal inflammation and peptic ulcer disease were made among subjects without dyspepsia, and only 10% of both those with and those without dyspepsia had normal endoscopic findings. Conclusions-The diagnostic findings, with possible exceptions of peptic ulcer disease and endoscopic duodenitis, showed no association of clinical value with dyspeptic symptoms. The small number of "normal" endoscopic findings in both those with and those without dyspepsia challenge well accepted endoscopic and histological diagnostic criteria with relation to the upper gastrointestinal tract.			JOHNSEN, R (corresponding author), UNIV TROMSO,GEN PRACTICE,N-9000 TROMSO,NORWAY.							AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; BARBARA L, 1989, DIGEST DIS SCI, V34, P1272, DOI 10.1007/BF01537277; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; CHELI R, 1982, SCAND J GASTROENTERO, V17, P84; CHELI R, 1986, ENDOSCOPY, V18, P125, DOI 10.1055/s-2007-1018350; CHELI R, 1983, HEPATO-GASTROENTEROL, V30, P21; COLINJONES DG, 1988, LANCET, V1, P576; DANIELSSON A, 1980, ANN CLIN RES, V12, P4; DELUCA VA, 1981, J CLIN GASTROENTEROL, V3, P17; EARLAM RJ, 1985, GUT, V26, P95, DOI 10.1136/gut.26.1.95; GREENLAW R, 1980, DIGEST DIS SCI, V25, P660, DOI 10.1007/BF01308325; GUSLANDI M, 1986, Digestive Diseases, V4, P231, DOI 10.1159/000171153; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P62; JOFFE SN, 1982, SCAND J GASTROENTERO, V17, P88; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JORDE R, 1986, LANCET, V1, P119; KREUNING J, 1978, J CLIN PATHOL, V31, P69, DOI 10.1136/jcp.31.1.69; MACKINNON M, 1982, DIGEST DIS SCI, V27, P217, DOI 10.1007/BF01296918; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NIE NH, 1975, STATISTICAL PACKAGE; OWEN DA, 1979, PATHOL ANNU, V1, P247; SAVARY M, 1977, LEHRBUCH ENDOSKOPISC; SIRCUS W, 1985, Q J MED, V56, P593; Siurala M, 1980, Front Gastrointest Res, V6, P148; Snedecor G. W., 1967, STATISTICAL METHODS, P432; SPIRO HM, 1974, NEW ENGL J MED, V291, P567, DOI 10.1056/NEJM197409122911107; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; THOMSON WO, 1977, LANCET, V1, P1197; TOUKAN AU, 1985, DIGEST DIS SCI, V30, P313, DOI 10.1007/BF01403839; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1984, ANN CLIN RES, V16, P192; VILLAKO K, 1976, SCAND J GASTROENTERO, V2, P817; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701; 1985, LANCET, V2, P1222	35	200	204	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					749	752		10.1136/bmj.302.6779.749	http://dx.doi.org/10.1136/bmj.302.6779.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021764	Bronze, Green Published			2022-12-01	WOS:A1991FF22900019
J	MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S				MAKI, M; AINE, L; LIPSANEN, V; KOSKIMIES, S			DENTAL ENAMEL DEFECTS IN 1ST-DEGREE RELATIVES OF CELIAC-DISEASE PATIENTS	LANCET			English	Note								To find out whether dental changes can be used to screen for coeliac disease among apparently healthy relatives of patients with the disorder, 56 healthy first-degree relatives of such patients were subjected to dental examination and small bowel biopsy. 25 had coeliac-type general permanent-tooth enamel lesions. All 7 who had histological evidence of coeliac disease also had enamel lesions. The finding that enamel defects may occur without small bowel changes must be borne in mind in screening. The coeliac-type enamel changes were strongly associated with HLA-DR3, and most of the DR3 alleles belonged to the extended haplotype A1; B8; DR3 group.	UNIV HOSP TAMPERE,DEPT ORAL & MAXILLOFACIAL SURG,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	Tampere University; Tampere University Hospital	MAKI, M (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,SF-33520 TAMPERE,FINLAND.							AINE L, 1986, Proceedings of the Finnish Dental Society, V82, P1; AINE L, 1990, J ORAL PATHOL MED, V19, P241, DOI 10.1111/j.1600-0714.1990.tb00834.x; AMOS DB, 1969, TRANSPLANTATION, V7, P220, DOI 10.1097/00007890-196903000-00023; DUPONT B, 1989, IMMUNOBIOLOGY HLA IM, V2; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, IN PRESS GUT; Massier M, 1941, AM J DIS CHILD, V62, P33; NIKIFORUK G, 1981, J PEDIATR-US, V98, P888, DOI 10.1016/S0022-3476(81)80580-X	8	47	48	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					763	764		10.1016/0140-6736(91)91375-5	http://dx.doi.org/10.1016/0140-6736(91)91375-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672395				2022-12-01	WOS:A1991FD88400007
J	MANTLE, J; VERSI, E				MANTLE, J; VERSI, E			PHYSIOTHERAPY FOR STRESS URINARY-INCONTINENCE - A NATIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the physiotherapeutic treatment of urinary stress incontinence in England. Design-Postal questionnaire survey. Setting-All 192 English district health authorities. Subjects-One physiotherapist from each district who was primarily concerned with urinary incontinence. A consensus view was requested. Main outcome measures-Responses to questionnaire and analysis of a visual analogue scale to indicate effectiveness. Results-There was a 98% response rate. Treatment was often by senior physiotherapists (108 senior I grade or above) who, in 117 districts, claimed to have made a specialty of treating the condition. Gynaecologists and obstetricians were far more likely to refer patients than any other agency (147 respondents said that they were the commonest source of referral). One hundred and fifty four respondents stated that physiotherapy was usually used as the first line of treatment. Pelvic floor exercises and interferential treatment were most commonly used (by 178 and 144 respondents respectively) and thought to be the most effective, especially in combination, though various techniques were used in applying them. Positive motivation (108), recent onset of symptoms (55), and youth (40) were viewed optimistically, and obesity (60), previous surgery (59), prolapse (42), and a chronic cough (36) were considered to be bad prognostic features. The number of patients treated varied greatly (range 10-360) between districts and was poorly correlated with catchment size (correlation coefficient 0.3). Conclusions-As physiotherapists are treating considerable numbers of patients with stress incontinence research is urgently needed to produce efficacy data to enable rationalisation of resources to cater for the whole population.	ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND; POLYTECH E LONDON,DIV PHYSIOTHERAPY,LONDON E15 4LZ,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of East London								Bo K, 1989, NEUROLOGY URODYNAMIC, V8, P355; Harrison S M, 1973, Physiotherapy, V59, P363; KEGEL A H, 1948, Ann West Med Surg, V2, P213; KLARSKOV P, 1986, UROL INT, V41, P129, DOI 10.1159/000281181; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; STANTON SL, 1990, CLIN OBSTET GYNAECOL, P346; STODDART GD, 1983, PHYSIOTHERAPY, V69, P143; SWITZER D, 1988, IRISH MED J, V81, P30; Tapp AJ, 1989, NEUROUROL URODYNAM, V8, P356; TAPP AJS, 1988, NEUROLOGY URODYNAMIC, V7, P259; TEHON D, 1988, PHYS THER, V68, P652; VERSI E, 1989, BRIT J OBSTET GYNAEC, V96, P752, DOI 10.1111/j.1471-0528.1989.tb03306.x; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P575, DOI 10.1111/j.1471-0528.1987.tb03153.x; 1987, SERIES VS OFFICE POP, V14, P74	14	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					753	755		10.1136/bmj.302.6779.753	http://dx.doi.org/10.1136/bmj.302.6779.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1888358	Bronze, Green Published			2022-12-01	WOS:A1991FF22900021
J	SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H				SALONEN, JT; SALONEN, R; SEPPANEN, K; KANTOLA, M; SUNTIOINEN, S; KORPELA, H			INTERACTIONS OF SERUM COPPER, SELENIUM, AND LOW-DENSITY-LIPOPROTEIN CHOLESTEROL IN ATHEROGENESIS	BRITISH MEDICAL JOURNAL			English	Article							PLASMA; OXIDATION; MAGNESIUM; SMOKING; ADULTS; ZINC	Objective-To investigate the interactions between serum cooper, selenium, and low density lipoprotein cholesterol concentrations with regard to the progression of carotid atherosclerosis. Design-Longitudinal study of a cohort of middle aged men followed up for 24 months. Setting-Epidemiological survey of the population of seven communities in eastern Finland. Subjects-126 men aged 42, 48, 54, or 60 at examination randomly selected from a population based sample of 2682 men. Main outcome measures-Increase in maximal carotid intima media thickness. Results-The mean increase in the maximal common carotid intima media thickness after two years was greater in men with high serum copper concentrations (0.16 mm compared with 0.08 mm in men with concentrations < 17.6-mu-mol/l; p = 0.010), those with low serum selenium concentrations (0.15 mm compared with 0.09 mm in men with concentrations greater-than-or-equal-to 1.40-mu-mol/l; p = 0.035), and those with raised serum low density lipoprotein cholesterol concentrations (0.15 mm compared with 0.08 mm in men with concentrations < 4.0-mmol/l; p = 0.032) after adjustment for age and cigarette pack years in a three way analysis of covariance. A raised serum low density lipoprotein concentration was associated with accelerated progression of atherosclerosis only in men with higher than median serum copper concentrations (net difference 0.22 mm; p < 0.001 for two way interaction), and this synergism was even more pronounced in men with serum selenium concentrations below the median value (net difference 0.41 mm; p = 0.042 for three way interaction). Conclusion-These data provide evidence of a synergistic effect of copper (a pro-oxidant), a low serum concentration of selenium (a cofactor of an enzyme that scavenges free radicals), and low density lipoprotein cholesterol concentration in atherogenesis.	KUOPIO RES INST EXERCISE MED,KUOPIO,FINLAND; UNIV KUOPIO,DEPT CHEM,KUOPIO,FINLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND	University of Eastern Finland; University of Eastern Finland	SALONEN, JT (corresponding author), UNIV KUOPIO,PUBL HLTH RES INST,POB 6,SF-70211 KUOPIO,FINLAND.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BLANKENHORN DH, 1990, CIRCULATION, V81, P470, DOI 10.1161/01.CIR.81.2.470; CARLSON K, 1973, J CLIN PATHOL S5, V26, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P342; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HATANO S, 1982, AM J CLIN NUTR, V35, P120, DOI 10.1093/ajcn/35.1.120; HIISVIRTA L, 1985, FINN J WATER EC HYDR, V26, P30; JEANDEL C, 1989, GERONTOLOGY, V35, P275, DOI 10.1159/000213037; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KANT AK, 1989, NUTR RES, V9, P717, DOI 10.1016/S0271-5317(89)80015-6; LEWIS KO, 1982, LANCET, V2, P188; LLOYD B, 1983, J EPIDEMIOL COMMUN H, V37, P213, DOI 10.1136/jech.37.3.213; LUDWIG PW, 1982, LANCET, V1, P348; MAKINEN P, 1989, WATER ENV, V38; MOORE JA, 1984, CLIN CHEM, V30, P1171; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARVIAINEN MT, 1986, J LIQ CHROMATOGR, V9, P2185, DOI 10.1080/01483918608074142; PUNSAR S, 1975, J CHRON DIS, V28, P259, DOI 10.1016/0021-9681(75)90009-0; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1982, LANCET, V2, P175; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, IN PRESS ULTRASOUND; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SHAMBERGER RJ, 1984, BIOCH ESSENTIAL ULTR, P201; SINGH A, 1989, AM J CLIN NUTR, V49, P695, DOI 10.1093/ajcn/49.4.695; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; 1983, SPSS X USERS GUIDE C; 1988, ARCH INTERN MED, V148, P36; 1989, INT J EPIDEMIOL S1, V18, pS46; 1988, EUR HEART J, V9, P571	33	195	201	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					756	760		10.1136/bmj.302.6779.756	http://dx.doi.org/10.1136/bmj.302.6779.756			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021765	Green Published, Bronze			2022-12-01	WOS:A1991FF22900022
J	VALLANCE, P; MONCADA, S				VALLANCE, P; MONCADA, S			HYPERDYNAMIC CIRCULATION IN CIRRHOSIS - A ROLE FOR NITRIC-OXIDE	LANCET			English	Article							L-ARGININE; ENDOTOXIN; INVIVO; BLOOD	Hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors are features of cirrhosis. These cardiovascular changes might be the result of increased synthesis of a vasodilator. Nitric oxide (NO), a potent vasodilator, is synthesised in and released from peripheral blood-vessels in man. Studies in animals indicate that bacterial endotoxin and cytokines induce NO synthase expression in vessel walls, with sustained NO release and consequent hypotension. Endotoxaemia is a common feature of cirrhosis; persistent induction of NO synthase may account for the associated haemodynamic changes.	WELLCOME RES LABS, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories								AISAKA K, 1989, BIOCHEM BIOPH RES CO, V163, P710, DOI 10.1016/0006-291X(89)92281-X; BENDTSEN F, 1990, J HEPATOL, V10, P198, DOI 10.1016/0168-8278(90)90052-S; BOSCH J, 1988, KIDNEY LIVER DISEASE, P286; BOURGOIGNIE JJ, 1988, KIDNEY LIVER DISEASE, P486; BURTON GA, 1990, BRIT J PHARMACOL, V99, P364, DOI 10.1111/j.1476-5381.1990.tb14709.x; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; FONG YM, 1990, J CLIN INVEST, V85, P1896, DOI 10.1172/JCI114651; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LINTRUP J, 1966, ACTA MED SCAND, V179, P13; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MIYASE S, 1990, Gastroenterologia Japonica, V25, P356; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADLOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; SCHRIER RW, 1988, KIDNEY LIVER DISEASE, P265; SHEARMAN DJC, 1989, DISEASES GASTROINTES, P795; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TOLINS JP, 1990, AM J PHYSIOL, V258, pH655, DOI 10.1152/ajpheart.1990.258.3.H655; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VALLANCE P, 1989, LANCET, V2, P997; WYKE RJ, 1989, BAILLIERE CLIN GASTR, V3, P187, DOI 10.1016/0950-3528(89)90052-3; YOMOTA M, 1989, J BIOCHEM BIOPH METH, V18, P97	27	580	603	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	1991	337	8744					776	778		10.1016/0140-6736(91)91384-7	http://dx.doi.org/10.1016/0140-6736(91)91384-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1706450				2022-12-01	WOS:A1991FD88400015
J	WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA				WARREN, N; HOLMES, JA; ALJADER, L; WEST, RR; LEWIS, DC; PADUA, RA			FREQUENCY OF CARRIERS OF CYSTIC-FIBROSIS GENE AMONG PATIENTS WITH MYELOID MALIGNANCY AND MELANOMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL CARDIFF,DEPT HAEMATOL,PRELEUKAEMIA UNIT,LEUKAEMIA RES FUND,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; 				ALJADER LN, 1989, BRIT MED J, V298, P164, DOI 10.1136/bmj.298.6667.164; ALJADER LN, 1991, ARCH DIS CHILD, V66, P317, DOI 10.1136/adc.66.3.317; ESTIVILL X, 1989, LANCET, V2, P140; MCINTOSH I, 1989, LANCET, V2, P1404; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657	5	18	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					760	761		10.1136/bmj.302.6779.760	http://dx.doi.org/10.1136/bmj.302.6779.760			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	2021766	Green Published, Bronze			2022-12-01	WOS:A1991FF22900023
J	WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC				WILKINSON, SM; CARTWRIGHT, PH; ENGLISH, JSC			HYDROCORTISONE - AN IMPORTANT CUTANEOUS ALLERGEN	LANCET			English	Note							CONTACT-DERMATITIS	We have found a high incidence (4.8%) of allergy to hydrocortisone in patients with suspected allergic contact dermatitis. In view of this finding we would suggest that, in any condition that does not improve or that deteriorates after administration of hydrocortisone, allergy to this compound should be considered.			WILKINSON, SM (corresponding author), N STAFFORDSHIRE HOSP,CENT OUTPATIENTS DEPT,DEPT DERMATOL,STOKE ON TRENT ST4 7PA,ENGLAND.			Wilkinson, Stephen Mark/0000-0001-7253-3461				ALANI MD, 1972, ANN ALLERGY, V30, P181; CHURCH R, 1960, BRIT J DERMATOL, V72, P341, DOI 10.1111/j.1365-2133.1960.tb13814.x; COMAISH S, 1969, BRIT J DERMATOL, V81, P919, DOI 10.1111/j.1365-2133.1969.tb15974.x; DOOMSGOOSSENS A, 1986, CONTACT DERMATITIS, V14, P94, DOI 10.1111/j.1600-0536.1986.tb01168.x; ENGLISH JSC, 1990, CONTACT DERMATITIS, V23, P196, DOI 10.1111/j.1600-0536.1990.tb04789.x; KING RA, 1960, LANCET, V2, P1093; LAUERMA AI, 1990, BRIT J DERMATOL, V123, P699, DOI 10.1111/j.1365-2133.1990.tb04186.x; PARAMSOTHY Y, 1988, CONTACT DERMATITIS, V18, P30, DOI 10.1111/j.1600-0536.1988.tb05486.x; WILKINSON M, 1990, CONTACT DERMATITIS, V23, P120, DOI 10.1111/j.1600-0536.1990.tb03240.x; 1989, CONTACT DERMATITIS, V20, P158	10	70	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1991	337	8744					761	762		10.1016/0140-6736(91)91373-3	http://dx.doi.org/10.1016/0140-6736(91)91373-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD884	1672393				2022-12-01	WOS:A1991FD88400005
J	CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME				CHAN, BMC; MATSUURA, N; TAKADA, Y; ZETTER, BR; HEMLER, ME			INVITRO AND INVIVO CONSEQUENCES OF VLA-2 EXPRESSION ON RHABDOMYOSARCOMA CELLS	SCIENCE			English	Article							INHIBITS EXPERIMENTAL METASTASIS; MELANOMA-CELLS; MONOCLONAL-ANTIBODY; INTEGRIN RECEPTORS; DEPENDENT ADHESION; SURFACE RECEPTORS; COLLAGEN RECEPTOR; LAMININ RECEPTOR; T-CELLS; FIBRONECTIN	Cloned integrin alpha-2 subunit complementary DNA was expressed on human rhabdomyosarcoma (RD) cells to give a functional VLA-2 (alpha-2-beta-1) adhesion receptor. The VLA-2-positive RDA2 cells not only showed increased adhesion to collagen and laminin in vitro, but also formed substantially more metastatic tumor colonies in nude mice after either intravenous or subcutaneous injection. These results show that a specific adhesion receptor (VLA-2) can markedly enhance both experimental and spontaneous metastasis. In contrast to the metastasis results, there was no difference in either the in vitro growth rate or apparent in vivo tumorigenicity of RD and RDA2 cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				takada, yoshikazu/0000-0001-5481-9589	NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37393] Funding Source: Medline; NIGMS NIH HHS [GM 38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1990, CANCER RES, V50, P1601; ANICHINI A, 1990, INT J CANCER, V46, P508, DOI 10.1002/ijc.2910460330; BAND H, 1989, J IMMUNOL, V142, P3267; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; NATALI P, 1990, CANCER RES, V50, P1271; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OTOOLE TE, 1989, BLOOD, V74, P14; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROOSSIEN FF, 1989, J CELL BIOL, V108, P1979, DOI 10.1083/jcb.108.5.1979; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGA S, 1988, CANCER RES, V48, P5510; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597; YAMADA KM, 1990, CANCER RES, V50, P4485; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; ZYLSTRA S, 1986, CANCER RES, V46, P6446	49	314	323	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1600	1602		10.1126/science.2011740	http://dx.doi.org/10.1126/science.2011740			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011740				2022-12-01	WOS:A1991FD89000034
J	DOUDNA, JA; COUTURE, S; SZOSTAK, JW				DOUDNA, JA; COUTURE, S; SZOSTAK, JW			A MULTISUBUNIT RIBOZYME THAT IS A CATALYST OF AND TEMPLATE FOR COMPLEMENTARY STRAND RNA-SYNTHESIS	SCIENCE			English	Article							GROUP-I INTRONS; DIRECTED SYNTHESIS; POLYMERASE; CONSERVATION; TETRAHYMENA; EVOLUTION	Derivatives of the sunY self-splicing intron efficiently catalyzed the synthesis of complementary strand RNA by template-directed assembly of oligonucleotides. These ribozymes were separated into three short RNA fragments that formed active catalytic complexes. One of the multisubunit sunY derivatives catalyzed the synthesis of a strand of RNA complementary to one of its own subunits. These results suggest that prebiotically synthesized oligonucleotides might have been able to assemble into a complex capable of self-replication.			DOUDNA, JA (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MICHEL F, IN PRESS J MOL BIOL; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; USMAN N, 1988, P NATL ACAD SCI USA, V85, P5764; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	21	100	103	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1605	1608		10.1126/science.1707185	http://dx.doi.org/10.1126/science.1707185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1707185				2022-12-01	WOS:A1991FD89000036
J	DRAKE, JM; KLAFTER, J; LEVITZ, P				DRAKE, JM; KLAFTER, J; LEVITZ, P			CHEMICAL AND BIOLOGICAL MICROSTRUCTURES AS PROBED BY DYNAMIC PROCESSES	SCIENCE			English	Article							DIRECT ENERGY-TRANSFER; EXCITATION TRANSFER; RESTRICTED GEOMETRIES; SURFACE; FLUORESCENCE; RELAXATION; MORPHOLOGY; SYSTEMS	The dynamic process of electronic energy transfer is shown to be an important tool for probing the microstructure of molecular systems, particularly those in which donors and acceptors occupy specifically labeled sites of spatially confining host matrices. Special attention is given to analyzing the temporal behavior of the direct energy transfer reaction for systems in which the dipolar coupling is between a donor and randomly distributed acceptors. This dynamic process is dependent on two competing lengths when the donor and acceptor distribution is determined by the microstructure of the confining system: R(p), the dominant length characterizing the size of the confinement, and R0, which scales the strength of the dipolar coupling. When energy transfer processes are viewed in the context of these two competing lengths, a picture emerges of the microstructure of the confinement that is consistent with and corroborated by other structural probes.	CNRS, CRSOCI, F-45071 ORLEANS 2, FRANCE; TEL AVIV UNIV, SCH CHEM, IL-69978 TEL AVIV, ISRAEL	Centre National de la Recherche Scientifique (CNRS); Tel Aviv University	DRAKE, JM (corresponding author), EXXON RES & ENGN CO, ANNANDALE, NJ 08801 USA.							BAUMANN J, 1986, J CHEM PHYS, V85, P4087, DOI 10.1063/1.450880; BENNETT RG, 1964, J CHEM PHYS, V41, P3037, DOI 10.1063/1.1725670; BLUMEN A, 1981, NUOVO CIMENTO B, V63, P50, DOI 10.1007/BF02721411; BLUMEN A, 1986, J CHEM PHYS, V84, P1397, DOI 10.1063/1.450481; Blumen A., 1986, OPTICAL SPECTROSCOPY, P199; BUCHER H, 1967, MOL CRYST, V2, P199, DOI 10.1080/15421406708083417; Cantor C. R., 1980, BIOPHYSICAL CHEM 2; CANTOR CR, 1971, P NATL ACAD SCI USA, V68, P2099, DOI 10.1073/pnas.68.9.2099; Drake J. M., 1986, MATER RES STAND, V73, P305; DRAKE JM, 1990, PHYS TODAY, V43, P46, DOI 10.1063/1.881244; EVEN U, 1984, PHYS REV LETT, V52, P2164, DOI 10.1103/PhysRevLett.52.2164; FERNANDEZ SM, 1976, NATURE, V264, P411, DOI 10.1038/264411a0; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FORSTER T, 1949, Z NATURFORSCH A, V4, P321; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063; KASATANI K, 1985, J PHYS CHEM-US, V89, P542, DOI 10.1021/j100249a035; KAUFFMANN HF, 1990, DYNAMICAL PROCESSES IN CONDENSED MOLECULAR SYSTEMS, P90; KLAFTER J, 1985, J LUMIN, V34, P77, DOI 10.1016/0022-2313(85)90096-1; KLAFTER J, 1984, J CHEM PHYS, V80, P875, DOI 10.1063/1.446743; KLAFTER J, 1986, P NATL ACAD SCI USA, V83, P848, DOI 10.1073/pnas.83.4.848; Klafter J, 1989, MOL DYNAMICS RESTRIC; KOPELMAN R, 1988, SCIENCE, V241, P1620, DOI 10.1126/science.241.4873.1620; LEVITZ P, 1987, PHYS REV LETT, V58, P686, DOI 10.1103/PhysRevLett.58.686; LEVITZ P, 1988, J CHEM PHYS, V89, P5224, DOI 10.1063/1.455613; LEVITZ P, 1988, CHEM PHYS LETT, V148, P557, DOI 10.1016/0009-2614(88)80330-0; LEVITZ P, UNPUB; Mandelbrot B.B., 1983, FRACTAL GEOMETRY NAT; MATAGA N, 1969, J PHYS CHEM-US, V73, P370, DOI 10.1021/j100722a016; OHMINE I, 1977, MACROMOLECULES, V10, P862, DOI 10.1021/ma60058a028; PEKCAN O, 1990, CHEM PHYS, V146, P283, DOI 10.1016/0301-0104(90)80049-4; PEKCAN O, 1988, PHYS REV LETT, V61, P641, DOI 10.1103/PhysRevLett.61.641; Rehm D, 1971, CHEM PHYS LETT, V9, P387, DOI 10.1016/0009-2614(71)80249-X; Steinberg I. Z., 1983, TIME RESOLVED FLUORE, P411; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAMAI N, 1988, CHEM PHYS LETT, V147, P25, DOI 10.1016/0009-2614(88)80217-3; TAMAI N, 1987, J PHYS CHEM-US, V91, P3503, DOI 10.1021/j100297a010; ULLMAN EF, 1976, J BIOL CHEM, V251, P4172; YANG CL, 1985, J PHYS CHEM-US, V89, P3442, DOI 10.1021/j100262a003; YANG CL, 1989, MOL DYNAMICS RESTRIC, P371; Yen W. M., 1981, LASER SPECTROSCOPY S	42	104	108	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1574	1579		10.1126/science.2011737	http://dx.doi.org/10.1126/science.2011737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011737				2022-12-01	WOS:A1991FD89000027
J	GILBERTSON, TA; SCOBEY, R; WILSON, M				GILBERTSON, TA; SCOBEY, R; WILSON, M			PERMEATION OF CALCIUM-IONS THROUGH NON-NMDA GLUTAMATE CHANNELS IN RETINAL BIPOLAR CELLS	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; EXCITATORY AMINO-ACIDS; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; NEUROMUSCULAR-JUNCTION; ACTIVATED CHANNELS; DIVALENT-CATIONS; PHOTORECEPTORS; QUISQUALATE; RECEPTORS	The conduction of calcium ions through glutamate-gated channels is important in the induction of long-term potentiation and may trigger other cellular changes. In retinal bipolar cells, which lack the N-methyl-D-aspartate (NMDA) type of glutamate-gated channel, calcium permeability through non-NMDA channels was examined. Changes in extracellular calcium concentration unexpectedly affected the reversal potential for glutamate-induced currents in a manner consistent with these channels being highly permeable to calcium. External magnesium ions promote desensitization of these non-NMDA channels in a voltage-independent way. Thus, in addition to non-NMDA channels that conduct only sodium and potassium, there is a class that is also permeable to calcium.	UNIV CALIF DAVIS, DEPT ZOOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis			Gilbertson, Timothy/G-7147-2011	Gilbertson, Timothy/0000-0003-2569-3096	NATIONAL EYE INSTITUTE [R01EY004112] Funding Source: NIH RePORTER; NEI NIH HHS [EY 04112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; ASCHER P, 1986, J PHYSIOL-LONDON, V377, pP34; ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; AULT B, 1980, J PHYSIOL-LONDON, V307, P413, DOI 10.1113/jphysiol.1980.sp013443; BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRANDON C, 1983, P NATL ACAD SCI-BIOL, V80, P5117, DOI 10.1073/pnas.80.16.5117; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; GILBERTSON TA, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARC RE, 1981, P NATL ACAD SCI-BIOL, V78, P7185, DOI 10.1073/pnas.78.11.7185; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILLER AM, 1983, J PHYSIOL-LONDON, V334, P325, DOI 10.1113/jphysiol.1983.sp014497; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P162, DOI 10.1152/jn.1989.61.1.162; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a	34	202	202	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1613	1615		10.1126/science.1849316	http://dx.doi.org/10.1126/science.1849316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1849316				2022-12-01	WOS:A1991FD89000039
J	HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA				HIBBS, ML; XU, H; STACKER, SA; SPRINGER, TA			REGULATION OF ADHESION TO ICAM-1 BY THE CYTOPLASMIC DOMAIN OF LFA-1 INTEGRIN BETA-SUBUNIT	SCIENCE			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; ALPHA-SUBUNIT; VONWILLEBRAND-FACTOR; CLONING; CD2; HOMOLOGY; FAMILY; CHAIN	Interactions between cytotoxic lymphocytes and their targets require the T cell antigen receptor (TCR) and the integrin lymphocyte function-associated molecule-1 (LFA-1, CD11a/CD18). LFA-1 is not constitutively avid for its counterreceptors, intercellular adhesion molecules (ICAMs)-1 and -2. Cross-linking of the TCR transiently converts LFA-1 to a high avidity state and thus provides a mechanism for regulating cellular adhesion and de-adhesion in an antigen-specific manner. Truncation of the cytoplasmic domain of the beta, but not the alpha, subunit of LFA-1 eliminated binding to ICAM-1 and sensitivity to phorbol esters. Thus, LFA-1 binding to ICAM-1 was found to be regulated by the cytoplasmic domain of the beta-subunit of LFA-1.	HARVARD UNIV, SCH MED, CTR BLOOD RES, 800 HUNTINGTON AVE, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School			Hibbs, Margaret L/D-7013-2011	Hibbs, Margaret L/0000-0002-3751-6751; Stacker, Steven/0000-0003-4096-9273	NCI NIH HHS [CA31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1990, J CLIN INVEST, V85, P674, DOI 10.1172/JCI114491; HIBBS ML, UNPUB; KAUFMANN Y, UNPUB; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WILSON RW, 1989, NUCLEIC ACIDS RES, V17, P5397, DOI 10.1093/nar/17.13.5397	25	255	256	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1611	1613		10.1126/science.1672776	http://dx.doi.org/10.1126/science.1672776			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1672776				2022-12-01	WOS:A1991FD89000038
J	LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB				LOBOS, E; WEISS, N; KARAM, M; TAYLOR, HR; OTTESEN, EA; NUTMAN, TB			AN IMMUNOGENIC ONCHOCERCA-VOLVULUS ANTIGEN - A SPECIFIC AND EARLY MARKER OF INFECTION	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; SEQUENCE	Onchocerciasis (river blindness) is a serious health problem and a severe obstacle to social and economic development, especially in Africa. A complementary DNA fragment coding for an Onchocerca volvulus antigen (OV-16) was cloned and expressed in the plasmid vector pCG808fx. Immune responses to this O. volvulus-specific recombinant antigen were detectable in patients with documented onchocerciasis; the antibody response was also detectable at 3 months and at more than 1 year before infection could otherwise be detected in humans and in chimpanzees experimentally infected with O. volvulus third-stage larvae.	JOHNS HOPKINS UNIV,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21205; SWISS TROP INST,CH-4051 BASEL,SWITZERLAND; WHO,ONCHOCERCIASIS CONTROL PROGRAMME,OUAGADOUGOU,BURKINA FASO	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Basel; Swiss Tropical & Public Health Institute; World Health Organization	LOBOS, E (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.			Taylor, Hugh/0000-0002-9437-784X				AZIZ M A, 1986, Parasitology Today, V2, P233, DOI 10.1016/0169-4758(86)90001-3; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GUAN C, 1987, GENE, V67, P21; KARAM M, 1985, AM J TROP MED HYG, V40, P261; LOBOS E, 1986, PARASITOLOGY, V93, P389, DOI 10.1017/S0031182000051556; LOBOS E, 1990, MOL BIOCHEM PARASIT, V39, P135, DOI 10.1016/0166-6851(90)90016-F; LOBOS E, UNPUB; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MORT JS, 1988, BIOL CHEM H-S, V369, P163; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TAYLOR HR, 1988, AM J TROP MED HYG, V39, P86, DOI 10.4269/ajtmh.1988.39.86; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WALSH J, 1986, SCIENCE, V232, P922, DOI 10.1126/science.3754652; WEISS N, UNPUB; WEISS N, 1987, CIBA F S, V27, P180; 1976, WHO TECH REP SER, V597; 1987, WHO TECH REP SER, V752	18	123	125	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1603	1605		10.1126/science.2011741	http://dx.doi.org/10.1126/science.2011741			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011741				2022-12-01	WOS:A1991FD89000035
J	OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J				OPPENHEIM, RW; PREVETTE, D; YIN, QW; COLLINS, F; MACDONALD, J			CONTROL OF EMBRYONIC MOTONEURON SURVIVAL INVIVO BY CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NORMAL-CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; NEURONAL DEATH; NEURONOTROPHIC FACTOR; PURIFICATION; REDUCTION; GANGLION; BRAIN	During development of the nervous system, neurons in many regions are overproduced by proliferation, after which the excess cells are eliminated by cell death. The survival of only a proportion of neurons during normal development is thought to be regulated by the limited availability of neurotrophic agents. One such putative trophic agent is ciliary neurotrophic factor (CNTF), a polypeptide that promotes the survival of ciliary, sensory, and sympathetic neurons in vitro. In contrast to the results of in vitro studies, however, the daily treatment of chick embryos in vivo with purified human recombinant CNTF failed to rescue any of these cell populations from cell death, whereas CNTF did promote the in vivo survival of spinal motoneurons. Thus, CNTF may not act as a neurotrophic agent in vivo for those embryonic neurons (especially ciliary neurons) on which it acts in vitro. Rather, CNTF may be required for in vivo survival of motoneurons.	SYNERGEN INC,BOULDER,CO 80301; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020402] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 20402] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bhattacharyya A., UNPUB; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; CHUWANG IW, 1978, J COMP NEUROL, V177, P33, DOI 10.1002/cne.901770105; CLARKE PGH, 1985, TRENDS NEUROSCI, V8, P345, DOI 10.1016/0166-2236(85)90120-1; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIES AM, 1988, TRENDS NEUROSCI, V11, P243, DOI 10.1016/0166-2236(88)90099-9; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ERNBERGER U, 1989, NEURON, V2, P1275; FURBER S, 1987, J NEUROSCI, V7, P1816; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOFFMANN HD, 1988, J NEUROCHEM, V51, P109; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES S, 1988, NATURE, V355, P70; LANDMESSER L, 1974, J PHYSIOL-LONDON, V241, P715, DOI 10.1113/jphysiol.1974.sp010680; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1990, J BIOL CHEM, V265, P8942; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MCMANAMAN JL, 1990, NEURON, V4, P891, DOI 10.1016/0896-6273(90)90142-3; MERINEY SD, 1985, SCIENCE, V228, P1451, DOI 10.1126/science.2990029; OPPENHEIM RC, UNPUB; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; PITTMAN RH, 1978, NATURE, V271, P364, DOI 10.1038/271364a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P7537; WALICKE PA, 1989, ANNU REV NEUROSCI, V12, P103, DOI 10.1146/annurev.neuro.12.1.103; WATTERS D, 1985, BIOCHEM INT, V11, P245; WATTERS DJ, 1987, J NEUROCHEM, V49, P705	50	417	438	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1616	1618		10.1126/science.2011743	http://dx.doi.org/10.1126/science.2011743			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011743				2022-12-01	WOS:A1991FD89000040
J	SATO, J; PERL, ER				SATO, J; PERL, ER			ADRENERGIC EXCITATION OF CUTANEOUS PAIN RECEPTORS INDUCED BY PERIPHERAL-NERVE INJURY	SCIENCE			English	Article							REFLEX SYMPATHETIC DYSTROPHY; UNMYELINATED C FIBERS; POLYMODAL NOCICEPTORS; STIMULATION; SENSITIVITY; CAUSALGIA; RAT; MECHANISMS; ACTIVATION; UNITS	The mechanisms by which peripheral nerve injuries sometimes lead to causalgia, aberrant burning pain peripheral to the site of nerve damage, are uncertain, although the sympathetic nervous system is known to be involved. Whether such syndromes could be the result of the development of responsiveness by some cutaneous pain receptors (C-fiber nociceptors) to sympathetic efferent activity as a consequence of the nerve injury was tested in an animal model. After nerve damage but not in its absence, sympathetic stimulation and norepinephrine were excitatory for a subset of skin C-fiber nociceptors and enhanced the responsiveness of these nociceptors to tissue-damaging stimulation. These effects were demonstrable within days after nerve lesions, occurred at the cutaneous receptive terminal region, were manifest in sensory fibers that had not degenerated after the injury, and were mediated by alpha-2-adrenergic-like receptors.	UNIV N CAROLINA,DEPT PHYSIOL,CB 7545,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NINDS NIH HHS [NS14899, NS10321] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS014899] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARASI S, 1986, BRAIN RES, V378, P21, DOI 10.1016/0006-8993(86)90282-9; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; CANNON WB, 1949, SUPERSENSITIVITY DEN, P25; COHEN RH, 1990, J NEUROPHYSIOL, V64, P457, DOI 10.1152/jn.1990.64.2.457; DAVIES B, 1982, J CLIN INVEST, V69, P779, DOI 10.1172/JCI110516; DEVOR M, 1983, J AUTONOM NERV SYST, V7, P371, DOI 10.1016/0165-1838(83)90090-5; DEVOR M, 1981, NEUROSCI LETT, V24, P43, DOI 10.1016/0304-3940(81)90356-6; ECKER A, 1984, PSYCHIAT ANN, V14, P787, DOI 10.3928/0048-5713-19841101-08; Feldberg W, 1926, J PHYSIOL-LONDON, V61, P518, DOI 10.1113/jphysiol.1926.sp002313; HANNINGTONKIFF JG, 1974, PAIN RELIEF, P75; HU SJ, 1989, PAIN, V38, P85, DOI 10.1016/0304-3959(89)90077-8; KORENMAN EMD, 1981, EXP NEUROL, V72, P63, DOI 10.1016/0014-4886(81)90127-8; Levitzki A, 1978, Rev Physiol Biochem Pharmacol, V82, P1, DOI 10.1007/BFb0030496; Mitchell SW, 1864, GUNSHOT WOUNDS OTHER; NATHAN PW, 1947, BRAIN, V70, P145, DOI 10.1093/brain/70.2.145; OCHOA J, 1983, ADV PAIN RES THER, V5, P99; RICHARDS RL, 1967, ARCH NEUROL-CHICAGO, V16, P339, DOI 10.1001/archneur.1967.00470220003001; ROBERTS WJ, 1985, SOMATOSENS RES, V3, P33, DOI 10.3109/07367228509144575; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8; SCADDING JW, 1981, EXP NEUROL, V73, P345, DOI 10.1016/0014-4886(81)90271-5; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SCHWARTZMAN RJ, 1987, ARCH NEUROL-CHICAGO, V44, P555, DOI 10.1001/archneur.1987.00520170081028; SHEA VK, 1985, J NEUROPHYSIOL, V54, P502, DOI 10.1152/jn.1985.54.3.502; SHEA VK, 1985, J NEUROPHYSIOL, V54, P491, DOI 10.1152/jn.1985.54.3.491; SHEA VK, 1985, J NEUROPHYSIOL, V54, P513, DOI 10.1152/jn.1985.54.3.513; TOREBJOR.HE, 1974, ACTA PHYSIOL SCAND, V92, P374, DOI 10.1111/j.1748-1716.1974.tb05755.x; WALLIN G, 1976, SENSORY FUNCTIONS SK, P489; WIESENFELDHALLIN Z, 1984, HUM NEUROBIOL, V3, P41	29	480	492	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 29	1991	251	5001					1608	1610		10.1126/science.2011742	http://dx.doi.org/10.1126/science.2011742			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	2011742				2022-12-01	WOS:A1991FD89000037
J	ANDERSON, C				ANDERSON, C			POLAR PSYCHOLOGY - COPING WITH IT ALL	NATURE			English	Editorial Material																			0	3	3	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					290	290		10.1038/350290a0	http://dx.doi.org/10.1038/350290a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008210				2022-12-01	WOS:A1991FD83800048
J	ANDERSON, RM; GUPTA, S; MAY, RM				ANDERSON, RM; GUPTA, S; MAY, RM			POTENTIAL OF COMMUNITY-WIDE CHEMOTHERAPY OR IMMUNOTHERAPY TO CONTROL THE SPREAD OF HIV-1	NATURE			English	Article							PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; DOUBLE-BLIND; INFECTION	WHETHER zidovudine (3'-azido-3'-deoxythymidine, AZT) should be offered to symptomless individuals infected with human immunodeficiency virus type-1 (HIV-1), in the hope of delaying or even preventing progression to AIDS, has been much debated 1. The discussion has focused on the efficacy of the drug in delaying progression to disease 2, the severity of its side-effects 3, and the likelihood of its prolonged and widespread use resulting in zidovudine-resistant strains of the virus 4. Little attention has been given to the degree to which treatment reduces the infectiousness of symptomless patients, and to the concomitant implications for the overall transmission rate of HIV-1 in the community. Here we use simple mathematical models to show that community treatment with antiviral drugs or immunotherapies that lengthen the incubation period of AIDS without significantly reducing the infectiousness of treated individuals, can increase the rate at which HIV-1 infection spreads (which is fairly obvious) and can even, under certain circumstances, increase the AIDS-related death rate in the community (which is less obvious).			ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOL,LONDON SW7 2BB,ENGLAND.			Anderson, Roy/0000-0002-9528-3175				ANDERSON R M, 1986, IMA Journal of Mathematics Applied in Medicine and Biology, V3, P229; ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1990, J ACQ IMMUN DEF SYND, V3, P417; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; CAPON DJ, 1989, NATURE, V337, P325; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JACKSON GG, 1988, ANN INTERN MED, V108, P175, DOI 10.7326/0003-4819-108-2-175; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MCLEAN AR, IN PRESS J MATH BIOL; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; RATNER L, 1989, AIDS RES HUM RETROV, V5, P115, DOI 10.1089/aid.1989.5.115; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, LANCET, V1, P415	18	95	95	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					356	359		10.1038/350356a0	http://dx.doi.org/10.1038/350356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008214				2022-12-01	WOS:A1991FD83800098
J	ANTONARAKIS, SE				ANTONARAKIS, SE			PARENTAL ORIGIN OF THE EXTRA CHROMOSOME IN TRISOMY-21 AS INDICATED BY ANALYSIS OF DNA POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONDISJUNCTION; SEQUENCES; RECOMBINATION; PROBES	Background. Over the past 20 years, the parental origin of the extra chromosome in children with trisomy 21 has been investigated with cytogenetic methods of identifying morphologic variations in chromosome 21. These studies have concluded that the origin of the extra chromosome 21 was maternal in approximately 80 percent of cases and paternal in about 20 percent. Methods. We studied 200 families, each with a single child with trisomy 21, using DNA polymorphisms as markers to determine the parental origin of the nondisjunction causing the extra chromosome 21. These polymorphisms spanned a region of about 120 centimorgans on the long arm of chromosome 21, from the D21S13 locus (the most centromeric) to the COL6A1 gene (the most telomeric). Results. The parental origin of nondisjunction could be determined for all but 7 of the 200 children. It was maternal in 184 children (proportion [+/- SE], 95.3 +/- 1.5 percent) and paternal in 9 (4.7 +/- 1.5 percent). In a subgroup of 31 families, we compared the results of DNA analysis with those of traditional cytogenetic analysis. According to the cytogenetic analyses, nondisjunction originated in the mother in 26 cases (84 percent) and in the father in 5 (16 percent). DNA analysis demonstrated the origin as maternal in 29 (94 percent) and paternal in 2 (6 percent). With the cytogenetic analyses, there were three false determinations of paternal origin. Conclusions. In trisomy 21 the extra chromosome 21 is maternal in origin in about 95 percent of the cases, and paternal in only about 5 percent - considerably less than has been reported with cytogenetic methods. DNA polymorphic analysis is now the method of choice for establishing the parental origin of nondisjunction.			ANTONARAKIS, SE (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR MED GENET,DEPT PEDIAT,CMSC 1003,BALTIMORE,MD 21205, USA.		Petersen, Michael Bjørn B/D-1483-2017; Antonarakis, Stylianos/N-8866-2014	Petersen, Michael Bjørn B/0000-0003-0316-8207; Antonarakis, Stylianos/0000-0001-8907-5823	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019591, P01HD024605, K04HD000774] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00774, R01HD19591, P01HD24605] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONARAKIS SE, 1985, P NATL ACAD SCI USA, V82, P3360, DOI 10.1073/pnas.82.10.3360; CAROTHERS AD, 1987, AM J HUM GENET, V40, P147; CHAKRAVARTI A, 1989, AM J HUM GENET, V44, P639; DAVIES KE, 1984, HUM GENET, V66, P54, DOI 10.1007/BF00275186; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; Jacobs P A, 1977, Prog Med Genet, V2, P251; JUBERG RC, 1970, NEW ENGL J MED, V282, P292, DOI 10.1056/NEJM197002052820602; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; MIKKELSEN M, 1980, ANN HUM GENET, V44, P17, DOI 10.1111/j.1469-1809.1980.tb00942.x; PETERSEN MB, 1990, GENOMICS, V7, P136, DOI 10.1016/0888-7543(90)90531-X; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; PETERSEN MB, IN PRESS GENOMICS; RUDD NL, 1988, HUM GENET, V78, P175, DOI 10.1007/BF00278191; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GD, 1988, AM J HUM GENET, V42, P227; STEWART GD, 1985, NUCLEIC ACIDS RES, V13, P4125, DOI 10.1093/nar/13.11.4125; WARREN AC, 1987, SCIENCE, V237, P652, DOI 10.1126/science.2955519; 1972, CYTOGENET CELL GENET, V11, P313	22	202	209	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					872	876		10.1056/NEJM199103283241302	http://dx.doi.org/10.1056/NEJM199103283241302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD111	1825697	Bronze			2022-12-01	WOS:A1991FD11100002
J	BARRY, M				BARRY, M			THE INFLUENCE OF THE UNITED-STATES TOBACCO INDUSTRY ON THE HEALTH, ECONOMY, AND ENVIRONMENT OF DEVELOPING-COUNTRIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SMOKING				BARRY, M (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06504, USA.							CHANDLER WU, 1986, 68 WORLDW I WORLDW P, P20; COCKBURN A, 1989, NATION          1030, P482; CONNOLLY G, 1989, 1989 TOB US AM C HOU, P49; CORTI EC, 1931, HIST SMOKING, P1; COYLE P, 1990, NEW HAVEN REGIS 0625, P5; COYLE P, 1990, NEW HAVEN REGIS 0625, P1; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P993; FORBES WF, 1985, STRATEGIES SMOKE FRE, P21; JACOBSON B, 1983, BRIT MED J, V287, P483, DOI 10.1136/bmj.287.6390.483; JONES D, 1989, TOBACCO REPORTER JAN, P32; LEWIN T, 1990, NY TIMES        0524, pB10; Lewin Tamar, 1990, N Y Times Web, pA15; MAKHYOUN NA, 1974, BRIT J CANCER, V30, P577, DOI 10.1038/bjc.1974.238; NATH UR, 1986, WORLD HLTH       JUN, P6; NATH UR, 1986, SMOKING 3RD WORLD AL, P192; PETO R, 1987, LANCET, V2, P211; SAYCEL K, 1987, ENCY ZIMBABWE, P380; STEBBINS KR, 1990, SOC SCI MED, V30, P227, DOI 10.1016/0277-9536(90)90084-6; Taylor SA, 1989, BUSINESS CONT WO WIN, V55, P55; WARNER KE, 1990, AM J PUBLIC HEALTH, V80, P529, DOI 10.2105/AJPH.80.5.529; WHELAN E, 1984, SMOKING GUN TOBACCO, P167; WILLCOX PA, 1982, THORAX, V37, P598, DOI 10.1136/thx.37.8.598; YACH D, 1986, INT J HEALTH SERV, V16, P279, DOI 10.2190/Q27T-A7ER-0PYK-9LED; 1983, WHO TECH REP SER, V695; 1989, FT889 DEP AGR REP; 1990, JAMA-J AM MED ASSOC, V263, P3312; 1988, ADVERTISING AGE 1121, P37; 1990, MMWR, V39, P1; 1988, ACTIVITIES P MORRIS; 1990, MMWR, V39, P261	31	36	37	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					917	920		10.1056/NEJM199103283241311	http://dx.doi.org/10.1056/NEJM199103283241311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000116				2022-12-01	WOS:A1991FD11100011
J	BLOOMFIELD, SA				BLOOMFIELD, SA			2 TYPES OF ORIENTATION-SENSITIVE RESPONSES OF AMACRINE CELLS IN THE MAMMALIAN RETINA	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; STRUCTURAL BASIS; ORGANIZATION; SELECTIVITY; CORTEX	NEURONS sensitive to the orientation of light stimuli exist throughout the mammalian visual system 1-3, suggesting that this spatial feature is a fundamental cue used by the brain to decipher visual information. The most peripheral neurons known to show orientation sensitivity are the retinal ganglion cells. Considerable morphological 4,5 and pharmacological 6-10 data suggest that the orientation sensitivity of ganglion cells is formed, at least partly, by the amacrine cells, which are laterally oriented interneurons presynaptic to the ganglion cells in the inner plexiform layer. So far there have been few studies of the responses of amacrine cells to oriented visual stimuli and their role in forming orientation-sensitive responses in the retina remains unclear. Here I report the novel finding of a population of amacrine cells in the rabbit retina which are orientation-sensitive. These amacrine cells can be divided into two subtypes, whose orientation sensitivity is manufactured by two distinct mechanisms. The orientation sensitivity of the first subtype of amacrine cell is formed from the interactions of excitatory, centre-receptive field synaptic inputs and inhibitory inputs of opposite polarity, whereas that for cells of the second subtype seems to be the product of a marked asymmetry in their dendritic arbors.			BLOOMFIELD, SA (corresponding author), NYU MED CTR,DEPT OPHTHALMOL,550 1ST AVE,NEW YORK,NY 10016, USA.				NEI NIH HHS [R01 EY007360] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007360] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1969, J NEUROPHYSIOL, V32, P424, DOI 10.1152/jn.1969.32.3.424; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; BLOOMFIELD SA, 1982, J COMP NEUROL, V208, P288, DOI 10.1002/cne.902080306; BLOOMFIELD SA, 1986, J NEUROSCI, V6, P1; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P257, DOI 10.1113/jphysiol.1978.sp012232; DOWLING JE, 1968, PROC R SOC SER B-BIO, V170, P205, DOI 10.1098/rspb.1968.0034; DUBIN MW, 1970, J COMP NEUROL, V140, P479, DOI 10.1002/cne.901400406; ELIAS SA, 1980, BRAIN RES, V196, P365; FAMGLIETTI EV, 1989, NEUROBIOLOGY INNER R, P169; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; FERSTER D, 1987, TRENDS NEUROSCI, V10, P487, DOI 10.1016/0166-2236(87)90126-3; HEGGELUND P, 1981, EXP BRAIN RES, V42, P89; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Hughes A., 1985, PROGR RETINAL RES, V4, P243; LEVENTHAL AG, 1983, J COMP NEUROL, V220, P465, DOI 10.1002/cne.902200408; LEVICK WR, 1967, J PHYSIOL-LONDON, V188, P285, DOI 10.1113/jphysiol.1967.sp008140; LEVICK WR, 1982, J PHYSIOL-LONDON, V329, P243, DOI 10.1113/jphysiol.1982.sp014301; MARIANI AP, 1982, NATURE, V298, P654, DOI 10.1038/298654a0; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; MILLER RF, 1979, NEUROSCIENCES 4TH ST, P227; VIDYASAGAR TR, 1982, EXP BRAIN RES, V46, P157; WYATT HJ, 1976, SCIENCE, V191, P204, DOI 10.1126/science.1857	24	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					347	350		10.1038/350347a0	http://dx.doi.org/10.1038/350347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1706822				2022-12-01	WOS:A1991FD83800095
J	BLUM, A				BLUM, A			THE MARLBORO GRAND-PRIX - CIRCUMVENTION OF THE TELEVISION BAN ON TOBACCO ADVERTISING	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											BLUM, A (corresponding author), BAYLOR UNIV,HOUSTON,TX 77005, USA.							BLUM A, 1985, NEW YORK STATE J MED, V85, P458; BUCHANAN DR, 1990, BEER FAST CARS BREWE, P25; DRAPE J, 1990, ATLANTA J CONST 0729, pA1; DRAPE J, 1990, ATLANTA J CONST 0729, pA12; FORKAN JP, 1986, ADVERTISING AGE 0324, P45; HARVEY P, 1991, RACETIME         NOV, P34; JOHNSON ME, 1990, ADVERTISING AGE 1105, P36; KING W, 1975, NY TIMES        0713, P36; KOTEN J, 1990, WALL STREET J   0524, pA1; KOTEN J, 1990, WALL STREET J   0524, P9; MILLER C, 1983, MED J AUSTRALIA, V1, P242; RAEBURN P, 1990, IDAHO STATESMAN 0115, pD1; WALTZ K, 1990, NATIONAL SPEED  1128, P8; 1989, TNN, V2, P1; 1991, RACETIME         NOV, P10; 1990, WHO REGIONAL PUBLICA, V30, P43; 1990, NATIONAL DRAGST 1207, P29; 1990, AUSTR HIGH COURT UPH; 1990, MMWR, V39, P261; 1989, CART, V7, P1	20	50	50	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					913	916		10.1056/NEJM199103283241310	http://dx.doi.org/10.1056/NEJM199103283241310			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000115				2022-12-01	WOS:A1991FD11100010
J	CHIANG, HL; SCHEKMAN, R				CHIANG, HL; SCHEKMAN, R			REGULATED IMPORT AND DEGRADATION OF A CYTOSOLIC PROTEIN IN THE YEAST VACUOLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; CATABOLITE INACTIVATION; STRUCTURAL GENE; FRUCTOSE-1,6-BISPHOSPHATASE; TRANSLOCATION; PHOSPHORYLATION; PROTEOLYSIS; ENCODES; GLUCOSE	The key regulatory enzyme in gluconeogenesis, fructose 1,6-bisphosphatase (FBPase) is subject to glucose-stimulated proteolytic degradation in Saccharomyces cerevisiae. This process involves the regulated transfer of FBPase directly from the cytosol into the vacuole or a vacuole-related organelle. Glucose may regulate the production of an FBPase receptor or import factor that is transported to the vacuole through the secretory pathway.			CHIANG, HL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DIV BIOCHEM & MOLEC BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURLINI N, 1988, BIOCHIM BIOPHYS ACTA, V972, P353, DOI 10.1016/0167-4889(88)90212-1; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; Guerra R. de la, 1988, FEBS Letters, V242, P149, DOI 10.1016/0014-5793(88)81004-4; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOLZER H, 1980, ANNU REV BIOCHEM, V49, P63, DOI 10.1146/annurev.bi.49.070180.000431; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAMPONI S, 1987, FEBS LETT, V216, P265, DOI 10.1016/0014-5793(87)80703-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SCHAFER W, 1987, BIOCHIM BIOPHYS ACTA, V925, P150, DOI 10.1016/0304-4165(87)90104-8; SEDIVY JM, 1985, J MOL BIOL, V186, P307, DOI 10.1016/0022-2836(85)90107-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265; ZUBENKO GS, 1981, GENETICS, V97, P45	32	140	140	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					313	318		10.1038/350313a0	http://dx.doi.org/10.1038/350313a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848921				2022-12-01	WOS:A1991FD83800082
J	DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL				DANIS, M; SOUTHERLAND, LI; GARRETT, JM; SMITH, JL; HIELEMA, F; PICKARD, CG; EGNER, DM; PATRICK, DL			A PROSPECTIVE-STUDY OF ADVANCE DIRECTIVES FOR LIFE-SUSTAINING CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The use of advance directives is recommended so that people can determine the medical care they will receive when they are no longer competent, but the effectiveness of such directives is not clear. Methods. In a prospective study conducted over a two-year period, 126 competent residents of a nursing home and 49 family members of incompetent patients were interviewed to determine their preferences with respect to hospitalization, intensive care, cardiopulmonary resuscitation, artificial ventilation, surgery, and tube feeding in the event of critical illness, terminal illness, or permanent unconsciousness. Advance directives, consisting of signed statements of treatment preferences, were placed in the medical record to assist in care in the nursing home and to be forwarded to the hospital if necessary. Results. In an analysis of 96 outcome events (hospitalization or death in the nursing home), care was consistent with previously expressed wishes 75 percent of the time; however, the presence of the written advance directive in the medical record did not facilitate consistency. Among the 24 events in which inconsistencies occurred, care was provided more aggressively than had been requested in 6 cases, largely because of unanticipated surgery or artificial ventilation, and less aggressively than requested in 18, largely because hospitalization or cardiopulmonary resuscitation was withheld. Inconsistencies were more likely in the nursing home than in the hospital. Conclusions. The effectiveness of written advance directives is limited by inattention to them and by decisions to place priority on considerations other than the patient's autonomy. Since our study was performed in only one nursing home and one hospital, other studies are necessary to determine the generalizability of our findings.	UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27514; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA,DEPT MED,DIV GEN MED & CLIN EPIDEMIOL,CAMPUS BOX 7110,5025A OLD CLIN BLDG,CHAPEL HILL,NC 27599, USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; HACKLER C, 1989, ADV DIRECTIVES MED S; JONSEN AR, 1982, CLIN ETHICS; KUTNER L, 1969, INDIANA LAW J, V44, P537; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; REDLEAF DL, 1979, STANFORD LAW REV, V31, P913, DOI 10.2307/1228530; 1982, SUDOC198203835158763; 1987, GUIDELINES TERMINATI; 1983, AM J PUBLIC HEALTH, V73, P918	12	387	389	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					882	888		10.1056/NEJM199103283241304	http://dx.doi.org/10.1056/NEJM199103283241304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000110				2022-12-01	WOS:A1991FD11100004
J	EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ				EMANUEL, LL; BARRY, MJ; STOECKLE, JD; ETTELSON, LM; EMANUEL, EJ			ADVANCE DIRECTIVES FOR MEDICAL-CARE - A CASE FOR GREATER USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; CARDIOPULMONARY RESUSCITATION; ELDERLY OUTPATIENTS; PHYSICIANS; DECISIONS; PREFERENCES; ATTITUDES; CHOICES; END	Background. Advance directives for medical care and the designation of proxy decision makers to guide medical care after a patient has become incompetent have been widely advocated but little studied. We investigated the attitudes of patients toward planning, perceived barriers to such planning, treatment preferences in four hypothetical scenarios, and the feasibility of using a particular document (the Medical Directive) in the outpatient setting to specify advance directives. Methods. We surveyed 405 outpatients of 30 primary care physicians at Massachusetts General Hospital and 102 members of the general public in Boston and asked them as part of the survey to complete the Medical Directive. Results. Advance directives were desired by 93 percent of the outpatients and 89 percent of the members of the general public (P > 0.2). Both the young and the healthy subgroups expressed at least as much interest in planning as those older than 65 and those in fair-to-poor health. Of the perceived barriers to issuing advance directives, the lack of physician initiative was among the most frequently mentioned, and the disturbing nature of the topic was among the least. The outpatients refused life-sustaining treatments in 71 percent of their responses to options in the four scenarios (coma with chance of recovery, 57 percent; persistent vegetative state, 85 percent; dementia, 79 percent; and dementia with a terminal illness, 87 percent), with small differences between widely differing types of treatments. Specific treatment preferences could not be usefully predicted according to age, self-rated state of health, or other demographic features. Completing the Medical Directive took a median of 14 minutes. Conclusions. When people are asked to imagine themselves incompetent with a poor prognosis, they decide against life-sustaining treatments about 70 percent of the time. Health, age, or other demographic features cannot be used, however, to predict specific preferences. Advance directives as part of a comprehensive approach such as that provided by the Medical Directive are desired by most people, require physician initiative, and can be achieved during a regular office visit.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,PROGRAM ETH & PROFESS,CAMBRIDGE,MA 02138	Harvard University; Beth Israel Deaconess Medical Center; Harvard University	EMANUEL, LL (corresponding author), MASSACHUSETTS GEN HOSP,GEN INTERNAL MED UNIT,BOSTON,MA 02114, USA.				AHRQ HHS [R01 HS06120] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; BUCHANAN A, 1988, PHILOS PUBLIC AFF, V17, P277; COLTON T, 1974, STAT MED, P120; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Lubitz J, 1984, Health Care Financ Rev, V5, P117; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; READLEAF DL, 1979, STANFORD LAW REV, V31, P913; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; Shapiro R S, 1986, Wis Med J, V85, P17; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; STARR TJ, 1986, J GEN INTERN MED, V1, P373, DOI 10.1007/BF02596420; STEIBER SR, 1987, HOSPITALS, V61, P72; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615; 1989, RESOLUTION LEGISLATI; 1989, CURRENT OPINIONS COU; 1987, HDB LIVING WILL LAWS	26	595	598	0	31	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					889	895		10.1056/NEJM199103283241305	http://dx.doi.org/10.1056/NEJM199103283241305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FD111	2000111				2022-12-01	WOS:A1991FD11100005
J	FOX, K; DAW, N; SATO, H; CZEPITA, D				FOX, K; DAW, N; SATO, H; CZEPITA, D			DARK-REARING DELAYS THE LOSS OF NMDA-RECEPTOR FUNCTION IN KITTEN VISUAL-CORTEX	NATURE			English	Article							METHYL-D-ASPARTATE; OCULAR DOMINANCE COLUMNS; CAT; PLASTICITY; NEURONS	SOME features of the visual cortex develop postnatally in mammals 1,2. For example, geniculocortical axons that initially overlap throughout cortical layer IV segregate postnatally into two sets of interleaved eye-specific bands 3,4. NMDA (N-methyl-D-aspartate) receptors are necessary for eye-specific axon-segregation in the frog tectum 5, and as NMDA receptors play a greater part in synaptic transmission in early life 6,7 and decrease in function during the period of axon segregation, they may be involved in the segregation of geniculocortical axons: they are well placed to do so as they transduce 8 retinally derived signals essential for segregation 9. Rearing animals in the dark in early life delays segregation 10,11 and prolongs the critical period for plasticity 12. We now report that dark-rearing of kittens also delays the loss of NMDA receptor function in the visual cortex, supporting the view that they play an important part in neuronal development and plasticity.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,MCDONNELL CTR STUDIES HIGHER BRAIN FUNCT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X				BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CLINE HT, 1990, J NEUROSCI, V10, P1197; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; FLATMAN JA, 1986, BRAIN RES, V363, P62, DOI 10.1016/0006-8993(86)90659-1; FOX K, 1989, J NEUROSCI, V9, P2443; FOX K, 1990, J NEUROPHYSIOL, V64, P1413, DOI 10.1152/jn.1990.64.5.1413; FREEMAN RD, 1979, SCIENCE, V206, P1093, DOI 10.1126/science.493996; GORDON B, 1990, SOC NEUR ABSTR, V17, P986; HAGIHARA K, 1988, EXP BRAIN RES, V69, P407; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Mitchell DE, 1984, HDB PHYSL 1 1, V3, P507; MOWER GD, 1985, J COMP NEUROL, V235, P448, DOI 10.1002/cne.902350404; REYNOLDS IJ, IN PRESS EXPL BRAIN; SHATZ CJ, 1988, CEREB CORTEX, V7, P35; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SWINDALE NV, 1988, J COMP NEUROL, V267, P47; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	22	105	107	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					342	344		10.1038/350342a0	http://dx.doi.org/10.1038/350342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1672557				2022-12-01	WOS:A1991FD83800093
J	HATTA, K; KIMMEL, CB; HO, RK; WALKER, C				HATTA, K; KIMMEL, CB; HO, RK; WALKER, C			THE CYCLOPS MUTATION BLOCKS SPECIFICATION OF THE FLOOR PLATE OF THE ZEBRAFISH CENTRAL-NERVOUS-SYSTEM	NATURE			English	Article							EMBRYO; CELLS	THE floor plate is a set of epithelial cells present in the ventral midline of the neural tube in vertebrates 1 that seems to have an important role in the developmental patterning 2 of central nervous system fibre pathways 3,4, and arrangements of specific neurons 5. The floor plate arises from dorsal ectodermal cells closely associated with the mesoderm that forms notochord 6, and it may depend on interactions from the notochord for its specification. To learn the nature of these interactions we have analysed mutations in zebrafish (Brachydanio rerio). We report here that in wild-type embryos the floor plate develops as a simply organized single cell row, but that its development fails in embryos bearing the newly discovered zygotic lethal 'cyclops' mutation, cyc-1(b16). Mosaic analysis establishes that cyc-1 blocks floor plate development autonomously and reveals the presence of homeogenetic induction between floor plate cells.			HATTA, K (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.							Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; Adelmann HB, 1936, Q REV BIOL, V11, P161, DOI 10.1086/394504; BOVOLENTA P, 1990, DEVELOPMENT, V109, P435; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HATTA K, 1990, Society for Neuroscience Abstracts, V16, P310; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Holtfreter J, 1934, ARCH EXP ZELLFORSCH, V15, P281; JACOBSON AG, 1981, MORPHOGENESIS PATTER, P233; JESSELL TM, 1989, CIBA F SYMP, V144, P255; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1988, TRENDS GENET, V4, P68, DOI 10.1016/0168-9525(88)90043-1; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KUWADA J Y, 1990, Society for Neuroscience Abstracts, V16, P309; KUWADA JY, 1990, J NEUROSCI, V10, P1299; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; METCALFE WK, 1990, DEVELOPMENT, V110, P491; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WALKER C, 1983, GENETICS, V103, P125; WARGA RM, 1990, DEVELOPMENT, V108, P569; YAMADA T, IN PRESS CELL	27	389	401	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					339	341		10.1038/350339a0	http://dx.doi.org/10.1038/350339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	2008211				2022-12-01	WOS:A1991FD83800092
J	LARKMAN, A; STRATFORD, K; JACK, J				LARKMAN, A; STRATFORD, K; JACK, J			QUANTAL ANALYSIS OF EXCITATORY SYNAPTIC ACTION AND DEPRESSION IN HIPPOCAMPAL SLICES	NATURE			English	Article							LONG-TERM POTENTIATION; TRANSMISSION; RELEASE; GLUTAMATE; SYNAPSES; NEURONS; CALCIUM	QUANTAL analysis can provide a quantitative description of important aspects of chemical synaptic transmission and its modification 1-3. The technique has recently been applied to excitatory synapses within the hippocampus 4-10, especially the form of synaptic plasticity known as long-term potentiation 11-13. However, these attempts have met with only limited success, in that the individual quantal amplitudes making up the synaptic response generally could not be resolved. Here we have paid attention to the possible instability of the quantal fluctuation pattern over time. We were able to resolve individual quantal component amplitudes for a high proportion of the experiments, and so demonstrate the quantal nature of excitatory transmission in the CA1 region of the hippocampus. Mean quantal amplitudes for individual excitatory postsynaptic potentials were 84-197-mu-V, with a mean of 131 +/- 29-mu-V. For periods during which the fluctuation pattern was stable, the variance associated with individual quantal amplitudes was low. We have also used quantal analysis to show that synaptic depression following prolonged stimulation at these synapses is primarily a presynaptic phenomenon.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENNETT MR, 1989, J PHYSIOL-LONDON, V418, P219, DOI 10.1113/jphysiol.1989.sp017836; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P574, DOI 10.1113/jphysiol.1954.sp005130; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; JACK JJB, IN PRESS COLD SPRING; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KORN H, 1984, J NEUROSCI, V4, P125; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SCHWARTZKROIN PA, 1987, CEREB CORTEX, V6, P295; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THIES RE, 1965, J NEUROPHYSIOL, V28, P427, DOI 10.1152/jn.1965.28.3.427; TITTERINGTON DM, 1985, STATISTICAL ANAL FIN, P52; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VILLANUEVA S, 1990, NEUROSCIENCE, V37, P23, DOI 10.1016/0306-4522(90)90188-A; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889; WALMSLEY B, 1987, J NEUROSCI, V7, P1037; YAMAMOTO C, 1982, EXP BRAIN RES, V46, P170	34	165	166	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					344	347		10.1038/350344a0	http://dx.doi.org/10.1038/350344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848922				2022-12-01	WOS:A1991FD83800094
J	PACHOLCZYK, T; BLAKELY, RD; AMARA, SG				PACHOLCZYK, T; BLAKELY, RD; AMARA, SG			EXPRESSION CLONING OF A COCAINE-SENSITIVE AND ANTIDEPRESSANT-SENSITIVE HUMAN NORADRENALINE TRANSPORTER	NATURE			English	Article							SK-N-SH; NOREPINEPHRINE UPTAKE; TRANSIENT-EXPRESSION; DNA TRANSFECTION; ACTIVE UPTAKE; CELL-LINE; DOPAMINE; RECEPTOR; STORAGE; INHIBITION	AT most synapses, chemical signalling is terminated by a rapid reaccumulation of neurotransmitter into presynaptic terminals 1-5. Uptake systems for the biogenic amines are the initial site of action for therapeutic antidepressants and drugs such as cocaine and the amphetamines. We have isolated a complementary DNA clone encoding a human noradrenaline transporter. The cDNA sequence predicts a protein of 617 amino acids, with 12-13 highly hydrophobic regions compatible with membrane-spanning domains. Expression of the cDNA clone in transfected HeLa cells indicates that noradrenaline transport activity is sodium-dependent and sensitive to selective noradrenaline transport inhibitors. Transporter RNA is localized to the brainstem and the adrenal gland. The predicted protein sequence demonstrates significant amino-acid identity with the Na+/gamma-aminobutyric acid transporter, thus identifying a new gene family for neurotransmitter transporter proteins. Analysis of its structure and function may lead to structure-based drug design for the treatment of human depression and could help determine whether transporter abnormalities underlie affective disorders.	YALE UNIV,PROGRAM NEUROSCI,NEW HAVEN,CT 06510	Yale University	PACHOLCZYK, T (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.			Amara, Susan/0000-0001-8914-1106				ANDERSEN PH, 1989, EUR J PHARMACOL, V166, P493, DOI 10.1016/0014-2999(89)90363-4; BIEDLER JL, 1973, CANCER RES, V33, P2643; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BUCK J, 1985, CANCER RES, V45, P6366; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Iversen L., 1967, UPTAKE STORAGE NORAD; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIMELBERG HK, 1983, J NEUROCHEM, V40, P1265, DOI 10.1111/j.1471-4159.1983.tb13565.x; KOSTRZEWA RM, 1974, PHARMACOL REV, V26, P199; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUHAR MJ, 1990, EUR NEUROL, V30, P15; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; RICHARDS ML, 1986, BRAIN RES, V384, P132, DOI 10.1016/0006-8993(86)91228-X; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROSS SB, 1976, J PHARM PHARMACOL, V28, P458, DOI 10.1111/j.2042-7158.1976.tb04659.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMETS LA, 1989, CANCER RES, V49, P2941; SNYDER S H, 1970, Biological Psychiatry, V2, P367; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0	37	804	850	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					350	354		10.1038/350350a0	http://dx.doi.org/10.1038/350350a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FD838	2008212				2022-12-01	WOS:A1991FD83800096
J	ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA				ALBRIGHT, GA; COHEN, H; FORSTER, RM; GLASSENBERG, R; BRUNNER, EA			ANESTHESIA FOR PATIENTS WITH PREECLAMPSIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611	Northwestern University	ALBRIGHT, GA (corresponding author), NW MEM HOSP,CHICAGO,IL 60611, USA.							1986, SURV ANESTHESIOL, V30, P306	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1587	1587		10.1001/jama.265.12.1587	http://dx.doi.org/10.1001/jama.265.12.1587			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999909				2022-12-01	WOS:A1991FC60400038
J	CLINTON, JJ				CLINTON, JJ			PHYSICIAN INPUT INVITED ON CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD 20857	Agency for Healthcare Research & Quality								1990, FED REG         1210, P55	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1508	1508		10.1001/jama.265.12.1508	http://dx.doi.org/10.1001/jama.265.12.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999893				2022-12-01	WOS:A1991FC60400005
J	PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA				PANLILIO, AL; FOY, DR; EDWARDS, JR; BELL, DM; WELCH, BA; PARRISH, CM; CULVER, DH; LOWRY, PW; JARVIS, WR; PERLINO, CA			BLOOD CONTACTS DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPERATIONS; RISK; AIDS	Operating room personnel are at risk for infection with blood-borne pathogens through blood contact. To describe the nature and frequency of blood contact and its risk factors, trained observers monitored a sample of operations performed by six surgical services at Grady Memorial Hospital, Atlanta, Ga, for 6 months. In 62 (30.1%) of 206 operations, at least one blood contact was observed. Of 1828 operating room person-procedures observed, 96 (5.3%) had 147 blood contacts (133 skin contacts [90%], 10 percutaneous injuries [7%], and four eye splashes [3%]). The mean number of blood contacts per 100 person-procedures was highest for surgeons (18.6). The frequency of percutaneous injury was similar among surgeons and scrub staff (mean, 1.2 per 100 worker-procedures for each group). Risk factors for surgeons' blood contacts were (1) performing a trauma, burn, or orthopedic emergency procedure (odds ratio [OR], 4.1; 95% confidence interval [Cl], 2.0 to 8.7); (2) patient blood loss exceeding 250mL (OR, 2.1; 95% Cl, 1.2 to 3.7); and (3) being in the operating room longer than 1 hour (OR, 3.3; 95% Cl, 1.6 to 7.1). Of 110 blood contacts among surgeons, 81 (74%) were potentially preventable by additional barrier precautions, such as face shields and fluid-resistant gowns. Twenty-one (84%) of 25 blood contacts among surgeons in procedures in which all three risk factors were present were potentially preventable by additional barriers. Of 29 blood contacts among anesthesia and circulating personnel, 20 (69%) would have been prevented by glove use. For surgical procedures in which operating room personnel are at increased risk of blood contact, reevaluation of surgical technique, use of appropriate barrier precautions, and development of puncture-resistant glove materials are indicated.	GRADY MEM HOSP,DEPT EPIDEMIOL,ATLANTA,GA; EMORY UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ATLANTA,GA 30322	Emory University	PANLILIO, AL (corresponding author), CTR DIS CONTROL,CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP C-10,ATLANTA,GA 30333, USA.							ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; Breslow N.E., 1980, STAT METHODS CANC RE, P192; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GRAVES EJ, 1989, VITAL HLTH STAT, V13, P99; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1990, 6TH INT C AIDS SAN F; POPEJOY SL, IN PRESS SURG GYNECO; TELFORD GL, 1987, SURG ROUNDS, V10, P30; TOKARS JI, 1990, 30TH INT C ANT AG CH; 1987, MMWR, V36, P285; 1987, MMWR, V36, P1; 1989, RECOMMENDATIONS PREV; 1987, MMWR, V36, P509	15	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1533	1537		10.1001/jama.265.12.1533	http://dx.doi.org/10.1001/jama.265.12.1533			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1999903				2022-12-01	WOS:A1991FC60400027
J	BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC				BOWER, M; COLSTON, KW; STEIN, RC; HEDLEY, A; GAZET, JC; FORD, HT; COOMBES, RC			TOPICAL CALCIPOTRIOL TREATMENT IN ADVANCED BREAST-CANCER	LANCET			English	Note							IMMUNOCYTOCHEMICAL DETECTION; 1,25-DIHYDROXYVITAMIN-D3; RECEPTOR; DIFFERENTIATION; PROLIFERATION; GROWTH	19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100-mu-g daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.	ST GEORGE HOSP,SCH MED,DEPT CELLULAR & MOLEC BIOL,CLIN ONCOL UNIT,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND; ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON,ENGLAND	St Georges University London; St Georges University London; St Georges University London			Stein, Robert C/N-6679-2015	Stein, Robert C/0000-0003-2969-0415; Bower, Mark/0000-0002-4077-6351; Coombes, Raoul Charles/0000-0002-4811-1100				BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BERGER U, 1987, CANCER RES, V47, P6793; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; COLSTON K, 1986, ENDOCRINOLOGY, V119, P397, DOI 10.1210/endo-119-1-397; FRAMPTON RJ, 1983, CANCER RES, V43, P4443; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; KOGA M, 1988, CANCER RES, V48, P2734; MATSUI T, 1986, CANCER RES, V46, P5827; MCGUIRE WL, 1973, J CLIN ENDOCR METAB, V37, P986, DOI 10.1210/jcem-37-6-986; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506	10	113	115	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					701	702		10.1016/0140-6736(91)90280-3	http://dx.doi.org/10.1016/0140-6736(91)90280-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672178				2022-12-01	WOS:A1991FD36700010
J	GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO				GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO			ENTEROVIRAL RNA SEQUENCES DETECTED BY POLYMERASE CHAIN-REACTION IN MUSCLE OF PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							VIRUSES	Objective-To determine the presence of enteroviral sequences in muscle of patients with the postviral fatigue syndrome. Design-Detection of sequences with the polymerase chain reaction in a well defined group of patients with the syndrome and controls over the same period. Setting-Institute of Neurological Sciences, Glasgow. Subjects-60 consecutive patients admitted to the institute with the postviral fatigue syndrome who had undergone extensive investigation to exclude other conditions. 41 controls from the same catchment area without evidence of fatigue, all undergoing routine surgery. Main outcome measures-Routine investigations, serological screen for antibodies to a range of viruses, and presence of enteroviral RNA sequences in muscle biopsy specimens. Results-15 (25%) patients and 10 (24.4%) controls had important serological findings. 12 patients had neutralising antibody titres of greater-than-or-equal-to 256 to coxsackieviruses B1-5 (six positive for enteroviral RNA sequences, six negative); three were positive for Epstein-Barr virus specific IgM (two positive, one negative). Six controls had similar neutralising antibody titres to coxsackieviruses (all negative); one was positive for Epstein-Barr virus specific IgM (negative); and three had titres of complement fixing antibody greater-than-or-equal-to 256 to cytomegalovirus (all negative). Overall, significantly more patients than controls had enteroviral RNA sequences in muscle (32/60, 53% v 6/41, 15%; odds ratio 6.7, 95% confidence interval 2.4 to 18.2). This was not correlated with duration of disease, patient and age, or to raised titres of antibodies to coxsackieviruses B1-5. Conclusions-Persistent enteroviral infection of muscle may occur in some patients with postviral fatigue syndrome and may have an aetiological role.	UNIV GLASGOW,DEPT NEUROL,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PATHOL,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; RUCHILL HOSP,SCOTTISH SERUM BANK,GLASGOW G20 9NB,SCOTLAND	University of Glasgow; University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHAPMAN NM, 1990, J CLIN MICROBIOL, V28, P843, DOI 10.1128/JCM.28.5.843-850.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P3; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HERMANS A, 1988, LEUKEMIA, V2, P628; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; JAMAL GA, 1989, EUR NEUROL, V29, P272; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; YOUSEF GE, 1988, LANCET, V1, P146	21	157	158	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					692	696		10.1136/bmj.302.6778.692	http://dx.doi.org/10.1136/bmj.302.6778.692			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1850635	Bronze, Green Published			2022-12-01	WOS:A1991FE33300022
J	LINDBLAD, B; STERNBY, NH; BERGQVIST, D				LINDBLAD, B; STERNBY, NH; BERGQVIST, D			INCIDENCE OF VENOUS THROMBOEMBOLISM VERIFIED BY NECROPSY OVER 30 YEARS	BRITISH MEDICAL JOURNAL			English	Article							AUTOPSY	Objective-To determine the incidence of venous thromboembolism in all necropsy reports over 30 years. Design-Study of all necropsies in one hospital in 1987 and longitudinal analysis of results of necropsy in 1957, 1964, 1975, and 1987. Setting-Departments of general surgery, infectious diseases, internal medicine, oncology, and orthopaedics in a Swedish general hospital. Main outcome measure-Number of cases of venous thromboembolism. Results-About a third of all necropsies showed venous thromboembolism. In 1987, 260 of 347 necropsies showing venous thromboembolism found pulmonary embolism, of which 93 were classified as fatal, 90 as contributory, and 77 as incidental. Only 21 contributory or fatal postoperative pulmonary emboli were seen. In only 106 of 260 patients with pulmonary embolism did routine necropsy not show the source of embolism. Calf veins were not routinely examined. Deep venous thrombosis was seen in 239 patients in 1987. The incidence of venous thromboembolism in the four years studied was remarkably stable except in the department of orthopaedics, where the proportion fell from 60.7% in 1975 to 32.2% in 1987 (p < 0.05), although there were only a few patients. Conclusions-The overall incidence of venous thromboembolism has not changed over 30 years. During this period the proportion of the population aged over 65 has doubled, and this may have masked the beneficial effects of prophylaxis and early mobilisation. Prevalences corrected for age are needed.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN PATHOL,S-21401 MALMO,SWEDEN	Lund University	LINDBLAD, B (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT SURG,S-21401 MALMO,SWEDEN.							BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; Havig O, 1977, Acta Chir Scand Suppl, V478, P1; KAIJ K, 1959, LAKARTIDNINGEN, V56, P1437; RUBINSTEIN I, 1988, ARCH INTERN MED, V148, P1425, DOI 10.1001/archinte.148.6.1425	4	302	334	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					709	711		10.1136/bmj.302.6778.709	http://dx.doi.org/10.1136/bmj.302.6778.709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021744	Green Published, Bronze			2022-12-01	WOS:A1991FE33300029
J	LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR				LITTLER, E; BAYLIS, SA; ZENG, Y; CONWAY, MJ; MACKETT, M; ARRAND, JR			DIAGNOSIS OF NASOPHARYNGEAL CARCINOMA BY MEANS OF RECOMBINANT EPSTEIN-BARR-VIRUS PROTEINS	LANCET			English	Article							ANTIBODY; DNASE; TRANSCRIPTION; EXPRESSION	The immune response of patients with nasopharyngeal carcinoma to Epstein-Barr virus (EBV) antigens is diagnostic of the tumour. Existing tests use EBV antigens produced in EBV-infected lymphoblastoid cells, but the virus replicates poorly in these cells. Serum samples from 18 patients diagnosed as having nasopharyngeal carcinoma were screened by western blot analysis, enzyme-linked immunosorbent assay (ELISA), and immunofluorescence tests for antibodies to the EBV-coded alkaline deoxyribonuclease (DNase), thymidine kinase, and membrane antigen (gp340/220) produced in recombinant baculovirus or bovine papillomavirus systems. Each protein was a useful diagnostic marker for nasopharyngeal carcinoma, although in the gp340/220 ELISAs there was substantial overlap for both IgG and IgA antibodies between serum samples from nasopharyngeal carcinoma patients and those from healthy donors seropositive for EBV. The EBV thymidine kinase was the most sensitive predictor of nasopharyngeal carcinoma; all such samples showed both IgG and IgA antibody responses to this protein and all gave clearly distinct titres from those of the EBV-seropositive donors in the IgA test. Each of the recombinant systems described is suitable for use in large-scale screening programmes for the early diagnosis of nasopharyngeal carcinoma.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,CANC RES CAMPAIGN LABS,MANCHESTER M20 9BX,LANCS,ENGLAND; CHINESE ACAD SCI,INST VIROL,BEIJING,PEOPLES R CHINA	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Chinese Academy of Sciences	LITTLER, E (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.							BAYLIS SA, 1989, NUCLEIC ACIDS RES, V17, P7609, DOI 10.1093/nar/17.19.7609; BAYLIS SA, 1991, VIROLOGY, V181, P390, DOI 10.1016/0042-6822(91)90511-9; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHENG YC, 1980, P NATL ACAD SCI-BIOL, V77, P6162, DOI 10.1073/pnas.77.10.6162; CONWAY M, 1989, J GEN VIROL, V70, P729, DOI 10.1099/0022-1317-70-3-729; HENLE W, 1970, J NATL CANCER I, V44, P225; HENLE W, 1973, JNCI-J NATL CANCER I, V51, P361; LI SL, 1982, TUMOURS HEAD NECK, P251; LITTLER E, 1990, INT J CANCER, V45, P1028, DOI 10.1002/ijc.2910450608; LIU MY, 1989, J MED VIROL, V28, P101, DOI 10.1002/jmv.1890280209; NEILSEN NH, 1977, ACTA PATHOL MICROB A, V5, P850; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; SHANMUGARATNAM K, 1979, CANCER, V44, P1029, DOI 10.1002/1097-0142(197909)44:3<1029::AID-CNCR2820440335>3.0.CO;2-5; SHANMUGARATNAM K, 1972, IARC SCI PUBL, V2, P239; SIMMONS MJ, 1982, UICC71 TECHN REP; TAN RS, 1982, INT J CANCER, V30, P561, DOI 10.1002/ijc.2910300505; TUGWOOD JD, 1987, J GEN VIROL, V68, P1081, DOI 10.1099/0022-1317-68-4-1081; TURENNETESSIER M, 1989, INT J CANCER, V43, P45; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZENG J, 1983, INT J CANCER, V31, P599, DOI 10.1002/ijc.2910310511; ZENG Y, 1983, INTERVIROLOGY, V20, P190, DOI 10.1159/000149391; ZENG Y, 1987, Chinese Journal of Virology, V3, P396; ZURHAUSEN H, 1970, NATURE, V228, P1956; 1950, NCI MONOGRAPH, V59	25	38	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					685	689		10.1016/0140-6736(91)90275-T	http://dx.doi.org/10.1016/0140-6736(91)90275-T			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672175				2022-12-01	WOS:A1991FD36700006
J	MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME				MALCOLM, S; CLAYTONSMITH, J; NICHOLS, M; ROBB, S; WEBB, T; ARMOUR, JAL; JEFFREYS, AJ; PEMBREY, ME			UNIPARENTAL PATERNAL DISOMY IN ANGELMANS SYNDROME	LANCET			English	Article							PRADER-WILLI SYNDROME; PARENTAL ORIGIN; CHROMOSOME-15 DELETION	Angelman's syndrome and Prader-Willi syndrome are both causes of mental retardation with recognisable, but quite different, clinical phenotypes. Both are associated with deletions of chromosome 15q11-13, of maternal origin in Angelman's and paternal in Prader-Willi. Prader-Willi can arise by inheritance of two chromosomes 15 from the mother and none from the father (uniparental maternal disomy). In 2 patients with Angelman's syndrome we found evidence of uniparental paternal disomy. The phenotypic effects of maternal and paternal disomy of chromosome 15 are very different and inheritance of two normal 15s from one parent does not lead to normal development-strong evidence in man for genomic imprinting, in which the same gene has different effects dependent upon its parental origin.	UNIV BIRMINGHAM,DEPT CLIN GENET,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,ENGLAND; HOSP SICK CHILDREN,DEPT NEUROL,LONDON WC1N 3JH,ENGLAND	University of Birmingham; University of Leicester; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	MALCOLM, S (corresponding author), INST CHILD HLTH,MOTHERCARE DEPT PAEDIAT GENET,GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Armour, John/0000-0002-8558-8506				ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; BOYD SG, 1988, EUR J PEDIATR, V147, P508, DOI 10.1007/BF00441976; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CREASY MR, 1982, CHROMOSOME ABERRATIO, P122; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; IMAIZUMI K, 1990, AM J MED GENET, V35, P314, DOI 10.1002/ajmg.1320350305; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KNOLL JHM, 1989, HUM GENET, V83, P205, DOI 10.1007/BF00286723; LEDBETTER DH, 1988, PRADERWILLI SYNDROME, P13; MAGENIS RE, 1987, AM J MED GENET, V28, P829, DOI 10.1002/ajmg.1320280407; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1990, AM J HUM GENET S, V47, pA227; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PEMBREY M, 1989, J MED GENET, V26, P73, DOI 10.1136/jmg.26.2.73; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313	24	267	267	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					694	697		10.1016/0140-6736(91)90278-W	http://dx.doi.org/10.1016/0140-6736(91)90278-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672177				2022-12-01	WOS:A1991FD36700008
J	MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L				MCKINNEY, PA; ALEXANDER, FE; CARTWRIGHT, RA; PARKER, L			PARENTAL OCCUPATIONS OF CHILDREN WITH LEUKEMIA IN WEST CUMBRIA, NORTH-HUMBERSIDE, AND GATESHEAD	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; LEUKEMIA; BIRTH; ASSOCIATION; EXPOSURES; AGE	Objective-To determine whether parental occupations and chemical and other specific exposures are risk factors for childhood leukaemia. Design-Case-control study. Information on parents was obtained by home interview. Setting-Three areas in north England: Copeland and South Lakeland (west Cumbria); Kingston upon Hull, Beverley, East Yorkshire, and Holderness (north Humberside), and Gateshead. Subjects-109 children aged 0-14 born and diagnosed as having leukaemia or non-Hodgkin's lymphoma in study areas during 1974-88. Two controls matched for sex and date and district of birth were obtained for each child. Main outcome measures-Occupations of parents and specific exposure of parents before the children's conception, during gestation, and after birth. Other adults living with the children were included in the postnatal analysis. Results-Few risk factors were identified for mothers, although preconceptional association with the food industry was significantly increased in case mothers (odds ratio 2.56; 95% confidence interval 1.32 to 5.00). Significant associations were found between childhood leukaemia and reported preconceptional exposure of fathers to wood dust (2.73, 1.44 to 5.16), radiation (3.23, 1.36 to 7.72), and benzene (5.81, 1.67 to 26.44); ionising radiation alone gave an odds ratio of 2.35 (0.92 to 6.22). Raised odds ratios were found for paternal exposure during gestation, but no independent postnatal effect was evident. Conclusion-These results should be interpreted cautiously because of the small numbers, overlap with another study, and multiple exposure of some parents. It is important to distinguish periods of parental exposures; identified risk factors were almost exclusively restricted to the time before the child's birth.	UNIV LEEDS,CTR CLIN EPIDEMIOL,LEUKAEMIA RES FUND,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND	University of Leeds; Newcastle University - UK				PARKER, LOUISE/0000-0002-5188-8113				ALEXANDER F, 1990, J EPIDEMIOL COMMUN H, V44, P39, DOI 10.1136/jech.44.1.39; ALEXANDER FE, IN PRESS PATTERN CHI; [Anonymous], 1980, CLASSIFICATION OCCUP; ARUNDEL SE, 1986, J EPIDEMIOL COMMUN H, V40, P30, DOI 10.1136/jech.40.1.30; BAXTER MS, 1990, REV RADIOACTIVITY CA; BLACK D, 1984, INVESTIGATION POSSIB; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; BUCKLEY JD, 1989, CANCER RES, V49, P4030; CARTWRIGHT RA, 1990, LEUKAEMIA LYMPHOMA A; CRAFT AW, 1983, LANCET, V2, P1299; CRONKITE EP, 1985, AM J IND MED, V7, P447, DOI 10.1002/ajim.4700070509; EVANS HJ, 1990, NATURE, V345, P16, DOI 10.1038/345016a0; FABIA J, 1974, BRIT J PREV SOC MED, V28, P98; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GOLD EB, 1982, J OCCUP ENVIRON MED, V24, P578, DOI 10.1097/00043764-198208000-00011; GRAHAM S, 1966, J NCI, V19, P347; HEMMINKI K, 1981, J EPIDEMIOL COMMUN H, V35, P11, DOI 10.1136/jech.35.1.11; HICKS N, 1984, CANCER, V53, P1637, DOI 10.1002/1097-0142(19840415)53:8<1637::AID-CNCR2820530802>3.0.CO;2-Y; INFANTE PF, 1990, LANCET, V336, P814, DOI 10.1016/0140-6736(90)93282-T; KWA SL, 1980, J OCCUP ENVIRON MED, V22, P792, DOI 10.1097/00043764-198012000-00012; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; MACFARLANE GJ, 1988, SEARCH COMPUTER PACK; MCKINNEY PA, 1989, LEUKEMIA, V3, P880; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279, DOI 10.1136/adc.62.3.279; MELITA CR, 1990, STAT XACT; MELITA CR, 1985, J AM STATISTICS ASS, V80, P969; OPENSHAW S, 1988, LANCET, V1, P272; PETO J, 1990, NATURE, V345, P389, DOI 10.1038/345389a0; REEVES JD, 1981, LANCET, V2, P300; SANDERS BM, 1981, J EPIDEMIOL COMMUN H, V35, P245, DOI 10.1136/jech.35.4.245; SAVITZ DA, 1990, ENVIRON HEALTH PERSP, V88, P325, DOI 10.2307/3431095; SHAW G, 1984, AM J EPIDEMIOL, V119, P788, DOI 10.1093/oxfordjournals.aje.a113799; SHU XO, 1988, CANCER-AM CANCER SOC, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; VANSTEENSELMOLL HA, 1985, AM J EPIDEMIOL, V121, P214; VIANNA NJ, 1984, J OCCUP ENVIRON MED, V26, P679; [No title captured]; 1987, IARC MONOGRAPH S7, V1	40	72	75	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					681	687		10.1136/bmj.302.6778.681	http://dx.doi.org/10.1136/bmj.302.6778.681			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	2021741	Green Published, Bronze			2022-12-01	WOS:A1991FE33300020
J	PAGE, CP				PAGE, CP			ONE EXPLANATION OF THE ASTHMA PARADOX - INHIBITION OF NATURAL ANTIINFLAMMATORY MECHANISM BY BETA-2-AGONISTS	LANCET			English	Note							MAST-CELL; BRONCHIAL RESPONSIVENESS; TRACHEAL EPITHELIUM; HEPARIN; DRUGS; TERBUTALINE; PROVOCATION; HISTAMINE; PROTEIN; AIRWAY	Our understanding of the mechanisms contributing to the pathogenesis of bronchial asthma has increased substantially over the past decade. This has been accompanied by the introduction of a range of new drugs for the treatment of this disorder, and the usage of anti-asthma drugs is increasing. Despite these changes and an increased awareness of the disease, asthma remains the only "preventable" disease where the morbidity and mortality are still increasing in most parts of the world. This "asthma paradox" requires explanation, and this article is an attempt to provide a plausible scientific one. The hypothesis expresses concern that a long recognised, but little publicised, pharmacological property of the drug class most widely prescribed for the treatment of asthma, the beta-2-adrenoceptor agonists-namely, the inhibition of mast-cell degranulation-may be contributing to the world wide increase in morbidity and mortality from asthma via the inhibition of a natural anti-inflammatory mechanism.			PAGE, CP (corresponding author), UNIV LONDON,KINGS COLL,DEPT PHARMACOL,LONDON SW3 6LX,ENGLAND.							BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BLOCK PE, 1980, BIOCHEM J, V191, P769; BOWLER S, 1988, HEPARIN RELATED POLY; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BUTTERFIELD JH, 1990, LAB INVEST, V62, P72; CARR J, 1979, THROMB RES, V16, P507, DOI 10.1016/0049-3848(79)90097-5; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39, DOI 10.1152/ajplung.1989.257.2.L39; CHIHARA J, 1988, AM REV RESPIR DIS, V137, pA421; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COHEN S, 1967, J IMMUNOL, V98, P351; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CRANE J, 1989, LANCET, V1, P917; DAHL S, 1962, Z Tuberk Erkr Thoraxorg, V118, P255; DOLOWITZ DA, 1965, ANN ALLERGY, V23, P309; DOUTREMEPUICH C, 1987, J LEUKOCYTE BIOL, V42, P628, DOI 10.1002/jlb.42.6.628; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; FRIERI M, 1983, J IMMUNOL, V131, P1942; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P78; GRAHAM MF, 1987, GASTROENTEROLOGY, V93, P801, DOI 10.1016/0016-5085(87)90443-4; HALES CA, 1983, AM REV RESPIR DIS, V128, P747; HANSS J G, 1989, American Review of Respiratory Disease, V139, pA134; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JEFFREY PK, 1990, AM REV RESPIR DIS, pA500; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAI CKW, 1987, AM REV RESPIR DIS, V140, P917; LASSER EC, 1987, ALLERGY, V42, P549, DOI 10.1111/j.1398-9995.1987.tb00381.x; LASSER EC, 1987, ALLERGY, V42, P619, DOI 10.1111/j.1398-9995.1987.tb00393.x; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LUNGREN R, 1988, EUR RESPIR J, V1, P883; MATZNER Y, 1984, THROMB HAEMOSTASIS, V52, P134; MCCLAIN E J, 1982, Journal of Allergy and Clinical Immunology, V69, P93; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; RASHAD S, 1989, LANCET, V2, P519; ROCHE WR, 1989, LANCET, V1, P520; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; STOKES TC, 1981, BR J DIS CHEST, V75, P11; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; Van de Carr FR, 1928, J IMMUNOL, V15, P13; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; YAMASHITA Y, 1990, American Review of Respiratory Disease, V141, pA912; 1985, J ALLERGY CLIN IMMUN, V75, P443	48	95	99	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					717	720		10.1016/0140-6736(91)90289-2	http://dx.doi.org/10.1016/0140-6736(91)90289-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706045				2022-12-01	WOS:A1991FD36700019
J	SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G				SHORT, RV; LEWIS, PR; RENFREE, MB; SHAW, G			CONTRACEPTIVE EFFECTS OF EXTENDED LACTATIONAL AMENORRHEA - BEYOND THE BELLAGIO CONSENSUS	LANCET			English	Article								We have recorded the duration of lactational anovulation and amenorrhoea in a well-nourished group of Australian women who breastfed their babies throughout the study. The data enabled us to compare the theoretical cumulative probability of conception among breastfeeding women who had unprotected intercourse irrespective of their menstrual status with that of those who had unprotected intercourse only during lactational amenorrhoea. Breastfeeding alone is not an effective form of contraception, since all the women in our study resumed normal ovulation while still breastfeeding. However, among women who have unprotected intercourse only during lactational amenorrhoea but adopt other contraceptive measures when they resume menstruation, only 1.7% would have become pregnant during the first 6 months of amenorrhoea, only 7% after 12 months, and only 13% after 24 months. Thus for our women it would be possible to extend the Bellagio Consensus Conference guidelines which stated that lactational amenorrhoea can only be relied on as a contraceptive for the first 6 months post-partum in women who are fully or almost fully breastfeeding. The lactational amenorrhoea method can be relied on for excellent contraceptive protection in the first 6 months of breastfeeding, irrespective of when supplements are introduced into the baby's diet; for women who continue to breastfeed the method can also give good protection for up to 12 months post partum. Once menstruation has returned, other forms of contraception are essential to prevent pregnancy.	NURSING MOTHERS ASSOC AUSTRALIAL,NUNAWADING,AUSTRALIA; MONASH UNIV,DEPT ANAT,MELBOURNE,VIC 3004,AUSTRALIA	Monash University	SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,MELBOURNE 3168,AUSTRALIA.		Shaw, Geoff/A-6916-2012	Shaw, Geoff/0000-0002-7421-7136; Renfree, Marilyn/0000-0002-4589-0436				GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KENNEDY KI, 1989, CONTRACEPTION, V39, P477, DOI 10.1016/0010-7824(89)90103-0; LEWIS PR, IN PRESS FERTIL STER; RODRIGUEZ G, 1988, BREASTFEEDING LENGTH; SIMPSONHEBERT M, 1981, STUD FAMILY PLANN, V12, P125, DOI 10.2307/1965593; THAPA S, 1988, NATURE, V335, P679, DOI 10.1038/335679a0; WOOD JW, 1989, OXFORD REV REPROD B, V11, P61; 1988, LANCET, V2, P1204	8	75	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					715	717		10.1016/0140-6736(91)90288-Z	http://dx.doi.org/10.1016/0140-6736(91)90288-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1672186				2022-12-01	WOS:A1991FD36700018
J	SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM				SPRINGALL, DR; HOWARTH, PH; COUNIHAN, H; DJUKANOVIC, R; HOLGATE, ST; POLAK, JM			ENDOTHELIN IMMUNOREACTIVITY OF AIRWAY EPITHELIUM IN ASTHMATIC-PATIENTS	LANCET			English	Article							SMOOTH-MUSCLE CELLS; VASOCONSTRICTOR PEPTIDE; VASOACTIVE PEPTIDE; GUINEA-PIG	There is extensive pharmacological and physiological evidence that endothelin-1 influences airway calibre. In mammals, endothelin receptors occur on airway smooth muscle, local storage and release of the peptide have been demonstrated, and inhalation of endothelin-1 induces bronchoconstriction. To investigate the relation between endothelins and asthma the expression of this peptide in endobronchial biopsy specimens was examined immunohistochemically with an antiserum against endothelin-1. Biopsy specimens from 17 asthmatic patients and 11 atopic and non-atopic healthy controls revealed striking differences, with endothelin expression being evident in airways epithelium and vascular endothelium in 11 of the 17 asthmatic patients but in only 1 of 11 controls. These results suggest that endothelins may play a part in the exaggerated bronchomotor tone of asthma.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton	SPRINGALL, DR (corresponding author), ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND.			Howarth, Peter/0000-0003-0619-7927; Djukanovic, Ratko/0000-0001-6039-5612				BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; CARDELL LO, 1990, ACTA PHYSIOL SCAND, V139, P103, DOI 10.1111/j.1748-1716.1990.tb08902.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITOH Y, 1988, FEBS LETT, V231, P440, DOI 10.1016/0014-5793(88)80867-6; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSKA T, 1989, FEBS LETT, V249, P42; LAGENTE V, 1989, BIOCHEM BIOPH RES CO, V158, P625, DOI 10.1016/0006-291X(89)92767-8; MAGGI CA, 1989, EUR J PHARMACOL, V160, P179; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; NAGASE T, 1990, BIOCHEM BIOPH RES CO, V168, P485, DOI 10.1016/0006-291X(90)92347-3; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NOMURA A, 1989, LANCET, V2, P747; Pepys J., 1975, BR J HOSP MED, V14, P412; POEER RF, 1989, J CARDIOVASC PHARM, V13, pS50; ROCHE WR, 1989, LANCET, V1, P520; ROZENGURT N, 1990, J PATHOL, V160, P5, DOI 10.1002/path.1711600104; SAKATA K, 1989, BRIT J PHARMACOL, V98, P483, DOI 10.1111/j.1476-5381.1989.tb12621.x; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SPRINGALL DR, 1990, AM REV RESPIR DIS, V141, P1538, DOI 10.1164/ajrccm/141.6.1538; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; SUNNERGREN KP, 1990, MOL CELL ENDOCRINOL, V68, P7; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TURNER NC, 1989, BRIT J PHARMACOL, V98, P361, DOI 10.1111/j.1476-5381.1989.tb12605.x; WATANABE A, 1990, 13TH WORLD C ASTHM G, P4; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	30	280	282	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1991	337	8743					697	701		10.1016/0140-6736(91)90279-X	http://dx.doi.org/10.1016/0140-6736(91)90279-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD367	1706044				2022-12-01	WOS:A1991FD36700009
J	SWAN, IRC; GATEHOUSE, S				SWAN, IRC; GATEHOUSE, S			CLINICAL AND FINANCIAL AUDIT OF DIAGNOSTIC PROTOCOLS FOR LESIONS OF THE CEREBELLOPONTINE ANGLE	BRITISH MEDICAL JOURNAL			English	Article							AUDIOLOGIC EVALUATION; ACOUSTIC NEUROMA; TESTS	Objective-To assess the diagnostic efficiency and costs of protocols used for investigating patients with suspected lesions of the cerebellopontine angle. Design-Prospective evaluation of tests of auditory brain stem responses and acoustic reflex thresholds, electronystagmography, and calorics. Positive test results were confirmed or refuted by high resolution computed tomography with intravenous enhancement. Setting-Single general otolaryngology clinic in a teaching hospital. Patients-270 consecutive patients with sensorineural hearing loss requiring investigation to exclude a lesion of the cerebellopontine angle. Main outcome measures-Estimated costs of various diagnostic protocols and performance in detecting tumours of the cerebellopontine angle. Results-Protocols including tests of auditory brain stem responses and acoustic reflex thresholds as sifting tests before computed tomography were clinically acceptable and presented considerable savings over the use of computed tomography in all patients (74000 pounds or 84000 pounds v 122000 pounds). The use of electronystagmography and calorics could not be justified on clinical or financial grounds. Conclusions-Audiological tests of auditory brain stem responses and acoustic reflex thresholds followed by computed tomography constitute the most cost effective protocol for determining suspected lesions of the cerebellopontine angle. Implications-The cost effectiveness of diagnostic protocols should be evaluated throughout the health service.	GLASGOW ROYAL INFIRM,MRC,INST HEARING RES,SCOTTISH SECT,GLASGOW G4 0SF,SCOTLAND	University of Glasgow	SWAN, IRC (corresponding author), UNIV GLASGOW,ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							BARRS DM, 1987, OTOLARYNG HEAD NECK, V96, P523, DOI 10.1177/019459988709600601; CASHMAN MZ, 1983, J OTOLARYNGOL, V12, P180; Harder H, 1988, Acta Otolaryngol Suppl, V452, P5; HART RG, 1981, NEUROSURGERY, V9, P450, DOI 10.1227/00006123-198110000-00021; JERGER S, 1983, AUDIOLOGY, V22, P144; JOHNSON EW, 1977, ARCH OTOLARYNGOL, V103, P152; Jongkees L B, 1973, Otolaryngol Clin North Am, V6, P73; JOSEY A F, 1987, Ear and Hearing, V8, p19S, DOI 10.1097/00003446-198708001-00006; MAIR IWS, 1988, SCAND AUDIOL, V17, P163, DOI 10.3109/01050398809042188; MOFFAT DA, 1989, J LARYNGOL OTOL, V103, P51, DOI 10.1017/S0022215100108023; MUSIEK FE, 1986, EAR HEARING, V7, P100, DOI 10.1097/00003446-198604000-00008; Norre M E, 1978, Acta Otorhinolaryngol Belg, V32, P421; PRIEDE VM, 1984, J LARYNGOL OTOL, V88, P641; REIMER A, 1987, SCAND AUDIOL, V16, P101, DOI 10.3109/01050398709042163; SANDERS JW, 1974, ARCH OTOLARYNGOL, V100, P283; THOMSEN J, 1988, ACTA OTOLARYNGOL S S, V452, P16; TURNER RG, 1984, EAR HEARING, V5, P187, DOI 10.1097/00003446-198407000-00002; 1988, LANCET, V2, P1294	18	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					701	704		10.1136/bmj.302.6778.701	http://dx.doi.org/10.1136/bmj.302.6778.701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1902384	Green Published, Bronze			2022-12-01	WOS:A1991FE33300027
J	URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA				URQUHART, JD; BLACK, RJ; MUIRHEAD, MJ; SHARP, L; MAXWELL, M; EDEN, OB; JONES, DA			CASE-CONTROL STUDY OF LEUKEMIA AND NON-HODGKINS-LYMPHOMA IN CHILDREN IN CAITHNESS NEAR THE DOUNREAY NUCLEAR INSTALLATION	BRITISH MEDICAL JOURNAL			English	Article							MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE; CANCER	Objective-To examine whether the observed excess of childhood leukaemia and non-Hodgkin's lymphoma in the area around the Dounreay nuclear installation is associated with established risk factors, or with factors related to the plant, or with parental occupation in the nuclear industry. Design-Case-control study. Setting-Caithness local government district. Subjects-14 cases of leukaemia and non-Hodgkin's lymphoma occurring in children aged under 15 years diagnosed in the area between 1970 and 1986 and 55 controls matched for sex, date of birth, and area of residence within Caithness at time of birth. Main outcome measures-Antenatal abdominal x ray examination; drugs taken and viral infections during pregnancy; father's occupation; father's employment at Dounreay and radiation dose; distance of usual residence from the path of microwave beams, preconceptional exposure to non-ionising radiation in the father; and other lifestyle factors. Results-No raised relative risks were found for prenatal exposure to x rays, social class of parents, employment at Dounreay before conception or diagnosis, father's dose of ionising radiation before conception, or child's residence within 50 m of the path of microwave transmission beams. Results also proved negative for all lifestyle factors except an apparent association with use of beaches within 25 km of Dounreay. However, this result was based on small numbers, arose in the context of multiple hypothesis testing, and is certainly vulnerable to possible systematic bias. Conclusion-The raised incidence of childhood leukaemia and non-Hodgkin's lymphoma around Dounreay cannot be explained by paternal occupation at Dounreay or by paternal exposure to external ionising radiation before conception. The observation of an apparent association between the use of beaches around Dounreay and the development of childhood leukaemia and non-Hodgkin's lymphoma might be an artefact of multiple testing and influenced by recall bias.	ROYAL HOSP SICK CHILDREN,DEPT PAEDIAT HAEMATOL,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND		URQUHART, JD (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BLACK D, 1984, INVESTIGATION POSSIB; BRESLOW N. E., 1980, STATISTICAL METHODS; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MCWHIRTER WR, 1982, BRIT J CANCER, V46, P640, DOI 10.1038/bjc.1982.249; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; 1988, 2ND COMM MED ASP RAD; 1989, EGRET	13	102	102	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					687	692		10.1136/bmj.302.6778.687	http://dx.doi.org/10.1136/bmj.302.6778.687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	2021742	Green Published, Bronze			2022-12-01	WOS:A1991FE33300021
J	BASLER, K; CHRISTEN, B; HAFEN, E				BASLER, K; CHRISTEN, B; HAFEN, E			LIGAND-INDEPENDENT ACTIVATION OF THE SEVENLESS RECEPTOR TYROSINE KINASE CHANGES THE FATE OF CELLS IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							PROTO-ONCOGENE PRODUCT; PUTATIVE RECEPTOR; POINT MUTATION; OPSIN GENE; RETINA; MELANOGASTER; DOMAIN; EXPRESSION; PATTERN; MUTANT	Cell fate in the developing eye is determined by a cascade of inductive interactions. In this process, the sevenless protein-a receptor tyrosine kinase-is required for the specification of the R7 photoreceptor cell fate. We have constructed a gain-of-function sevenless mutation (Sev(S11)) by overexpressing a truncated sevenless protein in the cells where sevenless is normally expressed. In Sev(S11) mutant flies, all sevenless-expressing cells initiate neural development. This results in the formation of multiple R7-like photoreceptors per ommatidium. Therefore, sevenless activity appears to be necessary and sufficient for the determination of R7 cell fate. These results illustrate the central role receptor tyrosine kinases can play in the specification of cell fate during development.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich				Basler, Konrad/0000-0003-3534-1529				BALLINGER DG, 1988, P NATL ACAD SCI USA, V85, P3960, DOI 10.1073/pnas.85.11.3960; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, IN PRESS GENES DEV; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; JARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MISMER D, 1987, GENETICS, V116, P565; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MONTELL C, 1987, J NEUROSCI, V7, P1558; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STARK WS, 1987, J NEUROGENET, V4, P227, DOI 10.3109/01677068709102343; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOMILINSON A, 1989, CIBA F S, V144, P281; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; ZUKER CS, 1987, J NEUROSCI, V7, P1550	51	223	225	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1069	1081		10.1016/0092-8674(91)90262-W	http://dx.doi.org/10.1016/0092-8674(91)90262-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004416	Green Accepted			2022-12-01	WOS:A1991FD55800005
J	BERNANDER, R; DASGUPTA, S; NORDSTROM, K				BERNANDER, R; DASGUPTA, S; NORDSTROM, K			THE ESCHERICHIA-COLI CELL-CYCLE AND THE PLASMID R1 REPLICATION CYCLE IN THE ABSENCE OF THE DNAA PROTEIN	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; MINICHROMOSOME REPLICATION; INITIATION; GENE; ORIGIN; EXPRESSION; MUTANTS; OVERPRODUCTION; SUPPRESSION	In E. coli strain EC::71CW chromosome replication is under the control of the R1 miniplasmid pOU71. A dnaA850::Tn10 derivative of EC::71CW was viable, which confirmed that R1 can replicate in the absence of the DnaA protein. The frequency of initiation of replication was, however, lowered and cell division was severely disturbed due to underreplication of the chromosome. Both replication and cell division could be restored to normal by increasing the production of RepA, the rate-limiting protein for initiation of replication from the integrated R1 origin. Therefore, the RepA protein seems to compensate for the absence of DnaA in the initiation of replication and assembly of replisomes. The role of the DnaA protein in the initiation of DNA replication, and as an overall regulator of the chromosome replication and cell division cycles of E. coli, is discussed in view of these results.			BERNANDER, R (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MICROBIOL,BOX 581,S-75123 UPPSALA,SWEDEN.							ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BERNANDER R, 1989, J BACTERIOL, V171, P674, DOI 10.1128/jb.171.2.674-683.1989; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BREMER H, 1985, J BACTERIOL, V164, P922, DOI 10.1128/JB.164.2.922-924.1985; CHANDLER M, 1977, J BACTERIOL, V131, P421, DOI 10.1128/JB.131.2.421-430.1977; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; CHURCHWARD G, 1983, MOL GEN GENET, V192, P506, DOI 10.1007/BF00392197; DONACHIE WD, 1989, J BACTERIOL, V171, P4633, DOI 10.1128/jb.171.9.4633-4639.1989; DONACHIE WD, 1984, MICROBIAL DEV, P27; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; GUSTAFSSON P, 1978, PLASMID, V1, P187, DOI 10.1016/0147-619X(78)90038-0; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; Maniatis T., 1982, MOL CLONING; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASAI H, 1983, P NATL ACAD SCI USA, V80, P6841; MESSER W, 1988, BIOCHIM BIOPHYS ACTA, V951, P351, DOI 10.1016/0167-4781(88)90106-6; Miller JH., 1972, EXPT MOL GENETICS; MORIYA S, 1990, EMBO J, V9, P2905, DOI 10.1002/j.1460-2075.1990.tb07481.x; NAGATA T, 1988, MOL GEN GENET, V213, P163, DOI 10.1007/BF00333414; NORDSTROM K, 1980, PLASMID, V4, P215, DOI 10.1016/0147-619X(80)90011-6; NORDSTROM K, 1991, IN PRESS MOL MICROBI; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; PIERUCCI O, 1987, J BACTERIOL, V169, P1871, DOI 10.1128/jb.169.5.1871-1877.1987; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; TANG XB, 1989, J BACTERIOL, V171, P5290, DOI 10.1128/jb.171.10.5290-5295.1989; XU YC, 1988, MOL GEN GENET, V211, P138, DOI 10.1007/BF00338404	40	38	38	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1145	1153		10.1016/0092-8674(91)90269-5	http://dx.doi.org/10.1016/0092-8674(91)90269-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1848482				2022-12-01	WOS:A1991FD55800012
J	BOYES, J; BIRD, A				BOYES, J; BIRD, A			DNA METHYLATION INHIBITS TRANSCRIPTION INDIRECTLY VIA A METHYL-CPG BINDING-PROTEIN	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; GLOBIN GENE-EXPRESSION; INVITRO METHYLATION; ADENOVIRUS TYPE-2; MAMMALIAN NUCLEI; KINASE GENE; 5' REGION; PROMOTER; SEQUENCE; DEMETHYLATION	We have studied the mechanism by which DNA methylation inhibits transcription both in cell-free nuclear extracts and in the living cell. Repression of transcription in vitro for four different promoters was shown to be an indirect effect. The mediator of repression had properties indistinguishable from those of a methyl-CpG binding protein (MeCP-1) that has been previously identified. Use of differentially methylated promoters and methylated competitors in transient transfection assays suggested that indirect repression via MeCP-1 also occurs in the living cell. This was supported by the fact that MeCP-1-deficient cells showed much reduced repression of methylated genes.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Boyes, Joan/0000-0002-8705-9827; Bird, Adrian/0000-0002-8600-0372				ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; BUSSLINGER M, 1983, GLOBIN GENE EXPRESSI, P193; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1988, J VIROL, V62, P3941, DOI 10.1128/JVI.62.11.3941-3946.1988; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMURA FK, 1981, CELL, V23, P809, DOI 10.1016/0092-8674(81)90445-1; GILMAN M, 1987, CURRENT PROTOCOLS MO; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HEIERMANN R, 1985, NUCLEIC ACIDS RES, V13, P2709, DOI 10.1093/nar/13.8.2709; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; HOELLER M, 1988, Genes and Development, V2, P1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARDIMON L, 1982, P NATL ACAD SCI-BIOL, V79, P1073, DOI 10.1073/pnas.79.4.1073; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638	40	617	632	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1123	1134		10.1016/0092-8674(91)90267-3	http://dx.doi.org/10.1016/0092-8674(91)90267-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004419				2022-12-01	WOS:A1991FD55800010
J	HE, JJ; QUIOCHO, FA				HE, JJ; QUIOCHO, FA			A NONCONSERVATIVE SERINE TO CYSTEINE MUTATION IN THE SULFATE-BINDING PROTEIN, A TRANSPORT RECEPTOR	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM	Serine 130 is one of seven residues that form a total of seven hydrogen bonds with the sulfate completely sequestered deep in the cleft between the two lobes of the bilobate sulfate-binding protein from Salmonella typhimurium. This residue has been replaced with Cys, Ala, and Gly by site-directed mutagenesis in an Escherichia coli expression system. Replacement with the isosteric Cys caused a 3200-fold decrease in the sulfate-binding activity relative to the wild-type activity, whereas replacement with Ala and Gly resulted in only 100- and 15-fold decreases, respectively. The effect of the Cys substitution is attributed largely to steric effect, whereas the Gly substitution more nearly reflects the loss of one hydrogen bond to the bound sulfate with a strength of only 1.6 kilocalories per mole.	BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR UNIV,DEPT BIOCHEM,HOUSTON,TX 77030	Baylor University; Howard Hughes Medical Institute; Baylor University								AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; FREY MN, 1973, ACTA CRYSTALLOGR B, VB 29, P876, DOI 10.1107/S0567740873003481; FURLONG CE, 1987, CELLULAR MOL BIOL, P768; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; ISHIHARA H, 1980, J BIOL CHEM, V255, P4614; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; JACOBSON BL, IN PRESS J BIOL CHEM; KERR KA, 1975, ACTA CRYSTALLOGR B, V31, P2022, DOI 10.1107/S0567740875006772; KISTENMACHER TJ, 1974, ACTA CRYSTALLOGR B, V30, P2573, DOI 10.1107/S0567740874007618; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MCGRATH ME, 1989, BIOCHEMISTRY-US, V28, P9264, DOI 10.1021/bi00450a005; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; PARDEE AB, 1966, J BIOL CHEM, V241, P5886; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; POLGAR L, 1966, J AM CHEM SOC, V88, P153; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; SACK JS, UNPUB	19	176	183	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1479	1481		10.1126/science.1900953	http://dx.doi.org/10.1126/science.1900953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900953				2022-12-01	WOS:A1991FC85300046
J	HEITZLER, P; SIMPSON, P				HEITZLER, P; SIMPSON, P			THE CHOICE OF CELL FATE IN THE EPIDERMIS OF DROSOPHILA	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; NEURONAL PRECURSOR CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; EARLY NEUROGENESIS; NOTCH LOCUS; GROWTH-FACTOR; GENE-PRODUCT; MELANOGASTER; LIN-12	In Drosophila, neural precursors are formed in a spaced pattern separated by intervening epidermal cells. Segregation of neural and epidermal lineages relies on cellular interactions. Failure of this cell communication, as in the mutants Notch (N), Delta, and shaggy, results in most or all of the cells becoming neural. Cells mutant for N and shaggy, but not Delta, autonomously adopt the neural fate when adjacent to wild-type cells in mosaics. Furthermore, wild-type cells adopt the epidermal fate if adjacent cells express a lower level of N activity than themselves, but produce neural precursors if adjacent cells express a higher level of N activity. This shows that there is competition between the cells and that the N protein is required for the mechanism whereby the cells choose between alternative fates. It also suggests that N acts as a receptor for an inhibitory signal emanating from the neural precursors.			HEITZLER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, F-67085 STRASBOURG, FRANCE.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1986, ROUX ARCH DEV BIOL, V195, P210, DOI 10.1007/BF02438953; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1966, J CELL SCI, V1, P475; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MITCHELL HK, 1990, DEV GENET, V11, P133, DOI 10.1002/dvg.1020110203; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHELLENBARGER DL, 1975, GENETICS, V81, P143; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1990, TRENDS GENET, V6, P343, DOI 10.1016/0168-9525(90)90260-D; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STERN CURT, 1954, AMER SCI, V42, P213; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILCOX M, 1973, J CELL SCI, V12, P707; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	654	663	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1083	1092		10.1016/0092-8674(91)90263-X	http://dx.doi.org/10.1016/0092-8674(91)90263-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004417				2022-12-01	WOS:A1991FD55800006
J	JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W				JUST, U; STOCKING, C; SPOONCER, E; DEXTER, TM; OSTERTAG, W			EXPRESSION OF THE GM-CSF GENE AFTER RETROVIRAL TRANSFER IN HEMATOPOIETIC STEM-CELL LINES INDUCES SYNCHRONOUS GRANULOCYTE-MACROPHAGE DIFFERENTIATION	CELL			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; AUTOCRINE STIMULATION; AUTONOMOUS GROWTH; SELF-RENEWAL; EGF RECEPTOR; INTERLEUKIN-3; MICROENVIRONMENT; IDENTIFICATION; TUMORIGENICITY	Multipotent murine stem cell lines (FDC-Pmix) depend on IL-3 for self-renewal and proliferation and can be induced to differentiate into multiple hematopoietic lineages. Single FDC-Pmix cells infected with retroviral vectors expressing GM-CSF are induced to differentiate into granulocytes and macrophages. This results in a complete loss of clonogenic cells if IL-3 is not exogenously supplied; however, multipotent variants can be selected that do not terminally differentiate if cells are kept in the presence of IL-3. Unidirectional and synchronous granulocyte and macrophage differentiation accompanied with loss of self-renewal capacity is induced when IL-3 is removed. Our data indicate that activation of the GM-CSF receptor induces differentiation of stem cells by an instructive mechanism that can be blocked by the activated IL-3 receptor. A model of how receptors can induce proliferation and cell-specific differentiation by two separate pathways is discussed.	PATERSON INST CANC RES,MANCHESTER M20 9BX,ENGLAND	Paterson Institute for Cancer Research	JUST, U (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Just, Ursula/E-6992-2010					ALLEN TD, 1984, EXP HEMATOL, V12, P517; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EISEN H, 1978, COLD SPRING HARBOR C, V5, P277; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; HEYWORTH CM, 1988, J CELL SCI, V91, P239; HOUSMAN D, 1978, COLD SPRING HARBOR C, V5, P193; IHLE JN, 1983, J IMMUNOL, V131, P282; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; LAKER C, 1989, MOD TRENDS HUM LEUK, V8, P188; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1984, HEMOPOIETIC COLONIES; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUESENBERRY P, 1988, BLOOD S, V1, P116; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SPOONCER E, 1989, CURR TOP MICROBIOL, V149, P109; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	39	77	80	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1163	1173		10.1016/0092-8674(91)90271-Y	http://dx.doi.org/10.1016/0092-8674(91)90271-Y			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004422				2022-12-01	WOS:A1991FD55800014
J	KATO, H; HORIKOSHI, M; ROEDER, RG				KATO, H; HORIKOSHI, M; ROEDER, RG			REPRESSION OF HIV-1 TRANSCRIPTION BY A CELLULAR PROTEIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PREINITIATION COMPLEX; GENE-EXPRESSION; T-ANTIGEN; BINDING; PROMOTER; TATA; REGION	A cellular DNA binding protein, LBP-1, sequentially interacts in a concentration-dependent manner with two sites that surround the transcriptional initiation site of the human immunodeficiency virus type 1 (HIV-1) promoter. Although sequences in the downstream site (site I) were found to enhance transcription, purified LBP-1 specifically repressed transcription in vitro by binding to the upstream site (site II), which overlaps the TATA element. The binding of human TATA binding factor (TFIID) to the promoter before LBP-1 blocked repression, suggesting that repression resulted from an inhibition of TFIID binding to the TATA element. Furthermore, mutations that eliminated binding to site II both prevented repression in vitro and increased HIV-1 transcription in stably transformed cells. These findings suggest that a cellular factor regulates HIV-1 transcription in a manner that is characteristic of bacterial repressors and that this factor could be important in HIV-1 latency.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; Horikoshi M., UNPUB; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KATO H, UNPUB; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PAVLAKIS GN, 1990, BIOLOGIST, V2, P20; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	38	142	145	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1476	1479		10.1126/science.2006421	http://dx.doi.org/10.1126/science.2006421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006421				2022-12-01	WOS:A1991FC85300045
J	LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D				LUNDGREN, K; WALWORTH, N; BOOHER, R; DEMBSKI, M; KIRSCHNER, M; BEACH, D			MIK1 AND WEE1 COOPERATE IN THE INHIBITORY TYROSINE PHOSPHORYLATION OF CDC2	CELL			English	Article							CYCLE CONTROL GENE; YEAST SCHIZOSACCHAROMYCES-POMBE; P34CDC2 PROTEIN-KINASE; CELL-DIVISION CYCLE; FISSION YEAST; MITOTIC CONTROL; M-PHASE; SACCHAROMYCES-CEREVISIAE; MITOSIS; DNA	wee1 acts antagonistically to cdc25 in the tyrosine dephosphorylation and activation of cdc2, yet biochemical evidence suggests that wee1 is not required for tyrosine phosphorylation and its role is obscure. We show here that a related 66 kd kinase, called mik1, acts redundantly with wee1 in the negative regulation of cdc2 in S. pombe. A null allele of mik1 has no discernible phenotype, but a mik1 wee1 double mutant is hypermitotically lethal: all normal M phase checkpoints are bypassed, including the requirement for initiation of cell cycle "start," completion of S phase, and function of the cdc25+ mitotic activator. In the absence of mik1 and wee1 activity, cdc2 rapidly loses phosphate on tyrosine, both in strains undergoing mitotic lethality and in those that are viable owing to a compensating mutation within cdc2. The data suggest that mik1 and wee1 act cooperatively on cdc2, either directly as the inhibitory tyrosine kinase or as essential activators of that kinase.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LUNDGREN, K (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.			Walworth, Nancy/0000-0001-5940-8236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; CREANOR J, 1979, J GEN MICROBIOL, V112, P385, DOI 10.1099/00221287-112-2-385; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; FANTES PA, 1981, J BACTERIOL, V146, P746, DOI 10.1128/JB.146.2.746-754.1981; FEATHERSTONE C, 1991, IN PRESS NATURE; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KOHLI J, 1977, GENETICS, V87, P471; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1765, DOI 10.1093/nar/14.4.1765; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MITCHISON JMM, 1974, CELL CYCLE CONTROLS; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1980, GENETICS, V96, P101; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	67	586	596	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1111	1122		10.1016/0092-8674(91)90266-2	http://dx.doi.org/10.1016/0092-8674(91)90266-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1706223				2022-12-01	WOS:A1991FD55800009
J	MARTINEZ, C; MODOLELL, J				MARTINEZ, C; MODOLELL, J			CROSS-REGULATORY INTERACTIONS BETWEEN THE PRONEURAL ACHAETE AND SCUTE GENES OF DROSOPHILA	SCIENCE			English	Article							HAIRY-WING MUTATIONS; PATTERN FORMATION; FATE MAP; MELANOGASTER; COMPLEX; REGENERATION; DUPLICATION; HUNCHBACK; ELEMENTS; SYSTEM	The achaete (ac) and scute (sc) genes of Drosophila allow cells to become sensory organ mother cells. Although ac and sc have similar patterns of expression, deletion of either gene removes specific subsets of sensory organs. This specificity was shown to reside in the peculiar regulation of ac and sc expression. These genes are first activated in complementary spatial domains in response to different cis-regulatory sequences. Each gene product then stimulates expression of the other gene, thus generating similar patterns of expression. Therefore, removal of one gene leads to the absence of both proneural gene products and sensory organs in the sites specified by its cis-regulatory sequences.	UNIV AUTONOMA MADRID,MADRID 34,SPAIN	Autonomous University of Madrid	MARTINEZ, C (corresponding author), CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN.							ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ALONSO LG, 1986, ROUX ARCH DEV BIOL, V195, P259, DOI 10.1007/BF02438959; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, COMMUNICATION; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1989, DEVELOPMENT, V105, P35; HUANG F, IN PRESS DEVELOPMENT; LEYNS L, 1989, ROUX ARCH DEV BIOL, V198, P227, DOI 10.1007/BF00375909; MARTINEZ CJ, UNPUB; MURRAY MA, 1984, DEV BIOL, V104, P259, DOI 10.1016/0012-1606(84)90082-4; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RODRIGUEZ I, 1990, EMBO J, V11, P3583; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SKEATH J, COMMUNICATION; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VAESSIN H, COMMUNICATION; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8	28	105	105	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1485	1487		10.1126/science.1900954	http://dx.doi.org/10.1126/science.1900954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	1900954				2022-12-01	WOS:A1991FC85300048
J	ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE				ORCI, L; TAGAYA, M; AMHERDT, M; PERRELET, A; DONALDSON, JG; LIPPINCOTTSCHWARTZ, J; KLAUSNER, RD; ROTHMAN, JE			BREFELDIN-A, A DRUG THAT BLOCKS SECRETION, PREVENTS THE ASSEMBLY OF NON-CLATHRIN-COATED BUDS ON GOLGI CISTERNAE	CELL			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; INTRACELLULAR-TRANSPORT; RAT HEPATOCYTES; FUSION PROTEIN; STACK; YEAST; RECONSTITUTION; COMPLEX	We report that brefeldin A prevents the assembly of non-clathrin-coated vesicles from Golgi cisternae in a cell-free system. This finding provides a simple molecular explanation for the primary effect of this remarkable compound in blocking constitutive secretion. We further report that when coated vesicle assembly is blocked, extensive tubule networks form that connect previously separate cisternae and stacks into a single topological unit, allowing the intermixing of contents of Golgi cisternae, presumably by lateral diffusion. Formation of the tubule networks requires ATP, cytosol, and the general fusion protein NSF. Tubule networks may be related to the membrane tubules mediating retrograde transport in vivo.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	Princeton University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	ORCI, L (corresponding author), UNIV GENEVA,SCH MED,INST HISTOL & EMBRYOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.				NIDDK NIH HHS [DK 27044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027044, R37DK027044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ARMBRUSTER BL, 1982, J MICROSC-OXFORD, V126, P77, DOI 10.1111/j.1365-2818.1982.tb00358.x; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; COREY E J, 1976, Tetrahedron Letters, V51, P4701; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, IN PRESS J CELL BIOL; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; LEDRIAN C, 1982, J AM CHEM SOC, V104, P5473, DOI 10.1021/ja00384a038; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, NATURE, V349, P215; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; TANDLER B, 1990, J ELECTRON MICR TECH, V16, P81, DOI 10.1002/jemt.1060160110; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	40	439	447	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1183	1195						13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004424				2022-12-01	WOS:A1991FD55800016
J	PETERSON, CL; KRUGER, W; HERSKOWITZ, I				PETERSON, CL; KRUGER, W; HERSKOWITZ, I			A FUNCTIONAL INTERACTION BETWEEN THE C-TERMINAL DOMAIN OF RNA POLYMERASE-II AND THE NEGATIVE REGULATOR SIN1	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; HO GENE; ESCHERICHIA-COLI; REPEAT DOMAIN; YEAST; EXPRESSION; PROTEIN; BINDING	The C-terminal domain (CTD) of the largest subunit of yeast RNA polymerase II contains 26-27 tandem copies of a conserved heptapeptide of unknown function. Yeast strains whose CTD contains ten heptamers are viable but defective for transcription of the INO1 gene and cold sensitive for growth. Deletion of the SIN1 gene, which codes for a DNA-binding protein that negatively regulates HO transcription, restores INO1 transcription and reduces the cold sensitivity of such strains. A SIN1 deletion suppresses the lethality of a CTD with nine heptamer repeats but not with seven repeats. These observations indicate a functional relationship between SIN1 and the CTD: the CTD might remove SIN1 from DNA, or removal of SIN1 may be a prerequisite for function of the CTD. The SWI1, SWI2, and SWI3 genes, whose products activate HO transcription by antagonizing SIN1, are also required for INO1 transcription and may assist the CTD. In addition, an intact CTD binds nonspecifically to DNA in vitro.			PETERSON, CL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROEDER GS, 1985, MOL CELL BIOL, V5, P1543, DOI 10.1128/MCB.5.7.1543; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHROTER H, 1982, EUR J BIOCHEM, V127, P429, DOI 10.1111/j.1432-1033.1982.tb06890.x; SILVERMAN SJ, 1984, MOL CELL BIOL, V4, P1246, DOI 10.1128/MCB.4.7.1246; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	39	163	163	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1135	1143		10.1016/0092-8674(91)90268-4	http://dx.doi.org/10.1016/0092-8674(91)90268-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004420				2022-12-01	WOS:A1991FD55800011
J	PETITTO, LA; MARENTETTE, PF				PETITTO, LA; MARENTETTE, PF			BABBLING IN THE MANUAL MODE - EVIDENCE FOR THE ONTOGENY OF LANGUAGE	SCIENCE			English	Article							AMERICAN SIGN LANGUAGE; SPEECH-PERCEPTION; CONTINUITY	Infant vocal babbling has been assumed to be a speech-based phenomenon that reflects the maturation of the articulatory apparatus responsible for spoken language production. Manual babbling has now been reported to occur in deaf children exposed to signed languages from birth. The similarities between manual and vocal babbling suggest that babbling is a product of an amodal, brain-based language capacity under maturational control, in which phonetic and syllabic units are produced by the infant as a first step toward building a mature linguistic system. Contrary to prevailing accounts of the neurological basis of babbling in language ontogeny, the speech modality is not critical in babbling. Rather, babbling is tied to the abstract linguistic structure of language and to an expressive capacity capable of processing different types of signals (signed or spoken).			PETITTO, LA (corresponding author), MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA.		Marentette, Paula/D-2888-2011	Marentette, Paula/0000-0002-4098-0571				CHOMSKY N, 1980, BEHAV BRAIN SCI, V3, P1, DOI 10.1017/S0140525X00001515; ELBERS L, 1982, COGNITION, V12, P45, DOI 10.1016/0010-0277(82)90029-4; GLEITMAN LR, 1981, COGNITION, V10, P103; HUTTENLOCHER J, 1987, COGNITIVE PSYCHOL, V19, P63, DOI 10.1016/0010-0285(87)90004-1; JUSCZYK PW, 1986, INVARIANCE VARIABILI, P1; Klima E., 1979, SIGNS LANGUAGE; LENNEBERG EH, 1967, BIOL F LANGUAGE; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1985, COGNITION, V21, P1, DOI 10.1016/0010-0277(85)90021-6; LIDDELL SK, 1984, LANGUAGE, V60, P372, DOI 10.2307/413645; Lieberman P., 1984, BIOL EVOLUTION LANGU; Locke J., 1983, PHONOLOGICAL ACQUISI, DOI DOI 10.2307/414500; MARENTETTE PF, UNPUB; MEHLER J, 1986, CR ACAD SCI III-VIE, V303, P637; Oller D. K., 1980, CHILD PHONOLOGY, V1, P93, DOI [DOI 10.1016/B978-0-12-770601-6.50011-5, 10.1016/B978-0-12-770601-6.50011-5]; OLLER DK, 1988, CHILD DEV, V59, P441, DOI 10.2307/1130323; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; SHATZ M, 1985, MERRILL PALMER QUART, V31, P211; Stokoe W. C., 1976, DICT AM SIGN LANGUAG; van der Stelt J. M., 1986, WENNER GREN CTR IN B, P163; VIHMAN MM, 1985, LANGUAGE, V61, P397, DOI 10.2307/414151; VIHMAN MM, 1986, APPL PSYCHOLINGUIST, V7, P3, DOI 10.1017/S0142716400007165	23	240	246	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1493	1496		10.1126/science.2006424	http://dx.doi.org/10.1126/science.2006424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FC853	2006424				2022-12-01	WOS:A1991FC85300051
J	SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC				SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC			KINESIN HEAVY-CHAIN IS ESSENTIAL FOR VIABILITY AND NEUROMUSCULAR FUNCTIONS IN DROSOPHILA, BUT MUTANTS SHOW NO DEFECTS IN MITOSIS	CELL			English	Article							BOVINE BRAIN KINESIN; MICROTUBULE MOTILITY; ELECTRON-MICROSCOPY; IMAGINAL DISKS; IDENTIFICATION; MELANOGASTER; LOCALIZATION; AXOPLASM; PROTEIN	The in vivo function of the microtubule motor protein kinesin was examined in Drosophila using genetics and immunolocalization. Kinesin heavy chain mutations (khc) cause abnormal behavior and lethality. Mutant larvae exhibit loss of mobility and tactile responsiveness in the most posterior segments, followed by general paralysis and death during larval or pupal development. Adults homozygous for a temperature-sensitive allele also exhibit a loss in mobility and sensory responses. The data indicate that kinesin function is essential and suggest that kinesin has an important role in the neuromuscular system, perhaps as a motor for axonal transport. The possibility of more general cellular functions remains open, but observation of embryogenesis and morphogenesis in khc mutants suggests that mitosis and the cell cycle can proceed in spite of impaired kinesin function. Immunolocalization suggests that kinesin may have some general cellular functions but that it is not a major component of mitotic spindles.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	SAXTON, WM (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016739] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16739] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOS LA, 1987, J CELL SCI, V87, P105; ANSTROM JA, 1987, DEVELOPMENT, V101, P255; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BONNER JJ, 1976, CHROMOSOMA, V58, P87, DOI 10.1007/BF00293443; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; COHN SA, 1989, J BIOL CHEM, V264, P4290; CURTIS D, 1989, GENETICS, V122, P653; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Fischer S G, 1979, Methods Enzymol, V68, P183; FOE VE, 1983, J CELL SCI, V61, P31; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Maniatis T., 1982, MOL CLONING; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WARN RM, 1986, J CELL SCI S, V5, P311; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	43	177	180	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1093	1102		10.1016/0092-8674(91)90264-Y	http://dx.doi.org/10.1016/0092-8674(91)90264-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1825937				2022-12-01	WOS:A1991FD55800007
J	SUN, H; TRECO, D; SZOSTAK, JW				SUN, H; TRECO, D; SZOSTAK, JW			EXTENSIVE 3'-OVERHANGING, SINGLE-STRANDED-DNA ASSOCIATED WITH THE MEIOSIS-SPECIFIC DOUBLE-STRAND BREAKS AT THE ARG4 RECOMBINATION INITIATION SITE	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOME; SYNAPSIS; EXCHANGE	Meiosis-specific double-strand breaks occur at the initiation site for meiotic gene conversion in the yeast ARG4 gene. Here we show that the break fragments end in extensive 3'-overhanging, single-stranded tails. The single-stranded tails vary in length, generating a gradient of single-strandedness that parallels the gradient of gene conversion frequencies in ARG4. In strains carrying a rad50S mutation, which blocks meiotic recombination, the extensive single-stranded tails do not form, suggesting that their generation is an obligatory step in meiotic recombination. Using the rad50S mutant, we have mapped the site of the ARG4 break to a small region within the genetically defined recombination initiation site. These results strongly support the double-strand break model of meiotic recombination.			SUN, H (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORTS RH, 1986, GENETICS, V113, P551; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; FOGEL S, 1981, MOL BIOL YEAST SACCH, V1, P289; GAME JC, 1980, GENETICS, V94, P51; GAME JC, 1989, GENETICS, V123, P695; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1985, GENETICS, V110, P187; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LICHTEN MJ, 1983, NUCLEIC ACIDS RES, V11, P3959, DOI 10.1093/nar/11.12.3959; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; Maniatis T., 1982, MOL CLONING; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WHITE JH, 1985, NATURE, V315, P350, DOI 10.1038/315350a0; Whitehouse H. L. K., 1982, GENETIC RECOMBINATIO; WILLIAMSON MS, 1985, GENETICS, V110, P609	32	460	466	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1155	1161		10.1016/0092-8674(91)90270-9	http://dx.doi.org/10.1016/0092-8674(91)90270-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	2004421				2022-12-01	WOS:A1991FD55800013
J	TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR				TSAO, J; CHAPMAN, MS; AGBANDJE, M; KELLER, W; SMITH, K; WU, H; LUO, M; SMITH, TJ; ROSSMANN, MG; COMPANS, RW; PARRISH, CR			THE 3-DIMENSIONAL STRUCTURE OF CANINE PARVOVIRUS AND ITS FUNCTIONAL IMPLICATIONS	SCIENCE			English	Article							RECEPTOR ATTACHMENT SITE; TOBACCO NECROSIS VIRUS; BEAN MOSAIC-VIRUS; GENOME ORGANIZATION; NUCLEOTIDE-SEQUENCE; 2.9-A RESOLUTION; 3.0-A RESOLUTION; PROTEIN GENE; MINUTE VIRUS; RNA	The three-dimensional atomic structure of a single-stranded DNA virus has been determined. Infectious virions of canine parvovirus contain 60 protein subunits that are predominantly VP-2. The central structural motif of VP-2 has the same topology (an eight-stranded anti-parallel beta-barrel) as has been found in many other icosahedral viruses but represents only about one-third of the capsid protein. There is a 22 angstrom (angstrom) long protrusion on the threefold axes, a 15 angstrom deep canyon circulating about each of the five cylindrical structures at the fivefold axes, and a 15 angstrom deep depression at the twofold axes. By analogy with rhinoviruses, the canyon may be the site of receptor attachment. Residues related to the antigenic properties of the virus are found on the threefold protrusions. Some of the amino termini of VP-2 run to the exterior in full but not empty virions, which is consistent with the observation that some VP-2 polypeptides in full particles can be cleaved by trypsin. Eleven nucleotides are seen in each of 60 symmetry-related pockets on the interior surface of the capsid and together account for 13 percent of the genome.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; CORNELL UNIV,NEW YORK STATE COLL VET MED,JAMES A BAKER INST ANIM HLTH,ITHACA,NY 14853; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Cornell University; University of Alabama System; University of Alabama Birmingham			Keller, Walter/AAW-1501-2021; Compans, Richard W/I-4087-2013; Smith, Thomas J/K-9086-2013	Keller, Walter/0000-0002-2261-958X; Compans, Richard W/0000-0003-2360-335X; Smith, Thomas J/0000-0003-3528-6793; Chapman, Michael/0000-0001-8525-8585				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ANDERSON LJ, 1989, NEW ENGL J MED, V321, P536, DOI 10.1056/NEJM198908243210809; ARNOTT S, 1973, J MOL BIOL, V81, P107, DOI 10.1016/0022-2836(73)90183-6; BASAK S, 1989, J VIROL, V63, P3164, DOI 10.1128/JVI.63.7.3164-3167.1989; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P224; CARTER BJ, 1987, ANIMAL VIRUS STRUCTU, P325; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHAPMAN M, UNPUB; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLINTON GM, 1976, VIROLOGY, V74, P57, DOI 10.1016/0042-6822(76)90127-6; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; ERICKSON JW, 1985, SCIENCE, V229, P625, DOI 10.1126/science.4023701; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1984, J MOL BIOL, V177, P735, DOI 10.1016/0022-2836(84)90047-0; JONGENEEL CV, 1986, J VIROL, V59, P564, DOI 10.1128/JVI.59.3.564-573.1986; KELLY DC, 1977, J VIROL, V21, P408, DOI 10.1128/JVI.21.1.408-410.1977; KIM S, 1989, J APPL CRYSTALLOGR, V22, P53, DOI 10.1107/S0021889888010878; Koch G., 1985, MOL BIOL POLIOVIRUS; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; LUO M, 1988, J MOL BIOL, V200, P209, DOI 10.1016/0022-2836(88)90346-4; MATTHEWS BW, 1985, METHOD ENZYMOL, V115, P397; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PARRISH CR, 1988, VIROLOGY, V163, P230, DOI 10.1016/0042-6822(88)90255-3; PARRISH CR, 1988, J GEN VIROL, V69, P1111, DOI 10.1099/0022-1317-69-5-1111; PARRISH CR, 1985, SCIENCE, V230, P1046, DOI 10.1126/science.4059921; PARRISH CR, 1988, VIROLOGY, V166, P293, DOI 10.1016/0042-6822(88)90500-4; RANZ AI, 1989, J GEN VIROL, V70, P2541, DOI 10.1099/0022-1317-70-10-2541; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; REED AP, 1988, J VIROL, V62, P266, DOI 10.1128/JVI.62.1.266-276.1988; RHODE SL, 1985, J VIROL, V54, P630, DOI 10.1128/JVI.54.2.630-633.1985; ROBERTS MM, 1986, SCIENCE, V232, P1148, DOI 10.1126/science.3704642; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; ROSSMANN MG, 1987, BIOESSAYS, V7, P99, DOI 10.1002/bies.950070302; ROSSMANN MG, 1988, VIROLOGY, V164, P373, DOI 10.1016/0042-6822(88)90550-8; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; STUDDERT MJ, 1990, HDB PARVOVIRUSES, V2, P27; TATTERSALL P, 1988, P5; TATTERSALL P, 1977, J MOL BIOL, V111, P375, DOI 10.1016/S0022-2836(77)80060-0; TATTERSALL P, 1990, HDB PARVOVIRUSES, P123; TATTERSALL P, 1990, HDB PARVOVIRUSES, V1, P111; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WOBBE CR, 1984, BIOCHEMISTRY-US, V23, P6565, DOI 10.1021/bi00321a044; 1985, EUR J BIOCHEM, V150, P1	59	428	458	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1456	1464		10.1126/science.2006420	http://dx.doi.org/10.1126/science.2006420			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006420				2022-12-01	WOS:A1991FC85300040
J	VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR				VU, TKH; HUNG, DT; WHEATON, VI; COUGHLIN, SR			MOLECULAR-CLONING OF A FUNCTIONAL THROMBIN RECEPTOR REVEALS A NOVEL PROTEOLYTIC MECHANISM OF RECEPTOR ACTIVATION	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN-PLATELETS; LIGAND-BINDING; HOMOLOGOUS DESENSITIZATION; BOVINE TRYPSINOGEN; EXPRESSION SYSTEM; INDUCED RELEASE; CDNA; PROTEIN; CELL	We isolated a cDNA encoding a functional human thrombin receptor by direct expression cloning in Xenopus oocytes. mRNA encoding this receptor was detected in human platelets and vascular endothelial cells. The deduced amino acid sequence revealed a new member of the seven transmembrane domain receptor family with a large amino-terminal extracellular extension containing a remarkable feature. A putative thrombin cleavage site (LDPR/S) resembling the activation cleavage site in the zymogen protein C (LDPR/I) was noted 41 amino acids carboxyl to the receptor's start methionine. A peptide mimicking the new amino terminus created by cleavage at R41 was a potent agonist for both thrombin receptor activation and platelet activation. "Uncleavable" mutant thrombin receptors failed to respond to thrombin but were responsive to the new amino-terminal peptide. These data reveal a novel signaling mechanism in which thrombin cleaves its receptor's amino-terminal extension to create a new receptor amino terminus that functions as a tethered ligand and activates the receptor.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VU, TKH (corresponding author), UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA.				NHLBI NIH HHS [HL 43322, HL 43821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL043322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Baenziger N L, 1974, Methods Enzymol, V31, P149; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COLEMAN A, 1984, TRANSCRIPTION TRANSL, P271; DAHLBACK B, 1986, J BIOL CHEM, V261, P5111; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P2462, DOI 10.1021/bi00737a015; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRASER CM, 1989, J BIOL CHEM, V264, P9266; GREENBERG SM, 1988, BLOOD, V72, P1968; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANSON SR, 1988, P NATL ACAD SCI USA, V85, P3184, DOI 10.1073/pnas.85.9.3184; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Muszbek L, 1984, THROMBIN, P83; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PAPAYANNOPOULOU T, 1987, J CLIN INVEST, V79, P859, DOI 10.1172/JCI112895; PARIS S, 1988, J BIOL CHEM, V263, P11250; PHILLIPS DR, 1974, THROMB DIATH HAEMOST, V32, P207, DOI 10.1055/s-0038-1647686; PIPILISYNETOS E, 1990, BIOCHEM BIOPH RES CO, V171, P913, DOI 10.1016/0006-291X(90)90770-N; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERAGA HA, 1977, CHEM BIOL THROMBIN, P145; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; STENFLO J, 1982, J BIOL CHEM, V257, P2180; SUMIKAWA K, 1982, NUCLEIC ACIDS RES, V10, P5809, DOI 10.1093/nar/10.19.5809; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VANOBBERGHENSCHILLING E, 1990, FEBS LETT, V262, P330, DOI 10.1016/0014-5793(90)80221-4; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WORKMAN EF, 1977, J BIOL CHEM, V252, P7118	60	2843	2984	0	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1991	64	6					1057	1068		10.1016/0092-8674(91)90261-V	http://dx.doi.org/10.1016/0092-8674(91)90261-V			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1672265				2022-12-01	WOS:A1991FD55800004
J	WILLIS, WD; KOPPE, JA				WILLIS, WD; KOPPE, JA			BRAIN BROWSER - HYPERCARD APPLICATION FOR THE MACINTOSH	SCIENCE			English	Software Review									UNIV TEXAS,MED BRANCH,INST MARINE BIOMED,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	WILLIS, WD (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANAT & NEUROSCI,GALVESTON,TX 77550, USA.							MACINTOSH HYPERCARD; BRAIN BROWSER	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 22	1991	251	5000					1500	1502		10.1126/science.2006425	http://dx.doi.org/10.1126/science.2006425			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC853	2006425				2022-12-01	WOS:A1991FC85300052
J	ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H				ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H			CLONAL DELETION OF V-BETA 14-BEARING T-CELLS IN MICE TRANSGENIC FOR MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LONG TERMINAL REPEAT; POSITIVE SELECTION; PROVIRAL DNA; MOUSE; RECEPTOR; TOLERANCE; REGION; MLSA; DETERMINANTS	Autoreactive T lymphocytes are clonally deleted during maturation in the thymus. Deletion of T cells expressing particular receptor V-beta elements is controlled by poorly defined autosomal dominant genes. A gene has now been identified by expression of transgenes in mice which causes deletion of V-beta-14+ T cells. The gene lies in the open reading frame of the long terminal repeat of the mouse mammary tumour virus.	UNIV ZURICH,INST IMMUNOL & VIROL,CH-8051 ZURICH,SWITZERLAND; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Zurich; Swiss Institute Experimental Cancer Research	ACHAORBEA, H (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.							ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BERUMEN L, 1983, EUR J IMMUNOL, V13, P292, DOI 10.1002/eji.1830130405; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLOCHLINGER K, 1986, THESIS U LAUSANNE; BUETTI E, 1981, CELL, V23, P335, DOI 10.1016/0092-8674(81)90129-X; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EICHER EM, 1990, GENETICS, V125, P431; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUO WL, 1988, J VIROL, V62, P2394, DOI 10.1128/JVI.62.7.2394-2402.1988; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1989, PROGR IMMUNOLOGY, V7, P561; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MOLINA IJ, 1989, J IMMUNOL, V143, P39; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVERENP, 1988, J VIROL, V62, P4410; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	51	317	323	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					207	211		10.1038/350207a0	http://dx.doi.org/10.1038/350207a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1848685				2022-12-01	WOS:A1991FC77900047
J	CHOI, YW; KAPPLER, JW; MARRACK, P				CHOI, YW; KAPPLER, JW; MARRACK, P			A SUPERANTIGEN ENCODED IN THE OPEN READING FRAME OF THE 3' LONG TERMINAL REPEAT OF MOUSE MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECOGNITION; GENE-PRODUCTS; MLS-LOCUS; REGION; EXPRESSION; RECEPTOR; SEQUENCE; TOLERANCE; ANTIGENS	Mice express a collection of superantigens, which bind to class II major histocompatibility proteins and interact with T cells bearing particular V-beta chains as part of their alpha-beta-receptors. These superantigens have been suggested to be encoded by exogenous or endogenous mouse mammary tumour viruses. One such superantigen is now shown to be encoded in the open reading frame of the long terminal repeat of a mammary tumour virus, a gene of previously unknown function.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, YW (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,DEPT MED,DIV BASIC IMMUNOL,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE AM, 1988, J IMMUNOL, V141, P1369; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CROUSE CA, 1989, VIRUS RES, V12, P123, DOI 10.1016/0168-1702(89)90059-2; DICKSON C, 1981, NATURE, V291, P511, DOI 10.1038/291511a0; DONEHOWER LA, 1983, J VIROL, V45, P941, DOI 10.1128/JVI.45.3.941-949.1983; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HIZI A, 1987, P NATL ACAD SCI USA, V84, P7041, DOI 10.1073/pnas.84.20.7041; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KING LB, 1990, J IMMUNOL, V144, P3218; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T, 1989, DECONTAMINATION DILU; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTINEZ C, 1964, NATURE, V203, P1199; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; RACEVSKIS J, 1984, J VIROL, V51, P604, DOI 10.1128/JVI.51.3.604-610.1984; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SQUARTINI F, 1970, CANCER RES, V30, P2069; TOMONARI K, IN PRESS IMMUNOGENET; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEISS R, 1985, RNA TUMOR VIRUSES, P582; WHITE J, 1989, J IMMUNOL, V143, P1822; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	52	414	419	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					203	207		10.1038/350203a0	http://dx.doi.org/10.1038/350203a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706480				2022-12-01	WOS:A1991FC77900046
J	COOPER, E; COUTURIER, S; BALLIVET, M				COOPER, E; COUTURIER, S; BALLIVET, M			PENTAMERIC STRUCTURE AND SUBUNIT STOICHIOMETRY OF A NEURONAL NICOTINIC ACETYLCHOLINE-RECEPTOR	NATURE			English	Article							AFFINITY BINDING-SITE; FUNCTIONAL EXPRESSION; NONCOMPETITIVE BLOCKERS; H-3 CHLORPROMAZINE; XENOPUS OOCYTES; ALPHA-SUBUNIT; ION CHANNEL; CDNA; BRAIN; SEQUENCE	NEURONAL nicotinic acetylcholine receptors are members of a gene family of ligand-gated transmitter receptors that includes muscle nicotinic receptors, GABA(A) receptors and glycine receptors 1-4. Several lines of evidence indicate that neuronal nicotinic receptors can be made up of only two subunits, an alpha (alpha) subunit which binds ligand, and a non-alpha (n-alpha) or beta (beta) subunit 5-13. The stoichiometry of each subunit in the functional receptor has been difficult to assess, however. Estimates of the molecular weight of neuronal nicotinic receptor macromolecules suggest that these receptors contain at least four subunits but probably not more than five 5,12. We have examined the subunit stoichiometry of the chick neuronal alpha-4/n-alpha-1 receptor 7,9 by first using site-directed mutagenesis to create subunits that confer different single channel properties on the receptor. Co-injection with wild-type and mutant subunits led to the appearance of receptors with wild-type, mutant and hybrid conductances. From the number of hybrid conductances, we could deduce the number of each subunit in the functional receptor.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	COOPER, E (corresponding author), MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1YG,QUEBEC,CANADA.							BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BERTRAND D, 1990, P NATL ACAD SCI USA, V87, P1993, DOI 10.1073/pnas.87.5.1993; BERTRAND D, IN PRESS ELECTROPHYS; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GREENINGLOH G, 1987, NATURE, V328, P215; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KUNDEL TA, 1985, P NATL ACAD SCI USA, V82, P488; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Press W.H., 1986, NUMERICAL RECIPES AR; RAFFERTY MA, 1980, SCIENCE, V208, P1454; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WHITING PJ, 1987, J NEUROSCI, V7, P4005; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	24	416	425	1	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					235	238		10.1038/350235a0	http://dx.doi.org/10.1038/350235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005979	Green Published			2022-12-01	WOS:A1991FC77900059
J	DILLON, N; GROSVELD, F				DILLON, N; GROSVELD, F			HUMAN GAMMA-GLOBIN GENES SILENCED INDEPENDENTLY OF OTHER GENES IN THE BETA-GLOBIN LOCUS	NATURE			English	Article							TRANSGENIC MICE; EXPRESSION	ERYTHROPOIESIS during human development is characterized by switches in expression of beta-like globin genes during the transition from the embryonic through fetal to adult stages. Activation and high-level expression of the genes is directed by the locus control region (LCR), located 5' to the epsilon-gene 1-3. The location of the LCR and its role in directing high-level expression of the globin genes has led to the suggestion that competition from the beta-gene for interaction with the LCR has a major role in silencing the fetal gamma-genes during adult life 4,5. We have now constructed lines of transgenic mice containing the human A-gamma-globin gene linked to the LCR. We observe high-level expression of the transgene in the embryonic stages but silencing of the gene in adult animals. We conclude that the gamma-gene is not deregulated by the presence of the LCR and that competition from the beta-gene is not required for silencing of the gamma-genes in adult life. The silencing is therefore likely to be mediated by stage-specific factors binding to sequences immediately flanking the genes.			DILLON, N (corresponding author), NATL INST MED RES,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.							ANAGNOU NP, 1990, CLIN RES, V38, pA301; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FEINGOLD EA, 1989, BLOOD, V74, P2178; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PONCZ M, 1989, GLOBIN GENE EXPRESSI; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHIH DM, 1990, NUCLEIC ACIDS RES, V18, P5465, DOI 10.1093/nar/18.18.5465; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; Weatherall DJ., 2008, THALASSAEMIA SYNDROM; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596	19	165	167	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					252	254		10.1038/350252a0	http://dx.doi.org/10.1038/350252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706482				2022-12-01	WOS:A1991FC77900065
J	GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC				GASSER, RA; MAGILL, AJ; OSTER, CN; TRAMONT, EC			THE THREAT OF INFECTIOUS-DISEASE IN AMERICANS RETURNING FROM OPERATION DESERT STORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGO HEMORRHAGIC-FEVER; SAUDI-ARABIA; CUTANEOUS LEISHMANIASIS; NOSOCOMIAL OUTBREAK; TYPHOID-FEVER; WILD ANIMALS; CLINICAL EFFICACY; DRUG-RESISTANCE; WESTERN REGION; KUWAIT		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	GASSER, RA (corresponding author), WALTER REED ARMY MED CTR, INFECT DIS SERV, WASHINGTON, DC 20307 USA.							ABDELHAFEZ MMA, 1986, ANN TROP MED PARASIT, V80, P631, DOI 10.1080/00034983.1986.11812078; AHMED M M, 1989, Journal of the Egyptian Society of Parasitology, V19, P583; ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; ALMOFLEH IA, 1990, ANN SAUDI MED, V10, P620, DOI 10.5144/0256-4947.1990.620; ALNAKIB W, 1984, T ROY SOC TROP MED H, V78, P474, DOI 10.1016/0035-9203(84)90065-8; ALORAINEY IO, 1989, TUBERCLE, V70, P207, DOI 10.1016/0041-3879(89)90052-4; ALTIKRITI SK, 1981, B WORLD HEALTH ORGAN, V59, P85; ALTIKRITI SK, 1981, J TROP MED HYG, V84, P117; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P621, DOI 10.1016/0035-9203(89)90376-3; ALZAHRANI MA, 1989, T ROY SOC TROP MED H, V83, P503, DOI 10.1016/0035-9203(89)90267-8; ASHI J, 1989, J TROP MED HYG, V92, P27; ASPERILLA MO, 1990, REV INFECT DIS, V12, P873; AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BADARO R, 1986, LANCET, V1, P647; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BAHMANYAR M, 1972, AM J TROP MED HYG, V21, P123, DOI 10.4269/ajtmh.1972.21.123; BARTELLONI PJ, 1976, AM J TROP MED HYG, V25, P456, DOI 10.4269/ajtmh.1976.25.456; BASSILY S, 1970, T ROY SOC TROP MED H, V64, P723, DOI 10.1016/0035-9203(70)90013-1; BERMAN JD, 1988, REV INFECT DIS, V10, P560; BIENZLE U, 1978, TROPENMED PARASITOL, V29, P188; BURNEY MI, 1980, AM J TROP MED HYG, V29, P941, DOI 10.4269/ajtmh.1980.29.941; CHUGH TD, 1983, TROP GEOGR MED, V35, P37; CHUGH TD, 1985, J HYG-CAMBRIDGE, V95, P391, DOI 10.1017/S0022172400062811; DAMJANOVIC V, 1984, J HYG-CAMBRIDGE, V92, P205, DOI 10.1017/S0022172400064226; EITREM R, 1990, AM J TROP MED HYG, V43, P207, DOI 10.4269/ajtmh.1990.43.207; ELBIHARI S, 1987, TROP MED PARASITOL, V38, P89; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P427; ELHAZMI MAF, 1989, J TROP MED HYG, V92, P56; FARID Z, 1970, J TROP MED HYG, V73, P153; GAMRA EMA, 1983, J EGYPT SOC PARASITO, V13, P227; GILMAN RH, 1975, LANCET, V1, P1211; GUERRACACERES JG, 1979, T ROY SOC TROP MED H, V73, P680, DOI 10.1016/0035-9203(79)90020-8; GUNN RA, 1981, B WORLD HEALTH ORGAN, V59, P61; HATHOUT SED, 1967, AM J TROP MED HYG, V16, P462, DOI 10.4269/ajtmh.1967.16.462; Hertig M., 1964, PREVENTIVE MED WORLD, V7, P109; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; ISLAM A, 1988, J INFECT DIS, V158, P742, DOI 10.1093/infdis/158.4.742; JOPLING WH, 1955, BRIT MED J, V2, P1013, DOI 10.1136/bmj.2.4946.1013-a; KAPLAN M M, 1955, Bull World Health Organ, V13, P829; KARAWYA EM, 1990, ANN SAUDI MED, V10, P165, DOI 10.5144/0256-4947.1990.165; KASIM AA, 1983, ACTA TROP, V40, P155; KASSIMI MA, 1985, J HOSP INFECT, V6, P234; KHAIRY N, 1980, ANN TROP MED PARASIT, V74, P29, DOI 10.1080/00034983.1980.11687307; Khuffash F A, 1982, Ann Trop Paediatr, V2, P123; KIEL FW, 1987, J CLIN MICROBIOL, V25, P1384, DOI 10.1128/JCM.25.8.1384-1387.1987; KILLICKKENDRICK R, 1985, T ROY SOC TROP MED H, V79, P252, DOI 10.1016/0035-9203(85)90350-5; Marrie T. J., 1988, Biology of rickettsial diseases. Volume II., P1; MATOSSIAN RM, 1963, AM J TROP MED HYG, V12, P82, DOI 10.4269/ajtmh.1963.12.82; MCKEE K, 1990, DIAGNOSIS TREATMENT; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; MOORE PS, 1989, LANCET, V2, P260; MOUSA ARM, 1988, REV INFECT DIS, V10, P211; MURPHY C, 1991, WASHINGTON POST 0126, pA1; MURPHY C, 1991, WASHINGTON POST 0126, pA15; NEVES J, 1967, T ROY SOC TROP MED H, V61, P541, DOI 10.1016/0035-9203(67)90105-8; NEVES J, 1969, T ROY SOC TROP MED H, V63, P79, DOI 10.1016/0035-9203(69)90070-4; NOAH MS, 1986, ANN TROP MED PARASIT, V80, P607, DOI 10.1080/00034983.1986.11812075; OLDFIELD EC, 1991, REV INFECT DIS, V13, pS199; PETERS W, 1987, SAUDI MED J, V8, P333; PETERS W, 1988, T ROY SOC TROP MED H, V82, P179, DOI 10.1016/0035-9203(88)90400-2; QADRI MH, 1990, ANN SAUDI MED, V10, P280, DOI 10.5144/0256-4947.1990.280; QADRI SMH, 1989, J NATL MED ASSOC, V81, P1061; RAMIA S, 1987, T ROY SOC TROP MED H, V81, P317, DOI 10.1016/0035-9203(87)90251-3; RAMIA S, 1986, TROP GEOGR MED, V38, P63; RAMIREZ CA, 1985, ANTIMICROB AGENTS CH, V28, P128, DOI 10.1128/AAC.28.1.128; SALIH SY, 1977, J TROP MED HYG, V80, P14; SCHIOTT CR, 1985, SAUDI MED J, V6, P375; SCOTT DA, 1990, T ROY SOC TROP MED H, V84, P288, DOI 10.1016/0035-9203(90)90290-U; SEBAI ZA, 1988, TROP DOCT, V18, P183, DOI 10.1177/004947558801800415; SETHI S K, 1989, Journal of Diarrhoeal Diseases Research, V7, P85; SETHI SK, 1989, PEDIATR INFECT DIS J, V8, P593, DOI 10.1097/00006454-198909000-00005; SHOBOKSHI OA, 1987, T ROY SOC TROP MED H, V81, P219, DOI 10.1016/0035-9203(87)90220-3; SULEIMAN MNEH, 1980, LANCET, V2, P939; TESH RB, 1989, ISRAEL J MED SCI, V25, P214; VANDEWAL BW, 1985, S AFR MED J, V68, P729; VANEEDEN PJ, 1985, S AFR MED J, V68, P718; VANEEDEN PJ, 1985, S AFR MED J, V68, P711; VASSALLO L, 1985, ANN TROP MED PARASIT, V79, P349, DOI 10.1080/00034983.1985.11811931; WATTS DM, 1989, AM J TROP MED HYG, V41, P581, DOI 10.4269/ajtmh.1989.41.581; WEINRAUCH L, 1987, BRIT J DERMATOL, V117, P666, DOI 10.1111/j.1365-2133.1987.tb07504.x; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680; YOUSIF AA, 1989, J BAHRAIN MED SOC, V1, P52; 1985, WHO TECH REP SER, V721, P1; 1990, MED LETT DRUGS THER, V32, P23; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WKLY EPIDEMIOL REC, V65, P321; 1987, MMWR, V36, P559; 1990, WKLY EPIDEMIOL REC, V65, P337	89	41	41	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					859	864		10.1056/NEJM199103213241229	http://dx.doi.org/10.1056/NEJM199103213241229			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997866	Bronze			2022-12-01	WOS:A1991FC44200036
J	HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A				HASTY, P; RAMIREZSOLIS, R; KRUMLAUF, R; BRADLEY, A			INTRODUCTION OF A SUBTLE MUTATION INTO THE HOX-2.6 LOCUS IN EMBRYONIC STEM-CELLS	NATURE			English	Article							GERM-LINE TRANSMISSION; HOMOLOGOUS RECOMBINATION; ES CELLS; GENE; EXPRESSION; MURINE; ORGANIZATION; DISRUPTION; REGIONS	GENE targeting in embryonic stem (ES) cells is a powerful tool for generating mice with null alleles 1. Current methods of gene inactivation in ES cells introduce a neomycin gene (neo) cassette both as a mutagen and a selection marker for transfected cells 2-11. Although null alleles are valuable, changes at the nucleotide level of a gene are very important for functional analysis. One gene family in which subtle mutations would be particularly valuable are the clusters of Hox homeobox genes 12-16. Inactivation of genes in a cluster with a neo cassette that includes promoter/enhancer elements may deregulate transcription of neighbouring genes and generate a phenotype which is difficult to interpret. We describe here a highly efficient gene targeting method, termed the 'hit and run' procedure. This generates ES cells with subtle site-specific mutations with no selectable marker and may be useful for most genes. We have developed this procedure at the hypoxanthine phosphoribosyltransferase (hprt) locus and subsequently isolated ES cells with a premature stop codon in the homeobox of Hox-2.6 (ref. 14).	BAYLOR UNIV, INST MOLEC GENET, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Baylor College of Medicine; Baylor University; MRC National Institute for Medical Research			Krumlauf, Robb/AAH-5012-2019	Krumlauf, Robb/0000-0001-9102-7927; Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X; Hasty, Paul/0000-0003-3046-0131				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAKER MD, 1988, P NATL ACAD SCI USA, V85, P6432, DOI 10.1073/pnas.85.17.6432; BAKER MD, 1989, MOL CELL BIOL, V9, P5500, DOI 10.1128/MCB.9.12.5500; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIMMER A, 1989, NATURE, V338, P150, DOI 10.1038/338150a0	27	265	301	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					243	246		10.1038/350243a0	http://dx.doi.org/10.1038/350243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672446				2022-12-01	WOS:A1991FC77900062
J	HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM				HYMAN, C; HOFER, M; BARDE, YA; JUHASZ, M; YANCOPOULOS, GD; SQUINTO, SP; LINDSAY, RM			BDNF IS A NEUROTROPHIC FACTOR FOR DOPAMINERGIC-NEURONS OF THE SUBSTANTIA-NIGRA	NATURE			English	Article							INVITRO MATURATION; MESENCEPHALIC NEURONS; GROWTH-FACTOR; CELLS; SURVIVAL; BRAIN; CULTURES; DENSITY; MPTP	Brain-derived neurotrophic factor (BDNF), present in minute amounts in the adult central nervous system 1, is a member of the nerve growth factor (NGF) (ref. 2) family, which includes neurotrophin-3 (NT-3) (refs 3-5). NGF, BDNF and NT-3 all support survival of subpopulations of neural crest-derived sensory neurons 3-5; most sympathetic neurons are responsive to NGF (ref. 2), but not to BDNF 1,6,7; NT-3 and BDNF, but not NGF (ref. 6), promote survival of sensory neurons of the nodose ganglion 3-8. BDNF, but not NGF, supports the survival of cultured retinal ganglion cells 9 but both NGF and BDNF promote the survival of septal cholinergic neurons in vitro 10,11. However, knowledge of their precise physiological role in development and maintenance of the nervous system neurons is still limited. The BDNF gene is expressed in many regions of the adult CNS 12-14, including the striatum 12. A protein partially purified from bovine striatum, a target of nigral dopaminergic neurons, with characteristics apparently similar to those of BDNF, can enhance the survival of dopaminergic neurons in mesencephalic cultures 15. BDNF seems to be a trophic factor for mesencephalic dopaminergic neurons, increasing their survival, including that of neuronal cells which degenerate in Parkinson's disease. Here we report the effects of BDNF on the survival of dopaminergic neurons of the developing substantia nigra.	MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, W-8033 PLANEGG, GERMANY	Max Planck Society	HYMAN, C (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Lindsay, Ronald/GQP-8001-2022; Barde, Yves/F-6019-2011	Barde, Yves/0000-0002-7627-461X				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; DALTOSO R, 1988, J NEUROSCI, V8, P733; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DENISDONINI S, 1983, J NEUROSCI, V3, P2292; DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0; FERRARI G, 1989, DEV BIOL, V133, P140, DOI 10.1016/0012-1606(89)90305-9; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; KNUSEL B, 1990, J NEUROSCI, V10, P558; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MICHEL PP, 1990, J NEUROCHEM, V54, P1102, DOI 10.1111/j.1471-4159.1990.tb01935.x; OTTO D, 1990, J NEUROSCI, V10, P1912; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; PROCHIANTZ A, 1979, P NATL ACAD SCI USA, V76, P5387, DOI 10.1073/pnas.76.10.5387; PROCHIANTZ A, 1981, NATURE, V293, P570, DOI 10.1038/293570a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SANCHEZRAMOS J, 1986, NEUROSCI LETT, V72, P215, DOI 10.1016/0304-3940(86)90083-2; SANCHEZRAMOS JR, 1988, J NEUROCHEM, V50, P1934, DOI 10.1111/j.1471-4159.1988.tb02500.x; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANCOPOULOS GD, IN PRESS COLD SPRING; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	34	1330	1377	4	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1991	350	6315					230	232		10.1038/350230a0	http://dx.doi.org/10.1038/350230a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005978				2022-12-01	WOS:A1991FC77900057
J	LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP				LIPSHULTZ, SE; COLAN, SD; GELBER, RD; PEREZATAYDE, AR; SALLAN, SE; SANDERS, SP			LATE CARDIAC EFFECTS OF DOXORUBICIN THERAPY FOR ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTHRACYCLINE CARDIOTOXICITY; INTENSIVE ASPARAGINASE; BICYCLE EXERCISE; CHILDREN; ADRIAMYCIN; GROWTH; INDUCTION; TREADMILL; FAILURE; HEART	Background. Cardiotoxicity is a recognized complication of doxorubicin therapy, but the long-term effects of doxorubicin are not well documented. We therefore-assessed the cardiac status of 115 children who had been treated for acute lymphoblastic leukemia with doxorubicin 1 to 15 years earlier in whom the disease was in continuous remission. Methods. Eighteen patients received one dose of doxorubicin (45 mg per square meter of body-surface area), and 97 received multiple doses totaling 228 to 550 mg per square meter (median, 360). The median interval between the end of treatment and the cardiac evaluation was 6.4 years. Our evaluation consisted of a history, 24-hour ambulatory electrocardiographic recording, exercise testing, and echocardiography. Results. Fifty-seven percent of the patients had abnormalities of left ventricular afterload (measured as end-systolic wall stress) or contractility (measured as the stress-velocity index). The cumulative dose of doxorubicin was the most significant predictor of abnormal cardiac function (P < 0.002). Seventeen percent of patients who received one dose of doxorubicin had slightly elevated-age-adjusted afterload, and none had decreased contractility. In contrast, 65 percent of patients who received at least 228 mg of doxorubicin per square meter had increased afterload (59 percent of patients), decreased contractility (23 percent), or both. Increased afterload was due to reduced ventricular wall thickness, not to hypertension or ventricular dilatation. In multivariate analyses restricted to patients who received at least 228 mg of doxorubicin per square meter, the only significant predictive factors were a higher cumulative dose (P = 0.01), which predicted decreased contractility, and an age of less than four years at treatment (P = 0.003), which predicted increased afterload. Afterload increased progressively in 24 of 34 patients evaluated serially (71 percent). Reported symptoms correlated poorly with indexes of exercise tolerance or ventricular function. Eleven patients had congestive heart failure within one year of treatment with doxorubicin; five of them had recurrent heart failure 3.7 to 10.3 years after completing doxorubicin treatment, and two required heart transplantation. No patient had late heart failure as a new event. Conclusions. Doxorubicin therapy in childhood impairs myocardial growth in a dose-related fashion and results in a progressive increase in left ventricular afterload, sometimes accompanied by reduced contractility. We hypothesize that the loss of myocytes during doxorubicin therapy in childhood might result in inadequate left ventricular mass and clinically important heart disease in later years.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NCI NIH HHS [CA34183, CA06516] Funding Source: Medline; NHLBI NIH HHS [HL01816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034183, P30CA006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOROW KM, 1985, CIRCULATION, V72, P515, DOI 10.1161/01.CIR.72.3.515; BRISTOW MR, 1978, AM J MED, V65, P823, DOI 10.1016/0002-9343(78)90802-1; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BRUCE R A, 1963, Pediatrics, V32, P742; CAULFIELD JB, 1988, AM J PATHOL, V133, P298; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; CLUBB FJ, 1987, LAB INVEST, V56, P189; CLUBB FJ, 1984, LAB INVEST, V50, P571; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; CUMMING GR, 1978, AM J CARDIOL, V41, P69, DOI 10.1016/0002-9149(78)90134-0; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; FURMAN L, 1976, Medical and Pediatric Oncology, V2, P157, DOI 10.1002/mpo.2950020205; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; JAMES FW, 1980, CIRCULATION, V61, P902, DOI 10.1161/01.CIR.61.5.902; KANTROWITZ NE, 1984, PROG CARDIOVASC DIS, V27, P195, DOI 10.1016/0033-0620(84)90004-5; KOH E, 1988, PEDIATR HEMAT ONCOL, V5, P245, DOI 10.3109/08880018809031275; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEWIS AB, 1978, MED PEDIATR ONCOL, V5, P167, DOI 10.1002/mpo.2950050123; LIPSHULTZ SE, 1990, PEDIATR RES, V27, pA145; LIPSHULTZ SE, 1989, AM J CARDIOL, V64, P416; LIPSHULTZ SE, 1989, PEDIATR RES S, V25, pA53; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; LOWN B, 1977, AM J CARDIOL, V39, P910, DOI 10.1016/S0002-9149(77)80046-5; NAG AC, 1980, CYTOBIOS, V28, P41; Riehm H, 1990, Haematol Blood Transfus, V33, P439; SALLAN SE, 1978, BLOOD, V51, P425; SALLAN SE, 1983, CANCER RES, V43, P5601; SALLAN SE, 1989, BLOOD S, V74, pA79; SALLAN SE, 1984, LEUKAMIEBEHANDLUNG K, P35; STEINHERZ LJ, 1988, AM J CARDIOL, V62, P505; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WETHERBEE JN, 1988, J AM COLL CARDIOL, V11, P330, DOI 10.1016/0735-1097(88)90098-8; ZAK R, 1974, CIRC RES, V35, P17	37	1095	1113	1	45	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					808	815		10.1056/NEJM199103213241205	http://dx.doi.org/10.1056/NEJM199103213241205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997853	Bronze			2022-12-01	WOS:A1991FC44200005
J	LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; JOHNSTON, LH			COORDINATION OF EXPRESSION OF DNA-SYNTHESIS GENES IN BUDDING YEAST BY A CELL-CYCLE REGULATED TRANS FACTOR	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; PERIODIC TRANSCRIPTION; GEL-ELECTROPHORESIS; LIGASE GENES; CDC9; IDENTIFICATION; ACTIVATION; SEQUENCES; BINDING	ALL of the DNA synthesis genes of budding yeast examined so far are periodically expressed and hence under cell-cycle control (Table 1). Expression occurs near the G1/S phase boundary and the genes seem to be coordinately regulated (reviewed in ref. 4). The upstream promoter sequences of these genes have only a hexamer element, ACGCGT (an MluI restriction site), in common. Here we show that this hexamer is able to impart periodic expression to a heterologous gene and, significantly, this expression occurs coincidentally with that of CDC9, one of the DNA synthesis genes (Table 1). We have also identified a protein that binds specifically to these sequences in a similar periodic manner. These ACGCGT sequences and the transcription factor that binds to them therefore seem to be the elements controlling both the periodic expression and coordinate regulation of the DNA synthesis genes.	NATL INST MED RES,CELL PROPAGAT LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427				ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARTISHEVSKY A, 1987, NATURE, V328, P822; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BARKER DG, 1985, MOL GEN GENET, V200, P458, DOI 10.1007/BF00425731; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSON AL, 1986, CURR GENET, V11, P107, DOI 10.1007/BF00378201; Johnston LH, 1990, CURR OPIN CELL BIOL, V2, P274, DOI 10.1016/0955-0674(90)90019-B; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; JOHNSTON LH, 1990, MOL GEN GENET, V221, P44, DOI 10.1007/BF00280366; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Osley M. A., 1987, MOL CELL BIOL, V7, P4202; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WHITE JHM, 1988, THESIS COUNCIL NATIO	27	185	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					247	250		10.1038/350247a0	http://dx.doi.org/10.1038/350247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005980				2022-12-01	WOS:A1991FC77900063
J	MACKINNON, R				MACKINNON, R			DETERMINATION OF THE SUBUNIT STOICHIOMETRY OF A VOLTAGE-ACTIVATED POTASSIUM CHANNEL	NATURE			English	Article							CHARYBDOTOXIN BLOCK; K+ CHANNELS; DROSOPHILA; INHIBITOR; JUNCTION	The voltage-activated K+, Na+ and Ca2+ channels are responsible for the generation and propagation of electrical signals in cell membranes. The K+ channels are multimeric membrane proteins formed by the aggregation of an unknown number of independent subunits 1-3. By studying the interaction of a scorpion toxin with coexpressed wild-type and toxin-insensitive mutant Shaker K+ channels, the subunit stoichiometry can be determined. The Shaker K+ channel is found to have a tetrameric structure. This is consistent with the sequence relationship between a K+ channel and each of the four internally homologous repeats of Na+ and Ca2+ channels 4-6.			MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115, USA.							AGNEW WS, 1988, NATURE, V331, P114, DOI 10.1038/331114a0; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1990, NEURON, V2, P405; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Hille B, 1984, IONIC CHANNELS EXCIT, P426; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MASSEFSKI W, 1990, SCIENCE, V249, P449; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OLIVA C, 1991, Biophysical Journal, V59, p450A; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3	23	808	825	0	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					232	235		10.1038/350232a0	http://dx.doi.org/10.1038/350232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1706481				2022-12-01	WOS:A1991FC77900058
J	RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M				RUDEN, DM; MA, J; LI, Y; WOOD, K; PTASHNE, M			GENERATING YEAST TRANSCRIPTIONAL ACTIVATORS CONTAINING NO YEAST PROTEIN SEQUENCES	NATURE			English	Article								WE previously reported that roughly 1% of the short peptides encoded by Escherichia coli genomic DNA fragments act as transcriptional activating regions in yeast when fused to GAL4(1-147), a DNA-binding portion of the yeast transcriptional activator GAL4 (ref. 1). Struhl questioned the conclusion that we had identified new transcriptional activating sequences that function in the absence of yeast transcriptional activating sequences 2. His criticism was based on two considerations: first, GAL4(1-147) contains an acidic segment (and subsequent experiments have shown that this region contains a weak activating region in vitro 3); second, attempts to isolate new activating regions failed when the DNA-binding domain of a bacterial repressor, LexA(1-87), was used as the DNA-binding unit 2. We report here a repeat of our original experiment using the complete LexA molecule LexA(1-202) as the DNA-binding region, instead of GAL4(1-147) or LexA(1-87). We find that, as in the original experiment, about 1% of the short peptides encoded by E. coli genomic fragments act as transcriptional activating regions when fused to intact LexA. All of the new activating regions whose sequences we determined bore an excess of acidic amino acids (see Table 1).	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138	Harvard University			Ma, Jun/GLT-4809-2022; Ruden, Douglas/A-5008-2016; Ruden, Douglas/ABE-1418-2021	Ma, Jun/0000-0002-1609-3294; Ruden, Douglas/0000-0002-0070-437X; 				BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0	8	136	143	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					250	252		10.1038/350250a0	http://dx.doi.org/10.1038/350250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	2005981				2022-12-01	WOS:A1991FC77900064
J	VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S				VOLLBRECHT, E; VEIT, B; SINHA, N; HAKE, S			THE DEVELOPMENTAL GENE KNOTTED-1 IS A MEMBER OF A MAIZE HOMEOBOX GENE FAMILY	NATURE			English	Article							DROSOPHILA; ANTENNAPEDIA; EXPRESSION; PROTEINS; HOMEODOMAIN; TRANSCRIPTS; SEQUENCES; REGION; LOCUS	THE Knotted-1 (Kn1) locus is defined by several dominant gain-of-function mutations that alter leaf development. Foci of cells along the lateral veins do not differentiate properly, but continue to divide, forming outpocketings or knots. The ligule, a fringe normally found at the junction of leaf blade and sheath, is often displaced and perpendicular to its normal position 1-3. The phenotype is manifested in all cell layers of the leaf blade, but is controlled by a subgroup of cells of the inner layer 4. Mutations result from the insertion of transposable elements 5 or a tandem duplication 6. We show that the Kn1 gene encodes a homeodomain-containing protein, the first identified in the plant kingdom. Sequence comparisons strongly suggest that Kn1 acts as a transcription factor. Here we use the Kn1 homeobox to isolate other expressed homeobox genes in maize. The Kn1 homeobox may permit the isolation of genes that, like animal and fungal counterparts 7, regulate cell fate determination.	USDA ARS,CTR PLANT GENE EXPRESS,800 BUCHANAN ST,ALBANY,CA 94710; UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	United States Department of Agriculture (USDA); University of California System; University of California Berkeley				Sinha, Neelima/0000-0002-1494-7065; Vollbrecht, Erik/0000-0003-4919-1365				Bryan AA, 1941, J HERED, V32, P343, DOI 10.1093/oxfordjournals.jhered.a104959; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FREELING M, 1985, GENETICS, V111, P617; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GELINAS D, 1969, AM J BOT, V56, P671, DOI 10.2307/2440442; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAKE S, 1985, PLANT GENETICS, P61; HANLEY BA, 1988, NUCLEIC ACIDS RES, V16, P7159, DOI 10.1093/nar/16.14.7159; HARDING K, 1986, SCIENCE, V233, P953, DOI 10.1126/science.3755551; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LANGDALE JA, 1989, DEV BIOL, V133, P128, DOI 10.1016/0012-1606(89)90304-7; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SINHA N, 1990, DEV BIOL, V141, P203, DOI 10.1016/0012-1606(90)90115-Y; VEIT B, 1990, GENETICS, V125, P623; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	34	571	631	3	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					241	243		10.1038/350241a0	http://dx.doi.org/10.1038/350241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1672445				2022-12-01	WOS:A1991FC77900061
J	WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI				WIERSMA, SR; ORTEGA, J; SOBEL, E; WEINBERG, KI			CLINICAL IMPORTANCE OF MYELOID-ANTIGEN EXPRESSION IN ACUTE LYMPHOBLASTIC-LEUKEMIA OF CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CANCER-STUDY-GROUP; PROGNOSTIC-SIGNIFICANCE; LINEAGE LEUKEMIA; DISCRETE STAGES; DIFFERENTIATION; LYMPHOMA; CLASSIFICATION; TRANSLOCATION; PHENOTYPES; PROTOCOL	Background. Leukemic cells in 15 to 25 percent of patients with acute lymphoblastic leukemia (ALL) express myeloid antigens as well as lymphoid antigens (the latter reflecting B-cell or T-cell lineage). The relations of myeloid-antigen expression to other features of ALL and to prognosis have been controversial. Methods. We analyzed clinical and laboratory features present at diagnosis in 236 consecutive cases of ALL in children. Immunophenotyping, including single- and dual-fluorescence analyses, was used to classify leukemic cells as B or T lymphoblasts and also to identify myeloid-antigen expression - the simultaneous expression of lymphoid-associated antigens and at least one of three myeloid-associated antigens and at least one of three myeloid-associated antigens (CD33, CD13, and CD14) on cells classified as L1 or L2 according to the French-American-British system. Results. Forty-five of 185 patients with B-lineage ALL had myeloid-antigen expression, as did 8 of 41 patients with T-lineage ALL. In 10 patients, the lineage could not be determined. Myeloid-antigen expression was associated with L2 morphology (P < 0.05), but it did not correlate with other prognostic features recognized previously. Multivariate analysis showed that myeloid-antigen expression was an important predictor of relapse in childhood ALL and the most significant prognostic factor statistically (P < 0.0001). A white-cell count greater-than-or-equal-to 50 x 10(9) per liter at diagnosis was also an important and highly significant prognostic feature (P < 0.001). After 40 months, the estimated disease-free survival for patients with ALL was 84 percent for those without myeloid-antigen expression and with a low white-cell count, 57 percent for those without myeloid-antigen expression and with a high white-cell count, 47 percent for those with myeloid-antigen expression and a low white-cell count, and 26 percent for those with myeloid-antigen expression and a high white-cell count (P < 0.00001). Conclusions. Myeloid-antigen expression is an important independent predictor of a poor response to chemotherapy in childhood ALL.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90089; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California								ARTHUR DC, 1982, BLOOD, V59, P96; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1986, MED PEDIATR ONCOL, V14, P271, DOI 10.1002/mpo.2950140506; CIVIN CI, 1990, EXP HEMATOL, V18, P461; COX DR, 1972, J R STAT SOC B, V34, P187; CROCE CM, 1985, BLOOD, V65, P1; DUQUEHAMMERSHAIMB L, 1983, CANCER, V52, P39, DOI 10.1002/1097-0142(19830701)52:1<39::AID-CNCR2820520109>3.0.CO;2-S; FOON KA, 1986, BLOOD, V68, P1; GAYNON P, 1985, P AM SOC CLIN ONCOL, V4, P173; GAYNON PS, 1988, LANCET, V2, P921; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GREAVES MF, 1986, BLOOD, V67, P1; GRIESINGER F, 1989, J EXP MED, V169, P1101, DOI 10.1084/jem.169.3.1101; HANECAK R, 1989, MOL CELL BIOL, V9, P2264, DOI 10.1128/MCB.9.5.2264; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERSEY JH, 1979, AM J CLIN PATHOL, V72, P746; LAWLESS JF, 1982, STATISTICAL MODELS M; MCCULLOCH EA, 1983, BLOOD, V62, P1; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MIRRO J, 1985, BLOOD, V66, P1115; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; NEAME PB, 1985, BLOOD, V65, P142; PUI CH, 1990, BLOOD, V75, P198; PUI CH, 1984, BRIT J HAEMATOL, V56, P121, DOI 10.1111/j.1365-2141.1984.tb01277.x; REAMAN G, 1989, P AN M AM SOC CLIN, V8, P211; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIEHM H, 1983, LEUKEMIA RES ADV CEL, P251; ROBISON LL, 1980, AM J PEDIAT HEMATOL, V2, P5; SALLAN SE, 1980, BLOOD, V55, P395; SMITH LJ, 1983, BLOOD, V61, P1138; SOBOL RE, 1987, NEW ENGL J MED, V316, P111; STASS S, 1984, BLOOD, V64, P701; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; STOCKINGER H, 1984, J NATL CANCER I, V73, P7	36	172	176	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 21	1991	324	12					800	808		10.1056/NEJM199103213241204	http://dx.doi.org/10.1056/NEJM199103213241204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC442	1997852				2022-12-01	WOS:A1991FC44200004
J	EDDY, DM				EDDY, DM			THE INDIVIDUAL VS SOCIETY - IS THERE A CONFLICT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,DURHAM,NC 27706	Duke University								CANELLOS GP, 1990, J CLIN ONCOL, V8, P1775, DOI 10.1200/JCO.1990.8.11.1775; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1161, DOI 10.1001/jama.264.9.1161; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1169; EDDY DM, 1986, NCI MONOGRAPHS, V2, P75; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1165; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1170	7	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1446	&		10.1001/jama.265.11.1446	http://dx.doi.org/10.1001/jama.265.11.1446			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999888				2022-12-01	WOS:A1991FB55000029
J	GREENBERGER, PA				GREENBERGER, PA			ALLERGY TO SULFA DRUGS WITH POSTCOITAL URTICARIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				GREEN RL, 1985, JAMA-J AM MED ASSOC, V254, P531, DOI 10.1001/jama.254.4.531; SELL MB, 1985, AM J PSYCHIAT, V142, P271	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999889				2022-12-01	WOS:A1991FB55000031
J	JABLON, S; HRUBEC, Z; BOICE, JD				JABLON, S; HRUBEC, Z; BOICE, JD			CANCER IN POPULATIONS LIVING NEAR NUCLEAR-FACILITIES - A SURVEY OF MORTALITY NATIONWIDE AND INCIDENCE IN 2 STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD LEUKEMIA; POWER PLANT; INSTALLATIONS; PATTERNS; VICINITY; SITES	Reports from the United Kingdom have described increases in leukemia and lymphoma among young persons living near certain nuclear installations. Because of concerns raised by these reports, a mortality survey was conducted in populations living near nuclear facilities in the United States. All facilities began service before 1982. Over 900 000 cancer deaths occurred from 1950 through 1984 in 107 counties with or near nuclear installations. Each study county was matched for comparison to three "control counties" in the same region. There were 1.8 million cancer deaths in the 292 control counties during the 35 years studied. Deaths due to leukemia or other cancers were not more frequent in the study counties than in the control counties. For childhood leukemia mortality, the relative risk comparing the study counties with their controls before plant start-up was 1.08, while after start-up it was 1.03. For leukemia mortality at all ages, the relative risks were 1.02 before start-up and 0.98 after. For counties in two states, cancer incidence data were also available. For one facility, the standardized registration ratio for childhood leukemia was increased significantly after start-up. However, the increase also antedated the operation of this facility. The study is limited by the correlational approach and the large size of the geographic areas (counties) used. It does not prove the absence of any effect. If, however, any excess cancer risk was present in US counties with nuclear facilities, it was too small to be detected with the methods employed.			JABLON, S (corresponding author), NCI,RADIAT EPIDEMIOL BRANCH,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BLOT WJ, 1978, NEW ENGL J MED, V299, P620, DOI 10.1056/NEJM197809212991202; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CLAPP RW, 1987, LANCET, V2, P1324; CLARKE EA, 1989, CHILDHOOD LEUKAEMIA; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; COOKMOZAFFARI PJ, 1987, CANCER INCIDENCE MOR; CRUMP KS, 1987, AM J EPIDEMIOL, V126, P127, DOI 10.1093/oxfordjournals.aje.a114644; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DOUSSET M, 1989, HEALTH PHYS, V56, P875, DOI 10.1097/00004032-198906000-00005; ENSTROM JE, 1983, AM J PUBLIC HEALTH, V73, P83, DOI 10.2105/AJPH.73.1.83; EWINGS PD, 1989, BRIT MED J, V299, P289, DOI 10.1136/bmj.299.6694.289; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HEASMAN MA, 1986, LANCET, V1, P266; HILL C, 1990, NATURE, V347, P755, DOI 10.1038/347755a0; JABLON S, 1990, NIH90874 PHS DEP HLT; Kemeny JohnG., 1979, REPORT PRESIDENTS CO; KINLEN L, 1988, LANCET, V2, P1323; RIGGAN WB, 1983, US CANCER MORTALITY; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; VIEL JF, 1990, BRIT MED J, V300, P580, DOI 10.1136/bmj.300.6724.580; 1989, 3RD REPORT INCIDENCE; 1988, 2ND REPORT INVESTIGA; 1984, INVESTIGATION POSSIB; 1986, 1ST REPORT IMPLICATI; 1987, NCRP92 NAT COUNC RAD; 1990, PNL7410 HEDR DOC	30	78	79	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1403	1408						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB550	1999880				2022-12-01	WOS:A1991FB55000020
J	LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP				LESTINA, DC; WILLIAMS, AF; LUND, AK; ZADOR, P; KUHLMANN, TP			MOTOR-VEHICLE CRASH INJURY PATTERNS AND THE VIRGINIA SEAT-BELT LAW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SAFETY BELTS; SEVERITY; CARE	Injuries to front seat occupants in tow-away crashes in the Charlottesville, Va, area were compared for 1 year before and 1 year after Virginia's seat belt use law took effect. Vehicle and occupant data were combined to examine crash and injury patterns. Reported seat belt use in crashes increased after the law, and there were substantial decreases in injuries. Front seat occupants were less likely to receive medical treatment following a crash in the postlaw period. The reduction in the number of injuries was greater for passengers in the right front seat than for drivers and for frontal crashes than for other types of crashes. The injury reduction effects occurred primarily through reductions in the number of head and face injuries, particularly those that occur from contact with windshields and instrument panels.	INSURANCE INST HIGHWAY SAFETY,ARLINGTON,VA; UNIV VIRGINIA,EMERGENCY MED SERV,CHARLOTTESVILLE,VA 22903	University of Virginia								BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARANCIK JI, 1988, B NEW YORK ACAD MED, V64, P742; BERNSTEIN E, 1989, AM J EMERG MED, V7, P271, DOI 10.1016/0735-6757(89)90168-X; Campbell B, 1988, PREVENTING AUTOMOBIL, P24; CAMPBELL BJ, 1987, J TRAUMA, V27, P733, DOI 10.1097/00005373-198707000-00007; CRUBUIB JD, 1975, ACCIDENT ANAL PREV, V7, P81; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; GLOYNS PF, 1990, 12TH P EXP SAF C WAS, P529; LUND AK, 1987, SAE870224 SOC AUT EN; ORSAY EM, 1988, JAMA-J AM MED ASSOC, V260, P3598, DOI 10.1001/jama.260.24.3598; Partyka SC, 1990, COMP BELT EFFECTIVEN; Preusser D F, 1986, J Public Health Policy, V7, P470, DOI 10.2307/3342236; RUTHERFORD WH, 1985, MED EFFECTS SEAT BEL; SAALBERG JH, 1990, IMPACT MICHIGAN SAFE; SKINNER D, 1988, DOTTSC81570PM885 NAT; STATES JD, 1989, 33RD P AM ASS AUT ME, P265; WILLIAMS AF, 1988, PREVENTING AUTOMOBIL, P51; 1986, NASS DATA COLLECTION; 1988, INSURANCE INJURY LOS; 1985, SAS USERS GUIDE STAT; 1982, COLLISION DEFORMATIO; 1985, COMPULSORY SEAT BELT; 1985, ABBREVIATED INJURY S	23	23	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1409	1413		10.1001/jama.265.11.1409	http://dx.doi.org/10.1001/jama.265.11.1409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999881				2022-12-01	WOS:A1991FB55000021
J	MEADOR, CK				MEADOR, CK			A LAMENT FOR INVALIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Pickering GW., 1974, CREATIVE MALADY ILLN; WHEELER EO, 1950, JAMA-J AM MED ASSOC, V142, P878, DOI 10.1001/jama.1950.02910300016005	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1374	1375		10.1001/jama.265.11.1374	http://dx.doi.org/10.1001/jama.265.11.1374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999875				2022-12-01	WOS:A1991FB55000008
J	SAVITZ, DA				SAVITZ, DA			POWER-LINES AND CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SAVITZ, DA (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,CHAPEL HILL,NC 27514, USA.		Savitz, David A/I-2211-2014					AHLBOM A, 1988, SCAND J WORK ENV HEA, V14, P337, DOI 10.5271/sjweh.1909; COLEMAN M, 1988, INT J EPIDEMIOL, V17, P1, DOI 10.1093/ije/17.1.1; MORGAN M, 1988, PUBLIC UTILITIES MAR, P49; WILSON BW, 1990, EXTREMELY LOW FREQUE	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1458	1458						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999890				2022-12-01	WOS:A1991FB55000030
J	WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL				WING, S; SHY, CM; WOOD, JL; WOLF, S; CRAGLE, DL; FROME, EL			MORTALITY AMONG WORKERS AT OAK RIDGE NATIONAL LABORATORY - EVIDENCE OF RADIATION EFFECTS IN FOLLOW-UP THROUGH 1984	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RATES; COHORT; MISCLASSIFICATION; SELECTION; SURVIVAL; EXPOSURE; PLANT	White men hired at the Oak Ridge (Tenn) National Laboratory between 1943 and 1972 were followed up for vital status through 1984 (N = 8318, 1524 deaths). Relatively low mortality compared with that in US white men was observed for most causes of death, but leukemia mortality was elevated in the total cohort (63% higher, 28 deaths) and in workers who had at some time been monitored for internal radionuclide contamination (123% higher, 16 deaths). Median cumulative dose of external penetrating radiation was 1.4 mSv; 638 workers had cumulative doses above 50 mSv (5 rem). After accounting for age, birth cohort, a measure of socioeconomic status, and active worker status, external radiation with a 20-year exposure lag was related to all causes of death (2.68% increase per 10 mSv) primarily due to an association with cancer mortality (4.94% per 10 mSv). Studies of this population through 1977 did not find radiation-cancer mortality associations, and identical analyses using the shorter follow-up showed that associations with radiation did not appear until after 1977. The radiation-cancer dose response is 10 times higher than estimates from the follow-up of survivors of the bombings of Hiroshima and Nagasaki, Japan, but similar to one previous occupational study. Dose-response estimates are subject to uncertainties due to potential problems, including measurement of radiation doses and cancer outcomes. Longer-term follow-up of this and other populations with good measurement of protracted low-level exposures will be critical to evaluating the generalizability of the results reported herein.	OAK RIDGE TENN ASSOCIATED UNIV,CTR EPIDEMIOL RES,OAK RIDGE,TN; OAK RIDGE NATL LAB,MATH SCI SECT,OAK RIDGE,TN 37830	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory	WING, S (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CB 7400,CHAPEL HILL,NC 27599, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; AXELSON O, 1989, BRIT J IND MED, V46, P505; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHECKOWAY H, 1985, BRIT J IND MED, V42, P525; CLAPP RW, 1987, LANCET, V2, P1324; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; DEVESA SS, 1989, J NATL CANCER I, V81, P1568, DOI 10.1093/jnci/81.20.1568; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILBERT ES, 1990, AM J EPIDEMIOL, V131, P917, DOI 10.1093/oxfordjournals.aje.a115581; GILBERT ES, 1983, BIOMETRICS, V39, P161, DOI 10.2307/2530816; GILBERT ES, 1989, RADIAT RES, V120, P19, DOI 10.2307/3577633; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; LAND CE, 1980, SCIENCE, V209, P1197, DOI 10.1126/science.7403879; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; MCMICHAEL AJ, 1976, J OCCUP ENVIRON MED, V18, P165, DOI 10.1097/00043764-197603000-00009; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORRIS M, 1990, INVESTIGATION LEUKEM; PEARCE N, 1986, SCAND J WORK ENV HEA, V12, P97, DOI 10.5271/sjweh.2161; SHORE RE, 1990, HEALTH PHYS, V59, P63, DOI 10.1097/00004032-199007000-00007; SHY CM, 1978, B NEW YORK ACAD MED, V54, P1155; TORNQVIST L, 1985, AM STAT, V39, P43, DOI 10.2307/2683905; UPTON AC, 1990, JNCI-J NATL CANCER I, V82, P448, DOI 10.1093/jnci/82.6.448; WILCOSKY T, 1987, SCAND J WORK ENV HEA, V13, P70, DOI 10.5271/sjweh.2078; WING S, 1988, AM J PUBLIC HEALTH, V78, P1415, DOI 10.2105/AJPH.78.11.1415; WOOLHANDLER S, 1985, LANCET, V1, P1375; 1985, NIH852748 PUBL	29	153	156	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1397	1402		10.1001/jama.265.11.1397	http://dx.doi.org/10.1001/jama.265.11.1397			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1999879				2022-12-01	WOS:A1991FB55000019
J	BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ				BERAL, V; BULL, D; JAFFE, H; EVANS, B; GILL, N; TILLETT, H; SWERDLOW, AJ			IS RISK OF KAPOSIS-SARCOMA IN AIDS PATIENTS IN BRITAIN INCREASED IF SEXUAL PARTNERS CAME FROM UNITED-STATES OR AFRICA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the risk of Kaposi's sarcoma in patients with AIDS is increased by sexual contact with groups from abroad with a high incidence of Kaposi's sarcoma. Design-Analysis of data on patients with AIDS and Kaposi's sarcoma. Setting-United Kingdom. Patients-2830 patients with AIDS reported to the Communicable Disease Surveillance Centre and the Communicable Disease (Scotland) Unit up to March 1990, of whom 566 had Kaposi's sarcoma. Main outcome measures-Number of patients with Kaposi's sarcoma and possible source of HIV infection. Results-537 of 2291 men (23%) who acquired AIDS through sexual contact had Kaposi's sarcoma; the risk associated with heterosexual contact was 10% (14/135). None of the patients with Kaposi's sarcoma for whom information on source of infection was available had contracted AIDS through non-sexual means. Kaposi's sarcoma was more common among homosexual men whose likely source of infection included the United States (171/551, 31%) or Africa (9/134, 26%) than among those infected in the United Kingdom (119/625, 19%; p < 0.05). Conclusion-The data suggest that Kaposi's sarcoma is caused by a transmissible agent and that an important route of transmission is sexual contact.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; PUBL HLTH LAB SERV,CTR AIDS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine	BERAL, V (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159				BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; LIFSON AR, 1990, AM J EPIDEMIOL, V131, P221, DOI 10.1093/oxfordjournals.aje.a115492; 1989, J INFECTION, V18, P77	4	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					624	625		10.1136/bmj.302.6777.624	http://dx.doi.org/10.1136/bmj.302.6777.624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FC071	2012875	Green Published, Bronze			2022-12-01	WOS:A1991FC07100020
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; GREENWOOD, BM; MCMICHAEL, AJ			HLA CLASS-I TYPING BY PCR - HLA-B27 AND AN AFRICAN B27 SUBTYPE	LANCET			English	Article							ANKYLOSING-SPONDYLITIS; POPULATION; ANTIGENS; DNA	We describe a rapid method of HLA class I typing using the polymerase chain reaction and oligonucleotide hybridisation that eliminates the requirements for viable lymphocytes and allows subtypes to be defined. We have used this to demonstrate that the predominant subtype of HLA-B27 in the Gambia, West Africa, is HLA-B*2703, which is very rare or absent in other racial groups. This subtype differs from the common Caucasian HLA-B27 subtypes in its recognition by cytotoxic T cells. We propose that HLA*B-2703, unlike other HLA-B27 subtypes, may not be associated with ankylosing spondylitis, thus accounting in part for the rarity of this condition in black populations.	MRC LABS,FAJARA,SENEGAMBIA		HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BREURVRIESENDORP BS, 1987, ANN RHEUM DIS, V46, P353, DOI 10.1136/ard.46.5.353; BREWERTON DA, 1973, LANCET, V1, P904; CALVO V, 1990, J IMMUNOL, V144, P4038; Cave L, 1965, Rhumatologie, V17, P153; CHERTKOFF LP, 1988, HUM IMMUNOL, V23, P241, DOI 10.1016/0198-8859(88)90060-2; CHOO SY, 1988, HUM IMMUNOL, V21, P209; DECASTRO JAL, 1989, IMMUNOL TODAY, V10, P239, DOI 10.1016/0167-5699(89)90261-2; DEWAAL L, 1987, J IMMUNOL, V139, P3396; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTON JSH, 1990, CLIN EXP IMMUNOL, V82, P1; GREENWOOD BM, 1970, ANN RHEUM DIS, V29, P56, DOI 10.1136/ard.29.1.56; KALIDI I, 1988, TISSUE ANTIGENS, V31, P98, DOI 10.1111/j.1399-0039.1988.tb02070.x; KHAN MA, 1977, J RHEUMATOL, V4, P39; OKOYE RC, 1989, TISSUE ANTIGENS, V33, P445, DOI 10.1111/j.1399-0039.1989.tb01693.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; SCARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0	24	151	161	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					640	642		10.1016/0140-6736(91)92452-8	http://dx.doi.org/10.1016/0140-6736(91)92452-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671992				2022-12-01	WOS:A1991FB73000004
J	KALK, WJ; VERIAVA, Y				KALK, WJ; VERIAVA, Y			HOSPITAL MANAGEMENT OF VOLUNTARY TOTAL FASTING AMONG POLITICAL PRISONERS	LANCET			English	Editorial Material								In 1989 20 political detainees, held without trial for up to 32 months, were admitted, on hunger strike, to the Johannesburg Hospital, South Africa. Most were held under the regulations of the State of Emergency (since revoked) and 5 were held incommunicado under section 29 of the Internal Security Act (still in force). Guidelines for ethical management were based on the Declaration of Tokyo, which included the understanding that such detentions constituted mental torture. Conditions of detention in hospital were complicated by police interference in medical and nursing care, and by the chaining of some prisoners to their beds. Doctors are in a unique position to protest against inhuman treatment of prisoners, and should use this authority.	CORONAT HOSP,DEPT MED,JOHANNESBURG,SOUTH AFRICA; NATL & MED DENT ASSOC DETAINEES SERV,PARKTOWN 2193,SOUTH AFRICA; UNIV WITWATERSRAND,SCH MED,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand; University of Witwatersrand	KALK, WJ (corresponding author), UNIV WITWATERSRAND,SCH MED,DEPT MED,PARKTOWN 2193,SOUTH AFRICA.							FROMMEL D, 1984, LANCET, V1, P1451, DOI 10.1016/S0140-6736(84)91941-X; HARDING TW, 1989, LANCET, V1, P1191; LEVIN J, 1988, S AFR MED J, V74, P460; VERIAVA Y, 1989, CRITICAL HLTH, V26, P39; 1975, WORLD MED J, V22, P87; 1989, S89278 U WITW FM DOC; 1989, WEEKLY MAIL     0303; 1988, LANCET, V2, P1402; 1989, NATAL MERCURY   1028; 1981, HDB MED ETHICS	10	20	20	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					660	662		10.1016/0140-6736(91)92465-E	http://dx.doi.org/10.1016/0140-6736(91)92465-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FB730	1672002				2022-12-01	WOS:A1991FB73000015
J	KHONG, TY; HEALY, DL; MCCLOUD, PI				KHONG, TY; HEALY, DL; MCCLOUD, PI			PREGNANCIES COMPLICATED BY ABNORMALLY ADHERENT PLACENTA AND SEX-RATIO AT BIRTH	BRITISH MEDICAL JOURNAL			English	Article									MONASH UNIV,MONASH MED CTR,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH UNIV,DEPT MATH,CLAYTON,VIC 3168,AUSTRALIA	Monash University; Monash University								Fox H, 1972, OBSTET GYNECOL SURV, V27, P475; JAMES WH, 1987, HUM BIOL, V59, P721; KHONG TY, IN PRESS IMMUNOLOGIC; METTLER L, 1984, GYNECOL OBSTET INVES, V18, P281, DOI 10.1159/000299094; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					625	626		10.1136/bmj.302.6777.625	http://dx.doi.org/10.1136/bmj.302.6777.625			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012876	Green Published, Bronze			2022-12-01	WOS:A1991FC07100021
J	MILES, KA; HAYBALL, M; DIXON, AK				MILES, KA; HAYBALL, M; DIXON, AK			COLOR PERFUSION IMAGING - A NEW APPLICATION OF COMPUTED-TOMOGRAPHY	LANCET			English	Note							BLOOD-FLOW	We describe a new application for imaging with computed tomography (CT) in which a quantifiable map of tissue perfusion is created and displayed by means of a colour scale. A rapid sequence of images is acquired without table movement immediately after a bolus intravenous injection of radiographic contrast medium. The rate of enhancement in each pixel within the chosen slice can then be used to determine perfusion. The technique provides a quantifiable display of regional perfusion combined with the high spatial resolution afforded by CT.	ADDENBROOKES HOSP,DEPT NUCL MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED PHYS,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	MILES, KA (corresponding author), ADDENBROOKES HOSP,DEPT RADIOL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Miles, Kenneth/0000-0002-5920-381X				AXEL L, 1979, INVEST RADIOL, V14, P389; Hindmarsh T, 1975, Acta Radiol Suppl, V346, P45; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; MILES KA, 1990, BRIT J RADIOL, V63, P991; MILES KA, IN PRESS BR J RADIOL; PETERS AM, 1987, CARDIOVASC RES, V21, P830, DOI 10.1093/cvr/21.11.830; PETERS AM, 1987, NUCL MED COMMUN, V8, P823, DOI 10.1097/00006231-198710000-00009; RUSSELL SB, 1974, BRIT J RADIOL, V47, P268, DOI 10.1259/0007-1285-47-557-268	8	136	215	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					643	645		10.1016/0140-6736(91)92455-B	http://dx.doi.org/10.1016/0140-6736(91)92455-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1671994				2022-12-01	WOS:A1991FB73000006
J	MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV				MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV			CARDIOPULMONARY-RESUSCITATION SKILLS OF PREREGISTRATION HOUSE OFFICERS - 5 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT ANAESTHESIA,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	MORRIS, F (corresponding author), ST BARTHOLOMEWS HOSP,DEPT ACCID & EMERGENCY,LONDON EC1A 7BE,ENGLAND.							BASKETT PJF, 1985, BRIT MED J, V290, P1531, DOI 10.1136/bmj.290.6481.1531; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CURRY L, 1987, CAN MED ASSOC J, V137, P491; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; 1987, J R COLL PHYSICIANS, V21, P175	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					626	627		10.1136/bmj.302.6777.626	http://dx.doi.org/10.1136/bmj.302.6777.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	1878021	Green Published, Bronze			2022-12-01	WOS:A1991FC07100022
J	NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K				NUNN, P; KIBUGA, D; GATHUA, S; BRINDLE, R; IMALINGAT, A; WASUNNA, K; LUCAS, S; GILKS, C; OMWEGA, M; WERE, J; MCADAM, K			CUTANEOUS HYPERSENSITIVITY REACTIONS DUE TO THIACETAZONE IN HIV-1 SEROPOSITIVE PATIENTS TREATED FOR TUBERCULOSIS	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; ASSOCIATION; INFECTION; VIRUS	The effects of the human immunodeficiency virus (HIV) on tuberculosis management was investigated in 227 patients initially treated with a regimen containing streptomycin, isoniazid, and thiacetazone (STH). 93 of these 227 were HIV-seropositive. 60 patients, of whom 18 were HIV-seropositive, received a regimen consisting of streptomycin, isoniazid, rifampicin, and pyrazinamide (SHRZ) in the initial phase, and thiacetazone and isoniazid (TH) in the continuation phase. Cutaneous hypersensitivity reactions occurred in 22 of 111 (20%) HIV-seropositive patients, and in 2 of 176 (1%) HIV-seronegative patients (RR = 18, 95% CI 4.4-76, p < 10(-7). During the first 8 weeks of treatment 18 reactions occurred among the 93 HIV-seropositive patients on STH, whereas no reaction occurred in 17 HIV-seropositive patients during the initial phase of SHRZ/TH (p = 0.04). None of the 18 HIV-seropositive patients with cutaneous reactions who were subsequently challenged with isoniazid reacted, nor did any of the 10 tested with streptomycin, but 6 of the 7 challenged with thiacetazone reacted. 3 patients (all HIV-positive and with toxic epidermal necrolysis) died as a result of the cutaneous reaction. These results have major implications for tuberculosis control programmes in Africa.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; UNIV COLL & MIDDLESEX HOSP MED SCH LONDON,LONDON,ENGLAND; NUFFIELD DEPT MED,OXFORD,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB,OXFORD,ENGLAND	Kenya Medical Research Institute; University of London; University College London; University of Oxford; Kenyatta National Hospital; University of London; London School of Hygiene & Tropical Medicine			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN A, 1987, DIFFERENTIAL DIAGNOS, P28; BRICE SL, 1989, J INVEST DERMATOL, V93, P183, DOI 10.1111/1523-1747.ep12277397; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chonde T M, 1989, Bull Int Union Tuberc Lung Dis, V64, P37; CITRON KM, 1983, OXFORD TXB MED, V1; FERGUSON G C, 1971, Tubercle, V52, P166, DOI 10.1016/0041-3879(71)90040-7; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P451, DOI 10.1016/S0190-9622(88)70197-8; Kadende P, 1988, Med Trop (Mars), V48, P19; KIBUGA D, 4TH INT C AIDS ASS C, P99; MANN J, 1986, JAMA-J AM MED ASSOC, V256, P346, DOI 10.1001/jama.1986.03380030048011; Miller A B, 1966, Tubercle, V47, P33; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; SEN PK, 1974, INDIAN J MED RES, V62, P557; STANDAERT B, 1989, AIDS RES HUM RETROV, V5, P247, DOI 10.1089/aid.1989.5.247; SUGARMAN J, 1990, 4TH INT C AIDS SAN F, V1, P249; WILLAME JC, 1988, ANN SOC BELG MED TR, V68, P165; 1973, TUBERCLE, V54, P169	19	176	177	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1991	337	8742					627	630						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB730	1705647				2022-12-01	WOS:A1991FB73000001
J	POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E				POUW, EM; PRUMMEL, MF; OOSTING, H; ROOS, CM; ENDERT, E			BECLOMETHASONE INHALATION DECREASES SERUM OSTEOCALCIN CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								BARNES PJ, 1989, NEW ENGL J MED, V321, P571; BROWN JP, 1984, LANCET, V1, P1091; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem-72-2-382	5	130	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					627	628		10.1136/bmj.302.6777.627	http://dx.doi.org/10.1136/bmj.302.6777.627			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012877	Bronze, Green Published			2022-12-01	WOS:A1991FC07100023
J	THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM				THORPEBEESTON, JG; NICOLAIDES, KH; GOSDEN, CM; MCGREGOR, AM			THYROID-FUNCTION IN FETUSES WITH CHROMOSOMAL-ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article							FETAL		KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	University of London; King's College London; University of Edinburgh; University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				CUTLER AT, 1986, AM J DIS CHILD, V140, P479, DOI 10.1001/archpedi.1986.02140190089034; DEESCOBAR GM, 1987, HORM RES, V26, P12, DOI 10.1159/000180681; NICOLAIDES KH, 1986, LANCET, V1, P1065; PUESCHEL SM, 1985, AM J DIS CHILD, V139, P636, DOI 10.1001/archpedi.1985.02140080106045; THORPEBEESTON JG, 1991, NEW ENGL J MED, V324, P532, DOI 10.1056/NEJM199102213240805	5	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					628	628		10.1136/bmj.302.6777.628	http://dx.doi.org/10.1136/bmj.302.6777.628			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012878	Bronze, Green Published			2022-12-01	WOS:A1991FC07100024
J	VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ				VANDONSELAAR, CA; GEERTS, AT; SCHIMSHEIMER, RJ			IDIOPATHIC 1ST SEIZURE IN ADULT LIFE - WHO SHOULD BE TREATED	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNPROVOKED SEIZURE; EPILEPSY; PROGNOSIS; CARBAMAZEPINE; RECURRENCE; PHENYTOIN; CHILDHOOD; VALPROATE; PATIENT	Objective-To assess the accuracy of the diagnosis, recurrence rate, and fate after the first recurrence in adult patients with an untreated idiopathic first seizure. Design-Hospital based follow up study. Setting-One university hospital and three general hospitals in The Netherlands. Patients-165 patients aged 15 years or more with a clinically presumed idiopathic seizure; diagnosis was based on a description of the episode according to prespecified diagnostic criteria. Main outcome measures-Results of additional investigations and follow up regarding the accuracy of the diagnosis; first recurrence; and response to treatment after the first recurrence. Results-Computed tomography showed major abnormalities in 5.5% of the patients and follow up led to doubts about the initial clinical diagnosis in another 6%. Cumulative risk of recurrence was 40% at two years. The cumulative risk of recurrence at two years was 81% (95% confidence interval 66% to 97%) in patients with epileptic discharges on a standard or partial sleep deprivation electroencephalogram, 39% (27% to 51%) in patients with other electroencephalographic abnormalities, and 12% (3% to 21%) in patients with normal electroencephalograms. Treatment was initiated in most patients who had one or more recurrences; 40 (70%) patients were completely controlled, eight (14%) had sporadic seizures, and nine (16%) did not become free of seizures within one year despite treatment. Conclusions-The decision to initiate or delay treatment should be based on electroencephalographic findings.	ERASMUS UNIV, DEPT PUBL HLTH & SOCIAL MED, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	VANDONSELAAR, CA (corresponding author), ERASMUS UNIV, HOSP DIJKZIGT, DEPT NEUROL, 3015 GD ROTTERDAM, NETHERLANDS.							ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1981, Epilepsia, V22, P489; BODENSTEINER JB, 1988, EPILEPSIA, V29, P123, DOI 10.1111/j.1528-1157.1988.tb04407.x; CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; CAMFIELD P, 1989, NEUROLOGY, V39, P851, DOI 10.1212/WNL.39.6.851; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; ELWES RDC, 1988, LANCET, V2, P36; ELWES RDC, 1984, NEW ENGL J MED, V311, P944, DOI 10.1056/NEJM198410113111503; ELWES RDC, 1985, LANCET, V2, P752; ELWES RDC, 1988, BMJ-BRIT MED J, V47, P620; HACHINSKI V, 1986, ARCH NEUROL-CHICAGO, V43, P1290, DOI 10.1001/archneur.1986.00520120066019; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P1289, DOI 10.1001/archneur.1986.00520120065018; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HAUSER WA, 1986, ARCH NEUROL-CHICAGO, V43, P1287, DOI 10.1001/archneur.1986.00520120063017; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOLMES GL, 1988, POSTGRAD MED, V83, P199, DOI 10.1080/00325481.1988.11700149; HOPKINS A, 1988, LANCET, V1, P721; JOHNSON LC, 1972, ARCH NEUROL-CHICAGO, V27, P193, DOI 10.1001/archneur.1972.00490150001001; LUHDORF K, 1986, ACTA NEUROL SCAND, V74, P409; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; RAMSAY RE, 1983, NEUROLOGY, V33, P904, DOI 10.1212/WNL.33.7.904; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; REYNOLDS EH, 1983, LANCET, V2, P952; SAUNDERS M, 1975, EPILEPSIA, V16, P731, DOI 10.1111/j.1528-1157.1975.tb04757.x; SCHOTT GD, 1977, BRIT MED J, V1, P1454, DOI 10.1136/bmj.1.6074.1454; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; SHORVON SD, 1982, BMJ-BRIT MED J, V285, P1699, DOI 10.1136/bmj.285.6356.1699; THOMAS MH, 1959, JAMA-J AM MED ASSOC, V169, P457, DOI 10.1001/jama.1959.03000220037008; TURNBULL DM, 1985, BRIT MED J, V290, P815, DOI 10.1136/bmj.290.6471.815; VANDONSELAAR CA, 1989, NEUROLOGY, V39, P267, DOI 10.1212/WNL.39.2.267; VANDONSELAAR CA, 1990, EPILEPSIA, V31, P529; 1981, STATISTICAL SOFTWARE	33	50	51	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 16	1991	302	6777					620	623		10.1136/bmj.302.6777.620	http://dx.doi.org/10.1136/bmj.302.6777.620			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012874	Green Published, Bronze			2022-12-01	WOS:A1991FC07100019
J	YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG				YELLAND, A; GRAHAM, MD; TROTT, PA; FORD, HT; COOMBES, RC; GAZET, JC; POLSON, NG			DIAGNOSING BREAST-CARCINOMA IN YOUNG-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							ASPIRATION CYTOLOGY; MAMMOGRAPHY; MANAGEMENT; CANCER	Objective-To assess the individual and combined diagnostic accuracy of clinical examination, mammography, and fine needle aspiration biopsy in young women with breast cancer. Design-Analysis based on case notes of patients presenting with breast cancer during 1971-89. Setting-A combined breast clinic. Patients-Consecutive series of 81 women aged < 36 with histologically proved breast cancer presenting with a discrete mass over 19 years. Main outcome measures-Results of clinical examination, xeromammography or conventional mammography, fine needle aspiration biopsy, and examination of tissue removed by surgery. Results-The clinical diagnosis was correct in 47 women and radiography in 35. Fine needle aspiration biopsy was correct in 47 of the 63 women in whom it was successfully performed. Fine needle aspiration was significantly more accurate than mammography (78% v 45%, p < 0.01). Ten (16%) patients had negative results on clinical examination, mammography, and fine needle aspiration. Conclusion-Mammography alone seems inadequately sensitive to detect breast cancer in young patients. When all investigations give negative results excision biopsy is the only way of obtaining a definitive diagnosis.	ST GEORGE HOSP,COMBINED BREAST CLIN,LONDON SW17 0QT,ENGLAND	St Georges University London				Coombes, Raoul Charles/0000-0002-4811-1100				ASHLEY S, 1989, BRIT J SURG, V76, P835, DOI 10.1002/bjs.1800760825; CAHILL CJ, 1981, BRIT J SURG, V68, P882, DOI 10.1002/bjs.1800681215; CANT PJ, 1987, BRIT J SURG, V74, P857, DOI 10.1002/bjs.1800740936; DIXON JM, 1984, BRIT J SURG, V71, P593, DOI 10.1002/bjs.1800710809; SMALLWOOD J, 1985, BRIT J SURG, V72, P841, DOI 10.1002/bjs.1800721022; TEIXIDOR HS, 1977, AM J ROENTGENOL, V128, P409, DOI 10.2214/ajr.128.3.409; THOMAS MJ, 1978, BMJ, V2, P1139; TROTT PA, 1981, DIAGNOSIS PRIMARY BR, P1; WARWICK DJ, 1988, BRIT J SURG, V75, P243, DOI 10.1002/bjs.1800750319; WILKINSON S, 1985, BRIT J SURG, V72, P838, DOI 10.1002/bjs.1800721021; 1989, LANCET, V1, P973	11	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					618	620		10.1136/bmj.302.6777.618	http://dx.doi.org/10.1136/bmj.302.6777.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	2012873	Green Published, Bronze			2022-12-01	WOS:A1991FC07100018
J	BEAL, PA; DERVAN, PB				BEAL, PA; DERVAN, PB			2ND STRUCTURAL MOTIF FOR RECOGNITION OF DNA BY OLIGONUCLEOTIDE-DIRECTED TRIPLE-HELIX FORMATION	SCIENCE			English	Article							SEQUENCE-SPECIFIC CLEAVAGE; STRANDED-DNA; DUPLEX DNA; BINDING; SITE; INHIBITION; GUANINE	Relative orientations of the DNA strands within a purine.purine.pyrimidine triple helix have been determined by affinity cleaving. A purine-rich oligonucleotide bound in the major groove of double-helical DNA antiparallel to the Watson-Crick purine strand. Binding depended upon the concentration of multivalent cations such as spermine or Mg2+, and appeared to be relatively independent of pH. Two models with specific hydrogen-bonding patterns for base triplets (G.GC, A.AT, and T.AT) are proposed to explain the sequence specificity of binding. The two models differ in the conformation about the glycosyl bond (syn or anti) and the location of the phosphate-deoxyribose backbone in the major groove of DNA. This motif broadens the structural frameworks available as a basis for the design of sequence-specific DNA binding molecules.	CALTECH,DIV CHEM & CHEM ENGN,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125	California Institute of Technology								BROITMAN SL, 1987, P NATL ACAD SCI USA, V85, P3781; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P192; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DERVAN PB, UNPUB; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1989, J BIOL CHEM, V264, P5891; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P7749; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LUEBKE KJ, 1989, J AM CHEM SOC, V111, P8733, DOI 10.1021/ja00205a033; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARK C, 1978, NUCLEIC ACIDS RES, V5, P1017; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJOGOPAL P, 1989, NATURE, V339, P637; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P119; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1989, J AM CHEM SOC, V111, P7286, DOI 10.1021/ja00200a073; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1989, P NATL ACAD SCI USA, V86, P8198; WILLIAMS NG, 1989, J AM CHEM SOC, V111, P7205, DOI 10.1021/ja00200a046	28	586	732	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1360	1363		10.1126/science.2003222	http://dx.doi.org/10.1126/science.2003222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003222				2022-12-01	WOS:A1991FB73300045
J	EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP				EPSTEIN, WV; HENKE, CJ; YELIN, EH; KATZ, PP			EFFECT OF PARENTERALLY ADMINISTERED GOLD THERAPY ON THE COURSE OF ADULT RHEUMATOID-ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; SODIUM THIOMALATE; HEALTH-STATUS; DISABILITY; MORTALITY; OUTCOMES; PLACEBO; DISEASE	Objective: To describe the course of rheumatoid arthritis over 5 years in adults and to evaluate the effect of parenterally administered gold salts on that course. Design: A prospective observational study of adults with rheumatoid arthritis. Data derived from annual interviews with patients from 1983 to 1988 and from physician surveys in 1983 and 1987. Setting: Rheumatology practices in the community. Patients: The study began in 1982 with 822 adults who had rheumatoid arthritis and were under the care of rheumatologists. Interventions: Those selected by rheumatologists in the management of their patients. Measurements: Information describing sociodemographic and clinical characteristics, course, and therapy was collected from patients and verified by physician reports. Functional status, measured by the Health Assessment Questionnaire, and the number of painful joints were used as outcome variables. Outcome variables were adjusted for age, sex, disease duration, baseline values of the outcome variable, and the use of four disease-remittive agents other than gold. Main Results: Multivariate repeated-measures analysis of variance showed no change in the course of rheumatoid arthritis over 5 years. The use of parenteral gold for at least 2 consecutive years at the start of the observation period produced, on average, no change in the course over 5 years in the two outcome variables. Conclusion: In our study of a community-based population of adults with rheumatoid arthritis who were under the care of community rheumatologists, we found that there was, on average, no statistically significant change in function or number of painful joints between 1983 and 1988. Patients receiving parenteral gold therapy for at least 2 consecutive years did not show a statistically significant difference in outcome when compared with those not receiving such therapy.	UNIV CALIF SAN FRANCISCO, ROSALIND RUSSELL ARTHRITIS CTR, SAN FRANCISCO, CA 94143 USA; KAISER PERMANENTE MED CTR, OAKLAND, CA USA	University of California System; University of California San Francisco; Kaiser Permanente					NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIA NIH HHS [K04AG00273] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000273] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P844; [Anonymous], 1960, ANN RHEUM DIS, V19, P95; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BOMBARDIER C, 1985, J RHEUMATOL, V12, P403; BOMBARDIER C, 1982, J RHEUMATOL, V9, P798; BRADLEY LA, 1989, ARTHRITIS RHEUM, V32, P1611, DOI 10.1002/anr.1780321220; BYE B, 1982, SSA1311745 PUBL, P1; EPSTEIN WV, 1989, J RHEUMATOL, V16, P1291; GABRIEL SE, 1988, MEDICINE, V67, P58, DOI 10.1097/00005792-198801000-00004; GOLDMAN AE, 1983, AM J MED, V75, P79, DOI 10.1016/0002-9343(83)90479-5; GORDON DA, 1989, TXB RHEUMATOLOGY, P804; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; KUSHNER I, 1989, J RHEUMATOL, V16, P1; LOUIS TA, 1988, STAT MED, V7, P29, DOI 10.1002/sim.4780070108; MEENAN RF, 1988, AM J PUBLIC HEALTH, V78, P1484, DOI 10.2105/AJPH.78.11.1484; NEVITT MC, 1986, ANN INTERN MED, V105, P421, DOI 10.7326/0003-4819-105-3-421; OREGLIA A, 1986, ABRIDGED LIFE TABLES; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAGAN C, 1951, B NEW YORK ACAD MED, V27, P63; SHARP JT, 1982, ARTHRITIS RHEUM, V25, P540, DOI 10.1002/art.1780250508; SHERRER YS, 1987, J RHEUMATOL, V14, P705; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1990, J RHEUMATOL, V17, P24; YELIN E, 1987, ARTHRITIS RHEUM, V30, P507, DOI 10.1002/art.1780300504; YELIN E, 1987, J RHEUMATOL, V14, P710; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1961, ANN RHEUM DIS, V20, P315	34	54	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					437	444		10.7326/0003-4819-114-6-437	http://dx.doi.org/10.7326/0003-4819-114-6-437			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1671630				2022-12-01	WOS:A1991FB64000001
J	FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C				FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C			AN INVIVO MODEL OF SOMATIC-CELL GENE-THERAPY FOR HUMAN SEVERE COMBINED IMMUNODEFICIENCY	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; HUMAN ADENOSINE-DEAMINASE; RETROVIRUS-MEDIATED TRANSFER; STEM-CELLS; B-CELLS; EXPRESSION; MICE; DEFICIENCY; VECTOR; CULTURE	Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.	IST SCI HS RAFFAELE,HEMATOL SERV,HEMATOL LAB,VIA OLGETTINA 60,I-20132 MILAN,ITALY; IST RIC MARIO NEGRI BERGAMO,BERGAMO,ITALY; MEM SLOAN KETTERING CANC CTR,DEPT MOLEC BIOL,NEW YORK,NY 10021	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Memorial Sloan Kettering Cancer Center			Giavazzi, Raffaella/J-7424-2018; Daniela, Maggioni/AAN-6553-2020; Giavazzi, Raffaella/ABB-9768-2020; Ferrari, Giuliana/AAB-5546-2019	Daniela, Maggioni/0000-0001-9894-6387; Giavazzi, Raffaella/0000-0001-5249-8208; Ferrari, Giuliana/0000-0003-0790-3133; Mavilio, Fulvio/0000-0003-0459-4320				ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; BELMONT JW, 1988, MOL CELL BIOL, V8, P5116, DOI 10.1128/MCB.8.12.5116; BELMONT JW, 1986, NATURE, V322, P385, DOI 10.1038/322385a0; BENDER MA, 1989, MOL CELL BIOL, V9, P1426, DOI 10.1128/MCB.9.4.1426; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; BORDIGNON C, 1989, P NATL ACAD SCI USA, V86, P6748, DOI 10.1073/pnas.86.17.6748; BORDIGNON C, UNPUB; COLLINS SJ, 1983, P NATL ACAD SCI USA, V80, P4831; CULLITON BJ, 1989, SCIENCE, V246, P751, DOI 10.1126/science.2814495; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DISEGNI C, 1981, NUCLEIC ACIDS RES, V9, P6709; EGLITIS MA, 1985, SCIENCE, V230, P1395, DOI 10.1126/science.2999985; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GERSHON D, 1990, NATURE, V346, P402, DOI 10.1038/346402a0; GRUBER HE, 1985, SCIENCE, V230, P1057, DOI 10.1126/science.3864246; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HOCK RA, 1986, NATURE, V320, P275, DOI 10.1038/320275a0; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KHAN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470, DOI 10.1016/S0003-9861(71)80007-3; KWOK WW, 1986, P NATL ACAD SCI USA, V83, P4552, DOI 10.1073/pnas.83.12.4552; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; MARTINI A, 1985, INT J CLIN PHARM RES, V5, P149; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; ROSEN A, 1983, J IMMUNOL, V130, P2899; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANDERWEYDEN MB, 1978, CLIN CHIM ACTA, V82, P179, DOI 10.1016/0009-8981(78)90041-4; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877	39	113	125	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1363	1366		10.1126/science.1848369	http://dx.doi.org/10.1126/science.1848369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1848369				2022-12-01	WOS:A1991FB73300046
J	HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH				HAYES, JJ; STEWART, RB; GREENE, HL; BARDY, GH			NARROW QRS VENTRICULAR-TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							BUNDLE-BRANCH-BLOCK; DIFFERENTIAL-DIAGNOSIS; FASCICULAR TACHYCARDIA; COMPLEX TACHYCARDIA; THERAPY; REENTRY	Objective: To determine the frequency and clinical characteristics of narrow Design: Consecutive survey of patients with ventricular tachycardia. Setting: Tertiary, referral-based arrhythmia service at a university medical center. Patients: Sequential sample of patients with inducible ventricular tachycardia who had a 12-lead electrocardiogram of the tachycardia available for review. Measurements and Main Results: Of 106 patients with ventricular tachycardia, 5 (4.7%; 95% CI, 2.1% to 10.6%) had ventricular tachycardia with a QRS duration less-than-or-equal-to 0.11 seconds. Three of the five patients were previously incorrectly diagnosed as having supraventricular tachycardia. All five patients had at least two electrocardiographic findings other than QRS duration to suggest ventricular tachycardia. Conclusions: Narrow QRS ventricular tachycardia should be considered in the differential diagnosis of narrow QRS tachycardias. Electrocardiographic findings other than QRS duration are usually present to suggest the diagnosis.			HAYES, JJ (corresponding author), UNIV WASHINGTON, MED CTR, MAIL STOP RG-22, 1959 NE PACIFIC, SEATTLE, WA 98195 USA.				PHS HHS [36170, 31472] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAR FW, 1984, AM J CARDIOL, V54, P555, DOI 10.1016/0002-9149(84)90247-9; BROHET C, 1988, ACTA CLIN BELG, V43, P236; CACERES J, 1989, CIRCULATION, V79, P256, DOI 10.1161/01.CIR.79.2.256; COHEN HC, 1972, CIRCULATION, V45, P1035, DOI 10.1161/01.CIR.45.5.1035; FORSSELL G, 1976, ACTA MED SCAND, V199, P143; GOOLSBY JP, 1974, AM HEART J, V88, P351, DOI 10.1016/0002-8703(74)90471-2; JOSEPHSON ME, 1978, CIRCULATION, V57, P431, DOI 10.1161/01.CIR.57.3.431; JOSEPHSON ME, 1979, CIRCULATION, V59, P459, DOI 10.1161/01.CIR.59.3.459; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; KREMERS MS, 1988, AM J CARDIOL, V62, P1208, DOI 10.1016/0002-9149(88)90261-5; KUCHAR DL, 1988, PACE, V11, P61, DOI 10.1111/j.1540-8159.1988.tb03930.x; MASON JW, 1978, CIRCULATION, V58, P971, DOI 10.1161/01.CIR.58.6.971; MASSUMI RA, 1973, CIRCULATION, V47, P543, DOI 10.1161/01.CIR.47.3.543; PRITCHETT EL, 1978, PRAC CARDIOL, V4, P84; REDDY CP, 1980, CIRCULATION, V61, P641, DOI 10.1161/01.CIR.61.3.641; ROELANDT J, 1969, DIS CHEST, V56, P166, DOI 10.1378/chest.56.2.166; RUFFY R, 1985, J AM COLL CARDIOL, V5, P1008, DOI 10.1016/S0735-1097(85)80451-4; SHIMIZU A, 1988, PACE, V11, P384, DOI 10.1111/j.1540-8159.1988.tb05997.x; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; VANDEPOL CJ, 1980, AM J CARDIOL, V45, P725, DOI 10.1016/0002-9149(80)90114-9; WEISS J, 1986, AM HEART J, V112, P843, DOI 10.1016/0002-8703(86)90485-0; WELLENS HJJ, 1978, AM J MED, V64, P27, DOI 10.1016/0002-9343(78)90176-6; WELLENS HJJ, 1979, AM J CARDIOL, V43, P400	23	20	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					460	463		10.7326/0003-4819-114-6-460	http://dx.doi.org/10.7326/0003-4819-114-6-460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994792				2022-12-01	WOS:A1991FB64000005
J	JUNG, LJ; SCHELLER, RH				JUNG, LJ; SCHELLER, RH			PEPTIDE PROCESSING AND TARGETING IN THE NEURONAL SECRETORY PATHWAY	SCIENCE			English	Article							EGG-LAYING HORMONE; BAG CELL NEURONS; LARGE HERMAPHRODITIC DUCT; ATRIAL GLAND PEPTIDES; SEMLIKI FOREST VIRUS; APLYSIA-CALIFORNICA; BEHAVIORAL-PATTERNS; ELICITED BEHAVIORS; PROLONGED ACTIONS; ENDOCRINE CELLS	The abdominal ganglion of the marine mollusk Aplysia contains a pair of identified neuronal clusters, the bag cells, which control egg laying by means of a number of unique regulatory mechanisms. Each neuron in the bag cell clusters synthesizes several peptides derived from a single prohormone and packages them into separate vesicles. These vesicles are then differentially localized in specific neuronal processes, thus segregating peptides destined for autocrine and hormonal release sites. Therefore in this system, protein trafficking through the secretory pathway organizes multiple peptide neurochemical messengers to efficiently regulate simple behaviors.			JUNG, LJ (corresponding author), STANFORD UNIV, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							ARCH S, 1977, BEHAV BIOL, V19, P45, DOI 10.1016/S0091-6773(77)91331-1; ARCH S, 1980, J COMP PHYSIOL, V141, P131, DOI 10.1007/BF00611886; ARCH S, 1978, J COMP PHYSIOL, V128, P67, DOI 10.1007/BF00668374; ARCH S, 1976, AM ZOOL, V16, P167; AUDESIRK TE, 1977, BEHAV BIOL, V20, P235, DOI 10.1016/S0091-6773(77)90799-4; BEARD M, 1982, TISSUE CELL, V14, P297, DOI 10.1016/0040-8166(82)90028-3; BERRY RW, 1986, PEPTIDES, V7, P637, DOI 10.1016/0196-9781(86)90039-2; BLANKENSHIP JE, 1979, J NEUROPHYSIOL, V42, P347, DOI 10.1152/jn.1979.42.2.347; BRANTON WD, 1978, P NATL ACAD SCI USA, V75, P5732, DOI 10.1073/pnas.75.11.5732; BRANTON WD, 1978, NATURE, V274, P70, DOI 10.1038/274070a0; CAREFOOT TH, 1967, J MAR BIOL ASSOC UK, V47, P565, DOI 10.1017/S0025315400035190; CHIU AY, 1979, P NATL ACAD SCI USA, V76, P6656, DOI 10.1073/pnas.76.12.6656; COBBS JS, 1982, J COMP PHYSIOL, V147, P523, DOI 10.1007/BF00612018; COBBS JS, 1982, J COMP PHYSIOL, V147, P537, DOI 10.1007/BF00612019; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; COGGESHALL RE, 1972, AM ZOOL, V12, P521; DALE HENRY, 1935, PROC ROY SOC MED, V28, P319; DUDEK FE, 1977, J NEUROPHYSIOL, V40, P1301, DOI 10.1152/jn.1977.40.6.1301; EALES NB, 1921, LIVERPOOL MARINE BIO, V24, P183; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; FINK LA, 1988, J NEUROSCI, V8, P2544; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FRAZIER WT, 1967, J NEUROPHYSIOL, V30, P1288, DOI 10.1152/jn.1967.30.6.1288; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HAND AR, 1977, J CELL BIOL, V74, P399, DOI 10.1083/jcb.74.2.399; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; JOHNSON DC, 1980, VIROLOGY, V103, P407, DOI 10.1016/0042-6822(80)90200-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; KACZMAREK LK, 1982, BRAIN RES, V238, P105, DOI 10.1016/0006-8993(82)90774-0; Kandel ER, 1976, CELLULAR BASIS BEHAV; KANDEL ER, 1979, BEHAVIORAL BIOL APLY; KAUER JA, 1987, J NEUROSCI, V7, P3623; KUPFERMA.I, 1974, BEHAV BIOL, V12, P317, DOI 10.1016/S0091-6773(74)91503-X; KUPFERMANN I, 1976, J GEN PHYSIOL, V67, P113, DOI 10.1085/jgp.67.1.113; KUPFERMANN I, 1967, NATURE, V216, P814, DOI 10.1038/216814a0; LEVITAN ES, 1987, P NATL ACAD SCI USA, V84, P6307, DOI 10.1073/pnas.84.17.6307; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; Macginitie GE, 1934, BIOL BULL-US, V67, P300, DOI 10.2307/1537166; MAHON AC, 1985, J NEUROSCI, V5, P1872; Mayeri E., 1985, P285; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1185, DOI 10.1152/jn.1979.42.4.1185; MAYERI E, 1981, NEUROSECRETION MOL C, P305; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGLE GT, 1986, J BIOL CHEM, V261, P7853; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; NAMBU JR, 1986, J NEUROSCI, V6, P2026; NEWCOMB R, 1988, J BIOL CHEM, V263, P12514; NEWCOMB R, 1987, J NEUROSCI, V7, P854; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; NOVIKOFF PM, 1971, J CELL BIOL, V50, P859, DOI 10.1083/jcb.50.3.859; ORCI L, 1984, CELL, V39, P39, DOI 10.1016/0092-8674(84)90189-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PAINTER SD, 1985, J MORPHOL, V186, P167, DOI 10.1002/jmor.1051860204; PAINTER SD, 1989, BEHAV NEURAL BIOL, V51, P222, DOI 10.1016/S0163-1047(89)90857-1; PINSKER HM, 1977, SCIENCE, V197, P490, DOI 10.1126/science.197.4302.490; ROCK MK, 1986, J NEUROBIOL, V17, P273, DOI 10.1002/neu.480170403; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; ROTHMAN BS, 1986, J BIOL CHEM, V261, P1616; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1983, GEN COMP ENDOCR, V52, P134, DOI 10.1016/0016-6480(83)90166-1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SOSSIN WS, 1990, P NATL ACAD SCI USA, V87, P4845, DOI 10.1073/pnas.87.12.4845; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V41, P7, DOI 10.1016/S0163-1047(84)90667-8; SUSSWEIN AJ, 1984, BEHAV NEURAL BIOL, V42, P127, DOI 10.1016/S0163-1047(84)90968-3; SUSSWEIN AJ, 1985, NEUROSCI LETT, V59, P325, DOI 10.1016/0304-3940(85)90153-3; SWEETCORDERO A, 1990, J NEUROCHEM, V55, P1933, DOI 10.1111/j.1471-4159.1990.tb05779.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1986, SCIENCE, V232, P1641, DOI 10.1126/science.3754979; THOMPSON T E, 1969, Malacologia, V7, P347; TOOZE J, 1987, J CELL BIOL, V105, P155, DOI 10.1083/jcb.105.1.155; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551	90	101	105	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1330	1335		10.1126/science.2003219	http://dx.doi.org/10.1126/science.2003219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003219				2022-12-01	WOS:A1991FB73300037
J	MUNOZ, DP; PELISSON, D; GUITTON, D				MUNOZ, DP; PELISSON, D; GUITTON, D			MOVEMENT OF NEURAL ACTIVITY ON THE SUPERIOR COLLICULUS MOTOR MAP DURING GAZE SHIFTS	SCIENCE			English	Article							SACCADIC EYE-MOVEMENTS; RETICULO-SPINAL NEURONS; VESTIBULO-OCULAR REFLEX; ALERT CAT; HEAD COORDINATION; PRIMATE; STIMULATION; ORIENTATION; HUMANS	The superior colliculus contains neurons that cause displacements of the visual axis (gaze shifts). These cells are arranged topographically in a motor map on which the vector (amplitude and direction) of the coded movement varies continuously with location. How this spatial representation becomes a temporal code (frequency and duration) in the motoneurons is unknown. During a gaze shift, a zone of neural activity moved continuously on the map from an initial location, defining the vector of the desired gaze shift, to a final "zero" position containing neurons that were active during fixation. Thus, the spatial-temporal transformation may be accomplished by control of gaze throughout the spatial trajectory of activity on the motor map.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL & NEUROSURG,3801 UNIV,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University			Pelisson, Denis/H-2916-2017	Pelisson, Denis/0000-0002-9114-7758				BERTHOZ A, 1986, NEUROSCI LETT, V72, P289, DOI 10.1016/0304-3940(86)90528-8; CROMMELINCK M, 1990, Society for Neuroscience Abstracts, V16, P1082; DROULEZ J, 1988, NEURAL COMPUTERS, P345; DROULEZ J, IN PRESS P NATL ACAD; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GRANTYN A, 1985, EXP BRAIN RES, V57, P417; GRANTYN A, 1982, EXP BRAIN RES, V46, P243; GUITTON D, 1980, EXP BRAIN RES, V39, P63; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; GUITTON D, 1984, J NEUROPHYSIOL, V52, P1030, DOI 10.1152/jn.1984.52.6.1030; GUITTON D, 1990, J NEUROPHYSIOL, V64, P509, DOI 10.1152/jn.1990.64.2.509; GUITTON D, IN PRESS EYE MOVEMEN; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LEFEVRE P, 1990, Society for Neuroscience Abstracts, V16, P1084; MEREDITH MA, 1986, J NEUROPHYSIOL, V56, P640, DOI 10.1152/jn.1986.56.3.640; MOSCHOVAKIS AK, 1985, J COMP NEUROL, V239, P276, DOI 10.1002/cne.902390304; MUNOZ D, UNPUB; MUNOZ D P, 1988, Society for Neuroscience Abstracts, V14, P956; MUNOZ D P, 1990, Society for Neuroscience Abstracts, V16, P1084; MUNOZ DP, 1986, BRAIN RES, V398, P185, DOI 10.1016/0006-8993(86)91267-9; MUNOZ DP, 1989, REV NEUROL-FRANCE, V145, P567; MUNOZ DP, 1988, THESIS MCGILL U MONT; PELISSON D, 1986, BRAIN RES, V380, P397, DOI 10.1016/0006-8993(86)90244-1; PELISSON D, 1988, J NEUROPHYSIOL, V59, P997, DOI 10.1152/jn.1988.59.3.997; PELISSON P, 1989, EXP BRAIN RES, V78, P654; Pitts Walter, 1947, BULL MATH BIOPHYS, V9, P127, DOI 10.1007/BF02478291; ROUCOUX A, 1980, EXP BRAIN RES, V39, P75; SPARKS DL, 1990, ANNU REV NEUROSCI, V13, P309, DOI 10.1146/annurev.ne.13.030190.001521; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; TOMLINSON RD, 1986, J NEUROPHYSIOL, V56, P1558, DOI 10.1152/jn.1986.56.6.1558; WURTZ RH, 1980, ANNU REV NEUROSCI, V3, P189, DOI 10.1146/annurev.ne.03.030180.001201	31	129	129	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1358	1360		10.1126/science.2003221	http://dx.doi.org/10.1126/science.2003221			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003221				2022-12-01	WOS:A1991FB73300044
J	OGORMAN, S; FOX, DT; WAHL, GM				OGORMAN, S; FOX, DT; WAHL, GM			RECOMBINASE-MEDIATED GENE ACTIVATION AND SITE-SPECIFIC INTEGRATION IN MAMMALIAN-CELLS	SCIENCE			English	Article							FLP RECOMBINASE; YEAST PLASMID; HEAT-SHOCK; DNA; SEQUENCES; CIRCLE; GENOME	A binary system for gene activation and site-specific integration, based on the conditional recombination of transfected sequences mediated by the FLP recombinase from yeast, was implemented in mammalian cells. In several cell lines, FLP rapidly and precisely recombined copies of its specific target sequence to activate an otherwise silent beta-galactosidase reporter gene. Clones of marked cells were generated by excisional recombination within a chromosomally integrated copy of the silent reporter. By the reverse reaction, integration of transfected DNA was targeted to a specific chromosomal site. The results suggest that FLP could be used to mosaically activate or inactivate transgenes for analysis of vertebrate development, and to efficiently integrate transfected DNA at predetermined chromosomal locations.			OGORMAN, S (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037, USA.							ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOND U, 1988, EMBO J, V7, P3509, DOI 10.1002/j.1460-2075.1988.tb03227.x; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; DEWET J, 1987, MOL CELL BIOL, V72, P725; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OGORMAN S, UNPUB; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SAUER B, 1990, New Biologist, V2, P441; SENECOFF JF, 1988, J MOL BIOL, V201, P405, DOI 10.1016/0022-2836(88)90147-7; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	25	438	617	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1351	1355		10.1126/science.1900642	http://dx.doi.org/10.1126/science.1900642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1900642				2022-12-01	WOS:A1991FB73300042
J	SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D				SEPKOWITZ, KA; TELZAK, EE; GOLD, JWM; BERNARD, EM; BLUM, S; CARROW, M; DICKMEYER, M; ARMSTRONG, D			PNEUMOTHORAX IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; FEATURES	Objective: To determine risk factors for the development of pneumothorax in p Design: Prospective cohort study. Setting: Tertiary care center. Patients: Of 1030 patients with AIDS who were followed at Memorial Sloan-Kettering Cancer Center between 1 January 1980 and 30 September 1989, 20 (2%) developed pneumothorax that was unrelated to trauma or a pulmonary procedure. Results: Of 20 patients with AIDS who presented with pneumothorax, 19 had compelling evidence of concurrent Pneumocystis carinii pneumonia. Using bivariate analysis, patients receiving aerosol pentamidine prophylaxis (relative risk, 17.6) and those with a history of P. carinii pneumonia (relative risk, 14.5) were more likely to develop pneumothorax. By Mantel-Haenszel stratified analysis, aerosol pentamidine use was a statistically significant risk factor independent of a history of P. carinii pneumonia. The pneumothorax-related mortality rate was 10% and there was considerable morbidity. Conclusions: Patients with AIDS at the highest risk for developing pneumothorax are those with a history of P. carinii pneumonia who are receiving aerosol pentamidine prophylaxis but who nevertheless develop P. carinii pneumonia. The benefits of aerosol pentamidine prophylaxis in these patients far outweigh this risk. Pneumocystis carinii pneumonia should be considered as the most likely diagnosis in any patient with AIDS who develops a pneumothorax.	MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	Memorial Sloan Kettering Cancer Center; New York City Department of Health & Mental Hygiene					NIAID NIH HHS [5 UO1 AI27669-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFESSA B, 1988, ARCH INTERN MED, V148, P2651, DOI 10.1001/archinte.148.12.2651; BERNARD EM, 1989, 5 P INT C AIDS MONTR; BYRNES TA, 1989, J THORAC CARDIOV SUR, V98, P546; DELORENZO LJ, 1987, CHEST, V91, P323, DOI 10.1378/chest.91.3.323; DOPPMAN JL, 1975, RADIOLOGY, V114, P39, DOI 10.1148/114.1.39; ENG RHK, 1987, ARCH INTERN MED, V147, P746, DOI 10.1001/archinte.147.4.746; FELZENBERG JD, 1987, CHEST, V91, P934, DOI 10.1378/chest.91.6.934a; FEUERSTEIN IM, 1990, RADIOLOGY, V174, P697, DOI 10.1148/radiology.174.3.2305052; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEISHER AG, 1988, ANN THORAC SURG, V45, P21, DOI 10.1016/S0003-4975(10)62388-0; GOODMAN PC, 1986, AM J ROENTGENOL, V147, P29, DOI 10.2214/ajr.147.1.29; HOPEWELL PC, 1985, CHEST, V87, P104, DOI 10.1378/chest.87.1.104; JACOBSON SJ, 1989, 5 P INT C AIDS MONTR; JOE L, 1986, ARCH INTERN MED, V146, P1816, DOI 10.1001/archinte.146.9.1816; JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750; LEE M, 1990, CHEST, V97, P510, DOI 10.1378/chest.97.2.510-c; LEOUNG GS, 1989, 5 P INT C AIDS MONTR; LOVE L, 1954, ANN INTERN MED, V40, P153, DOI 10.7326/0003-4819-40-1-153; MARTINEZ CM, 1988, CHEST, V94, P1317, DOI 10.1378/chest.94.6.1317b; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; NEWSOME GS, 1989, 5 P INT C AIDS MONTR; SANDHU JS, 1989, RADIOLOGY, V173, P33, DOI 10.1148/radiology.173.1.2789413; SCANNELL KA, 1990, CHEST, V97, P479, DOI 10.1378/chest.97.2.479; SELIK RM, 1987, AIDS, V1, P175; SEPKOWITZ KA, 1989, 5 P INT C AIDS MONTR; SHERMAN M, 1986, CHEST, V90, P609, DOI 10.1378/chest.90.4.609; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; WOLLSCHLAGER CM, 1984, CHEST, V85, P197, DOI 10.1378/chest.85.2.197; 1990, CHEST, V97, P510	30	104	106	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					455	459		10.7326/0003-4819-114-6-455	http://dx.doi.org/10.7326/0003-4819-114-6-455			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994791				2022-12-01	WOS:A1991FB64000004
J	STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D				STEWART, DJ; LEVY, RD; CERNACEK, P; LANGLEBEN, D			INCREASED PLASMA ENDOTHELIN-1 IN PULMONARY-HYPERTENSION - MARKER OR MEDIATOR OF DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							RELAXING FACTOR; RELEASE; CELLS; SHOCK	Objective: To explore the role of endothelin-1, a potent endothelial-derived vasoconstrictor peptide, in pulmonary hypertension, by measuring its concentration in arterial and venous plasma. Design: A survey, case series study. Setting: University-affiliated hospitals and outpatient clinics. Patients: Twenty-seven patients with pulmonary hypertension: 7 with primary, and 20 with secondary pulmonary hypertension of various causes. The control groups (n = 16) comprised 8 healthy volunteers and 8 patients with coronary artery disease but without evidence of pulmonary hypertension. Measurements and Main Results: Pulmonary artery pressure was markedly increased (94/43 +/- 23/13 mm Hg) in the patients with pulmonary hypertension. Venous plasma immunoreactive endothelin-1, measured by a specific radioimmunoassay, was significantly higher in patients with pulmonary hypertension (3.5 +/- 2.5 pg/mL, P < 0.001) than in normal subjects (1.45 +/- 0.45 pg/mL), or patients with coronary disease (0.75 +/- 0.64 pg/mL). The arterial-to-venous ratio of immunoreactive endothelin-1 was significantly greater than unity in primary pulmonary hypertension (2.21 +/- 0.72, P = 0.01), whereas the patients with secondary pulmonary hypertension had a mean ratio not different from 1 (0.97 +/- 0.42). In contrast, the mean arterial-to-venous ratios were significantly less than unity in both control groups (0.59 +/- 0.35, and 0.54 +/- 0.64; P < 0.02, for normal subjects and coronary disease patients, respectively), indicating a possible clearance of endothelin-1 across the healthy lung. Conclusions: Patients with pulmonary hypertension have substantial alterations in plasma immunoreactive endothelin-1, which may reflect changes in net release or clearance of endothelin-1 by the lung. In patients with primary pulmonary hypertension, the high levels in arterial compared with venous plasma suggest pulmonary production of endothelin-1, which may contribute to elevated pulmonary vascular resistance.	SIR MORTIMER B DAVIS JEWISH HOSP, MONTREAL H3T 1E2, QUEBEC, CANADA	McGill University	STEWART, DJ (corresponding author), ROYAL VICTORIA HOSP, DIV CARDIOL, ROOM M476, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA.		Langleben, David/AAJ-9152-2020					ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS46; BRAQUET P, 1989, J CARDIOVASC PHARM, V13, pS143, DOI 10.1097/00005344-198900135-00036; CERNACEK P, 1989, BIOCHEM BIOPH RES CO, V161, P562, DOI 10.1016/0006-291X(89)92636-3; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DINH XUAN AT, 1989, EUR RESPIR J, V2, P409; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; Dubin D, 1989, J VASC MED BIOL, V1, P150; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HEATH D, 1987, BRIT HEART J, V58, P204; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HILEY CR, 1989, J CARDIOVASC PHARM, V13, pS197, DOI 10.1097/00005344-198900135-00055; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; LIPPTON HL, 1989, J APPL PHYSIOL, V66, P1008, DOI 10.1152/jappl.1989.66.2.1008; Meyrick B, 1989, Prog Clin Biol Res, V308, P91; MONCADA S, 1978, PHARMACOL REV, V30, P293; MOON DG, 1989, P NATL ACAD SCI USA, V86, P9529, DOI 10.1073/pnas.86.23.9529; MOREL DR, 1989, EUR J PHARMACOL, V167, P427, DOI 10.1016/0014-2999(89)90454-8; NEWMAN JH, 1989, J AM COLL CARDIOL, V14, P551, DOI 10.1016/0735-1097(89)90091-0; NICOD P, 1989, CIRCULATION, V80, P1486, DOI 10.1161/01.CIR.80.5.1486; OHTSUKA M, 1989, American Review of Respiratory Disease, V139, pA51; PERNOW J, 1989, ACTA PHYSIOL SCAND, V137, P317, DOI 10.1111/j.1748-1716.1989.tb08756.x; RAE GA, 1989, J CARDIOVASC PHARM, V13, pS89, DOI 10.1097/00005344-198900135-00022; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; Reeves JT, 1984, PULMONARY HYPERTENSI, P1; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RIMAR S, 1989, CIRCULATION S2, V80, P213; RYAN US, 1989, J CARDIOVASC PHARM, V13, pS57, DOI 10.1097/00005344-198900135-00014; RYAN US, 1987, PULMONARY ENDOTHELIU, P3; SIRVIO ML, 1990, BIOCHEM BIOPH RES CO, V167, P1191, DOI 10.1016/0006-291X(90)90649-8; STELZNER TJ, 1990, FASEB J, V4, pA1147; STEWART DJ, 1990, CARDIOVASC RES, V24, P7, DOI 10.1093/cvr/24.1.7; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1220, DOI 10.1016/0006-291X(89)91372-7; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VOELKEL NF, 1989, PULMONARY VASCULAR P, P513; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD P, 1958, BRIT HEART J, V20, P557; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	40	843	889	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					464	469		10.7326/0003-4819-114-6-464	http://dx.doi.org/10.7326/0003-4819-114-6-464			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1994793				2022-12-01	WOS:A1991FB64000006
J	TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH				TALBOT, JD; MARRETT, S; EVANS, AC; MEYER, E; BUSHNELL, MC; DUNCAN, GH			MULTIPLE REPRESENTATIONS OF PAIN IN HUMAN CEREBRAL-CORTEX	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SUBMODALITY DISTRIBUTION; HUMAN SOMATOSENSORY CORTEX; RESPONSE CHARACTERISTICS; EPILEPTIC SEIZURES; CINGULATE CORTEX; M FASCICULARIS; PET IMAGES; NEURONS; MONKEY	The representation of pain in the cerebral cortex is less well understood than that of any other sensory system. However, with the use of magnetic resonance imaging and positron emission tomography in humans, it has now been demonstrated that painful heat causes significant activation of the contralateral anterior cingulate, secondary somatosensory, and primary somatosensory cortices. This contrasts with the predominant activation of primary somatosensory cortex caused by vibrotactile stimuli in similar experiments. Furthermore, the unilateral cingulate activation indicates that this forebrain area, thought to regulate emotions, contains an unexpectedly specific representation of pain.	UNIV MONTREAL, FAC MED DENT, NEUROPHYSIOL COMPORTEMENTALE LAB, MONTREAL H3C 3J7, QUEBEC, CANADA; MONTREAL NEUROL HOSP & INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL H3A 2B4, QUEBEC, CANADA	Universite de Montreal; McGill University				Marrett, Sean/0000-0001-8179-6511				ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P108; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DEANE GE, 1961, J EXP PSYCHOL, V61, P489, DOI 10.1037/h0049220; DONG WK, 1989, BRAIN RES, V484, P314, DOI 10.1016/0006-8993(89)90375-2; DOSTROVSKY JR, 1990, APR S NEUR NOC KAW; DUCLAUX R, 1980, J NEUROPHYSIOL, V43, P1; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, IN PRESS IEEE T MED; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HENSEL H, 1971, PFLUG ARCH EUR J PHY, V329, P1, DOI 10.1007/BF00586896; Hurt R W, 1974, Clin Neurosurg, V21, P334; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; LARSON MA, 1987, J NEUROSCI, V7, P547; LASSEN NA, 1978, SCI AM, V239, P62, DOI 10.1038/scientificamerican1078-62; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; MAIXNER W, 1989, J NEUROPHYSIOL, V62, P437, DOI 10.1152/jn.1989.62.2.437; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; MELZACK R, 1968, P423; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MUSIL SY, 1988, J COMP NEUROL, V272, P203, DOI 10.1002/cne.902720205; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W, 1954, EPILEPSY FUNCTIONAL, P77; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; RAINVILLE P, 1989, AM PAIN SOC ABSTR, V8, P64; REIMAN EM, 1989, SCIENCE, V243, P1071, DOI 10.1126/science.2784226; ROBINSON CJ, 1980, J COMP NEUROL, V192, P93, DOI 10.1002/cne.901920106; SANTO JL, 1990, PAIN, V41, P55, DOI 10.1016/0304-3959(90)91109-V; SUMINO R, 1981, BRAIN RES REV, V3, P105, DOI 10.1016/0165-0173(81)90001-1; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TALBOT JD, 1987, PAIN, V30, P221, DOI 10.1016/0304-3959(87)91078-5; TSUBOKAWA T, 1981, BRAIN RES, V217, P179, DOI 10.1016/0006-8993(81)90197-9; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; White JC., 1969, PAIN NEUROSURGEON, P6; WILLER JC, 1984, BRAIN, V107, P1095, DOI 10.1093/brain/107.4.1095; WILSON DH, 1974, CONFIN NEUROL, V36, P61; YASUI Y, 1988, J COMP NEUROL, V274, P91, DOI 10.1002/cne.902740109; YOUNG GB, 1986, ANN NEUROL, V19, P412, DOI 10.1002/ana.410190423; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537	49	761	774	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1991	251	4999					1355	1358		10.1126/science.2003220	http://dx.doi.org/10.1126/science.2003220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	2003220				2022-12-01	WOS:A1991FB73300043
J	DALLOS, P; EVANS, BN; HALLWORTH, R				DALLOS, P; EVANS, BN; HALLWORTH, R			NATURE OF THE MOTOR ELEMENT IN ELECTROKINETIC SHAPE CHANGES OF COCHLEAR OUTER HAIR-CELLS	NATURE			English	Article							MECHANICAL RESPONSES	IT is the prevailing notion that cochlear outer hair cells function as mechanical effectors as well as sensory receptors 1-3. Electrically induced changes in the shape of mammalian outer hair cells 4,5, studied in vitro, are commonly assumed to represent an aspect of their effector process that may occur in vivo. The nature of the motile process is obscure, even though none of the established cellular motors can be involved 6. Although it is known that the motile response is under voltage control 7, it is uncertain whether the stimulus is a drop in the voltage along the long axis of the cell or variation in the transmembrane potential. We have now performed experiments with cells partitioned in differing degrees between two chambers. Applied voltage stimulates the cell membrane segments in opposite polarity to an amount dependent on the partitioning. The findings show, in accordance with previous suggestions 6,8, that the driving stimulus is a local transmembrane voltage drop and that the cellular motor consists of many independent elements, distributed along the cell membrane and its associated cortical structures. We further show that the primary action of the motor elements is along the longitudinal dimension of the cell without necessarily involving changes in intracellular hydrostatic pressure. This establishes the outer hair cell motor as unique among mechanisms that control cell shape 9.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,HUGH KNOWLES CTR,AUDITORY PHYSIOL LAB,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; Bannister L H, 1988, Prog Brain Res, V74, P213; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; BROWNELL WE, 1990, EAR HEARING, V11, P82, DOI 10.1097/00003446-199004000-00003; BROWNELL WE, 1986, PERIPHERAL AUDITORY, P369; BROWNELL WE, 1983, MECHANISMS HEARING, P5; CLARK BA, 1990, PFLUG ARCH EUR J PHY, V415, P490, DOI 10.1007/BF00373629; DALLOS P, 1985, P207; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365, DOI 10.1152/jn.1978.41.2.365; DALLOS P, 1988, AUDITORY FUNCTION NE, P153; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; EVANS BN, 1990, HEARING RES, V45, P265, DOI 10.1016/0378-5955(90)90126-A; EVANS BN, 1988, THESIS U TEXAS HLTH; FLOCK A, 1986, ARCH OTO-RHINO-LARYN, V243, P83, DOI 10.1007/BF00453755; GUINAN JJ, 1983, J COMP NEUROL, V221, P358, DOI 10.1002/cne.902210310; HOLLEY MC, 1988, NATURE, V335, P635, DOI 10.1038/335635a0; HOLLEY MC, 1990, J CELL SCI, V96, P283; HOLLEY MC, 1988, PROC R SOC SER B-BIO, V232, P413, DOI 10.1098/rspb.1988.0004; JEN DH, 1987, J ACOUST SOC AM, V82, P1667, DOI 10.1121/1.395158; KIM DO, 1986, HEARING RES, V22, P105, DOI 10.1016/0378-5955(86)90088-2; Lackie J.M., 1986, CELL MOVEMENT CELL B, P253, DOI [10.1007/978-94-009-4071-0_10, DOI 10.1007/978-94-009-4071-0_10]; SAITO K, 1983, CELL TISSUE RES, V229, P467; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SMITH CA, 1957, AM J ANAT, V100, P337, DOI 10.1002/aja.1001000304; SPOENDLIN H, 1969, ACTA OTO-LARYNGOL, V67, P239, DOI 10.3109/00016486909125448	26	190	196	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					155	157		10.1038/350155a0	http://dx.doi.org/10.1038/350155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005965				2022-12-01	WOS:A1991FB64500059
J	DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW				DOUGLAS, SE; MURPHY, CA; SPENCER, DF; GRAY, MW			CRYPTOMONAD ALGAE ARE EVOLUTIONARY CHIMERAS OF 2 PHYLOGENETICALLY DISTINCT UNICELLULAR EUKARYOTES	NATURE			English	Article							SUBUNIT RIBOSOMAL-RNA; C-CONTAINING ALGA; ORGANELLES; ORIGINS; DNA	ALTHOUGH it is widely accepted that the plastids of plants and algae originated as endosymbionts 1, the details of this evolutionary process are unclear 2,3. It has been proposed that in organisms whose plastids are surrounded by more than two membranes, the endosymbiont was a eukaryotic alga rather than a photosynthetic prokaryote 4. The DNA-containing 5 nucleomorph 6 of cryptomonad algae appears to be the vestigial nucleus of such an algal endosymbiont 7. Eukaryotic-type ribosomal RNA sequences have been localized to a nucleolus-like structure in the nucleomorph 8. In support of the hypothesis that cryptomonads are evolutionary chimaeras of two distinct eukaryotic cells, we show here that Cryptomonas PHI contains two phylogenetically separate, nuclear-type small-subunit rRNA genes, both of which are transcriptionally active. We incorporate our rRNA sequence data into phylogenetic trees, from which we infer the evolutionary ancestry of the host and symbiont components of Cryptomonas PHI. Such trees do not support the thesis 3 that chromophyte algae evolved directly from a cryptomonad-like ancestor.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA	Dalhousie University	DOUGLAS, SE (corresponding author), NATL RES COUNCIL CANADA,ATLANTIC REG LAB,INST MARINE BIOSCI,1411 OXFORD ST,HALIFAX B3H 3Z1,NS,CANADA.			Gray, Michael/0000-0001-7125-2625				BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BIRD CJ, 1990, NUCLEIC ACIDS RES, V18, P4023, DOI 10.1093/nar/18.13.4023; Cavalier-Smith T., 1986, Progress phycol. Res., V4, P309; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DOUGLAS SE, 1989, PLANT MOL BIOL, V13, P13, DOI 10.1007/BF00027331; DOUGLAS SE, 1988, CURR GENET, V14, P591, DOI 10.1007/BF00434085; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; GRAY MW, 1984, NUCLEIC ACIDS RES, V12, P5837, DOI 10.1093/nar/12.14.5837; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; GREENWOOD A D, 1977, British Phycological Journal, V12, P119; GUNDERSON JH, 1987, P NATL ACAD SCI USA, V84, P5823, DOI 10.1073/pnas.84.16.5823; HENDRIKS L, 1989, SYST APPL MICROBIOL, V12, P223, DOI 10.1016/S0723-2020(89)80066-9; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; LUDWIG M, 1987, ANN NY ACAD SCI, V503, P198, DOI 10.1111/j.1749-6632.1987.tb40609.x; LUDWIG M, 1985, PROTOPLASMA, V127, P9, DOI 10.1007/BF01273697; Maxam A M, 1980, Methods Enzymol, V65, P499; MCFADDEN GI, 1990, J CELL SCI, V95, P303; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNARE MN, 1986, J BIOL CHEM, V261, P5187; Sogin M. L, 1990, PCR PROTOCOLS GUIDE, P307, DOI DOI 10.1016/B978-0-12-372180-8.50041-X; SWOFFORD DL, 1989, PAUP VERSION 3 0 ILL; WHATLEY JM, 1981, NEW PHYTOL, V87, P233, DOI 10.1111/j.1469-8137.1981.tb03195.x	27	244	246	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					148	151		10.1038/350148a0	http://dx.doi.org/10.1038/350148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005963				2022-12-01	WOS:A1991FB64500056
J	GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR				GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR			A HEMOPROTEIN WITH KINASE-ACTIVITY ENCODED BY THE OXYGEN SENSOR OF RHIZOBIUM-MELILOTI	NATURE			English	Article							ESCHERICHIA-COLI; PHOSPHORYLATION; EXPRESSION; GENES; NIFA	THE expression of the nitrogen-fixation genes of Rhizobium meliloti is controlled by oxygen 1,2. These genes are induced when the free oxygen concentration is reduced to microaerobic levels. Two regulator proteins, FixL and FixJ, initiate the oxygen-response cascade, and the genes that encode them have been cloned 2,3. The fixL product seems to be a transmembrane sensor that modulates the activity of the fixJ product, a cytoplasmic regulator 3. FixL and FixJ are homologous to a family of bacterial two-component regulators 4, for which the mode of signal transduction is phosphorylation (reviewed in refs 5-9). We report here the purification of both FixJ and a soluble truncated FixL (FixL*), overproduced from a single plasmid construct. FixL* catalyses its own phosphorylation and the transfer of the gamma-phosphate of ATP to FixJ. The resulting FixJ-phosphate linkage is sensitive to base, as are the aspartyl phosphates of homologous systems. Visible spectra of purified FixL* show that it is an oxygen-binding haemoprotein. We propose that FixL senses oxygen through its haem moiety and transduces this signal by controlling the phosphorylation of FixJ.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GILLESGONZALEZ, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,0634,LA JOLLA,CA 92093, USA.							ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	16	435	440	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					170	172		10.1038/350170a0	http://dx.doi.org/10.1038/350170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848683				2022-12-01	WOS:A1991FB64500065
J	HUANG, S; LEE, WH; LEE, EYHP				HUANG, S; LEE, WH; LEE, EYHP			A CELLULAR PROTEIN THAT COMPETES WITH SV40 T-ANTIGEN FOR BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							SUSCEPTIBILITY GENE; EXPRESSION; CELLS	TUMOUR-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation 1. This role is indicated, in part, by the suppression of tumorigenicity of human tumour cells after retrovirus-mediated Rb replacement 2-4. How Rb acts to bring about this suppression is not clear 5 but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses 6-8, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells 9,10. These observations suggest that endogenous cellular proteins might exist that bind to the same regions of Rb and thereby mediate its function. We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46). Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb. The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.			HUANG, S (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.							BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; Lee W.-H., 1990, TUMOR SUPPRESSOR GEN, P169; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807	18	145	165	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					160	162		10.1038/350160a0	http://dx.doi.org/10.1038/350160a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	2005966				2022-12-01	WOS:A1991FB64500061
J	JAP, BK; WALIAN, PJ; GEHRING, K				JAP, BK; WALIAN, PJ; GEHRING, K			STRUCTURAL ARCHITECTURE OF AN OUTER-MEMBRANE CHANNEL AS DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; SENSITIVE SPECIMENS; LIPID BILAYERS; PHOE PROTEIN; PORIN; RESOLUTION; BEAM	PORINS are a family of membrane channels commonly found in the outer membranes of Gram-negative bacteria where they serve as diffusional pathways for waste products, nutrients and antibiotics, and can also be receptors for bacteriophages 1,2. Porin channels have been shown in vitro to be voltage-gated 3-6. They can exhibit slight selectivities for certain solutes; for example PhoE porin has some selectivity for anionic and phosphate-containing compounds 1,7. Unlike many known membrane proteins which often contain long stretches of hydrophobic segments that are believed to traverse the membrane in a helical conformation, porins are found to have charged residues distributed almost uniformly along their primary sequences and have most of their secondary structure in a beta-sheet conformation 8-10. We have made crystalline patches of PhoE porin embedded in a lipid bilayer and have used these to determine the structure of PhoE porin by electron crystallography to a resolution of 6 angstrom. The basic structure consists of a trimer of elliptically shaped, cylindrical walls of beta-sheet. Each cylinder has an inner lining, formed by parts of the polypeptide, that defines the channel size. The structure provides a clue as to how deletions of segments of polypeptide, which are found in certain mutants, can result in an actual increase in the channel size.			JAP, BK (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DONNER LAB,BERKELEY,CA 94720, USA.		Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOENGER A, 1990, J STRUCT BIOL, V103, P185, DOI 10.1016/1047-8477(90)90022-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KORTELAND J, 1982, BIOCHIM BIOPHYS ACTA, V690, P282, DOI 10.1016/0005-2736(82)90332-7; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WALIAN PJ, 1990, J MOL BIOL, V215, P429, DOI 10.1016/S0022-2836(05)80362-6; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1989, FEBS LETT, V256, P143, DOI 10.1016/0014-5793(89)81735-1; XU GZ, 1986, BIOCHIM BIOPHYS ACTA, V862, P57, DOI 10.1016/0005-2736(86)90468-2	26	132	134	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					167	170		10.1038/350167a0	http://dx.doi.org/10.1038/350167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848682				2022-12-01	WOS:A1991FB64500064
J	KAPLAN, DR; MARTINZANCA, D; PARADA, LF				KAPLAN, DR; MARTINZANCA, D; PARADA, LF			TYROSINE PHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY OF THE TRK PROTOONCOGENE PRODUCT INDUCED BY NGF	NATURE			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELL LINE; ACETYLCHOLINE; ACTIVATION; INCREASE; RECEPTOR	NERVE growth factor (NGF) is a neurotrophic factor responsible for the differentiation and survival of sympathetic and sensory neurons as well as selective populations of cholinergic neurons 1,2. NGF binds to specific cell-surface receptors but the mechanism for transduction of the neurotrophic signal is unknown. Several experiments using the NGF-responsive pheochromocytoma cell line, PC12, have implicated tyrosine phosphorylation in NGF-mediated responses, although no NGF-specific tyrosine kinases have been identified 3. Here we show that NGF induces tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product, a tyrosine kinase receptor whose expression is restricted in vivo to neurons of the sensory spinal and cranial ganglia of neural crest origin 4. Tyrosine phosphorylation of trk by NGF is rapid, specific and occurs with picomolar quantities of factor, indicating that the response is mediated by physiological amounts of NGF. Activation of the trk tyrosine kinase receptor provides a possible mechanism for signal transduction by NGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KAPLAN, DR (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,EUKARYOT SIGNAL TRANSDUCT GRP,POB B,BETHESDA,MD 20892, USA.		Parada, luis F/B-9400-2014					ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; CHAO MV, 1990, HDB EXPT PHARM, V95, P135; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIM UH, IN PRESS J BIOL CHEM; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284	21	963	994	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					158	160		10.1038/350158a0	http://dx.doi.org/10.1038/350158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1706478				2022-12-01	WOS:A1991FB64500060
